"Name" "MOA" "Target" "Disease.Area" "Indication" "Id" "SMILES" "InChIKey" "Phase"
"1" "A-317491" "purinergic receptor antagonist" "P2RX3" "" "" "BRD-K38019854-323-01-4, BRD-K38019854-001-01-6" "OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12, OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12" "VQGBOYBIENNKMI-LJAQVGFWSA-N, VQGBOYBIENNKMI-LJAQVGFWSA-N" "Preclinical"
"2" "A-33903" "" "" "" "" "BRD-A40302156-001-01-9" "CC(=O)NC1C(=O)Nc2ccccc2C(=N1)c1ccccc1" "MMXSDWJOQSEPSM-UHFFFAOYSA-N" "Phase 2"
"3" "A-366" "histone lysine methyltransferase inhibitor" "EHMT1, EHMT2" "" "" "BRD-K06182768-001-02-3, BRD-K06182768-001-01-5, BRD-K06182768-001-03-1" "COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1, COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1" "BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N, BKCDJTRMYWSXMC-UHFFFAOYSA-N" "Preclinical"
"4" "A-674563" "AKT inhibitor" "AKT1, PKIA, PRKACA" "" "" "BRD-K78177893-001-02-4" "Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1" "BPNUQXPIQBZCMR-IBGZPJMESA-N" "Preclinical"
"5" "A-7" "calmodulin antagonist" "" "" "" "BRD-K03301001-003-02-5" "NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12" "JLUUJHIQVIXTGT-UHFFFAOYSA-N" "Preclinical"
"6" "A-769662" "AMPK activator" "" "" "" "BRD-K41918892-001-05-9, BRD-K41918892-001-06-7" "Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C" "" ""
"7" "A-803467" "sodium channel blocker" "SCN10A" "" "" "BRD-K28570407-001-02-0" "COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1" "VHKBTPQDHDSBSP-UHFFFAOYSA-N" "Preclinical"
"8" "abacavir" "nucleoside reverse transcriptase inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-A95032015-065-01-2, BRD-K17443395-065-01-4" "Nc1nc(NC2CC2)c2ncn(C3C[C@H](CO)C=C3)c2n1, Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1" "MCGSCOLBFJQGHM-HNHGDDPOSA-N, MCGSCOLBFJQGHM-SCZZXKLOSA-N" "Launched"
"9" "abafungin" "sterol methyltransferase inhibitor" "" "" "" "BRD-K77432251-001-01-2" "Cc1ccc(Oc2ccccc2-c2csc(N=C3NCCCN3)n2)c(C)c1" "TYBHXIFFPVFXQW-UHFFFAOYSA-N" "Phase 3"
"10" "abamectin" "benzodiazepine receptor agonist" "GABBR1, GABBR2" "infectious disease" "gastrointestinal parasites" "BRD-A25579302-001-04-8" "CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C" "RRZXIRBKKLTSOM-ONDMGMIHSA-N" "Launched"
"11" "abametapir" "metalloproteinase inhibitor" "MMP9" "" "" "BRD-K65498798-001-01-7" "Cc1ccc(nc1)-c1ccc(C)cn1" "PTRATZCAGVBFIQ-UHFFFAOYSA-N" "Phase 3"
"12" "ABC-294640" "sphingosine kinase inhibitor" "SPHK2" "" "" "BRD-A70814879-001-01-2, BRD-A70814879-003-02-6" "Clc1ccc(cc1)C12CC3CC(CC(C3)(C1)C(=O)NCc1ccncc1)C2, Clc1ccc(cc1)C12CC3CC(CC(C3)(C1)C(=O)NCc1ccncc1)C2" "CAOTVXGYTWCKQE-UHFFFAOYSA-N, CAOTVXGYTWCKQE-UHFFFAOYSA-N" "Phase 1/Phase 2"
"13" "abiraterone" "androgen biosynthesis inhibitor" "CYP11B1, CYP17A1" "oncology" "prostate cancer" "BRD-K00111504-001-01-9" "C[C@]12CC[C@@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1" "GZOSMCIZMLWJML-APXSMTNNSA-N" "Launched"
"14" "abiraterone-acetate" "androgen biosynthesis inhibitor" "CYP17A1" "oncology" "prostate cancer" "BRD-K24048528-001-01-7, BRD-K16133773-001-01-9" "CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1, CC(=O)O[C@H]1CC[C@]2(C)[C@@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@H]3CC=C2C1" "UVIQSJCZCSLXRZ-UBUQANBQSA-N, UVIQSJCZCSLXRZ-HCWFNAMGSA-N" "Launched"
"15" "ABT-202" "acetylcholine receptor agonist" "" "" "" "BRD-A29844814-300-01-5" "NC1CCN(C1)c1cccnc1" "LVGMMVAWLISWJD-UHFFFAOYSA-N" "Phase 1"
"16" "ABT-239" "histamine receptor antagonist" "HRH1, HRH2, HRH3" "" "" "BRD-K22749967-046-02-3" "C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C" "" ""
"17" "ABT-491" "platelet activating factor receptor antagonist" "PTAFR" "" "" "BRD-K97233161-003-01-5" "CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C" "" ""
"18" "ABT-639" "calcium channel blocker" "CACNA1G, CACNA1H, CACNA1I" "" "" "BRD-K11792081-001-01-4" "Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F" "AGPIHNZOZNKRGT-CYBMUJFWSA-N" "Phase 2"
"19" "ABT-702" "adenosine kinase inhibitor" "ADK" "" "" "BRD-K36021395-300-02-4" "Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1" "RQCXKDWOCUJWQZ-UHFFFAOYSA-N" "Preclinical"
"20" "ABT-724" "dopamine receptor agonist" "DRD4" "" "" "BRD-K37714784-305-02-1" "C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1" "FRPJGTNLZNXQEX-UHFFFAOYSA-N" "Phase 2"
"21" "ABT-737" "BCL inhibitor" "BCL2, BCL2L1, BCL2L2" "" "" "BRD-K56301217-001-07-4, BRD-K56301217-001-10-8" "CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1, CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1" "HPLNQCPCUACXLM-PGUFJCEWSA-N, HPLNQCPCUACXLM-PGUFJCEWSA-N" "Phase 1/Phase 2"
"22" "ABT-751" "tubulin polymerization inhibitor" "TUBB" "" "" "BRD-K91623615-001-05-0, BRD-K91623615-001-04-3" "COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1, COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1" "URCVCIZFVQDVPM-UHFFFAOYSA-N, URCVCIZFVQDVPM-UHFFFAOYSA-N" "Phase 2"
"23" "AC-264613" "PAR agonist" "F2RL1" "" "" "BRD-K81548480-001-01-2" "C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1" "RQKXQCSEZPQBNZ-QSBCOWLBSA-N" "Preclinical"
"24" "AC-55541" "PARP inhibitor" "PARP2" "" "" "BRD-A27911617-001-01-7" "C\C(=N/NC(=O)C(NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1" "UCUHFWIFSHROPY-RWPZCVJISA-N" "Preclinical"
"25" "AC-55649" "retinoid receptor agonist" "RARA, RARB" "" "" "BRD-K93176058-001-03-6" "CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O" "HXBKPYIEQLLNBK-UHFFFAOYSA-N" "Preclinical"
"26" "AC-7954-(+/-)" "urotensin receptor agonist" "UTS2R" "" "" "BRD-A49544621-003-02-8" "CN(C)CCC1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1" "HIVBATDUVFEJFZ-UHFFFAOYSA-N" "Preclinical"
"27" "acadesine" "AMPK activator" "" "" "" "BRD-K53448858-001-07-0, BRD-K04797704-001-01-9" "NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N, NC(=O)c1ncn([C@@H]2O[C@@H](CO)[C@@H](O)[C@H]2O)c1N" "RTRQQBHATOEIAF-UUOKFMHZSA-N, RTRQQBHATOEIAF-HAVMAKPUSA-N" "Phase 3"
"28" "acalabrutinib" "Brutons tyrosine kinase (BTK) inhibitor	BTK			BRD-K64034691-001-01-9	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12	WDENQIQQYWYTPO-IBGZPJMESA-N	Phase 3
acalisib	PI3K inhibitor	PIK3CB, PIK3CD			BRD-K92517771-001-01-2	C[C@H](Nc1ncnc2[nH]cnc12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1	DOCINCLJNAXZQF-LBPRGKRZSA-N	Phase 1
acamprosate	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5	neurology/psychiatry	abstinence from alcohol	BRD-K26262077-238-01-5	CC(=O)NCCCS(O)(=O)=O	AFCGFAGUEYAMAO-UHFFFAOYSA-N	Launched
acarbose	glucosidase inhibitor	AMY2A, GAA, MGAM, SI	endocrinology	diabetes mellitus	BRD-A16444946-001-09-7, BRD-K01621533-001-01-1, BRD-K44276885-001-05-8	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@H](O[C@@H]2[C@H](CO)O[C@H](O[C@@H]3[C@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@@H]1O, C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O	XUFXOAAUWZOOIT-UGEKTDRHSA-N, XUFXOAAUWZOOIT-PCKYEMPFSA-N, XUFXOAAUWZOOIT-SXARVLRPSA-N	Launched
ACDPP	glutamate receptor antagonist	GRM5			BRD-K68633617-003-02-9	CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	RNGRUHWJJPTYNR-UHFFFAOYSA-N	Preclinical
acebutolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, ventricular arrhythmias	BRD-A29260609-003-26-0, BRD-A29260609-003-25-2	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O, CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	GOEMGAFJFRBGGG-UHFFFAOYSA-N, GOEMGAFJFRBGGG-UHFFFAOYSA-N	Launched
acecainide	polarization inhibitor	SCN5A			BRD-K07753030-003-17-6	CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1	KEECCEWTUVWFCV-UHFFFAOYSA-N	Phase 3
aceclidine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	glaucoma	BRD-A32673558-003-03-9, BRD-A32673558-001-02-5, BRD-K68075732-001-11-8, BRD-A80567352-003-02-4	CC(=O)OC1CN2CCC1CC2, CC(=O)OC1CN2CCC1CC2, CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1, CC(=O)OC1CN2CC[C@H]1CC2	WRJPSSPFHGNBMG-UHFFFAOYSA-N, WRJPSSPFHGNBMG-UHFFFAOYSA-N, METKIMKYRPQLGS-GFCCVEGCSA-N, WRJPSSPFHGNBMG-UHFFFAOYSA-N	Launched
aceclofenac	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia	BRD-K68538666-001-12-3	OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	MNIPYSSQXLZQLJ-UHFFFAOYSA-N	Launched
acedapsone			infectious disease	leprosy	BRD-K97417064-001-02-4	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	AMTPYFGPPVFBBI-UHFFFAOYSA-N	Launched
acedoben					BRD-K47195926-001-06-6	CC(=O)Nc1ccc(cc1)C(O)=O	QCXJEYYXVJIFCE-UHFFFAOYSA-N	Phase 2
acefylline	adenosine receptor agonist	ADORA1	pulmonary	asthma	BRD-K44004064-001-07-3	Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	HCYFGRCYSCXKNQ-UHFFFAOYSA-N	Launched
aceglutamide			gastroenterology	peptic ulcer disease (PUD)	BRD-K13619941-213-01-8	CC(=O)N[C@@H](CCC(N)=O)C(O)=O	KSMRODHGGIIXDV-YFKPBYRVSA-N	Launched
acemetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis	BRD-K67563174-001-17-6, BRD-K67563174-001-16-8	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	FSQKKOOTNAMONP-UHFFFAOYSA-N, FSQKKOOTNAMONP-UHFFFAOYSA-N	Launched
aceneuramic-acid		AZGP1, CES1, MBL2, REG1A, SELE, SELP, SIGLEC1			BRD-K36262466-001-06-3	CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SQVRNKJHWKZAKO-PFQGKNLYSA-N	Phase 3
acenocoumarol	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	BRD-A65051990-001-12-9	CC(=O)CC(c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O	VABCILAOYCMVPS-UHFFFAOYSA-N	Launched
acepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	sedative	BRD-K37814297-050-09-6	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	NOSIYYJFMPDDSA-UHFFFAOYSA-N	Launched
acesulfame-potassium					BRD-K50850824-237-04-8, BRD-K50850824-237-02-2, BRD-K50850824-237-03-0	CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1, CC1=CC(=O)NS(=O)(=O)O1	YGCFIWIQZPHFLU-UHFFFAOYSA-N, YGCFIWIQZPHFLU-UHFFFAOYSA-N, YGCFIWIQZPHFLU-UHFFFAOYSA-N	Phase 3
acetanilide	hydrogen peroxide decomposition inhibitor				BRD-K11094367-001-10-1, BRD-K11094367-001-09-3	CC(=O)Nc1ccccc1, CC(=O)Nc1ccccc1	FZERHIULMFGESH-UHFFFAOYSA-N, FZERHIULMFGESH-UHFFFAOYSA-N	Preclinical
acetarsol			gastroenterology	diarrhea	BRD-K99048103-001-19-2, BRD-K99048103-001-18-4	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O, CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	ODFJOVXVLFUVNQ-UHFFFAOYSA-N, ODFJOVXVLFUVNQ-UHFFFAOYSA-N	Launched
acetazolamide	carbonic anhydrase inhibitor	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	BRD-K43457670-001-27-8	CC(=O)Nc1nnc(s1)S(N)(=O)=O	BZKPWHYZMXOIDC-UHFFFAOYSA-N	Launched
acetohexamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	BRD-K52960356-001-15-5, BRD-K52960356-001-13-0	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	VGZSUPCWNCWDAN-UHFFFAOYSA-N, VGZSUPCWNCWDAN-UHFFFAOYSA-N	Launched
acetohydroxamic-acid	urease inhibitor	MMP12	infectious disease	urinary tract infections	BRD-K21615095-001-08-4	CC(=O)NO	RRUDCFGSUDOHDG-UHFFFAOYSA-N	Launched
acetophenazine	dopamine receptor antagonist	DRD1, DRD2	neurology/psychiatry	psychosis	BRD-K42938903-332-01-1	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	WNTYBHLDCKXEOT-UHFFFAOYSA-N	Launched
acetriazoic-acid					BRD-K46416130-001-07-7, BRD-K46416130-001-06-9	CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I, CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I	GNOGSFBXBWBTIG-UHFFFAOYSA-N, GNOGSFBXBWBTIG-UHFFFAOYSA-N	Preclinical
acetyl-farnesyl-cysteine	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	BRD-K79437791-001-05-7, BRD-K79437791-001-06-5	CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O, CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O	XTURYZYJYQRJDO-BNAHBJSTSA-N, XTURYZYJYQRJDO-BNAHBJSTSA-N	Launched
acetyl-l-leucine			neurology/psychiatry	vertigo	BRD-K27406233-001-07-7	CC(C)C[C@H](NC(C)=O)C(O)=O	WXNXCEHXYPACJF-ZETCQYMHSA-N	Launched
acetyl-11-keto-beta-boswellic-acid	lipoxygenase inhibitor	HSD11B1, HSD11B2			BRD-A44696962-001-01-4	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)C4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)(C5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C	HMMGKOVEOFBCAU-MFIYSICPSA-N	Phase 2
acetylcholine	acetylcholine receptor agonist	ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry, gastroenterology, pulmonary	drowsiness, fatigue, headache, indigestion, chest congestion	BRD-K82381502-003-23-1, BRD-K82381502-003-24-9	CC(=O)OCC[N+](C)(C)C, CC(=O)OCC[N+](C)(C)C	OIPILFWXSMYKGL-UHFFFAOYSA-N, OIPILFWXSMYKGL-UHFFFAOYSA-N	Launched
acetylcysteine	mucolytic agent	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	BRD-K67174965-001-02-7, BRD-K59058747-001-19-1, BRD-K59058747-001-18-3	CC(=O)N[C@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O, CC(=O)N[C@@H](CS)C(O)=O	PWKSKIMOESPYIA-SCSAIBSYSA-N, PWKSKIMOESPYIA-BYPYZUCNSA-N, PWKSKIMOESPYIA-BYPYZUCNSA-N	Launched
acetylsalicylsalicylic-acid	cyclooxygenase inhibitor				BRD-K46585355-001-14-3	CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	DDSFKIFGAPZBSR-UHFFFAOYSA-N	Preclinical
acexamic-acid	5 alpha reductase inhibitor	GAST	dermatology	wound healing	BRD-K72215350-001-06-5	CC(=O)NCCCCCC(O)=O	WDSCBUNMANHPFH-UHFFFAOYSA-N	Launched
acifran	cholesterol inhibitor	HCAR2, HCAR3			BRD-A29520968-001-02-7	CC1(OC(=CC1=O)C(O)=O)c1ccccc1	DFDGRKNOFOJBAJ-UHFFFAOYSA-N	Phase 3
acipimox	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	BRD-K63736853-001-04-8, BRD-K63736853-001-03-0	Cc1cnc(c[n+]1[O-])C(O)=O, Cc1cnc(c[n+]1[O-])C(O)=O	DJQOOSBJCLSSEY-UHFFFAOYSA-N, DJQOOSBJCLSSEY-UHFFFAOYSA-N	Launched
acitazanolast	mediator release inhibitor		allergy	allergic rhinitis	BRD-K74236708-001-02-7, BRD-K74236708-001-01-9	OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1, OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1	VWQZJJZGISNFOE-UHFFFAOYSA-N, VWQZJJZGISNFOE-UHFFFAOYSA-N	Launched
acitretin	retinoid receptor agonist	RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3	dermatology	psoriasis	BRD-K62012036-001-14-4, BRD-K62012036-001-13-6	COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C, COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C	IHUNBGSDBOWDMA-AQFIFDHZSA-N, IHUNBGSDBOWDMA-AQFIFDHZSA-N	Launched
acivicin	gamma glutamyltransferase Inhibitors	CTPS1			BRD-K13050541-001-01-9	N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O	QAWIHIJWNYOLBE-ZAFYKAAXSA-N	Phase 2
aclarubicin	topoisomerase inhibitor	TOP1, TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	BRD-A80805100-001-01-9, BRD-A80805100-001-02-7	CCC1(O)CC(OC2CC(C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)N(C)C)c2c(cc3C(=O)c4cccc(O)c4C(=O)c3c2O)C1C(=O)OC, CCC1(O)CC(OC2CC(C(OC3CC(O)C(OC4CCC(=O)C(C)O4)C(C)O3)C(C)O2)N(C)C)c2c(cc3C(=O)c4cccc(O)c4C(=O)c3c2O)C1C(=O)OC	USZYSDMBJDPRIF-UHFFFAOYSA-N, USZYSDMBJDPRIF-UHFFFAOYSA-N	Launched
aclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)	BRD-K74363950-004-01-0	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	ASMXXROZKSBQIH-VITNCHFBSA-N	Launched
ACPC	glutamate receptor antagonist				BRD-K66465025-001-05-1	NC1(CC1)C(O)=O	PAJPWUMXBYXFCZ-UHFFFAOYSA-N	Phase 1
acriflavine	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	BRD-M87138257-003-01-1	Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	BCBIBQWDFMQRSJ-UHFFFAOYSA-O	Launched
acriflavinium	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	BRD-K97874492-003-12-3	C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	XSIOKTWDEOJMGG-UHFFFAOYSA-O	Launched
acrisorcin	other antifungal		infectious disease	fungal infection	BRD-M49658242-001-04-1	CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12	YZODJQFXMFEJRM-UHFFFAOYSA-N	Launched
acrivastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	BRD-K50163129-001-01-4	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	PWACSDKDOHSSQD-IUTFFREVSA-N	Launched
acrylate	mucus protecting agent				BRD-M00184283-001-01-1	[Na].OC(=O)C=C	MNNFZYTXMPWOTA-UHFFFAOYSA-N	Phase 3
ACT-132577	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	BRD-K34843150-001-02-2, BRD-K34843150-001-01-4	NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	DKULOVKANLVDEA-UHFFFAOYSA-N, DKULOVKANLVDEA-UHFFFAOYSA-N	Launched
ACT-462206	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K19781342-001-01-4	COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	NHPQGZOBHSVTAQ-IBGZPJMESA-N	Phase 1
actarit	interleukin receptor agonist		rheumatology	rheumatoid arthritis	BRD-K33483813-001-10-0	CC(=O)Nc1ccc(CC(O)=O)cc1	MROJXXOCABQVEF-UHFFFAOYSA-N	Launched
ACTB-1003	FGFR inhibitor, VEGFR inhibitor	KDR, TEK			BRD-K35936936-001-01-6	COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1	GZPJCJKUZPUFAL-UHFFFAOYSA-N	Phase 1
actinomycin-d	RNA polymerase inhibitor		oncology	Wilms tumor, Ewings sarcoma, rhabdomyosarcoma, testicular carcinoma	BRD-A42383464-001-06-3	CC(C)C1NC(=O)C(NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)NC5C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C6CCCN6C(=O)C(NC5=O)C(C)C)c4nc23)C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C1=O	RJURFGZVJUQBHK-UHFFFAOYSA-N	Launched
actinoquinol					BRD-K08837089-236-01-6	CCOc1ccc(c2cccnc12)S(O)(=O)=O	YAMVZYRZAMBCED-UHFFFAOYSA-N	Preclinical
ACY-1215	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8			BRD-K82928847-001-04-7	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	QGZYDVAGYRLSKP-UHFFFAOYSA-N	Phase 1/Phase 2
acyclovir	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes, shingles, chicken pox	BRD-K32318651-001-24-5, BRD-K32318651-001-23-7, BRD-K32318651-001-21-1, BRD-K32318651-001-22-9	Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1, Nc1nc2n(COCCO)cnc2c(=O)[nH]1	MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N, MKUXAQIIEYXACX-UHFFFAOYSA-N	Launched
AC1NDSS5					BRD-K10226125-245-01-5	CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC	VZXULFIUJKSVJY-UHFFFAOYSA-N	Phase 1
AD-5467	aldose reductase inhibitor	AKR1B1			BRD-A80280426-001-03-8, BRD-A80280426-001-02-0	CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C, CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C	CLDJCRWXLDLJLO-UHFFFAOYSA-N, CLDJCRWXLDLJLO-UHFFFAOYSA-N	Phase 2
adapalene	retinoid receptor agonist	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	BRD-K33127281-001-05-6, BRD-K33127281-001-04-9	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O, COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	LZCDAPDGXCYOEH-UHFFFAOYSA-N, LZCDAPDGXCYOEH-UHFFFAOYSA-N	Launched
adaprev	TGF beta receptor inhibitor	IGF2R, M6PR			BRD-A73427433-240-01-3	OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O	NBSCHQHZLSJFNQ-GASJEMHNSA-N	Phase 3
adaptavir	CC chemokine receptor antagonist	CCR5			BRD-K37151368-001-01-7	C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	AKWRNBWMGFUAMF-ZESMOPTKSA-N	Phase 2
adarotene	retinoid receptor agonist	RARB, RARG			BRD-K00152668-001-01-5	OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	QAWBIEIZDDIEMW-FPYGCLRLSA-N	Phase 1
adatanserin	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR2A			BRD-K67789209-001-01-0	O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2	HPFLVTSWRFCPCV-UHFFFAOYSA-N	Phase 2
ADD-233089	benzodiazepine receptor agonist				BRD-K43055376-001-01-2	Clc1ccc(cc1)N1CC(=NC1=O)N1CCOCC1	IQHYCZKIFIHTAI-UHFFFAOYSA-N	Phase 1
adefovir	DNA polymerase inhibitor		infectious disease	hepatitis B	BRD-K77484724-001-03-8, BRD-K77484724-001-02-0	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12, Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	SUPKOOSCJHTBAH-UHFFFAOYSA-N, SUPKOOSCJHTBAH-UHFFFAOYSA-N	Launched
adefovir-dipivoxil	DNA polymerase inhibitor		infectious disease	hepatitis B	BRD-K96159438-001-06-3, BRD-K96159438-001-07-1	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	WOZSCQDILHKSGG-UHFFFAOYSA-N, WOZSCQDILHKSGG-UHFFFAOYSA-N	Launched
adelmidrol	anti-inflammatory agent				BRD-K78097265-001-01-6	OCCNC(=O)CCCCCCCC(=O)NCCO	PAHZPHDAJQIETD-UHFFFAOYSA-N	Phase 2/Phase 3
ademetionine	methyltransferase stimulant, phosphodiesterase inhibitor	AMD1, CBS, COMT, GNMT, MAT1A, MAT2A	neurology/psychiatry	depression, attention-deficit/hyperactivity disorder (ADHD)	BRD-K78185697-001-01-7	C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	MEFKEPWMEQBLKI-AIRLBKTGSA-O	Launched
adenine	protein synthesis stimulant	ACACB, ACP1, APRT, MTAP, PECR, SRPK2			BRD-K26060080-065-05-6, BRD-K26060080-001-10-1, BRD-K26060080-003-07-3, BRD-K26060080-001-11-9	Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12, Nc1ncnc2[nH]cnc12	GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N, GFFGJBXGBJISGV-UHFFFAOYSA-N	Preclinical
adenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	BRD-K01577834-001-15-1, BRD-K63038995-001-01-4	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@H]1O[C@H](CO)[C@@H](O)[C@H]1O	OIRDTQYFTABQOQ-KQYNXXCUSA-N, OIRDTQYFTABQOQ-CRKDRTNXSA-N	Launched
adenosine-phosphate	adenosine receptor agonist	ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4			BRD-A10111329-001-04-6	Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	UDMBCSSLTHHNCD-VTHZCTBJSA-N	Launched
adenosine-triphosphate	adenosine receptor agonist	ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7			BRD-A76560018-304-02-3, BRD-A31990649-304-02-3, BRD-A31990649-304-03-1	Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	ZKHQWZAMYRWXGA-VTHZCTBJSA-N, ZKHQWZAMYRWXGA-KQYNXXCUSA-N, ZKHQWZAMYRWXGA-KQYNXXCUSA-N	Phase 2
adiphenine	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	BRD-K60907894-003-23-5, BRD-K60907894-003-22-7	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1, CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	JGOAIQNSOGZNBX-UHFFFAOYSA-N, JGOAIQNSOGZNBX-UHFFFAOYSA-N	Launched
adipic-acid	solute carrier family member inhibitor	SLC22A6			BRD-K10656395-001-02-1	OC(=O)CCCCC(O)=O	WNLRTRBMVRJNCN-UHFFFAOYSA-N	Preclinical
adiporon	adiponectin receptor agonist	ADIPOR1, ADIPOR2			BRD-K68810443-001-02-7, BRD-K68810443-003-01-5, BRD-K68810443-001-01-9	O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1, O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N, SHHUPGSHGSNPDB-UHFFFAOYSA-N	Preclinical
ADL5859	opioid receptor agonist	OPRD1			BRD-K39624409-003-03-4, BRD-K39624409-003-02-6	CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12, CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12	OPIKUXLJQFYMSC-UHFFFAOYSA-N, OPIKUXLJQFYMSC-UHFFFAOYSA-N	Phase 2
adoprazine	dopamine receptor antagonist, serotonin receptor agonist	DRD2, HTR1A			BRD-K34870043-001-01-8	Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	IUVSEUFHPNITEQ-UHFFFAOYSA-N	Phase 2
adrafinil	adrenergic receptor agonist		neurology/psychiatry	fatigue	BRD-A90926615-001-02-7, BRD-A90926615-001-01-9	ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1, ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1	CGNMLOKEMNBUAI-UHFFFAOYSA-N, CGNMLOKEMNBUAI-UHFFFAOYSA-N	Launched
adrenalone	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	BRD-K82343404-003-02-4, BRD-K82343404-003-03-2	CNCC(=O)c1ccc(O)c(O)c1, CNCC(=O)c1ccc(O)c(O)c1	PZMVOUYYNKPMSI-UHFFFAOYSA-N, PZMVOUYYNKPMSI-UHFFFAOYSA-N	Launched
adrenosterone	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1, HSD11B2			BRD-K17368287-001-18-3	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O	RZRPTBIGEANTGU-IRIMSJTPSA-N	Preclinical
ADX-47273	glutamate receptor modulator	GRM5			BRD-K56543881-001-02-7	Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	VXQCCZHCFBHTTD-HNNXBMFYSA-N	Preclinical
AEE788	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR			BRD-K40718343-001-04-2, BRD-K40718343-001-02-6, BRD-K40718343-001-03-4	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1, CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N, OONFNUWBHFSNBT-HXUWFJFHSA-N	Phase 1/Phase 2
AEG3482	HSP inducer				BRD-K77634909-001-03-5	NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	MQUYTXDAVCOCMX-UHFFFAOYSA-N	Preclinical
afalanine	dopamine receptor agonist	DRD2			BRD-K53205568-001-02-6	CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	CBQJSKKFNMDLON-JTQLQIEISA-N	Phase 3
afatinib	EGFR inhibitor	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	BRD-K66175015-332-01-6, BRD-K66175015-001-09-0, BRD-K66175015-001-13-2	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N, ULXXDDBFHOBEHA-CWDCEQMOSA-N	Launched
afimoxifene	estrogen receptor antagonist	ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ			BRD-K04210847-001-21-9	CC\C(c1ccccc1)=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1	TXUZVZSFRXZGTL-QPLCGJKRSA-N	Phase 2
afloqualone	acetylcholine receptor antagonist		neurology/psychiatry	sedative	BRD-K69247067-001-01-8	Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O	VDOSWXIDETXFET-UHFFFAOYSA-N	Launched
AFN-1252	FABI inhibitor				BRD-K23791635-001-01-3	CN(Cc1oc2ccccc2c1C)C(=O)\C=C\C1=CNC2=NC(=O)CCC2=C1	QXTWSUQCXCWEHF-JXMROGBWSA-N	Phase 2
afobazole	anxiolytic		neurology/psychiatry	anxiety	BRD-K37793595-003-01-7	CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1	WWNUCVSRRUDYPP-UHFFFAOYSA-N	Launched
AF38469	sortilin inhibitor	SORT1			BRD-K47816470-001-01-8	Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1	JWCUSQCZMQIBMR-UHFFFAOYSA-N	Preclinical
AG-1024	insulin growth factor receptor inhibitor	IGF1R			BRD-K08310154-001-03-8	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O	ABBADGFSRBWENF-UHFFFAOYSA-N	Preclinical
AG-14361	PARP inhibitor	PARP1			BRD-K00615600-001-13-7, BRD-K00615600-001-12-9	CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23, CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	SEKJSSBJKFLZIT-UHFFFAOYSA-N, SEKJSSBJKFLZIT-UHFFFAOYSA-N	Preclinical
AG-490	EGFR inhibitor, JAK inhibitor	EGFR, JAK2, JAK3			BRD-K47105409-001-14-5, BRD-K47105409-001-15-2, BRD-K47105409-001-13-7	Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1, Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1, Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1	TUCIOBMMDDOEMM-RIYZIHGNSA-N, TUCIOBMMDDOEMM-RIYZIHGNSA-N, TUCIOBMMDDOEMM-RIYZIHGNSA-N	Preclinical
AG-555	tyrosine kinase inhibitor	CDK2			BRD-K34428485-001-18-4	Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O	GSQOBTOAOGXIFL-LFIBNONCSA-N	Preclinical
AG-556	tyrosine kinase inhibitor				BRD-K81048131-001-02-4	Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O	GWCNJMUSWLTSCW-SFQUDFHCSA-N	Preclinical
AGI-5198	isocitrate dehydrogenase inhibitor	IDH1			BRD-A56371469-001-03-3	Cc1nccn1CC(=O)N(C(C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1	FNYGWXSATBUBER-UHFFFAOYSA-N	Preclinical
AGI-6780	isocitrate dehydrogenase inhibitor	IDH2			BRD-K04691817-001-01-8	FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	CCAWRGNYALGPQH-UHFFFAOYSA-N	Preclinical
AGM-1470	cell cycle inhibitor	METAP2			BRD-A78111609-001-01-2	CO[C@@H]1[C@@H](CC[C@]2(CO2)C1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl	MSHZHSPISPJWHW-MIQCOGSQSA-N	Phase 2
agmatine	nitric oxide synthase inhibitor	ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH			BRD-K49738308-065-04-9	NCCCCNC(N)=N	QYPPJABKJHAVHS-UHFFFAOYSA-N	Phase 3
AGN-192403	imidazoline receptor ligand	NISCH			BRD-A79038507-003-02-3, BRD-A79038507-003-03-1	CC(C)C1C2CCC(C2)C1N, CC(C)C1C2CCC(C2)C1N	SHXVJSFOJHMEEQ-UHFFFAOYSA-N, SHXVJSFOJHMEEQ-UHFFFAOYSA-N	Preclinical
AGN-194310	retinoid receptor antagonist	RXRA, RXRB, RXRG			BRD-K70262971-001-01-9	CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O	LHUPKWKWYWOMSK-UHFFFAOYSA-N	Phase 3
AGN-195183	retinoid receptor agonist	RARA			BRD-K32533226-001-01-3	CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1	PNAWUIKCVQSLFG-UHFFFAOYSA-N	Phase 1/Phase 2
agomelatine	melatonin receptor agonist, serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B	neurology/psychiatry	depression	BRD-K84698278-001-03-4	COc1ccc2cccc(CCNC(C)=O)c2c1	YJYPHIXNFHFHND-UHFFFAOYSA-N	Launched
AGP-103	membrane permeability inhibitor				BRD-K91495480-001-02-2	CCCCCCCCCCCCCCCCCCCCCC(O)=O	UKMSUNONTOPOIO-UHFFFAOYSA-N	Launched
AH11110	adrenergic receptor ligand	ADRA1B			BRD-A64808605-003-02-7	OC(COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1	HSVZQQYIMKLNLN-UHFFFAOYSA-N	Preclinical
AH6809	prostanoid receptor antagonist	PTGDR, PTGER1, PTGER2, PTGER3			BRD-K59339270-001-02-6	CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	AQFFXPQJLZFABJ-UHFFFAOYSA-N	Preclinical
AI-10-49	core binding factor inhibitor	CBFB			BRD-K89899948-001-01-7	FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1	WJBSSBFGPKTMQQ-UHFFFAOYSA-N	Preclinical
ajmaline	sodium channel blocker	SCN5A	cardiology	Wolff-Parkinson-White Syndrome (WPW)	BRD-A48300215-001-04-8	CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O	CJDRUOGAGYHKKD-FYGXBCQKSA-N	Launched
AJ76-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4			BRD-K76677554-003-02-1	CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	YGHLYBIUVOLKCV-SMDDNHRTSA-N	Preclinical
AKBA	lipoxygenase inhibitor	ALOX5			BRD-K54907283-001-01-2	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C	HMMGKOVEOFBCAU-BCDBGHSCSA-N	Phase 3
aklomide			infectious disease	coccidiosis	BRD-K26807903-001-04-3	NC(=O)c1ccc(cc1Cl)[N+]([O-])=O	GFGSZUNNBQXGMK-UHFFFAOYSA-N	Launched
alacepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-K51784806-001-01-6	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	FHHHOYXPRDYHEZ-COXVUDFISA-N	Launched
alafosfalin	bacterial cell wall synthesis inhibitor				BRD-K80403280-001-02-1	C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O	BHAYDBSYOBONRV-IUYQGCFVSA-N	Phase 1
alagebrium	glycosylation inhibitor				BRD-K96029467-003-01-9	Cc1sc[n+](CC(=O)c2ccccc2)c1C	LYLFQLCLUXOFOL-UHFFFAOYSA-N	Phase 2/Phase 3
alanine		AARS, AARS2, ABAT, AGXT, AGXT2, GPRC6A, GPT, GPT2, KYNU, NFS1, PHYKPL, SLC1A4, SLC36A1, SLC7A8			BRD-A33317514-001-01-3	CC(N)C(O)=O	QNAYBMKLOCPYGJ-UHFFFAOYSA-N	Launched
alaproclate	serotonin receptor antagonist	SLC6A4			BRD-A14966924-003-07-7	CC(N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1	FZSPJBYOKQPKCD-UHFFFAOYSA-N	Phase 2
alarelin	gonadotropin releasing factor hormone receptor antagonist	GNRH1			BRD-K42140276-402-01-4	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	QLGKMLRGKPKGKI-QWQCQAQZSA-N	Launched
albendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	BRD-K79131256-001-17-9, BRD-K79131256-001-18-7	CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1, CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1	HXHWSAZORRCQMX-UHFFFAOYSA-N, HXHWSAZORRCQMX-UHFFFAOYSA-N	Launched
albendazole-oxide	anthelmintic agent		infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	BRD-A67060370-001-02-9	CCCS(=O)c1ccc2nc(NC(=O)OC)[nH]c2c1	VXTGHWHFYNYFFV-UHFFFAOYSA-N	Launched
albuterol	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	BRD-A88254928-001-07-9, BRD-A88254928-065-04-1	CC(C)(C)NCC(O)c1ccc(O)c(CO)c1, CC(C)(C)NCC(O)c1ccc(O)c(CO)c1	NDAUXUAQIAJITI-UHFFFAOYSA-N, NDAUXUAQIAJITI-UHFFFAOYSA-N	Launched
alcaftadine	histamine receptor antagonist	HRH1	allergy	allergic conjunctivitis	BRD-K55991142-001-01-6	CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12	MWTBKTRZPHJQLH-UHFFFAOYSA-N	Launched
alclofenac	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis	BRD-K47492008-001-02-7	OC(=O)Cc1ccc(OCC=C)c(Cl)c1	ARHWPKZXBHOEEE-UHFFFAOYSA-N	Launched
alclometasone-dipropionate	glucocorticoid receptor agonist	CYP3A4, NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	BRD-A17407635-001-04-0	CCC(=O)OCC(=O)C1(OC(=O)CC)[C@H](C)C[C@H]2C3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	DJHCCTTVDRAMEH-VBIVFILRSA-N	Launched
alcuronium	muscle relaxant	CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7	neurology/psychiatry	muscle relaxant	BRD-A84907376-300-03-8	OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2C5[C@]6(CC[N@@+]7(CC=C)C\C(=C/CO)[C@H](C[C@@H]67)\C5=C\N(C31)c1ccccc41)c1ccccc21	MUQUYTSLDVKIOF-CNCPGNHZSA-N	Launched
aldoxorubicin	topoisomerase inhibitor	TOP2A			BRD-K68928792-001-01-6, BRD-K68928792-001-02-4	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O	OBMJQRLIQQTJLR-USGQOSEYSA-N, OBMJQRLIQQTJLR-USGQOSEYSA-N	Phase 3
alectinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	BRD-K11267252-001-04-4, BRD-K11267252-001-06-9	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	KDGFLJKFZUIJMX-UHFFFAOYSA-N, KDGFLJKFZUIJMX-UHFFFAOYSA-N	Launched
alendronate	bone resorption inhibitor	ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS	orthopedics	osteoporosis	BRD-K75527158-360-06-4, BRD-K75527158-360-05-6, BRD-K75527158-360-04-9	NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCCC(O)(P(O)(O)=O)P(O)(O)=O	OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N, OGSPWJRAVKPPFI-UHFFFAOYSA-N	Launched
alexidine	phosphatidylglycerophosphatase inhibitor	PTPMT1			BRD-A27883417-300-01-6	CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC	LFVVNPBBFUSSHL-UHFFFAOYSA-N	Preclinical
alfacalcidol	vitamin D receptor agonist	CYP27B1, VDR	endocrinology	vitamin D deficiency	BRD-K92644009-001-02-6, BRD-K84280765-001-01-5	CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C\C=C1/C[C@@H](O)C[C@H](O)C1=C, CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	OFHCOWSQAMBJIW-GITLSTMWSA-N, OFHCOWSQAMBJIW-QLSRQBPNSA-N	Launched
alfadolone-acetate	benzodiazepine receptor agonist				BRD-K51751936-001-09-1	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	QRJOQYLXZPQQMX-FWROMSNXSA-N	Phase 2
alfaxalone	chloride channel agonist, benzodiazepine receptor agonist	GABBR1	neurology/psychiatry	general anaesthetic	BRD-K41445866-001-18-8	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	DUHUCHOQIDJXAT-OLVMNOGESA-N	Launched
alfuzosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, KCNH2	urology	benign prostatic hyperplasia (BPH)	BRD-A09056319-003-07-7, BRD-A09056319-003-08-5	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1, COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1	WNMJYKCGWZFFKR-UHFFFAOYSA-N, WNMJYKCGWZFFKR-UHFFFAOYSA-N	Launched
algestone-acetophenide			endocrinology	contraceptive	BRD-A41774846-001-01-4	CC(=O)[C@@]12OC(C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1	AHBKIEXBQNRDNL-BXXPAUNWSA-N	Launched
alibendol	antispasmodic		gastroenterology	bile stimulation	BRD-K60102752-001-02-2	COc1cc(CC=C)cc(C(=O)NCCO)c1O	UMJHTFHIQDEGKB-UHFFFAOYSA-N	Launched
alimemazine	histamine receptor agonist	HRH1	neurology/psychiatry	sedative	BRD-A49225603-045-10-0	CC(CN(C)C)CN1c2ccccc2Sc2ccccc12	ZZHLYYDVIOPZBE-UHFFFAOYSA-N	Launched
alisertib	Aurora kinase inhibitor	AURKA			BRD-K75295174-001-05-0	COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O	ZLHFILGSQDJULK-UHFFFAOYSA-N	Phase 3
aliskiren-hemifumarate	renin inhibitor	REN	cardiology	hypertension	BRD-K30020243-051-02-5, BRD-K30020243-051-03-3	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC, COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	UXOWGYHJODZGMF-QORCZRPOSA-N, UXOWGYHJODZGMF-QORCZRPOSA-N	Launched
alizapride	dopamine receptor antagonist	DRD2	gastroenterology	nausea	BRD-A03061970-003-07-3	COc1cc2[nH]nnc2cc1C(=O)NCC1CCCN1CC=C	KSEYRUGYKHXGFW-UHFFFAOYSA-N	Launched
alizarin					BRD-K73191876-001-12-0, BRD-K73191876-001-11-2	Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O, Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	RGCKGOZRHPZPFP-UHFFFAOYSA-N, RGCKGOZRHPZPFP-UHFFFAOYSA-N	Preclinical
allantoin	cosmetic		dermatology	skin protectant	BRD-A96407378-001-15-1	NC(=O)NC1NC(=O)NC1=O	POJWUDADGALRAB-UHFFFAOYSA-N	Launched
allicin	cytokine production inhibitor	TRPA1, TRPV1			BRD-A60402836-001-01-0	C=CCSS(=O)CC=C	JDLKFOPOAOFWQN-UHFFFAOYSA-N	Phase 2
allopurinol	xanthine oxidase inhibitor	XDH	rheumatology, urology	gout, kidney stones	BRD-K86307448-001-19-1, BRD-K86307448-001-17-5, BRD-K86307448-001-16-7	O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12, O=c1[nH]cnc2[nH]ncc12	OFCNXPDARWKPPY-UHFFFAOYSA-N, OFCNXPDARWKPPY-UHFFFAOYSA-N, OFCNXPDARWKPPY-UHFFFAOYSA-N	Launched
allopurinol-riboside	anti-leishmanial agent				BRD-A93407926-001-01-1	OC[C@H]1O[C@H](C(O)[C@H]1O)n1[nH]cc2c1ncnc2=O	UKNHQPDCWMADJW-VTUMKUEMSA-N	Phase 2
allylestrenol	steroidal progestin	ESR1, PGR, SLC6A9	obstetrics/gynecology	premature labor	BRD-K12872829-001-01-0	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C	ATXHVCQZZJYMCF-XUDSTZEESA-N	Launched
allylisothiocyanate	TRPV agonist	TRPA1			BRD-K33219225-001-01-9	C=CCN=C=S	ZOJBYZNEUISWFT-UHFFFAOYSA-N	Preclinical
allylthiourea	nitrification inhibitor				BRD-K89634775-001-09-9, BRD-K89634775-001-08-1	NC(S)=NCC=C, NC(S)=NCC=C	HTKFORQRBXIQHD-UHFFFAOYSA-N, HTKFORQRBXIQHD-UHFFFAOYSA-N	Preclinical
almitrine	neurotransmitter agonist	ATP1A1	pulmonary	chronic obstructive pulmonary disease (COPD)	BRD-K82677201-001-01-6	Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1	OBDOVFRMEYHSQB-UHFFFAOYSA-N	Launched
almorexant	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K84810405-003-01-1	CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	DKMACHNQISHMDN-RPLLCQBOSA-N	Phase 3
almotriptan	serotonin receptor agonist	HTR1B, HTR1D	neurology/psychiatry	migraine headache	BRD-K67601717-037-02-4, BRD-K67601717-001-03-8	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12, CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	WKEMJKQOLOHJLZ-UHFFFAOYSA-N, WKEMJKQOLOHJLZ-UHFFFAOYSA-N	Launched
aloe-emodin	anticancer agent	CASP8			BRD-K04851519-001-06-8	OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	YDQWDHRMZQUTBA-UHFFFAOYSA-N	Preclinical
alogliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K83003151-001-03-0, BRD-K83003151-001-02-2, BRD-A27084604-057-01-0	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O, Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O	ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ZSBOMTDTBDDKMP-OAHLLOKOSA-N, ZSBOMTDTBDDKMP-UHFFFAOYSA-N	Launched
aloin	angiogenesis inhibitor				BRD-A63615100-001-03-9, BRD-A63615100-001-02-1, BRD-K02074536-001-01-9	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12, OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	AFHJQYHRLPMKHU-CGISPIQUSA-N, AFHJQYHRLPMKHU-CGISPIQUSA-N, AFHJQYHRLPMKHU-OSYMLPPYSA-N	Preclinical
aloperine					BRD-K96391852-001-02-8	C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1	SKOLRLSBMUGVOY-GBJTYRQASA-N	Preclinical
alosetron	serotonin receptor antagonist	HTR3A			BRD-K46742498-003-11-0	Cc1[nH]cnc1CN1CCc2c(C1=O)c1ccccc1n2C	JSWZEAMFRNKZNL-UHFFFAOYSA-N	Withdrawn
aloxistatin	protease inhibitor	CTSG			BRD-K91188791-001-14-2, BRD-K91188791-001-15-9, BRD-A12987505-001-01-9	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C, CCOC(=O)C1OC1C(=O)NC(CC(C)C)C(=O)NCCC(C)C	SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-IHRRRGAJSA-N, SRVFFFJZQVENJC-UHFFFAOYSA-N	Phase 3
alpelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K54997624-001-06-0	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	STUWGJZDJHPWGZ-LBPRGKRZSA-N	Phase 3
alpha-Asarone	cytochrome P450 inhibitor, HMGCR inhibitor	HMGCR			BRD-K72536715-001-01-5	COc1cc(OC)c(\C=C\C)cc1OC	RKFAZBXYICVSKP-AATRIKPKSA-N	Preclinical
alpha-D-glucopyranose					BRD-K87424134-001-01-0	OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	WQZGKKKJIJFFOK-DVKNGEFBSA-N	Preclinical
alpha-linolenic-acid	omega 3 fatty acid stimulant	ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1			BRD-K33396764-001-08-7, BRD-K33396764-001-11-1	CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O, CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	DTOSIQBPPRVQHS-PDBXOOCHSA-N, DTOSIQBPPRVQHS-PDBXOOCHSA-N	Phase 3
alpha-methylhistamine-dihydrobromide-(R)-(-)	histamine receptor agonist	HRH3			BRD-K80028314-303-02-6	C[C@@H](N)Cc1c[nH]cn1	XNQIOISZPFVUFG-RXMQYKEDSA-N	Preclinical
alpha-methylhistamine-dihydrobromide-(S)-(+)	histamine receptor agonist	HRH3			BRD-K28308851-303-01-8	C[C@H](N)Cc1c[nH]cn1	XNQIOISZPFVUFG-YFKPBYRVSA-N	Preclinical
alpha-methylserotonin	serotonin receptor agonist	HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4			BRD-A17745711-050-05-4	CC(N)Cc1c[nH]c2ccc(O)cc12	LYPCGXKCQDYTFV-UHFFFAOYSA-N	Preclinical
alpha-tochopherol	antioxidant		endocrinology	vitamin E deficiency	BRD-A82892199-001-04-1	CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(O)c(C)c(C)c2O1	GVJHHUAWPYXKBD-UHFFFAOYSA-N	Launched
alpha-tochopheryl-acetate	antioxidant		endocrinology	vitamin E deficiency	BRD-A61850409-001-10-7	CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1	ZAKOWWREFLAJOT-UHFFFAOYSA-N	Launched
alpidem	benzodiazepine receptor agonist	GABRA1			BRD-K66896751-001-02-4	CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1	JRTIDHTUMYMPRU-UHFFFAOYSA-N	Withdrawn
alprenolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A	cardiology	angina pectoris	BRD-A00993607-003-24-6	CC(C)NCC(O)COc1ccccc1CC=C	PAZJSJFMUHDSTF-UHFFFAOYSA-N	Launched
alprostadil	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR	cardiology	congenital heart defects	BRD-K52459643-001-15-1, BRD-K73691377-001-01-6	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](O)CC(=O)[C@H]1CCCCCCC(O)=O	GMVPRGQOIOIIMI-DWKJAMRDSA-N, GMVPRGQOIOIIMI-AIJKCLAYSA-N	Launched
alrestatin	aldose reductase inhibitor	AKR1B1			BRD-K35498378-001-06-1, BRD-K35498378-001-07-9	OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	GCUCIFQCGJIRNT-UHFFFAOYSA-N, GCUCIFQCGJIRNT-UHFFFAOYSA-N	Preclinical
ALS-8176	RNA polymerase inhibitor				BRD-K21415491-001-01-4	Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1	AWSRKKBIPSQHOJ-IBCQBUCCSA-N	Phase 1
altanserin	serotonin receptor antagonist	HTR2A			BRD-K00610438-003-02-5	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	SMYALUSCZJXWHG-UHFFFAOYSA-N	Phase 2
althiazide	diuretic		cardiology	hypertension	BRD-A56675431-001-12-3	NS(=O)(=O)c1cc2c(NC(CSCC=C)NS2(=O)=O)cc1Cl	VGLGVJVUHYTIIU-UHFFFAOYSA-N	Launched
altinicline	nicotinic receptor agonist	CHRNA4, CHRNB2			BRD-K52681925-050-01-6	CN1CCC[C@H]1c1cncc(c1)C#C	NUPUDYKEEJNZRG-LBPRGKRZSA-N	Phase 2
altiratinib	VEGFR inhibitor, MET inhibitor	KDR, MET, TEK			BRD-K78627070-001-01-5	Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1	GNNDEPIMDAZHRQ-UHFFFAOYSA-N	Phase 1
altrenogest	progestogen hormone	PGR	endocrinology	estrus	BRD-K14619660-001-01-5, BRD-A27554692-001-02-1	C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(O)CC=C, C[C@]12C=CC3=C4CCC(=O)C=C4CCC3C1CC[C@@]2(O)CC=C	VWAUPFMBXBWEQY-IVAOSVALSA-N, VWAUPFMBXBWEQY-JSRAGOMMSA-N	Launched
altretamine	DNA synthesis inhibitor		oncology	ovarian cancer	BRD-K67043667-001-26-4, BRD-K67043667-001-25-6	CN(C)c1nc(nc(n1)N(C)C)N(C)C, CN(C)c1nc(nc(n1)N(C)C)N(C)C	UUVWYPNAQBNQJQ-UHFFFAOYSA-N, UUVWYPNAQBNQJQ-UHFFFAOYSA-N	Launched
alverine	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome, diverticular disease	BRD-K89055274-048-22-7, BRD-K89055274-048-23-5	CCN(CCCc1ccccc1)CCCc1ccccc1, CCN(CCCc1ccccc1)CCCc1ccccc1	ZPFXAOWNKLFJDN-UHFFFAOYSA-N, ZPFXAOWNKLFJDN-UHFFFAOYSA-N	Launched
alvespimycin	HSP inhibitor	HSP90AA1			BRD-K83988098-003-03-4, BRD-K23499943-003-01-6	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C/C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O	KUFRQPKVAWMTJO-LMZWQJSESA-N, KUFRQPKVAWMTJO-TYVPZVKISA-N	Phase 2
alvimopan	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	postoperative ileus	BRD-K07857022-002-01-1	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	UPNUIXSCZBYVBB-JVFUWBCBSA-N	Launched
alvocidib	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM			BRD-K87909389-003-04-2, BRD-K87909389-003-03-4	CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	BIIVYFLTOXDAOV-YVEFUNNKSA-N, BIIVYFLTOXDAOV-YVEFUNNKSA-N	Phase 2
ALX-5407	Glycine transporter 1 inhibitor	SLC6A9			BRD-K53979406-003-02-8	CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	FDORQEIHOKEJNX-HSZRJFAPSA-N	Phase 1
AM-1241	cannabinoid receptor agonist	CNR1, CNR2			BRD-A66116161-001-02-3	CN1CCCCC1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12	ZUHIXXCLLBMBDW-UHFFFAOYSA-N	Preclinical
AM-24	lipoxygenase inhibitor	ALOX5			BRD-K59013864-001-01-1	Oc1c(I)cc(I)cc1I	VAPDZNUFNKUROY-UHFFFAOYSA-N	Phase 2
AM-251	cannabinoid receptor antagonist	CNR1, GPR18, GPR55			BRD-K92000912-001-12-6, BRD-K92000912-001-11-8	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1, Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	BUZAJRPLUGXRAB-UHFFFAOYSA-N, BUZAJRPLUGXRAB-UHFFFAOYSA-N	Preclinical
AM-281	cannabinoid receptor antagonist	CNR1, CNR2, GPR55			BRD-K59419204-001-02-7	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	AJFFBPZYXRNAIC-UHFFFAOYSA-N	Preclinical
AM-404	cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist	CNR1, CNR2, FAAH, TRPV1			BRD-K55462201-001-07-3	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	IJBZOOZRAXHERC-DOFZRALJSA-N	Preclinical
AM-580	retinoid receptor agonist	RARA			BRD-K06854232-001-19-9	CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	SZWKGOZKRMMLAJ-UHFFFAOYSA-N	Preclinical
AM-630	cannabinoid receptor antagonist	CNR1, CNR2			BRD-K63533170-001-02-9	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	JHOTYHDSLIUKCJ-UHFFFAOYSA-N	Preclinical
AM-92016	potassium channel blocker	GRIN1			BRD-A11813248-003-02-4	CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1	BQBSHJUQVIWEFM-UHFFFAOYSA-N	Preclinical
amantadine	glutamate receptor antagonist	DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A	infectious disease, neurology/psychiatry	influenza A virus infection, Parkinsons Disease" "BRD-K70330367-003-07-9, BRD-K70330367-003-08-7" "NC12CC3CC(CC(C3)C1)C2, NC12CC3CC(CC(C3)C1)C2" "DKNWSYNQZKUICI-UHFFFAOYSA-N, DKNWSYNQZKUICI-UHFFFAOYSA-N" "Launched" "" "" ""
"29" "ambazone" "DNA damage inducer" "" "" "" "BRD-K11244467-002-01-8, BRD-K11244467-001-08-5" "NC(=N)N=Nc1ccc(NNC(S)=N)cc1, NC(=N)N=Nc1ccc(NNC(S)=N)cc1" "HQDSAVMTLKVTGJ-UHFFFAOYSA-N, HQDSAVMTLKVTGJ-UHFFFAOYSA-N" "Phase 1"
"30" "ambenonium" "cholinesterase inhibitor" "ACHE" "neurology/psychiatry" "myasthenia gravis" "BRD-K11292736-300-02-8" "CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl" "OMHBPUNFVFNHJK-UHFFFAOYSA-P" "Launched"
"31" "ambrisentan" "endothelin receptor antagonist" "EDNRA, EDNRB" "pulmonary" "pulmonary arterial hypertension (PAH)" "BRD-K41185545-001-02-3" "COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1" "OUJTZYPIHDYQMC-LJQANCHMSA-N" "Launched"
"32" "ambroxol" "sodium channel blocker" "CYP3A4" "pulmonary" "bronchitis" "BRD-K56558538-003-11-9, BRD-K56558538-003-12-7, BRD-K11223672-003-05-2" "Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1, Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1, Nc1c(Br)cc(Br)cc1CNC1CCC(O)CC1" "JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-XYPYZODXSA-N, JBDGDEWWOUBZPM-UHFFFAOYSA-N" "Launched"
"33" "amcinonide" "glucocorticoid receptor agonist" "ANXA1, NR3C1" "dermatology" "corticosteroid-responsive dermatoses" "BRD-A36010170-001-04-0" "CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1CC1C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C" "ILKJAFIWWBXGDU-ZYDCGBIBSA-N" "Launched"
"34" "amdinocillin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "urinary tract infections, gram-negative bacterial infections" "BRD-K41051431-001-02-4" "CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O" "BWWVAEOLVKTZFQ-ISVUSNJMSA-N" "Launched"
"35" "AMD11070" "CC chemokine receptor antagonist" "CXCR4" "" "" "BRD-K42948882-305-01-1" "NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12" "WVLHHLRVNDMIAR-IBGZPJMESA-N" "Phase 1/Phase 2"
"36" "ameltolide" "anticonvulsant" "" "" "" "BRD-K48173020-001-01-8" "Cc1cccc(C)c1NC(=O)c1ccc(N)cc1" "HZIWGOAXOBPQGY-UHFFFAOYSA-N" "Preclinical"
"37" "amezinium" "adrenergic receptor agonist" "ADRB2" "" "" "BRD-K51387999-067-01-6" "COc1cc(N)cn[n+]1-c1ccccc1" "VXROHTDSRBRJLN-UHFFFAOYSA-O" "Launched"
"38" "amfenac" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "neurology/psychiatry" "pain relief" "BRD-K82122102-323-01-1" "Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1" "SOYCMDCMZDHQFP-UHFFFAOYSA-N" "Launched"
"39" "amfepramone" "adrenergic receptor agonist" "SLC6A2, SLC6A3" "endocrinology" "obesity" "BRD-A37288617-003-02-2" "CCN(CC)C(C)C(=O)c1ccccc1" "XXEPPPIWZFICOJ-UHFFFAOYSA-N" "Launched"
"40" "amflutizole" "xanthine oxidase inhibitor" "XDH" "" "" "BRD-K50813454-001-01-9" "Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O" "KVMCEGAWQYTFKC-UHFFFAOYSA-N" "Phase 2"
"41" "AMG-208" "tyrosine kinase inhibitor" "MET" "" "" "BRD-K32285926-001-02-1" "COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1" "HEAIZQNMNCHNFD-UHFFFAOYSA-N" "Phase 1"
"42" "AMG-232" "MDM inhibitor" "MDM2" "" "" "BRD-K64925568-001-01-8" "CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1" "DRLCSJFKKILATL-YWCVFVGNSA-N" "Phase 1/Phase 2"
"43" "AMG-319" "PI3K inhibitor" "PIK3CD" "" "" "BRD-K21077415-001-01-5" "C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1" "KWRYMZHCQIOOEB-LBPRGKRZSA-N" "Phase 2"
"44" "AMG-337" "MET inhibitor" "MET" "" "" "BRD-K27061362-001-01-6" "COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1" "DWHXUGDWKAIASB-CQSZACIVSA-N" "Phase 2"
"45" "AMG-487" "CC chemokine receptor antagonist" "CXCR3" "" "" "BRD-K90239174-001-01-8" "CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1" "WQTKNBPCJKRYPA-OAQYLSRUSA-N" "Phase 2"
"46" "AMG-517" "TRPV antagonist" "TRPV1" "" "" "BRD-K34185671-001-02-8" "CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1" "YUTIXVXZQIQWGY-UHFFFAOYSA-N" "Phase 1"
"47" "AMG-548" "MAP kinase inhibitor" "MAPK11, MAPK12, MAPK13, MAPK14" "" "" "BRD-K86673452-001-01-7, BRD-K86673452-001-02-5" "Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O, Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O" "RQVKVJIRFKVPBF-VWLOTQADSA-N, RQVKVJIRFKVPBF-VWLOTQADSA-N" "Phase 1"
"48" "AMG-837" "free fatty acid receptor agonist" "FFAR1" "" "" "BRD-K43802723-340-01-9" "CC" "" ""
"49" "AMG-925" "CDK inhibitor, FLT3 inhibitor" "CDK4, CDK6, FLT3" "" "" "BRD-K97452254-001-01-3" "C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12" "BBUVDDPUURMFOX-SAABIXHNSA-N" "Phase 1"
"50" "AMG-9810" "TRPV antagonist" "TRPV1" "" "" "BRD-K01995783-001-01-6" "CC(C)(C)c1ccc(cc1)\C=C\C(=O)Nc1ccc2OCCOc2c1" "GZTFUVZVLYUPRG-IZZDOVSWSA-N" "Preclinical"
"51" "AMG319" "PI3K inhibitor" "PIK3CD" "" "" "BRD-A58947127-001-01-6" "CC(Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1" "KWRYMZHCQIOOEB-UHFFFAOYSA-N" "Phase 2"
"52" "AMG458" "MET inhibitor" "MET" "" "" "BRD-K21782625-001-03-2, BRD-K21782625-001-02-4" "COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1, COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1" "GLBZSOQDAOLMGC-UHFFFAOYSA-N, GLBZSOQDAOLMGC-UHFFFAOYSA-N" "Preclinical"
"53" "AMG900" "Aurora kinase inhibitor" "AURKA, AURKB, AURKC" "" "" "BRD-K21728777-001-02-3" "Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12" "IVUGFMLRJOCGAS-UHFFFAOYSA-N" "Phase 1"
"54" "AMI-1" "protein arginine N-methyltransferase inhibitor" "PRMT1" "" "" "BRD-K75114721-304-02-6" "Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O" "PCGISRHGYLRXSR-UHFFFAOYSA-N" "Preclinical"
"55" "amibegron" "adrenergic receptor agonist" "ADRB3" "" "" "BRD-K24610819-003-01-8" "CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1" "RDJQCOBTKKAQAH-FPOVZHCZSA-N" "Phase 3"
"56" "amidopyrine" "analgesic agent" "" "dermatology" "dermatitis herpetiformis (DH)" "BRD-K12568846-001-16-1, BRD-K12568846-001-14-6, BRD-K12568846-001-15-3" "CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O, CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O" "RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N, RMMXTBMQSGEXHJ-UHFFFAOYSA-N" "Launched"
"57" "amifampridine" "potassium channel blocker" "" "neurology/psychiatry" "Lambert-Eaton myasthenic syndrome (LEMS)" "BRD-K80262108-001-07-0" "Nc1ccncc1N" "OYTKINVCDFNREN-UHFFFAOYSA-N" "Launched"
"58" "amiflamine" "monoamine oxidase inhibitor" "MAOA, SLC6A2" "" "" "BRD-A19401019-001-01-3" "CC(N)Cc1ccc(cc1C)N(C)C" "HFQMYSHATTXRTC-UHFFFAOYSA-N" "Phase 1"
"59" "amifostine" "reducing agent" "ALPPL2, ENPP1" "nephrology" "renal toxicity" "BRD-K73947551-001-04-4" "NCCCNCCSP(O)(O)=O" "JKOQGQFVAUAYPM-UHFFFAOYSA-N" "Launched"
"60" "amikacin" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-A30051119-002-01-8, BRD-A01603276-001-02-0, BRD-K50698959-315-01-8, BRD-A01603276-001-01-2, BRD-K88043978-315-02-8" "NCC[C@@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)C1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1OC1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1OC1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O" "LKCWBDHBTVXHDL-CJMFXXNZSA-N, LKCWBDHBTVXHDL-MRUMTBQISA-N, LKCWBDHBTVXHDL-OFRZPCDPSA-N, LKCWBDHBTVXHDL-MRUMTBQISA-N, LKCWBDHBTVXHDL-RMDFUYIESA-N" "Launched"
"61" "amiloride" "sodium channel blocker" "AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2" "cardiology" "hypertension, congestive heart failure" "BRD-K97181089-003-24-7, BRD-K97181089-310-06-3, BRD-K97181089-003-22-1, BRD-K97181089-003-23-9" "NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N, NC(=N)NC(=O)c1nc(Cl)c(N)nc1N" "XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N, XSDQTOBWRPYKKA-UHFFFAOYSA-N" "Launched"
"62" "amineptine" "dopamine receptor agonist" "SLC6A2, SLC6A4" "" "" "BRD-K24219278-001-01-6" "OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12" "ONNOFKFOZAJDHT-UHFFFAOYSA-N" "Withdrawn"
"63" "aminocaproic-acid" "plasminogen activator inhibitor" "LPA, PLAT, PLG" "hematology" "fibrinolytic bleeding" "BRD-K64931368-003-01-4, BRD-K64931368-001-13-3, BRD-K64931368-001-14-1" "NCCCCCC(O)=O, NCCCCCC(O)=O, NCCCCCC(O)=O" "SLXKOJJOQWFEFD-UHFFFAOYSA-N, SLXKOJJOQWFEFD-UHFFFAOYSA-N, SLXKOJJOQWFEFD-UHFFFAOYSA-N" "Launched"
"64" "aminoglutethimide" "glucocorticoid receptor antagonist" "CYP11A1, CYP19A1" "endocrinology, oncology" "Cushings syndrome, breast cancer	BRD-A25234499-001-18-3, BRD-A25234499-001-19-1, BRD-A25234499-001-17-5	CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1	ROBVIMPUHSLWNV-UHFFFAOYSA-N, ROBVIMPUHSLWNV-UHFFFAOYSA-N, ROBVIMPUHSLWNV-UHFFFAOYSA-N	Launched
aminoguanidine	nitric oxide synthase inhibitor	NOS2			BRD-K25114078-003-08-1, BRD-K25114078-003-07-3	NNC(N)=N, NNC(N)=N	HAMNKKUPIHEESI-UHFFFAOYSA-N, HAMNKKUPIHEESI-UHFFFAOYSA-N	Phase 3
aminohydroxybutyric-acid			neurology/psychiatry	epilepsy	BRD-A40777960-001-04-2	NCC(O)CC(O)=O	YQGDEPYYFWUPGO-UHFFFAOYSA-N	Launched
aminolevulinic-acid-benzyl-ester					BRD-K59998349-003-01-4	NCC(=O)CCC(=O)OCc1ccccc1	AFFZCQDLQIEQGB-UHFFFAOYSA-N	Phase 1
aminomethyltransferase	nitric oxide synthase inhibitor	NOS2			BRD-A28318179-003-08-5	CC1CCN=C(N)S1	BATVOUKHGLKDGQ-UHFFFAOYSA-N	Preclinical
aminopentamide	acetylcholine receptor antagonist	CHRM1	gastroenterology	acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea	BRD-A69917777-065-02-2	CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C	NARHAGIVSFTMIG-UHFFFAOYSA-N	Launched
aminophylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma, bronchitis, emphysema	BRD-K97799481-205-02-7, BRD-K97799481-230-01-7	Cn1c2nc[nH]c2c(=O)n(C)c1=O, Cn1c2nc[nH]c2c(=O)n(C)c1=O	ZFXYFBGIUFBOJW-UHFFFAOYSA-N, ZFXYFBGIUFBOJW-UHFFFAOYSA-N	Launched
aminopterin	dihydrofolate reductase inhibitor	DHFR, SLC46A1			BRD-A86736466-001-05-9, BRD-K87544030-001-01-0	Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)cnc2n1, Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	TVZGACDUOSZQKY-UHFFFAOYSA-N, TVZGACDUOSZQKY-LBPRGKRZSA-N	Phase 3
aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	CDK1, CDK2, CDK5, CDK6			BRD-K07762753-001-04-4, BRD-K07762753-001-05-1	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	RAMROQQYRRQPDL-HNNXBMFYSA-N, RAMROQQYRRQPDL-HNNXBMFYSA-N	Preclinical
aminosalicylate	cyclooxygenase inhibitor	ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2	gastroenterology	inflammatory bowel disease, ulcerative colitis	BRD-K80267133-001-19-3, BRD-K80267133-001-17-7, BRD-K80267133-001-18-5	Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1, Nc1ccc(C(O)=O)c(O)c1	WUBBRNOQWQTFEX-UHFFFAOYSA-N, WUBBRNOQWQTFEX-UHFFFAOYSA-N, WUBBRNOQWQTFEX-UHFFFAOYSA-N	Launched
aminothiadiazole	inosine monophosphate dehydrogenase inhibitor	ADORA3, IMPDH1			BRD-K94837153-001-02-8, BRD-K94837153-001-01-0	Nc1nncs1, Nc1nncs1	QUKGLNCXGVWCJX-UHFFFAOYSA-N, QUKGLNCXGVWCJX-UHFFFAOYSA-N	Phase 2
aminothiazole	cyclin D inhibitor	NOS2			BRD-K13421763-001-06-2, BRD-K13421763-001-05-4, BRD-K13421763-001-07-0	Nc1nccs1, Nc1nccs1, Nc1nccs1	RAIPHJJURHTUIC-UHFFFAOYSA-N, RAIPHJJURHTUIC-UHFFFAOYSA-N, RAIPHJJURHTUIC-UHFFFAOYSA-N	Preclinical
amiodarone	potassium channel blocker	ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2	cardiology	ventricular arrhythmias	BRD-K17561142-003-35-8, BRD-K17561142-003-32-5, BRD-K17561142-003-33-3	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1, CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N, IYIKLHRQXLHMJQ-UHFFFAOYSA-N	Launched
amiprilose	CD antagonist				BRD-K97643133-003-09-3	CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	YXBQLONCIPUQKO-UJPOAAIJSA-N	Phase 3
amisulpride	dopamine receptor antagonist	DRD2, DRD3, HTR2A, HTR7	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	BRD-A60197193-001-14-6, BRD-A60197193-001-13-8	CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC, CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC	NTJOBXMMWNYJFB-UHFFFAOYSA-N, NTJOBXMMWNYJFB-UHFFFAOYSA-N	Launched
amitifadine	serotonin transporter (SERT) inhibitor	SLC6A2, SLC6A3, SLC6A4			BRD-A68942014-003-01-7	Clc1ccc(cc1Cl)C12CC1CNC2	BSMNRYCSBFHEMQ-UHFFFAOYSA-N	Phase 3
amitraz	adrenergic receptor agonist	ADRA1A, ADRA2A	infectious disease	generalized demodicosis	BRD-K33335792-001-04-0	CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C	QXAITBQSYVNQDR-ZIOPAAQOSA-N	Launched
amitriptyline	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin–norepinephrine reuptake inhibitor (SNRI)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K53737926-003-27-8, BRD-K53737926-003-25-2	CN(C)CCC=C1c2ccccc2CCc2ccccc12, CN(C)CCC=C1c2ccccc2CCc2ccccc12	KRMDCWKBEZIMAB-UHFFFAOYSA-N, KRMDCWKBEZIMAB-UHFFFAOYSA-N	Launched
amlexanox	histamine receptor modulator	FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13	dental, pulmonary, ophthalmology, allergy	aphthous ulcers, asthma, conjunctivitis, allergic rhinitis	BRD-K29530284-001-06-2, BRD-K29530284-001-07-0	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O, CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	SGRYPYWGNKJSDL-UHFFFAOYSA-N, SGRYPYWGNKJSDL-UHFFFAOYSA-N	Launched
amlodipine	calcium channel blocker	CA1, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1, CACNA2D3, CACNB1, CACNB2, SMPD1	cardiology	hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)	BRD-A22032524-074-06-5, BRD-A22032524-074-07-3, BRD-A22032524-074-09-9, BRD-A22032524-001-05-0, BRD-A22032524-001-03-5	CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC	HTIQEAQVCYTUBX-UHFFFAOYSA-N, HTIQEAQVCYTUBX-UHFFFAOYSA-N, HTIQEAQVCYTUBX-UHFFFAOYSA-N, HTIQEAQVCYTUBX-UHFFFAOYSA-N, HTIQEAQVCYTUBX-UHFFFAOYSA-N	Launched
ammonium-glycyrrhizinate	thrombin inhibitor	HSD11B1, HSD11B2, SLCO1B1, SLCO1B3	dermatology	cosmetic	BRD-K15318383-201-01-5, BRD-K70038931-001-01-2	C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)[C@@H]3[C@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O, C[C@]12CC[C@@](C)(C[C@@H]1C1=CC(=O)[C@H]3[C@@]4(C)CC[C@H](O[C@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@@H]5O)C(O)=O)C(O)=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O	LPLVUJXQOOQHMX-FKSWRZCVSA-N, LPLVUJXQOOQHMX-OFONILRHSA-N	Launched
ammonium-lactate		HCAR1	dermatology	xerosis cutis, ichthyosis vulgaris	BRD-M29182745-001-01-4	N.CC(O)C(O)=O	RZOBLYBZQXQGFY-UHFFFAOYSA-N	Launched
ammonium-perfluorocaprylate	Pim kinase inhibitor	PIM1			BRD-K32531356-001-01-9	OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	SNGREZUHAYWORS-UHFFFAOYSA-N	Phase 1
AMN-082	glutamate receptor modulator	GRM7			BRD-K23335153-300-02-5	C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	DTZDSNQYNPNCPK-UHFFFAOYSA-N	Preclinical
amodiaquine	histamine receptor agonist	HNMT	infectious disease	malaria	BRD-K91290917-300-01-8, BRD-K91290917-336-05-3	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O, CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	OVCDSSHSILBFBN-UHFFFAOYSA-N, OVCDSSHSILBFBN-UHFFFAOYSA-N	Launched
amonafide	topoisomerase inhibitor	TOP2A, TOP2B			BRD-K56334280-001-05-1	CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	UPALIKSFLSVKIS-UHFFFAOYSA-N	Phase 3
amorolfine	membrane integrity inhibitor		infectious disease	onychomycosis	BRD-A37390343-003-03-5, BRD-A37390343-003-02-7	CCC(C)(C)c1ccc(CC(C)CN2C[C@H](C)O[C@H](C)C2)cc1, CCC(C)(C)c1ccc(CC(C)CN2C[C@H](C)O[C@H](C)C2)cc1	MQHLMHIZUIDKOO-AYHJJNSGSA-N, MQHLMHIZUIDKOO-AYHJJNSGSA-N	Launched
amoxapine	norepinephrine reputake inhibitor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-K02265150-001-27-3, BRD-K02265150-001-26-5, BRD-K02265150-001-25-7	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1, Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1	QWGDMFLQWFTERH-UHFFFAOYSA-N, QWGDMFLQWFTERH-UHFFFAOYSA-N, QWGDMFLQWFTERH-UHFFFAOYSA-N	Launched
amoxicillin	penicillin binding protein inhibitor	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	BRD-K55044200-001-14-6, BRD-K58632460-001-01-7, BRD-K55044200-236-02-3, BRD-K39234907-236-01-9, BRD-K08635111-001-04-8	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-PUHVVEEASA-N, LSQZJLSUYDQPKJ-NJBDSQKTSA-N, LSQZJLSUYDQPKJ-ZHSDAYTOSA-N, LSQZJLSUYDQPKJ-BBGACYKPSA-N	Launched
AMPA-(RS)	glutamate receptor agonist	GRIN1			BRD-A34716233-004-03-5, BRD-A34716233-001-02-3	Cc1onc(O)c1CC(N)C(O)=O, Cc1onc(O)c1CC(N)C(O)=O	UUDAMDVQRQNNHZ-UHFFFAOYSA-N, UUDAMDVQRQNNHZ-UHFFFAOYSA-N	Preclinical
AMPA-(S)	glutamate receptor agonist	GRIN1			BRD-K92493880-001-03-0	Cc1onc(O)c1C[C@H](N)C(O)=O	UUDAMDVQRQNNHZ-YFKPBYRVSA-N	Preclinical
ampalex	glutamate receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K24771047-001-01-6	O=C(N1CCCCC1)c1ccc2nccnc2c1	ANDGGVOPIJEHOF-UHFFFAOYSA-N	Phase 2
amperozide	dopamine receptor antagonist	FAAH, HTR2A	neurology/psychiatry	psychosis	BRD-K52397688-003-06-4	CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	NNAIYOXJNVGUOM-UHFFFAOYSA-N	Launched
amphotericin-b	membrane permeability enhancer		infectious disease	fungal infection	BRD-K27352494-001-03-6, BRD-A75647097-001-03-3, BRD-K94561406-001-01-1, BRD-K69849489-001-01-1	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, CC1OC(O[C@@H]2CC3O[C@@](O)(C[C@H](O)C3C(O)=O)CC(O)CC(O)C(O)CCC(O)CC(O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)C(O)[C@H](N)C1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C/2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@](O)(C[C@H](O)[C@@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O	APKFDSVGJQXUKY-INPOYWNPSA-N, APKFDSVGJQXUKY-BFZQMCKISA-N, APKFDSVGJQXUKY-LWRHGOSYSA-N, APKFDSVGJQXUKY-HZJABQFESA-N	Launched
ampicillin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections	BRD-K68432770-236-23-1, BRD-K68432770-236-22-3, BRD-K68432770-236-19-9, BRD-K94927753-341-01-3, BRD-K68432770-341-05-6, BRD-K68432770-236-21-5, BRD-K68432770-236-20-7	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-PUHVVEEASA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N, AVKUERGKIZMTKX-NJBDSQKTSA-N	Launched
ampiroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-A39172021-001-11-1, BRD-A39172021-001-10-3, BRD-A39172021-001-13-7, BRD-A39172021-001-09-5	CCOC(=O)OC(C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1, CCOC(=O)OC(C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1, CCOC(=O)OC(C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1, CCOC(=O)OC(C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1	LSNWBKACGXCGAJ-UHFFFAOYSA-N, LSNWBKACGXCGAJ-UHFFFAOYSA-N, LSNWBKACGXCGAJ-UHFFFAOYSA-N, LSNWBKACGXCGAJ-UHFFFAOYSA-N	Launched
amprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K47827687-001-02-2	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	YMARZQAQMVYCKC-OEMFJLHTSA-N	Launched
amprolium	thiamine uptake blocker		infectious disease	coccidiosis	BRD-K90027121-003-01-7, BRD-K90027121-300-13-2	CCCc1ncc(C[n+]2ccccc2C)c(N)n1, CCCc1ncc(C[n+]2ccccc2C)c(N)n1	IPZFPROOBOUEIG-UHFFFAOYSA-N, IPZFPROOBOUEIG-UHFFFAOYSA-N	Launched
ampyrone	cyclooxygenase inhibitor				BRD-K20484910-001-14-7	Cc1c(N)c(=O)n(-c2ccccc2)n1C	RLFWWDJHLFCNIJ-UHFFFAOYSA-N	Preclinical
amrinone	phosphodiesterase inhibitor	PDE3A, PDE3B, PDE4B, TNF	cardiology	congestive heart failure	BRD-K45924332-001-16-8	Nc1cc(c[nH]c1=O)-c1ccncc1	RNLQIBCLLYYYFJ-UHFFFAOYSA-N	Launched
amrubicin	topoisomerase inhibitor	TOP2A, TOP2B	oncology	small cell lung cancer, small cell lung cancer	BRD-K13843533-001-01-7, BRD-K13843533-001-02-5	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1, CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1	VJZITPJGSQKZMX-XDPRQOKASA-N, VJZITPJGSQKZMX-XDPRQOKASA-N	Launched
amsacrine	topoisomerase inhibitor	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	BRD-K68346641-001-02-2, BRD-K68346641-001-01-4	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12, COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	XCPGHVQEEXUHNC-UHFFFAOYSA-N, XCPGHVQEEXUHNC-UHFFFAOYSA-N	Launched
amthamine	histamine receptor agonist	HRH2			BRD-K39670393-303-02-1	Cc1nc(N)sc1CCN	LHVRFUVVRXGZPV-UHFFFAOYSA-N	Preclinical
amtolmetin-guacil	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K70924353-001-01-2	COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C	CWJNMKKMGIAGDK-UHFFFAOYSA-N	Launched
amuvatinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor	KIT, MET			BRD-K66538826-001-07-2	S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	FOFDIMHVKGYHRU-UHFFFAOYSA-N	Phase 2
amygdalin	caspase activator	CASP3			BRD-K03504028-001-07-6, BRD-K11478426-001-01-4	OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1O	XUCIJNAGGSZNQT-JHSLDZJXSA-N, XUCIJNAGGSZNQT-AGRCMGMNSA-N	Phase 2
amyl-nitrite	atrial natriuretic peptide receptor agonist	NPR1			BRD-K03326591-001-01-4	CCCCCO[N+][O-]	CSDTZUBPSYWZDX-UHFFFAOYSA-N	Preclinical
amyleine	local anesthetic				BRD-A09062839-003-10-0	CCC(C)(CN(C)C)OC(=O)c1ccccc1	FDMBBCOBEAVDAO-UHFFFAOYSA-N	Preclinical
amylene-hydrate	local anesthetic				BRD-K93502141-001-01-6	CCC(C)(C)O	MSXVEPNJUHWQHW-UHFFFAOYSA-N	Preclinical
AMZ30	protein phosphatase inhibitor				BRD-K00256256-001-06-1	[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1	GUCUORSUHTZMBW-YBFXNURJSA-N	Preclinical
AM679	cannabinoid receptor agonist, lipoxygenase inhibitor	ALOX5AP, CNR1, CNR2			BRD-K88443722-001-01-7	COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1	VYXWHVDEWWHDLH-LJAQVGFWSA-N	Preclinical
anabasine	acetylcholine receptor agonist				BRD-A24284985-001-09-9	C1CCC(NC1)c1cccnc1	MTXSIJUGVMTTMU-UHFFFAOYSA-N	Preclinical
anacetrapib	cholesteryl ester transfer protein inhibitor	CETP			BRD-K44366189-001-01-9	COc1cc(F)c(cc1-c1ccc(cc1CN1[C@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C	MZZLGJHLQGUVPN-WZQKQDCOSA-N	Phase 3
anagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K05355328-001-01-1	Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	LDXYBEHACFJIEL-HNNXBMFYSA-N	Launched
anagrelide	phosphodiesterase inhibitor	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	BRD-K62200014-001-02-6, BRD-K62200014-003-10-5, BRD-K62200014-003-11-3	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl	OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N, OTBXOEAOVRKTNQ-UHFFFAOYSA-N	Launched
anamorelin	growth hormone secretagogue receptor agonist	GHSR			BRD-K01174345-001-01-9	CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	VQPFSIRUEPQQPP-MXBOTTGLSA-N	Phase 3
anandamide	cannabinoid receptor agonist	CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1			BRD-K42352790-001-05-3	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	LGEQQWMQCRIYKG-DOFZRALJSA-N	Phase 2
anastrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	BRD-K52172416-001-11-4, BRD-K52172416-001-10-6	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N, CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	YBBLVLTVTVSKRW-UHFFFAOYSA-N, YBBLVLTVTVSKRW-UHFFFAOYSA-N	Launched
andarine	androgen receptor modulator	AR			BRD-K82164249-001-03-5	CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	YVXVTLGIDOACBJ-SFHVURJKSA-N	Phase 1
andrographolide	tumor necrosis factor production inhibitor	NFKB1			BRD-A63236097-001-01-3	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@@H](C\C=C3/C(O)COC3=O)C(=C)CC[C@H]12	BOJKULTULYSRAS-JDTKQMTISA-N	Phase 2
androstenone	steroid				BRD-A64011898-001-01-0	CC12CCC3C(CCC4CC(=O)CCC34C)C1CC=C2	HFVMLYAGWXSTQI-UHFFFAOYSA-N	Preclinical
androsterone	androgen receptor agonist				BRD-K12329651-001-18-8	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-HLUDHZFRSA-N	Preclinical
anecortave-acetate	angiogenesis inhibitor		ophthalmology	macular degeneration	BRD-A53566267-001-01-9	CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C	YUWPMEXLKGOSBF-SQIVGGFUSA-N	Launched
anethole	glutathione transferase stimulant				BRD-K49060658-001-05-6, BRD-K49060658-001-07-2	COc1ccc(cc1)\C=C\C, COc1ccc(cc1)\C=C\C	RUVINXPYWBROJD-ONEGZZNKSA-N, RUVINXPYWBROJD-ONEGZZNKSA-N	Launched
anethole-trithione	glutathione transferase stimulant				BRD-K92490248-001-06-6, BRD-K92490248-001-04-1	COc1ccc(cc1)-c1cc(=S)ss1, COc1ccc(cc1)-c1cc(=S)ss1	KYLIZBIRMBGUOP-UHFFFAOYSA-N, KYLIZBIRMBGUOP-UHFFFAOYSA-N	Launched
anguidine	protein synthesis inhibitor	SLC5A1			BRD-K45724504-001-01-6	CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1	AUGQEEXBDZWUJY-ZLJUKNTDSA-N	Phase 2
anidulafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, fungal infection, esophageal candidiasis	BRD-A75305484-001-01-3	CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(C)CN2C(=O)C(NC(=O)C(NC(=O)C2CC(O)CN2C(=O)C(NC1=O)C(C)O)C(O)C(O)c1ccc(O)cc1)C(C)O	JHVAMHSQVVQIOT-UHFFFAOYSA-N	Launched
aniracetam	glutamate receptor agonist	DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A			BRD-K88611939-001-22-4, BRD-K88611939-001-23-2	COc1ccc(cc1)C(=O)N1CCCC1=O, COc1ccc(cc1)C(=O)N1CCCC1=O	ZXNRTKGTQJPIJK-UHFFFAOYSA-N, ZXNRTKGTQJPIJK-UHFFFAOYSA-N	Launched
anisindione	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	BRD-K47458712-001-20-7, BRD-K47458712-001-18-1, BRD-K47458712-001-21-5, BRD-K47458712-001-19-9, BRD-K47458712-001-17-3	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O, COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N, XRCFXMGQEVUZFC-UHFFFAOYSA-N	Launched
anisodamine	lipid peroxidase inhibitor	ADRA1A			BRD-A29623586-001-01-3	CN1C2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1	WTQYWNWRJNXDEG-GZPFGDLZSA-N	Phase 3
anisomycin	DNA synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			BRD-K91370081-001-25-1	COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	YKJYKKNCCRKFSL-RDBSUJKOSA-N	Preclinical
anisotropine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	BRD-A06771424-004-01-7	CCCC(CCC)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C	XGGHHHBGPSNXFE-XYPWUTKMSA-N	Launched
anlotinib	VEGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor	KDR, PDGFRB			BRD-K36949735-001-01-1	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1	KSMZEXLVHXZPEF-UHFFFAOYSA-N	Phase 2/Phase 3
anpirtoline	serotonin receptor agonist	HTR1B			BRD-K55424922-003-02-8	Clc1cccc(SC2CCNCC2)n1	GGALEXMXDMUMDM-UHFFFAOYSA-N	Phase 1
ansamitocin-p-3	apoptosis stimulant				BRD-K53252847-001-01-3	CO[C@@H]1C=C\C=C(C)/Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2	OPQNCARIZFLNLF-UMXLAOKQSA-N	Preclinical
antagonist-g	neuropeptide receptor antagonist	MAPK8			BRD-K25863791-001-01-8	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	CUCSSYAUKKIDJV-FAXBSAIASA-N	Phase 1
antazoline	antihistamine	HRH1	ophthalmology, otolaryngology	conjunctivitis, nasal congestion	BRD-K99300445-003-21-6, BRD-K99300445-003-20-8, BRD-K99300445-001-01-2	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1, C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1	REYFJDPCWQRWAA-UHFFFAOYSA-N, REYFJDPCWQRWAA-UHFFFAOYSA-N, REYFJDPCWQRWAA-UHFFFAOYSA-N	Launched
anthralin	DNA synthesis inhibitor		dermatology	psoriasis	BRD-K04725460-001-10-5, BRD-K04725460-001-11-3	Oc1cccc2Cc3cccc(O)c3C(=O)c12, Oc1cccc2Cc3cccc(O)c3C(=O)c12	NUZWLKWWNNJHPT-UHFFFAOYSA-N, NUZWLKWWNNJHPT-UHFFFAOYSA-N	Launched
anthranilic-acid					BRD-K75167327-001-01-6	OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2	XKZLSYWCDJZTMW-UHFFFAOYSA-N	Preclinical
anthraquinone	CDC inhibitor	CDC25B			BRD-K15957397-001-04-2	O=C1c2ccccc2C(=O)c2ccccc12	RZVHIXYEVGDQDX-UHFFFAOYSA-N	Preclinical
antimony-potassium					BRD-A53836783-409-01-6	OC(=O)C1O[Sb]2OC(C(O[Sb]3OC1C(=O)O3)C(O)=O)C(=O)O2	JFVMOLRNQCNLCH-UHFFFAOYSA-L	Phase 2
antimonyl					BRD-A74328360-409-01-0	O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O	ZCIXFSVENQDMCK-UHFFFAOYSA-J	Phase 1
antimycin-a	ATP synthase inhibitor	CYCS			BRD-A67709388-001-05-4	CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)C(NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O	UIFFUZWRFRDZJC-KSVNMYRZSA-N	Preclinical
antioxine					BRD-K15541734-001-01-2, BRD-K15541734-001-02-0	CC(C)c1ccc(C)c(O)c1, CC(C)c1ccc(C)c(O)c1	RECUKUPTGUEGMW-UHFFFAOYSA-N, RECUKUPTGUEGMW-UHFFFAOYSA-N	Launched
AN2718	leucyl-tRNA synthetase inhibitor				BRD-K21920947-001-02-1, BRD-K21920947-001-01-3	OB1OCc2cc(Cl)ccc12, OB1OCc2cc(Cl)ccc12	HMAFTPZYFJFEHK-UHFFFAOYSA-N, HMAFTPZYFJFEHK-UHFFFAOYSA-N	Phase 1
apabetalone	apolipoprotein expression enhancer	BRD3			BRD-K20001883-001-02-7	COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1	NETXMUIMUZJUTB-UHFFFAOYSA-N	Phase 3
apafant	platelet activating factor receptor antagonist	PTAFR			BRD-K28115081-001-02-7	Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl	JGPJQFOROWSRRS-UHFFFAOYSA-N	Phase 3
apatinib	RET tyrosine kinase inhibitor	CSK, KDR, KIT, RET			BRD-K25244359-066-03-4, BRD-K25244359-066-02-6	O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1, O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	WPEWQEMJFLWMLV-UHFFFAOYSA-N, WPEWQEMJFLWMLV-UHFFFAOYSA-N	Phase 3
APC-100	anti-inflammatory agent, androgen receptor antagonist	AR			BRD-K07449869-001-01-5	Cc1c(C)c2OC(C)(C)CCc2c(C)c1O	SEBPXHSZHLFWRL-UHFFFAOYSA-N	Phase 1/Phase 2
APD597	glucose dependent insulinotropic receptor agonist	GPR119			BRD-K86226872-001-01-6	COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C	WPDCHTSXOPUOII-UHFFFAOYSA-N	Phase 1
APD668	glucose dependent insulinotropic receptor agonist	GPR119			BRD-K10859802-001-01-0	CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	XTRUQJBVQBUKSQ-UHFFFAOYSA-N	Phase 1
aphidicolin	RNA synthesis inhibitor				BRD-K85140930-001-12-7	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	NOFOAYPPHIUXJR-APNQCZIXSA-N	Phase 1
API-001	sigma receptor antagonist	SIGMAR1			BRD-K26325692-003-01-3	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	DGPGXHRHNRYVDH-UHFFFAOYSA-N	Phase 2
apigenin	casein kinase inhibitor, cell proliferation inhibitor	AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1			BRD-K01493881-001-29-4, BRD-K01493881-001-28-6	Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1, Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	KZNIFHPLKGYRTM-UHFFFAOYSA-N, KZNIFHPLKGYRTM-UHFFFAOYSA-N	Preclinical
apixaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)	BRD-K67121414-001-03-3, BRD-K67121414-001-02-5	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O, COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	QNZCBYKSOIHPEH-UHFFFAOYSA-N, QNZCBYKSOIHPEH-UHFFFAOYSA-N	Launched
apocynin	NADPH oxidase inhibitor	NOX4			BRD-K64990520-001-08-4	COc1cc(ccc1O)C(C)=O	DFYRUELUNQRZTB-UHFFFAOYSA-N	Phase 1
apoptosis-activator-II	carboxylesterase inhibitor	BCHE, CES1			BRD-K15164005-001-05-6, BRD-K15164005-001-04-9	Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl, Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	KGRJPLRFGLMQMV-UHFFFAOYSA-N, KGRJPLRFGLMQMV-UHFFFAOYSA-N	Preclinical
APR-246	p53 activator	TP53			BRD-A09004963-001-01-3	COCC1(CO)N2CCC(CC2)C1=O	BGBNULCRKBVAKL-UHFFFAOYSA-N	Phase 1/Phase 2
apraclonidine	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C	ophthalmology	glaucoma, intraocular pressure	BRD-K38911213-003-01-6	Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1	IEJXVRYNEISIKR-UHFFFAOYSA-N	Launched
apramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	BRD-K36062294-001-04-0	CN[C@H]1[C@@H](O)[C@H]2O[C@@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O	XZNUGFQTQHRASN-XYPKRARZSA-N	Launched
apratastat	matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor	ADAM17, MMP1, MMP13, MMP9			BRD-K06883221-001-01-9	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	MAVDNGWEBZTACC-HNNXBMFYSA-N	Phase 2
apremilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology, rheumatology	psoriasis, psoriatic arthritis	BRD-K93208532-001-02-5	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	IMOZEMNVLZVGJZ-QGZVFWFLSA-N	Launched
aprepitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	BRD-K65170927-001-01-6	C[C@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	ATALOFNDEOCMKK-OCCQLPPTSA-N	Launched
apricitabine	nucleoside reverse transcriptase inhibitor				BRD-K55172746-001-01-3	Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1	RYMCFYKJDVMSIR-RNFRBKRXSA-N	Phase 3
aprindine	voltage-gated sodium channel blocker	CALM1, SCN5A	cardiology	cardiac arrythmia	BRD-K53236343-003-03-7	CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1	NZLBHDRPUJLHCE-UHFFFAOYSA-N	Launched
aptiganel	glutamate receptor antagonist	GRIN1			BRD-K63919159-003-07-0	CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	BFNCJMURTMZBTE-UHFFFAOYSA-N	Phase 3
APTO-253	krüppel-like factor expression enhancer	KLF4			BRD-K68003372-001-01-6	Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21	NIRXBXIPHUTNNI-UHFFFAOYSA-N	Phase 1
APY0201	phosphoinositide dependent kinase inhibitor	IL12A, IL12B, PIKFYVE			BRD-K38627885-001-01-9	Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1	RFZQYGBLRIKROZ-PCLIKHOPSA-N	Preclinical
AP1903					BRD-K28383148-001-01-4	CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	GQLCLPLEEOUJQC-ZTQDTCGGSA-N	Phase 1/Phase 2
AP26113	ALK tyrosine kinase receptor inhibitor	ALK, EGFR			BRD-K56032964-001-02-1	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	OVDSPTSBIQCAIN-UHFFFAOYSA-N	Phase 2
AQ-RA741	acetylcholine receptor antagonist	CHRM2			BRD-K81729199-001-02-8	CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	BCUGCHZRMKTPMU-UHFFFAOYSA-N	Preclinical
AR-A014418	glycogen synthase kinase inhibitor	GSK3B			BRD-K67860401-001-07-2, BRD-K67860401-001-05-6	COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1, COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	YAEMHJKFIIIULI-UHFFFAOYSA-N, YAEMHJKFIIIULI-UHFFFAOYSA-N	Preclinical
AR-C155858	monocarboxylate transporter inhibitor	SLC16A1, SLC16A7			BRD-K42325600-001-01-8	CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O	ISIVOJWVBJIOFM-ZDUSSCGKSA-N	Preclinical
AR-12	phosphoinositide dependent kinase inhibitor	PDPK1			BRD-K90497590-001-07-5, BRD-K90497590-001-08-3, BRD-K90497590-001-04-2, BRD-K90497590-001-05-9	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F, NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N, YULUCECVQOCQFQ-UHFFFAOYSA-N	Phase 1
AR-42	HDAC inhibitor	HDAC1			BRD-K13167095-001-02-9	CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	LAMIXXKAWNLXOC-INIZCTEOSA-N	Phase 1
arachidonic-acid	cytochrome P450 inhibitor	CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2			BRD-K03070961-001-08-5, BRD-K03070961-001-10-1	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	YZXBAPSDXZZRGB-DOFZRALJSA-N, YZXBAPSDXZZRGB-DOFZRALJSA-N	Phase 1
arbidol	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	BRD-K73881242-003-04-6, BRD-K73881242-003-03-8, BRD-K73881242-003-02-0	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12, CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	KCFYEAOKVJSACF-UHFFFAOYSA-N, KCFYEAOKVJSACF-UHFFFAOYSA-N, KCFYEAOKVJSACF-UHFFFAOYSA-N	Launched
arbutin	melanin inhibitor	TYR			BRD-K08037784-001-12-6	OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	BJRNKVDFDLYUGJ-RMPHRYRLSA-N	Phase 2/Phase 3
ARC-239	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			BRD-K93188295-300-02-2	COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	JFNKXGOEOQCXDM-UHFFFAOYSA-N	Preclinical
arctigenin	MEK inhibitor	CHUK, MAP2K1			BRD-K53523901-001-04-4	COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O	NQWVSMVXKMHKTF-JKSUJKDBSA-N	Preclinical
arcyriaflavin-a	CDK inhibitor	CCND1, CDK4			BRD-K72726508-001-02-1, BRD-K72726508-001-03-9	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21, O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	KAJXOWFGKYKMMZ-UHFFFAOYSA-N, KAJXOWFGKYKMMZ-UHFFFAOYSA-N	Preclinical
ardeparin	thrombin inhibitor	SERPINC1, SERPIND1			BRD-A83644949-236-01-6	CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O	HTTJABKRGRZYRN-UHFFFAOYSA-N	Withdrawn
arecaidine-but-2-ynyl-ester	acetylcholine receptor agonist	CHRM2			BRD-K63792901-075-02-1	CC#CCOC(=O)C1=CCCN(C)C1	LBFWTPRSXIRKMZ-UHFFFAOYSA-N	Preclinical
arecaidine-propargyl-ester	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K23922020-075-02-9	CN1CCC=C(C1)C(=O)OCC#C	SPHRJZBOFYIKMC-UHFFFAOYSA-N	Preclinical
arecoline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K88646909-004-16-2, BRD-K88646909-004-15-4	COC(=O)C1=CCCN(C)C1, COC(=O)C1=CCCN(C)C1	HJJPJSXJAXAIPN-UHFFFAOYSA-N, HJJPJSXJAXAIPN-UHFFFAOYSA-N	Phase 1
argatroban	thrombin inhibitor	F2	hematology	thrombocytopenia	BRD-A10012892-001-01-9	C[C@@H]1CCN([C@@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2CC(C)CNc12	KXNPVXPOPUZYGB-YZYLHUITSA-N	Launched
arglabin	farnesyltransferase inhibitor	FNTA, NFKB1			BRD-K62734952-001-01-0	CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13	UVJYAKBJSGRTHA-CUZKYEQNSA-N	Launched
aripiprazole	serotonin receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7	neurology/psychiatry	depression, schizophrenia, bipolar disorder	BRD-K70358946-001-15-7, BRD-K70358946-001-14-0	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl, Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	CEUORZQYGODEFX-UHFFFAOYSA-N, CEUORZQYGODEFX-UHFFFAOYSA-N	Launched
armodafinil	adrenergic receptor agonist	SLC6A3	pulmonary, neurology/psychiatry	obstructive sleep apnea, narcolepsy, shift work disorder (SWD)	BRD-K87278688-001-01-0	NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1	YFGHCGITMMYXAQ-LJQANCHMSA-N	Launched
ARN-509	androgen receptor antagonist	AR			BRD-K91308639-001-02-7	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	HJBWBFZLDZWPHF-UHFFFAOYSA-N	Phase 3
arofylline	phosphodiesterase inhibitor	PDE4A			BRD-K33852358-001-09-9	CCCn1c(=O)n(-c2ccc(Cl)cc2)c2[nH]cnc2c1=O	GVTLDPJNRVMCAL-UHFFFAOYSA-N	Phase 3
arotinolol	adrenergic receptor antagonist	ADRB3	cardiology, neurology/psychiatry	hypertension, tremors	BRD-A28044053-001-01-7	CC(C)(C)NCC(O)CSc1nc(cs1)-c1ccc(s1)C(N)=O	BHIAIPWSVYSKJS-UHFFFAOYSA-N	Launched
ARQ-092	AKT inhibitor	AKT2			BRD-K60171656-001-01-6	Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1	HNFMVVHMKGFCMB-UHFFFAOYSA-N	Phase 1
ARQ-621	kinesin-like spindle protein inhibitor	KIF11			BRD-K43436647-001-01-7	NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F	UPJSUQWHUVLLNW-XMMPIXPASA-N	Phase 1
ARRY-334543	EGFR inhibitor	ERBB2			BRD-K46386702-001-02-1	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1	UWXSAYUXVSFDBQ-CYBMUJFWSA-N	Phase 2
arsanilic-acid		LYZ			BRD-K24179883-001-16-7	Nc1ccc(cc1)[As](O)(O)=O	XKNKHVGWJDPIRJ-UHFFFAOYSA-N	Phase 1
arsenic-trioxide	apoptosis stimulant	AKT1, CCND1, IKBKB, JUN, MAPK1, MAPK3, TXNRD1	gastroenterology	diarrhea	BRD-K47190141-396-01-1	O[AsH]O[AsH]O	NWBBZCLIZUATJF-UHFFFAOYSA-N	Launched
artemether	antimalarial agent	ATP1A1	infectious disease	malaria	BRD-K17916327-001-02-5, BRD-A45966947-001-02-8, BRD-K39621635-001-05-5, BRD-K12393844-001-01-8	CO[C@H]1O[C@@H]2O[C@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, COC1O[C@@H]2O[C@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CO[C@H]1O[C@H]2O[C@@]3(C)CC[C@H]4[C@@H](C)CC[C@@H]([C@@H]1C)[C@@]24OO3	SXYIRMFQILZOAM-WJMRQGARSA-N, SXYIRMFQILZOAM-DAWBJHCGSA-N, SXYIRMFQILZOAM-HVNFFKDJSA-N, SXYIRMFQILZOAM-RDAPPBCGSA-N	Launched
artemisinin	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	BRD-K27678847-001-06-1, BRD-K01715490-001-01-2, BRD-K13112821-001-14-1	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4, C[C@H]1CC[C@H]2[C@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BLUAFEHZUWYNDE-DKGJTOOQSA-N, BLUAFEHZUWYNDE-KNAQKBOSSA-N, BLUAFEHZUWYNDE-NNWCWBAJSA-N	Launched
artemotil			infectious disease	malaria	BRD-K96006160-001-02-9, BRD-K96006160-001-01-1	CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3, CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	NLYNIRQVMRLPIQ-XQLAAWPRSA-N, NLYNIRQVMRLPIQ-XQLAAWPRSA-N	Launched
artesunate	DNA synthesis inhibitor		infectious disease	malaria	BRD-K17944737-001-02-1, BRD-K65768634-001-01-1	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4, C[C@H]1CC[C@H]2[C@H](C)[C@@H](OC(=O)CCC(O)=O)O[C@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	FIHJKUPKCHIPAT-AXFKQHSWSA-N, FIHJKUPKCHIPAT-PNDUOAGUSA-N	Launched
articaine	local anesthetic		neurology/psychiatry	local anesthetic	BRD-A70514680-003-11-2	CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC	QTGIAADRBBLJGA-UHFFFAOYSA-N	Launched
arundic-acid	astrocyte modulating agent	PTGS2, S100B			BRD-K49223707-001-01-0	CCCCCC[C@@H](CCC)C(O)=O	YCYMCMYLORLIJX-SNVBAGLBSA-N	Phase 2/Phase 3
ARV-825	bromodomain inhibitor	BRD4			BRD-A00047421-001-01-7	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N(C5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1	RWLOGRLTDKDANT-TYIYNAFKSA-N	Preclinical
AS-1949490	SHIP2 phosphatase inhibitor	INPP5D			BRD-K61936403-001-01-7	C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	RFZPGNRLOKVZJY-AWEZNQCLSA-N	Preclinical
AS-252424	PI3K inhibitor	PIK3CG			BRD-K14988953-001-04-4, BRD-K14988953-001-03-6	Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1, Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1	OYYVWNDMOQPMGE-SDQBBNPISA-N, OYYVWNDMOQPMGE-SDQBBNPISA-N	Preclinical
AS-604850	PI3K inhibitor	PIK3CA, PIK3CG			BRD-K63915849-001-03-7	FC1(F)Oc2ccc(cc2O1)\C=C1/SC(=O)NC1=O	SRLVNYDXMUGOFI-YWEYNIOJSA-N	Preclinical
AS-703026	MEK inhibitor	MAP2K1, MAP2K2			BRD-K89014967-001-04-3	OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	VIUAUNHCRHHYNE-JTQLQIEISA-N	Phase 2
AS-77	potassium channel blocker	KCNA3, KCNA5, KCNN4			BRD-K62427771-001-01-0	O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	KINMYBBFQRSVLL-UHFFFAOYSA-N	Preclinical
ASA-404	angiogenesis inhibitor				BRD-K27938825-001-02-4	Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	XGOYIMQSIKSOBS-UHFFFAOYSA-N	Phase 3
asaraldehyde	cyclooxygenase inhibitor	PTGS2			BRD-K88219015-001-10-8	COc1cc(OC)c(C=O)cc1OC	IAJBQAYHSQIQRE-UHFFFAOYSA-N	Preclinical
ASC-J9	androgen receptor enhancer	AR			BRD-K30331124-001-03-3, BRD-K30331124-001-01-7, BRD-K30331124-001-02-5	COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1, COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1	HMJSBVCDPKODEX-NXZHAISVSA-N, HMJSBVCDPKODEX-NXZHAISVSA-N, HMJSBVCDPKODEX-NXZHAISVSA-N	Phase 2
ascomycin	calcineurin inhibitor	FKBP1A			BRD-A72381333-001-01-0	CCC1\C=C(C)\CC(C)CC(OC)C2OC(O)(C(C)CC2OC)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)C(O)CC1=O)C(\C)=C\C1CCC(O)C(C1)OC	ZDQSOHOQTUFQEM-AMASXYNMSA-N	Preclinical
ascorbic-acid	antioxidant	ALKBH2, ALKBH3, BBOX1, DBH, EGLN1, EGLN2, EGLN3, KDM5D, LCT, OGFOD1, OGFOD2, P3H1, P3H2, P3H3, P4HA1, P4HTM, PAM, PHYH, PLOD1, PLOD2, PLOD3, SLC23A1, SLC23A2, TMLHE	endocrinology	scurvy	BRD-A08112603-001-04-5, BRD-A85242401-001-10-7, BRD-A85242401-001-05-7, BRD-A85242401-001-07-3, BRD-A85242401-001-09-9	OCC(O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, OC[C@H](O)[C@H]1OC(=O)C(=O)C1O	KRGQEOSDQHTZMX-VUYXPMRHSA-N, KRGQEOSDQHTZMX-IGCYCDGOSA-N, KRGQEOSDQHTZMX-IGCYCDGOSA-N, KRGQEOSDQHTZMX-IGCYCDGOSA-N, KRGQEOSDQHTZMX-IGCYCDGOSA-N	Launched
asenapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, HRH1, HRH2, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K95260951-050-03-1, BRD-K95260951-050-02-3	CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21, CN1C[C@H]2[C@H](C1)c1cc(Cl)ccc1Oc1ccccc21	VSWBSWWIRNCQIJ-HUUCEWRRSA-N, VSWBSWWIRNCQIJ-HUUCEWRRSA-N	Launched
asiatic-acid	apoptosis stimulant	PYGM			BRD-K35079116-001-02-5, BRD-K88350560-001-01-9	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@H]2[C@@H]1C)C(O)=O	JXSVIVRDWWRQRT-UYDOISQJSA-N, JXSVIVRDWWRQRT-AVSSEJMHSA-N	Preclinical
ASP-2535	glycine transporter inhibitor	SLC6A9			BRD-K07150325-001-01-7	CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12	FQGLDGKVKDPVLO-UHFFFAOYSA-N	Phase 1
aspartame		TAS1R2, TRPV1			BRD-K78841970-001-13-8, BRD-K78841970-001-14-6, BRD-K78841970-001-12-0, BRD-K78841970-001-11-2	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O, COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N, IAOZJIPTCAWIRG-QWRGUYRKSA-N	Launched
aspirin	cyclooxygenase inhibitor	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	BRD-K11433652-001-17-0, BRD-K11433652-001-16-2, BRD-K11433652-001-18-8	CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O, CC(=O)Oc1ccccc1C(O)=O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N, BSYNRYMUTXBXSQ-UHFFFAOYSA-N	Launched
ASP3026	ALK tyrosine kinase receptor inhibitor	ALK			BRD-K06542892-001-02-7, BRD-K06542892-001-01-9	COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	MGGBYMDAPCCKCT-UHFFFAOYSA-N, MGGBYMDAPCCKCT-UHFFFAOYSA-N	Phase 1
AST-1306	EGFR inhibitor	EGFR, ERBB2			BRD-K26838195-075-04-9	Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	MVZGYPSXNDCANY-UHFFFAOYSA-N	Phase 1
astaxanthin	antioxidant				BRD-K51832961-001-01-4	CC(\C=C\C=C(C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C	MQZIGYBFDRPAKN-UWFIBFSHSA-N	Launched
astemizole	histamine receptor antagonist	HRH1, KCNH1, KCNH2			BRD-K37249724-001-25-7, BRD-K37249724-001-24-0	COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1, COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	GXDALQBWZGODGZ-UHFFFAOYSA-N, GXDALQBWZGODGZ-UHFFFAOYSA-N	Withdrawn
astragaloside-a	antiinflammatory agent				BRD-K56653660-001-01-3	CC(C)(O)[C@H]1CC[C@](C)(O1)[C@@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)[C@@H]4[C@]5(C[C@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	QMNWISYXSJWHRY-LIUCSYQYSA-N	Preclinical
asunaprevir	HCV inhibitor				BRD-K87028197-001-01-3	COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	XRWSZZJLZRKHHD-WVWIJVSJSA-N	Phase 3
asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	NOS2, NOS3			BRD-K36269323-300-02-6	CN(C)C(=N)NCCC[C@H](N)C(O)=O	YDGMGEXADBMOMJ-LURJTMIESA-N	Phase 1
AT-7519	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9			BRD-K13390322-001-06-3	Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1	OVPNQJVDAFNBDN-UHFFFAOYSA-N	Phase 2
AT-9283	Aurora kinase inhibitor, JAK inhibitor	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A			BRD-K24576554-001-04-8	O=C(NC1CC1)Nc1c[nH]nc1-c1nc2cc(CN3CCOCC3)ccc2[nH]1	LOLPPWBBNUVNQZ-UHFFFAOYSA-N	Phase 2
ataluren	CFTR channel agonist, dystrophin stimulant	DMD	genetics, pulmonary	duchenne muscular dystrophy (DMD), cystic fibrosis	BRD-K94830329-001-03-0	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	OOUGLTULBSNHNF-UHFFFAOYSA-N	Launched
atazanavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K09757388-065-04-0	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	AXRYRYVKAWYZBR-GASGPIRDSA-N	Launched
ATB-346	cyclooxygenase inhibitor	PTGER2			BRD-A52551912-001-01-1	COc1ccc2cc(ccc2c1)C(C)C(=O)Oc1ccc(cc1)C(N)=S	YCNMAPLPQYQJFC-UHFFFAOYSA-N	Phase 2
atenolol-(+/-)	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris	BRD-A20239487-001-24-9, BRD-A20239487-001-25-6	CC(C)NCC(O)COc1ccc(CC(N)=O)cc1, CC(C)NCC(O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-UHFFFAOYSA-N, METKIMKYRPQLGS-UHFFFAOYSA-N	Launched
atenolol-(-)	adrenergic receptor antagonist				BRD-K44993696-001-12-3	CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-LBPRGKRZSA-N	Preclinical
atglistatin	adipose triglyceride lipase inhibitor				BRD-K43363084-001-02-1, BRD-K43363084-001-01-3	CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C, CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	AWOPBSAJHCUSAS-UHFFFAOYSA-N, AWOPBSAJHCUSAS-UHFFFAOYSA-N	Preclinical
atipamezole	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	BRD-K39252998-003-01-5	CCC1(Cc2ccccc2C1)c1cnc[nH]1	HSWPZIDYAHLZDD-UHFFFAOYSA-N	Launched
atiprimod	JAK inhibitor, STAT inhibitor	JAK2, STAT3			BRD-K38527262-300-01-0	CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	SERHTTSLBVGRBY-UHFFFAOYSA-N	Phase 2
atizoram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			BRD-K76614248-001-01-2	COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	LITNEAPWQHVPOK-FFSVYQOJSA-N	Phase 2
ATN-161	integrin antagonist	ITGA5, ITGAV, ITGB1, ITGB3			BRD-K00521308-019-01-9	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	MMHDBUJXLOFTLC-WOYTXXSLSA-N	Phase 2
atomoxetine	norepinephrine transporter inhibitor	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	BRD-K20141153-003-13-7, BRD-K20141153-003-12-9, BRD-K20141153-001-01-6	CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1, CNCC[C@@H](Oc1ccccc1C)c1ccccc1	VHGCDTVCOLNTBX-QGZVFWFLSA-N, VHGCDTVCOLNTBX-QGZVFWFLSA-N, VHGCDTVCOLNTBX-QGZVFWFLSA-N	Launched
atorvastatin	HMGCR inhibitor	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	BRD-K69726342-238-02-4, BRD-K69726342-001-03-4	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1, CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	XUKUURHRXDUEBC-KAYWLYCHSA-N, XUKUURHRXDUEBC-KAYWLYCHSA-N	Launched
atosiban	oxytocin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR	neurology/psychiatry, cardiology, endocrinology	stroke, angina pectoris, myocardial infarction, hyperlipidemia	BRD-A85261566-001-02-5, BRD-A85261566-001-01-7	CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1, CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1	VWXRQYYUEIYXCZ-AVTFEHRISA-N, VWXRQYYUEIYXCZ-AVTFEHRISA-N	Launched
atovaquone	mitochondrial electron transport inhibitor	DHODH	infectious disease	pneumonia	BRD-A19795905-001-08-0, BRD-A19795905-001-07-2	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)c2ccccc2C1=O, Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)C1C(=O)C(=O)c2ccccc2C1=O	UYFLKEIEOREOFC-KWRXGGKWSA-N, UYFLKEIEOREOFC-KWRXGGKWSA-N	Launched
ATPA	glutamate receptor agonist	GRIA2, GRIK1			BRD-A65145453-001-06-1	CC(C)(C)c1onc(O)c1CC(N)C(O)=O	PIXJURSCCVBKRF-UHFFFAOYSA-N	Preclinical
atracurium	acetylcholine receptor antagonist	CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	BRD-K17498618-344-02-6, BRD-A75935363-344-05-8, BRD-K17498618-344-03-4, BRD-A75935363-344-07-4, BRD-A75935363-344-06-6	COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC, COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC	YXSLJKQTIDHPOT-LJCJQEJUSA-N, YXSLJKQTIDHPOT-UHFFFAOYSA-N, YXSLJKQTIDHPOT-LJCJQEJUSA-N, YXSLJKQTIDHPOT-UHFFFAOYSA-N, YXSLJKQTIDHPOT-UHFFFAOYSA-N	Launched
atrasentan	endothelin receptor antagonist	EDNRA			BRD-K16295392-003-01-3	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1	MOTJMGVDPWRKOC-QPVYNBJUSA-N	Phase 3
atropine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	cycloplegia, mydriasis, amblyopia	BRD-A93739713-065-04-3, BRD-A27290375-065-01-3	CN1C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1	RKUNBYITZUJHSG-UHFFFAOYSA-N, RKUNBYITZUJHSG-SPUOUPEWSA-N	Launched
atropine-oxide	acetylcholine receptor antagonist				BRD-A70067498-001-01-8	C[N+]1([O-])C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1	HGWPFSBHDACWNL-UHFFFAOYSA-N	Preclinical
AT13148	protein kinase inhibitor	AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3			BRD-A77091532-001-01-9, BRD-K32127727-001-02-6, BRD-K32127727-001-01-8	NCC(O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1, NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	IIRWNGPLJQXWFJ-UHFFFAOYSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N, IIRWNGPLJQXWFJ-KRWDZBQOSA-N	Phase 1
AT13387	HSP antagonist	HSP90AA1			BRD-K58435339-001-03-0, BRD-K58435339-001-06-3	CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	IFRGXKKQHBVPCQ-UHFFFAOYSA-N, IFRGXKKQHBVPCQ-UHFFFAOYSA-N	Phase 2
AT7867	AKT inhibitor	AKT2, GSK3B, PKIA, PRKACA			BRD-K12040459-001-07-8, BRD-K12040459-001-06-0	Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1, Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	LZMOSYUFVYJEPY-UHFFFAOYSA-N, LZMOSYUFVYJEPY-UHFFFAOYSA-N	Preclinical
auranofin	NFkB pathway inhibitor	IKBKB, PRDX5, TRPA1	rheumatology	rheumatoid arthritis	BRD-A28431708-001-01-5, BRD-K63171558-001-01-2	CCP(CC)(CC)=[Au]S[C@H]1OC(COC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C1OC(C)=O, CCP(CC)(CC)[Au+][SH-][C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	AUJRCFUBUPVWSZ-GHGYJOQJSA-M, IYUHJBHUQSINCX-XTZHGVARSA-O	Launched
aurora-a-inhibitor-i	Aurora kinase inhibitor	AURKA			BRD-K53561341-001-09-1, BRD-K53561341-001-07-5	CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1, CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	AKSIZPIFQAYJGF-UHFFFAOYSA-N, AKSIZPIFQAYJGF-UHFFFAOYSA-N	Preclinical
aurothioglucose	PKC inhibitor	PRKCI	rheumatology	rheumatoid arthritis	BRD-A89825407-001-01-8	OC[C@H]1OC(S[Au])[C@H](O)[C@@H](O)[C@@H]1O	XHVAWZZCDCWGBK-BMZZJELJSA-M	Launched
autotaxin-modulator-1	autotaxin inhibitor	ENPP2			BRD-A94640958-001-01-7	C[C@@H](N1C2CCC1CC(C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F	PZASAAIJIFDWSB-RQDPYJAVSA-N	Preclinical
AV-412	protein tyrosine kinase inhibitor	EGFR, ERBB2			BRD-K23190681-001-01-1	CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	ZAJXXUDARPGGOC-UHFFFAOYSA-N	Phase 1
AV-608	tachykinin antagonist	TACR1			BRD-K96615647-001-01-2	FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	NXLUTEDAEFXMQR-BJKOFHAPSA-N	Phase 2
avagacestat	gamma secretase inhibitor	PSEN1			BRD-K83720053-001-03-8	NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	XEAOPVUAMONVLA-QGZVFWFLSA-N	Phase 2
avanafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	BRD-K65781196-001-03-0, BRD-K65781196-001-04-8	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl, COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	WEAJZXNPAWBCOA-INIZCTEOSA-N, WEAJZXNPAWBCOA-INIZCTEOSA-N	Launched
avasimibe	ACAT inhibitor	CES1			BRD-K67901620-001-03-8, BRD-K67901620-001-02-0	CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C, CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	PTQXTEKSNBVPQJ-UHFFFAOYSA-N, PTQXTEKSNBVPQJ-UHFFFAOYSA-N	Phase 3
avatrombopag	thrombopoietin receptor agonist	MPL			BRD-K68544925-001-01-1	OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1	OFZJKCQENFPZBH-UHFFFAOYSA-N	Phase 3
AVE-0991	angiotensin receptor agonist	MRGPRX1			BRD-K36154108-001-01-7	CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1	QTOZBSNPDCWHPV-UHFFFAOYSA-N	Preclinical
avibactam	beta lactamase inhibitor		infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis, intra-abdominal infections, urinary tract infections, pyelonephritis, intra-abdominal infections, urinary tract infections, pyelonephritis	BRD-K85882401-323-01-5, BRD-K85882401-236-01-9, BRD-K85882401-236-02-7	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O, NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	NDCUAPJVLWFHHB-UHNVWZDZSA-N, NDCUAPJVLWFHHB-UHNVWZDZSA-N, NDCUAPJVLWFHHB-UHNVWZDZSA-N	Launched
AVL-292	Brutons tyrosine kinase (BTK) inhibitor" "BTK, YES1" "" "" "BRD-K87782578-001-01-4"
"65" "COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1" "KXBDTLQSDKGAEB-UHFFFAOYSA-N" "Phase 2" "" "" "" "" "" ""
"66" "AVN-944" "inosine monophosphate dehydrogenase inhibitor" "IMPDH1, IMPDH2" "" "" "BRD-K62196610-001-01-6" "CC[C@H](CC" "" ""
"67" "avobenzone" "UV blocker" "TYR" "dermatology" "cosmetic, sunscreen lotion" "BRD-K14401183-001-10-7, BRD-K14401183-001-11-5" "COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C, COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C" "XNEFYCZVKIDDMS-UHFFFAOYSA-N, XNEFYCZVKIDDMS-UHFFFAOYSA-N" "Launched"
"68" "avridine" "immunostimulant" "" "" "" "BRD-K26665484-001-01-8" "CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO" "WXNRAKRZUCLRBP-UHFFFAOYSA-N" "Preclinical"
"69" "axitinib" "PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "CSF1, FLT1, FLT4, KDR, PLK4" "oncology" "renal cell carcinoma (RCC)" "BRD-K29905972-001-12-1, BRD-K29905972-001-11-3, BRD-K29905972-001-06-3, BRD-K29905972-001-08-9, BRD-K29905972-001-10-5" "CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1" "RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N, RITAVMQDGBJQJZ-FMIVXFBMSA-N" "Launched"
"70" "AY-9944" "hedgehog pathway modulator" "" "" "" "BRD-K77012840-300-01-6" "Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1" "RZRPZWGIOOZIBE-IYARVYRRSA-N" "Preclinical"
"71" "AZ-10417808" "caspase inhibitor" "CASP3" "" "" "BRD-K36258877-001-03-1" "[O-][N+](=O)c1cc(C(=O)NCC=C)c2nc(Nc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1" "VUBILPOZTRGZJK-UHFFFAOYSA-N" "Preclinical"
"72" "AZ-628" "RAF inhibitor" "BRAF, RAF1" "" "" "BRD-K05804044-001-14-4, BRD-K05804044-001-09-4, BRD-K05804044-001-06-0, BRD-K05804044-001-12-8" "Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C" "" ""
"73" "azacitidine" "DNA methyltransferase inhibitor" "DNMT1, DNMT3A" "hematologic malignancy, hematology" "myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)" "BRD-K55026842-001-01-4, BRD-K03406345-001-21-1" "Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1" "NMUSYJAQQFHJEW-ARQDHWQXSA-N, NMUSYJAQQFHJEW-KVTDHHQDSA-N" "Launched"
"74" "azacyclonol" "histamine receptor antagonist" "HRH1" "" "" "BRD-K97061094-001-21-4, BRD-K97061094-001-20-6" "OC(C1CCNCC1)(c1ccccc1)c1ccccc1, OC(C1CCNCC1)(c1ccccc1)c1ccccc1" "ZMISODWVFHHWNR-UHFFFAOYSA-N, ZMISODWVFHHWNR-UHFFFAOYSA-N" "Preclinical"
"75" "azaguanine-8" "purine antagonist" "PNP" "" "" "BRD-K53114651-001-12-7, BRD-K53114651-001-11-9" "Nc1nc2[nH]nnc2c(=O)[nH]1, Nc1nc2[nH]nnc2c(=O)[nH]1" "LPXQRXLUHJKZIE-UHFFFAOYSA-N, LPXQRXLUHJKZIE-UHFFFAOYSA-N" "Preclinical"
"76" "azalomycin-b" "bacterial 50S ribosomal subunit inhibitor" "" "" "" "BRD-K96104201-001-01-5" "CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1" "OSERMIPXNLXAPD-UBZOKEKOSA-N" "Preclinical"
"77" "azaperone" "dopamine receptor antagonist" "DRD2, DRD3" "neurology/psychiatry" "sedative" "BRD-K45861246-001-15-9, BRD-K45861246-001-13-4, BRD-K45861246-001-14-2" "Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1, Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1" "XTKDAFGWCDAMPY-UHFFFAOYSA-N, XTKDAFGWCDAMPY-UHFFFAOYSA-N, XTKDAFGWCDAMPY-UHFFFAOYSA-N" "Launched"
"78" "azapropazone" "cyclooxygenase inhibitor" "PTGS2" "" "" "BRD-A70182876-001-10-8" "CCCC1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C" "MPHPHYZQRGLTBO-UHFFFAOYSA-N" "Withdrawn"
"79" "azaserine" "purine antagonist" "" "" "" "BRD-A67065070-001-04-7" "NC(COC(=O)C=[N+]=[N-])C(O)=O" "MZZGOOYMKKIOOX-UHFFFAOYSA-N" "Preclinical"
"80" "azasetron" "serotonin receptor antagonist" "HTR3A, HTR3B" "infectious disease" "genitial herpes" "BRD-A44133049-003-07-8" "CN1C(=O)COc2c1cc(Cl)cc2C(=O)NC1CN2CCC1CC2" "WUKZPHOXUVCQOR-UHFFFAOYSA-N" "Launched"
"81" "azatadine" "histamine receptor antagonist" "HRH1" "allergy" "allergic rhinitis" "BRD-K77821588-364-01-2, BRD-K77821588-050-01-7" "CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12, CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12" "SEBMTIQKRHYNIT-UHFFFAOYSA-N, SEBMTIQKRHYNIT-UHFFFAOYSA-N" "Launched"
"82" "azathioprine" "dehydrogenase inhibitor" "HPRT1, IMPDH1, PPAT" "transplant, rheumatology" "renal homotransplantation, rheumatoid arthritis" "BRD-K32821942-001-21-3, BRD-K32821942-001-20-5" "Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O, Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O" "LMEKQMALGUDUQG-UHFFFAOYSA-N, LMEKQMALGUDUQG-UHFFFAOYSA-N" "Launched"
"83" "AZD1080" "glycogen synthase kinase inhibitor" "GSK3A, GSK3B" "" "" "BRD-K61041538-001-03-0, BRD-K61041538-001-01-4, BRD-K61041538-001-04-8" "Oc1[nH]c2ccc(cc2c1-c1ccc(CN2CCOCC2)cn1)C" "" ""
"84" "AZD1208" "Pim kinase inhibitor" "PIM1, PIM2, PIM3" "" "" "BRD-K21908111-001-01-8" "N[C@@H]1CCCN(C1)c1c(cccc1-c1ccccc1)\C=C1/SC(=O)NC1=O" "MCUJKPPARUPFJM-UWCCDQBKSA-N" "Phase 1"
"85" "AZD1283" "purinergic receptor antagonist" "P2RY12" "" "" "BRD-K77060810-001-01-5" "CCOC(=O)c1cc(C" "" ""
"86" "AZD1446" "acetylcholine receptor agonist" "CHRNA4, CHRNB2" "" "" "BRD-A44188509-001-01-2" "Clc1ccc(o1)C(=O)N1CC2CNCC2C1" "GTUIQNHJSXQMKW-UHFFFAOYSA-N" "Phase 2"
"87" "AZD1480" "JAK inhibitor" "JAK1, JAK2, JAK3" "" "" "BRD-K65928735-001-04-3" "C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1" "PDOQBOJDRPLBQU-QMMMGPOBSA-N" "Phase 1"
"88" "AZD1981" "CRTH receptor antagonist" "PTGDR2" "" "" "BRD-K83186168-001-01-8" "CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12" "JWYIGNODXSRKGP-UHFFFAOYSA-N" "Phase 2"
"89" "AZD2014" "mTOR inhibitor" "MTOR" "" "" "BRD-K99113996-001-02-0" "CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C" "JUSFANSTBFGBAF-IRXDYDNUSA-N" "Phase 2"
"90" "AZD2461" "PARP inhibitor" "" "" "" "BRD-K85014146-001-02-5" "COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F" "HYNBNUYQTQIHJK-UHFFFAOYSA-N" "Phase 1"
"91" "AZD2858" "glycogen synthase kinase inhibitor" "GSK3B" "" "" "BRD-K85849709-001-01-5" "CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1" "FHCSBLWRGCOVPT-UHFFFAOYSA-N" "Preclinical"
"92" "AZD3264" "IKK inhibitor" "IKBKB" "" "" "BRD-K14287049-001-01-3" "Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1" "NMFIXEFNQPDISY-ZDUSSCGKSA-N" "Preclinical"
"93" "AZD3463" "ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor" "ALK, IGF1R" "" "" "BRD-K24593301-001-02-3, BRD-K24593301-001-01-5" "COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1, COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1" "GCYIGMXOIWJGBU-UHFFFAOYSA-N, GCYIGMXOIWJGBU-UHFFFAOYSA-N" "Preclinical"
"94" "AZD3514" "androgen receptor modulator" "AR" "" "" "BRD-K84996356-001-01-1" "CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1" "JMEYDSHPKCSIJC-UHFFFAOYSA-N" "Phase 1"
"95" "AZD3759" "EGFR inhibitor" "EGFR" "" "" "BRD-K41626799-001-01-1" "COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C" "MXDSJQHFFDGFDK-CYBMUJFWSA-N" "Phase 1"
"96" "AZD3839" "beta-secretase inhibitor" "BACE1" "" "" "BRD-A54654253-001-01-8" "NC1N[C@](c2cccc(F)c12)(c1ccnc(c1)C(F)F)c1cccc(c1)-c1cncnc1" "QXKYWSDUVAJHNZ-CGAIIQECSA-N" "Phase 1"
"97" "AZD3965" "monocarboxylate transporter inhibitor" "SLC16A1" "" "" "BRD-K25210703-001-01-9" "CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O" "PRNXOFBDXNTIFG-FQEVSTJZSA-N" "Phase 1"
"98" "AZD4282" "glutamate receptor antagonist" "AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9" "" "" "BRD-K72369578-001-04-1" "NCC(O)=O" "DHMQDGOQFOQNFH-UHFFFAOYSA-N" "Phase 1"
"99" "AZD4547" "FGFR inhibitor" "FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR" "" "" "BRD-K28392481-001-05-1" "COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)n[nH]2)cc(OC)c1" "VRQMAABPASPXMW-HDICACEKSA-N" "Phase 2/Phase 3"
"100" "AZD5069" "CC chemokine receptor antagonist" "CXCR2" "" "" "BRD-K34801930-001-01-9" "C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO" "QVKPEMXUBULFBM-FZMZJTMJSA-N" "Phase 2"
"101" "AZD5363" "AKT inhibitor" "AKT1, AKT2, AKT3" "" "" "BRD-K99023089-001-03-7" "NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1" "JDUBGYFRJFOXQC-KRWDZBQOSA-N" "Phase 2"
"102" "AZD5438" "CDK inhibitor" "KCNH2" "" "" "BRD-K72414522-001-10-9, BRD-K72414522-001-06-7, BRD-K72414522-001-08-3" "CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1, CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1" "WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N, WJRRGYBTGDJBFX-UHFFFAOYSA-N" "Phase 1"
"103" "AZD5582" "XIAP inhibitor" "BIRC2, BIRC3, XIAP" "" "" "BRD-K88767641-001-01-7" "CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC" "" ""
"104" "AZD6482" "PI3K inhibitor" "PIK3CA, PIK3CB, PIK3CD, PIK3CG" "" "" "BRD-K58772419-001-08-8, BRD-K58772419-001-07-0" "C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1" "IRTDIKMSKMREGO-OAHLLOKOSA-N, IRTDIKMSKMREGO-OAHLLOKOSA-N" "Phase 1"
"105" "AZD6738" "ATR kinase inhibitor" "ATR" "" "" "BRD-A36013532-001-01-3" "C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)S(C)(=N)=O" "OHUHVTCQTUDPIJ-RNHBAAACSA-N" "Phase 1/Phase 2"
"106" "AZD6765" "glutamate receptor antagonist" "GRIN1" "" "" "BRD-A94033181-001-01-4" "NC(Cc1ccccn1)c1ccccc1" "FWUQWDCOOWEXRY-UHFFFAOYSA-N" "Phase 2"
"107" "AZD7545" "pyruvate dehydrogenase kinase inhibitor" "PDK1" "" "" "BRD-A87435144-001-01-6" "CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)C(C)(O)C(F)(F)F)c(Cl)c1" "DTDZLJHKVNTQGZ-UHFFFAOYSA-N" "Phase 1"
"108" "AZD7687" "diacylglycerol O acyltransferase inhibitor" "DGAT1" "" "" "BRD-K31495718-001-01-1" "Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1" "YXFNPRHZMOGREC-SHTZXODSSA-N" "Phase 1"
"109" "AZD7762" "CHK inhibitor" "CHEK1, CHEK2" "" "" "BRD-K86525559-003-01-7, BRD-K86525559-001-07-8, BRD-K86525559-001-04-5" "NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1, NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1" "IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N, IAYGCINLNONXHY-LBPRGKRZSA-N" "Phase 1"
"110" "AZD8055" "mTOR inhibitor" "MTOR" "" "" "BRD-K69932463-001-10-6" "COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C" "KVLFRAWTRWDEDF-IRXDYDNUSA-N" "Phase 1"
"111" "AZD8186" "PI3K inhibitor" "PIK3CB, PIK3CD" "" "" "BRD-K47289408-001-01-5, BRD-A57210235-001-01-9" "C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C, CC(Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C" "LMJFJIDLEAWOQJ-CQSZACIVSA-N, LMJFJIDLEAWOQJ-UHFFFAOYSA-N" "Phase 1"
"112" "AZD8330" "MEK inhibitor" "" "" "" "BRD-K37687095-001-06-9, BRD-K37687095-001-07-7" "Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O, Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O" "RWEVIPRMPFNTLO-UHFFFAOYSA-N, RWEVIPRMPFNTLO-UHFFFAOYSA-N" "Phase 1"
"113" "AZD8835" "PI3K inhibitor" "PIK3CA, PIK3CD" "" "" "BRD-K82894950-001-01-0" "CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO" "ZGRDYKFVDCFJCZ-UHFFFAOYSA-N" "Phase 1"
"114" "AZD8931" "EGFR inhibitor" "EGFR, ERBB2, ERBB3" "" "" "BRD-K98572433-001-02-9" "CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC" "DFJSJLGUIXFDJP-UHFFFAOYSA-N" "Phase 2"
"115" "AZD9496" "estrogen receptor agonist" "ESR1" "" "" "BRD-K73235735-001-02-7, BRD-K73235735-050-01-6" "C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F, C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F" "DFBDRVGWBHBJNR-BBNFHIFMSA-N, DFBDRVGWBHBJNR-BBNFHIFMSA-N" "Phase 1"
"116" "AZD9668" "elastase inhibitor" "ELANE" "" "" "BRD-K31476763-001-01-5" "Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C" "QNQZWEGMKJBHEM-UHFFFAOYSA-N" "Phase 2"
"117" "azelaic-acid" "tyrosinase inhibitor" "AKR1D1, SRD5A2, TYR" "dermatology" "rosacea" "BRD-K08976401-001-18-5" "OC(=O)CCCCCCCC(O)=O" "BDJRBEYXGGNYIS-UHFFFAOYSA-N" "Launched"
"118" "azelastine" "histamine receptor antagonist" "HRH1" "ophthalmology" "conjunctivitis" "BRD-A68888262-003-15-1, BRD-A68888262-003-16-9" "CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O, CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O" "MBUVEWMHONZEQD-UHFFFAOYSA-N, MBUVEWMHONZEQD-UHFFFAOYSA-N" "Launched"
"119" "azeliragon" "RAGE receptor antagonist" "AGER" "" "" "BRD-K51899933-001-02-6" "CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1" "KJNNWYBAOPXVJY-UHFFFAOYSA-N" "Phase 3"
"120" "azelnidipine" "calcium channel blocker" "CACNA1C" "cardiology" "hypertension" "BRD-A01098288-001-06-0, BRD-A01098288-001-02-9, BRD-A01098288-001-04-5" "CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1, CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1, CC(C)OC(=O)C1=C(C)NC(N)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1" "ZKFQEACEUNWPMT-UHFFFAOYSA-N, ZKFQEACEUNWPMT-UHFFFAOYSA-N, ZKFQEACEUNWPMT-UHFFFAOYSA-N" "Launched"
"121" "azilsartan" "angiotensin receptor antagonist" "AGTR1, AGTR2" "cardiology" "hypertension" "BRD-K81074237-001-02-3" "CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1" "KGSXMPPBFPAXLY-UHFFFAOYSA-N" "Launched"
"122" "azilsartan-medoxomil" "angiotensin receptor antagonist" "AGTR1, AGTR2" "cardiology" "hypertension" "BRD-K25723200-001-03-5, BRD-K25723200-001-02-7, BRD-K25723200-237-01-9" "CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1, CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1" "QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N, QJFSABGVXDWMIW-UHFFFAOYSA-N" "Launched"
"123" "azimilide" "potassium channel blocker" "KCNA5, KCNE1, KCNH2, KCNQ1" "" "" "BRD-K38913877-300-01-9" "CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1" "MREBEPTUUMTTIA-PCLIKHOPSA-N" "Phase 3"
"124" "azithromycin" "bacterial 50S ribosomal subunit inhibitor" "MLNR" "infectious disease" "pelvic inflammatory disease, pneumonia" "BRD-A37438244-335-01-2, BRD-K73794685-001-01-5, BRD-K74501079-001-15-7" "CC[C@@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)C(C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O" "MQTOSJVFKKJCRP-ZCGCJHLLSA-N, MQTOSJVFKKJCRP-MTXCBGCVSA-N, MQTOSJVFKKJCRP-BICOPXKESA-N" "Launched"
"125" "azlocillin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections, gram-negative bacterial infections" "BRD-A46717658-236-03-3, BRD-A46717658-236-02-5, BRD-A95218818-236-05-4, BRD-A95218818-001-01-1" "CC1(C)SC2C(NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2C1C(O)=O, CC1(C)SC2C(NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2C1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2C1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2C1C(O)=O" "JTWOMNBEOCYFNV-MPXNVAGNSA-N, JTWOMNBEOCYFNV-MPXNVAGNSA-N, JTWOMNBEOCYFNV-MCQMVECXSA-N, JTWOMNBEOCYFNV-MCQMVECXSA-N" "Launched"
"126" "azodicarbonamide" "DNA synthesis inhibitor" "" "" "" "BRD-K87036601-001-01-6" "NC(=O)\N=N\C(N)=O" "XOZUGNYVDXMRKW-AATRIKPKSA-N" "Phase 2"
"127" "azomycin-(2-nitroimidazole)" "protein synthesis inhibitor" "" "" "" "BRD-K26824830-001-03-8, BRD-K26824830-001-02-0" "[O-][N+](=O)c1ncc[nH]1, [O-][N+](=O)c1ncc[nH]1" "YZEUHQHUFTYLPH-UHFFFAOYSA-N, YZEUHQHUFTYLPH-UHFFFAOYSA-N" "Preclinical"
"128" "azosemide" "electrolyte reabsorption inhibitor" "SLC12A1, SLC12A2" "cardiology" "edema" "BRD-K68770713-001-01-8" "NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl" "HMEDEBAJARCKCT-UHFFFAOYSA-N" "Launched"
"129" "aztreonam" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections" "BRD-K62607865-001-09-7, BRD-K36547807-001-03-2, BRD-K41270709-001-01-7" "C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@H]1[C@H](NC(=O)C(=N\OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O, C[C@@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O" "WZPBZJONDBGPKJ-VEHQQRBSSA-N, WZPBZJONDBGPKJ-IYZXUIDESA-N, WZPBZJONDBGPKJ-DZIOLEBDSA-N" "Launched"
"130" "AZ191" "DYRK inhibitor" "DYRK1B" "" "" "BRD-K80935598-001-01-1, BRD-K80935598-001-02-9" "COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1, COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1" "ZYVXTMKTGDARKR-UHFFFAOYSA-N, ZYVXTMKTGDARKR-UHFFFAOYSA-N" "Preclinical"
"131" "AZ20" "ATR kinase inhibitor" "ATR, MTOR" "" "" "BRD-K42436189-001-03-8, BRD-K42436189-001-01-2" "C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O, C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O" "SCGCBAAYLFTIJU-CQSZACIVSA-N, SCGCBAAYLFTIJU-CQSZACIVSA-N" "Preclinical"
"132" "AZ3146" "monopolar spindle 1 kinase inhibitor" "" "" "" "BRD-K59146805-001-04-5, BRD-K59146805-001-05-2, BRD-K59146805-001-03-7" "COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1, COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1" "YUKWVHPTFRQHMF-UHFFFAOYSA-N, YUKWVHPTFRQHMF-UHFFFAOYSA-N, YUKWVHPTFRQHMF-UHFFFAOYSA-N" "Preclinical"
"133" "AZ505" "histone lysine methyltransferase inhibitor" "SMYD2" "" "" "BRD-K76244476-362-02-5, BRD-K76244476-362-01-7" "Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12, Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12" "LIBVHXXKHSODII-UHFFFAOYSA-N, LIBVHXXKHSODII-UHFFFAOYSA-N" "Preclinical"
"134" "AZ5104" "EGFR inhibitor" "EGFR" "" "" "BRD-K81958169-001-01-1" "COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12" "IQNVEOMHJHBNHC-UHFFFAOYSA-N" "Preclinical"
"135" "AZ960" "JAK inhibitor" "JAK2" "" "" "BRD-K64888243-001-04-5, BRD-K64888243-001-03-7" "C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C" "" ""
"136" "A0001" "" "" "" "" "BRD-K57865272-001-01-2, BRD-K57865272-001-02-0" "CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O" "LTVDFSLWFKLJDQ-IEOSBIPESA-N, LTVDFSLWFKLJDQ-IEOSBIPESA-N" "Phase 2"
"137" "A205804" "ICAM1 expression inhibitor" "ICAM1, SELE" "" "" "BRD-K77627880-001-04-0, BRD-K77627880-001-03-2" "Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1, Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1" "QQGWEXFLMJGCAL-UHFFFAOYSA-N, QQGWEXFLMJGCAL-UHFFFAOYSA-N" "Preclinical"
"138" "A61603" "adrenergic receptor agonist" "ADRA1A" "" "" "BRD-A83650191-004-02-8" "CS(=O)(=O)Nc1c(O)ccc2C(CCCc12)C1=NCCN1" "OQFCXJDXHCDLHX-UHFFFAOYSA-N" "Preclinical"
"139" "A66" "PI3K inhibitor" "PIK3CA" "" "" "BRD-K49055432-001-07-5, BRD-K49055432-001-04-2" "Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C, Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C" "HBPXWEPKNBHKAX-NSHDSACASA-N, HBPXWEPKNBHKAX-NSHDSACASA-N" "Preclinical"
"140" "A740003" "purinergic receptor antagonist" "P2RX7" "" "" "BRD-A78952587-001-01-5" "COc1ccc(CC(=O)NC(N\C(Nc2cccc3ncccc23)=N\C" "" ""
"141" "A77636" "dopamine receptor agonist" "CALY" "" "" "BRD-K72226571-003-01-2" "NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2" "QLJOSZATCBCBDR-KLONBWLYSA-N" "Preclinical"
"142" "A922500" "diacylglycerol O acyltransferase inhibitor" "DGAT1" "" "" "BRD-K28861668-001-01-9" "OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1" "BOZRFEQDOFSZBV-PKTZIBPZSA-N" "Preclinical"
"143" "bacampicillin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections, gram-negative bacterial infections" "BRD-A41698174-003-12-0, BRD-A10481343-003-03-3, BRD-A41698174-003-11-2" "CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O, CCOC(=O)OC(C)OC(=O)C1N2C(SC1(C)C)C(NC(=O)[C@H](N)c1ccccc1)C2=O, CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O" "PFOLLRNADZZWEX-FFGRCDKISA-N, PFOLLRNADZZWEX-SAAUIKKPSA-N, PFOLLRNADZZWEX-FFGRCDKISA-N" "Launched"
"144" "bacitracin" "bacterial cell wall synthesis inhibitor" "A2M, IDE" "infectious disease" "first-aid antibiotic" "BRD-A49374018-001-04-1, BRD-A30186914-001-01-1, BRD-A21002158-001-01-6" "CCC(C)C(N)C1=NC(CS1)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)CC)C(=O)NCCCCC1NC(=O)C(CC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]cn2)NC(=O)C(Cc2ccccc2)NC(=O)C(NC(=O)C(CCCN)NC1=O)C(C)CC, CCC(C)[C@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)C1CN=C(S1)[C@H](N)C(C)C)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)C(C)CC, CC[C@@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)C1CN=C(S1)[C@H](N)C(C)C)C(=O)N[C@@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@H](C)CC" "VRKHYMXTJQCIND-UHFFFAOYSA-N, RHKCFWGPEDXSNT-IGRZHKPHSA-N, RHKCFWGPEDXSNT-MQEQNYHJSA-N" "Launched"
"145" "bacitracin-zinc" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "first-aid antibiotic" "BRD-A06016120-001-01-0, BRD-M45010341-001-01-5, BRD-A06016120-001-02-8" "CC[C@H](C)[C@H](N)C1=NCC(S1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@H](C)CC)[C@H](C)CC, [Zn++].CCC(C)C(N)C1=NC(CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](NC(=O)[C@@H](CCCN)NC1=O)[C@H](C)CC, CC[C@H](C)[C@H](N)C1=NCC(S1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@H](C)CC)[C@H](C)CC" "NKULICGUDKGGRL-SVBGOZHZSA-L, UCRLQOPRDMGYOA-BWBYNRQYSA-N, NKULICGUDKGGRL-SVBGOZHZSA-L" "Launched"
"146" "baclofen" "benzodiazepine receptor agonist" "GABBR1, GABBR2, KCTD12, KCTD16, KCTD8" "neurology/psychiatry" "multiple sclerosis, spasms" "BRD-A84174873-003-07-4" "NCC(CC(O)=O)c1ccc(Cl)cc1" "KPYSYYIEGFHWSV-UHFFFAOYSA-N" "Launched"
"147" "baclofen-(R)" "benzodiazepine receptor agonist" "GABBR1, GABBR2" "" "" "BRD-K62353271-001-04-7, BRD-K62353271-001-02-1" "NC[C@H](CC(O)=O)c1ccc(Cl)cc1, NC[C@H](CC(O)=O)c1ccc(Cl)cc1" "KPYSYYIEGFHWSV-QMMMGPOBSA-N, KPYSYYIEGFHWSV-QMMMGPOBSA-N" "Preclinical"
"148" "BADGE" "PPAR receptor antagonist" "PPARG" "" "" "BRD-A16694057-001-06-8" "CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1" "LCFVJGUPQDGYKZ-UHFFFAOYSA-N" "Preclinical"
"149" "bafetinib" "Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor" "ABL1, BCR, LYN" "" "" "BRD-A75975749-001-01-4" "CN(C)C1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3ncc(cn3)-c3cncnc3)c2)C1" "ZOPBZHLJXQAQON-UHFFFAOYSA-N" "Phase 2"
"150" "baicalein" "lipoxygenase inhibitor" "ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH" "" "" "BRD-K72327355-001-15-4, BRD-K72327355-001-14-7, BRD-K72327355-001-13-9" "Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1, Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1" "FXNFHKRTJBSTCS-UHFFFAOYSA-N, FXNFHKRTJBSTCS-UHFFFAOYSA-N, FXNFHKRTJBSTCS-UHFFFAOYSA-N" "Preclinical"
"151" "baicalin" "beta glucuronidase inhibitor" "PREP" "" "" "BRD-K98733875-001-01-4, BRD-K99455969-001-02-8" "O[C@H]1[C@@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@H]([C@@H](O)[C@@H]1O)C(O)=O, O[C@H]1[C@@H](Oc2cc3oc(cc(=O)c3c(O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O" "IKIIZLYTISPENI-RFBJODPTSA-N, IKIIZLYTISPENI-UNJWAJPSSA-N" "Launched"
"152" "bakuchiol" "DNA polymerase inhibitor" "HIF1A" "" "" "BRD-K09785578-001-02-0, BRD-K09785578-001-01-2" "CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1, CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1" "LFYJSSARVMHQJB-QIXNEVBVSA-N, LFYJSSARVMHQJB-QIXNEVBVSA-N" "Phase 2"
"153" "balaglitazone" "insulin sensitizer, PPAR receptor partial agonist" "PPARG" "" "" "BRD-A00147595-001-01-5" "Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O" "IETKPTYAGKZLKY-UHFFFAOYSA-N" "Phase 3"
"154" "balapiravir" "RNA polymerase inhibitor" "" "" "" "BRD-K47976015-001-01-2" "CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]" "VKXWOLCNTHXCLF-DXEZIKHYSA-N" "Phase 2"
"155" "balicatib" "cathepsin inhibitor" "CTSK" "" "" "BRD-K27204852-001-01-9" "CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC" "" ""
"156" "balofloxacin" "bacterial DNA gyrase inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-A47790386-001-03-6, BRD-A47790386-001-02-8" "CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1, CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1" "MGQLHRYJBWGORO-UHFFFAOYSA-N, MGQLHRYJBWGORO-UHFFFAOYSA-N" "Launched"
"157" "balsalazide" "cyclooxygenase inhibitor" "ALOX5, PPARG, PTGS1, PTGS2" "gastroenterology" "ulcerative colitis" "BRD-K41410256-304-02-2" "OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(O)c(c1)C(O)=O" "IPOKCKJONYRRHP-UHFFFAOYSA-N" "Launched"
"158" "bambuterol" "adrenergic receptor agonist" "ADRB2, BCHE" "pulmonary" "asthma" "BRD-A17462676-003-11-6" "CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C" "ANZXOIAKUNOVQU-UHFFFAOYSA-N" "Launched"
"159" "BAM7" "BAX activator" "BAX" "" "" "BRD-K07442505-001-03-6" "CCOc1ccccc1N\N=C1C(=O)N(N=C\1C)c1nc(cs1)-c1ccccc1" "KOCVKGYKBLJEPK-LYBHJNIJSA-N" "Preclinical"
"160" "BAN-ORL-24" "nociceptin/orphanin FQ receptor antagonist" "OPRL1" "" "" "BRD-K47049295-300-01-5" "O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1" "MAKMQGKJURAJEN-RUZDIDTESA-N" "Preclinical"
"161" "barasertib" "Aurora kinase inhibitor" "AURKA, AURKB" "" "" "BRD-K31928526-001-02-1" "CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O" "GBJVVSCPOBPEIT-UHFFFAOYSA-N" "Phase 2/Phase 3"
"162" "barasertib-HQPA" "Aurora kinase inhibitor" "AURKB" "" "" "BRD-K63923597-001-10-0, BRD-K63923597-001-11-8" "CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1, CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1" "QYZOGCMHVIGURT-UHFFFAOYSA-N, QYZOGCMHVIGURT-UHFFFAOYSA-N" "Phase 2/Phase 3"
"163" "barbital" "sedative" "CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GRIA2, GRIK2" "neurology/psychiatry" "sedative, seizures" "BRD-K83359602-001-02-3" "CCC1(CC)C(=O)NC(=O)NC1=O" "FTOAOBMCPZCFFF-UHFFFAOYSA-N" "Launched"
"164" "bardoxolone" "nuclear factor erythroid derived, like (NRF2) activator" "NOS2, PPARG" "" "" "BRD-K20545304-001-01-6" "CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C" "" ""
"165" "bardoxolone-methyl" "nuclear factor erythroid derived, like (NRF2) activator" "PPARG, STAT3" "" "" "BRD-K22848513-001-01-9" "COC(=O)[C@]12CCC(C)(C)C[C@@H]1[C@@H]1C(=O)C=C3[C@]4(C)C=C(C" "" ""
"166" "baricitinib" "JAK inhibitor" "JAK1, JAK2" "" "" "BRD-K53581288-001-02-9" "CCS(=O)(=O)N1CC(CC" "" ""
"167" "barnidipine" "calcium channel blocker" "" "cardiology" "hypertension" "BRD-K78781788-003-01-9" "COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1" "VXMOONUMYLCFJD-DHLKQENFSA-N" "Launched"
"168" "basic-fuchsin" "" "" "" "" "BRD-K26362911-003-01-1" "CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1" "YDCMWLQSPFTWCS-UHFFFAOYSA-N" "Preclinical"
"169" "basimglurant" "glutamate receptor antagonist" "GRM5" "" "" "BRD-K62387885-001-01-9" "Cc1nc(C" "" ""
"170" "batimastat" "matrix metalloprotease inhibitor" "ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8" "" "" "BRD-K82818427-001-02-2, BRD-K25361343-001-01-6" "CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO" "XFILPEOLDIKJHX-QYZOEREBSA-N, XFILPEOLDIKJHX-GBESFXJTSA-N" "Phase 3"
"171" "bavisant" "histamine receptor antagonist" "HRH3" "" "" "BRD-K79595931-312-01-3" "O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1" "BGBVSGSIXIIREO-UHFFFAOYSA-N" "Phase 2"
"172" "BAX-channel-blocker" "cytochrome C release inhibitor" "BAX" "" "" "BRD-A18763547-300-05-5" "OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12" "KUUJEXLRLIPQQJ-UHFFFAOYSA-N" "Preclinical"
"173" "BAY-K-8644-(+/-)" "L-type calcium channel activator" "" "" "" "BRD-A05457250-001-08-4" "COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1C(F)(F)F)[N+]([O-])=O" "ZFLWDHHVRRZMEI-UHFFFAOYSA-N" "Preclinical"
"174" "BAY-K-8644-(s)-(-)" "L-type calcium channel activator" "CACNA1C" "" "" "BRD-K14329163-001-03-9" "COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O" "ZFLWDHHVRRZMEI-ZDUSSCGKSA-N" "Preclinical"
"175" "bay-w-9798" "antioxidant" "" "" "" "BRD-K44471774-001-01-8" "COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC" "AVFYPHPSIBAAME-UHFFFAOYSA-N" "Phase 2"
"176" "BAY-11-7082" "NFkB pathway inhibitor" "RELA" "" "" "BRD-K15025317-001-17-7, BRD-K15025317-001-15-1, BRD-K15025317-001-14-4" "Cc1ccc(cc1)S(=O)(=O)\C=C\C" "" ""
"177" "BAY-11-7085" "NFkB pathway inhibitor" "NFKBIA" "" "" "BRD-K48684885-001-04-2" "CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C" "" ""
"178" "bay-60-7550" "phosphodiesterase inhibitor" "PDE2A" "" "" "BRD-K86932920-001-02-9" "COc1ccc(Cc2nn3c(nc(C)c3c(=O)[nH]2)[C@@H](CCCc2ccccc2)[C@@H](C)O)cc1OC" "MYTWFJKBZGMYCS-NQIIRXRSSA-N" "Preclinical"
"179" "BAY-61-3606" "syk inhibitor" "SYK" "" "" "BRD-K53281329-300-01-5" "COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1" "JWQOJVOKBAAAAR-UHFFFAOYSA-N" "Preclinical"
"180" "BAY-85-8050" "" "" "" "" "BRD-A11731518-001-01-7" "NC(CC(F)C(O)=O)C(O)=O" "JPSHPWJJSVEEAX-UHFFFAOYSA-N" "Phase 1"
"181" "BAY-87-2243" "hypoxia inducible factor inhibitor" "HIF1A" "" "" "BRD-K70463136-001-01-5" "Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1" "CDJNNOJINJAXPV-UHFFFAOYSA-N" "Phase 1"
"182" "bazedoxifene" "selective estrogen receptor modulator (SERM)" "ESR1, ESR2" "orthopedics, endocrinology" "osteoporosis, menopause" "BRD-K90195324-003-03-3, BRD-K90195324-003-02-5" "Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12, Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12" "UCJGJABZCDBEDK-UHFFFAOYSA-N, UCJGJABZCDBEDK-UHFFFAOYSA-N" "Launched"
"183" "BCI-540" "glutamate receptor agonist" "" "" "" "BRD-K23672206-001-01-4" "Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C" "PSPGQHXMUKWNDI-UHFFFAOYSA-N" "Phase 2"
"184" "BCX-1470" "serine protease inhibitor, complement inhibitor" "CFD" "" "" "BRD-K90472149-066-01-0" "NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1" "OTGQTQBPQCRNRG-UHFFFAOYSA-N" "Phase 1"
"185" "BD-1008" "sigma receptor antagonist" "" "" "" "BRD-K17008822-303-02-1" "CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1" "ASGIQUHBAVIOTI-UHFFFAOYSA-N" "Preclinical"
"186" "BD-1047" "adrenergic receptor antagonist" "SIGMAR1" "" "" "BRD-K36864847-303-02-5" "CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1" "MGVRNMUKTZOQOW-UHFFFAOYSA-N" "Preclinical"
"187" "BD-1063" "sigma receptor antagonist" "SIGMAR1" "" "" "BRD-K29668683-300-02-2" "CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1" "SUIZRDJCBVPASY-UHFFFAOYSA-N" "Preclinical"
"188" "BE-2254" "adrenergic receptor antagonist" "ADRA1A" "" "" "BRD-A24429032-003-02-4, BRD-A24429032-003-03-2" "Oc1ccc(CCNCC2CCc3ccccc3C2=O)cc1, Oc1ccc(CCNCC2CCc3ccccc3C2=O)cc1" "PZZOEXPDTYIBPI-UHFFFAOYSA-N, PZZOEXPDTYIBPI-UHFFFAOYSA-N" "Phase 2"
"189" "beclamide" "anticonvulsant" "" "neurology/psychiatry" "sedative, seizures" "BRD-K44824027-001-02-1" "ClCCC(=O)NCc1ccccc1" "JPYQFYIEOUVJDU-UHFFFAOYSA-N" "Launched"
"190" "beclomethasone" "glucocorticoid receptor agonist" "NR3C1, SERPINA6" "allergy" "allergic rhinitis" "BRD-A73385064-001-01-5" "CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC2(C)C1(O)C(=O)CO" "NBMKJKDGKREAPL-UHFFFAOYSA-N" "Launched"
"191" "beclomethasone-dipropionate" "glucocorticoid receptor agonist" "GPR97, NR3C1" "allergy" "allergic rhinitis" "BRD-K97810537-001-12-8, BRD-A11319535-001-03-6, BRD-K97429934-001-01-9" "CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)C1(OC(=O)CC)C(C)CC2C3CCC4=CC(=O)C=CC4(C)C3(Cl)C(O)CC12C, CCC(=O)OCC(=O)[C@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(Cl)[C@H](O)C[C@]12C" "KUVIULQEHSCUHY-XYWKZLDCSA-N, KUVIULQEHSCUHY-UHFFFAOYSA-N, KUVIULQEHSCUHY-GMKZLEGCSA-N" "Launched"
"192" "bedaquiline" "ATPase inhibitor" "" "infectious disease" "tuberculosis" "BRD-K90817094-001-02-6, BRD-K90817094-001-03-4" "COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12, COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12" "QUIJNHUBAXPXFS-XLJNKUFUSA-N, QUIJNHUBAXPXFS-XLJNKUFUSA-N" "Launched"
"193" "befuraline" "" "" "" "" "BRD-K99077012-001-01-9" "O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1" "SRIJFPBZWUFLFD-UHFFFAOYSA-N" "Phase 2"
"194" "begacestat" "gamma secretase inhibitor" "PSEN1" "" "" "BRD-K58319700-001-01-1" "OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F" "PSXOKXJMVRSARX-SCSAIBSYSA-N" "Phase 1"
"195" "bekanamycin" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K73425385-065-04-8, BRD-K73425385-001-01-9" "NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O" "SKKLOUVUUNMCJE-FQSMHNGLSA-N, SKKLOUVUUNMCJE-FQSMHNGLSA-N" "Launched"
"196" "belinostat" "HDAC inhibitor" "HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9" "hematologic malignancy" "peripheral T-cell lymphoma (PTCL)" "BRD-K17743125-001-08-4" "ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1" "NCNRHFGMJRPRSK-MDZDMXLPSA-N" "Launched"
"197" "bemegride" "chemoreceptor agonist" "GABRA1" "critical care" "poison antidote" "BRD-K14993104-001-05-9" "CCC1(C)CC(=O)NC(=O)C1" "ORRZGUBHBVWWOP-UHFFFAOYSA-N" "Launched"
"198" "bemesetron" "serotonin receptor antagonist" "HTR3A, HTR3B" "" "" "BRD-A85587465-001-03-3" "CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1" "MNJNPLVXBISNSX-UHFFFAOYSA-N" "Phase 3"
"199" "bemotrizinol" "" "" "dermatology" "sunscreen lotion" "BRD-A92974210-396-01-0" "CCCCC(CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OCC(CC)CCCC)cc1O)-c1ccc(OC)cc1" "XVAMCHGMPYWHNL-UHFFFAOYSA-N" "Launched"
"200" "benaxibine" "" "" "" "" "BRD-A90642009-001-03-2" "OC1COC(Nc2ccc(cc2)C(O)=O)C(O)C1O" "HLDUHCYBUVVDOT-UHFFFAOYSA-N" "Phase 1"
"201" "benazepril" "angiotensin converting enzyme inhibitor" "ACE" "cardiology" "hypertension" "BRD-K49807096-003-15-5, BRD-K49807096-003-14-8, BRD-K49807096-003-16-3" "CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O" "XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N, XPCFTKFZXHTYIP-PMACEKPBSA-N" "Launched"
"202" "bendamustine" "DNA inhibitor" "" "hematologic malignancy" "chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)" "BRD-K17068645-003-04-2, BRD-K17068645-003-05-9" "Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl, Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl" "YTKUWDBFDASYHO-UHFFFAOYSA-N, YTKUWDBFDASYHO-UHFFFAOYSA-N" "Launched"
"203" "bendazac" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "neurology/psychiatry, rheumatology" "muscle pain, joint pain" "BRD-K19515365-001-02-6" "OC(=O)COc1nn(Cc2ccccc2)c2ccccc12" "BYFMCKSPFYVMOU-UHFFFAOYSA-N" "Launched"
"204" "bendroflumethiazide" "sodium/potassium/chloride transporter inhibitor" "CA1, CA2, CA4, KCNMA1, SLC12A1, SLC12A3" "cardiology" "hypertension" "BRD-A80017228-001-25-7, BRD-A80017228-001-24-0" "NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F, NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F" "HDWIHXWEUNVBIY-UHFFFAOYSA-N, HDWIHXWEUNVBIY-UHFFFAOYSA-N" "Launched"
"205" "benethamine" "" "" "" "" "BRD-K13473780-001-02-1" "C(Cc1ccccc1)NCc1ccccc1" "UPABQMWFWCMOFV-UHFFFAOYSA-N" "Preclinical"
"206" "benfluorex" "gluconeogenesis inhibitor" "HMGCR" "" "" "BRD-A22305049-003-13-6" "CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1" "CJAVTWRYCDNHSM-UHFFFAOYSA-N" "Withdrawn"
"207" "benfluralin" "" "CYP1A1, CYP1A2, CYP2B6, CYP3A4, ESR1, MMP1, SULT2A1, UGT1A1" "" "" "BRD-K33903083-001-03-5" "CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O" "SMDHCQAYESWHAE-UHFFFAOYSA-N" "Phase 3"
"208" "benfotiamine" "antioxidant" "AGER" "rheumatology" "lumbago" "BRD-K07359318-001-03-9, BRD-K05319475-001-04-2, BRD-K07359318-396-01-7" "C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1, C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCOP(O)(O)=O)SC(=O)c1ccccc1" "BTNNPSLJPBRMLZ-GHRIWEEISA-N, BTNNPSLJPBRMLZ-LGMDPLHJSA-N, BTNNPSLJPBRMLZ-GHRIWEEISA-N" "Launched"
"209" "benidipine" "calcium channel blocker" "CACNA1C, CACNA1G" "cardiology" "hypertension" "BRD-K97181463-003-02-9, BRD-K97181463-003-01-1" "COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1, COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1" "QZVNQOLPLYWLHQ-ZEQKJWHPSA-N, QZVNQOLPLYWLHQ-ZEQKJWHPSA-N" "Launched"
"210" "benperidol" "dopamine receptor antagonist" "DRD2" "neurology/psychiatry" "schizophrenia" "BRD-K79425933-001-09-3" "Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O" "FEBOTPHFXYHVPL-UHFFFAOYSA-N" "Launched"
"211" "benproperine" "antitussive" "SCN5A" "pulmonary" "cough suppressant" "BRD-A42423104-001-01-4" "CC(COc1ccccc1Cc1ccccc1)N1CCCCC1" "JTUQXGZRVLWBCR-UHFFFAOYSA-N" "Launched"
"212" "benserazide" "DOPA decarboxylase inhibitor" "DDC" "neurology/psychiatry" "Parkinsons Disease	BRD-A61194565-003-27-0, BRD-A61194565-003-28-8	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O, NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	BNQDCRGUHNALGH-UHFFFAOYSA-N, BNQDCRGUHNALGH-UHFFFAOYSA-N	Launched
bentazepam	benzodiazepine receptor agonist		neurology/psychiatry	anxiety, sedative, muscle relaxant	BRD-K89490285-001-08-1	O=C1CN=C(c2c3CCCCc3sc2N1)c1ccccc1	AIZFEOPQVZBNGH-UHFFFAOYSA-N	Launched
bentiromide		HPN	gastroenterology	pancreas diagnostic agent	BRD-K58794715-001-02-6, BRD-K58794715-001-01-8	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1, OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	SPPTWHFVYKCNNK-FQEVSTJZSA-N, SPPTWHFVYKCNNK-FQEVSTJZSA-N	Launched
benurestat	urease inhibitor				BRD-K88553858-001-02-7	ONC(=O)CNC(=O)c1ccc(Cl)cc1	JFZGBMJPJZDNNT-UHFFFAOYSA-N	Phase 1
benzalkonium	Cationic surfactant		dermatology	abrasions, superficial cuts	BRD-K34234316-003-04-7	CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	VVZBFOKBSDGVGZ-UHFFFAOYSA-N	Launched
benzamil	sodium channel blocker	ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1			BRD-K97688263-001-03-7	N\C(NCc1ccccc1)=N/C(=O)c1nc(Cl)c(N)nc1N	KXDROGADUISDGY-UHFFFAOYSA-N	Phase 2
benzbromarone	chloride channel blocker	ABCC1	rheumatology	gout	BRD-K11717138-001-30-3, BRD-K11717138-001-29-5	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1, CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	WHQCHUCQKNIQEC-UHFFFAOYSA-N, WHQCHUCQKNIQEC-UHFFFAOYSA-N	Launched
benzethonium	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	BRD-K72723676-003-17-8, BRD-K72723676-003-16-0	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1, CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	SIYLLGKDQZGJHK-UHFFFAOYSA-N, SIYLLGKDQZGJHK-UHFFFAOYSA-N	Launched
benznidazole	DNA synthesis inhibitor		infectious disease	Chagas disease	BRD-K56156805-001-09-6	[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1	CULUWZNBISUWAS-UHFFFAOYSA-N	Launched
benzo[d]thiazole-2(3h)-thione					BRD-K55160477-001-04-7	Sc1nc2ccccc2s1	YXIWHUQXZSMYRE-UHFFFAOYSA-N	Phase 1
benzocaine	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	BRD-K75466013-001-14-4, BRD-K75466013-001-13-6	CCOC(=O)c1ccc(N)cc1, CCOC(=O)c1ccc(N)cc1	BLFLLBZGZJTVJG-UHFFFAOYSA-N, BLFLLBZGZJTVJG-UHFFFAOYSA-N	Launched
benzoclidine					BRD-A45929034-001-09-5	O=C(OC1CN2CCC1CC2)c1ccccc1	AHKAOMZZTQULDS-UHFFFAOYSA-N	Preclinical
benzofenac					BRD-K26556907-001-01-8	OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1	DFHBBMJTBBLQSA-UHFFFAOYSA-N	Phase 1
benzoic-acid	food preservative	DAO, HRSP12, PRDX5, RAB9A	infectious disease	tinea pedis	BRD-K53397409-001-13-1, BRD-K53397409-001-12-3, BRD-K53397409-001-11-5	OC(=O)c1ccccc1, OC(=O)c1ccccc1, OC(=O)c1ccccc1	WPYMKLBDIGXBTP-UHFFFAOYSA-N, WPYMKLBDIGXBTP-UHFFFAOYSA-N, WPYMKLBDIGXBTP-UHFFFAOYSA-N	Launched
benzoin		CES1			BRD-A55748233-001-08-7	OC(C(=O)c1ccccc1)c1ccccc1	ISAOCJYIOMOJEB-UHFFFAOYSA-N	Preclinical
benzonatate	local anesthetic	SCN5A	pulmonary	cough suppressant	BRD-K91699951-001-10-2	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	MAFMQEKGGFWBAB-UHFFFAOYSA-N	Launched
benzoquinonium-dibromide	cholinergic receptor antagonist	CHRNA1			BRD-K18772613-303-02-4	CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1	YERABYSOHUZTPQ-UHFFFAOYSA-P	Preclinical
benzotript	CCK receptor antagonist	CCKAR, CCKBR			BRD-A87983072-001-01-1	OC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	QJERBBQXOMUURJ-UHFFFAOYSA-N	Phase 1
benzoxiquine	antiinfective drug				BRD-K70327191-001-02-2	O=C(Oc1cccc2cccnc12)c1ccccc1	BHKPHCKISVSDGV-UHFFFAOYSA-N	Preclinical
benzoyl-peroxide	oxidizing agent		dermatology	acne vulgaris (AV)	BRD-K59986511-001-04-9, BRD-K59986511-001-06-4	O=C(OOC(=O)c1ccccc1)c1ccccc1, O=C(OOC(=O)c1ccccc1)c1ccccc1	OMPJBNCRMGITSC-UHFFFAOYSA-N, OMPJBNCRMGITSC-UHFFFAOYSA-N	Launched
benzoylpas					BRD-K20431737-001-08-1	OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	GNZCRYWFWKFIDM-UHFFFAOYSA-N	Preclinical
benzthiazide	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA4, CA9, SLC12A3	cardiology	hypertension, edema	BRD-K21450440-001-14-6, BRD-K21450440-001-13-8	NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O, NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O	NDTSRXAMMQDVSW-UHFFFAOYSA-N, NDTSRXAMMQDVSW-UHFFFAOYSA-N	Launched
benztropine-mesylate	acetylcholine receptor antagonist	CHRM1, HRH1, SLC6A3	neurology/psychiatry	extrapyramidal symptoms (EPS), Parkinsons Disease" "BRD-K48061146-066-01-7" "CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1" "GIJXKZJWITVLHI-RTBURBONSA-N" "Launched"
"213" "benzydamine" "prostanoid receptor antagonist" "" "dental, otolaryngology" "mouth inflammation, throat inflammation" "BRD-K28542495-003-13-5, BRD-K28542495-003-12-7" "CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12, CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12" "CNBGNNVCVSKAQZ-UHFFFAOYSA-N, CNBGNNVCVSKAQZ-UHFFFAOYSA-N" "Launched"
"214" "benzyl-alcohol" "local anesthetic" "" "infectious disease" "virus herpes simplex (HSV)" "BRD-K98494274-001-03-6, BRD-K98494274-001-05-1" "OCc1ccccc1, OCc1ccccc1" "WVDDGKGOMKODPV-UHFFFAOYSA-N, WVDDGKGOMKODPV-UHFFFAOYSA-N" "Launched"
"215" "benzyl-benzoate" "lipase inhibitor" "LIPE" "allergy" "sweet itch" "BRD-K52072429-001-10-3, BRD-K52072429-001-12-9, BRD-K52072429-001-11-1" "O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1, O=C(OCc1ccccc1)c1ccccc1" "SESFRYSPDFLNCH-UHFFFAOYSA-N, SESFRYSPDFLNCH-UHFFFAOYSA-N, SESFRYSPDFLNCH-UHFFFAOYSA-N" "Launched"
"216" "benzyl-isothiocyanate" "methylazoxymethanol acetate inhibitor" "" "" "" "BRD-K80253852-001-04-4" "S=C=NCc1ccccc1" "MDKCFLQDBWCQCV-UHFFFAOYSA-N" "Preclinical"
"217" "benzyldimethylhexadecylammonium" "cationic surfactant" "" "" "" "BRD-K23403298-003-01-9" "CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1" "QDYLMAYUEZBUFO-UHFFFAOYSA-N" "Preclinical"
"218" "benzyldimethyloctylammonium" "" "" "" "" "BRD-K11576103-003-01-1" "CCCCCCCC[N+](C)(C)Cc1ccccc1" "SHFLYPPECXRCFO-UHFFFAOYSA-N" "Preclinical"
"219" "benzylpenicillin" "penicillin binding protein inhibitor" "" "infectious disease" "celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia" "BRD-K55191674-237-18-3, BRD-K55191674-236-06-0, BRD-K55191674-236-07-8" "CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O" "JGSARLDLIJGVTE-MBNYWOFBSA-N, JGSARLDLIJGVTE-MBNYWOFBSA-N, JGSARLDLIJGVTE-MBNYWOFBSA-N" "Launched"
"220" "bephenium-hydroxynaphthoate" "anthelmintic agent" "" "infectious disease" "ascariasis" "BRD-K47878171-086-06-0, BRD-K47878171-086-05-2, BRD-K47878171-086-07-8" "C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1, C[N+](C)(CCOc1ccccc1)Cc1ccccc1" "AVWWVJUMXRXPNF-UHFFFAOYSA-N, AVWWVJUMXRXPNF-UHFFFAOYSA-N, AVWWVJUMXRXPNF-UHFFFAOYSA-N" "Launched"
"221" "bepotastine" "histamine receptor antagonist" "HRH1" "ophthalmology" "conjunctivitis" "BRD-K98624455-074-02-8" "OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1" "YWGDOWXRIALTES-NRFANRHFSA-N" "Launched"
"222" "bepridil" "calcium channel blocker" "ATP1A1, CACNA1A, CACNA1H, CACNA2D2, CALM1, KCNQ1, KCNQ4, PDE1A, PDE1B, TNNC1" "cardiology" "angina pectoris" "BRD-A91008255-003-25-5, BRD-A91008255-003-24-8" "CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1, CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1" "UIEATEWHFDRYRU-UHFFFAOYSA-N, UIEATEWHFDRYRU-UHFFFAOYSA-N" "Launched"
"223" "berberine" "LDL receptor activator" "LDLR" "" "" "BRD-K14796088-003-26-8, BRD-K14796088-003-25-0" "COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC, COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC" "YBHILYKTIRIUTE-UHFFFAOYSA-N, YBHILYKTIRIUTE-UHFFFAOYSA-N" "Phase 2/Phase 3"
"224" "bergapten" "" "" "" "" "BRD-K12968785-001-13-3, BRD-K12968785-001-12-5" "COc1c2ccoc2cc2oc(=O)ccc12, COc1c2ccoc2cc2oc(=O)ccc12" "BGEBZHIAGXMEMV-UHFFFAOYSA-N, BGEBZHIAGXMEMV-UHFFFAOYSA-N" "Preclinical"
"225" "bergenin" "interleukin inhibitor" "IL1B, TNF" "" "" "BRD-K04176066-001-08-3, BRD-K18550767-001-03-6" "COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O, COc1c(O)cc2C(=O)O[C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]3c2c1O" "YWJXCIXBAKGUKZ-HJJNZUOJSA-N, YWJXCIXBAKGUKZ-BPTACTMOSA-N" "Preclinical"
"226" "besifloxacin" "bacterial DNA gyrase inhibitor" "" "ophthalmology" "conjunctivitis" "BRD-K10196357-003-02-0" "N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1" "QFFGVLORLPOAEC-SNVBAGLBSA-N" "Launched"
"227" "BET-BAY-002" "bromodomain inhibitor" "" "" "" "BRD-K72735080-001-01-0" "Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1" "AGYIAWHWIUZNSD-INIZCTEOSA-N" "Preclinical"
"228" "beta-amyloid-synthesis-inhibitor" "beta amyloid synthesis inhibitor" "APP" "" "" "BRD-K38687824-001-02-5" "Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1" "GYNDFOLSPPBBIK-UHFFFAOYSA-N" "Preclinical"
"229" "beta-carotene" "" "" "" "" "BRD-K74225533-001-08-8, BRD-K34538779-001-01-1, BRD-K74225533-001-09-6, BRD-K74225533-001-10-4" "CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C, CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C\C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C, CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C, CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C" "OENHQHLEOONYIE-JLTXGRSLSA-N, OENHQHLEOONYIE-KBPBZLIPSA-N, OENHQHLEOONYIE-JLTXGRSLSA-N, OENHQHLEOONYIE-JLTXGRSLSA-N" "Launched"
"230" "beta-CCB" "benzodiazepine receptor ligand" "GABRA1, GABRG2" "" "" "BRD-K87349602-001-03-8" "CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21" "WGNGIELOOKACSB-UHFFFAOYSA-N" "Launched"
"231" "beta-elemene" "apoptosis stimulant" "MMP2, MMP9" "" "" "BRD-K21045639-001-01-2" "CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C" "OPFTUNCRGUEPRZ-QLFBSQMISA-N" "Launched"
"232" "beta-funaltrexamine" "opioid receptor antagonist" "OPRD1, OPRK1, OPRM1" "" "" "BRD-K95110148-003-01-5" "COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45" "PQKHESYTSKMWFP-WZJCLRDWSA-N" "Preclinical"
"233" "beta-glycerophosphoric-acid" "" "" "" "" "BRD-K39061174-001-01-0" "OCC(CO)OP(O)(O)=O" "DHCLVCXQIBBOPH-UHFFFAOYSA-N" "Preclinical"
"234" "beta-hydroxy-beta-methylbutyrate" "protein synthesis stimulant" "MTOR" "" "" "BRD-M02899238-238-01-6" "CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O" "KORPMXSVHOHPMS-UHFFFAOYSA-N" "Phase 2/Phase 3"
"235" "beta-Hydroxybutyrate" "" "HCAR2" "" "" "BRD-A41387824-001-06-0" "CC(O)CC(O)=O" "WHBMMWSBFZVSSR-UHFFFAOYSA-N" "Phase 1"
"236" "beta-lapachone" "topoisomerase inhibitor" "TOP1" "" "" "BRD-K28061410-001-06-6, BRD-K28061410-001-07-4, BRD-K28061410-001-05-8" "CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O, CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O" "QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N, QZPQTZZNNJUOLS-UHFFFAOYSA-N" "Phase 2"
"237" "beta-naphthol" "" "" "" "" "BRD-K21164796-001-02-8" "Oc1ccc2ccccc2c1" "JWAZRIHNYRIHIV-UHFFFAOYSA-N" "Preclinical"
"238" "betahistine" "histamine receptor agonist, histamine receptor antagonist" "HRH1, HRH3" "neurology/psychiatry" "Menieres disease	BRD-K91315211-300-05-7, BRD-K91315211-300-06-5	CNCCc1ccccn1, CNCCc1ccccn1	UUQMNUMQCIQDMZ-UHFFFAOYSA-N, UUQMNUMQCIQDMZ-UHFFFAOYSA-N	Launched
betaine	nitric oxide donor		metabolism	homocystinuria	BRD-K12014493-001-02-2	C[N+](C)(C)CC(O)=O	KWIUHFFTVRNATP-UHFFFAOYSA-O	Launched
betamethasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-A02180903-001-04-5	C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	UREBDLICKHMUKA-REKGUKDCSA-N	Launched
betamethasone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-A92177080-001-02-1	C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O	AKUJBENLRBOFTD-DKNQJTFPSA-N	Launched
betamethasone-dipropionate	anti-inflammatory agent		dermatology	corticosteroid-responsive dermatoses	BRD-A66861218-001-04-3, BRD-K95691366-001-01-3	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C, CCC(=O)OCC(=O)[C@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C	CIWBQSYVNNPZIQ-YMSYXYNZSA-N, CIWBQSYVNNPZIQ-GMKZLEGCSA-N	Launched
betamethasone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-A80594172-001-04-6, BRD-K57769959-001-01-6, BRD-K34032314-001-02-5	CCCCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(O)C[C@]12C)C(=O)CO, CCCCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CO, CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO	SNHRLVCMMWUAJD-FHOZUDJNSA-N, SNHRLVCMMWUAJD-MTDSSPGGSA-N, SNHRLVCMMWUAJD-SUYDQAKGSA-N	Launched
betamipron	panipenem uptake inhibitor		nephrology	renal toxicity	BRD-K82142815-001-19-1, BRD-K82142815-001-18-3	OC(=O)CCNC(=O)c1ccccc1, OC(=O)CCNC(=O)c1ccccc1	CWXYHOHYCJXYFQ-UHFFFAOYSA-N, CWXYHOHYCJXYFQ-UHFFFAOYSA-N	Launched
betaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-A02759312-003-24-5, BRD-A02759312-001-03-3, BRD-A02759312-003-25-2, BRD-A02759312-003-23-7, BRD-K43883465-003-01-5, BRD-A02759312-001-02-5	CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1, CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1, CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1	NWIUTZDMDHAVTP-UHFFFAOYSA-N, NWIUTZDMDHAVTP-UHFFFAOYSA-N, NWIUTZDMDHAVTP-UHFFFAOYSA-N, NWIUTZDMDHAVTP-UHFFFAOYSA-N, NWIUTZDMDHAVTP-KRWDZBQOSA-N, NWIUTZDMDHAVTP-UHFFFAOYSA-N	Launched
betazole	histamine receptor agonist	HRH2	gastroenterology	gastric hypersecretion diagnostic	BRD-K20075662-300-04-0	NCCc1cc[nH]n1	JXDFEQONERDKSS-UHFFFAOYSA-N	Launched
bethanechol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	urology	urinary retention	BRD-A99833829-003-27-1, BRD-A99833829-003-26-3, BRD-A99833829-003-25-5	CC(C[N+](C)(C)C)OC(N)=O, CC(C[N+](C)(C)C)OC(N)=O, CC(C[N+](C)(C)C)OC(N)=O	NZUPCNDJBJXXRF-UHFFFAOYSA-O, NZUPCNDJBJXXRF-UHFFFAOYSA-O, NZUPCNDJBJXXRF-UHFFFAOYSA-O	Launched
betrixaban	coagulation factor inhibitor	KCNH2			BRD-K45275534-001-01-3	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	XHOLNRLADUSQLD-UHFFFAOYSA-N	Phase 3
betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	GPBAR1			BRD-K45401373-001-20-9, BRD-K38744518-001-01-7	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O, CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@H]12)C(O)=O	QGJZLNKBHJESQX-FZFNOLFKSA-N, QGJZLNKBHJESQX-XNWPAUOFSA-N	Phase 1/Phase 2
bevantolol	adrenergic receptor antagonist	ADRA1A, ADRB1, ADRB2	cardiology	angina pectoris, hypertension	BRD-A18233884-003-02-7	COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC	HXLAFSUPPDYFEO-UHFFFAOYSA-N	Launched
bevirimat-dimeglumine	HIV capsid assembly inhibitor				BRD-K16898998-001-01-6	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	YJEJKUQEXFSVCJ-WRFMNRASSA-N	Phase 2
bexarotene	retinoid receptor agonist	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	BRD-K92441787-001-04-1	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	NAVMQTYZDKMPEU-UHFFFAOYSA-N	Launched
bezafibrate	PPAR receptor agonist	PPARA, PPARD, PPARG	cardiology	cholesterol	BRD-K46018455-001-27-6, BRD-K46018455-001-26-8	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O, CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	IIBYAHWJQTYFKB-UHFFFAOYSA-N, IIBYAHWJQTYFKB-UHFFFAOYSA-N	Launched
BF2.649	histamine receptor antagonist	HRH3			BRD-K21673112-003-01-3	Clc1ccc(CCCOCCCN2CCCCC2)cc1	NNACHAUCXXVJSP-UHFFFAOYSA-N	Phase 3
BGT226	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CG			BRD-K29415052-050-05-5, BRD-K29415052-050-04-8	COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1, COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	BMMXYEBLEBULND-UHFFFAOYSA-N, BMMXYEBLEBULND-UHFFFAOYSA-N	Phase 1/Phase 2
BHQ	ATPase inhibitor	ATP2A1			BRD-K95603879-001-07-5	CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C	JZODKRWQWUWGCD-UHFFFAOYSA-N	Preclinical
BI-D1870	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6			BRD-A81370665-001-03-6, BRD-A81370665-001-04-4	CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12, CC(C)CCN1C(C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12	DTEKTGDVSARYDS-UHFFFAOYSA-N, DTEKTGDVSARYDS-UHFFFAOYSA-N	Preclinical
BI-224436	HIV integrase inhibitor				BRD-K53422148-001-01-8	Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O	MIXIIJCBELCMCZ-VWLOTQADSA-N	Phase 1
BI-2536	PLK inhibitor	BRD4, PLK1, PLK2, PLK3			BRD-K64890080-001-13-8	CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	XQVVPGYIWAGRNI-JOCHJYFZSA-N	Phase 2
BI-78D3	JNK inhibitor	MAPK8			BRD-K73982490-001-03-7, BRD-K73982490-001-02-9	Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1, Oc1nnc(Sc2ncc(s2)[N+]([O-])=O)n1-c1ccc2OCCOc2c1	QFRLDZGQEZCCJZ-UHFFFAOYSA-N, QFRLDZGQEZCCJZ-UHFFFAOYSA-N	Preclinical
BI-847325	MEK inhibitor, Aurora kinase inhibitor	AURKA, AURKB, AURKC, MAP2K1, MAP2K2			BRD-K37492701-001-02-9, BRD-K37492701-001-01-1	CCNC(=O)C#Cc1ccc2c(NC(=O)\C2=C(\Nc2ccc(CN(C)C)cc2)c2ccccc2)c1, CCNC(=O)C#Cc1ccc2c(NC(=O)\C2=C(\Nc2ccc(CN(C)C)cc2)c2ccccc2)c1	FLBNLJLONKAPLR-BYYHNAKLSA-N, FLBNLJLONKAPLR-BYYHNAKLSA-N	Phase 1
biapenem	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, pneumonia, urinary tract infections	BRD-A80321291-001-03-2, BRD-A80321291-001-04-0, BRD-A80321291-001-01-6, BRD-A80321291-001-05-7, BRD-A80321291-001-02-4	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O	MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O, MRMBZHPJVKCOMA-YJFSRANCSA-O	Launched
BIBN4096	calcitonin antagonist	CALCA, CALCRL, RAMP1			BRD-K43927145-001-02-0, BRD-K43927145-001-01-2	NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1, NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	ITIXDWVDFFXNEG-JHOUSYSJSA-N, ITIXDWVDFFXNEG-JHOUSYSJSA-N	Phase 2
BIBR-1532	telomerase inhibitor	TERT			BRD-K04623885-001-07-5	C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	PGFQXGLPJUCTOI-WYMLVPIESA-N	Preclinical
BIBU-1361	EGFR inhibitor	EGFR			BRD-K49294207-300-03-8	CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	JUGSLZCFNSTKBN-UHFFFAOYSA-N	Preclinical
BIBX-1382	EGFR inhibitor	EGFR, ERBB2			BRD-K70914287-300-02-8, BRD-K70914287-300-03-6	CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1, CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	FTFRZXFNZVCRSK-UHFFFAOYSA-N, FTFRZXFNZVCRSK-UHFFFAOYSA-N	Phase 1
bicalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	BRD-A29485665-001-12-8, BRD-A29485665-001-11-0	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F, CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	LKJPYSCBVHEWIU-UHFFFAOYSA-N, LKJPYSCBVHEWIU-UHFFFAOYSA-N	Launched
bicuculline-(+)	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1			BRD-A07870296-001-07-4, BRD-A07870296-001-06-6	CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, CN1CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21	IYGYMKDQCDOMRE-QRWMCTBCSA-N, IYGYMKDQCDOMRE-QRWMCTBCSA-N	Preclinical
bicuculline-methochloride-(-)	GABA receptor antagonist				BRD-A57798559-004-02-3, BRD-A57798559-003-02-5, BRD-A57798559-005-02-0	C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21, C[N+]1(C)CCc2cc3OCOc3cc2C1[C@@H]1OC(=O)c2c1ccc1OCOc21	WDIQXKYUSINZME-MUMRKEEXSA-N, WDIQXKYUSINZME-MUMRKEEXSA-N, WDIQXKYUSINZME-MUMRKEEXSA-N	Preclinical
bicyclol	NFkB pathway inhibitor	HSPA1A, HSPB1			BRD-K16546375-001-01-4	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO	KXMTXZACPVCDMH-UHFFFAOYSA-N	Launched
bifemelane	acetylcholine release enhancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	BRD-K18779551-003-07-8	CNCCCCOc1ccccc1Cc1ccccc1	QSQQPMHPCBLLGX-UHFFFAOYSA-N	Launched
bifendate					BRD-K26581543-001-01-6	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC	JMZOMFYRADAWOG-UHFFFAOYSA-N	Launched
bifonazole	sterol demethylase inhibitor	CYP2B6	infectious disease	tinea pedis, tinea cruris	BRD-A94543220-001-24-7, BRD-A94543220-001-23-9	c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1, c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1	OCAPBUJLXMYKEJ-UHFFFAOYSA-N, OCAPBUJLXMYKEJ-UHFFFAOYSA-N	Launched
BIIB021	HSP inhibitor	HSP90AA1			BRD-K51967704-001-03-6, BRD-K51967704-001-04-4	COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	QULDDKSCVCJTPV-UHFFFAOYSA-N, QULDDKSCVCJTPV-UHFFFAOYSA-N	Phase 2
bilastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	BRD-K51937257-001-01-4	CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	ACCMWZWAEFYUGZ-UHFFFAOYSA-N	Launched
bilobalide	GABA receptor modulator	GLRA1, GLRA2, GLRB, HTR3A, HTR3B			BRD-A35837007-001-01-2	CC(C)(C)[C@@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@H]3OC(=O)[C@H](O)C123	MOLPUWBMSBJXER-IHLOTJOASA-N	Preclinical
bimatoprost	prostanoid receptor agonist	AKR1C3, PTGER1, PTGER3, PTGFR	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-A45153512-001-01-0	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(O)CCc1ccccc1	AQOKCDNYWBIDND-GCYMYIANSA-N	Launched
bindarit	NFkB pathway inhibitor	CCL2, CCL7, CCL8			BRD-K36467523-001-02-8	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	MTHORRSSURHQPZ-UHFFFAOYSA-N	Phase 2
BIO-1211	integrin antagonist	ITGA4, ITGB1			BRD-K03399463-001-01-6	CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O	NVVGCQABIHSJSQ-KFZSMJGVSA-N	Phase 2
biotin	vitamin B	ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6			BRD-K95496960-001-01-7, BRD-A36603537-001-13-1	OC(=O)CCCC[C@H]1SC[C@@H]2NC(=O)N[C@H]12, OC(=O)CCCCC1SCC2NC(=O)NC12	YBJHBAHKTGYVGT-OOZYFLPDSA-N, YBJHBAHKTGYVGT-UHFFFAOYSA-N	Launched
bipenamol	dipeptidyl peptidase inhibitor	CTSC			BRD-K47690382-001-03-0	NCc1ccccc1Sc1ccccc1CO	HLAFSNJRKZLMPT-UHFFFAOYSA-N	Phase 2
biperiden	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry	Parkinsons Disease" "BRD-A00546892-001-02-6, BRD-A00546892-003-05-5" "OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1, OC(CCN1CCCCC1)(C1CC2CC1C=C2)c1ccccc1" "YSXKPIUOCJLQIE-UHFFFAOYSA-N, YSXKPIUOCJLQIE-UHFFFAOYSA-N" "Launched"
"239" "birinapant" "XIAP inhibitor" "BIRC2, XIAP" "" "" "BRD-K71221037-001-02-4, BRD-K71221037-001-01-6" "CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC, CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC" "PKWRMUKBEYJEIX-DXXQBUJASA-N, PKWRMUKBEYJEIX-DXXQBUJASA-N" "Phase 2"
"240" "bis(maltolato)oxovanadium(IV)" "tyrosine phosphatase inhibitor" "PTPN1" "" "" "BRD-K16180792-001-01-7" "Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O" "XUOLEICXAPEOSI-UHFFFAOYSA-L" "Phase 2"
"241" "bisacodyl" "laxative" "" "gastroenterology" "constipation" "BRD-K39987650-001-24-1, BRD-K39987650-001-23-3" "CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1, CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1" "KHOITXIGCFIULA-UHFFFAOYSA-N, KHOITXIGCFIULA-UHFFFAOYSA-N" "Launched"
"242" "bisindolylmaleimide-ix" "PKC inhibitor" "AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1" "" "" "BRD-K06543683-066-04-7, BRD-K06543683-066-05-4, BRD-K06543683-066-02-1, BRD-K06543683-066-03-9" "Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12" "DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N, DSXXEELGXBCYNQ-UHFFFAOYSA-N" "Preclinical"
"243" "bismuth(iii)-trifluoromethanesulfonate" "direct substitution catalyst" "" "" "" "BRD-M56276249-001-01-1" "[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F" "BQFARKYNYLKHRD-UHFFFAOYSA-N" "Preclinical"
"244" "bismuth-oxalate" "" "" "" "" "BRD-M02179497-001-01-1" "[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O" "PEBMBOMJLWXKFI-UHFFFAOYSA-N" "Preclinical"
"245" "bismuth-subcitrate-potassium" "" "" "gastroenterology" "duodenal ulcer disease" "BRD-A03880619-001-01-0, BRD-A03880619-001-02-8" "OC(=O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O, OC(=O)CC(O)(CC(=O)O[Bi]1OC(=O)CC(O)(CC(O)=O)C(=O)O1)C(O)=O" "KNOSZBQOKCZXTI-UHFFFAOYSA-K, KNOSZBQOKCZXTI-UHFFFAOYSA-K" "Launched"
"246" "bismuth-subgallate" "nitric oxide synthase inhibitor" "NOS1" "" "" "BRD-K65978409-001-01-9" "O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O" "JAONZGLTYYUPCT-UHFFFAOYSA-K" "Launched"
"247" "bismuth-subsalicylate" "antacid" "" "gastroenterology" "diarrhea" "BRD-K80528473-001-04-8, BRD-K80528473-001-05-5, BRD-K80528473-001-03-0, BRD-K80528473-001-07-1" "O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1, O[Bi]1OC(=O)c2ccccc2O1" "ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K, ZREIPSZUJIFJNP-UHFFFAOYSA-K" "Launched"
"248" "bisoctrizole" "" "" "" "" "BRD-K00228584-396-01-8" "CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1" "FQUNFJULCYSSOP-UHFFFAOYSA-N" "Phase 2"
"249" "bisoprolol" "adrenergic receptor antagonist" "ADRB1, ADRB2" "cardiology" "hypertension" "BRD-A89175223-051-16-3, BRD-A89175223-051-14-8, BRD-A89175223-051-13-0, BRD-A89175223-051-15-5" "CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1, CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1" "VHYCDWMUTMEGQY-UHFFFAOYSA-N, VHYCDWMUTMEGQY-UHFFFAOYSA-N, VHYCDWMUTMEGQY-UHFFFAOYSA-N, VHYCDWMUTMEGQY-UHFFFAOYSA-N" "Launched"
"250" "bisphenol-a" "synthetic estrogen" "AR, ESR1, ESR2, ESRRG, PPARG" "" "" "BRD-K41494493-001-13-8" "CC(C)(c1ccc(O)cc1)c1ccc(O)cc1" "IISBACLAFKSPIT-UHFFFAOYSA-N" "Phase 1"
"251" "bithionol" "autotaxin inhibitor" "ESR1, ESR2, MCL1" "" "" "BRD-K39120595-304-04-7" "Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O" "JFIOVJDNOJYLKP-UHFFFAOYSA-N" "Withdrawn"
"252" "bitopertin" "glycine transporter inhibitor, GlyT-1 inhibitor" "SLC6A5, SLC6A9" "" "" "BRD-K13756951-001-01-4" "C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F" "YUUGYIUSCYNSQR-LBPRGKRZSA-N" "Phase 3"
"253" "bitoscanate" "anthelmintic agent" "" "" "" "BRD-K77548206-001-02-9" "S=C=Nc1ccc(cc1)N=C=S" "OMWQUXGVXQELIX-UHFFFAOYSA-N" "Preclinical"
"254" "bivalirudin" "thrombin inhibitor" "F2" "cardiology" "angina pectoris" "BRD-K73504359-001-01-3, BRD-A64231665-019-01-7" "CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O, [2H]N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NC(CC(N)=O)C(=O)NCC(=O)NC(CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)NC(CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O" "OIRCOABEOLEUMC-GEJPAHFPSA-N, OIRCOABEOLEUMC-DRWUPLGZSA-N" "Launched"
"255" "BIX-01294" "histone lysine methyltransferase inhibitor" "EHMT1, EHMT2" "" "" "BRD-K26818574-305-07-6, BRD-K26818574-001-06-3, BRD-K26818574-305-04-3" "COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1, COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1" "OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N, OSXFATOLZGZLSK-UHFFFAOYSA-N" "Preclinical"
"256" "BIX-02188" "MEK inhibitor" "MAP2K5" "" "" "BRD-K20290250-001-01-3, BRD-K20290250-001-02-1" "CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1" "FSZPIAXLCCQFCM-FCQUAONHSA-N, FSZPIAXLCCQFCM-FCQUAONHSA-N" "Preclinical"
"257" "BIX-02189" "MEK inhibitor" "MAP2K5, MAPK7" "" "" "BRD-K73368362-001-08-3, BRD-K73368362-001-07-5" "CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1, CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c1" "HOMJAAIVTDVQJA-IZHYLOQSSA-N, HOMJAAIVTDVQJA-IZHYLOQSSA-N" "Preclinical"
"258" "BL-5583" "hypercalcaemic agent" "" "" "" "BRD-K75282704-001-02-4" "OC(=O)c1cc2ccccc2s1" "DYSJMQABFPKAQM-UHFFFAOYSA-N" "Preclinical"
"259" "blebbistatin-(+/-)" "ATPase inhibitor" "MYH2" "" "" "BRD-A75817871-001-06-7" "Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c1ccccc1" "LZAXPYOBKSJSEX-UHFFFAOYSA-N" "Preclinical"
"260" "blebbistatin-(-)" "ATPase inhibitor" "" "" "" "BRD-K61295575-001-03-6" "Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1" "LZAXPYOBKSJSEX-GOSISDBHSA-N" "Preclinical"
"261" "bleomycetin" "EGFR expression inhibitor" "" "" "" "BRD-A94813917-001-01-0" "C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)C(NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN" "QYOAUOAXCQAEMW-OUNSJABCSA-N" "Phase 2"
"262" "bleomycin" "DNA synthesis inhibitor" "LIG1, LIG3" "hematologic malignancy, pulmonary, oncology" "non-Hodgkin lymphoma (NHL), Hodgkins lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma	BRD-A42083487-065-05-9, BRD-A42083487-065-06-7, BRD-A12918100-065-01-8, BRD-A42083487-001-01-3	C[C@@H](O)[C@@H](NC(=O)[C@H](C)[C@@H](O)[C@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C, C[C@@H](O)[C@@H](NC(=O)[C@H](C)[C@@H](O)[C@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C, CC(O)C(NC(=O)C(C)C(O)C(C)NC(=O)C(NC(=O)c1nc(nc(N)c1C)C(CC(N)=O)NCC(N)C(N)=O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C, C[C@@H](O)[C@@H](NC(=O)[C@H](C)[C@@H](O)[C@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(O[C@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCC[S+](C)C	OYVAGSVQBOHSSS-NHOVFDEISA-O, OYVAGSVQBOHSSS-NHOVFDEISA-O, OYVAGSVQBOHSSS-UHFFFAOYSA-O, OYVAGSVQBOHSSS-NHOVFDEISA-O	Launched
blonanserin	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	BRD-K25943794-001-02-3	CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	XVGOZDAJGBALKS-UHFFFAOYSA-N	Launched
BLU9931	FGFR inhibitor	FGFR4			BRD-K72898849-001-01-8	COc1cc(OC)c(Cl)c(-c2ccc3nc(Nc4c(C)cccc4NC(=O)C=C)ncc3c2)c1Cl	TXEBNKKOLVBTFK-UHFFFAOYSA-N	Preclinical
BML-190	cannabinoid receptor inverse agonist	CNR2			BRD-K94379058-001-06-8, BRD-K94379058-001-05-0	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	BJSDNVVWJYDOLK-UHFFFAOYSA-N, BJSDNVVWJYDOLK-UHFFFAOYSA-N	Preclinical
BML-284	WNT agonist				BRD-K42624714-001-04-1	COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1	FABQUVYDAXWUQP-UHFFFAOYSA-N	Preclinical
BMS-182874	endothelin receptor antagonist	EDNRA			BRD-K56509348-003-02-1	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	MJRGSRRZKSJHOE-UHFFFAOYSA-N	Phase 2
BMS-191011	potassium channel activator	KCNMA1			BRD-K95609758-001-03-7	Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	QKOWACXSXTXRKA-UHFFFAOYSA-N	Preclinical
BMS-191095	KATP activator, potassium channel agonist				BRD-K01231377-001-01-8	CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N	SMIKIPXIDLITMP-LEWJYISDSA-N	Phase 1
BMS-265246	CDK inhibitor	CDK1, CDK2			BRD-K62814476-001-04-1, BRD-K62814476-001-03-3	CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F, CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F	SCFMWQIQBVZOQR-UHFFFAOYSA-N, SCFMWQIQBVZOQR-UHFFFAOYSA-N	Preclinical
BMS-299897	gamma secretase inhibitor				BRD-K02950022-001-02-9	C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O	IZAOBRWCUGOKNH-OAHLLOKOSA-N	Phase 1
BMS-345541	IKK inhibitor	CHUK, IKBKB			BRD-K13566078-003-06-0, BRD-K13566078-001-02-3	Cc1cnc2c(NCCN)nc3ccc(C)cc3n12, Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	PSPFQEBFYXJZEV-UHFFFAOYSA-N, PSPFQEBFYXJZEV-UHFFFAOYSA-N	Preclinical
BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	CDK2, CDK7, CDK9			BRD-K43389698-001-09-9, BRD-K43389698-001-07-3	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1, CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	OUSFTKFNBAZUKL-UHFFFAOYSA-N, OUSFTKFNBAZUKL-UHFFFAOYSA-N	Phase 1
BMS-536924	IGF-1 inhibitor	AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB			BRD-K34581968-001-05-3, BRD-K34581968-001-04-6	Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1, Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1	ZWVZORIKUNOTCS-OAQYLSRUSA-N, ZWVZORIKUNOTCS-OAQYLSRUSA-N	Preclinical
BMS-587101	integrin antagonist	ITGAL, ITGB2			BRD-K20093108-001-02-3	CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1	NXNKJLOEGWSJGI-BKMJKUGQSA-N	Phase 2
BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	EGFR, ERBB2, ERBB4			BRD-K07106112-300-01-2, BRD-K07106112-003-03-8	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12, Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	LUJZZYWHBDHDQX-QFIPXVFZSA-N, LUJZZYWHBDHDQX-QFIPXVFZSA-N	Phase 1
BMS-626529	HIV attachment inhibitor				BRD-K97883416-001-01-4	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	QRPZBKAMSFHVRW-UHFFFAOYSA-N	Phase 3
BMS-649	retinoid receptor agonist	RXRA			BRD-K25991633-001-01-9	CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	ZZUKALQMHNSWTK-UHFFFAOYSA-N	Preclinical
BMS-688521	leukocyte function-associated antigen receptor antagonist, ICAM1 antagonist	ICAM1			BRD-K85649978-001-02-1	CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1	LILGMDXLRPEBNH-HFZDXXHNSA-N	Preclinical
BMS-690514	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, FLT3, KDR			BRD-K76239644-001-02-6, BRD-K76239644-001-01-8	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	CSGQVNMSRKWUSH-IAGOWNOFSA-N, CSGQVNMSRKWUSH-IAGOWNOFSA-N	Phase 2
BMS-707035	HIV integrase inhibitor				BRD-K49555808-001-03-9	Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	VNIWZCGZPBJWBI-UHFFFAOYSA-N	Phase 2
BMS-754807	IGF-1 inhibitor	AKT1, IGF1R			BRD-K13049116-001-04-0, BRD-K47200824-001-01-8, BRD-K13049116-001-03-2	C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@@]1(CCCN1c1nc(Nc2cc([nH]n2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	LQVXSNNAFNGRAH-QHCPKHFHSA-N, LQVXSNNAFNGRAH-HSZRJFAPSA-N, LQVXSNNAFNGRAH-QHCPKHFHSA-N	Phase 2
BMS-777607	AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor	AXL, MERTK, MET, MST1R, TYRO3			BRD-K40738845-001-05-0	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	VNBRGSXVFBYQNN-UHFFFAOYSA-N	Phase 1/Phase 2
BMS-806	HIV attachment inhibitor				BRD-K55773932-001-03-8, BRD-K55773932-001-02-0	COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12, COc1cc[nH]c2ncc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	OKGPFTLYBPQBIX-CQSZACIVSA-N, OKGPFTLYBPQBIX-CQSZACIVSA-N	Phase 1
BMS-817378	c-Met inhibitor, VEGFR inhibitor	KDR, MET			BRD-K81026553-234-01-8	Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	KXDZWUPUSDCGDD-UHFFFAOYSA-N	Phase 1
BMS-833923	smoothened receptor antagonist	SMO			BRD-K33245965-001-03-4, BRD-K33245965-001-02-6, BRD-K33245965-001-01-8	CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1, CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N, KLRRGBHZCJLIEL-UHFFFAOYSA-N	Phase 2
BMS-863233	CDC inhibitor	CDC7, PIM1			BRD-K12511835-003-02-0, BRD-K12511835-003-01-2	Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1, Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1	JJWLXRKVUJDJKG-VIFPVBQESA-N, JJWLXRKVUJDJKG-VIFPVBQESA-N	Phase 1/Phase 2
BMS-927711	calcitonin antagonist	CALCA			BRD-K55781385-001-01-7	N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	KRNAOFGYEFKHPB-ANJVHQHFSA-N	Phase 2
BMS-983970	notch signaling inhibitor				BRD-K22316123-001-01-9	NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O	RANYIWAZSQWERN-WLENULPWSA-N	Phase 1
BMS-986020	lysophosphatidic acid receptor antagonist	LPAR1			BRD-K23952234-236-01-8	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	LNDDRUPAICPXIN-GOSISDBHSA-N	Phase 2
BMY-14802	sigma receptor antagonist	HTR1A			BRD-A15435692-003-02-3	OC(CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1	ZXUYYZPJUGQHLQ-UHFFFAOYSA-N	Phase 2
BMY-45618	PKC activator	PRKCE			BRD-A77494669-001-01-0	CCC\C=C\C=C\C(=O)O[C@H]1\C(CC2C[C@@H](OC(=O)C[C@H](O)C[C@@H]3C[C@H](OC(C)=O)C(C)(C)[C@](O)(C[C@@H]4C\C(C[C@@H](O4)\C=C\C(C)(C)[C@]1(O)O2)=C\C(=O)OC)O3)[C@@H](C)O)=C\C(=O)OC	MJQUEDHRCUIRLF-MDGOTRLRSA-N	Phase 2
BMY-45778	IP1 prostacyclin receptor agonist	PTGIR			BRD-K84895041-001-02-4	OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	DSRSEEYZGWTODH-UHFFFAOYSA-N	Preclinical
BMY-7378	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A			BRD-K31054881-300-04-7, BRD-K31054881-300-03-9	COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1, COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	AYYCFGDXLUPJAQ-UHFFFAOYSA-N, AYYCFGDXLUPJAQ-UHFFFAOYSA-N	Preclinical
BNC105	tubulin polymerization inhibitor				BRD-K20468903-001-01-6	COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	RADMJHVVIZTENA-UHFFFAOYSA-N	Phase 2
BNTX	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			BRD-A55484088-050-02-5	Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1	WXOUFNFMPVMGFZ-WLNGDWEISA-N	Preclinical
boceprevir	HCV inhibitor	CMA1, CTSA, CTSF, CTSK, CTSL, CTSS	infectious disease	hepatitis C	BRD-A09735281-001-02-5, BRD-A09735281-001-03-3	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C, CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C	LHHCSNFAOIFYRV-DOVBMPENSA-N, LHHCSNFAOIFYRV-DOVBMPENSA-N	Launched
bonaphthone					BRD-K34149328-001-01-3, BRD-K34149328-001-02-1	Brc1ccc2C(=O)C(=O)C=Cc2c1, Brc1ccc2C(=O)C(=O)C=Cc2c1	MXWZRRPNVLCHMY-UHFFFAOYSA-N, MXWZRRPNVLCHMY-UHFFFAOYSA-N	Phase 3
bopindolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3, HTR1A, HTR1B	cardiology	hypertension, coronary artery disease (CAD)	BRD-A07563059-035-01-3	Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1	UUOJIACWOAYWEZ-UHFFFAOYSA-N	Launched
bornyl-acetate					BRD-A41385909-001-01-3	CC(=O)OC1CC2CCC1(C)C2(C)C	KGEKLUUHTZCSIP-UHFFFAOYSA-N	Preclinical
boronophenylalanine					BRD-K50122911-001-01-2, BRD-K70071822-001-01-5	N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O, N[C@H](Cc1ccc(cc1)B(O)O)C(O)=O	NFIVJOSXJDORSP-QMMMGPOBSA-N, NFIVJOSXJDORSP-MRVPVSSYSA-N	Phase 2
bortezomib	NFkB pathway inhibitor, proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	BRD-K50691590-001-02-2, BRD-K88510285-001-18-6, BRD-K88510285-001-17-8, BRD-K88510285-001-11-1, BRD-K50691590-001-05-5	CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)C1=CNC=CN1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)C1=CNC=CN1)B(O)O	RFGAQTOFZHCFHG-NVXWUHKLSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, GXJABQQUPOEUTA-RDJZCZTQSA-N, RFGAQTOFZHCFHG-NVXWUHKLSA-N	Launched
bosentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	BRD-K74763371-002-04-0	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	GJPICJJJRGTNOD-UHFFFAOYSA-N	Launched
bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	BRD-K99964838-001-12-7, BRD-K99964838-001-11-9	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl, COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	UBPYILGKFZZVDX-UHFFFAOYSA-N, UBPYILGKFZZVDX-UHFFFAOYSA-N	Launched
BP-554	serotonin receptor agonist	HTR1A			BRD-K45479396-050-01-5	C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	VUSNBQDZGKZEDL-UHFFFAOYSA-N	Preclinical
BP-897	dopamine receptor agonist	ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B			BRD-K17378184-300-05-9	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	MNHDKMDLOJSCGN-UHFFFAOYSA-N	Phase 2
BQ-123	endothelin receptor antagonist	EDNRA			BRD-A59961917-001-01-0	CC(C)CC1NC(=O)C(NC(=O)C2CCCN2C(=O)C(CC(O)=O)NC(=O)C(Cc2c[nH]c3ccccc23)NC1=O)C(C)C	VYCMAAOURFJIHD-UHFFFAOYSA-N	Phase 2
BQ-788	endothelin receptor antagonist	EDNRB			BRD-K02490038-236-01-2	CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O	LPAHKJMGDSJDRG-DJYQTOCQSA-N	Phase 1
BQU57	Ras GTPase inhibitor	RALA, RALB			BRD-A40257118-001-01-2	Cc1nn(C)c2OC(N)=C(C#N)C(c12)c1ccc(cc1)C(F)(F)F	IJCMHHSFXFMZAI-UHFFFAOYSA-N	Preclinical
BRD4770	histone lysine methyltransferase inhibitor	EHMT2			BRD-K72264770-001-03-2, BRD-K72264770-001-04-0	COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1, COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	UCGWYCMPZXDHNR-UHFFFAOYSA-N, UCGWYCMPZXDHNR-UHFFFAOYSA-N	Preclinical
brefeldin-a	protein synthesis inhibitor	ARF1, CYTH2			BRD-A84228258-001-04-4, BRD-K77841042-001-11-7	C[C@H]1CCC\C=C\C2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1, C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1	KQNZDYYTLMIZCT-KFKPYADVSA-N, KQNZDYYTLMIZCT-KQPMLPITSA-N	Preclinical
bremelanotide	melanocortin receptor agonist	MC1R, MC2R, MC3R, MC4R, MC5R			BRD-K06328344-015-01-7	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O	FFHBJDQSGDNCIV-MFVUMRCOSA-N	Phase 3
brequinar	dihydroorotate dehydrogenase inhibitor	DHODH			BRD-K96123349-236-02-8	Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	PHEZJEYUWHETKO-UHFFFAOYSA-N	Phase 2
bretazenil	GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			BRD-K96936751-001-01-4	CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	Phase 2
bretylium	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)	BRD-K49669424-001-01-6, BRD-K49669424-075-19-2	CC[N+](C)(C)Cc1ccccc1Br, CC[N+](C)(C)Cc1ccccc1Br	AAQOQKQBGPPFNS-UHFFFAOYSA-N, AAQOQKQBGPPFNS-UHFFFAOYSA-N	Launched
brexpiprazole	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression, schizophrenia	BRD-K00911143-001-01-9	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	ZKIAIYBUSXZPLP-UHFFFAOYSA-N	Launched
briciclib	cyclin D inhibitor	CCND1			BRD-K05531427-001-01-7	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1	LXENKEWVEVKKGV-BQYQJAHWSA-N	Phase 1
brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	ALK, EGFR			BRD-K56981171-001-01-0	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	AILRADAXUVEEIR-UHFFFAOYSA-N	Phase 3
brilliant-green					BRD-K60348325-065-09-9	CCN(CC)c1ccc(cc1)C(c1ccccc1)=C1C=CC(C=C1)=[N+](CC)CC	HXCILVUBKWANLN-UHFFFAOYSA-N	Launched
brimonidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-K68264559-045-04-0, BRD-K68264559-045-02-4, BRD-K68264559-001-13-4, BRD-K68264559-045-03-2	Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12, Brc1c(NC2=NCCN2)ccc2nccnc12	XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N, XYLJNLCSTIOKRM-UHFFFAOYSA-N	Launched
brinzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA5A, CA7	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-K74913225-001-13-2, BRD-K74913225-001-12-4, BRD-A82599487-001-01-9	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O, CCNC1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	HCRKCZRJWPKOAR-JTQLQIEISA-N, HCRKCZRJWPKOAR-JTQLQIEISA-N, HCRKCZRJWPKOAR-UHFFFAOYSA-N	Launched
brivanib	FGFR inhibitor, VEGFR inhibitor	CYP3A4, FGFR1, FLT1, KCNH2, KDR			BRD-K28428262-001-04-1	C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	WCWUXEGQKLTGDX-LLVKDONJSA-N	Phase 3
brivanib-alaninate	FGFR inhibitor, VEGFR inhibitor	FGFR3			BRD-K57187269-001-02-4, BRD-K57187269-001-04-0, BRD-K57187269-001-03-2	C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N, C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N, LTEJRLHKIYCEOX-OCCSQVGLSA-N	Phase 3
brivaracetam	voltage-gated sodium channel blocker	SV2A	neurology/psychiatry	seizures	BRD-K00634421-001-01-0	CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1	MSYKRHVOOPPJKU-BDAKNGLRSA-N	Launched
brivudine	DNA directed DNA polymerase inhibitor		infectious disease	shingles	BRD-A63675168-001-01-6	OC[C@H]1O[C@H](CC1O)n1cc(\C=C\Br)c(=O)[nH]c1=O	ODZBBRURCPAEIQ-GIANCMQGSA-N	Launched
BRL-15572	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			BRD-A51829654-300-03-6, BRD-A51829654-003-07-7, BRD-A51829654-300-02-8	OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1, OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1, OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1	QJHCTHPYUOXOGM-UHFFFAOYSA-N, QJHCTHPYUOXOGM-UHFFFAOYSA-N, QJHCTHPYUOXOGM-UHFFFAOYSA-N	Preclinical
BRL-26314	cholesterol inhibitor	LPL			BRD-A57806482-001-01-4	OC(=O)C(Cc1ccccc1)NCc1ccc(Cl)cc1	SAOHCSVJQIAGDD-UHFFFAOYSA-N	Phase 1
BRL-37344	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			BRD-K07507905-236-02-6	C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	ZGGNJJJYUVRADP-ACJLOTCBSA-N	Phase 2
BRL-44408	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			BRD-A67949680-050-01-7	CC1N(CC2=NCCN2)Cc2ccccc12	SGOFAUSEYBZKDQ-UHFFFAOYSA-N	Preclinical
BRL-50481	phosphodiesterase inhibitor	PDE7A, PDE7B			BRD-K84266862-001-03-2	CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	IFIUFCJFLGCQPH-UHFFFAOYSA-N	Preclinical
BRL-52537	opioid receptor agonist	OPRK1			BRD-A37347161-003-02-6	Clc1ccc(CC(=O)N2CCCCC2CN2CCCC2)cc1Cl	GHCCBWMZKJQGLS-UHFFFAOYSA-N	Preclinical
BRL-54443	serotonin receptor agonist	HTR1E, HTR1F			BRD-K17868609-001-05-0, BRD-K17868609-001-04-3	CN1CCC(CC1)c1c[nH]c2ccc(O)cc12, CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	WKNFADCGOAHBPG-UHFFFAOYSA-N, WKNFADCGOAHBPG-UHFFFAOYSA-N	Preclinical
brolitene	muscle relaxant	RYR1			BRD-K76021681-001-01-4, BRD-K76021681-001-02-2	OCCNC(=O)\C=C\c1ccccc1, OCCNC(=O)\C=C\c1ccccc1	OSCTXCOERRNGLW-VOTSOKGWSA-N, OSCTXCOERRNGLW-VOTSOKGWSA-N	Launched
bromantan	dopamine reuptake inhibitor, serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	BRD-K86358349-001-02-0, BRD-K86358349-001-01-2	Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1, Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	LWJALJDRFBXHKX-UHFFFAOYSA-N, LWJALJDRFBXHKX-UHFFFAOYSA-N	Launched
bromebric-acid	purine antagonist, DNA synthesis inhibitor				BRD-K17874929-236-02-0	COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O	UPZFHUODAYGHDZ-TWGQIWQCSA-N	Preclinical
bromfenac	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-K47679368-236-01-7	Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1	ZBPLOVFIXSTCRZ-UHFFFAOYSA-N	Withdrawn
bromhexine	mucolytic agent		pulmonary	chest congestion	BRD-K47631482-003-06-2, BRD-K47631482-003-07-0	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1, CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	OJGDCBLYJGHCIH-UHFFFAOYSA-N, OJGDCBLYJGHCIH-UHFFFAOYSA-N	Launched
bromindione	anticoagulant				BRD-K50490982-001-08-2	Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NPUZIGSOEWMFKK-UHFFFAOYSA-N	Phase 2
bromocriptine	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	endocrinology, neurology/psychiatry	hyperprolactinemia, Parkinsons Disease, acromegaly" "BRD-A80151636-066-04-8, BRD-K14496212-066-02-2" "CC(C)CC1N2C(=O)[C@](NC(=O)C3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(OC2(O)[C@@H]2CCCN2C1=O)C(C)C, CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C" "OZVBMTJYIDMWIL-NXIPCUEUSA-N, OZVBMTJYIDMWIL-AYFBDAFISA-N" "Launched"
"263" "bromopride" "dopamine receptor antagonist" "DRD2" "gastroenterology" "nausea, vomiting, gastroesophageal reflux disease (GERD)" "BRD-K73642618-001-13-3" "CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC" "GIYAQDDTCWHPPL-UHFFFAOYSA-N" "Launched"
"264" "bromosporine" "bromodomain inhibitor" "" "" "" "BRD-K44665581-001-01-8" "CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1" "UYBRROMMFMPJAN-UHFFFAOYSA-N" "Preclinical"
"265" "bromperidol" "dopamine receptor antagonist" "DRD2" "neurology/psychiatry" "schizophrenia" "BRD-K78643075-001-11-6" "OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1" "RKLNONIVDFXQRX-UHFFFAOYSA-N" "Launched"
"266" "brompheniramine" "histamine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1" "allergy, otolaryngology" "allergic rhinitis, common cold" "BRD-A68723818-050-32-5, BRD-A68723818-050-31-7" "CN(C)CCC(c1ccc(Br)cc1)c1ccccn1, CN(C)CCC(c1ccc(Br)cc1)c1ccccn1" "ZDIGNSYAACHWNL-UHFFFAOYSA-N, ZDIGNSYAACHWNL-UHFFFAOYSA-N" "Launched"
"267" "bronopol" "" "" "" "" "BRD-K33457401-001-01-1" "OCC(Br)(CO)[N+]([O-])=O" "LVDKZNITIUWNER-UHFFFAOYSA-N" "Launched"
"268" "bropirimine" "interferon inducer" "" "" "" "BRD-K17500877-001-02-1" "Nc1nc(-c2ccccc2)c(Br)c(=O)[nH]1" "CIUUIPMOFZIWIZ-UHFFFAOYSA-N" "Phase 3"
"269" "broxaldine" "" "" "" "" "BRD-K36222532-001-01-8" "Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1" "IJTPLVAAROHGGB-UHFFFAOYSA-N" "Preclinical"
"270" "broxaterol" "adrenergic receptor agonist" "ADRB2" "" "" "BRD-A08316590-001-01-3" "CC(C)(C)NCC(O)c1cc(Br)no1" "JBRBWHCVRGURBA-UHFFFAOYSA-N" "Phase 3"
"271" "broxuridine" "antimetabolite" "" "" "" "BRD-K79095980-001-09-6" "OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O" "WOVKYSAHUYNSMH-RRKCRQDMSA-N" "Phase 2"
"272" "broxyquinoline" "antiprotozoal agent" "" "" "" "BRD-K23301018-001-11-7, BRD-K23301018-001-10-9, BRD-K23301018-001-09-1" "Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12, Oc1c(Br)cc(Br)c2cccnc12" "ZDASUJMDVPTNTF-UHFFFAOYSA-N, ZDASUJMDVPTNTF-UHFFFAOYSA-N, ZDASUJMDVPTNTF-UHFFFAOYSA-N" "Phase 1"
"273" "bruceantin" "protein synthesis inhibitor" "" "" "" "BRD-A36057565-001-01-0" "COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O" "KMCZIPGKKBSLEX-JLNWNYEJSA-N" "Phase 2"
"274" "brucine" "glycine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "" "" "BRD-A41995253-330-02-2, BRD-A41995253-001-04-5, BRD-A41995253-330-01-4" "COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC, COc1cc2N3C4[C@@H]5C(CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC" "RRKTZKIUPZVBMF-PLNGPGDESA-N, RRKTZKIUPZVBMF-PLNGPGDESA-N, RRKTZKIUPZVBMF-PLNGPGDESA-N" "Preclinical"
"275" "BS-181" "CDK inhibitor" "CDK7" "" "" "BRD-K31313613-300-01-8, BRD-K31313613-003-05-9, BRD-K31313613-003-04-2" "CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12, CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12" "DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N, DNYBIOICMDTDAP-UHFFFAOYSA-N" "Preclinical"
"276" "BTB06584" "ATPase inhibitor" "ATP5F1" "" "" "BRD-K37933329-001-01-6, BRD-K37933329-001-02-4" "[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1, [O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1" "WNDWKKPBLAKXMI-UHFFFAOYSA-N, WNDWKKPBLAKXMI-UHFFFAOYSA-N" "Preclinical"
"277" "BTS" "" "" "" "" "BRD-K64178227-001-09-0" "Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1" "WTHKAJZQYNKTCJ-UHFFFAOYSA-N" "Preclinical"
"278" "BTS-54505" "dopamine reuptake inhibitor" "SLC6A2, SLC6A3, SLC6A4" "" "" "BRD-A68304895-003-02-2" "CC(C)CC(N)C1(CCC1)c1ccc(Cl)cc1" "WQSACWZKKZPCHN-UHFFFAOYSA-N" "Withdrawn"
"279" "BTS-72664" "GABA receptor antagonist" "GABBR1" "" "" "BRD-A65793993-001-01-6" "CC(Oc1ccc(Cl)cc1)c1ccnc2ncnn12" "FCEPUTGEUCVRRI-UHFFFAOYSA-N" "Phase 1"
"280" "BTZ043-racemate" "DPRE1 inhibitor" "" "" "" "BRD-A53037217-001-02-0" "CC1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1" "GTUIRORNXIOHQR-UHFFFAOYSA-N" "Preclinical"
"281" "BU-224" "imidazoline receptor ligand" "MAOA, MAOB" "" "" "BRD-K55344148-003-02-6" "C1CN=C(N1)c1ccc2ccccc2n1" "OSUVWJGCKQEMHK-UHFFFAOYSA-N" "Preclinical"
"282" "BU-239" "imidazoline receptor ligand, imidazoline receptor agonist" "" "" "" "BRD-K11696279-003-02-3" "C1CN=C(N1)c1cnc2ccccc2n1" "MQSSFHXQKUSFIW-UHFFFAOYSA-N" "Preclinical"
"283" "bucetin" "analgesic agent" "" "" "" "BRD-A88684804-001-04-3" "CCOc1ccc(NC(=O)CC(C)O)cc1" "LIAWQASKBFCRNR-UHFFFAOYSA-N" "Withdrawn"
"284" "bucillamine" "immunosuppressant" "" "rheumatology" "rheumatoid arthritis" "BRD-K24697665-001-01-4" "CC(C)(S)C(=O)N[C@@H](CS)C(O)=O" "VUAFHZCUKUDDBC-BYPYZUCNSA-N" "Launched"
"285" "bucladesine" "adenosine receptor agonist, cAMP stimulant" "PRKACA" "dermatology" "skin ulcer" "BRD-A94624445-236-17-0, BRD-A15931911-001-03-8" "CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC, CCCC(=O)Nc1ncnc2n(cnc12)C1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC" "CJGYSWNGNKCJSB-YVLZZHOMSA-N, CJGYSWNGNKCJSB-ZBSNKJFMSA-N" "Launched"
"286" "buclizine" "histamine receptor antagonist" "CHRM1, HRH1" "neurology/psychiatry" "migraine headache" "BRD-A91444184-300-01-9" "CC(C)(C)c1ccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)cc1" "MOYGZHXDRJNJEP-UHFFFAOYSA-N" "Launched"
"287" "budesonide" "glucocorticoid receptor agonist" "NR3C1" "gastroenterology" "Crohns disease	BRD-A34299591-001-25-7, BRD-A60571864-001-04-1, BRD-A34299591-001-22-4, BRD-A34299591-001-26-5, BRD-K90758956-001-02-9, BRD-K17742695-001-01-1	CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CCCC1O[C@@H]2CC3C4CCC5=CC(=O)C=CC5(C)C4[C@@H](O)CC3(C)[C@@]2(O1)C(=O)CO, CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@H]4[C@H](O)C[C@]3(C)[C@]2(O1)C(=O)CO	VOVIALXJUBGFJZ-KWVAZRHASA-N, VOVIALXJUBGFJZ-NECQTEFJSA-N, VOVIALXJUBGFJZ-KWVAZRHASA-N, VOVIALXJUBGFJZ-KWVAZRHASA-N, VOVIALXJUBGFJZ-VXKMTNQYSA-N, VOVIALXJUBGFJZ-XPZXLBDFSA-N	Launched
budipine	glutamate receptor antagonist	GRIN1	neurology/psychiatry	Parkinsons Disease" "BRD-K18324993-001-01-6" "CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1" "QIHLUZAFSSMXHQ-UHFFFAOYSA-N" "Launched"
"288" "bufexamac" "cyclooxygenase inhibitor" "HDAC10, HDAC6" "" "" "BRD-K36660044-001-24-2, BRD-K36660044-001-23-4" "CCCCOc1ccc(CC(=O)NO)cc1, CCCCOc1ccc(CC(=O)NO)cc1" "MXJWRABVEGLYDG-UHFFFAOYSA-N, MXJWRABVEGLYDG-UHFFFAOYSA-N" "Withdrawn"
"289" "buflomedil" "adrenergic receptor antagonist, calcium channel blocker" "ADRA1A" "cardiology" "peripheral artery disease (PAD)" "BRD-K19462402-003-24-6, BRD-K19462402-003-23-8" "COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1, COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1" "OWYLAEYXIQKAOL-UHFFFAOYSA-N, OWYLAEYXIQKAOL-UHFFFAOYSA-N" "Launched"
"290" "bumetanide" "solute carrier family member inhibitor" "CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5" "cardiology" "edema, congestive heart failure" "BRD-K38197229-001-29-9, BRD-K38197229-001-28-1" "CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O, CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O" "MAEIEVLCKWDQJH-UHFFFAOYSA-N, MAEIEVLCKWDQJH-UHFFFAOYSA-N" "Launched"
"291" "bunazosin" "adrenergic receptor antagonist" "ADRA1A" "ophthalmology" "glaucoma, intraocular pressure" "BRD-K35034482-001-01-8" "CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1" "RHLJLALHBZGAFM-UHFFFAOYSA-N" "Launched"
"292" "buparlisib" "PI3K inhibitor" "PIK3CA, PIK3CG" "" "" "BRD-K42191735-001-08-7, BRD-K42191735-001-05-3" "Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F, Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F" "CWHUFRVAEUJCEF-UHFFFAOYSA-N, CWHUFRVAEUJCEF-UHFFFAOYSA-N" "Phase 3"
"293" "buparvaquone" "antiprotozoal agent" "" "" "" "BRD-A07947329-001-01-4" "CC(C)(C)C1CCC(CC2C(=O)C(=O)c3ccccc3C2=O)CC1" "OMMKCJLAGTXGLC-UHFFFAOYSA-N" "Launched"
"294" "buphenine" "adrenergic receptor agonist" "ADRB2" "rheumatology" "Raynauds disease	BRD-A36267905-003-19-2, BRD-A36267905-003-18-4	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1, CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	PTGXAUBQBSGPKF-UHFFFAOYSA-N, PTGXAUBQBSGPKF-UHFFFAOYSA-N	Launched
bupicomide	adrenergic receptor antagonist	ADRB1			BRD-K51700582-001-01-2	CCCCc1ccc(nc1)C(N)=O	VKSPIPWLHGKJQO-UHFFFAOYSA-N	Phase 1
bupivacaine	sodium channel blocker	KCNA5, PTGER1, SCN10A, SCN4A	neurology/psychiatry	peripheral nerve block, caudal epidural block, lumbar epidural block	BRD-A01636364-003-15-1, BRD-A01636364-003-14-4	CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C, CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C	LEBVLXFERQHONN-UHFFFAOYSA-N, LEBVLXFERQHONN-UHFFFAOYSA-N	Launched
bupranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology, ophthalmology	hypertension, glaucoma	BRD-A48420483-001-02-3, BRD-A48420483-001-01-5	Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1, Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1	HQIRNZOQPUAHHV-UHFFFAOYSA-N, HQIRNZOQPUAHHV-UHFFFAOYSA-N	Launched
bupropion	dopamine uptake inhibitor	CHRNA3, SLC6A2, SLC6A3	neurology/psychiatry	depression	BRD-A05186015-003-19-8, BRD-A05186015-003-20-6	CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1, CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1	SNPPWIUOZRMYNY-UHFFFAOYSA-N, SNPPWIUOZRMYNY-UHFFFAOYSA-N	Launched
buramate	antiepileptic				BRD-K30360804-001-01-3	OCCOC(=O)NCc1ccccc1	YFLRYAVDPKONNX-UHFFFAOYSA-N	Preclinical
buspirone	serotonin receptor agonist	DRD2, HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	BRD-K93461745-003-25-0, BRD-K93461745-003-24-3, BRD-K93461745-003-23-5	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1, O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	QWCRAEMEVRGPNT-UHFFFAOYSA-N, QWCRAEMEVRGPNT-UHFFFAOYSA-N, QWCRAEMEVRGPNT-UHFFFAOYSA-N	Launched
busulfan	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	BRD-K23204545-001-16-4, BRD-K23204545-001-18-0, BRD-K23204545-001-15-6	CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O, CS(=O)(=O)OCCCCOS(C)(=O)=O	COVZYZSDYWQREU-UHFFFAOYSA-N, COVZYZSDYWQREU-UHFFFAOYSA-N, COVZYZSDYWQREU-UHFFFAOYSA-N	Launched
butabindide	tripeptidyl peptidase inhibitor	TPP2			BRD-K40581315-034-01-5	CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC	HAQIRIMIVLFYIX-ZFWWWQNUSA-N	Preclinical
butacaine	local anesthetic		neurology/psychiatry	local anesthetic	BRD-K99622919-001-23-0, BRD-K99622919-001-22-2	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1, CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	HQFWVSGBVLEQGA-UHFFFAOYSA-N, HQFWVSGBVLEQGA-UHFFFAOYSA-N	Launched
butaclamol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A			BRD-K23082237-003-01-5	CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34	ZZJYIKPMDIWRSN-TZBSWOFLSA-N	Phase 2
butalbital	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	headache, muscle relaxant	BRD-K71350836-001-02-4	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	Launched
butamben	sodium channel blocker				BRD-K27217864-001-22-3	CCCCOC(=O)c1ccc(N)cc1	IUWVALYLNVXWKX-UHFFFAOYSA-N	Withdrawn
butein	EGFR inhibitor, src inhibitor	ACE			BRD-K17497770-001-03-6, BRD-K17497770-001-04-4	Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1, Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	AYMYWHCQALZEGT-ORCRQEGFSA-N, AYMYWHCQALZEGT-ORCRQEGFSA-N	Preclinical
butenafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	BRD-K90630139-003-05-9	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	ABJKWBDEJIDSJZ-UHFFFAOYSA-N	Launched
buthionine-sulfoximine	glutathione transferase inhibitor	GCLM			BRD-A47706533-001-02-6	CCCCS(=N)(=O)CC[C@H](N)C(O)=O	KJQFBVYMGADDTQ-CVSPRKDYSA-N	Phase 1
butibufen	cyclooxygenase inhibitor				BRD-A46136514-001-01-2	CCC(C(O)=O)c1ccc(CC(C)C)cc1	UULSXYSSHHRCQK-UHFFFAOYSA-N	Withdrawn
butoconazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	BRD-A16665823-001-02-0, BRD-A16665823-008-12-4	Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1, Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1	SWLMUYACZKCSHZ-UHFFFAOYSA-N, SWLMUYACZKCSHZ-UHFFFAOYSA-N	Launched
butofilolol	adrenergic receptor antagonist				BRD-A27274504-001-01-6	CCCC(=O)c1cc(F)ccc1OCC(O)CNC(C)(C)C	NMBNQRJDEPOXCP-UHFFFAOYSA-N	Phase 2
butorphanol-(+)-tartrate	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry, gastroenterology	muscle pain, headache, abdominal pain	BRD-K42417338-045-01-9	Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]4(CCCC[C@@]34O)c2c1	IFKLAQQSCNILHL-QHAWAJNXSA-N	Launched
butyl-paraben	DNA synthesis inhibitor				BRD-K08287586-001-14-3	CCCCOC(=O)c1ccc(O)cc1	QFOHBWFCKVYLES-UHFFFAOYSA-N	Preclinical
butylated-hydroxyanisole	antioxidant				BRD-K93035859-001-07-6	COc1ccc(O)c(c1)C(C)(C)C	MRBKEAMVRSLQPH-UHFFFAOYSA-N	Preclinical
butylated-hydroxytoluene	carbonic anhydrase inhibitor	CA2			BRD-K53153417-001-10-4	Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	NLZUEZXRPGMBCV-UHFFFAOYSA-N	Phase 1
butylphthalide	potassium channel antagonist	KCNK2	neurology/psychiatry	stroke	BRD-A59378440-001-01-3	CCCCC1OC(=O)c2ccccc12	HJXMNVQARNZTEE-UHFFFAOYSA-N	Launched
butylscopolamine-bromide	cholinergic receptor antagonist		gastroenterology	abdominal pain	BRD-A53951045-004-01-6	CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)c1ccccc1	YBCNXCRZPWQOBR-NQNPYAFXSA-N	Launched
BU226	imidazoline receptor ligand				BRD-K56115039-003-02-1	C1CN=C(N1)c1cc2ccccc2cn1	ZXRSVNHYTSSFMN-UHFFFAOYSA-N	Preclinical
BVD-523	MAP kinase inhibitor				BRD-K28965160-001-01-1	CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	KSERXGMCDHOLSS-LJQANCHMSA-N	Phase 1/Phase 2
BVT-2733	11-beta hydroxysteroid dehydrogenase inhibitor	HSD17B1			BRD-K01742705-001-01-7	CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1	YDPRNGAPPNPYQQ-UHFFFAOYSA-N	Preclinical
BVT-948	tyrosine phosphatase inhibitor	PTPN1, PTPN11, PTPN2			BRD-K68567222-001-01-2	CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21	LLPBUXODFQZPFH-UHFFFAOYSA-N	Preclinical
BW-A4C	lipoxygenase inhibitor	ALOX5			BRD-K80194255-001-01-9	CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1	CEUDWZXMLMKPNN-SOFGYWHQSA-N	Phase 1
BW-B70C	lipoxygenase inhibitor	ALOX5			BRD-A55946879-001-03-7	CC(\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O	UAIYNMRLUHHRMF-AATRIKPKSA-N	Preclinical
BW-180C	opioid receptor agonist	OPRD1, OPRM1			BRD-K57927309-001-01-7	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	ZHUJMSMQIPIPTF-IMNFJDCFSA-N	Phase 2
BW-373U86	opioid receptor agonist	OPRD1			BRD-K74990253-001-02-8	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	LBLDMHBSVIVJPM-YZIHRLCOSA-N	Preclinical
BW-616U	monoamine oxidase inhibitor	MAOA			BRD-K07061232-001-01-8	CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1	MLPSDBJCWIYSEA-UHFFFAOYSA-N	Preclinical
BW-723C86	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			BRD-A17428743-003-09-0	CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12	ALFGDCNSEBJYSP-UHFFFAOYSA-N	Preclinical
BX-795	IKK inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			BRD-K47983010-001-12-0, BRD-K47983010-001-14-6, BRD-K47983010-001-09-6	Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1, Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	VAVXGGRQQJZYBL-UHFFFAOYSA-N, VAVXGGRQQJZYBL-UHFFFAOYSA-N, VAVXGGRQQJZYBL-UHFFFAOYSA-N	Preclinical
BX-912	pyruvate dehydrogenase kinase inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			BRD-K49669041-001-08-4	Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1c[nH]cn1	DMMILYKXNCVKOJ-UHFFFAOYSA-N	Preclinical
BYK-204165	PARP inhibitor	PARP1			BRD-K61665160-001-01-5	Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	BTYSIDSTHDDAJW-LCYFTJDESA-N	Preclinical
C-1	protein kinase inhibitor	PRKCA			BRD-K72462751-001-02-7	O=S(=O)(N1CCNCC1)c1cccc2cnccc12	UPTYCYWTFGTCCG-UHFFFAOYSA-N	Preclinical
C-751					BRD-K15337272-001-01-3	CCOC(=O)c1c[nH]cn1	KLWYPRNPRNPORS-UHFFFAOYSA-N	Preclinical
cabagin			gastroenterology	dyspepsia	BRD-K41504985-005-01-5	C[S+](C)CC[C@H](N)C(O)=O	YDBYJHTYSHBBAU-YFKPBYRVSA-O	Launched
cabaletta	pharmacological chaperone				BRD-K54028654-001-02-6	OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	HDTRYLNUVZCQOY-LIZSDCNHSA-N	Phase 2
cabazitaxel	microtubule inhibitor	TUBA4A, TUBB, TUBB1	oncology	prostate cancer	BRD-K06858286-001-01-3	CO[C@@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C	BMQGVNUXMIRLCK-VCPXPHFHSA-N	Launched
cabergoline	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7	endocrinology	hyperprolactinemia	BRD-K86882815-001-03-2	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	KORNTPPJEAJQIU-KJXAQDMKSA-N	Launched
cabotegravir	HIV integrase inhibitor				BRD-A95114378-001-01-4, BRD-A07738941-001-01-5	C[C@H]1CO[C@@H]2CN3C=C(C(=O)NCc4ccc(F)cc4F)C(=O)C(=O)C3C(=O)N12, CC1COC2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	MMMSEONUUDDKJS-KHVYEAMJSA-N, WCWSTNLSLKSJPK-UHFFFAOYSA-N	Phase 2/Phase 3
cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	KDR, MET	oncology	medullary thyroid cancer (MTC)	BRD-K51544265-001-06-7, BRD-K51544265-001-04-2	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	ONIQOQHATWINJY-UHFFFAOYSA-N, ONIQOQHATWINJY-UHFFFAOYSA-N	Launched
cadralazine	adrenergic receptor antagonist		cardiology	hypertension	BRD-A78134170-001-01-3	CCOC(=O)NNc1ccc(nn1)N(CC)CC(C)O	QLTVVOATEHFXLT-UHFFFAOYSA-N	Launched
cafestol	pregnane X receptor agonist				BRD-K46741531-001-02-4	C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	DNJVYWXIDISQRD-HWUKTEKMSA-N	Launched
caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	ALOX5, MIF			BRD-K09900591-001-26-7, BRD-K09900591-001-25-9	OC(=O)\C=C\c1ccc(O)c(O)c1, OC(=O)\C=C\c1ccc(O)c(O)c1	QAIPRVGONGVQAS-DUXPYHPUSA-N, QAIPRVGONGVQAS-DUXPYHPUSA-N	Preclinical
caffeic-acid-phenethyl-ester	HIV integrase inhibitor	RELA			BRD-K96188950-001-16-9, BRD-K96188950-001-15-1	Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O, Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	SWUARLUWKZWEBQ-VQHVLOKHSA-N, SWUARLUWKZWEBQ-VQHVLOKHSA-N	Preclinical
caffeine	adenosine receptor antagonist, phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3	neurology/psychiatry	fatigue, drowsiness, fatigue, drowsiness	BRD-K02404261-001-16-7	Cn1cnc2n(C)c(=O)n(C)c(=O)c12	RYYVLZVUVIJVGH-UHFFFAOYSA-N	Launched
calcifediol	vitamin D receptor agonist	VDR			BRD-K77175907-001-08-0, BRD-K77175907-002-01-3, BRD-K77175907-001-06-4, BRD-K34907920-001-01-6	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, C[C@H](CCCC(C)(C)O)[C@@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)CCC1=C	JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-DTOXIADCSA-N, JWUBBDSIWDLEOM-UESUBFASSA-N	Launched
calcipotriol	vitamin D receptor agonist	VDR	dermatology	psoriasis	BRD-K56429665-001-09-6, BRD-K56429665-002-01-1, BRD-K56429665-001-07-0	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N, LWQQLNNNIPYSNX-UROSTWAQSA-N	Launched
calcitriol	vitamin D receptor agonist	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	BRD-K27316855-001-13-3, BRD-K28731095-001-01-7, BRD-K27316855-001-15-8	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C, C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	GMRQFYUYWCNGIN-NKMMMXOESA-N, GMRQFYUYWCNGIN-WEARQXOYSA-N, GMRQFYUYWCNGIN-NKMMMXOESA-N	Launched
calcium-gluceptate					BRD-M41172429-238-02-8, BRD-K35952844-238-01-2	OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)C(O)=O, OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	RPLTXWVLGFJQNR-WERYRILLSA-N, KWMLJOLKUYYJFJ-VFUOTHLCSA-N	Launched
calcium-levofolinate					BRD-K97009491-238-03-8, BRD-K97009491-238-02-0	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	VVIAGPKUTFNRDU-STQMWFEESA-N, VVIAGPKUTFNRDU-STQMWFEESA-N	Launched
calpeptin	calpain inhibitor				BRD-K26134695-001-03-6	CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	PGGUOGKHUUUWAF-ROUUACIJSA-N	Preclinical
camicinal	motilin receptor agonist	MLNR			BRD-K23248433-001-01-8	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	RZKDEGZIFSJVNA-IBGZPJMESA-N	Phase 2
CaMKII-IN-1	calcium/calmodulin dependent protein kinase inhibitor	AKT1, CAMK2A, CAMK4, MYLK			BRD-K35772771-001-02-1, BRD-K35772771-001-01-3	Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12, Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12	LGUUETDTMQTHML-UHFFFAOYSA-N, LGUUETDTMQTHML-UHFFFAOYSA-N	Preclinical
camostat-mesilate	protease inhibitor	PRSS1	gastroenterology	pancreatitis	BRD-K43806473-066-02-1	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	XASIMHXSUQUHLV-UHFFFAOYSA-N	Launched
camphor-(+)		TRPV1			BRD-K10034334-001-03-3	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2	DSSYKIVIOFKYAU-XCBNKYQSSA-N	Phase 2
camphor-(1r)	TRPV activator				BRD-K15714472-001-04-5	CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2	DSSYKIVIOFKYAU-GMSGAONNSA-N	Phase 1
camptothecin	topoisomerase inhibitor	TOP1			BRD-K37890730-001-15-1, BRD-K37890730-001-17-7, BRD-K37890730-001-16-9	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N, VSJKWCGYPAHWDS-FQEVSTJZSA-N	Phase 3
camylofine-chlorhydrate			gastroenterology	abdominal pain	BRD-A91733352-300-04-5, BRD-A91733352-300-05-2, BRD-A91733352-300-03-7	CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1, CCN(CC)CCNC(C(=O)OCCC(C)C)c1ccccc1	RYOOHIUJEJZCFT-UHFFFAOYSA-N, RYOOHIUJEJZCFT-UHFFFAOYSA-N, RYOOHIUJEJZCFT-UHFFFAOYSA-N	Launched
canagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	BRD-K90868879-001-03-8, BRD-K90868879-001-02-0	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N, XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	Launched
candesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	BRD-K84091759-001-07-1, BRD-K84091759-001-08-9	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	HTQMVQVXFRQIKW-UHFFFAOYSA-N, HTQMVQVXFRQIKW-UHFFFAOYSA-N	Launched
candesartan-cilextil	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension, congestive heart failure	BRD-A65671304-001-07-5, BRD-A65671304-001-08-3	CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	GHOSNRCGJFBJIB-UHFFFAOYSA-N, GHOSNRCGJFBJIB-UHFFFAOYSA-N	Launched
candicidin	fungal ergosterol inhibitor		infectious disease	vulvovaginal candidiasis	BRD-A37348498-015-01-4	CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC(=O)CC(O)C(C(O)CC(O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)C(O)=O)C(O)CC(=O)c1ccc(N)cc1	HYIZCDMXFDRDFE-RTQJASBYSA-N	Launched
canertinib	EGFR inhibitor	AKT1, EGFR, ERBB2, ERBB4			BRD-K50168500-001-07-9	Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	OMZCMEYTWSXEPZ-UHFFFAOYSA-N	Phase 3
canrenone	mineralocorticoid receptor antagonist	NR3C2			BRD-A20644369-001-08-6	C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1	UJVLDDZCTMKXJK-GMTJQTPWSA-N	Withdrawn
cantharidin	protein phosphatase inhibitor		dermatology	blisters	BRD-K80684056-001-05-1, BRD-K80684056-001-06-9, BRD-K80684056-001-04-4	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O, C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	DHZBEENLJMYSHQ-XCVPVQRUSA-N, DHZBEENLJMYSHQ-XCVPVQRUSA-N, DHZBEENLJMYSHQ-XCVPVQRUSA-N	Launched
capadenoson	adenosine receptor agonist	ADORA1			BRD-K97025174-001-01-4	Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	CITWCLNVRIKQAF-UHFFFAOYSA-N	Phase 2
capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	BRD-K61192372-001-05-5, BRD-A91877226-001-01-4, BRD-K15574380-001-01-0	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)C1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@@H]1O	GAGWJHPBXLXJQN-UORFTKCHSA-N, GAGWJHPBXLXJQN-LXGADPQPSA-N, GAGWJHPBXLXJQN-GMTLJSCSSA-N	Launched
capobenic-acid					BRD-K04282412-001-16-3	COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O	MPTXLVRHYGBOQY-UHFFFAOYSA-N	Preclinical
capreomycin	protein synthesis inhibitor		infectious disease	tuberculosis	BRD-A31362467-065-01-3, BRD-A33801468-065-04-1	CC1NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC(=O)C(CNC(=O)CC(N)CCCN)NC1=O)=C/NC(N)=O)C1CCNC(=N)N1, NCCCC(N)CC(=O)NCC1NC(=O)C(CO)NC(=O)C(N)CNC(=O)C(NC(=O)\C(NC1=O)=C/NC(N)=O)C1CCNC(=N)N1	FRXNXDHFQYZYNA-MHWRWJLKSA-N, JNIIDKODPGHQSS-OQLLNIDSSA-N	Launched
caprylic-acid					BRD-K35170555-001-09-5	CCCCCCCC(O)=O	WWZKQHOCKIZLMA-UHFFFAOYSA-N	Launched
capsaicin	TRPV agonist	CFTR, TRPV1	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis	BRD-K50590187-001-19-9, BRD-K50590187-001-20-7	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O, COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	YKPUWZUDDOIDPM-SOFGYWHQSA-N, YKPUWZUDDOIDPM-SOFGYWHQSA-N	Launched
capsazepine	TRPV agonist	TRPV1, TRPV4			BRD-K44849676-001-10-5	Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	DRCMAZOSEIMCHM-UHFFFAOYSA-N	Preclinical
captamine					BRD-K81645907-001-01-1	CN(C)CCS	DENMGZODXQRYAR-UHFFFAOYSA-N	Preclinical
captan					BRD-A79857384-001-03-6	ClC(Cl)(Cl)SN1C(=O)C2CC=CCC2C1=O	LDVVMCZRFWMZSG-UHFFFAOYSA-N	Phase 1
captopril	angiotensin converting enzyme inhibitor	ACE, LTA4H, MMP2, MMP9	cardiology, endocrinology, nephrology	hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy	BRD-K54529596-001-26-3, BRD-K54529596-001-25-5, BRD-K96855766-001-01-9	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](CS)C(=O)N1CCC[C@@H]1C(O)=O	FAKRSMQSSFJEIM-RQJHMYQMSA-N, FAKRSMQSSFJEIM-RQJHMYQMSA-N, FAKRSMQSSFJEIM-RNFRBKRXSA-N	Launched
caracemide	ribonucleotide reductase inhibitor	RRM1			BRD-K62790656-001-01-1	CNC(=O)ON(C(C)=O)C(=O)NC	JURAJLFHWXNPHG-UHFFFAOYSA-N	Phase 2
caramiphen	cholinergic receptor antagonist	CHRM1, CHRM2	neurology/psychiatry	Parkinsons Disease" "BRD-K59895502-001-01-9" "CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1" "OFAIGZWCDGNZGT-UHFFFAOYSA-N" "Launched"
"295" "carazolol" "adrenergic receptor antagonist" "ADRB1, ADRB2, ADRB3" "cardiology" "angina pectoris, cardiac arrythmia, hypertension, myocardial infarction" "BRD-A50675490-001-01-0" "CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12" "BQXQGZPYHWWCEB-UHFFFAOYSA-N" "Launched"
"296" "carbachol" "cholinergic receptor agonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2" "ophthalmology" "intraocular pressure" "BRD-K75037734-003-13-9, BRD-K75037734-003-14-7" "C[N+](C)(C)CCOC(N)=O, C[N+](C)(C)CCOC(N)=O" "VPJXQGSRWJZDOB-UHFFFAOYSA-O, VPJXQGSRWJZDOB-UHFFFAOYSA-O" "Launched"
"297" "carbadox" "other antibiotic" "" "infectious disease, gastroenterology" "dysentry, enteritis" "BRD-K56735750-001-07-6, BRD-K56735750-001-06-8, BRD-K06386100-001-01-9" "COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-], COC(=O)\N=N\C=C1/C=[N+]([O-])c2ccccc2N1O" "OVGGLBAWFMIPPY-WUXMJOGZSA-N, OVGGLBAWFMIPPY-WUXMJOGZSA-N, BPMVRAQIQQEBLN-JQAHBYNNSA-N" "Launched"
"298" "carbamazepine" "carboxamide antiepileptic" "SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "seizures" "BRD-K71799949-001-36-4, BRD-K71799949-001-35-6" "NC(=O)N1c2ccccc2C=Cc2ccccc12, NC(=O)N1c2ccccc2C=Cc2ccccc12" "FFGPTBGBLSHEPO-UHFFFAOYSA-N, FFGPTBGBLSHEPO-UHFFFAOYSA-N" "Launched"
"299" "carbaril" "acetylcholinesterase inhibitor" "" "" "" "BRD-K54208592-001-09-4" "CNC(=O)Oc1cccc2ccccc12" "CVXBEEMKQHEXEN-UHFFFAOYSA-N" "Launched"
"300" "carbarsone" "antiprotozoal agent" "" "infectious disease" "amebiasis" "BRD-K94848716-001-11-6" "NC(=O)Nc1ccc(cc1)[As](O)(O)=O" "WWXBHTZSYYGCSG-UHFFFAOYSA-N" "Launched"
"301" "carbazochrome" "" "" "hematology" "hemorrhage" "BRD-A11070335-236-02-1" "CN1C(CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O" "OZCACMPSTYQSMM-SDQBBNPISA-N" "Launched"
"302" "carbendazim" "microtubule inhibitor, tubulin polymerization inhibitor" "TP53, TUBB" "infectious disease" "fungicide" "BRD-K12906202-001-06-2" "COC(=O)Nc1nc2ccccc2[nH]1" "TWFZGCMQGLPBSX-UHFFFAOYSA-N" "Launched"
"303" "carbenicillin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-A13078313-304-06-5, BRD-A13078313-304-05-7, BRD-A13078313-304-07-3, BRD-A13078313-304-08-1" "CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O" "FPPNZSSZRUTDAP-UWFZAAFLSA-N, FPPNZSSZRUTDAP-UWFZAAFLSA-N, FPPNZSSZRUTDAP-UWFZAAFLSA-N, FPPNZSSZRUTDAP-UWFZAAFLSA-N" "Launched"
"304" "carbenoxolone" "11-beta hydroxysteroid dehydrogenase inhibitor" "GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3" "gastroenterology, dental" "peptic ulcer disease (PUD), mouth inflammation" "BRD-A25216804-304-02-2, BRD-A98702003-304-04-8, BRD-A25216804-304-01-4" "CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3CC(C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)C2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O, CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3CC(C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O" "OBZHEBDUNPOCJG-XPDVRYJBSA-N, OBZHEBDUNPOCJG-YQNKGXRGSA-N, OBZHEBDUNPOCJG-XPDVRYJBSA-N" "Launched"
"305" "carbetapentane" "acetylcholine receptor antagonist" "CHRM2" "otolaryngology, pulmonary" "common cold, nasal congestion, bronchitis" "BRD-K06181161-048-15-1, BRD-K06181161-048-16-9" "CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1, CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1" "CFJMRBQWBDQYMK-UHFFFAOYSA-N, CFJMRBQWBDQYMK-UHFFFAOYSA-N" "Launched"
"306" "carbetocin" "oxytocin receptor agonist" "OXTR" "hematology" "hemorrhage" "BRD-K56107812-001-01-7" "CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O" "NSTRIRCPWQHTIA-DTRKZRJBSA-N" "Launched"
"307" "carbidopa" "aromatic L-amino acid decarboxylase inhibitor" "DDC" "neurology/psychiatry" "Parkinsons Disease	BRD-K78712176-001-11-7, BRD-A69512159-001-06-5, BRD-K78712176-001-12-5, BRD-K78712176-001-13-3, BRD-K78712176-001-14-1	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, CC(Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O, C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-UHFFFAOYSA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N, TZFNLOMSOLWIDK-JTQLQIEISA-N	Launched
carbimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	BRD-K87156652-001-12-7, BRD-K87156652-001-11-9, BRD-K87156652-001-13-5	CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S, CCOC(=O)n1ccn(C)c1=S	CFOYWRHIYXMDOT-UHFFFAOYSA-N, CFOYWRHIYXMDOT-UHFFFAOYSA-N, CFOYWRHIYXMDOT-UHFFFAOYSA-N	Launched
carbinoxamine	histamine receptor antagonist	HRH1	allergy, ophthalmology, otolaryngology, dermatology	allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism	BRD-A29426959-050-13-2	CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1	OJFSXZCBGQGRNV-UHFFFAOYSA-N	Launched
carboplatin	DNA alkylating agent, DNA inhibitor		oncology	ovarian cancer	BRD-K90947825-001-05-0, BRD-K90947825-001-03-5, BRD-K90947825-001-04-3, BRD-K90947825-001-02-7	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1, N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L, YAYRGNWWLMLWJE-UHFFFAOYSA-L	Launched
carboxyamidotriazole	calcium channel blocker	CXCL8			BRD-K68408772-001-05-4	NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	WNRZHQBJSXRYJK-UHFFFAOYSA-N	Phase 3
carboxylosartan	angiotensin antagonist	AGTR1			BRD-K23533833-001-01-9	CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	ZEUXAIYYDDCIRX-UHFFFAOYSA-N	Phase 1
carboxypyridine-disulfide					BRD-K26530649-001-01-6	OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	GSASOFRDSIKDSN-UHFFFAOYSA-N	Phase 2
cardiogenol-c	cardiomyogenesis inducer				BRD-K99174507-003-02-0	COc1ccc(Nc2nccc(NCCO)n2)cc1	LKBSMPFEKIBRGC-UHFFFAOYSA-N	Preclinical
carebastine	histamine receptor antagonist	HRH1			BRD-K49554218-001-01-0	CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	XGHOVGYJHWQGCC-UHFFFAOYSA-N	Phase 1
carfilzomib	proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	BRD-K15179879-001-03-2	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	BLMPQMFVWMYDKT-NZTKNTHTSA-N	Launched
carglumic-acid	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	BRD-K60240222-001-01-4	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	LCQLHJZYVOQKHU-VKHMYHEASA-N	Launched
caricotamide	NADPH quinone oxidoreductase inhibitor	NQO2			BRD-K90215590-001-01-4	NC(=O)CN1C=CCC(=C1)C(N)=O	WEJRSYKFMCUCRQ-UHFFFAOYSA-N	Phase 2
cariporide	sodium/hydrogen exchanger inhibitor	SLC9A1			BRD-K21670884-001-01-9	CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	IWXNYAIICFKCTM-UHFFFAOYSA-N	Phase 3
cariprazine	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	schizophrenia	BRD-K57764956-001-02-8	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1	KPWSJANDNDDRMB-QAQDUYKDSA-N	Launched
carisoprodol	acetylcholine receptor antagonist	CYP2C19	neurology/psychiatry	muscle relaxant	BRD-A99939097-001-24-2	CCCC(C)(COC(N)=O)COC(=O)NC(C)C	OFZCIYFFPZCNJE-UHFFFAOYSA-N	Launched
carmofur	thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	BRD-K11630072-001-13-2, BRD-K11630072-001-12-4, BRD-K11630072-001-11-6	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	AOCCBINRVIKJHY-UHFFFAOYSA-N, AOCCBINRVIKJHY-UHFFFAOYSA-N, AOCCBINRVIKJHY-UHFFFAOYSA-N	Launched
carmoterol	adrenergic receptor agonist	ADRB2			BRD-K25095405-001-01-5	COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3nc(O)ccc23)cc1	IHOXNOQMRZISPV-YJYMSZOUSA-N	Phase 2
carmoxirole	dopamine receptor agonist	DRD2			BRD-K82484965-003-04-3, BRD-K82484965-003-03-5	OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1, OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1	AFSOIHMEOKEZJF-UHFFFAOYSA-N, AFSOIHMEOKEZJF-UHFFFAOYSA-N	Phase 2
carmustine	DNA alkylating agent, DNA inhibitor	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkins lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma" "BRD-K36234266-001-09-8" "[O-][N+]N(CCCl)C(=O)NCCCl" "DLGOEMSEDOSKAD-UHFFFAOYSA-N" "Launched"
"308" "carnitine-(D/L)" "" "" "" "" "BRD-A89594340-003-12-3, BRD-A89594340-003-11-5" "C[N+](C)(C)CC(O)CC(O)=O, C[N+](C)(C)CC(O)CC(O)=O" "PHIQHXFUZVPYII-UHFFFAOYSA-O, PHIQHXFUZVPYII-UHFFFAOYSA-O" "Phase 3"
"309" "carnosine" "antiglycating agent" "" "" "" "BRD-A96051074-001-02-2" "NCCC(=O)NC(Cc1cnc[nH]1)C(O)=O" "CQOVPNPJLQNMDC-UHFFFAOYSA-N" "Phase 2"
"310" "caroverine" "glutamate receptor antagonist, calcium channel blocker" "" "neurology/psychiatry" "tinnitus" "BRD-K65900713-003-01-0" "CCN(CC)CCN1C(=O)C(Nc2ccccc12)=Cc1ccc(OC)cc1" "GVZONAHBJMFJOW-UHFFFAOYSA-N" "Launched"
"311" "caroxazone" "monoamine oxidase inhibitor" "MAOA, MAOB" "" "" "BRD-K92129045-001-01-6" "NC(=O)CN1Cc2ccccc2OC1=O" "KYCBWEZLKCTALM-UHFFFAOYSA-N" "Withdrawn"
"312" "carprofen" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "rheumatology" "osteoarthritis" "BRD-A17411484-001-11-9, BRD-A17411484-001-10-1" "CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21, CC(C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21" "PUXBGTOOZJQSKH-UHFFFAOYSA-N, PUXBGTOOZJQSKH-UHFFFAOYSA-N" "Launched"
"313" "carsalam" "analgesic agent" "" "" "" "BRD-K13238618-001-05-9" "O=c1[nH]c(=O)c2ccccc2o1" "OAYRYNVEFFWSHK-UHFFFAOYSA-N" "Preclinical"
"314" "carteolol" "adrenergic receptor antagonist" "ADRB1, ADRB2" "ophthalmology" "intraocular pressure, glaucoma, ocular hypertension" "BRD-A42167015-003-10-2" "CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12" "LWAFSWPYPHEXKX-UHFFFAOYSA-N" "Launched"
"315" "carumonam" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "urinary tract infections, gram-negative bacterial infections" "BRD-K71026158-304-01-0" "NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O" "UIMOJFJSJSIGLV-JNHMLNOCSA-N" "Launched"
"316" "carvedilol" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, GJA1, HIF1A, KCNH2, NDUFC2, NPPB, SELE, VCAM1, VEGFA" "cardiology" "myocardial infarction, hypertension" "BRD-A10977446-001-12-1, BRD-A10977446-011-01-3, BRD-A10977446-001-13-9, BRD-A10977446-001-14-7" "COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12, COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12" "OGHNVEJMJSYVRP-UHFFFAOYSA-N, OGHNVEJMJSYVRP-UHFFFAOYSA-N, OGHNVEJMJSYVRP-UHFFFAOYSA-N, OGHNVEJMJSYVRP-UHFFFAOYSA-N" "Launched"
"317" "carzenide" "" "CA1, CA12, CA14, CA2, CA6, CA9" "" "" "BRD-K09295674-001-09-8" "NS(=O)(=O)c1ccc(cc1)C(O)=O" "UCAGLBKTLXCODC-UHFFFAOYSA-N" "Preclinical"
"318" "casanthranol-variant" "" "" "" "" "BRD-K12413266-001-01-3" "OC[C@H]1O[C@@H](O[C@@H]2c3cccc(O)c3C(=O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O" "CPUHNROBVJNNPW-VVBPCJSVSA-N" "Launched"
"319" "caspofungin" "fungal 1,3-beta-D-glucan synthase inhibitor, bacterial cell wall synthesis inhibitor" "" "infectious disease" "candidemia, esophageal candidiasis, aspergillosis, fungal infection" "BRD-A31685486-402-01-9" "CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@@H](O)[C@H](O)c1ccc(O)cc1)[C@H](O)CCN" "JYIKNQVWKBUSNH-QPUODBGRSA-N" "Launched"
"320" "caspofungin-acetate" "fungal 1,3-beta-D-glucan synthase inhibitor" "" "infectious disease" "candidemia, esophageal candidiasis, aspergillosis, peritonitis" "BRD-K49793107-402-02-6, BRD-K33838583-402-01-2" "CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN, CC[C@@H](C)C[C@@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](O)CCN" "JYIKNQVWKBUSNH-JYEVSGHCSA-N, JYIKNQVWKBUSNH-GGHYDEHXSA-N" "Launched"
"321" "castanospermine" "glucosidase inhibitor" "GAA, GBA" "" "" "BRD-K20897876-001-10-0" "O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12" "JDVVGAQPNNXQDW-TVNFTVLESA-N" "Phase 2"
"322" "catharanthine" "tubulin polymerization inhibitor" "" "" "" "BRD-K92377961-001-03-7, BRD-K92377961-001-02-9" "CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC, CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC" "CMKFQVZJOWHHDV-NQZBTDCJSA-N, CMKFQVZJOWHHDV-NQZBTDCJSA-N" "Preclinical"
"323" "cathepsin-inhibitor-1" "cathepsin inhibitor" "CTSB, CTSL, CTSV" "" "" "BRD-K40269473-001-02-2" "Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC" "" ""
"324" "CAY10505" "PI3K inhibitor" "PIK3CG" "" "" "BRD-K40366680-001-04-1, BRD-K40366680-001-03-3" "Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1, Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1" "UFBTYTGRUBUUIL-KPKJPENVSA-N, UFBTYTGRUBUUIL-KPKJPENVSA-N" "Preclinical"
"325" "CB-03-01" "androgen receptor antagonist" "AR" "" "" "BRD-K41779183-001-02-0, BRD-K41779183-001-01-2" "CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO, CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO" "GPNHMOZDMYNCPO-PDUMRIMRSA-N, GPNHMOZDMYNCPO-PDUMRIMRSA-N" "Phase 3"
"326" "CB-10-277" "DNA synthesis inhibitor" "" "" "" "BRD-K59929863-001-01-9" "CN(C)\N=N\c1ccc(cc1)C(O)=O" "GUAZPUYTLMUTMA-ZHACJKMWSA-N" "Phase 1"
"327" "CB-5083" "valosin-containing protein inhibitor" "VCP" "" "" "BRD-K49048664-001-02-0, BRD-K49048664-001-01-2" "Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O, Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O" "RDALZZCKQFLGJP-UHFFFAOYSA-N, RDALZZCKQFLGJP-UHFFFAOYSA-N" "Phase 1"
"328" "CB-839" "glutaminase inhibitor" "GLS" "" "" "BRD-K58070273-001-04-1, BRD-K58070273-001-03-3" "FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1, FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1" "PRAAPINBUWJLGA-UHFFFAOYSA-N, PRAAPINBUWJLGA-UHFFFAOYSA-N" "Phase 1/Phase 2"
"329" "CBS-1114" "lipoxygenase inhibitor" "ALOX5" "" "" "BRD-K91874254-001-01-4" "N=C(NNc1ccccc1)c1ccccc1" "ZOBKPJRHDMKXQG-UHFFFAOYSA-N" "Phase 1"
"330" "CC-115" "mTOR inhibitor, DNA protein kinase inhibitor" "MTOR" "" "" "BRD-K16755045-003-01-7, BRD-K16755045-001-01-1" "CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1, CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1" "GMYLVKUGJMYTFB-UHFFFAOYSA-N, GMYLVKUGJMYTFB-UHFFFAOYSA-N" "Phase 1"
"331" "CC-223" "mTOR inhibitor" "MTOR" "" "" "BRD-K88737571-001-01-4" "CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O" "UFKLYTOEMRFKAD-SHTZXODSSA-N" "Phase 1/Phase 2"
"332" "CC-401" "JNK inhibitor" "MAPK8" "" "" "BRD-K45746021-003-01-9" "C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1ncn[nH]1" "XDJCLCLBSGGNKS-UHFFFAOYSA-N" "Phase 1"
"333" "CC-930" "JNK inhibitor" "" "" "" "BRD-K48213016-001-01-8" "O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1" "IBGLGMOPHJQDJB-IHRRRGAJSA-N" "Phase 2"
"334" "CCG-50014" "G protein signaling inhibitor" "RGS4, RGS8" "" "" "BRD-K08893438-001-04-9, BRD-K08893438-001-03-1" "Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O, Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O" "QUIIIYITNGOFEI-UHFFFAOYSA-N, QUIIIYITNGOFEI-UHFFFAOYSA-N" "Preclinical"
"335" "CCG-63802" "G protein signaling inhibitor" "RGS4" "" "" "BRD-K26970495-001-01-9" "Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C" "" ""
"336" "CCG-63808" "G protein signaling inhibitor" "RGS4" "" "" "BRD-K68474505-001-01-9" "Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C" "" ""
"337" "CCMI" "acetylcholine receptor allosteric modulator" "CHRNA7" "" "" "BRD-K19859123-001-01-3" "Cc1cc(on1)C(=C/Nc1ccc(Cl)cc1)\C(=O)Nc1ccc(Cl)cc1" "VMAKIACTLSBBIY-GZTJUZNOSA-N" "Preclinical"
"338" "CCMQ" "homoquinolinic acid binding inhibitor" "" "" "" "BRD-K06159959-001-02-0" "OC(=O)Cc1cc2ccccc2nc1C(O)=O" "IFXJDEHFADWURH-UHFFFAOYSA-N" "Preclinical"
"339" "CCT018159" "HSP inhibitor" "HSP90AA1, HSP90AB1" "" "" "BRD-K65503129-001-06-3" "CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O" "OWPMENVYXDJDOW-UHFFFAOYSA-N" "Preclinical"
"340" "CCT128930" "AKT inhibitor" "PKIA, PRKACA" "" "" "BRD-K76406695-001-02-9" "NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12" "RZIDZIGAXXNODG-UHFFFAOYSA-N" "Preclinical"
"341" "CCT129202" "Aurora kinase inhibitor" "AURKA, AURKB, AURKC" "" "" "BRD-K57136142-001-02-4, BRD-K57136142-001-03-2" "CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1, CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1" "QYKHWEFPFAGNEV-UHFFFAOYSA-N, QYKHWEFPFAGNEV-UHFFFAOYSA-N" "Preclinical"
"342" "CCT137690" "Aurora kinase inhibitor" "AURKA, AURKB, AURKC" "" "" "BRD-K03289018-001-04-3, BRD-K03289018-001-03-5, BRD-K03289018-001-02-7" "CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1, CN1CCN(CC1)c1ccc(cc1)-c1nc2c(N3CCN(Cc4cc(C)on4)CC3)c(Br)cnc2[nH]1" "GFLQCBTXTRCREJ-UHFFFAOYSA-N, GFLQCBTXTRCREJ-UHFFFAOYSA-N, GFLQCBTXTRCREJ-UHFFFAOYSA-N" "Preclinical"
"343" "CD-1530" "retinoid receptor agonist" "RARG" "" "" "BRD-K09619322-001-03-8" "OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2" "VCQGNUWOMLYNNG-UHFFFAOYSA-N" "Preclinical"
"344" "CD-437" "retinoid receptor agonist" "RARG" "" "" "BRD-K28907958-001-04-3" "OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2" "LDGIHZJOIQSHPB-UHFFFAOYSA-N" "Preclinical"
"345" "CDBA" "" "" "" "" "BRD-A08079565-001-01-8" "OCC1OC2OC3C(CO)OC(OC4C(CO)OC(OC5C(CO)OC(OC6C(CO)OC(OC7C(CO)OC(OC8C(CO)OC(OC1C(O)C2O)C(O)C8O)C(O)C7O)C(O)C6O)C(O)C5O)C(O)C4O)C(O)C3O" "WHGYBXFWUBPSRW-UHFFFAOYSA-N" "Phase 3"
"346" "CDK1-5-inhibitor" "CDK inhibitor, glycogen synthase kinase inhibitor" "CDK1, CDK5, GSK3B" "" "" "BRD-K87932577-001-02-4" "Nc1n[nH]c2nc3ccccc3nc12" "DWHVZCLBMTZRQM-UHFFFAOYSA-N" "Preclinical"
"347" "CDK9-IN-6" "CDK inhibitor" "CDK9" "" "" "BRD-K43914553-001-01-5" "COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C" "" ""
"348" "cebranopadol" "opioid receptor agonist" "OPRL1, OPRM1" "" "" "BRD-K48141473-001-01-7" "CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1" "CSMVOZKEWSOFER-RQNOJGIXSA-N" "Phase 3"
"349" "cediranib" "KIT inhibitor, VEGFR inhibitor" "CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB" "" "" "BRD-K86930074-001-05-0" "COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1" "XXJWYDDUDKYVKI-UHFFFAOYSA-N" "Phase 3"
"350" "cedrol" "" "" "" "" "BRD-A61188230-001-01-6" "CC1CCC2C(C)(C)C3CC12CCC3(C)O" "SVURIXNDRWRAFU-UHFFFAOYSA-N" "Phase 2"
"351" "cedrol-(+)" "sedative" "" "" "" "BRD-K96362839-001-01-9" "C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O" "SVURIXNDRWRAFU-OGMFBOKVSA-N" "Phase 2"
"352" "cefaclor" "bacterial cell wall synthesis inhibitor" "" "infectious disease, otolaryngology" "pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis" "BRD-K20338176-001-17-7, BRD-K20338176-001-16-9, BRD-K20338176-001-18-5" "N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1, N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1" "QYIYFLOTGYLRGG-GPCCPHFNSA-N, QYIYFLOTGYLRGG-GPCCPHFNSA-N, QYIYFLOTGYLRGG-GPCCPHFNSA-N" "Launched"
"353" "cefadroxil" "bacterial cell wall synthesis inhibitor" "SLC15A1, SLC15A2, SLC22A6, SLC22A8" "infectious disease, otolaryngology" "urinary tract infections, skin infections, tonsillitis, pharyngitis" "BRD-A56858165-001-04-4" "CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O" "BOEGTKLJZSQCCD-HUFXEGEASA-N" "Launched"
"354" "cefalonium" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections" "BRD-K15514357-001-05-6" "NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1" "FMZXNVLFJHCSAF-DNVCBOLYSA-O" "Launched"
"355" "cefamandole" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections, urinary tract infections, respiratory tract infections" "BRD-A23933379-236-04-9, BRD-K27130738-236-14-1" "Cn1nnnc1SCC1=C(N2C(SC1)C(NC(=O)C(O)c1ccccc1)C2=O)C(O)=O, Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O" "OLVCFLKTBJRLHI-UHFFFAOYSA-N, OLVCFLKTBJRLHI-AXAPSJFSSA-N" "Launched"
"356" "cefamandole-nafate" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections, urinary tract infections, respiratory tract infections" "BRD-K17903788-236-01-9, BRD-A02439449-236-04-8" "Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O, Cn1nnnc1SCC1=C(N2C(SC1)C(NC(=O)C(OC=O)c1ccccc1)C2=O)C(O)=O" "RRJHESVQVSRQEX-SUYBPPKGSA-N, RRJHESVQVSRQEX-UHFFFAOYSA-N" "Launched"
"357" "cefathiamidine" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections" "BRD-K63835048-001-01-0" "CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C" "JYXACOFERDBGGQ-RHSMWYFYSA-N" "Launched"
"358" "cefazolin" "bacterial cell wall synthesis inhibitor" "PON1" "infectious disease" "urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections" "BRD-K99750640-236-18-7, BRD-K99750640-236-19-5" "Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1, Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1" "MLYYVTUWGNIJIB-BXKDBHETSA-N, MLYYVTUWGNIJIB-BXKDBHETSA-N" "Launched"
"359" "cefcapene-pivoxil" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections, pneumonia, urinary tract infections" "BRD-K27515606-003-01-3, BRD-K27515606-311-02-8, BRD-K27515606-311-01-0" "CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1" "WVPAABNYMHNFJG-QDVBXLKVSA-N, WVPAABNYMHNFJG-QDVBXLKVSA-N, WVPAABNYMHNFJG-QDVBXLKVSA-N" "Launched"
"360" "cefdinir" "bacterial cell wall synthesis inhibitor" "MPO" "infectious disease, otolaryngology, pulmonary" "pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis" "BRD-K15766189-001-10-6, BRD-K15766189-001-09-8, BRD-K15766189-001-08-0" "Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O" "RTXOFQZKPXMALH-GHXIOONMSA-N, RTXOFQZKPXMALH-GHXIOONMSA-N, RTXOFQZKPXMALH-GHXIOONMSA-N" "Launched"
"361" "cefditoren-pivoxil" "bacterial cell wall synthesis inhibitor" "" "infectious disease, pulmonary, otolaryngology" "pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis" "BRD-K72167406-001-02-1, BRD-K05878591-001-01-2, BRD-A39056513-001-04-6" "CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)NC1C2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1" "AFZFFLVORLEPPO-UVYJNCLZSA-N, AFZFFLVORLEPPO-OUOWMNRXSA-N, AFZFFLVORLEPPO-DGQFBIKGSA-N" "Launched"
"362" "cefepime" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "pneumonia, urinary tract infections, skin infections, intra-abdominal infections" "BRD-A12077521-003-01-5" "CO\N=C(\C(=O)NC1C2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1" "HVFLCNVBZFFHBT-FSJBWODESA-O" "Launched"
"363" "cefetamet" "bacterial cell wall synthesis inhibitor" "" "infectious disease, otolaryngology, pulmonary" "ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections" "BRD-K27798832-001-01-5" "CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1" "MQLRYUCJDNBWMV-GHXIOONMSA-N" "Launched"
"364" "cefetamet-pivoxil" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections" "BRD-K21372554-003-02-5, BRD-K21372554-003-01-7, BRD-K21372554-001-01-1" "CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1" "DASYMCLQENWCJG-XUKDPADISA-N, DASYMCLQENWCJG-XUKDPADISA-N, DASYMCLQENWCJG-XUKDPADISA-N" "Launched"
"365" "cefixime" "bacterial cell wall synthesis inhibitor" "" "infectious disease, otolaryngology, pulmonary" "urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis" "BRD-K71059170-341-02-5, BRD-K71059170-001-12-4, BRD-K71059170-001-11-6" "Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O" "OKBVVJOGVLARMR-QSWIMTSFSA-N, OKBVVJOGVLARMR-QSWIMTSFSA-N, OKBVVJOGVLARMR-QSWIMTSFSA-N" "Launched"
"366" "cefmenoxime" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-A20839672-003-01-5" "CO\N=C(\C(=O)NC1C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1" "HJJDBAOLQAWBMH-ODCIPOBUSA-N" "Launched"
"367" "cefmetazole" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "urinary tract infections, skin infections" "BRD-K48470486-236-10-8, BRD-A97040294-236-04-6" "CO[C@]1(NC(=O)CSCC" "" ""
"368" "cefminox" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K77073709-435-01-2" "CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O" "JSDXOWVAHXDYCU-VXSYNFHWSA-N" "Launched"
"369" "cefodizime" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "respiratory tract infections, skin infections, gonorrhea" "BRD-K72150952-304-01-5, BRD-A42969929-001-01-9" "CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(\C(=O)NC1C2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1" "XDZKBRJLTGRPSS-ZSKFQXOHSA-N, XDZKBRJLTGRPSS-BRJLIKDPSA-N" "Launched"
"370" "cefonicid" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections" "BRD-A65872513-304-01-7, BRD-K34058848-304-01-5" "O[C@@H](C(=O)NC1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1, O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1" "DYAIAHUQIPBDIP-ZUZSALNQSA-N, DYAIAHUQIPBDIP-AXAPSJFSSA-N" "Launched"
"371" "cefoperazone" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K02292852-001-02-1, BRD-A73079885-001-01-1" "CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O, CCN1CCN(C(=O)NC(C(=O)NC2C3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O" "GCFBRXLSHGKWDP-XCGNWRKASA-N, GCFBRXLSHGKWDP-UHFFFAOYSA-N" "Launched"
"372" "ceforanide" "penicillin binding protein inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K37848908-001-05-6, BRD-A38738672-001-01-3" "NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O, NCc1ccccc1CC(=O)NC1C2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O" "SLAYUXIURFNXPG-CRAIPNDOSA-N, SLAYUXIURFNXPG-UHFFFAOYSA-N" "Launched"
"373" "cefoselis" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-K37910175-065-03-0, BRD-K20284063-065-01-8, BRD-K02689172-065-01-8" "CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccc(N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(\C(=O)N[C@@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1" "ZINFAXPQMLDEEJ-HQUYFYFUSA-N, BHXLLRXDAYEMPP-SBGRAJFYSA-O, ZINFAXPQMLDEEJ-NTOXNIMASA-N" "Launched"
"374" "cefotaxime" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "respiratory tract infections, bone and joint infections, pelvic inflammatory disease, intra-abdominal infections, skin infections, bone and joint infections, meningitis, urinary tract infections, bacterial septicemia, gynecologic infections" "BRD-K99586414-236-04-9, BRD-K78364995-236-17-5, BRD-K78364995-236-16-7" "CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1" "GPRBEKHLDVQUJE-VINNURBNSA-N, GPRBEKHLDVQUJE-QSWIMTSFSA-N, GPRBEKHLDVQUJE-QSWIMTSFSA-N" "Launched"
"375" "cefotetan" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis" "BRD-A78723049-001-01-2" "CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O" "SRZNHPXWXCNNDU-PGEKIEPBSA-N" "Launched"
"376" "cefotiam" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections" "BRD-K02275692-300-02-6, BRD-K02275692-300-01-8" "CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O, CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O" "QYQDKDWGWDOFFU-IUODEOHRSA-N, QYQDKDWGWDOFFU-IUODEOHRSA-N" "Launched"
"377" "cefotiam-cilexetil" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-A76661185-300-01-6, BRD-A76661185-300-02-4" "CC(OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CSC2C(NC(=O)Cc3csc(N)n3)C(=O)N12, CC(OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CSC2C(NC(=O)Cc3csc(N)n3)C(=O)N12" "VVFDMWZLBPUKTD-UHFFFAOYSA-N, VVFDMWZLBPUKTD-UHFFFAOYSA-N" "Launched"
"378" "cefoxitin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections" "BRD-K70976396-236-26-0, BRD-K70976396-236-25-2" "CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O, CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O" "WZOZEZRFJCJXNZ-ZBFHGGJFSA-N, WZOZEZRFJCJXNZ-ZBFHGGJFSA-N" "Launched"
"379" "cefozopran" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-K46970505-003-01-9" "CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1" "QDUIJCOKQCCXQY-WHJQOFBOSA-O" "Launched"
"380" "cefpiramide" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K92872987-001-01-1, BRD-A39975020-001-01-9, BRD-K92872987-236-03-9" "Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1C2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1, Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1" "PWAUCHMQEXVFJR-PMAPCBKXSA-N, PWAUCHMQEXVFJR-JGUPTHKFSA-N, PWAUCHMQEXVFJR-PMAPCBKXSA-N" "Launched"
"381" "cefpirome" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K56542719-065-01-4" "CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1" "DKOQGJHPHLTOJR-PUIFZAHNSA-O" "Launched"
"382" "cefpodoxime" "bacterial cell wall synthesis inhibitor" "" "otolaryngology, infectious disease, pulmonary" "pharyngitis, pneumonia, bronchitis, gonorrhea, skin infections, urinary tract infections, sinusitis, tonsillitis" "BRD-A34205213-001-03-9, BRD-A87387433-001-03-5" "COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)OC(C)OC(=O)OC(C)C, COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N\OC)\c1csc(N)n1)C2=O)C(=O)OC(C)OC(=O)OC(C)C" "LTINZAODLRIQIX-FBXRGJNPSA-N, LTINZAODLRIQIX-ZFEISNGRSA-N" "Launched"
"383" "cefprozil" "bacterial cell wall synthesis inhibitor" "" "otolaryngology, infectious disease, pulmonary" "pharyngitis, tonsillitis, otitis, sinusitis, respiratory tract infections, skin infections, bronchitis" "BRD-K24871708-002-04-6, BRD-K24871708-002-03-8, BRD-A85137183-001-03-8, BRD-K24871708-002-02-0" "C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O, C\C=C/C1=C(N2C(SC1)C(NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O, C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O" "WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N, WDLWHQDACQUCJR-IHWYPQMZSA-N, WDLWHQDACQUCJR-ZAMMOSSLSA-N" "Launched"
"384" "cefradine" "bacterial cell wall synthesis inhibitor" "CYP3A4" "infectious disease, otolaryngology" "respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia" "BRD-K13797099-001-01-1" "CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O" "RDLPVSKMFDYCOR-UEKVPHQBSA-N" "Launched"
"385" "cefsulodin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-A86462796-236-04-8, BRD-K03907181-236-04-3, BRD-K03907181-236-05-0" "NC(=O)c1cc[n+](CC2=C(N3C(SC2)C(NC(=O)C(c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1, NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1" "SYLKGLMBLAAGSC-UHFFFAOYSA-O, SYLKGLMBLAAGSC-QLVMHMETSA-O, SYLKGLMBLAAGSC-QLVMHMETSA-O" "Launched"
"386" "ceftaroline-fosamil" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections, pneumonia" "BRD-K37252028-349-01-8" "CCO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Sc3nc(cs3)-c3cc[n+](C)cc3)=C(N2C1=O)C(O)=O)c1nsc(NP(O)(O)=O)n1" "ZCCUWMICIWSJIX-XHNDKCDBSA-O" "Launched"
"387" "ceftazidime" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "respiratory tract infections, skin infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, meningitis" "BRD-K52117081-345-03-1, BRD-A73933229-396-01-8, BRD-K52117081-001-02-2, BRD-K57502136-345-02-6, BRD-K57502136-345-03-4" "CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O, CC(C)(O\N=C(/C(=O)N[C@H]1C2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O, CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O, CC(C)(O\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O, CC(C)(O\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O" "ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-MMWTVJBSSA-O, ORFOPKXBNMVMKC-DWVKKRMSSA-O, ORFOPKXBNMVMKC-KZBLUZIOSA-O, ORFOPKXBNMVMKC-KZBLUZIOSA-O" "Launched"
"388" "ceftibuten" "bacterial cell wall synthesis inhibitor" "" "pulmonary, otolaryngology" "bronchitis, otitis, pharyngitis, tonsillitis" "BRD-K11124378-002-01-0, BRD-K11124378-001-04-6, BRD-K11124378-335-02-2, BRD-K11124378-335-01-4" "Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O, Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O" "UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N, UNJFKXSSGBWRBZ-BJCIPQKHSA-N" "Launched"
"389" "ceftiofur" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "pneumonia, respiratory tract infections" "BRD-K21017401-003-02-1, BRD-K82960980-003-01-9, BRD-K15436267-003-01-6" "CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(\C(=O)N[C@@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1" "ZBHXIWJRIFEVQY-HURQQZHVSA-N, ZBHXIWJRIFEVQY-IHMPYVIRSA-N, ZBHXIWJRIFEVQY-UUWJRZORSA-N" "Launched"
"390" "ceftizoxim" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "respiratory tract infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, intra-abdominal infections, bacterial septicemia, skin infections, bone and joint infections, meningitis" "BRD-K04301924-236-02-4, BRD-K04301924-236-01-6" "CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1" "NNULBSISHYWZJU-LLKWHZGFSA-N, NNULBSISHYWZJU-LLKWHZGFSA-N" "Launched"
"391" "ceftriaxone" "bacterial cell wall synthesis inhibitor" "" "infectious disease, otolaryngology" "gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis" "BRD-K96734425-304-01-7, BRD-K38010979-324-03-7" "CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1, CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1" "VAAUVRVFOQPIGI-SPQHTLEESA-N, VAAUVRVFOQPIGI-TYHRLYECSA-N" "Launched"
"392" "cefuroxime" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-A76746748-236-04-5, BRD-K02733959-236-05-1" "CO\N=C(\C(=O)NC1C2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1, CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1" "JFPVXVDWJQMJEE-DJKKODMXSA-N, JFPVXVDWJQMJEE-IZRZKJBUSA-N" "Launched"
"393" "cefuroxime-axetil" "bacterial cell wall synthesis inhibitor" "" "otolaryngology" "pharyngitis, tonsillitis, otitis, sinusitis" "BRD-A22303829-001-01-6, BRD-A36322567-001-02-4" "CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)c1ccco1, CO\N=C(\C(=O)NC1C2SCC(COC(N)=O)=C(N2C1=O)C(=O)OC(C)OC(C)=O)c1ccco1" "KEJCWVGMRLCZQQ-YJBYXUATSA-N, KEJCWVGMRLCZQQ-YDZHTSKRSA-N" "Launched"
"394" "celecoxib" "cyclooxygenase inhibitor" "CA12, PDPK1, PTGS2" "rheumatology, endocrinology" "osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)" "BRD-K02637541-001-18-0, BRD-K02637541-001-17-2" "Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F, Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F" "RZEKVGVHFLEQIL-UHFFFAOYSA-N, RZEKVGVHFLEQIL-UHFFFAOYSA-N" "Launched"
"395" "celiprolol" "adrenergic receptor antagonist" "ADRA2A, ADRB1, ADRB2" "genetics" "Ehlers-Danlos syndrome (EDS)" "BRD-A95602221-003-02-1" "CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(c1)C(C)=O" "JOATXPAWOHTVSZ-UHFFFAOYSA-N" "Launched"
"396" "centazolone" "monoamine oxidase inhibitor" "" "" "" "BRD-K31329721-001-08-2" "Nn1cnc2cc3ccccc3cc2c1=O" "CZXUQBVMAUWSBX-UHFFFAOYSA-N" "Phase 1"
"397" "centpropazine" "inositol monophosphatase inhibitor" "" "" "" "BRD-A28958257-001-02-0, BRD-A28958257-001-01-2" "CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1, CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1" "ZQPXSRTZFYHSFB-UHFFFAOYSA-N, ZQPXSRTZFYHSFB-UHFFFAOYSA-N" "Phase 3"
"398" "CEP-32496" "RAF inhibitor" "BRAF, RAF1" "" "" "BRD-K20722021-001-02-1" "COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC" "DKNUPRMJNUQNHR-UHFFFAOYSA-N" "Phase 1/Phase 2"
"399" "CEP-33779" "JAK inhibitor" "JAK2" "" "" "BRD-K37237504-001-03-5, BRD-K37237504-001-02-7" "CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1, CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1" "RFZKSQIFOZZIAQ-UHFFFAOYSA-N, RFZKSQIFOZZIAQ-UHFFFAOYSA-N" "Preclinical"
"400" "CEP-37440" "ALK tyrosine kinase receptor inhibitor" "ALK" "" "" "BRD-K72827473-001-01-0" "CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl" "BCSHRERPHLTPEE-NRFANRHFSA-N" "Phase 1"
"401" "cephalexin" "bacterial cell wall synthesis inhibitor" "" "infectious disease, otolaryngology" "respiratory tract infections, otitis, skin infections, bone and joint infections, genitourinary tract infections" "BRD-A37536726-001-04-2, BRD-K90733503-001-06-1, BRD-K90733503-001-07-9, BRD-K90733503-001-05-3, BRD-K64997193-001-01-0" "CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(N)c1ccccc1)C2=O)C(O)=O, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O, CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O, CC1=C(N2[C@@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O" "ZAIPMKNFIOOWCQ-HUFXEGEASA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-UEKVPHQBSA-N, ZAIPMKNFIOOWCQ-HFAKWTLXSA-N" "Launched"
"402" "cephalomannine" "DNA polymerase inhibitor" "" "" "" "BRD-K68904758-001-02-7, BRD-K99571587-001-01-6" "C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1, C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@@H](O)[C@@]3(C)C(=O)[C@@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1" "DBXFAPJCZABTDR-WBYYIXQISA-N, DBXFAPJCZABTDR-CXQLXMQYSA-N" "Preclinical"
"403" "cephalosporin-c-zn" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-A44936478-001-01-1" "CC(=O)OCC1=C2N3C(SC1)[C@H](NC(=O)CCCC(N)C(=O)O[Zn]OC2=O)C3=O" "TVMXJQZBKOMFQK-XLCFFBBVSA-L" "Preclinical"
"404" "cephalothin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections, surgical prophylaxis" "BRD-K28210218-236-08-1" "CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O" "XIURVHNZVLADCM-IUODEOHRSA-N" "Launched"
"405" "cephapirin" "bacterial cell wall synthesis inhibitor" "" "obstetrics/gynecology" "mastitis" "BRD-K49880111-236-09-2, BRD-K25085912-236-01-4" "CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O" "UQLLWWBDSUHNEB-CZUORRHYSA-N, UQLLWWBDSUHNEB-CJNGLKHVSA-N" "Launched"
"406" "cepharanthine" "NFkB pathway inhibitor" "" "" "" "BRD-K96194081-001-11-0, BRD-K96194081-001-10-2, BRD-K78936063-001-01-9" "COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34, COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@H](Cc7ccc(Oc1c2)cc7)c56)cc34" "YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-WDYNHAJCSA-N, YVPXVXANRNDGTA-URLMMPGGSA-N" "Phase 2"
"407" "cephradine" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections, respiratory tract infections, urinary tract infections" "BRD-A90807417-001-04-5" "CC1=C(N2C(SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O" "RDLPVSKMFDYCOR-MHSSMOFYSA-N" "Launched"
"408" "ceramide" "phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator" "" "dermatology" "cosmetic" "BRD-K41707108-001-05-6" "CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O" "BLTCBVOJNNKFKC-QUDYQQOWSA-N" "Launched"
"409" "ceritinib" "ALK tyrosine kinase receptor inhibitor" "ALK, FLT3, IGF1R, INSR, TSSK1B" "oncology" "non-small cell lung cancer (NSCLC)" "BRD-K22149900-001-03-9, BRD-K22149900-001-05-4, BRD-K22149900-001-01-3" "CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1, CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1" "VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N, VERWOWGGCGHDQE-UHFFFAOYSA-N" "Launched"
"410" "cerulenin" "fatty acid synthase inhibitor" "FASN" "infectious disease" "fungal infection" "BRD-K52075040-001-09-7" "C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O" "GVEZIHKRYBHEFX-NQQPLRFYSA-N" "Launched"
"411" "cetaben" "cholesterol inhibitor, ACAT inhibitor" "PPARA" "" "" "BRD-K86954340-001-01-7" "CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O" "QXWKHSSBFQDQPR-UHFFFAOYSA-N" "Phase 2"
"412" "cetilistat" "triacylglycerol lipase inhibitor" "PNLIP" "" "" "BRD-K94863486-001-01-4, BRD-K94863486-001-02-2" "CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1, CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1" "MVCQKIKWYUURMU-UHFFFAOYSA-N, MVCQKIKWYUURMU-UHFFFAOYSA-N" "Phase 3"
"413" "cetirizine" "histamine receptor antagonist" "HRH1" "allergy" "allergic rhinitis" "BRD-A42571354-300-12-0, BRD-A42571354-300-13-8, BRD-A42571354-300-11-2" "OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1" "ZKLPARSLTMPFCP-UHFFFAOYSA-N, ZKLPARSLTMPFCP-UHFFFAOYSA-N, ZKLPARSLTMPFCP-UHFFFAOYSA-N" "Launched"
"414" "cetrimonium" "" "" "dermatology" "cosmetic" "BRD-K47079459-004-04-6, BRD-K47079459-004-05-3" "CCCCCCCCCCCCCCCC[N+](C)(C)C, CCCCCCCCCCCCCCCC[N+](C)(C)C" "RLGQACBPNDBWTB-UHFFFAOYSA-N, RLGQACBPNDBWTB-UHFFFAOYSA-N" "Launched"
"415" "cetrorelix" "gonadotropin releasing factor hormone receptor antagonist" "GNRHR, LHCGR" "endocrinology" "premature luteinizing hormone surges" "BRD-K76315403-015-02-5" "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O" "SBNPWPIBESPSIF-MHWMIDJBSA-N" "Launched"
"416" "cetylpyridinium" "" "" "dental" "gingivitis, mouth inflammation" "BRD-K87700323-003-06-9, BRD-K87700323-003-05-1, BRD-K87700323-003-04-4" "CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1, CCCCCCCCCCCCCCCC[n+]1ccccc1" "NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N, NEUSVAOJNUQRTM-UHFFFAOYSA-N" "Launched"
"417" "cevimeline" "acetylcholine receptor agonist" "CHRM1, CHRM3" "rheumatology" "sjogrens syndrome	BRD-M98279124-300-01-1	C[C@H]1O[C@]2(CS1)CN1CCC2CC1.C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1	YMMKDPCCYMGDHD-JWGPUQBJSA-N	Launched
cevipabulin	microtubule stimulant, tubulin polymerization inhibitor	TUBB			BRD-A02473266-001-01-1	CNCCCOc1cc(F)c(c(F)c1)-c1c(Cl)nc2ncnn2c1NC(C)C(F)(F)F	ZUZPCOQWSYNWLU-UHFFFAOYSA-N	Phase 1
CFM-1571	guanylate cyclase activator				BRD-K64341947-003-02-4	COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	YZCSJBGQLATPMH-UHFFFAOYSA-N	Preclinical
CFM-2	glutamate receptor antagonist				BRD-K42859542-001-03-3	COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC	MJKADKZSYQWGLL-UHFFFAOYSA-N	Preclinical
CFTRinh-172	chloride channel blocker	CFTR			BRD-K72004355-001-01-9, BRD-K72004355-001-02-7	OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F, OC(=O)c1ccc(cc1)\C=C1\SC(=S)N(C1=O)c1cccc(c1)C(F)(F)F	JIMHYXZZCWVCMI-RIYZIHGNSA-N, JIMHYXZZCWVCMI-RIYZIHGNSA-N	Preclinical
CF102	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K52396582-001-06-7	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	IPSYPUKKXMNCNQ-PFHKOEEOSA-N	Phase 2
CG-400549	FABI inhibitor				BRD-K48888725-001-02-7, BRD-K48888725-001-01-9	Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O, Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	YCLREGRRHGLOAK-UHFFFAOYSA-N, YCLREGRRHGLOAK-UHFFFAOYSA-N	Phase 2
CGH2466	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			BRD-K82028950-300-02-9	Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	BEPGKLOHQTXUHX-UHFFFAOYSA-N	Preclinical
CGK-733	ATM kinase inhibitor, ATR kinase inhibitor	ATM, ATR			BRD-A50737080-001-05-5, BRD-A50737080-001-03-0, BRD-A50737080-001-06-3, BRD-A50737080-001-02-2	[O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F, [O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F	HLCDNLNLQNYZTK-UHFFFAOYSA-N, HLCDNLNLQNYZTK-UHFFFAOYSA-N, HLCDNLNLQNYZTK-UHFFFAOYSA-N, HLCDNLNLQNYZTK-UHFFFAOYSA-N	Preclinical
CGM097	MDM inhibitor	MDM2			BRD-K79584249-001-02-1, BRD-K79584249-001-01-3	COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1, COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	CLRSLRWKONPSRQ-IIPSPAQQSA-N, CLRSLRWKONPSRQ-IIPSPAQQSA-N	Phase 1
CGP-12177	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			BRD-A40084411-003-07-7	CC(C)(C)NCC(O)COc1cccc2[nH]c(O)nc12	UMQUQWCJKFOUGV-UHFFFAOYSA-N	Phase 1
CGP-13501	GABA receptor modulator	GABBR1			BRD-K95851186-001-07-8	CC(C)(Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C=O	XGWATTXMMMANFJ-UHFFFAOYSA-N	Preclinical
CGP-20712A	adrenergic receptor antagonist	ADRB1, ADRB3			BRD-A31575449-066-07-8	Cn1cc(nc1-c1ccc(OCC(O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F	GKJZEKSHCJELPL-UHFFFAOYSA-N	Preclinical
CGP-37157	mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor	SLC8A1			BRD-A35623999-001-05-7	Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1	KQEPIRKXSUIUTH-UHFFFAOYSA-N	Preclinical
CGP-37849	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-A90272038-001-01-7	C\C(CP(O)(O)=O)=C/C(N)C(O)=O	BDYHNCZIGYIOGJ-DUXPYHPUSA-N	Phase 1
CGP-52411	EGFR inhibitor	EGFR			BRD-K13087974-001-02-5	O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	AAALVYBICLMAMA-UHFFFAOYSA-N	Preclinical
CGP-53353	EGFR inhibitor, PKC inhibitor	EGFR, PRKCB			BRD-K32292990-001-03-6, BRD-K32292990-001-04-4	Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1, Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	RONQPWQYDRPRGG-UHFFFAOYSA-N, RONQPWQYDRPRGG-UHFFFAOYSA-N	Preclinical
CGP-54626	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			BRD-A74208568-003-01-5	C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1	JGGVBBYJRQOPPA-BBRMVZONSA-N	Preclinical
CGP-55845	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			BRD-A89672324-001-03-0	C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	ZODSPDOOCZZEIM-BBRMVZONSA-N	Preclinical
CGP-57380	MAP kinase inhibitor	AURKB, LCK, MKNK1, MKNK2, SGK1			BRD-K42500029-001-03-5, BRD-K42500029-001-06-8, BRD-K42500029-001-04-3	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12, Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12, Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12	UQPMANVRZYYQMD-UHFFFAOYSA-N, UQPMANVRZYYQMD-UHFFFAOYSA-N, UQPMANVRZYYQMD-UHFFFAOYSA-N	Preclinical
CGP-71683	neuropeptide receptor antagonist	NPY5R			BRD-K34321528-003-01-2	Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12	UULIGRNKXHCLQN-WGSAOQKQSA-N	Preclinical
CGP-78608	glutamate receptor antagonist				BRD-K60946979-003-01-7	C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O	DPFHVUSPVHRVFL-YFKPBYRVSA-N	Preclinical
CGP-7930	GABA receptor modulator	GABBR1			BRD-K65786282-001-07-5	CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	XLWJPQQFJNGUPA-UHFFFAOYSA-N	Preclinical
CGS-15943	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K49049886-001-08-7	Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	MSJODEOZODDVGW-UHFFFAOYSA-N	Preclinical
CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			BRD-K68103045-001-02-9	COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O	XRUUVUYJUULCBQ-UHFFFAOYSA-N	Phase 1
CGS-21680	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K12614344-003-01-8	CCNC(=O)[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12	PAOANWZGLPPROA-VDNWNZSNSA-N	Preclinical
CGS-9896	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			BRD-K54093161-001-01-8	Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O	QCBUAKLOWCOUCR-UHFFFAOYSA-N	Preclinical
CH-170					BRD-K24820488-001-01-7	Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	JBXSBZBZASARMY-UHFFFAOYSA-N	Phase 1
CH-5183284	fibroblast growth factor inhibitor	FGFR1, FGFR2, FGFR3			BRD-K11683436-001-01-7, BRD-K11683436-001-02-5	Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N, Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N	BEMNJULZEQTDJY-UHFFFAOYSA-N, BEMNJULZEQTDJY-UHFFFAOYSA-N	Phase 1
chenodeoxycholic-acid	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	NR1H4	cardiology, gastroenterology	cerebral cholesterosis, gallstones	BRD-K18135438-001-14-2	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-BSWAIDMHSA-N	Launched
chenodiol	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1	gastroenterology	gallstones	BRD-K43723251-001-01-5	C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C	RUDATBOHQWOJDD-CIKBIKKZSA-N	Launched
CHF5074	gamma secretase modulator	PSEN1			BRD-K34508702-001-02-4	OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1	LIYLTQQDABRNRX-UHFFFAOYSA-N	Phase 2
chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	MIF			BRD-K56483981-342-06-4	COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1	OHMJKMNGYYWCHB-HVMBLDELSA-N	Preclinical
chidamide	HDAC inhibitor	HDAC10, HDAC3			BRD-K28537285-001-01-8	Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	WXHHICFWKXDFOW-BJMVGYQFSA-N	Launched
chiniofon	antiprotozoal agent		infectious disease	amebiasis	BRD-K52284881-236-02-4	Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	ZBJWWKFMHOAPNS-UHFFFAOYSA-N	Launched
CHIR-124	CHK inhibitor	CHEK1			BRD-K02241333-001-02-7	Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	MOVBBVMDHIRCTG-LJQANCHMSA-N	Preclinical
CHIR-98014	glycogen synthase kinase inhibitor	GSK3A, GSK3B			BRD-K42973005-001-04-0	Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	MDZCSIDIPDZWKL-UHFFFAOYSA-N	Preclinical
CHIR-99021	glycogen synthase kinase inhibitor	CDK1, GSK3A, GSK3B, MAPK1			BRD-K16189898-003-03-3	Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	AQGNHMOJWBZFQQ-UHFFFAOYSA-N	Preclinical
chloralose					BRD-A98174560-001-02-1	OCC(O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl	OJYGBLRPYBAHRT-YCNXOVPFSA-N	Preclinical
chlorambucil	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), Hodgkins lymphoma" "BRD-K29458283-001-29-9" "OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl" "JCKYGMPEJWAADB-UHFFFAOYSA-N" "Launched"
"418" "chloramine-t" "" "" "infectious disease" "bacterial gill disease" "BRD-K93546328-236-02-8" "Cc1ccc(cc1)S(=O)(=O)NCl" "NXTVQNIVUKXOIL-UHFFFAOYSA-N" "Launched"
"419" "chloramphenicol" "bacterial 50S ribosomal subunit inhibitor" "CD55" "infectious disease, endocrinology" "meningitis, fever, cholera" "BRD-K22969690-001-04-2, BRD-K08111712-001-14-2" "OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O, OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O" "WIIZWVCIJKGZOK-DTWKUNHWSA-N, WIIZWVCIJKGZOK-RKDXNWHRSA-N" "Launched"
"420" "chloramphenicol-palmitate" "protein synthesis inhibitor" "" "infectious disease, endocrinology" "meningitis, fever, cholera" "BRD-K96424892-001-02-9" "CCCCCCCCCCCCCCCC(=O)OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O" "PXKHGMGELZGJQE-UKILVPOCSA-N" "Launched"
"421" "chloramphenicol-sodium-succinate" "protein synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K25209357-236-01-2" "O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O" "LIRCDOVJWUGTMW-ZWNOBZJWSA-N" "Launched"
"422" "chlorazanil" "" "" "" "" "BRD-K21452876-003-01-8" "Nc1ncnc(Nc2ccc(Cl)cc2)n1" "YRZQHIVOIFJEEE-UHFFFAOYSA-N" "Preclinical"
"423" "chlorcyclizine" "histamine receptor antagonist" "HRH1" "allergy" "allergic rhinitis" "BRD-A57133233-003-11-0" "CN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1" "WFNAKBGANONZEQ-UHFFFAOYSA-N" "Launched"
"424" "chlorfenson" "other antifungal" "" "" "" "BRD-K89409436-001-01-4" "Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1" "RZXLPPRPEOUENN-UHFFFAOYSA-N" "Phase 2"
"425" "chlorhexidine" "membrane integrity inhibitor" "" "dermatology, infectious disease, dental" "cosmetic, skin infections, gingivitis" "BRD-K52256627-300-06-6" "Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1" "GHXZTYHSJHQHIJ-UHFFFAOYSA-N" "Launched"
"426" "chlorindanol" "" "" "" "" "BRD-K01653460-001-01-1" "Oc1ccc(Cl)c2CCCc12" "ATAJVFBUUIBIEO-UHFFFAOYSA-N" "Preclinical"
"427" "chlorindione" "" "" "" "" "BRD-K61802864-001-08-8" "Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O" "NJDUWAXIURWWLN-UHFFFAOYSA-N" "Preclinical"
"428" "chlorisondamine-diiodide" "acetylcholine receptor antagonist" "CHRNA1" "" "" "BRD-K18030938-302-02-7" "C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl" "IXWDUZLHWJKVPX-UHFFFAOYSA-N" "Preclinical"
"429" "chlormadinone-acetate" "5 alpha reductase inhibitor" "PGR" "endocrinology" "hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea" "BRD-A01593789-001-03-1" "CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O" "QMBJSIBWORFWQT-GDMUWPLKSA-N" "Launched"
"430" "chlormezanone" "GABA receptor modulator" "GABRA1, TSPO" "" "" "BRD-A20348246-001-15-8, BRD-A20348246-001-14-1, BRD-A20348246-001-13-3" "CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O, CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O, CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O" "WEQAYVWKMWHEJO-UHFFFAOYSA-N, WEQAYVWKMWHEJO-UHFFFAOYSA-N, WEQAYVWKMWHEJO-UHFFFAOYSA-N" "Withdrawn"
"431" "chlormidazole" "fungal lanosterol demethylase inhibitor" "" "infectious disease" "fungal infection" "BRD-K60443845-001-08-6" "Cc1nc2ccccc2n1Cc1ccc(Cl)cc1" "WNAQOLSMVPFGTE-UHFFFAOYSA-N" "Launched"
"432" "chlorobutanol" "" "" "neurology/psychiatry" "anesthetic, sedative" "BRD-K39495750-001-01-2" "CC(C)(O)C(Cl)(Cl)Cl" "OSASVXMJTNOKOY-UHFFFAOYSA-N" "Launched"
"433" "chlorocresol" "ryanodine receptor activator" "" "infectious disease" "first-aid antiseptic" "BRD-K89056082-001-07-7, BRD-K89056082-001-06-9, BRD-K89056082-001-08-5" "Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl, Cc1cc(O)ccc1Cl" "CFKMVGJGLGKFKI-UHFFFAOYSA-N, CFKMVGJGLGKFKI-UHFFFAOYSA-N, CFKMVGJGLGKFKI-UHFFFAOYSA-N" "Launched"
"434" "chlorogenic-acid" "antioxidant" "SLC37A4" "neurology/psychiatry, pulmonary, allergy" "headache, chest congestion, allergic rhinitis" "BRD-K47114202-001-14-6, BRD-K46579573-001-01-9" "O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O, O[C@@H]1C[C@@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O" "CWVRJTMFETXNAD-JUHZACGLSA-N, CWVRJTMFETXNAD-QHEBTOHLSA-N" "Launched"
"435" "chlorophyllide-cu-complex-na-salt" "" "" "" "" "BRD-A09283158-314-01-5" "CCC1=C(C)C2=Cc3c(C=C)c(C)c4C=C5C(C)C(CCC(O)=O)C6=[N+]5[Cu]5(n34)n3c(=CC1=[N+]25)c(C)c(C(O)=O)c3=C6CC(O)=O" "YJPOIBSDHKWDGX-UHFFFAOYSA-L" "Preclinical"
"436" "chlorophyllin" "" "" "urology" "urinary incontinence" "BRD-K23728266-001-01-1" "CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C" "OYINILBBZAQBEV-UWJYYQICSA-N" "Preclinical"
"437" "chlorophyllin-copper" "cytochrome P450 inhibitor" "" "" "" "BRD-A92960111-314-01-2" "CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C(C(CCC(O)=O)C5C)/C(CC(O)=O)=c5/c(C(O)=O)c(C)/c(=C/C1=N/2)n5[Cu]n34" "ZDOYGJNADZJRFB-UHFFFAOYSA-L" "Phase 1"
"438" "chloroprocaine" "sodium channel blocker" "ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3" "neurology/psychiatry" "local anesthetic" "BRD-K86864073-001-01-1" "CCN(CC)CCOC(=O)c1ccc(N)cc1Cl" "VDANGULDQQJODZ-UHFFFAOYSA-N" "Launched"
"439" "chloropyramine" "histamine receptor antagonist" "HRH1" "cardiology, ophthalmology, allergy, pulmonary" "edema, conjunctivitis, allergic rhinitis, asthma" "BRD-K83257731-003-23-5" "CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1" "ICKFFNBDFNZJSX-UHFFFAOYSA-N" "Launched"
"440" "chloroquine" "antimalarial agent" "GSTA2, MRGPRX1, TLR9, TNF" "infectious disease" "malaria, amebiasis" "BRD-A91699651-316-11-7, BRD-A91699651-316-10-9, BRD-A91699651-316-09-1" "CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12" "WHTVZRBIWZFKQO-UHFFFAOYSA-N, WHTVZRBIWZFKQO-UHFFFAOYSA-N, WHTVZRBIWZFKQO-UHFFFAOYSA-N" "Launched"
"441" "chlorothiazide" "diuretic" "CA1, CA2, CA4, SLC12A3" "cardiology" "hypertension" "BRD-K88682005-001-15-8, BRD-K88682005-001-16-6" "NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O, NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O" "JBMKAUGHUNFTOL-UHFFFAOYSA-N, JBMKAUGHUNFTOL-UHFFFAOYSA-N" "Launched"
"442" "chlorothymol" "" "" "" "" "BRD-K04358951-001-01-0" "CC(C)c1cc(Cl)c(C)cc1O" "KFZXVMNBUMVKLN-UHFFFAOYSA-N" "Launched"
"443" "chlorotrianisene" "estrogenic hormone" "ESR1, ESR2" "endocrinology, oncology" "menopause, prostate cancer" "BRD-K27062708-001-23-1" "COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1" "BFPSDSIWYFKGBC-UHFFFAOYSA-N" "Launched"
"444" "chloroxine" "opioid receptor antagonist" "OPRK1" "gastroenterology, infectious disease, dermatology" "diarrhea, inflammatory bowel disease, giardiasis, dandruff" "BRD-K17075857-001-18-4, BRD-K17075857-001-17-6, BRD-K17075857-001-16-8" "Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12, Oc1c(Cl)cc(Cl)c2cccnc12" "WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N, WDFKMLRRRCGAKS-UHFFFAOYSA-N" "Launched"
"445" "chloroxoquinoline" "" "" "" "" "BRD-K83335125-001-07-0" "Oc1ccnc2cc(Cl)ccc12" "XMFXTXKSWIDMER-UHFFFAOYSA-N" "Launched"
"446" "chloroxylenol" "ATP synthase inhibitor" "" "infectious disease" "skin infections" "BRD-K17223896-001-10-0" "Cc1cc(O)cc(C)c1Cl" "OSDLLIBGSJNGJE-UHFFFAOYSA-N" "Launched"
"447" "chlorphenamine" "histamine receptor antagonist" "HRH1, SLC6A2, SLC6A3, SLC6A4" "allergy" "allergic rhinitis, urticaria" "BRD-A04553218-050-16-2" "CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1" "SOYKEARSMXGVTM-UHFFFAOYSA-N" "Launched"
"448" "chlorphenesin" "muscle relaxant" "" "neurology/psychiatry" "muscle relaxant, sedative" "BRD-A92262698-001-02-5, BRD-A92262698-001-01-7" "OCC(O)COc1ccc(Cl)cc1, OCC(O)COc1ccc(Cl)cc1" "MXOAEAUPQDYUQM-UHFFFAOYSA-N, MXOAEAUPQDYUQM-UHFFFAOYSA-N" "Launched"
"449" "chlorphensin-carbamate" "muscle relaxant" "" "" "" "BRD-A39230911-001-10-2" "NC(=O)OCC(O)COc1ccc(Cl)cc1" "SKPLBLUECSEIFO-UHFFFAOYSA-N" "Preclinical"
"450" "chlorproguanil" "dihydrofolate reductase inhibitor" "DHFR" "infectious disease" "malaria" "BRD-K25494650-003-01-8" "CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1" "ISZNZKHCRKXXAU-UHFFFAOYSA-N" "Launched"
"451" "chlorpromazine" "dopamine receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5" "neurology/psychiatry, gastroenterology, hematology, infectious disease" "schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus" "BRD-K89997465-003-44-8, BRD-K89997465-003-43-0, BRD-K89997465-001-10-3" "CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12" "ZPEIMTDSQAKGNT-UHFFFAOYSA-N, ZPEIMTDSQAKGNT-UHFFFAOYSA-N, ZPEIMTDSQAKGNT-UHFFFAOYSA-N" "Launched"
"452" "chlorpropamide" "ATP channel blocker" "ABCC8, KCNJ10, KCNJ11" "endocrinology" "diabetes mellitus" "BRD-K97746869-001-27-0, BRD-K97746869-001-26-2" "CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1, CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1" "RKWGIWYCVPQPMF-UHFFFAOYSA-N, RKWGIWYCVPQPMF-UHFFFAOYSA-N" "Launched"
"453" "chlorpropham" "antiviral" "" "" "" "BRD-K59590127-001-04-5" "CC(C)OC(=O)Nc1cccc(Cl)c1" "CWJSHJJYOPWUGX-UHFFFAOYSA-N" "Phase 1"
"454" "chlorprothixene" "dopamine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C" "neurology/psychiatry" "schizophrenia, bipolar disorder" "BRD-K36207157-001-07-0, BRD-K59058766-003-21-9, BRD-K59058766-001-01-5" "CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1/c2ccccc2Sc2ccc(Cl)cc12, CN(C)CC\C=C1/c2ccccc2Sc2ccc(Cl)cc12" "WSPOMRSOLSGNFJ-AUWJEWJLSA-N, WSPOMRSOLSGNFJ-VGOFMYFVSA-N, WSPOMRSOLSGNFJ-VGOFMYFVSA-N" "Launched"
"455" "chlorpyrifos" "acetylcholinesterase inhibitor" "ACHE" "" "" "BRD-K08303368-001-10-0" "CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl" "SBPBAQFWLVIOKP-UHFFFAOYSA-N" "Launched"
"456" "chlorquinaldol" "other antibiotic" "" "infectious disease" "fungal infection" "BRD-K90374350-001-09-2, BRD-K90374350-001-10-0" "Cc1ccc2c(Cl)cc(Cl)c(O)c2n1, Cc1ccc2c(Cl)cc(Cl)c(O)c2n1" "GPTXWRGISTZRIO-UHFFFAOYSA-N, GPTXWRGISTZRIO-UHFFFAOYSA-N" "Launched"
"457" "chlortetracycline" "protein synthesis inhibitor" "" "ophthalmology" "conjunctivitis" "BRD-A41555725-003-09-2, BRD-A41555725-003-08-4, BRD-A25492003-003-13-3" "CN(C)[C@H]1[C@@H]2CC3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2CC3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O" "RNPLSXLZRGPQCU-NRIWTTEBSA-N, RNPLSXLZRGPQCU-NRIWTTEBSA-N, RNPLSXLZRGPQCU-WYOUFOJNSA-N" "Launched"
"458" "chlorthalidone" "carbonic anhydrase inhibitor" "CA1, CA12, CA14, CA4, CA7, SLC12A1, SLC12A3" "cardiology, gastroenterology, rheumatology, nephrology" "hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure" "BRD-A26384407-001-25-1" "NS(=O)(=O)c1cc(ccc1Cl)C1(O)NC(=O)c2ccccc12" "JIVPVXMEBJLZRO-UHFFFAOYSA-N" "Launched"
"459" "chlorzoxazone" "bacterial 30S ribosomal subunit inhibitor" "KCNMA1, KCNN4" "neurology/psychiatry" "muscle relaxant" "BRD-K98174813-001-18-0, BRD-K98174813-001-17-2" "Clc1ccc2oc(=O)[nH]c2c1, Clc1ccc2oc(=O)[nH]c2c1" "TZFWDZFKRBELIQ-UHFFFAOYSA-N, TZFWDZFKRBELIQ-UHFFFAOYSA-N" "Launched"
"460" "cholecalciferol" "" "VDR" "endocrinology" "vitamin D deficiency" "BRD-K62779383-001-05-5, BRD-A56749456-001-04-3, BRD-K32793810-001-01-5" "CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCCC(C)C1CCC2\C(CCCC12C)=C\C=C1\C[C@@H](O)CCC1=C, CC(C)CCC[C@@H](C)[C@@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CCC1=C" "QYSXJUFSXHHAJI-YRZJJWOYSA-N, QYSXJUFSXHHAJI-JACFMPSKSA-N, QYSXJUFSXHHAJI-VKUJWBEVSA-N" "Launched"
"461" "cholesterol" "" "RORA" "" "" "BRD-A42883684-001-04-1" "CC(C)CCCC(C)[C@H]1CCC2C3CC=C4C[C@@H](O)CC[C@]4(C)C3CC[C@]12C" "HVYWMOMLDIMFJA-RJLWFLQPSA-N" "Preclinical"
"462" "cholic-acid" "bile acid" "ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B" "gastroenterology, neurology/psychiatry, genetics" "bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome" "BRD-K43164539-001-11-5" "C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C" "BHQCQFFYRZLCQQ-OELDTZBJSA-N" "Launched"
"463" "choline" "acetylcholine precursor" "ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2" "" "" "BRD-K77300776-001-02-5, BRD-K77300776-001-01-7" "C[N+](C)(C)CCO, C[N+](C)(C)CCO" "OEYIOHPDSNJKLS-UHFFFAOYSA-N, OEYIOHPDSNJKLS-UHFFFAOYSA-N" "Phase 3"
"464" "choline-alfoscerate" "acetylcholine precursor" "GM2A" "" "" "BRD-A72390365-001-15-2" "C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO" "SUHOQUVVVLNYQR-MRVPVSSYSA-O" "Launched"
"465" "CHPG" "glutamate receptor agonist" "GRM5" "" "" "BRD-A19381518-001-02-1" "NC(C(O)=O)c1cc(O)ccc1Cl" "UNIDAFCQFPGYJJ-UHFFFAOYSA-N" "Preclinical"
"466" "CHR-6494" "serine/threonine kinase inhibitor" "GSG2" "" "" "BRD-K76259716-019-01-1, BRD-K33892651-001-03-2, BRD-K76259716-001-01-9" "CCCNc1ccc2ncc(-c3ccc4[nH]ncc4c3)n2n1, COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, CCCNc1ccc2ncc(-c3ccc4[nH]ncc4c3)n2n1" "CZZCAOGIEGXMBZ-UHFFFAOYSA-N, FVRYPYDPKSZGNS-UHFFFAOYSA-N, CZZCAOGIEGXMBZ-UHFFFAOYSA-N" "Preclinical"
"467" "chromanol-(+/-)" "potassium channel blocker" "" "" "" "BRD-M02075109-001-01-1" "CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C" "" ""
"468" "chromocarb" "antispasmodic" "" "" "" "BRD-K94720315-001-10-4, BRD-K94720315-001-09-6" "OC(=O)c1cc(=O)c2ccccc2o1, OC(=O)c1cc(=O)c2ccccc2o1" "RVMGXWBCQGAWBR-UHFFFAOYSA-N, RVMGXWBCQGAWBR-UHFFFAOYSA-N" "Launched"
"469" "chrysin" "breast cancer resistance protein inhibitor" "AKR1B1, CDK6, CYP19A1, CYP1B1" "" "" "BRD-K22861715-001-17-4" "Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1" "RTIXKCRFFJGDFG-UHFFFAOYSA-N" "Phase 1"
"470" "chrysophanic-acid" "EGFR inhibitor" "EGFR, MTOR" "" "" "BRD-K59284035-001-07-9" "Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1" "LQGUBLBATBMXHT-UHFFFAOYSA-N" "Preclinical"
"471" "chuanxiongzine" "" "" "" "" "BRD-K25691735-001-09-5" "Cc1nc(C)c(C)nc1C" "FINHMKGKINIASC-UHFFFAOYSA-N" "Phase 2"
"472" "CH223191" "aryl hydrocarbon receptor antagonist" "AHR" "" "" "BRD-K22314899-001-02-4" "Cc1cc(ccc1NC(=O)c1ccnn1C)\N=N\c1ccccc1C" "LKTNEXPODAWWFM-GHVJWSGMSA-N" "Preclinical"
"473" "CH5132799" "PI3K inhibitor" "MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG" "" "" "BRD-K28352084-001-03-1, BRD-K28352084-001-02-3" "CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1, CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1" "JEGHXKRHKHPBJD-UHFFFAOYSA-N, JEGHXKRHKHPBJD-UHFFFAOYSA-N" "Phase 1"
"474" "CH55" "retinoid receptor binder" "RARA, RARB" "" "" "BRD-K71487808-001-02-8" "CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O" "FOUVTBKPJRMLPE-FMIVXFBMSA-N" "Preclinical"
"475" "CI-844" "" "" "" "" "BRD-K83022601-001-01-0" "O(c1ccccc1)c1cccnc1" "KDGUIKPOZGYLQJ-UHFFFAOYSA-N" "Phase 2"
"476" "CI-923" "acetylcholine receptor antagonist" "" "" "" "BRD-A50016482-001-01-7" "CCNC(C)CN1CCc2c(C1)c(=O)oc1ccccc21" "MJRICTKAEYTJAV-UHFFFAOYSA-N" "Phase 1"
"477" "CI-966" "GAT inhibitor" "SLC6A1" "" "" "BRD-K67680372-003-02-6" "OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1" "CMHQDSBIBSKHFP-UHFFFAOYSA-N" "Phase 1"
"478" "CI-976" "ACAT inhibitor" "ACAT1, CES1" "" "" "BRD-K88544581-001-06-1" "CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC" "WAFNZAURAWBNDZ-UHFFFAOYSA-N" "Phase 1"
"479" "ciaftalan-zinc" "reactive oxygen species stimulant" "" "" "" "BRD-K01423020-001-01-2" "[Zn]1n2c3\N=C4/N=C(c5ccccc45)/N=c4\n1\c(=N/C1=N/C(c5ccccc15)=N\c2c1ccccc31)c1ccccc41" "PODBBOVVOGJETB-UHFFFAOYSA-N" "Phase 1"
"480" "cianidanol" "fatty acid synthase inhibitor" "PTGS1" "" "" "BRD-K58736316-001-09-5" "O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1" "PFTAWBLQPZVEMU-DZGCQCFKSA-N" "Withdrawn"
"481" "cibenzoline" "sodium channel blocker" "" "" "" "BRD-K34251960-036-01-6" "C1C(=C2NCCN2)C1(c1ccccc1)c1ccccc1" "AMRFVEMXRRPNJH-UHFFFAOYSA-N" "Launched"
"482" "ciclesonide" "glucocorticoid receptor agonist" "NR3C1, SERPINA6" "allergy" "allergic rhinitis" "BRD-K35245662-001-01-2" "CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1" "LUKZNWIVRBCLON-GXOBDPJESA-N" "Launched"
"483" "ciclopirox" "membrane integrity inhibitor" "ATP1A1" "infectious disease" "onychomycosis" "BRD-K13044802-213-20-7, BRD-K13044802-001-02-4, BRD-K13044802-213-25-6, BRD-K13044802-213-24-9, BRD-K13044802-001-03-2, BRD-K13044802-213-21-5" "Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1, Cc1cc(C2CCCCC2)n(O)c(=O)c1" "SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N, SCKYRAXSEDYPSA-UHFFFAOYSA-N" "Launched"
"484" "cicloprofen" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "" "" "BRD-A94965935-001-01-6" "CC(C(O)=O)c1ccc-2c(Cc3ccccc-23)c1" "LRXFKKPEBXIPMW-UHFFFAOYSA-N" "Preclinical"
"485" "CID-5458317" "MAP kinase phosphatase inhibitor" "MAPK3" "" "" "BRD-A08840375-001-01-3" "O=C1c2ccccc2C(NC2CCCCC2)\C1=C/c1ccccc1" "XJDKPLZUXCIMIS-HMMYKYKNSA-N" "Preclinical"
"486" "cidofovir" "DNA polymerase inhibitor" "" "infectious disease" "acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis" "BRD-K96153583-001-05-1, BRD-K96153583-001-04-4" "Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1, Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1" "VWFCHDSQECPREK-LURJTMIESA-N, VWFCHDSQECPREK-LURJTMIESA-N" "Launched"
"487" "ciglitazone" "PPAR receptor agonist" "PPARG" "" "" "BRD-A93000692-001-08-1" "CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1" "YZFWTZACSRHJQD-UHFFFAOYSA-N" "Phase 2"
"488" "cilastatin" "dehydropeptidase inhibitor" "DPEP1" "" "" "BRD-K26556168-236-01-4, BRD-K62370608-001-02-9" "CC1(C)C[C@@H]1C(=O)N\C(C(O)=O)=C/CCCCSC[C@@H](N)C(O)=O, CC1(C)C[C@H]1C(=O)N\C(C(O)=O)=C/CCCCSC[C@@H](N)C(O)=O" "DHSUYTOATWAVLW-OYHMZJHOSA-N, DHSUYTOATWAVLW-RXOUDOFYSA-N" "Launched"
"489" "cilazapril" "angiotensin converting enzyme inhibitor" "ACE" "cardiology" "hypertension, congestive heart failure" "BRD-K65518078-002-01-1" "CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](N2C1=O)C(O)=O" "HHHKFGXWKKUNCY-GBESFXJTSA-N" "Launched"
"490" "cilengitide" "integrin antagonist" "ITGAV, ITGB3" "" "" "BRD-K57252450-001-02-5" "CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O" "AMLYAMJWYAIXIA-VWNVYAMZSA-N" "Phase 3"
"491" "cilnidipine" "calcium channel blocker" "CACNA1B" "cardiology" "hypertension" "BRD-A02743701-001-04-4, BRD-A02743701-001-03-6, BRD-A02743701-001-02-8" "COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1" "KJEBULYHNRNJTE-DHZHZOJOSA-N, KJEBULYHNRNJTE-DHZHZOJOSA-N, KJEBULYHNRNJTE-DHZHZOJOSA-N" "Launched"
"492" "cilomilast" "phosphodiesterase inhibitor" "PDE4A, PDE4B, PDE4D" "" "" "BRD-K38473998-001-02-0" "COc1ccc(cc1OC1CCCC1)C1(CCC(CC1)C(O)=O)C" "" ""
"493" "cilostamide" "phosphodiesterase inhibitor" "PDE3A, PDE3B" "" "" "BRD-K28578425-001-07-0" "CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1" "UIAYVIIHMORPSJ-UHFFFAOYSA-N" "Preclinical"
"494" "cilostazol" "phosphodiesterase inhibitor" "PDE3A, PDE3B" "cardiology" "claudication" "BRD-K67017579-001-28-1, BRD-K67017579-001-27-3, BRD-K67017579-001-26-5" "O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1, O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1" "RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N, RRGUKTPIGVIEKM-UHFFFAOYSA-N" "Launched"
"495" "cimaterol" "adrenergic receptor agonist" "ADRB1, ADRB2, ADRB3" "" "" "BRD-A65440446-001-04-1" "CC(C)NCC(O)c1ccc(N)c(c1)C" "" ""
"496" "cimetidine" "histamine receptor antagonist" "HRH2, SLC29A4, SLC47A1, SLC47A2" "gastroenterology, hematologic malignancy, endocrinology" "duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma" "BRD-K34157611-001-16-0, BRD-K34157611-001-15-2, BRD-K34157611-001-14-5" "CN\C(NCCSCc1nc[nH]c1C)=N/C" "" ""
"497" "cimetropium" "acetylcholine receptor antagonist" "CHRM1" "gastroenterology" "irritable bowel syndrome" "BRD-A99899486-004-01-9" "C[N+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1" "QVVOZYKELHAIPX-WVHCHWADSA-N" "Launched"
"498" "cinacalcet" "calcium channel activator" "CASR" "endocrinology, nephrology, oncology" "hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia" "BRD-K73838513-003-05-5" "C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12" "VDHAWDNDOKGFTD-MRXNPFEDSA-N" "Launched"
"499" "cinaciguat" "guanylate cyclase activator" "GUCY1A3, GUCY1B3" "" "" "BRD-K73440166-001-01-3" "OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O" "WPYWMXNXEZFMAK-UHFFFAOYSA-N" "Phase 2"
"500" "cinalukast" "leukotriene receptor antagonist" "CYSLTR1" "" "" "BRD-K53720352-001-04-0, BRD-K53720352-001-03-2" "CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O, CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O" "BZMKNPGKXJAIDV-VAWYXSNFSA-N, BZMKNPGKXJAIDV-VAWYXSNFSA-N" "Phase 2"
"501" "cinanserin" "serotonin receptor antagonist" "HTR2A" "" "" "BRD-K40901640-003-01-6" "CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1" "RSUVYMGADVXGOU-BUHFOSPRSA-N" "Preclinical"
"502" "cinchocaine" "sodium channel blocker" "CALM1, SCN10A, SCN5A" "neurology/psychiatry" "local anesthetic" "BRD-K99121711-003-19-7, BRD-K99121711-003-20-5" "CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1, CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1" "PUFQVTATUTYEAL-UHFFFAOYSA-N, PUFQVTATUTYEAL-UHFFFAOYSA-N" "Launched"
"503" "cinchonidine" "P glycoprotein inhibitor" "" "" "" "BRD-A54537387-001-02-2, BRD-K39079086-001-06-8" "O[C@@H]([C@@H]1CC2CCN1C[C@@H]2C=C)c1ccnc2ccccc12, O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12" "KMPWYEUPVWOPIM-YNRGSOABSA-N, KMPWYEUPVWOPIM-KODHJQJWSA-N" "Phase 1"
"504" "cinchonine" "P glycoprotein inhibitor" "CYP2D6" "" "" "BRD-K14693417-001-04-0" "O[C@@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12" "KMPWYEUPVWOPIM-YXUGBTPSSA-N" "Preclinical"
"505" "cinchophen" "analgesic agent" "" "rheumatology" "gout" "BRD-K72915123-001-18-1, BRD-K72915123-001-17-3" "OC(=O)c1cc(nc2ccccc12)-c1ccccc1, OC(=O)c1cc(nc2ccccc12)-c1ccccc1" "YTRMTPPVNRALON-UHFFFAOYSA-N, YTRMTPPVNRALON-UHFFFAOYSA-N" "Launched"
"506" "cinepazet" "vasodilator" "" "" "" "BRD-K00531707-001-01-3" "CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1" "XDUOTWNXVDBCDY-VOTSOKGWSA-N" "Launched"
"507" "cinepazide" "calcium channel activator" "" "" "" "BRD-K46839850-050-05-9, BRD-K46839850-050-04-2" "COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1, COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCN(CC(=O)N2CCCC2)CC1" "RCUDFXMNPQNBDU-VOTSOKGWSA-N, RCUDFXMNPQNBDU-VOTSOKGWSA-N" "Withdrawn"
"508" "cinflumide" "muscle relaxant" "" "" "" "BRD-K25154476-001-01-4" "Fc1cccc(c1)\C=C\C(=O)NC1CC1" "NCOOUEIQXVWKTO-QPJJXVBHSA-N" "Phase 2"
"509" "cinnamaldehyde" "aldose reductase inhibitor, TRPV agonist" "TRPA1" "" "" "BRD-K38088841-001-01-7" "O=CC=Cc1ccccc1" "KJPRLNWUNMBNBZ-UHFFFAOYSA-N" "Preclinical"
"510" "cinnarazine" "calcium channel blocker" "" "neurology/psychiatry, gastroenterology, ophthalmology" "Menieres disease, nausea, vomiting, Cogans syndrome" "BRD-K07220430-001-19-2, BRD-K07220430-001-18-4" "C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1, C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1" "DERZBLKQOCDDDZ-JLHYYAGUSA-N, DERZBLKQOCDDDZ-JLHYYAGUSA-N" "Launched"
"511" "cinoctramide" "" "" "" "" "BRD-K08699567-001-01-9" "COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCCCCCC1" "MDGVCMGGLSOVIQ-MDZDMXLPSA-N" "Preclinical"
"512" "cinoxacin" "topoisomerase inhibitor" "" "infectious disease" "urinary tract infections" "BRD-K14704277-001-22-6, BRD-K14704277-001-23-4" "CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12, CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12" "VDUWPHTZYNWKRN-UHFFFAOYSA-N, VDUWPHTZYNWKRN-UHFFFAOYSA-N" "Launched"
"513" "cinoxate" "" "" "dermatology" "sunscreen lotion" "BRD-K17828029-001-01-5" "CCOCCOC(=O)\C=C\c1ccc(OC)cc1" "CMDKPGRTAQVGFQ-RMKNXTFCSA-N" "Launched"
"514" "cinromide" "" "" "" "" "BRD-K66241279-001-01-8" "CCNC(=O)\C=C\c1cccc(Br)c1" "LDCXGZCEMNMWIL-VOTSOKGWSA-N" "Phase 3"
"515" "cintriamide" "" "" "" "" "BRD-K24507548-001-01-8" "COc1cc(cc(OC)c1OC)\C=C\C(N)=O" "LRLKZVMLJBNNPE-SNAWJCMRSA-N" "Preclinical"
"516" "cipemastat" "metalloproteinase inhibitor" "ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9" "" "" "BRD-K95362002-001-01-1" "CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C" "GFUITADOEPNRML-SJORKVTESA-N" "Phase 3"
"517" "ciprofibrate" "PPAR receptor agonist" "PPARA" "endocrinology" "hyperlipidemia" "BRD-A49358627-001-14-6, BRD-A49358627-001-13-8" "CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O, CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O" "KPSRODZRAIWAKH-UHFFFAOYSA-N, KPSRODZRAIWAKH-UHFFFAOYSA-N" "Launched"
"518" "ciprofloxacin" "bacterial DNA gyrase inhibitor" "TOP2A" "otolaryngology" "otitis" "BRD-K04804440-001-13-7, BRD-K04804440-001-09-5, BRD-K04804440-001-08-7" "OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O" "MYSWGUAQZAJSOK-UHFFFAOYSA-N, MYSWGUAQZAJSOK-UHFFFAOYSA-N, MYSWGUAQZAJSOK-UHFFFAOYSA-N" "Launched"
"519" "ciproxifan" "histamine receptor antagonist" "ADRA2A, ADRA2C, HRH3, HRH4, HTR3A" "" "" "BRD-K01767299-050-02-1" "O=C(C1CC1)c1ccc(OCCCc2c[nH]cn2)cc1" "ACQBHJXEAYTHCY-UHFFFAOYSA-N" "Preclinical"
"520" "cirazoline" "adrenergic receptor agonist" "ADRA1A" "" "" "BRD-K54142781-003-11-8" "C(Oc1ccccc1C1CC1)C1=NCCN1" "YAORIDZYZDUZCM-UHFFFAOYSA-N" "Preclinical"
"521" "cis-aconitic-acid" "" "ACO2" "" "" "BRD-K71756122-001-02-5" "OC(=O)C\C(=C\C(O)=O)C(O)=O" "GTZCVFVGUGFEME-IWQZZHSRSA-N" "Preclinical"
"522" "cis-ACPD" "glutamate receptor agonist" "GRM2, GRM3, GRM6, GRM7, GRM8" "" "" "BRD-M29936662-001-02-0" "N[C@]1(CC[C@@H](C1)C(O)=O)C(O)=O.N[C@@]1(CC[C@H](C1)C(O)=O)C(O)=O" "DXLSPTHQGVGVTN-ATXZCBKLSA-N" "Preclinical"
"523" "cis-urocanic acid" "serotonin receptor agonist" "HTR2A" "" "" "BRD-K25146005-001-01-0" "OC(=O)\C=C/c1c[nH]cn1" "LOIYMIARKYCTBW-UPHRSURJSA-N" "Phase 2"
"524" "cis-urocanic-acid" "serotonin receptor agonist" "HTR2A" "" "" "BRD-K52670952-003-01-4" "OC(=O)\C=C\c1c[nH]cn1" "LOIYMIARKYCTBW-OWOJBTEDSA-N" "Phase 2"
"525" "cisapride" "serotonin receptor agonist" "HTR2A, HTR3A, HTR4, KCNH2" "" "" "BRD-A12896037-001-04-3, BRD-K06895174-001-02-8" "COC1CN(CCCOc2ccc(F)cc2)CCC1NC(=O)c1cc(Cl)c(N)cc1OC, CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC" "DCSUBABJRXZOMT-UHFFFAOYSA-N, DCSUBABJRXZOMT-IRLDBZIGSA-N" "Withdrawn"
"526" "cisplatin" "DNA alkylating agent, DNA synthesis inhibitor" "XIAP" "oncology" "testicular carcinoma, ovarian cancer, bladder cancer" "BRD-K69172251-001-11-3, BRD-K69172251-001-09-7, BRD-K69172251-001-10-5, BRD-K69172251-001-08-9" "N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl, N[Pt](N)(Cl)Cl" "DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L, DQLATGHUWYMOKM-UHFFFAOYSA-L" "Launched"
"527" "citalopram" "selective serotonin reuptake inhibitor (SSRI)" "SLC6A2, SLC6A4" "neurology/psychiatry" "depression" "BRD-A47598013-004-16-0, BRD-A47598013-034-02-7, BRD-A47598013-004-18-6, BRD-A47598013-004-17-8" "CN(C)CCCC1(OCc2cc(ccc12)C" "" ""
"528" "CITCO" "constitutive androstane receptor (CAR) agonist" "NR1I3" "" "" "BRD-K53263234-001-05-2" "Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1" "ZQWBOKJVVYNKTL-AUEPDCJTSA-N" "Preclinical"
"529" "citicoline" "membrane permeability enhancer, glutathione transferase stimulant" "ACHE, SLC1A2" "neurology/psychiatry, ophthalmology" "stroke, Alzheimers disease, senile dementia, Parkinsons Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma" "BRD-A91728607-236-11-9, BRD-A91728607-001-01-8, BRD-A74441166-396-01-6" "C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O, C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1OC([C@H](O)[C@@H]1O)n1ccc(N)nc1=O" "RZZPDXZPRHQOCG-OJAKKHQRSA-O, RZZPDXZPRHQOCG-OJAKKHQRSA-O, RZZPDXZPRHQOCG-INCVAACISA-O" "Launched"
"530" "citiolone" "lipotropic, mucolytic agent" "" "" "" "BRD-A57957888-001-08-0" "CC(=O)NC1CCSC1=O" "NRFJZTXWLKPZAV-UHFFFAOYSA-N" "Preclinical"
"531" "citric-acid" "coagulation factor inhibitor" "AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2" "" "" "BRD-K76792669-001-08-1" "OC(=O)CC(O)(CC(O)=O)C(O)=O" "KRKNYBCHXYNGOX-UHFFFAOYSA-N" "Preclinical"
"532" "CK-636" "actin related protein inhibitor" "ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5" "" "" "BRD-K81572616-001-02-7, BRD-K81572616-001-01-9" "Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1, Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1" "ACAKNPKRLPMONU-UHFFFAOYSA-N, ACAKNPKRLPMONU-UHFFFAOYSA-N" "Preclinical"
"533" "CKD-712" "NFkB pathway inhibitor" "JAK2, STAT1" "" "" "BRD-A26458246-004-02-1, BRD-A26458246-004-01-3" "Oc1cc2CCNC(Cc3cccc4ccccc34)c2cc1O, Oc1cc2CCNC(Cc3cccc4ccccc34)c2cc1O" "YGCQFKVNIBDJFW-UHFFFAOYSA-N, YGCQFKVNIBDJFW-UHFFFAOYSA-N" "Phase 1"
"534" "CL-218872" "benzodiazepine receptor agonist" "GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2" "" "" "BRD-K00662280-001-09-4" "Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F" "GUOQUXNJZHGPQF-UHFFFAOYSA-N" "Phase 1"
"535" "CL-225385" "" "" "" "" "BRD-K87573013-001-01-0" "O=C(CC" "" ""
"536" "cladribine" "adenosine deaminase inhibitor, ribonucleotide reductase inhibitor" "ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B" "hematologic malignancy" "hairy cell leukemia" "BRD-K93034159-001-25-8" "Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1" "PTOAARAWEBMLNO-KVQBGUIXSA-N" "Launched"
"537" "clarithromycin" "bacterial 50S ribosomal subunit inhibitor" "CYP3A4" "otolaryngology, pulmonary, infectious disease" "pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis" "BRD-K49668410-001-16-2, BRD-K16762525-001-01-6" "CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC, CC[C@H]1OC(=O)[C@H](C)[C@H](O[C@@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC" "AGOYDEPGAOXOCK-KCBOHYOISA-N, AGOYDEPGAOXOCK-BVGAJGDJSA-N" "Launched"
"538" "clavulanate" "beta lactamase inhibitor" "" "otolaryngology" "otitis" "BRD-K94250879-235-03-9, BRD-K94250879-001-01-9" "OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O, OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O" "HZZVJAQRINQKSD-PBFISZAISA-N, HZZVJAQRINQKSD-PBFISZAISA-N" "Launched"
"539" "clebopride" "dopamine receptor antagonist" "ACHE, DRD2" "gastroenterology" "nausea" "BRD-K17294426-050-12-3" "COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1" "BVPWJMCABCPUQY-UHFFFAOYSA-N" "Launched"
"540" "clemastine" "histamine receptor antagonist" "HRH1" "allergy" "allergic rhinitis, urticaria" "BRD-K30240666-051-15-9, BRD-K30240666-051-14-2, BRD-K30240666-051-13-4" "CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1, CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1" "YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N, YNNUSGIPVFPVBX-NHCUHLMSSA-N" "Launched"
"541" "clemizole" "HCV inhibitor" "" "allergy" "allergic rhinitis" "BRD-K04704168-003-14-3" "Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1" "CJXAEXPPLWQRFR-UHFFFAOYSA-N" "Launched"
"542" "clenbuterol" "adrenergic receptor agonist" "ADRB1, ADRB2, ADRB3, NGF, TNF" "pulmonary" "chronic obstructive pulmonary disease (COPD), asthma" "BRD-A75726477-003-21-3" "CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1" "STJMRWALKKWQGH-UHFFFAOYSA-N" "Launched"
"543" "cleviprex" "calcium channel blocker" "CACNA1C, CACNA1D, CACNA1F, CACNA1S" "cardiology" "hypertension" "BRD-A01563671-001-02-7" "CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC" "KPBZROQVTHLCDU-UHFFFAOYSA-N" "Launched"
"544" "clevudine" "DNA polymerase inhibitor" "" "infectious disease" "hepatitis B" "BRD-K18948558-001-01-9" "Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O" "GBBJCSTXCAQSSJ-AZRUVXNYSA-N" "Launched"
"545" "clidinium" "acetylcholine receptor antagonist" "CHRM1, CHRM3" "gastroenterology" "peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis" "BRD-A46066006-004-22-6" "C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(c1ccccc1)c1ccccc1" "HOOSGZJRQIVJSZ-UHFFFAOYSA-N" "Launched"
"546" "climbazole" "enzyme inducer" "" "dermatology" "dandruff, eczema" "BRD-A61676498-001-06-6, BRD-A61676498-001-05-8" "CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1, CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1" "OWEGWHBOCFMBLP-UHFFFAOYSA-N, OWEGWHBOCFMBLP-UHFFFAOYSA-N" "Launched"
"547" "clinafloxacin" "bacterial DNA gyrase inhibitor" "" "" "" "BRD-A93964801-003-03-3, BRD-A93964801-003-02-5, BRD-A93964801-001-14-4, BRD-A93964801-001-15-1" "NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1, NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1" "QGPKADBNRMWEQR-UHFFFAOYSA-N, QGPKADBNRMWEQR-UHFFFAOYSA-N, QGPKADBNRMWEQR-UHFFFAOYSA-N, QGPKADBNRMWEQR-UHFFFAOYSA-N" "Phase 3"
"548" "clindamycin" "protein synthesis inhibitor" "" "infectious disease" "respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections" "BRD-A52252998-001-01-3, BRD-A52252998-003-01-9, BRD-A23034328-003-09-1" "CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H](C(C)Cl)[C@H]1O[C@@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H](C(C)Cl)[C@H]1O[C@@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)C1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O" "KDLRVYVGXIQJDK-NQQGAZBYSA-N, KDLRVYVGXIQJDK-NQQGAZBYSA-N, KDLRVYVGXIQJDK-SSDYFQDUSA-N" "Launched"
"549" "clindamycin-palmitate" "bacterial 50S ribosomal subunit inhibitor" "" "infectious disease" "intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections" "BRD-A76672327-003-02-0" "CCCCCCCCCCCCCCCC(=O)OC1C(O)C(O)C(OC1SC)C(NC(=O)C1CC(CCC)CN1C)C(C)Cl" "OYSKUZDIHNKWLV-UHFFFAOYSA-N" "Launched"
"550" "clindamycin-phosphate" "protein synthesis inhibitor" "" "obstetrics/gynecology" "bacterial vaginosis" "BRD-K52542745-001-01-1" "CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)Cl)[C@H]1O[C@@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O" "UFUVLHLTWXBHGZ-CMWKWAQQSA-N" "Launched"
"551" "clinofibrate" "lipase clearing factor inhibitor" "LPL" "endocrinology" "hypertriglyceridemia" "BRD-A90625545-001-02-0" "CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(OC(C)(CC)C(O)=O)cc1)C(O)=O" "BMOVQUBVGICXQN-UHFFFAOYSA-N" "Launched"
"552" "clioquinol" "chelating agent" "OPRK1" "" "" "BRD-K09255212-001-16-6" "Oc1c(I)cc(Cl)c2cccnc12" "QCDFBFJGMNKBDO-UHFFFAOYSA-N" "Withdrawn"
"553" "clobazam" "GABA benzodiazepine site receptor agonist" "GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ" "neurology/psychiatry" "seizures" "BRD-K52408781-001-02-8" "CN1c2ccc(Cl)cc2N(c2ccccc2)C(=O)CC1=O" "CXOXHMZGEKVPMT-UHFFFAOYSA-N" "Launched"
"554" "clobenpropit" "histamine receptor antagonist" "HRH1, HRH2, HRH3, HRH4" "" "" "BRD-K71430621-303-02-3" "Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1" "UCAIEVHKDLMIFL-UHFFFAOYSA-N" "Preclinical"
"555" "clobetasol-propionate" "glucocorticoid receptor agonist" "NR3C1, PLA2G1B" "dermatology" "corticosteroid-responsive dermatoses" "BRD-A26095496-001-04-0, BRD-K10799896-001-24-7, BRD-K91981767-001-01-7" "CCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl, CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl" "CBGUOGMQLZIXBE-BHPVMOEKSA-N, CBGUOGMQLZIXBE-XGQKBEPLSA-N, CBGUOGMQLZIXBE-YKAVRXPSSA-N" "Launched"
"556" "clobetasone-butyrate" "corticosteroid agonist" "NR3C1" "dermatology" "eczema, psoriasis, dermatitis" "BRD-K58810291-001-16-2" "CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl" "FBRAWBYQGRLCEK-AVVSTMBFSA-N" "Launched"
"557" "clobutinol" "antitussive" "" "" "" "BRD-A43809092-003-02-1" "CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1" "KVHHQGIIZCJATJ-UHFFFAOYSA-N" "Withdrawn"
"558" "clocortolone-pivalate" "steroid" "NR3C1, PLA2G1B" "dermatology" "corticosteroid-responsive dermatoses" "BRD-K38003476-001-09-1" "C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C" "SXYZQZLHAIHKKY-GSTUPEFVSA-N" "Launched"
"559" "clodronic-acid" "bone resorption inhibitor" "SLC25A4, SLC25A5, SLC25A6" "orthopedics, endocrinology, hematologic malignancy" "osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma" "BRD-K72542090-304-03-2, BRD-K72542090-304-02-4" "OP(O)(=O)C(Cl)(Cl)P(O)(O)=O, OP(O)(=O)C(Cl)(Cl)P(O)(O)=O" "ACSIXWWBWUQEHA-UHFFFAOYSA-N, ACSIXWWBWUQEHA-UHFFFAOYSA-N" "Launched"
"560" "clofarabine" "ribonucleotide reductase inhibitor" "POLA1, POLD1, POLE, RRM1, RRM2, RRM2B" "hematologic malignancy" "acute lymphoblastic leukemia (ALL)" "BRD-K34022604-001-06-6, BRD-K34022604-001-05-8" "Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F, Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F" "WDDPHFBMKLOVOX-AYQXTPAHSA-N, WDDPHFBMKLOVOX-AYQXTPAHSA-N" "Launched"
"561" "clofazimine" "GK0582 inhibitor" "" "infectious disease" "leprosy" "BRD-K56614220-001-19-0, BRD-K56614220-001-18-2, BRD-K56614220-001-21-6" "CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1, CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1" "WDQPAMHFFCXSNU-BGABXYSRSA-N, WDQPAMHFFCXSNU-BGABXYSRSA-N, WDQPAMHFFCXSNU-BGABXYSRSA-N" "Launched"
"562" "clofedanol" "histamine receptor antagonist" "HRH1" "pulmonary" "cough suppressant" "BRD-A15687940-001-05-6" "CN(C)CCC(O)(c1ccccc1)c1ccccc1Cl" "WRCHFMBCVFFYEQ-UHFFFAOYSA-N" "Launched"
"563" "clofibrate" "PPAR receptor agonist" "LPL, PPARA" "endocrinology, cardiology" "hyperlipidemia, cholesterol" "BRD-K45252063-001-13-6, BRD-K45252063-001-12-8, BRD-K45252063-001-14-4" "CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1, CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1" "KNHUKKLJHYUCFP-UHFFFAOYSA-N, KNHUKKLJHYUCFP-UHFFFAOYSA-N, KNHUKKLJHYUCFP-UHFFFAOYSA-N" "Launched"
"564" "clofibric-acid" "PPAR receptor agonist" "PPARA" "" "" "BRD-K19111024-001-20-9, BRD-K19111024-001-19-1, BRD-K19111024-001-18-3" "CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O, CC(C)(Oc1ccc(Cl)cc1)C(O)=O" "TXCGAZHTZHNUAI-UHFFFAOYSA-N, TXCGAZHTZHNUAI-UHFFFAOYSA-N, TXCGAZHTZHNUAI-UHFFFAOYSA-N" "Launched"
"565" "clofilium" "potassium channel blocker" "KCNA5, KCNH1" "" "" "BRD-K02680176-075-11-1, BRD-K02680176-075-12-9" "CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1, CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1" "WPSYTTKBGAZSCX-UHFFFAOYSA-N, WPSYTTKBGAZSCX-UHFFFAOYSA-N" "Phase 2"
"566" "clofoctol" "protein synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections" "BRD-K02900412-001-11-3, BRD-K02900412-001-12-1" "CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1, CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1" "HQVZOORKDNCGCK-UHFFFAOYSA-N, HQVZOORKDNCGCK-UHFFFAOYSA-N" "Launched"
"567" "clomesone" "DNA inhibitor" "" "" "" "BRD-K39230570-001-01-1" "CS(=O)(=O)CS(=O)(=O)OCCCl" "SEHSPJCWCBQHPF-UHFFFAOYSA-N" "Phase 1"
"568" "clomethiazole" "GABA receptor antagonist, GABA receptor modulator" "GABRA1" "neurology/psychiatry" "Parkinsons Disease, sedative, muscle relaxant	BRD-K50422030-001-05-3, BRD-K50422030-003-02-6	Cc1ncsc1CCCl, Cc1ncsc1CCCl	PCLITLDOTJTVDJ-UHFFFAOYSA-N, PCLITLDOTJTVDJ-UHFFFAOYSA-N	Launched
clomifene	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	BRD-K29950728-048-18-2, BRD-K29950728-048-17-4, BRD-K29950728-048-16-6	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1, CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N, GKIRPKYJQBWNGO-QPLCGJKRSA-N	Launched
clomipramine	serotonin transporter (SERT) inhibitor	GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	BRD-K52989797-003-26-4, BRD-K52989797-003-27-2, BRD-K52989797-003-28-0	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12, CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N, GDLIGKIOYRNHDA-UHFFFAOYSA-N	Launched
clonazepam	GABA benzodiazepine site receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	seizures, panic disorders	BRD-K38183498-001-02-0	[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1	DGBIGWXXNGSACT-UHFFFAOYSA-N	Launched
clonidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, neurology/psychiatry	hypertension, attention-deficit/hyperactivity disorder (ADHD)	BRD-K98530306-003-18-3, BRD-K98530306-003-17-5, BRD-K98530306-003-16-7	Clc1cccc(Cl)c1N=C1NCCN1, Clc1cccc(Cl)c1N=C1NCCN1, Clc1cccc(Cl)c1N=C1NCCN1	GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N, GJSURZIOUXUGAL-UHFFFAOYSA-N	Launched
clonixin-lysinate	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	BRD-M63173034-001-03-6, BRD-M63173034-001-02-8	NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O, NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	CVNFYQCHAWFYQI-ZSCHJXSPSA-N, CVNFYQCHAWFYQI-ZSCHJXSPSA-N	Launched
clopamide	sodium/chloride cotransporter inhibitor		cardiology	hypertension	BRD-A85651701-001-19-7	CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	LBXHRAWDUMTPSE-UHFFFAOYSA-N	Launched
cloperastine	antitussive		pulmonary	cough suppressant	BRD-A80908310-003-13-8	Clc1ccc(cc1)C(OCCN1CCCCC1)c1ccccc1	FLNXBVJLPJNOSI-UHFFFAOYSA-N	Launched
clopidogrel	purinergic receptor antagonist	P2RY12	cardiology, neurology/psychiatry	myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)	BRD-K27721098-065-10-2, BRD-K27721098-065-08-6, BRD-K27721098-065-09-4	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl, COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N, GKTWGGQPFAXNFI-HNNXBMFYSA-N	Launched
clopidol			infectious disease	coccidiosis	BRD-K80036624-001-04-0	Cc1nc(C)c(Cl)c(O)c1Cl	ZDPIZLCVJAAHHR-UHFFFAOYSA-N	Launched
cloprostenol-(+/-)	prostaglandin receptor agonist	PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R			BRD-K17850764-236-11-9	O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	Launched
cloranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			BRD-A04971881-003-01-3	CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl	XYCMOTOFHFTUIU-UHFFFAOYSA-N	Launched
clorgiline	monoamine oxidase inhibitor	MAOA			BRD-K73251053-003-22-2, BRD-K73251053-003-21-4	CN(CCCOc1ccc(Cl)cc1Cl)CC#C, CN(CCCOc1ccc(Cl)cc1Cl)CC#C	BTFHLQRNAMSNLC-UHFFFAOYSA-N, BTFHLQRNAMSNLC-UHFFFAOYSA-N	Phase 2
clorotepine	dopamine receptor antagonist, adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6	neurology/psychiatry	psychosis	BRD-A19053834-050-09-5	CN1CCN(CC1)C1Cc2ccccc2Sc2ccc(Cl)cc12	XRYLGRGAWQSVQW-UHFFFAOYSA-N	Launched
clorprenaline	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	BRD-A29281099-003-03-2	CC(C)NCC(O)c1ccccc1Cl	SSMSBSWKLKKXGG-UHFFFAOYSA-N	Launched
clorsulon	glycolysis inhibitor		infectious disease	gastrointestinal roundworms, lungworms, liver flukes, lice, mites	BRD-K97521363-001-16-1, BRD-K97521363-001-15-3	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O, Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	QOVTVIYTBRHADL-UHFFFAOYSA-N, QOVTVIYTBRHADL-UHFFFAOYSA-N	Launched
closantel	chitinase inhibitor, NFkB pathway inhibitor		infectious disease	liver flukes	BRD-A19952358-001-11-3, BRD-A19952358-236-01-6, BRD-A19952358-001-10-5, BRD-A19952358-001-12-1	Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O, Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O	JMPFSEBWVLAJKM-UHFFFAOYSA-N, JMPFSEBWVLAJKM-UHFFFAOYSA-N, JMPFSEBWVLAJKM-UHFFFAOYSA-N, JMPFSEBWVLAJKM-UHFFFAOYSA-N	Launched
clotiapine			neurology/psychiatry	psychosis	BRD-K10990317-001-04-5	CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12	KAAZGXDPUNNEFN-UHFFFAOYSA-N	Launched
clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	BRD-K15916496-001-27-9, BRD-K15916496-001-26-1	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1, Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	VNFPBHJOKIVQEB-UHFFFAOYSA-N, VNFPBHJOKIVQEB-UHFFFAOYSA-N	Launched
cloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K01244426-236-12-1, BRD-K01244426-323-07-7, BRD-K23933163-323-01-9	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-JKIFEVAISA-N, LQOLIRLGBULYKD-KEYYUXOJSA-N	Launched
cloxyquin	potassium channel activator	KCNK18			BRD-K46982791-001-09-4	Oc1ccc(Cl)c2cccnc12	CTQMJYWDVABFRZ-UHFFFAOYSA-N	Preclinical
clozapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia	BRD-K37289225-001-36-4, BRD-K37289225-001-35-6, BRD-K37289225-001-37-2, BRD-K37289225-001-34-9	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12, CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12	QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N, QZUDBNBUXVUHMW-UHFFFAOYSA-N	Launched
CL316243	adrenergic receptor agonist	ADRB3, UCP1, UCP2, UCP3			BRD-K06467130-304-02-7	C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1	JEDJMKTVUPSHFW-ABAIWWIYSA-N	Phase 2
CMPD-1	p38 MAPK inhibitor	GNRHR, MAPK14			BRD-K54095730-001-03-1	Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	ODYAQBDIXCVKAE-UHFFFAOYSA-N	Preclinical
CNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K19438463-001-05-5, BRD-K19438463-304-01-2	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	RPXVIAFEQBNEAX-UHFFFAOYSA-N, RPXVIAFEQBNEAX-UHFFFAOYSA-N	Phase 1
CNX-2006	EGFR inhibitor	EGFR			BRD-K24869513-001-02-1	COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	BFSRTTWIPACGMI-UHFFFAOYSA-N	Preclinical
CNX-774	Brutons tyrosine kinase (BTK) inhibitor" "BTK" "" "" "BRD-K48443249-001-01-0"
"569" "CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1" "VVLHQJDAUIPZFH-UHFFFAOYSA-N" "Preclinical" "" "" "" "" "" ""
"570" "CO-101244" "glutamate receptor antagonist" "GRIN2B" "" "" "BRD-K55677650-003-02-9" "Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1" "VKMFDKYCIKEDMR-UHFFFAOYSA-N" "Preclinical"
"571" "co-102862" "" "SCN4A, SCN9A" "" "" "BRD-K70912147-001-01-8" "NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1" "MHUUDVZSPFRUSK-RQZCQDPDSA-N" "Phase 1"
"572" "cobicistat" "cytochrome P450 inhibitor" "CYP3A4, CYP3A43, CYP3A5, CYP3A7" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K51040301-001-02-1" "CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1" "ZCIGNRJZKPOIKD-CQXVEOKZSA-N" "Launched"
"573" "cobimetinib" "MEK inhibitor" "" "oncology" "melanoma" "BRD-K03390685-001-01-7" "OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1" "BSMCAPRUBJMWDF-KRWDZBQOSA-N" "Launched"
"574" "coenzyme-a" "" "ACAT2, CRAT, CS, DBI, HMGCR, KAT2A, KAT2B, KAT5" "" "" "BRD-A67956599-002-01-3" "CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS" "RGJOEKWQDUBAIZ-IBOSZNHHSA-N" "Launched"
"575" "coenzyme-i" "" "AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, AMT, BDH1, BLVRA, BLVRB, CDO1, CYB5R3, CYP17A1, CYP4A11, DHCR7, DHFR, DLAT, DLD, EHHADH, GAPDH, GAPDHS, GLUD1, GLUD2, GPD1, GSR, H6PD, HADH, HADHA, HIBADH, HMGCR, HMOX1, HMOX2, HPGD, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, HSD17B3, HSD17B4, HSD17B7, HSD17B8, HSD3B1, HSD3B2, IDH3A, IDH3B, IDH3G, IMPDH1, IMPDH2, LDHA, LDHAL6A, LDHAL6B, LDHB, LDHC, MDH1, MDH2, ME1, ME2, ME3, MSMO1, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MTHFD1, MTHFD2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NNT, NQO2, NSDHL, OGDH, PDHA1, PDHA2, PDHB, PHGDH, PYCR1, PYCR2, QDPR, RDH5, SORD, TSTA3, TYR, UGDH" "" "" "BRD-A45839132-304-01-2, BRD-A84188517-304-01-1" "NC(=O)C1=CN(C=CC1)[C@H]1O[C@@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@H](O)[C@@H]1O, NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O" "BOPGDPNILDQYTO-DQQFMEOOSA-N, BOPGDPNILDQYTO-NNYOXOHSSA-N" "Phase 2"
"576" "coenzyme-q10" "" "" "" "" "BRD-K75043328-001-03-4, BRD-K75043328-001-05-9, BRD-K75043328-001-04-2" "COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O, COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O" "ACTIUHUUMQJHFO-UPTCCGCDSA-N, ACTIUHUUMQJHFO-UPTCCGCDSA-N, ACTIUHUUMQJHFO-UPTCCGCDSA-N" "Launched"
"577" "colchicine" "microtubule inhibitor" "GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8" "rheumatology, endocrinology" "gout, fever" "BRD-K00259736-001-16-4, BRD-A46684810-001-12-9" "COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC, COc1cc2CCC(NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC" "IAKHMKGGTNLKSZ-INIZCTEOSA-N, IAKHMKGGTNLKSZ-UHFFFAOYSA-N" "Launched"
"578" "colesevalam" "" "" "" "" "BRD-U08520523-000-01-0" "" "" "Preclinical"
"579" "colforsin" "adenylyl cyclase activator" "ADCY2, ADCY5" "" "" "BRD-A55416093-001-06-4" "CC(=O)O[C@H]1[C@@H](O)C2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C" "OHCQJHSOBUTRHG-VDCUXWMXSA-N" "Phase 2"
"580" "colforsin-daproate" "adenylyl cyclase activator" "" "" "" "BRD-K19388745-003-01-7" "CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C" "RSOZZQTUMVBTMR-XGUNBQNXSA-N" "Launched"
"581" "colfosceril-palmitate" "pulmonary surfactant" "" "pulmonary" "respiratory distress syndrome (RDS)" "BRD-A95886749-001-04-3, BRD-A95886749-001-03-5" "CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC" "KILNVBDSWZSGLL-KXQOOQHDSA-O, KILNVBDSWZSGLL-KXQOOQHDSA-O" "Launched"
"582" "colistimethate" "bacterial permeability inducer" "" "infectious disease" "gram-negative bacterial infections" "BRD-A13668387-319-04-7, BRD-A44942307-405-01-9" "CCC(C)C1NC(=O)C(NC(=O)C(CCNCS(O)(=O)=O)NC(=O)C(CCNC(=O)C(NC(=O)C(CCNCS(O)(=O)=O)NC(=O)C(CCNCS(O)(=O)=O)NC1=O)C(C)O)NC(=O)C(CCNCS(O)(=O)=O)NC(=O)C(NC(=O)C(CCNCS(O)(=O)=O)NC(=O)CCCCC(C)C)C(C)O)C(C)CC, CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O" "JGZYUDARLHNRKM-UHFFFAOYSA-N, XDJYMJULXQKGMM-KFZDXBANSA-N" "Launched"
"583" "colistin" "bacterial permeability inducer" "" "infectious disease" "gram-negative bacterial infections" "BRD-A18924964-065-01-5" "CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O" "YKQOSKADJPQZHB-QNPLFGSASA-N" "Launched"
"584" "colistin-b-sulfate" "bacterial permeability inducer" "" "infectious disease" "gram-negative bacterial infections" "BRD-A36456202-001-01-3" "CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O" "KNIWPHSUTGNZST-INRBSFJCSA-N" "Launched"
"585" "colistin-sulfate" "bacterial permeability inducer" "" "infectious disease" "gram-negative bacterial infections" "BRD-M52026403-001-01-6, BRD-A45201156-315-02-0, BRD-M52026403-001-02-4" "CC(C)CCCCC(=O)N[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O.CCC(C)CCCCC(=O)N[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O, CCC(C)C1NC(=O)C(NC(=O)C(CCN)NC(=O)C(CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC1=O)C(C)O)NC(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC(=O)CCCCC(C)C)C(C)O)C(C)CC, CC(C)CCCCC(=O)N[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O.CCC(C)CCCCC(=O)N[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O" "LWCVTMJWLSJYQN-BJVABBHKSA-N, VCRYFUBRFYUNTM-UHFFFAOYSA-N, LWCVTMJWLSJYQN-BJVABBHKSA-N" "Launched"
"586" "combretastatin-A-4" "tubulin polymerization inhibitor" "" "" "" "BRD-K61195623-001-01-4" "COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1" "HVXBOLULGPECHP-WAYWQWQTSA-N" "Phase 2"
"587" "compound-w" "beta-secretase inhibitor" "BACE1" "" "" "BRD-K98143539-001-02-2" "OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1" "JOSXKPZXMVHRKU-UHFFFAOYSA-N" "Preclinical"
"588" "compound-401" "DNA dependent protein kinase inhibitor" "MTOR, PRKDC" "" "" "BRD-K19655798-001-01-9" "O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1" "BVRDQVRQVGRNHG-UHFFFAOYSA-N" "Preclinical"
"589" "compound-58112" "" "" "" "" "BRD-K76139886-003-01-3" "COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1" "CUYLJVJMQPPTOS-UHFFFAOYSA-N" "Preclinical"
"590" "conivaptan" "vasopressin receptor antagonist" "AVPR1A, AVPR2" "endocrinology" "hyponatremia" "BRD-K37385792-003-02-1" "Cc1nc2CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc3-c2[nH]1" "IKENVDNFQMCRTR-UHFFFAOYSA-N" "Launched"
"591" "copanlisib" "PI3K inhibitor" "PIK3CA, PIK3CB, PIK3CD, PIK3CG" "" "" "BRD-K24666289-001-04-9, BRD-K24666289-001-02-3" "COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12, COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12" "PZBCKZWLPGJMAO-UHFFFAOYSA-N, PZBCKZWLPGJMAO-UHFFFAOYSA-N" "Phase 3"
"592" "copper-histidine" "" "HAL, HARS, HDC, SLC15A3, SLC15A4, SLC38A3, SLC38A5" "" "" "BRD-K36449075-001-01-0" "N[C@H](Cc1c[nH]cn1)C(O)=O" "HNDVDQJCIGZPNO-RXMQYKEDSA-N" "Phase 3"
"593" "cordycepin" "DNA inhibitor" "" "" "" "BRD-K65428967-001-08-4" "Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O" "OFEZSBMBBKLLBJ-BAJZRUMYSA-N" "Phase 1/Phase 2"
"594" "corosolic-acid" "PKC inhibitor, protein tyrosine kinase inhibitor" "HSD11B1, PTPN1" "" "" "BRD-K27885593-001-06-8" "C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O" "HFGSQOYIOKBQOW-ZSDYHTTISA-N" "Phase 2"
"595" "corticosterone" "mineralocorticoid receptor agonist" "HSD11B1, NCOA1, NR3C2" "" "" "BRD-K73589401-001-23-6" "C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO" "OMFXVFTZEKFJBZ-HJTSIMOOSA-N" "Preclinical"
"596" "cortisone" "glucocorticoid receptor agonist" "NR3C1" "gastroenterology, rheumatology, dermatology" "ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema" "BRD-A62731508-001-05-8" "C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO" "MFYSYFVPBJMHGN-BDQMTFAOSA-N" "Launched"
"597" "cortisone-acetate" "glucocorticoid receptor agonist" "NR3C1" "pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease" "asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis" "BRD-K86161929-001-11-7, BRD-A54487287-001-04-7, BRD-K83872210-001-01-1" "CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3C(=O)C[C@]12C, CC(=O)OCC(=O)[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@H]3C(=O)C[C@]12C" "ITRJWOMZKQRYTA-RFZYENFJSA-N, ITRJWOMZKQRYTA-XLSOAHDVSA-N, ITRJWOMZKQRYTA-GMNINMNUSA-N" "Launched"
"598" "cortodoxone" "androgen receptor antagonist" "AR" "" "" "BRD-K32891457-001-15-5, BRD-A95717758-001-07-1, BRD-K32891457-001-16-3" "C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, CC12CCC3C(CCC4=CC(=O)CCC34C)C1CC[C@]2(O)C(=O)CO, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO" "WHBHBVVOGNECLV-OBQKJFGGSA-N, WHBHBVVOGNECLV-VLAJLFEZSA-N, WHBHBVVOGNECLV-OBQKJFGGSA-N" "Phase 3"
"599" "costunolide" "telomerase inhibitor" "" "" "" "BRD-K26833429-001-02-8, BRD-K44887666-001-02-4, BRD-K26833429-001-03-6" "C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, CC1=CCC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1, C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1" "HRYLQFBHBWLLLL-AHNJNIBGSA-N, HRYLQFBHBWLLLL-RFXWPVDASA-N, HRYLQFBHBWLLLL-AHNJNIBGSA-N" "Preclinical"
"600" "cot-inhibitor-1" "MAPK-interacting kinase inhibitor" "MAP3K8" "" "" "BRD-K98710228-001-01-6" "Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C" "" ""
"601" "cot-inhibitor-2" "MAPK-interacting kinase inhibitor" "MAP3K8" "" "" "BRD-K49468759-001-04-2, BRD-K49468759-001-05-9" "CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C" "" ""
"602" "cotinine" "nicotine metabolite" "" "" "" "BRD-K94144010-001-13-9" "CN1[C@@H](CCC1=O)c1cccnc1" "UIKROCXWUNQSPJ-VIFPVBQESA-N" "Phase 2"
"603" "coumarin" "vitamin K antagonist" "CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6" "gastroenterology, pulmonary" "ulcerative colitis, asthma, celiac disease" "BRD-K23913458-001-20-7, BRD-K23913458-001-19-9" "O=c1ccc2ccccc2o1, O=c1ccc2ccccc2o1" "ZYGHJZDHTFUPRJ-UHFFFAOYSA-N, ZYGHJZDHTFUPRJ-UHFFFAOYSA-N" "Launched"
"604" "coumophos" "cholinesterase inhibitor" "" "" "" "BRD-K41567533-001-08-3" "CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1" "BXNANOICGRISHX-UHFFFAOYSA-N" "Preclinical"
"605" "CP-339818" "potassium channel blocker" "KCNA3" "" "" "BRD-K52113681-003-02-1" "CCCCCN=c1ccn(Cc2ccccc2)c2ccccc12" "MMGAVKCAGQCFHS-UHFFFAOYSA-N" "Preclinical"
"606" "CP-376395" "corticosteroid releasing factor receptor antagonist" "CRHR1" "" "" "BRD-K31394475-001-01-9" "CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C" "VIZBSVDBNLAVAW-UHFFFAOYSA-N" "Phase 1"
"607" "CP-532623" "cholesteryl ester transfer protein inhibitor" "CETP" "" "" "BRD-K36611520-001-01-6" "CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F" "TUPKOWFPVAXQFP-OFNKIYASSA-N" "Phase 1"
"608" "CP-640186" "acetyl-CoA carboxylase inhibitor" "ACACA, ACACB" "" "" "BRD-K26921335-003-01-2" "O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1" "LDQKDRLEMKIYMC-XMMPIXPASA-N" "Preclinical"
"609" "CP-673451" "PDGFR tyrosine kinase receptor inhibitor" "KIT, PDGFRA, PDGFRB" "" "" "BRD-K43621685-001-03-3, BRD-K43621685-001-02-5" "COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1, COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1" "DEEOXSOLTLIWMG-UHFFFAOYSA-N, DEEOXSOLTLIWMG-UHFFFAOYSA-N" "Preclinical"
"610" "CP-724714" "EGFR inhibitor, protein tyrosine kinase inhibitor" "ERBB2" "" "" "BRD-K76908866-001-07-6" "COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1" "LLVZBTWPGQVVLW-SNAWJCMRSA-N" "Phase 2"
"611" "CP-91149" "glycogen phosphorylase inhibitor" "PYGL" "" "" "BRD-K19171642-001-02-3" "CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1" "HINJNZFCMLSBCI-PKOBYXMFSA-N" "Preclinical"
"612" "CP-93129" "serotonin receptor agonist" "HTR1A" "" "" "BRD-K81876028-300-02-0" "O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1" "PJYVGMRFPFNZCT-UHFFFAOYSA-N" "Preclinical"
"613" "CP-94253" "serotonin receptor agonist" "HTR1B" "" "" "BRD-K33860217-003-03-2" "CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1" "KWQWBZIGHIOKIO-UHFFFAOYSA-N" "Preclinical"
"614" "CPA-inhibitor" "carboxypeptidase inhibitor" "CPA1, CPA2" "" "" "BRD-A69126730-001-01-3" "ON(CC(Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1" "PONANXDRJJIGPG-UHFFFAOYSA-N" "Preclinical"
"615" "CPCCOEt" "glutamate receptor antagonist" "GRM1" "" "" "BRD-A05729358-001-02-0" "CCOC(=O)C12CC1\C(=N/O)c1ccccc1O2" "FXCTZFMSAHZQTR-KAMYIIQDSA-N" "Preclinical"
"616" "CPI-0610" "bromodomain inhibitor" "BRD4" "" "" "BRD-K19871656-001-01-3" "Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12" "GCWIQUVXWZWCLE-INIZCTEOSA-N" "Phase 1"
"617" "CPI-1189" "tumor necrosis factor release inhibitor" "TNF" "" "" "BRD-K11073688-001-01-6" "CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C" "DJKNRCWSXSZACF-UHFFFAOYSA-N" "Phase 2"
"618" "CPI-169" "histone lysine methyltransferase inhibitor" "EZH2" "" "" "BRD-K97181972-001-01-9" "CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12" "LHGUZCKPFXXVPV-GOSISDBHSA-N" "Preclinical"
"619" "CPI-203" "bromodomain inhibitor" "BRD4" "" "" "BRD-K15811707-001-01-2" "Cc1sc-2c(c1C)C(=N[C@@H](CC(N)=O)c1nnc(C)n-21)c1ccc(Cl)cc1" "QECMENZMDBOLDR-AWEZNQCLSA-N" "Preclinical"
"620" "CPI-360" "histone lysine methyltransferase inhibitor" "EZH2" "" "" "BRD-K18319422-001-01-7" "COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12" "PFPSFENQCNMITC-MRXNPFEDSA-N" "Preclinical"
"621" "CPI-613" "pyruvate dehydrogenase inhibitor" "PDHA1" "" "" "BRD-A06916187-001-02-9" "OC(=O)CCCCC(CCSCc1ccccc1)SCc1ccccc1" "ZYRLHJIMTROTBO-UHFFFAOYSA-N" "Phase 2"
"622" "CPP" "glutamate receptor antagonist" "GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D" "" "" "BRD-A60832661-001-01-8, BRD-K66094457-001-01-5" "OC(=O)C1CN(CCCP(O)(O)=O)CCN1, OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1" "CUVGUPIVTLGRGI-UHFFFAOYSA-N, CUVGUPIVTLGRGI-SSDOTTSWSA-N" "Phase 2"
"623" "creatine" "" "CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8" "" "" "BRD-K19615002-001-02-3" "CN(CC(O)=O)C(N)=N" "CVSVTCORWBXHQV-UHFFFAOYSA-N" "Launched"
"624" "creatinine" "" "" "" "" "BRD-K13495773-001-11-4, BRD-K13495773-001-12-2" "CN1CC(=O)NC1=N, CN1CC(=O)NC1=N" "DDRJAANPRJIHGJ-UHFFFAOYSA-N, DDRJAANPRJIHGJ-UHFFFAOYSA-N" "Preclinical"
"625" "creatinol-phosphate" "" "" "" "" "BRD-K42991124-001-03-0" "CN(CCOP(O)(O)=O)C(N)=N" "FOIPWTMKYXWFGC-UHFFFAOYSA-N" "Launched"
"626" "crenolanib" "PDGFR tyrosine kinase receptor inhibitor" "CSF1R, FLT3, KIT, PDGFRA, PDGFRB" "" "" "BRD-K22127577-001-03-7, BRD-K22127577-001-02-9" "CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1, CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1" "DYNHJHQFHQTFTP-UHFFFAOYSA-N, DYNHJHQFHQTFTP-UHFFFAOYSA-N" "Phase 2"
"627" "cresol" "" "" "" "" "BRD-K56940914-001-04-2" "Cc1ccc(O)cc1" "IWDCLRJOBJJRNH-UHFFFAOYSA-N" "Launched"
"628" "cresopirine" "" "" "" "" "BRD-K58648841-001-04-7" "CC(=O)Oc1c(C)cccc1C(O)=O" "XRBMKGUDDJPAMH-UHFFFAOYSA-N" "Preclinical"
"629" "cridanimod" "progesterone receptor agonist" "PGR" "" "" "BRD-K97939847-001-12-0, BRD-K97939847-001-11-2" "OC(=O)Cn1c2ccccc2c(=O)c2ccccc12, OC(=O)Cn1c2ccccc2c(=O)c2ccccc12" "UOMKBIIXHQIERR-UHFFFAOYSA-N, UOMKBIIXHQIERR-UHFFFAOYSA-N" "Launched"
"630" "crisaborole" "phosphodiesterase inhibitor" "PDE4B" "" "" "BRD-K43230258-001-01-4" "OB1OCc2cc(Oc3ccc(cc3)C" "" ""
"631" "crizotinib" "ALK tyrosine kinase receptor inhibitor" "ALK, MET" "oncology" "non-small cell lung cancer (NSCLC)" "BRD-K78431006-001-11-0, BRD-K78431006-001-10-2" "C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl" "KTEIFNKAUNYNJU-GFCCVEGCSA-N, KTEIFNKAUNYNJU-GFCCVEGCSA-N" "Launched"
"632" "crizotinib-(S)" "MTH1 inhibitor" "NUDT1" "" "" "BRD-K40308497-001-01-2, BRD-A75349800-001-01-8" "C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, CC(Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl" "KTEIFNKAUNYNJU-LBPRGKRZSA-N, KTEIFNKAUNYNJU-UHFFFAOYSA-N" "Preclinical"
"633" "croconazole" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-K73701464-003-01-3" "Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1" "WHPAGCJNPTUGGD-UHFFFAOYSA-N" "Launched"
"634" "cromoglicic-acid" "immunosuppressant" "KCNMA1, S100P" "pulmonary, ophthalmology, allergy, gastroenterology" "asthma, conjunctivitis, urticaria, ulcerative colitis" "BRD-K20920669-304-09-1, BRD-K20920669-304-10-9" "OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O, OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O" "IMZMKUWMOSJXDT-UHFFFAOYSA-N, IMZMKUWMOSJXDT-UHFFFAOYSA-N" "Launched"
"635" "crotamiton" "antipruritic" "" "infectious disease" "scabies" "BRD-K57179821-001-15-4" "CCN(C(=O)\C=C\C)c1ccccc1C" "DNTGGZPQPQTDQF-XBXARRHUSA-N" "Launched"
"636" "CRT0044876" "" "" "" "" "BRD-K02816415-001-01-9" "OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1" "BIUCOFQROHIAEO-UHFFFAOYSA-N" "Preclinical"
"637" "cryptotanshinone" "acetylcholinesterase inhibitor, STAT inhibitor" "STAT3" "" "" "BRD-K33336844-001-09-5, BRD-K33336844-001-10-3, BRD-K53562481-001-01-6" "C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C, C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C, C[C@@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C" "GVKKJJOMQCNPGB-JTQLQIEISA-N, GVKKJJOMQCNPGB-JTQLQIEISA-N, GVKKJJOMQCNPGB-SNVBAGLBSA-N" "Preclinical"
"638" "crystal-violet" "other antibiotic" "" "" "" "BRD-K60025295-003-06-6, BRD-K60025295-003-07-4, BRD-K60025295-003-05-8" "CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C, CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C" "LGLFFNDHMLKUMI-UHFFFAOYSA-N, LGLFFNDHMLKUMI-UHFFFAOYSA-N, LGLFFNDHMLKUMI-UHFFFAOYSA-N" "Launched"
"639" "CR8-(R)" "CDK inhibitor" "CCNA2" "" "" "BRD-K40331046-305-01-5" "CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1" "HOCBJBNQIQQQGT-LJQANCHMSA-N" "Preclinical"
"640" "CS-110266" "dopamine receptor agonist" "SLC6A3" "" "" "BRD-K15519488-050-01-3" "C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1" "RGSVXQJPSWZXOP-UHFFFAOYSA-N" "Preclinical"
"641" "CS-917" "fructose biphosphate inhibitor" "FBP1" "" "" "BRD-K35601925-001-02-7, BRD-K35601925-001-01-9" "CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O, CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O" "XJMYIJPPDSZOPN-UHFFFAOYSA-N, XJMYIJPPDSZOPN-UHFFFAOYSA-N" "Phase 2"
"642" "CT-7758" "integrin antagonist" "ITGA4" "" "" "BRD-K40870905-001-01-7" "OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1" "KYHVWHYLKOHLKA-FQEVSTJZSA-N" "Phase 2"
"643" "CTEP" "glutamate receptor antagonist" "GRM5" "" "" "BRD-K30572193-001-02-0" "Cc1nc(C" "" ""
"644" "CTS-1027" "metalloproteinase inhibitor" "MMP1, MMP13, MMP2, MMP3, MMP9" "" "" "BRD-K53508936-001-01-0" "ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1" "ROSNVSQTEGHUKU-UHFFFAOYSA-N" "Phase 2"
"645" "CTS21166" "beta-secretase inhibitor" "BACE1" "" "" "BRD-K89071957-001-01-1" "CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O" "NIOCOJFPGCXNKL-ZKZXETMPSA-N" "Phase 1"
"646" "CUDC-101" "EGFR inhibitor" "EGFR, ERBB2" "" "" "BRD-K41278234-001-03-0" "COc1cc2ncnc(Nc3cccc(c3)C" "" ""
"647" "CUDC-427" "apoptosis inhibitor" "XIAP" "" "" "BRD-K69351586-001-01-0" "CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1" "HSHPBORBOJIXSQ-HARLFGEKSA-N" "Phase 1"
"648" "CUDC-907" "PI3K inhibitor" "HDAC2, PIK3R1" "" "" "BRD-K77638923-001-02-0" "COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1" "JOWXJLIFIIOYMS-UHFFFAOYSA-N" "Phase 2"
"649" "CUR-61414" "smoothened receptor antagonist" "DHH, IHH, SMO" "" "" "BRD-K69624312-001-01-1" "COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1" "WPHXYKUPFJRJDK-AHWVRZQESA-N" "Phase 1"
"650" "curcumin" "cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor" "APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH" "" "" "BRD-K07572174-001-39-4, BRD-K69690935-001-03-5, BRD-K07572174-001-38-6" "COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1, COc1ccc(C=CC(=O)CC(=O)C=Cc2cccc(O)c2OC)cc1O, COc1cc(ccc1O)\C=C\C(=O)CC(=O)\C=C\c1ccc(O)c(OC)c1" "VFLDPWHFBUODDF-FCXRPNKRSA-N, VZMSCIKIANDZNI-UHFFFAOYSA-N, VFLDPWHFBUODDF-FCXRPNKRSA-N" "Launched"
"651" "curcumol" "JAK inhibitor" "JAK1, JAK2, JAK3" "" "" "BRD-K41933240-001-02-4, BRD-K07241895-001-01-4" "CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C, CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@H]3C" "QRMPRVXWPCLVNI-YYFQZIEXSA-N, QRMPRVXWPCLVNI-CAEXGNQWSA-N" "Phase 1"
"652" "cutamesine" "sigma receptor agonist" "SIGMAR1" "" "" "BRD-K90777969-300-01-2, BRD-K90777969-300-02-0" "COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC, COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC" "UVSWWUWQVAQPJR-UHFFFAOYSA-N, UVSWWUWQVAQPJR-UHFFFAOYSA-N" "Phase 2"
"653" "CV-1808" "adenosine receptor agonist" "ADORA2A" "" "" "BRD-K49197823-001-09-8" "Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O" "SCNILGOVBBRMBK-SDBHATRESA-N" "Preclinical"
"654" "CVT-10216" "aldehyde dehydrogenase inhibitor" "ALDH2" "" "" "BRD-K60659193-001-02-8, BRD-K60659193-001-01-0" "CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O, CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O" "YYOOFJZTRCPVFD-UHFFFAOYSA-N, YYOOFJZTRCPVFD-UHFFFAOYSA-N" "Phase 1"
"655" "CX-4945" "casein kinase inhibitor" "CSNK2A1, CSNK2A2, DAPK3, HIPK3" "" "" "BRD-K81458380-001-04-9" "OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21" "MUOKSQABCJCOPU-UHFFFAOYSA-N" "Phase 1/Phase 2"
"656" "CX-516" "glutamate receptor modulator" "" "" "" "BRD-K25140590-001-03-0" "O=C(N1CCCCC1)c1ccc2OCOc2c1" "BXBNADAPIHHXJQ-UHFFFAOYSA-N" "Phase 2/Phase 3"
"657" "CX-5461" "RNA polymerase inhibitor" "" "" "" "BRD-K12787259-001-04-3" "CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O" "XGPBJCHFROADCK-UHFFFAOYSA-N" "Phase 1"
"658" "cyacetacide" "" "" "" "" "BRD-K39371216-001-01-3" "NNC(=O)CC" "" ""
"659" "cyamemazine" "serotonin receptor antagonist" "HTR1A, HTR2A, HTR2C, HTR7" "neurology/psychiatry" "schizophrenia, anxiety" "BRD-A42881122-001-01-1" "CC(CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C" "" ""
"660" "cyanocobalamin" "methylmalonyl CoA mutase stimulant, vitamin B" "MMAA, MMACHC, MTHFR, MTR, MTRR, MUT" "hematology, infectious disease, gastroenterology" "anemia, fish tapeworm infestation, celiac disease" "BRD-A97502381-001-01-3, BRD-A59561452-001-01-9" "C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@@H]2[N+]3=C1C(C)=C1[C@@H](CCC(N)=O)C(C)(C)C4=[N+]1[Co]31(C" "" ""
"661" "cyanopindolol" "adrenergic receptor antagonist" "ADRB1, HTR1A, HTR1D" "" "" "BRD-A47884604-051-01-2" "CC(C)(C)NCC(O)COc1cccc2[nH]c(cc12)C" "" ""
"662" "cyclamic-acid" "" "" "" "" "BRD-K50785021-001-02-1, BRD-K50785021-001-03-9, BRD-K50785021-001-04-7" "OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1, OS(=O)(=O)NC1CCCCC1" "HCAJEUSONLESMK-UHFFFAOYSA-N, HCAJEUSONLESMK-UHFFFAOYSA-N, HCAJEUSONLESMK-UHFFFAOYSA-N" "Preclinical"
"663" "cyclandelate" "calcium channel blocker" "CACNA2D1, CES1" "cardiology, rheumatology" "claudication, arteriosclerosis, Raynauds disease	BRD-A27370296-001-04-8, BRD-A27370296-001-03-0, BRD-A27370296-001-02-2	CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1, CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1, CC1CC(CC(C)(C)C1)OC(=O)C(O)c1ccccc1	WZHCOOQXZCIUNC-UHFFFAOYSA-N, WZHCOOQXZCIUNC-UHFFFAOYSA-N, WZHCOOQXZCIUNC-UHFFFAOYSA-N	Launched
cyclic-AMP		CNGA3, HCN2, PRKAR1A, PRKAR2B, TRPM7			BRD-A41840684-001-01-8	Nc1ncnc2n(cnc12)C1OC2COP(O)(=O)OC2C1O	IVOMOUWHDPKRLL-UHFFFAOYSA-N	Preclinical
cyclizine	histamine receptor modulator	HRH1, SULT1E1	gastroenterology, neurology/psychiatry	nausea, vomiting, vertigo, motion sickness	BRD-K79501723-001-04-6, BRD-K79501723-300-01-8	CN1CCN(CC1)C(c1ccccc1)c1ccccc1, CN1CCN(CC1)C(c1ccccc1)c1ccccc1	UVKZSORBKUEBAZ-UHFFFAOYSA-N, UVKZSORBKUEBAZ-UHFFFAOYSA-N	Launched
cyclobenzaprine	adrenergic receptor agonist, serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	BRD-K42348709-003-13-1	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12	JURKNVYFZMSNLP-UHFFFAOYSA-N	Launched
cyclocreatine	creatine kinase substrate				BRD-K14379200-001-04-7	OC(=O)CN1CCNC1=N	AMHZIUVRYRVYBA-UHFFFAOYSA-N	Phase 1
cyclocytidine	DNA synthesis inhibitor, RNA synthesis inhibitor				BRD-K81021983-003-02-6, BRD-K80834753-003-01-3	OC[C@@H]1O[C@H]2[C@H](Oc3nc(=N)ccn23)[C@H]1O, OC[C@H]1O[C@@H]2[C@H](Oc3nc(=N)ccn23)[C@H]1O	BBDAGFIXKZCXAH-JPCMASIJSA-N, BBDAGFIXKZCXAH-PXBUCIJWSA-N	Preclinical
cycloheximide	protein synthesis inhibitor	RPL3			BRD-K36055864-001-20-0, BRD-K36055864-001-19-2	C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1, C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	YPHMISFOHDHNIV-FSZOTQKASA-N, YPHMISFOHDHNIV-FSZOTQKASA-N	Preclinical
cyclopenthiazide	thiazide diuretic		cardiology	hypertension, congestive heart failure	BRD-A41250306-001-11-7	NS(=O)(=O)c1cc2c(NC(CC3CCCC3)NS2(=O)=O)cc1Cl	BKYKPTRYDKTTJY-UHFFFAOYSA-N	Launched
cyclopentolate	acetylcholine receptor antagonist	CHRM1	ophthalmology	mydriasis, cycloplegia	BRD-A77291778-003-22-0	CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1	SKYSRIRYMSLOIN-UHFFFAOYSA-N	Launched
cyclophosphamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7	hematologic malignancy, oncology	Hodgkins lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitts lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer	BRD-A09722536-002-19-8, BRD-A09722536-002-18-0, BRD-A09722536-002-17-2	ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1	CMSMOCZEIVJLDB-UHFFFAOYSA-N, CMSMOCZEIVJLDB-UHFFFAOYSA-N, CMSMOCZEIVJLDB-UHFFFAOYSA-N	Launched
cyclopiazonic-acid	ATPase inhibitor	ATP2A1			BRD-A10420615-001-04-4	CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O	TZCOBUQKVNFIQF-ARUUDZKJSA-N	Preclinical
cycloserine-(d)	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis	BRD-K87226815-001-17-1, BRD-K87226815-001-18-9, BRD-K87226815-001-20-5, BRD-K87226815-001-19-7	N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O, N[C@@H]1CONC1=O	DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N, DYDCUQKUCUHJBH-UWTATZPHSA-N	Launched
cyclosporin-a	calcineurin inhibitor	PPP3CA	rheumatology, dermatology	rheumatoid arthritis, psoriasis	BRD-A69815203-001-08-4, BRD-A69815203-001-07-6	CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C(C(O)C(C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PMATZTZNYRCHOR-IMVLJIQESA-N, PMATZTZNYRCHOR-IMVLJIQESA-N	Launched
cyclosporine	calcineurin inhibitor	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	transplant, rheumatology, dermatology	organ rejection, rheumatoid arthritis, psoriasis	BRD-K03152136-001-01-6, BRD-A11864475-001-02-5	CC[C@@H]1NC(=O)[C@@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCC1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PMATZTZNYRCHOR-ONJQHLSTSA-N, PMATZTZNYRCHOR-KMSBSJHKSA-N	Launched
cyclothiazide	glutamate receptor modulator	CA1, CA2, CA4, FXYD2, GRIA1, GRIA2, GRIA3, GRIA4, SLC12A3	cardiology	hypertension	BRD-A38675539-001-12-7, BRD-A38675539-001-11-9, BRD-A38675539-001-10-1, BRD-A38639147-001-17-6	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C2CC3CC2C=C3)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C2CC3CC2C=C3)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C2CC3CC2C=C3)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C2C[C@@H]3C[C@H]2C=C3)cc1Cl	BOCUKUHCLICSIY-UHFFFAOYSA-N, BOCUKUHCLICSIY-UHFFFAOYSA-N, BOCUKUHCLICSIY-UHFFFAOYSA-N, BOCUKUHCLICSIY-QJWLJZLASA-N	Launched
cyclovalone	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	BRD-K59866480-001-07-3, BRD-K84397942-001-01-3	COc1cc(ccc1O)\C=C1/CCC\C(C1=O)=C/c1ccc(O)c(OC)c1, COc1cc(ccc1O)\C=C1\CCC\C(C1=O)=C\c1ccc(O)c(OC)c1	DHKKONBXGAAFTB-OTYYAQKOSA-N, DHKKONBXGAAFTB-APGQMXJTSA-N	Launched
cyclovirobuxin-d	calcium channel modulator				BRD-K27799744-001-02-8, BRD-K35479987-001-01-5	CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C, CN[C@@H](C)[C@@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@]35CC[C@]12C)CC[C@H](NC)C4(C)C	GMNAPBAUIVITMI-ABNIRSKTSA-N, GMNAPBAUIVITMI-QNSOQNAKSA-N	Preclinical
CYC116	Aurora kinase inhibitor	AURKA, AURKB, KDR			BRD-K64866502-001-04-7, BRD-K64866502-001-03-9	Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	GPSZYOIFQZPWEJ-UHFFFAOYSA-N, GPSZYOIFQZPWEJ-UHFFFAOYSA-N	Phase 1
cypermethrin					BRD-A62798249-001-04-4	CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)c1cccc(Oc2ccccc2)c1	KAATUXNTWXVJKI-UHFFFAOYSA-N	Launched
cyproheptadine	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	BRD-K28143534-001-02-2, BRD-K28143534-003-25-9, BRD-K28143534-003-24-2, BRD-K28143534-003-26-7	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12, CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12	JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N, JJCFRYNCJDLXIK-UHFFFAOYSA-N	Launched
cyproterone	androgen receptor antagonist	AR	oncology	prostate cancer	BRD-A48103086-001-04-2	CC(=O)[C@@]1(O)CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5CC5[C@]4(C)C3CC[C@]12C	DUSHUSLJJMDGTE-AVWUXPBGSA-N	Launched
cyproterone-acetate	androgen receptor antagonist	ADORA1, AR	oncology	prostate cancer	BRD-K41141507-001-15-4, BRD-K59573506-001-01-8, BRD-A95207036-001-04-4	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@H]5[C@]4(C)[C@@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)C3CC[C@]12C)C(C)=O	UWFYSQMTEOIJJG-FDTZYFLXSA-N, UWFYSQMTEOIJJG-KTIWLQMPSA-N, UWFYSQMTEOIJJG-WMANOXGZSA-N	Launched
cyromazine					BRD-K36711084-001-02-0, BRD-K36711084-001-01-2	Nc1nc(N)nc(NC2CC2)n1, Nc1nc(N)nc(NC2CC2)n1	LVQDKIWDGQRHTE-UHFFFAOYSA-N, LVQDKIWDGQRHTE-UHFFFAOYSA-N	Launched
cysteamine	tissue transglutaminase inhibitor	NPY2R, SST	metabolism	cystinosis	BRD-K92611362-001-02-6, BRD-M77687198-001-10-6, BRD-M77687198-001-12-2	NCCS, Cl.NCCS, Cl.NCCS	UFULAYFCSOUIOV-UHFFFAOYSA-N, OGMADIBCHLQMIP-UHFFFAOYSA-N, OGMADIBCHLQMIP-UHFFFAOYSA-N	Launched
CYT-997	tubulin polymerization inhibitor	TUBB			BRD-K23363278-001-02-1	CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	MTJHLONVHHPNSI-IBGZPJMESA-N	Phase 2
cytarabine	ribonucleotide reductase inhibitor	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	BRD-K33106058-001-16-8, BRD-K71847383-001-07-5, BRD-A57371185-001-04-3	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ccn(C2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	UHDGCWIWMRVCDJ-CCXZUQQUSA-N, UHDGCWIWMRVCDJ-XVFCMESISA-N, UHDGCWIWMRVCDJ-STUHELBRSA-N	Launched
cytisine	acetylcholine receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4	neurology/psychiatry	nicotinism	BRD-K74186897-001-12-4, BRD-A55579717-001-04-0, BRD-K74186897-001-11-6, BRD-K74186897-001-10-8	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2C3CNC[C@@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12, O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-VEDVMXKPSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N, ANJTVLIZGCUXLD-DTWKUNHWSA-N	Launched
cytochalasin-b	microtubule inhibitor	ACTB			BRD-K47000838-001-01-6	C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C	GBOGMAARMMDZGR-FFXRSMCQSA-N	Phase 2
cytochlor					BRD-K48988407-001-01-2	Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	NGGRGTWYSXYVDK-FSDSQADBSA-N	Phase 1
cyt387		JAK1, JAK2, JAK3			BRD-K87737963-001-07-8, BRD-K87737963-001-06-0	O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	ZVHNDZWQTBEVRY-UHFFFAOYSA-N, ZVHNDZWQTBEVRY-UHFFFAOYSA-N	Phase 3
CY208-243	dopamine receptor agonist	CALY			BRD-K79353516-001-05-0, BRD-K79353516-001-04-3	CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	WRNKIDLXXXIELU-IEBWSBKVSA-N, WRNKIDLXXXIELU-IEBWSBKVSA-N	Phase 2
CZC24832	PI3K inhibitor	PIK3CG			BRD-K01377300-001-02-9, BRD-K01377300-001-01-1	CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1, CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	RXRZPHQBTHQXSV-UHFFFAOYSA-N, RXRZPHQBTHQXSV-UHFFFAOYSA-N	Preclinical
C106					BRD-M12328004-001-01-8	CN1CCCC1c1cccnc1.Cc1ccc(cc1)C(=O)OC(C(OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O	GEGPCGHEPLKDLY-UHFFFAOYSA-N	Phase 3
C11-Acetate		ABAT, ACE, AKR1C3, CA2, CELA1, ESR2, FFAR2, FFAR3, HPRT1, LTA4H, MMP12, NOS1, NOS3, PLA2G1B, PTPN1, SOD1, TXN			BRD-K83914624-415-01-3	[Y+3]	GRTBAGCGDOYUBE-UHFFFAOYSA-N	Phase 3
C646	histone acetyltransferase inhibitor	EP300			BRD-K19202888-001-01-1, BRD-K68548958-001-04-6	CC1=NN(C(=O)C\1=C/c1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O, CC1=NN(C(=O)C\1=C\c1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O	HEKJYZZSCQBJGB-UNOMPAQXSA-N, HEKJYZZSCQBJGB-XDHOZWIPSA-N	Preclinical
D-(+)-maltose		AMY2B, MGAM			BRD-K74377520-001-01-7	OC[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	GUBGYTABKSRVRQ-QUYVBRFLSA-N	Preclinical
D-alpha-tocopheryl-succinate					BRD-K64636206-001-02-7	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1	IELOKBJPULMYRW-NJQVLOCASA-N	Launched
D-delta-Tocopherol					BRD-K04657451-001-01-0	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1	GZIFEOYASATJEH-VHFRWLAGSA-N	Launched
D-limonene					BRD-A81494260-001-02-5, BRD-K20879694-001-01-7	CC(=C)C1CCC(C)=CC1, CC(=C)[C@@H]1CCC(C)=CC1	XMGQYMWWDOXHJM-UHFFFAOYSA-N, XMGQYMWWDOXHJM-JTQLQIEISA-N	Phase 1
D-Phenylalanine	enkephalinase inhibitor	CCBL1, CRH, HCAR3			BRD-K00911807-001-04-0, BRD-K00911807-003-01-2, BRD-K00911807-001-03-2	N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O, N[C@H](Cc1ccccc1)C(O)=O	COLNVLDHVKWLRT-MRVPVSSYSA-N, COLNVLDHVKWLRT-MRVPVSSYSA-N, COLNVLDHVKWLRT-MRVPVSSYSA-N	Preclinical
D-Serine	glutamate receptor agonist	GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3			BRD-K71822263-001-03-2	N[C@H](CO)C(O)=O	MTCFGRXMJLQNBG-UWTATZPHSA-N	Launched
D-4476	TGF beta receptor inhibitor	CSNK1A1, CSNK1D, TGFB1			BRD-K09132007-001-07-5	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1	DPDZHVCKYBCJHW-UHFFFAOYSA-N	Preclinical
D-64131	microtubule inhibitor	TUBB			BRD-K26997899-001-02-2	COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	ICMIJSRDISNKOC-UHFFFAOYSA-N	Preclinical
D-7193					BRD-K32372024-001-01-0	CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	YTPQSLLEROSACP-YUMQZZPRSA-N	Phase 2
DAA-1106	benzodiazepine receptor agonist	TSPO			BRD-K01080633-001-01-9	COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	DCRZYADKQRHHSF-UHFFFAOYSA-N	Preclinical
dabigatran	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	BRD-K38168441-001-03-7, BRD-K38168441-001-02-9, BRD-K38168441-001-04-5	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1, Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N, YBSJFWOBGCMAKL-UHFFFAOYSA-N	Launched
dabigatran-etexilate	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	BRD-K57041787-001-02-6, BRD-K57041787-066-01-1	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1, CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	KSGXQBZTULBEEQ-UHFFFAOYSA-N, KSGXQBZTULBEEQ-UHFFFAOYSA-N	Launched
dabrafenib	RAF inhibitor	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	BRD-K09951645-001-08-4, BRD-K09951645-001-06-8, BRD-K09951645-001-11-8	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N, BFSMGDJOXZAERB-UHFFFAOYSA-N	Launched
dacarbazine	DNA alkylating agent	PGD, POLA2	oncology, hematologic malignancy	melanoma, Hodgkins lymphoma" "BRD-K35520305-001-17-7, BRD-K35520305-001-16-9" "CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O" "FDKXTQMXEQVLRF-ZHACJKMWSA-N, FDKXTQMXEQVLRF-ZHACJKMWSA-N" "Launched"
"664" "dacinostat" "HDAC inhibitor" "HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9" "" "" "BRD-K56957086-001-09-7, BRD-K56957086-001-06-3" "OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1, OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1" "BWDQBBCUWLSASG-MDZDMXLPSA-N, BWDQBBCUWLSASG-MDZDMXLPSA-N" "Phase 1"
"665" "daclatasvir" "HCV inhibitor" "" "infectious disease" "hepatitis C" "BRD-K82861010-001-02-5" "COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C" "FKRSSPOQAMALKA-CUPIEXAXSA-N" "Launched"
"666" "dacomitinib" "EGFR inhibitor" "EGFR, ERBB2, ERBB4" "" "" "BRD-K57169635-001-04-5" "COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1" "LVXJQMNHJWSHET-AATRIKPKSA-N" "Phase 3"
"667" "dactinomycin" "RNA polymerase inhibitor" "POLR2A" "oncology" "testicular carcinoma, Wilms tumor, rhabdomyosarcoma, Ewings sarcoma, gestational trophoblastic disease (GTD)" "BRD-K70578146-001-06-7" "CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O" "RJURFGZVJUQBHK-IIXSONLDSA-N" "Launched"
"668" "daidzein" "estrogen receptor agonist" "ESRRA, ESRRB, ESRRG, TRPC5" "" "" "BRD-K42095107-001-21-3, BRD-K42095107-001-17-1, BRD-K42095107-001-16-3, BRD-K42095107-001-18-9" "Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O, Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O" "ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N, ZQSIJRDFPHDXIC-UHFFFAOYSA-N" "Phase 2"
"669" "dalargin" "opioid receptor agonist" "OPRM1" "" "" "BRD-A89196962-300-01-7" "CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)C(N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O" "GDPHPXYFLPDZGH-VSZNVKCOSA-N" "Phase 2"
"670" "dalbavancin" "bacterial cell wall synthesis inhibitor" "PNLIP" "infectious disease" "skin infections" "BRD-K30177383-001-01-0" "CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2" "KGPGQDLTDHGEGT-SZUNQUCBSA-N" "Launched"
"671" "dalcetrapib" "cholesteryl ester transfer protein inhibitor" "CETP" "" "" "BRD-K18849474-001-04-4, BRD-K18849474-001-03-6" "CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C, CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C" "YZQLWPMZQVHJED-UHFFFAOYSA-N, YZQLWPMZQVHJED-UHFFFAOYSA-N" "Phase 3"
"672" "dalfampridine" "potassium channel blocker" "KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2" "neurology/psychiatry" "multiple sclerosis" "BRD-K22482860-001-21-4, BRD-K22482860-001-20-6" "Nc1ccncc1, Nc1ccncc1" "NUKYPUAOHBNCPY-UHFFFAOYSA-N, NUKYPUAOHBNCPY-UHFFFAOYSA-N" "Launched"
"673" "daltroban" "thromboxane receptor antagonist" "TBXA2R" "" "" "BRD-K26813177-001-03-2" "OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1" "IULOBWFWYDMECP-UHFFFAOYSA-N" "Phase 3"
"674" "danazol" "estrogen receptor antagonist, progesterone receptor agonist" "AR, CCL2, ESR1, GNRHR, GNRHR2, PGR" "obstetrics/gynecology, cardiology" "endometriosis, angioedema" "BRD-A92537424-001-04-7" "C[C@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C1CC[C@@]2(O)C" "" ""
"675" "danegaptide" "gap junction modulator" "" "" "" "BRD-K35589454-003-01-1" "NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1" "BIZKIHUJGMSVFD-MNOVXSKESA-N" "Phase 2"
"676" "danirixin" "CC chemokine receptor antagonist" "CXCR2" "" "" "BRD-K13769342-001-01-5" "Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1" "NGYNBSHYFOFVLS-LBPRGKRZSA-N" "Phase 2"
"677" "danofloxacin" "bacterial DNA gyrase inhibitor" "" "pulmonary" "bovine respiratory disease (BRD)" "BRD-K45916615-066-02-5" "CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1" "QMLVECGLEOSESV-RYUDHWBXSA-N" "Launched"
"678" "danoprevir" "HCV inhibitor" "" "" "" "BRD-K08111240-001-02-8" "CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1" "ZVTDLPBHTSMEJZ-JSZLBQEHSA-N" "Phase 2"
"679" "dantrolene" "calcium channel blocker" "RYR1, RYR3" "neurology/psychiatry, endocrinology" "spasms, malignant hyperthermia (MH)" "BRD-K81272440-236-13-5, BRD-K81272440-236-12-7" "[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1" "OZOMQRBLCMDCEG-VIZOYTHASA-N, OZOMQRBLCMDCEG-VIZOYTHASA-N" "Launched"
"680" "dantron" "laxative" "" "" "" "BRD-K10065684-001-07-4" "Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12" "QBPFLULOKWLNNW-UHFFFAOYSA-N" "Withdrawn"
"681" "danusertib" "Aurora kinase inhibitor, growth factor receptor inhibitor" "AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK" "" "" "BRD-K07881437-001-04-6, BRD-K07881437-001-03-8" "CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1, CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1" "XKFTZKGMDDZMJI-HSZRJFAPSA-N, XKFTZKGMDDZMJI-HSZRJFAPSA-N" "Phase 2"
"682" "dapagliflozin" "sodium/glucose cotransporter inhibitor" "SLC5A1, SLC5A2" "endocrinology" "diabetes mellitus" "BRD-K46604138-001-01-3, BRD-K58160573-001-04-7" "CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc1, CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1" "JVHXJTBJCFBINQ-MJCUULBUSA-N, JVHXJTBJCFBINQ-ADAARDCZSA-N" "Launched"
"683" "daphnetin" "protein kinase inhibitor" "" "" "" "BRD-K61269089-001-05-5" "Oc1ccc2ccc(=O)oc2c1O" "ATEFPOUAMCWAQS-UHFFFAOYSA-N" "Preclinical"
"684" "dapiprazole" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D" "ophthalmology" "mydriasis" "BRD-K33133047-001-01-8" "Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1" "RFWZESUMWJKKRN-UHFFFAOYSA-N" "Launched"
"685" "dapivirine" "non-nucleoside reverse transcriptase inhibitor" "CYP3A4, CYP3A5" "" "" "BRD-K12885236-001-02-7" "Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C" "" ""
"686" "dapoxetine" "selective serotonin reuptake inhibitor (SSRI)" "HTR1A, HTR1B, HTR2C, SLC6A4" "urology" "premature ejaculation (PE)" "BRD-K51579475-003-02-4" "CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1" "USRHYDPUVLEVMC-FQEVSTJZSA-N" "Launched"
"687" "daprodustat" "hypoxia inducible factor inhibitor" "EGLN1" "" "" "BRD-K06455935-001-01-3" "OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O" "RUEYEZADQJCKGV-UHFFFAOYSA-N" "Phase 3"
"688" "dapsone" "bacterial antifolate" "DHFR" "dermatology, infectious disease" "dermatitis herpetiformis (DH), leprosy" "BRD-K62363391-001-24-9" "Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1" "MQJKPEGWNLWLTK-UHFFFAOYSA-N" "Launched"
"689" "DAPT" "gamma secretase inhibitor" "" "" "" "BRD-K47177710-001-03-1, BRD-K47177710-001-02-3" "C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1, C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1" "DWJXYEABWRJFSP-XOBRGWDASA-N, DWJXYEABWRJFSP-XOBRGWDASA-N" "Preclinical"
"690" "daptomycin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections, endocarditis" "BRD-K94358652-001-02-1, BRD-K25021320-001-01-3" "CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O, CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCCN)NC(=O)CNC1=O)[C@@H](C)CC(O)=O" "DOAKLVKFURWEDJ-QAMDLYIKSA-N, DOAKLVKFURWEDJ-VAJASXOXSA-N" "Launched"
"691" "darapladib" "phospholipase inhibitor" "PLA2G7" "" "" "BRD-K19085898-001-01-8" "CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1" "WDPFJWLDPVQCAJ-UHFFFAOYSA-N" "Phase 3"
"692" "darglitazone" "PPAR receptor antagonist" "PPARG" "" "" "BRD-K82908348-001-01-9" "Cc1oc(nc1CCC(=O)c1ccc(Cc2sc(O)nc2O)cc1)-c1ccccc1" "BUWFKENPFXXWGV-UHFFFAOYSA-N" "Phase 2"
"693" "darifenacin" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "urology" "urinary incontinence" "BRD-K95773607-004-03-8, BRD-A01118042-004-01-8" "NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1, NC(=O)C(C1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1" "HXGBXQDTNZMWGS-RUZDIDTESA-N, HXGBXQDTNZMWGS-UHFFFAOYSA-N" "Launched"
"694" "darunavir" "HIV protease inhibitor" "CYP3A4" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K84986517-001-01-8" "CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1" "CJBJHOAVZSMMDJ-HEXNFIEUSA-N" "Launched"
"695" "darusentan" "endothelin receptor antagonist" "EDNRA" "" "" "BRD-K54863166-001-01-9" "COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1" "FEJVSJIALLTFRP-LJQANCHMSA-N" "Phase 3"
"696" "dasabuvir" "HCV inhibitor" "" "infectious disease" "hepatitis C" "BRD-K02943813-001-01-9" "COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1" "NBRBXGKOEOGLOI-UHFFFAOYSA-N" "Launched"
"697" "dasatinib" "Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor" "ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1" "hematologic malignancy" "chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)" "BRD-K49328571-001-15-0, BRD-K49328571-001-19-2" "Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1" "ZBNZXTGUTAYRHI-UHFFFAOYSA-N, ZBNZXTGUTAYRHI-UHFFFAOYSA-N" "Launched"
"698" "DAU-5884" "acetylcholine receptor antagonist" "CHRM3" "" "" "BRD-K31633810-003-02-8" "CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O" "NWXCDQHBVVPPTL-WDNDVIMCSA-N" "Preclinical"
"699" "daucosterol" "apoptosis stimulant" "" "" "" "BRD-K14276241-001-01-2" "CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C" "NPJICTMALKLTFW-OFUAXYCQSA-N" "Phase 2"
"700" "daunorubicin" "RNA synthesis inhibitor, topoisomerase inhibitor" "TOP2A, TOP2B" "hematologic malignancy" "acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)" "BRD-K43389675-003-16-7, BRD-A68009927-003-03-7, BRD-K43389675-001-02-1, BRD-K91966436-003-02-3" "COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](OC5CC(N)C(O)C(C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O" "STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-JYZNYWJRSA-N, STQGQHZAVUOBTE-VGBVRHCVSA-N, STQGQHZAVUOBTE-INJOJONLSA-N" "Launched"
"701" "dazmegrel" "thromboxane synthase inhibitor" "TBXAS1" "" "" "BRD-K20738689-001-01-2" "Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O" "DEQLGSOHGTZKFB-UHFFFAOYSA-N" "Phase 2"
"702" "dazoxiben" "thromboxane synthase inhibitor" "TBXAS1" "" "" "BRD-K82767007-001-01-1" "OC(=O)c1ccc(OCCn2ccnc2)cc1" "XQGZSYKGWHUSDH-UHFFFAOYSA-N" "Phase 2"
"703" "DBeQ" "ATPase inhibitor" "CASP3" "" "" "BRD-K59204667-001-03-1" "C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1" "QAIMUUJJAJBPCL-UHFFFAOYSA-N" "Preclinical"
"704" "DBPR108" "dipeptidyl peptidase inhibitor" "DPP4" "" "" "BRD-K83020231-001-01-2" "CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C" "" ""
"705" "DCC-2618" "PDGFR tyrosine kinase receptor inhibitor, KIT inhibitor" "KIT, PDGFRA" "" "" "BRD-K49246350-001-01-1" "Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1" "WWOXKWLDMLMYQY-UHFFFAOYSA-N" "Phase 1"
"706" "DCEBIO" "potassium channel activator" "KCNN2, KCNN3, KCNN4" "" "" "BRD-K89299012-001-06-0, BRD-K89299012-001-07-8" "CCn1c(O)nc2cc(Cl)c(Cl)cc12, CCn1c(O)nc2cc(Cl)c(Cl)cc12" "LKHRMULASXZCLG-UHFFFAOYSA-N, LKHRMULASXZCLG-UHFFFAOYSA-N" "Preclinical"
"707" "DCPIB" "chloride channel blocker, gap junction modulator, glutamate inhibitor" "SLC1A2" "" "" "BRD-A39255369-001-03-1" "CCCCC1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1" "KHKGTPJPBOQECW-UHFFFAOYSA-N" "Preclinical"
"708" "debrisoquin" "adrenergic neuron blocker" "SLC6A2" "cardiology" "hypertension" "BRD-K80419150-001-02-4, BRD-K80419150-065-03-7" "NC(=N)N1CCc2ccccc2C1, NC(=N)N1CCc2ccccc2C1" "JWPGJSVJDAJRLW-UHFFFAOYSA-N, JWPGJSVJDAJRLW-UHFFFAOYSA-N" "Launched"
"709" "decamethonium" "acetylcholine receptor agonist" "ACHE, CHRNA2" "neurology/psychiatry" "muscle relaxant" "BRD-K49783248-303-08-4, BRD-K49783248-303-07-6" "C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C" "MTCUAOILFDZKCO-UHFFFAOYSA-N, MTCUAOILFDZKCO-UHFFFAOYSA-N" "Launched"
"710" "decamethoxine" "antiseptic" "" "" "" "BRD-A56320380-300-01-6" "CC(C)C1CCC(C)CC1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)OC1CC(C)CCC1C(C)C" "ZADGGFKUEYIBJC-UHFFFAOYSA-N" "Phase 2"
"711" "decernotinib" "JAK inhibitor" "JAK3" "" "" "BRD-A95300432-001-01-3" "CCC(C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F" "ASUGUQWIHMTFJL-UHFFFAOYSA-N" "Phase 2/Phase 3"
"712" "decitabine" "DNA methyltransferase inhibitor" "DNMT1, DNMT3A" "hematologic malignancy, hematology" "myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)" "BRD-K79254416-001-22-6, BRD-K79254416-001-21-8" "Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1" "XAUDJQYHKZQPEU-KVQBGUIXSA-N, XAUDJQYHKZQPEU-KVQBGUIXSA-N" "Launched"
"713" "decoquinate" "antiprotozoal agent" "" "infectious disease" "coccidiosis" "BRD-K17641316-001-04-8, BRD-K17641316-001-02-2, BRD-K17641316-001-03-0, BRD-K17641316-213-01-5" "CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC, CCCCCCCCCCOc1cc2c(O)c(cnc2cc1OCC)C(=O)OCC" "JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N, JHAYEQICABJSTP-UHFFFAOYSA-N" "Launched"
"714" "defactinib" "focal adhesion kinase inhibitor" "PTK2" "" "" "BRD-K43578482-001-01-4, BRD-K43578482-001-02-2" "CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1, CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1" "FWLMVFUGMHIOAA-UHFFFAOYSA-N, FWLMVFUGMHIOAA-UHFFFAOYSA-N" "Phase 2"
"715" "deferasirox" "chelating agent" "CYP3A4" "hematology" "transfusional hemosiderosis, thalassemia, iron overload" "BRD-K97010173-001-04-1" "OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O" "BOFQWVMAQOTZIW-UHFFFAOYSA-N" "Launched"
"716" "deferiprone" "chelating agent" "UGT1A6" "hematology" "transfusional hemosiderosis, thalassemia, iron overload" "BRD-K06878038-001-18-6, BRD-K06878038-001-17-8" "Cc1c(O)c(=O)ccn1C, Cc1c(O)c(=O)ccn1C" "TZXKOCQBRNJULO-UHFFFAOYSA-N, TZXKOCQBRNJULO-UHFFFAOYSA-N" "Launched"
"717" "deferoxamine-mesylate" "chelating agent" "" "hematology" "acute iron intoxication, iron overload" "BRD-K09821361-066-25-8, BRD-K09821361-066-24-1, BRD-K09821361-066-23-3" "CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN, CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN" "UBQYURCVBFRUQT-UHFFFAOYSA-N, UBQYURCVBFRUQT-UHFFFAOYSA-N, UBQYURCVBFRUQT-UHFFFAOYSA-N" "Launched"
"718" "deflazacort" "glucocorticoid receptor agonist" "NR3C1" "rheumatology" "joint inflammation" "BRD-K94177716-001-01-1" "CC(=O)OCC(=O)[C@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@H](O)C[C@]21C" "FBHSPRKOSMHSIF-XSJWMLFPSA-N" "Launched"
"719" "deforolimus" "mTOR inhibitor" "MTOR" "" "" "BRD-K09078998-001-01-4, BRD-K62304154-001-03-4" "CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OP(C)(C)=O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O" "BUROJSBIWGDYCN-HSPIJORXSA-N, BUROJSBIWGDYCN-GAUTUEMISA-N" "Phase 3"
"720" "degarelix" "gonadotropin releasing factor hormone receptor antagonist" "GNRHR" "oncology" "prostate cancer" "BRD-A88562598-001-01-7" "CC(C)CC(NC(=O)C(Cc1ccc(NC(N)=O)cc1)NC(=O)C(Cc1ccc(NC(=O)C2CC(=O)NC(=O)N2)cc1)NC(=O)C(CO)NC(=O)C(Cc1cccnc1)NC(=O)C(Cc1ccc(Cl)cc1)NC(=O)C(Cc1ccc2ccccc2c1)NC(C)=O)C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(N)=O" "MEUCPCLKGZSHTA-UHFFFAOYSA-N" "Launched"
"721" "dehydroacetic-acid" "" "" "" "" "BRD-A17300716-001-01-5" "CC(=O)C1C(=O)OC(C)=CC1=O" "PGRHXDWITVMQBC-UHFFFAOYSA-N" "Preclinical"
"722" "dehydrocholate" "" "" "" "" "BRD-A64125466-236-04-6" "C[C@H](CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)CC1CC3=O" "OHXPGWPVLFPUSM-NDGTYXLASA-N" "Preclinical"
"723" "dehydrocholate-acid" "" "" "" "" "BRD-A11551002-001-04-6" "CC(CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O" "OHXPGWPVLFPUSM-IWYXHJQRSA-N" "Preclinical"
"724" "dehydrocorydaline" "acetylcholinesterase inhibitor" "ACHE" "" "" "BRD-K67186445-001-02-1, BRD-K67186445-001-01-3" "COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC, COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4c(C)c3-c2cc1OC" "RFKQJTRWODZPHF-UHFFFAOYSA-N, RFKQJTRWODZPHF-UHFFFAOYSA-N" "Phase 3"
"725" "dehydroepiandrosterone" "protein synthesis stimulant" "ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1" "" "" "BRD-K85833139-001-01-9, BRD-A79445307-001-01-8" "C[C@]12CC[C@@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O" "FMGSKLZLMKYGDP-NPWKVKMJSA-N, FMGSKLZLMKYGDP-SNHNPKPASA-N" "Launched"
"726" "dehydroepiandrosterone-sulfate" "androgen receptor agonist, estrogen receptor agonist" "AR, ESR1, ESR2" "endocrinology" "menopause" "BRD-K15360631-325-01-4" "C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O" "CZWCKYRVOZZJNM-USOAJAOKSA-N" "Launched"
"727" "delamanid" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "tuberculosis" "BRD-K17480742-001-01-1" "C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O" "XDAOLTSRNUSPPH-XMMPIXPASA-N" "Launched"
"728" "delanzomib" "proteasome inhibitor" "CMA1, CTSG, CYP3A4, ELANE" "" "" "BRD-K59325863-001-03-6, BRD-K59325863-001-02-8, BRD-K59325863-001-01-0" "CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O, CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O" "SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N, SJFBTAPEPRWNKH-CCKFTAQKSA-N" "Phase 1/Phase 2"
"729" "delapril" "angiotensin converting enzyme inhibitor" "ACE" "cardiology" "hypertension" "BRD-K00573984-003-01-5" "CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1" "WOUOLAUOZXOLJQ-MBSDFSHPSA-N" "Launched"
"730" "delavirdine" "non-nucleoside reverse transcriptase inhibitor" "CYP3A4" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K34068325-066-03-7, BRD-K34068325-066-02-9, BRD-K34068325-066-01-1" "CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1, CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1" "WHBIGIKBNXZKFE-UHFFFAOYSA-N, WHBIGIKBNXZKFE-UHFFFAOYSA-N, WHBIGIKBNXZKFE-UHFFFAOYSA-N" "Launched"
"731" "delivert" "angiotensin receptor agonist" "AGTR1, AGTR2" "" "" "BRD-K45503887-001-01-1" "CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O" "CZGUSIXMZVURDU-FCWOTDAASA-N" "Launched"
"732" "delphinidin" "membrane permeability inhibitor" "GLO1" "" "" "BRD-K79107392-003-02-2, BRD-K79107392-003-01-4" "Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1, Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1" "JKHRCGUTYDNCLE-UHFFFAOYSA-O, JKHRCGUTYDNCLE-UHFFFAOYSA-O" "Phase 2"
"733" "delta-Tocotrienol" "HMGCR inhibitor" "HMGCR" "" "" "BRD-K85776940-001-01-9" "CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1" "ODADKLYLWWCHNB-LDYBVBFYSA-N" "Phase 1"
"734" "demecarium" "acetylcholinesterase inhibitor" "ACHE, BCHE" "ophthalmology" "intraocular pressure, glaucoma" "BRD-K51471001-303-04-7" "CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C" "RWZVPVOZTJJMNU-UHFFFAOYSA-N" "Launched"
"735" "demeclocycline" "bacterial 30S ribosomal subunit inhibitor" "" "endocrinology, infectious disease, ophthalmology, urology" "fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, cholera, syphilis, listeria, anthrax, actinomycosis, tularemia, brucellosis" "BRD-A34145622-003-22-8, BRD-A34145622-003-23-6, BRD-A50207110-003-01-8" "CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)c4c(Cl)ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@@H]3[C@H](O)c4c(Cl)ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@@H]1[C@@H]2C[C@@H]3[C@@H](O)c4c(Cl)ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O" "JHOHXJYRVSLQCB-AMESULRKSA-N, JHOHXJYRVSLQCB-AMESULRKSA-N, JHOHXJYRVSLQCB-SCYHNFTBSA-N" "Launched"
"736" "denatonium-benzoate" "" "" "" "" "BRD-K34122555-057-11-5" "CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1" "ZFQMTVNLDNXRNQ-UHFFFAOYSA-O" "Preclinical"
"737" "denotivir" "antiviral" "" "infectious disease" "virus herpes simplex (HSV), skin infections" "BRD-K01773083-001-01-4" "Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1" "ZPBLNADJHWHOEP-UHFFFAOYSA-N" "Launched"
"738" "deoxyarbutin" "tyrosinase inhibitor" "" "" "" "BRD-A62562325-001-02-5, BRD-A62562325-001-03-3" "Oc1ccc(OC2CCCCO2)cc1, Oc1ccc(OC2CCCCO2)cc1" "GFBCWCDNXDKFRH-UHFFFAOYSA-N, GFBCWCDNXDKFRH-UHFFFAOYSA-N" "Preclinical"
"739" "deoxycholic-acid" "biliverdin reductase A activator, G protein-coupled receptor agonist" "EFTUD1, FPR1, GPBAR1" "endocrinology" "submental fat" "BRD-K41170226-001-13-8" "C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C" "KXGVEGMKQFWNSR-LLQZFEROSA-N" "Launched"
"740" "deoxycorticosterone-acetate" "progestogen hormone" "NR3C2" "" "" "BRD-K24556098-001-17-5, BRD-A75402480-001-04-6, BRD-K24556098-001-16-7, BRD-K54733518-001-01-9" "CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C, CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C, CC(=O)OCC(=O)[C@@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C" "VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-CLIPTZFXSA-N, VPGRYOFKCNULNK-ACXQXYJUSA-N, VPGRYOFKCNULNK-UQGPTIMOSA-N" "Preclinical"
"741" "deoxyepinephrine" "adrenergic receptor agonist, dopamine receptor agonist" "ADRA1A, DRD1, DRD2" "" "" "BRD-K33151569-003-09-7" "CNCCc1ccc(O)c(O)c1" "NGKZFDYBISXGGS-UHFFFAOYSA-N" "Preclinical"
"742" "deptropine" "histamine receptor antagonist" "HRH1" "" "" "BRD-A65797496-048-09-3" "CN1[C@H]2CC[C@@H]1CC(C2)OC1c2ccccc2CCc2ccccc12" "ZWPODSUQWXAZNC-YOFSQIOKSA-N" "Preclinical"
"743" "dequalinium" "PKC inhibitor" "KCNN1, KCNN3" "" "" "BRD-K77685957-300-09-1, BRD-K77685957-300-08-3" "Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12, Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12" "PCSWXVJAIHCTMO-UHFFFAOYSA-P, PCSWXVJAIHCTMO-UHFFFAOYSA-P" "Launched"
"744" "deracoxib" "cyclooxygenase inhibitor" "PTGS2" "rheumatology" "osteoarthritis" "BRD-K68558722-001-04-0" "COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F" "WAZQAZKAZLXFMK-UHFFFAOYSA-N" "Launched"
"745" "deserpidine" "angiotensin converting enzyme inhibitor" "ACE, SLC18A2" "cardiology" "hypertension" "BRD-K29462201-001-02-7, BRD-K29462201-001-01-9" "CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1" "CVBMAZKKCSYWQR-WCGOZPBSSA-N, CVBMAZKKCSYWQR-WCGOZPBSSA-N" "Launched"
"746" "desipramine" "tricyclic antidepressant" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1" "neurology/psychiatry" "depression" "BRD-K60762818-003-26-0, BRD-K60762818-003-25-2" "CNCCCN1c2ccccc2CCc2ccccc12, CNCCCN1c2ccccc2CCc2ccccc12" "HCYAFALTSJYZDH-UHFFFAOYSA-N, HCYAFALTSJYZDH-UHFFFAOYSA-N" "Launched"
"747" "deslanoside" "Na/K-ATPase inhibitor" "ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2" "cardiology" "congestive heart failure, cardiac arrythmia" "BRD-K99919177-001-01-3" "C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1" "OBATZBGFDSVCJD-LALPQLPRSA-N" "Launched"
"748" "desloratadine" "histamine receptor antagonist" "HRH1" "allergy" "allergic rhinitis, urticaria" "BRD-K82357231-001-19-1, BRD-K82357231-001-17-5, BRD-K82357231-001-18-3" "Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1, Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1" "JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N, JAUOIFJMECXRGI-UHFFFAOYSA-N" "Launched"
"749" "desmethylclozapine" "acetylcholine receptor agonist" "HTR2C" "" "" "BRD-K10042277-001-05-0" "Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1" "JNNOSTQEZICQQP-UHFFFAOYSA-N" "Phase 2"
"750" "desmopressin-acetate" "vasopressin receptor agonist" "AVPR1A, AVPR1B, AVPR2, OXTR" "endocrinology, urology" "central diabetes insipidus, nocturnal enuresis" "BRD-A49399758-015-01-8" "NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CCSSCC(NC(=O)C(CC(N)=O)NC1=O)C(=O)N1CCCC1C(=O)NC(CCCNC(N)=N)C(=O)NCC(N)=O" "NFLWUMRGJYTJIN-UHFFFAOYSA-N" "Launched"
"751" "desogestrel" "progesterone receptor agonist" "ESR1, PGR" "endocrinology" "contraceptive" "BRD-K46061689-001-01-9" "CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C" "" ""
"752" "desonide" "glucocorticoid receptor agonist" "NR3C1, PLA2G1B" "gastroenterology" "Crohns disease	BRD-K21528677-001-02-8, BRD-K30131328-001-01-5, BRD-A26858303-001-02-8	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@H]4[C@H](O)C[C@]3(C)[C@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	WBGKWQHBNHJJPZ-LECWWXJVSA-N, WBGKWQHBNHJJPZ-MOEWUHMFSA-N, WBGKWQHBNHJJPZ-QHDHGWJCSA-N	Launched
desoximetasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	BRD-A49447682-001-02-4	C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO	VWVSBHGCDBMOOT-ZIKVJHDZSA-N	Launched
desoxycorticosterone-pivalate	corticosteroid agonist	NR3C2	endocrinology	Addisons disease" "BRD-K26024145-001-01-9" "CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C" "VVOIQBFMTVCINR-WWMZEODYSA-N" "Launched"
"753" "desoxycortone" "mineralocorticoid receptor agonist" "NR3C1, NR3C2" "" "" "BRD-K98521173-001-19-4" "C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO" "ZESRJSPZRDMNHY-YFWFAHHUSA-N" "Preclinical"
"754" "desoxypeganine" "acetylcholinesterase inhibitor, monoamine oxidase inhibitor" "ACHE" "" "" "BRD-K13819402-003-10-2" "C1CN2Cc3ccccc3N=C2C1" "WUFQLZTXIWKION-UHFFFAOYSA-N" "Phase 1"
"755" "desvenlafaxine" "serotonin–norepinephrine reuptake inhibitor (SNRI)" "SLC6A2, SLC6A3, SLC6A4" "neurology/psychiatry" "depression" "BRD-A98845662-001-03-1, BRD-A98845662-036-03-7, BRD-A98845662-036-02-9, BRD-A98845662-036-04-5, BRD-A98845662-001-02-3" "CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1, CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1" "KYYIDSXMWOZKMP-UHFFFAOYSA-N, KYYIDSXMWOZKMP-UHFFFAOYSA-N, KYYIDSXMWOZKMP-UHFFFAOYSA-N, KYYIDSXMWOZKMP-UHFFFAOYSA-N, KYYIDSXMWOZKMP-UHFFFAOYSA-N" "Launched"
"756" "detomidine" "adrenergic receptor agonist" "ADRA2A" "neurology/psychiatry" "sedative" "BRD-K77597856-003-02-5" "Cc1cccc(Cc2c[nH]cn2)c1C" "RHDJRPPFURBGLQ-UHFFFAOYSA-N" "Launched"
"757" "dexamethasone" "glucocorticoid receptor agonist" "ANXA1, NOS2, NR0B1, NR3C1, NR3C2" "endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology" "hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis" "BRD-A10188456-001-04-9, BRD-A27572786-001-01-2, BRD-K45192137-001-01-1, BRD-K12955147-001-01-8" "C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=CC4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)CO" "UREBDLICKHMUKA-QCYOSJOCSA-N, UREBDLICKHMUKA-LSGPFJJXSA-N, UREBDLICKHMUKA-UWJHKKLZSA-N, UREBDLICKHMUKA-AMDXKQBSSA-N" "Launched"
"758" "dexamethasone-acetate" "glucocorticoid receptor agonist" "" "endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology" "hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis" "BRD-A93424738-001-04-8, BRD-K40063336-001-01-8" "C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@]1(O)C(=O)COC(C)=O" "AKUJBENLRBOFTD-HIBZCRSPSA-N, AKUJBENLRBOFTD-OLDSRXINSA-N" "Launched"
"759" "dexamethasone-sodium-phosphate" "glucocorticoid receptor agonist" "NR3C1" "endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology" "hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis" "BRD-A83802939-304-04-2, BRD-A79380603-304-02-4" "C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O, C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O" "VQODGRNSFPNSQE-QCYOSJOCSA-N, VQODGRNSFPNSQE-REKGUKDCSA-N" "Launched"
"760" "dexchlorpheniramine" "histamine receptor antagonist" "" "allergy, cardiology" "allergic conjunctivitis, allergic rhinitis, urticaria, angioedema" "BRD-K39462424-050-09-8" "CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1" "SOYKEARSMXGVTM-HNNXBMFYSA-N" "Launched"
"761" "dexfenfluramine" "serotonin receptor agonist" "HTR2C, SLC6A4" "" "" "BRD-K58626373-003-07-8" "CCN[C@@H](C)Cc1cccc(c1)C(F)(F)F" "DBGIVFWFUFKIQN-VIFPVBQESA-N" "Withdrawn"
"762" "dexfosfoserine" "membrane integrity inhibitor" "CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2" "" "" "BRD-K30019776-003-01-5" "N[C@@H](COP(O)(O)=O)C(O)=O" "BZQFBWGGLXLEPQ-REOHCLBHSA-N" "Preclinical"
"763" "dexlansoprazole" "ATPase inhibitor" "ATP4A, ATP4B" "gastroenterology" "gastroesophageal reflux disease (GERD), erosive esophagitis (EE)" "BRD-K05900209-001-03-4, BRD-K05900209-001-02-6, BRD-K05900209-001-01-8" "Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1" "MJIHNNLFOKEZEW-RUZDIDTESA-N, MJIHNNLFOKEZEW-RUZDIDTESA-N, MJIHNNLFOKEZEW-RUZDIDTESA-N" "Launched"
"764" "dexloxiglumide" "CCK receptor antagonist" "CCKAR" "" "" "BRD-K07609981-001-01-7" "CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1" "QNQZBKQEIFTHFZ-GOSISDBHSA-N" "Phase 3"
"765" "dexniguldipine" "calmodulin antagonist" "ADORA3" "" "" "BRD-K44309363-003-02-1" "COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1" "SVJMLYUFVDMUHP-MGBGTMOVSA-N" "Phase 2"
"766" "dexpanthenol" "" "" "gastroenterology" "paralytic ileus" "BRD-A59413292-001-08-2, BRD-K71210479-001-05-5" "CC(C)(CO)C(O)C(=O)NCCCO, CC(C)(CO)[C@@H](O)C(=O)NCCCO" "SNPLKNRPJHDVJA-UHFFFAOYSA-N, SNPLKNRPJHDVJA-ZETCQYMHSA-N" "Launched"
"767" "dexrazoxane" "chelating agent, topoisomerase inhibitor" "TOP2A, TOP2B" "cardiology" "cardiomyopathy" "BRD-K07265709-003-05-6, BRD-K07265709-003-03-1, BRD-K07265709-003-04-9" "C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1, C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1" "BMKDZUISNHGIBY-ZETCQYMHSA-N, BMKDZUISNHGIBY-ZETCQYMHSA-N, BMKDZUISNHGIBY-ZETCQYMHSA-N" "Launched"
"768" "dextran" "" "" "hematology, critical care" "thrombosis, hypovolemia" "BRD-K67117832-001-01-9" "OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O" "FZWBNHMXJMCXLU-BLAUPYHCSA-N" "Launched"
"769" "dextroamphetamine" "monoamine oxidase inhibitor" "ADRA1A, ADRA1B, SLC18A2, SLC6A2, SLC6A3, TAAR1" "neurology/psychiatry" "attention-deficit/hyperactivity disorder (ADHD), narcolepsy" "BRD-K21160401-065-01-0" "C[C@H](N)Cc1ccccc1" "KWTSXDURSIMDCE-QMMMGPOBSA-N" "Launched"
"770" "dextromethorphan" "glutamate receptor antagonist, sigma receptor agonist" "CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4" "pulmonary" "cough suppressant" "BRD-K33211335-004-01-7" "COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1" "MKXZASYAUGDDCJ-NJAFHUGGSA-N" "Launched"
"771" "dextrose" "" "" "endocrinology" "hypoglycemia" "BRD-K51431759-001-02-9" "OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O" "GZCGUPFRVQAUEE-SLPGGIOYSA-N" "Launched"
"772" "DFB" "glutamate receptor agonist" "GRM5" "" "" "BRD-K82002057-001-01-2" "Fc1cccc(c1)\C=N\N=C\c1cccc(F)c1" "YYMCVDNIIFNDJK-BEQMOXJMSA-N" "Preclinical"
"773" "DH-97" "melatonin receptor antagonist" "MTNR1B" "" "" "BRD-K06014311-001-02-0" "CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12" "HDOIPCLEKCEANF-UHFFFAOYSA-N" "Preclinical"
"774" "DHBP" "ryanodine receptor blocker" "" "" "" "BRD-K41262162-303-02-2" "CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1" "XJGZGUSMZSXHJI-UHFFFAOYSA-N" "Preclinical"
"775" "diacerein" "interleukin inhibitor" "IL1B" "rheumatology" "osteoarthritis" "BRD-K69122748-001-10-1, BRD-K69122748-001-11-9, BRD-K69122748-001-09-3" "CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O, CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O" "TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N, TYNLGDBUJLVSMA-UHFFFAOYSA-N" "Launched"
"776" "diacetamate" "" "" "" "" "BRD-K93611241-001-02-2" "CC(=O)Nc1ccc(OC(C)=O)cc1" "UJAOSPFULOFZRR-UHFFFAOYSA-N" "Preclinical"
"777" "diadenosine-tetraphosphate" "adenosine kinase inhibitor" "P2RY13, P2RY2" "" "" "BRD-A15035311-001-01-8" "Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H](C(O)C2O)n2cnc3c(N)ncnc23)C(O)C1O" "YOAHKNVSNCMZGQ-GMKVLROZSA-N" "Phase 1"
"778" "dianhydrogalactitol" "DNA alkylating agent" "" "" "" "BRD-K68502831-001-01-2" "O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1" "AAFJXZWCNVJTMK-GUCUJZIJSA-N" "Phase 1"
"779" "diarylpropionitrile" "estrogen receptor agonist" "ESR2" "" "" "BRD-A27143604-001-02-0" "Oc1ccc(CC(C" "" ""
"780" "diatrizoic-acid" "" "" "radiology" "contrast agent" "BRD-K48247567-001-01-9" "CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I" "YVPYQUNUQOZFHG-UHFFFAOYSA-N" "Launched"
"781" "diaveridine" "dihydrofolate reductase inhibitor" "" "" "" "BRD-K97464279-001-03-5" "COc1ccc(Cc2cnc(N)nc2N)cc1OC" "LDBTVAXGKYIFHO-UHFFFAOYSA-N" "Launched"
"782" "diazepam" "benzodiazepine receptor agonist" "ADRA1A, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO" "neurology/psychiatry" "generalized anxiety disorder (GAD), abstinence from alcohol, hallucinosis, tremors" "BRD-K16508793-001-05-9" "CN1c2ccc(Cl)cc2C(=NCC1=O)c1ccccc1" "AAOVKJBEBIDNHE-UHFFFAOYSA-N" "Launched"
"783" "diazooxonorleucine" "glutamate receptor antagonist" "" "" "" "BRD-K38458514-001-01-8" "N[C@@H](CCC(=O)C=[N+]=N)C(O)=O" "LHGVYNDAWRBWGL-YFKPBYRVSA-O" "Phase 2"
"784" "diazoxide" "potassium channel activator" "ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3" "endocrinology" "hypoglycemia" "BRD-K73109821-001-20-1, BRD-K73109821-001-19-3" "CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1, CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1" "GDLBFKVLRPITMI-UHFFFAOYSA-N, GDLBFKVLRPITMI-UHFFFAOYSA-N" "Launched"
"785" "dibekacin" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K48427910-001-01-1" "NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1" "JJCQSGDBDPYCEO-XVZSLQNASA-N" "Launched"
"786" "dibenzepine" "norepinephrine reputake inhibitor" "" "" "" "BRD-K79145749-003-02-2" "CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O" "QPGGEKPRGVJKQB-UHFFFAOYSA-N" "Preclinical"
"787" "dibenzothiophene" "" "" "" "" "BRD-K46863940-001-06-2, BRD-K46863940-001-05-4, BRD-K46863940-001-04-7" "c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21, c1ccc2c(c1)sc1ccccc21" "IYYZUPMFVPLQIF-UHFFFAOYSA-N, IYYZUPMFVPLQIF-UHFFFAOYSA-N, IYYZUPMFVPLQIF-UHFFFAOYSA-N" "Preclinical"
"788" "dibutyl-phthalate" "" "TRPA1" "" "" "BRD-K73477617-001-08-5" "CCCCOC(=O)c1ccccc1C(=O)OCCCC" "DOIRQSBPFJWKBE-UHFFFAOYSA-N" "Preclinical"
"789" "dichlorisone-acetate" "" "" "" "" "BRD-K54187111-001-08-4, BRD-A40195998-001-02-7, BRD-K54187111-001-07-6" "CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C" "YNNURTVKPVJVEI-GSLJADNHSA-N, YNNURTVKPVJVEI-JORUCDAYSA-N, YNNURTVKPVJVEI-GSLJADNHSA-N" "Phase 2"
"790" "dichloroacetate" "pyruvate dehydrogenase kinase inhibitor" "PDK1" "" "" "BRD-M97302542-001-04-4, BRD-M97302542-001-03-6" "[Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl" "FLWQSOHPGISTPX-UHFFFAOYSA-N, FLWQSOHPGISTPX-UHFFFAOYSA-N" "Phase 3"
"791" "dichlorophen" "anticestodal agent" "" "" "" "BRD-K62326629-001-19-0" "Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O" "MDNWOSOZYLHTCG-UHFFFAOYSA-N" "Launched"
"792" "dichlorvos" "acetylcholinesterase inhibitor" "" "" "" "BRD-K23779958-001-05-8" "COP(=O)(OC)OC=C(Cl)Cl" "OEBRKCOSUFCWJD-UHFFFAOYSA-N" "Launched"
"793" "diclazuril" "antiprotozoal agent" "" "infectious disease" "equine protozoal myeloencephalitis (EPM)" "BRD-A06426627-001-03-5, BRD-A06426627-001-04-3" "Clc1ccc(cc1)C(C" "" ""
"794" "diclofenac" "cyclooxygenase inhibitor" "AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A" "rheumatology, neurology/psychiatry" "rheumatoid arthritis, osteoarthritis, migraine headache" "BRD-K08252256-236-33-8, BRD-K08252256-236-32-0, BRD-K08252256-224-02-9, BRD-K08252256-237-02-1" "OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl, OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl" "DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N, DCOPUUMXTXDBNB-UHFFFAOYSA-N" "Launched"
"795" "diclofenamide" "carbonic anhydrase inhibitor" "CA1, CA12, CA2, CA4, CA7" "ophthalmology, neurology/psychiatry" "glaucoma, epilepsy" "BRD-K71499074-001-12-9" "NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O" "GJQPMPFPNINLKP-UHFFFAOYSA-N" "Launched"
"796" "diclofensine" "dopamine reuptake inhibitor" "DRD1, MAOA, MAOB" "" "" "BRD-A51078674-003-01-0" "COc1ccc2C(CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1" "ZJDCGVDEEHWEIG-UHFFFAOYSA-N" "Phase 3"
"797" "dicloralurea" "" "" "" "" "BRD-A41657926-001-03-0" "OC(NC(=O)NC(O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl" "PPJXIHLNYDVTDI-UHFFFAOYSA-N" "Preclinical"
"798" "dicloxacillin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections" "BRD-K05673000-236-12-1, BRD-K59843513-323-01-4, BRD-K05673000-323-12-7" "Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl" "YFAGHNZHGGCZAX-JKIFEVAISA-N, YFAGHNZHGGCZAX-KEYYUXOJSA-N, YFAGHNZHGGCZAX-JKIFEVAISA-N" "Launched"
"799" "dicoumarol" "NADPH inhibitor" "CRYZ, NQO1, VKORC1" "hematology" "deep vein thrombosis (DVT)" "BRD-K82236179-213-01-0" "Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12" "DOBMPNYZJYQDGZ-UHFFFAOYSA-N" "Launched"
"800" "dicyclohexylamine" "" "" "" "" "BRD-K57091285-001-07-7" "C1CCC(CC1)NC1CCCCC1" "XBPCUCUWBYBCDP-UHFFFAOYSA-N" "Preclinical"
"801" "dicycloverine" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3" "gastroenterology" "irritable bowel syndrome" "BRD-K68507560-003-25-3, BRD-K68507560-003-24-6" "CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1, CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1" "CURUTKGFNZGFSE-UHFFFAOYSA-N, CURUTKGFNZGFSE-UHFFFAOYSA-N" "Launched"
"802" "didanosine" "nucleoside reverse transcriptase inhibitor" "PNP" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K99063460-001-13-1, BRD-K99063460-001-12-3" "OC[C@@H]1CC[C@@H](O1)n1cnc2c(O)ncnc12, OC[C@@H]1CC[C@@H](O1)n1cnc2c(O)ncnc12" "BXZVVICBKDXVGW-NKWVEPMBSA-N, BXZVVICBKDXVGW-NKWVEPMBSA-N" "Launched"
"803" "dideoxyadenosine" "nucleoside reverse transcriptase inhibitor" "" "" "" "BRD-K84794093-001-07-5" "Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1" "WVXRAFOPTSTNLL-NKWVEPMBSA-N" "Phase 1"
"804" "didox" "ribonucleotide reductase inhibitor" "RRM1" "oncology" "breast cancer" "BRD-K94146583-001-01-6" "ONC(=O)c1ccc(O)c(O)c1" "QJMCKEPOKRERLN-UHFFFAOYSA-N" "Launched"
"805" "dienestrol" "estrogen receptor agonist" "ESR1" "endocrinology" "menopause" "BRD-K95309561-001-24-7" "C\C=C(c1ccc(O)cc1)\C(c1ccc(O)cc1)=C\C" "NFDFQCUYFHCNBW-SCGPFSFSSA-N" "Launched"
"806" "dienogest" "progesterone receptor agonist" "PGR" "endocrinology, obstetrics/gynecology" "contraceptive, endometriosis" "BRD-K64504314-001-01-8" "C[C@@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC" "" ""
"807" "diethylcarbamazine" "lipoxygenase inhibitor" "ALOX5, PTGS1" "infectious disease" "filariasis" "BRD-K45542189-048-22-1" "CCN(CC)C(=O)N1CCN(C)CC1" "RCKMWOKWVGPNJF-UHFFFAOYSA-N" "Launched"
"808" "diethylstilbestrol" "estrogen receptor agonist" "ESR1, ESR2, ESRRB, ESRRG" "" "" "BRD-K45330754-001-21-7, BRD-K45330754-001-22-5" "CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1, CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1" "RGLYKWWBQGJZGM-ISLYRVAYSA-N, RGLYKWWBQGJZGM-ISLYRVAYSA-N" "Withdrawn"
"809" "diethyltoluamide" "ionotropic receptor IR40a activator" "" "dermatology" "sunscreen lotion" "BRD-K94080537-001-09-7" "CCN(CC)C(=O)c1cccc(C)c1" "MMOXZBCLCQITDF-UHFFFAOYSA-N" "Launched"
"810" "difenpiramide" "cyclooxygenase inhibitor, prostaglandin inhibitor" "" "" "" "BRD-K96206066-001-07-9" "O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1" "PWHROYKAGRUWDQ-UHFFFAOYSA-N" "Launched"
"811" "diflorasone-diacetate" "glucocorticoid receptor agonist" "NR3C1" "dermatology" "corticosteroid-responsive dermatoses" "BRD-A66869276-001-02-9" "C[C@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O" "BOBLHFUVNSFZPJ-LIRARCAYSA-N" "Launched"
"812" "difloxacin" "bacterial DNA gyrase inhibitor" "" "infectious disease" "skin infections, urinary tract infections" "BRD-K73923631-003-02-9, BRD-K73923631-003-01-1" "CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1, CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1" "NOCJXYPHIIZEHN-UHFFFAOYSA-N, NOCJXYPHIIZEHN-UHFFFAOYSA-N" "Launched"
"813" "diflunisal" "prostanoid receptor antagonist" "PTGS1, PTGS2" "rheumatology" "rheumatoid arthritis, osteoarthritis" "BRD-K22031190-001-23-6" "OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F" "HUPFGZXOMWLGNK-UHFFFAOYSA-N" "Launched"
"814" "difluprednate" "glucocorticoid receptor agonist" "NR3C1" "ophthalmology" "endogenous uveitis" "BRD-K33720171-001-01-0" "CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O" "WYQPLTPSGFELIB-QXNOXDERSA-N" "Launched"
"815" "diftalone" "cyclooxygenase inhibitor" "" "endocrinology" "thyroiditis" "BRD-K80076813-001-08-8" "O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12" "CXSJGNHRBWJXEA-UHFFFAOYSA-N" "Launched"
"816" "digitoxigenin" "ATPase inhibitor" "ATP1A1" "" "" "BRD-K18518344-001-15-9" "C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1" "XZTUSOXSLKTKJQ-CESUGQOBSA-N" "Preclinical"
"817" "digitoxin" "ATPase inhibitor" "ATP1A1" "" "" "BRD-A93236127-001-04-5" "C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C" "WDJUZGPOPHTGOT-KSVSUYAUSA-N" "Launched"
"818" "digoxigenin" "steroid" "" "" "" "BRD-K18619710-001-14-4" "C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1" "SHIBSTMRCDJXLN-KCZCNTNESA-N" "Preclinical"
"819" "digoxin" "ATPase inhibitor" "ATP1A1" "cardiology" "congestive heart failure, atrial fibrillation (AF)" "BRD-A94756469-001-04-7" "C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C" "LTMHDMANZUZIPE-QVYPYPLASA-N" "Launched"
"820" "dihomo-gamma-linolenic-acid" "prostanoid receptor agonist" "PTGS1, PTGS2" "" "" "BRD-K20152659-001-04-6, BRD-K20152659-001-07-9" "CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O" "HOBAELRKJCKHQD-QNEBEIHSSA-N, HOBAELRKJCKHQD-QNEBEIHSSA-N" "Phase 2"
"821" "dihydrexidine" "dopamine receptor agonist" "DRD1, DRD2, DRD3, DRD4, DRD5" "" "" "BRD-K31471398-003-01-5" "Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O" "BGOQGUHWXBGXJW-RHSMWYFYSA-N" "Phase 2"
"822" "dihydroartemisinin" "antimalarial agent" "" "infectious disease" "malaria" "BRD-K11421397-001-01-9, BRD-A82452087-001-02-3" "C[C@H]1CC[C@H]2[C@@H](C)[C@H](O)O[C@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4, C[C@@H]1CC[C@H]2[C@@H](C)C(O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4" "BJDCWCLMFKKGEE-FVRYGFSNSA-N, BJDCWCLMFKKGEE-SUZORCHOSA-N" "Launched"
"823" "dihydroergocristine" "adrenergic receptor antagonist, prolactin inhibitor" "ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7" "" "" "BRD-K97440753-066-18-1" "CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O" "DEQITUUQPICUMR-HJPBWRTMSA-N" "Launched"
"824" "dihydroergotamine" "serotonin receptor agonist" "ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7" "neurology/psychiatry" "migraine headache" "BRD-K72166146-066-05-4, BRD-K72166146-066-04-7" "CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O, CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O" "LUZRJRNZXALNLM-JGRZULCMSA-N, LUZRJRNZXALNLM-JGRZULCMSA-N" "Launched"
"825" "dihydromyricetin" "" "" "" "" "BRD-K01614093-001-03-4, BRD-K01614093-001-02-6, BRD-K01614093-001-04-2" "O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1" "KJXSIXMJHKAJOD-LSDHHAIUSA-N, KJXSIXMJHKAJOD-LSDHHAIUSA-N, KJXSIXMJHKAJOD-LSDHHAIUSA-N" "Preclinical"
"826" "dihydrostreptomycin" "bacterial 30S ribosomal subunit inhibitor" "" "" "" "BRD-A67363467-001-01-3" "CN[C@H]1C(O)C(O)C(CO)OC1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)OC(C)[C@]1(O)CO" "ASXBYYWOLISCLQ-DAOCWCMRSA-N" "Withdrawn"
"827" "dihydrotachysterol" "vitamin analog" "VDR" "orthopedics, endocrinology" "rickets, hypocalcemia, osteomalacia" "BRD-A34455052-001-01-8" "CC(C)C(C)\C=C\C(C)C1CCC2C1(C)CCC\C2=C/C=C1\CC(O)CCC1C" "ILYCWAKSDCYMBB-ZJGOHBTISA-N" "Launched"
"828" "dihydrotestosterone" "androgen receptor agonist" "AR, HSD17B1" "neurology/psychiatry, endocrinology" "tetany, hypoparathyroidism" "BRD-K22525962-001-05-0" "C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O" "NVKAWKQGWWIWPM-ABEVXSGRSA-N" "Launched"
"829" "dihydroxyacetone" "" "" "dermatology" "skin protectant" "BRD-K18637542-001-01-7" "OCC(=O)CO" "RXKJFZQQPQGTFL-UHFFFAOYSA-N" "Launched"
"830" "dihydroxyphenylglycine" "glutamate receptor agonist" "GRM1, GRM5" "" "" "BRD-A20589515-001-02-9" "NC(C(O)=O)c1cc(O)cc(O)c1" "HOOWCUZPEFNHDT-UHFFFAOYSA-N" "Preclinical"
"831" "diiodothyropropionic-acid" "thyroid hormone stimulant" "" "" "" "BRD-K36802417-001-01-7" "OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1" "WONYMNWUJVKVII-UHFFFAOYSA-N" "Phase 2"
"832" "dilazep" "adenosine reuptake inhibitor" "SLC29A1" "" "" "BRD-K48722258-300-10-2, BRD-K48722258-300-11-0" "COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1, COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1" "QVZCXCJXTMIDME-UHFFFAOYSA-N, QVZCXCJXTMIDME-UHFFFAOYSA-N" "Launched"
"833" "diloxanide" "protein synthesis inhibitor" "" "infectious disease" "amebiasis" "BRD-K10974103-001-21-1" "CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1" "BDYYDXJSHYEDGB-UHFFFAOYSA-N" "Launched"
"834" "diltiazem" "calcium channel blocker" "CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5" "cardiology" "hypertension, angina pectoris" "BRD-A69636825-003-04-7, BRD-K24023109-003-25-2, BRD-K24023109-003-26-0" "COc1ccc(cc1)C1Sc2ccccc2N(CCN(C)C)C(=O)C1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O, COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O" "HSUGRBWQSSZJOP-UHFFFAOYSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N, HSUGRBWQSSZJOP-RTWAWAEBSA-N" "Launched"
"835" "dimaprit" "histamine receptor agonist" "HRH2, HRH3, HRH4" "" "" "BRD-K23541596-300-08-0, BRD-K23541596-300-07-2" "CN(C)CCCSC(N)=N, CN(C)CCCSC(N)=N" "OLHQOJYVQUNWPL-UHFFFAOYSA-N, OLHQOJYVQUNWPL-UHFFFAOYSA-N" "Preclinical"
"836" "dimemorfan" "sigma receptor agonist" "SIGMAR1" "pulmonary" "cough suppressant" "BRD-K29812331-011-01-7" "CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31" "KBEZZLAAKIIPFK-NJAFHUGGSA-N" "Launched"
"837" "dimenhydrinate" "histamine receptor antagonist" "HRH1" "neurology/psychiatry, gastroenterology" "motion sickness, nausea, vomiting" "BRD-M98649031-001-08-6, BRD-M98649031-001-09-4" "Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1, Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1" "NFLLKCVHYJRNRH-UHFFFAOYSA-N, NFLLKCVHYJRNRH-UHFFFAOYSA-N" "Launched"
"838" "dimercaprol" "chelating agent" "" "neurology/psychiatry" "metal toxicity" "BRD-A56152450-001-02-0" "OCC(S)CS" "WQABCVAJNWAXTE-UHFFFAOYSA-N" "Launched"
"839" "dimercaptosuccinic-acid" "chelating agent" "DNMT1" "neurology/psychiatry" "metal toxicity" "BRD-K88701661-001-02-9" "OC(=O)[C@@H](S)[C@@H](S)C(O)=O" "ACTRVOBWPAIOHC-XIXRPRMCSA-N" "Launched"
"840" "dimesna" "tubulin polymerization inhibitor" "" "" "" "BRD-K30126819-304-02-7, BRD-K30126819-304-03-5" "OS(=O)(=O)CCSSCCS(O)(=O)=O, OS(=O)(=O)CCSSCCS(O)(=O)=O" "BYUKOOOZTSTOOH-UHFFFAOYSA-N, BYUKOOOZTSTOOH-UHFFFAOYSA-N" "Phase 3"
"841" "dimethadione" "oxazolidine antiepileptic" "" "" "" "BRD-K43687498-001-09-8" "CC1(C)OC(=O)NC1=O" "JYJFNDQBESEHJQ-UHFFFAOYSA-N" "Preclinical"
"842" "dimethicone" "" "" "dermatology" "cosmetic" "BRD-K26674746-001-01-4" "C[Si](C)(C)O[Si](C)(C)C" "UQEAIHBTYFGYIE-UHFFFAOYSA-N" "Launched"
"843" "dimethindene-(S)-(+)" "acetylcholine receptor antagonist" "HRH1" "" "" "BRD-K83192048-050-02-7" "C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1" "MVMQESMQSYOVGV-OAHLLOKOSA-N" "Preclinical"
"844" "dimethisoquin" "local anesthetic" "" "neurology/psychiatry" "local anesthetic" "BRD-K73391359-003-10-2" "CCCCc1cc2ccccc2c(OCCN(C)C)n1" "XNMYNYSCEJBRPZ-UHFFFAOYSA-N" "Launched"
"845" "dimethyl-fumarate" "nuclear factor erythroid derived, like (NRF2) activator" "KEAP1" "neurology/psychiatry" "multiple sclerosis" "BRD-K31111078-001-04-2, BRD-K31111078-001-03-4, BRD-K31111078-001-05-9" "COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC, COC(=O)\C=C\C(=O)OC" "LDCRTTXIJACKKU-ONEGZZNKSA-N, LDCRTTXIJACKKU-ONEGZZNKSA-N, LDCRTTXIJACKKU-ONEGZZNKSA-N" "Launched"
"846" "dimethyl-isosorbide" "cosmetic moisturizer" "" "" "" "BRD-A17224697-001-01-0" "COC1COC2C(COC12)OC" "MEJYDZQQVZJMPP-UHFFFAOYSA-N" "Preclinical"
"847" "dimetindene" "histamine receptor antagonist, cholinergic receptor antagonist" "CHRM2, HRH1" "allergy" "allergic rhinitis" "BRD-A54141700-001-01-5" "CC(C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1" "MVMQESMQSYOVGV-UHFFFAOYSA-N" "Launched"
"848" "dimetridazole" "bacterial DNA inhibitor" "" "" "" "BRD-K72728560-001-01-4" "Cc1ncc(n1C)[N+]([O-])=O" "IBXPYPUJPLLOIN-UHFFFAOYSA-N" "Launched"
"849" "diminazene-aceturate" "angiotensin converting enzyme activator" "AOC1, PRDX5, PRSS1" "" "" "BRD-K92848252-001-01-9, BRD-K92848252-001-02-7, BRD-K92848252-001-03-5" "NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1" "XNYZHCFCZNMTFY-UHFFFAOYSA-N, XNYZHCFCZNMTFY-UHFFFAOYSA-N, XNYZHCFCZNMTFY-UHFFFAOYSA-N" "Phase 3"
"850" "dimpylate" "acetylcholinesterase inhibitor" "ACHE" "" "" "BRD-K60567437-001-10-2" "CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C" "FHIVAFMUCKRCQO-UHFFFAOYSA-N" "Launched"
"851" "dinaciclib" "CDK inhibitor" "CDK1, CDK2, CDK5, CDK9" "" "" "BRD-K13662825-001-07-5" "CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO" "PIMQWRZWLQKKBJ-SFHVURJKSA-N" "Phase 3"
"852" "dinitolmide" "" "" "infectious disease" "coccidiosis" "BRD-K93240442-001-08-4" "Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O" "ZEFNOZRLAWVAQF-UHFFFAOYSA-N" "Launched"
"853" "dinoprost" "prostacyclin analog" "PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R" "obstetrics/gynecology" "labor induction" "BRD-K81672972-001-03-1" "CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O" "PXGPLTODNUVGFL-YNNPMVKQSA-N" "Launched"
"854" "dinoprostone" "prostanoid receptor agonist" "CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R" "" "" "BRD-K26521938-001-09-8, BRD-K26521938-001-07-2" "CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O, CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O" "XEYBRNLFEZDVAW-ARSRFYASSA-N, XEYBRNLFEZDVAW-ARSRFYASSA-N" "Withdrawn"
"855" "dioscin" "apoptosis stimulant" "CXCR3" "" "" "BRD-K37723606-001-01-5" "C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@@H]2O[C@@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1" "VNONINPVFQTJOC-OXSREHLTSA-N" "Preclinical"
"856" "diosgenin" "steroid" "" "" "" "BRD-K15864401-001-01-0" "C[C@@H]1[C@@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1" "WQLVFSAGQJTQCK-AIKZTMDKSA-N" "Preclinical"
"857" "diosmetin" "aryl hydrocarbon receptor agonist" "CYP1B1" "dermatology" "cosmetic" "BRD-K26862302-001-05-2" "COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1" "MBNGWHIJMBWFHU-UHFFFAOYSA-N" "Launched"
"858" "diosmin" "aryl hydrocarbon receptor agonist, capillary stabilizing agent" "AHR" "cardiology, hematology, dermatology" "chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome" "BRD-K94436377-001-11-0, BRD-K94436377-001-10-2, BRD-K22902927-001-01-4" "COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1, COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1" "GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-YFAPSIMESA-N, GZSOSUNBTXMUFQ-JFROJUBNSA-N" "Launched"
"859" "dioxybenzone" "topical sunscreen agent" "" "" "" "BRD-K22193694-001-13-6" "COc1ccc(C(=O)c2ccccc2O)c(O)c1" "MEZZCSHVIGVWFI-UHFFFAOYSA-N" "Preclinical"
"860" "dipeptamin" "" "" "" "" "BRD-K11595419-001-01-4" "C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O" "HJCMDXDYPOUFDY-WHFBIAKZSA-N" "Launched"
"861" "diperodon" "local anesthetic" "" "" "" "BRD-A30693873-003-12-8, BRD-A30693873-003-11-0" "O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1, O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1" "YUGZHQHSNYIFLG-UHFFFAOYSA-N, YUGZHQHSNYIFLG-UHFFFAOYSA-N" "Preclinical"
"862" "diphemanil" "acetylcholine receptor antagonist" "CHRM3" "neurology/psychiatry" "spasms" "BRD-K93441486-067-12-8" "C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1" "LCTZPQRFOZKZNK-UHFFFAOYSA-N" "Launched"
"863" "diphencyprone" "immunostimulant" "" "" "" "BRD-K51730347-001-06-4, BRD-K51730347-001-05-6" "O=c1c(c1-c1ccccc1)-c1ccccc1, O=c1c(c1-c1ccccc1)-c1ccccc1" "HCIBTBXNLVOFER-UHFFFAOYSA-N, HCIBTBXNLVOFER-UHFFFAOYSA-N" "Phase 2"
"864" "diphenhydramine" "histamine receptor antagonist" "HRH1" "neurology/psychiatry" "headache" "BRD-K47278471-003-26-3, BRD-K47278471-003-25-5" "CN(C)CCOC(c1ccccc1)c1ccccc1, CN(C)CCOC(c1ccccc1)c1ccccc1" "ZZVUWRFHKOJYTH-UHFFFAOYSA-N, ZZVUWRFHKOJYTH-UHFFFAOYSA-N" "Launched"
"865" "diphenidol" "acetylcholine receptor agonist" "CHRM1, CHRM2, CHRM3, CHRM4" "neurology/psychiatry" "vertigo" "BRD-K01663662-003-20-2" "OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1" "OGAKLTJNUQRZJU-UHFFFAOYSA-N" "Launched"
"866" "diphenyleneiodonium" "nitric oxide synthase inhibitor" "NOS2, NOS3" "" "" "BRD-K65814004-003-02-9" "[I+]1c2ccccc2-c2ccccc12" "QFXKXRXFBRLLPQ-UHFFFAOYSA-N" "Preclinical"
"867" "diphenylguanidine" "" "" "" "" "BRD-K12362304-001-07-3" "N=C(Nc1ccccc1)Nc1ccccc1" "OWRCNXZUPFZXOS-UHFFFAOYSA-N" "Preclinical"
"868" "diphenylpyraline" "dopamine uptake inhibitor" "HRH1, SLC6A3" "allergy" "allergic rhinitis" "BRD-K22936972-003-23-6, BRD-K22936972-003-22-8" "CN1CCC(CC1)OC(c1ccccc1)c1ccccc1, CN1CCC(CC1)OC(c1ccccc1)c1ccccc1" "OWQUZNMMYNAXSL-UHFFFAOYSA-N, OWQUZNMMYNAXSL-UHFFFAOYSA-N" "Launched"
"869" "dipivefrine" "adrenergic receptor agonist" "ACHE, ADRA1A, ADRA2A, ADRB2, BCHE" "ophthalmology" "glaucoma, intraocular pressure" "BRD-A47494775-003-11-3" "CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1" "OCUJLLGVOUDECM-UHFFFAOYSA-N" "Launched"
"870" "dipraglurant" "glutamate receptor negative allosteric modulator" "GRM5" "" "" "BRD-K64838454-001-01-0" "Fc1ccc2nc(CCC" "" ""
"871" "DIPT" "dopamine reuptake inhibitor, serotonin reuptake inhibitor" "HTR1A, HTR2A, HTR2C" "" "" "BRD-K75385383-001-01-5" "CC(C)N(CCc1c[nH]c2ccccc12)C(C)C" "ZRVAAGAZUWXRIP-UHFFFAOYSA-N" "Launched"
"872" "dipyridamole" "phosphodiesterase inhibitor" "ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1" "cardiology" "coronary artery disease (CAD), peripheral artery disease (PAD), hypertension" "BRD-K86301799-001-34-8, BRD-K86301799-001-36-3, BRD-K86301799-001-37-1, BRD-K86301799-001-35-5" "OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO, OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO" "IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N, IZEKFCXSFNUWAM-UHFFFAOYSA-N" "Launched"
"873" "dipyrocetyl" "chelating agent" "" "endocrinology, neurology/psychiatry" "fever, pain relief" "BRD-K47608922-001-04-7" "CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O" "NYIZXMGNIUSNKL-UHFFFAOYSA-N" "Launched"
"874" "dirithromycin" "bacterial 50S ribosomal subunit inhibitor" "" "pulmonary" "bronchitis" "BRD-K15706428-001-01-2, BRD-K52756523-001-24-7, BRD-A44120870-001-01-6, BRD-A77786295-001-01-1, BRD-A83603976-001-01-6" "CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)OC([C@H]2C)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H](C2C)C1(C)O, CC[C@@H]1OC(=O)[C@@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@@H](O[C@@H]2O[C@@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)OC([C@@H]2C)[C@]1(C)O" "WLOHNSSYAXHWNR-KJMPFYDISA-N, WLOHNSSYAXHWNR-DWIOZXRMSA-N, WLOHNSSYAXHWNR-TUMOPFDVSA-N, WLOHNSSYAXHWNR-GHZCURSSSA-N, WLOHNSSYAXHWNR-JDMGOBCSSA-N" "Launched"
"875" "diroximel-fumarate" "anti-inflammatory agent" "" "" "" "BRD-K87386013-001-01-7" "COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O" "YIMYDTCOUQIDMT-SNAWJCMRSA-N" "Phase 3"
"876" "disodium sebacate" "" "HBA1, HBB" "" "" "BRD-K66672047-304-01-3" "OC(=O)CCCCCCCCC(O)=O" "CXMXRPHRNRROMY-UHFFFAOYSA-N" "Phase 1"
"877" "disopyramide" "sodium channel blocker" "CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A" "cardiology" "ventricular tachycardia (VT), ventricular arrhythmias" "BRD-A29734509-011-13-6, BRD-A29734509-011-12-8" "CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C, CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C" "UVTNFZQICZKOEM-UHFFFAOYSA-N, UVTNFZQICZKOEM-UHFFFAOYSA-N" "Launched"
"878" "disulfiram" "aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist" "ALDH2, DBH" "neurology/psychiatry" "abstinence from alcohol" "BRD-K32744045-001-31-2, BRD-K32744045-001-30-4" "CCN(CC)C(=S)SSC(=S)N(CC)CC, CCN(CC)C(=S)SSC(=S)N(CC)CC" "AUZONCFQVSMFAP-UHFFFAOYSA-N, AUZONCFQVSMFAP-UHFFFAOYSA-N" "Launched"
"879" "dithranol" "DNA synthesis inhibitor" "" "dermatology" "psoriasis" "BRD-K51807679-001-06-8" "Oc1cccc2cc3cccc(O)c3c(O)c12" "YUTJCNNFTOIOGT-UHFFFAOYSA-N" "Launched"
"880" "ditiocarb-sodium-trihydrate" "immunostimulant" "CA1, CA2, CA4" "" "" "BRD-K40654626-236-01-5" "CCN(CC)C(S)=S" "LMBWSYZSUOEYSN-UHFFFAOYSA-N" "Phase 3"
"881" "ditolylguanidine" "sigma receptor agonist" "GRIN1, GRIN2A, GRIN2B, SIGMAR1" "" "" "BRD-K33459542-001-07-4" "Cc1ccccc1NC(=N)Nc1ccccc1C" "OPNUROKCUBTKLF-UHFFFAOYSA-N" "Preclinical"
"882" "divalproex-sodium" "benzodiazepine receptor agonist" "ALDH5A1" "neurology/psychiatry" "epilepsy, seizures" "BRD-K41260949-001-18-2, BRD-K41260949-236-20-0, BRD-K41260949-236-19-2" "CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O" "NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N" "Launched"
"883" "dixanthogen" "" "" "" "" "BRD-K05919151-001-01-6" "CCOC(=S)SSC(=S)OCC" "FVIGODVHAVLZOO-UHFFFAOYSA-N" "Preclinical"
"884" "dizocilpine-(+)" "glutamate receptor antagonist" "GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D" "" "" "BRD-K58930050-050-15-8, BRD-K58930050-001-05-2" "C[C@]12N[C@H](Cc3ccccc13)c1ccccc21, C[C@]12N[C@H](Cc3ccccc13)c1ccccc21" "LBOJYSIDWZQNJS-CVEARBPZSA-N, LBOJYSIDWZQNJS-CVEARBPZSA-N" "Preclinical"
"885" "dizocilpine-(-)" "glutamate receptor antagonist" "" "" "" "BRD-K23163214-050-15-1, BRD-K23163214-051-01-9" "C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21, C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21" "LBOJYSIDWZQNJS-JKSUJKDBSA-N, LBOJYSIDWZQNJS-JKSUJKDBSA-N" "Phase 1"
"886" "DMAB-anabaseine" "adrenergic receptor agonist" "CHRNA7" "" "" "BRD-K26573499-300-02-1" "CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1" "KHUUTHZSRXABAC-DTQAZKPQSA-N" "Preclinical"
"887" "DMeOB" "" "GRM5" "" "" "BRD-K36775483-001-01-4" "COc1cccc(c1)\C=N\N=C\c1cccc(OC)c1" "FBNPHFBYHYNMHC-JYFOCSDGSA-N" "Preclinical"
"888" "DMH1" "ALK tyrosine kinase receptor inhibitor" "ACVR1" "" "" "BRD-K39381259-001-01-0" "CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12" "JMIFGARJSWXZSH-UHFFFAOYSA-N" "Preclinical"
"889" "DMNB" "DNA dependent protein kinase inhibitor" "" "" "" "BRD-K03564313-001-03-3" "COc1cc(C=O)c(cc1OC)[N+]([O-])=O" "YWSPWKXREVSQCA-UHFFFAOYSA-N" "Preclinical"
"890" "DMP-543" "acetylcholine release enhancer" "" "" "" "BRD-K89274813-001-02-3" "Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1" "MUJBUUDUXGDXLW-UHFFFAOYSA-N" "Phase 2"
"891" "DMP-777" "elastase inhibitor" "MPO" "" "" "BRD-K54936858-001-01-6" "CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1" "ZSDCIRYNTCVTMF-GIGWZHCTSA-N" "Phase 2"
"892" "DMPS" "chelating agent" "" "" "" "BRD-A22971209-001-01-0" "OS(=O)(=O)CC(S)CS" "JLVSRWOIZZXQAD-UHFFFAOYSA-N" "Phase 1"
"893" "DMSO" "control vehicle" "" "" "" "BRD-M56212252-001-01-0" "CS(C)=O.CS(C)=O" "CETRZFQIITUQQL-UHFFFAOYSA-N" "Preclinical"
"894" "DNQX" "glutamate receptor antagonist" "GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B" "" "" "BRD-K64400208-001-08-3, BRD-K64400208-304-01-6" "[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O, [O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O" "RWVIMCIPOAXUDG-UHFFFAOYSA-N, RWVIMCIPOAXUDG-UHFFFAOYSA-N" "Preclinical"
"895" "dobutamine" "adrenergic receptor agonist" "ADRB1, ADRB2" "cardiology" "congestive heart failure" "BRD-A78322124-003-14-0, BRD-A78322124-003-15-7" "CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1, CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1" "JRWZLRBJNMZMFE-UHFFFAOYSA-N, JRWZLRBJNMZMFE-UHFFFAOYSA-N" "Launched"
"896" "docebenone" "lipoxygenase inhibitor" "ALOX5" "" "" "BRD-K08290224-001-14-5" "CC1=C(C)C(=O)C(CCCCC" "" ""
"897" "docetaxel" "tubulin polymerization inhibitor" "BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1" "oncology" "breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)" "BRD-A05821830-001-05-6, BRD-A05821830-341-01-5, BRD-A28612473-001-01-3" "CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)C2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)C2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C2[C@@H](OC(=O)c2ccccc2)[C@@]2(O)C[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C" "ZDZOTLJHXYCWBA-JXHJHTFNSA-N, ZDZOTLJHXYCWBA-JXHJHTFNSA-N, ZDZOTLJHXYCWBA-VSKOJUHESA-N" "Launched"
"898" "doconexent" "PPAR receptor agonist" "FFAR1, PTGS1, PTGS2" "" "" "BRD-K39965020-001-12-5, BRD-K39965020-001-09-1" "CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O" "MBMBGCFOFBJSGT-KUBAVDMBSA-N, MBMBGCFOFBJSGT-KUBAVDMBSA-N" "Launched"
"899" "doconexent-ethyl-ester" "omega 3 fatty acid stimulant" "" "" "" "BRD-K61937613-001-01-1" "CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC" "ITNKVODZACVXDS-YNUSHXQLSA-N" "Launched"
"900" "docosanol" "lipase clearing factor inhibitor" "TLR7" "dental" "cold sore" "BRD-K50050533-001-04-7, BRD-K50050533-001-03-9, BRD-K50050533-001-02-1" "CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCCCCCCCO" "NOPFSRXAKWQILS-UHFFFAOYSA-N, NOPFSRXAKWQILS-UHFFFAOYSA-N, NOPFSRXAKWQILS-UHFFFAOYSA-N" "Launched"
"901" "docusate" "laxative" "" "gastroenterology" "constipation" "BRD-A00092689-236-03-8" "CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(O)(=O)=O" "HNSDLXPSAYFUHK-UHFFFAOYSA-N" "Launched"
"902" "dodecyl-sulfate" "" "LYZ" "" "" "BRD-K05680146-001-01-2" "CCCCCCCCCCCCOS(O)(=O)=O" "MOTZDAYCYVMXPC-UHFFFAOYSA-N" "Preclinical"
"903" "dofequidar" "MRP inhibitor, P glycoprotein inhibitor" "ABCB1" "" "" "BRD-A14941520-051-01-0" "OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1" "KLWUUPVJTLHYIM-UHFFFAOYSA-N" "Phase 3"
"904" "dofetilide" "potassium channel blocker" "KCNH1, KCNH2, KCNJ12, KCNK2" "" "" "BRD-K86887724-001-10-6, BRD-K86887724-001-09-8" "CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1, CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1" "IXTMWRCNAAVVAI-UHFFFAOYSA-N, IXTMWRCNAAVVAI-UHFFFAOYSA-N" "Withdrawn"
"905" "dolasetron" "serotonin receptor antagonist" "HTR3A" "gastroenterology" "nausea, vomiting" "BRD-K34008116-001-01-7" "O=C(O[C@H]1C[C@@H]2C[C@@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12" "UKTAZPQNNNJVKR-XDQVBPFNSA-N" "Launched"
"906" "dolastatin-10" "tubulin polymerization inhibitor" "TUBB" "" "" "BRD-K78567475-001-01-4" "CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C" "OFDNQWIFNXBECV-VFSYNPLYSA-N" "Phase 2"
"907" "dolutegravir" "HIV integrase inhibitor" "CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K36386086-001-01-1" "C[C@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12" "RHWKPHLQXYSBKR-BONVTDFDSA-N" "Launched"
"908" "domiphen" "" "" "" "" "BRD-K30431096-004-01-3" "CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1" "YXUPZGKORWTXID-UHFFFAOYSA-N" "Preclinical"
"909" "domperidone" "dopamine receptor antagonist" "DRD2, DRD3" "infectious disease" "fescue toxicosis" "BRD-K38305202-001-17-4, BRD-K38305202-001-18-2, BRD-K38305202-001-16-6" "Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1, Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1" "FGXWKSZFVQUSTL-UHFFFAOYSA-N, FGXWKSZFVQUSTL-UHFFFAOYSA-N, FGXWKSZFVQUSTL-UHFFFAOYSA-N" "Launched"
"910" "donepezil" "acetylcholinesterase inhibitor" "ACHE, HTR2A" "neurology/psychiatry" "Alzheimers disease	BRD-A49160188-003-12-7, BRD-A49160188-003-11-9	COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC, COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC	ADEBPBSSDYVVLD-UHFFFAOYSA-N, ADEBPBSSDYVVLD-UHFFFAOYSA-N	Launched
donitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6			BRD-K31092604-003-03-5	NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12	SOHCKWZVTCTQBG-UHFFFAOYSA-N	Phase 2
dopamine	dopamine receptor agonist	DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4	cardiology, neurology/psychiatry	ventricular arrhythmias, depression, headache, tremors	BRD-K43887077-003-26-3, BRD-K43887077-003-27-1, BRD-K43887077-003-25-5	NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1, NCCc1ccc(O)c(O)c1	VYFYYTLLBUKUHU-UHFFFAOYSA-N, VYFYYTLLBUKUHU-UHFFFAOYSA-N, VYFYYTLLBUKUHU-UHFFFAOYSA-N	Launched
doramapimod	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			BRD-K74065929-001-08-0, BRD-K74065929-001-07-2	Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	MVCOAUNKQVWQHZ-UHFFFAOYSA-N, MVCOAUNKQVWQHZ-UHFFFAOYSA-N	Phase 2
doramectin			infectious disease	gastrointestinal roundworms	BRD-A16350940-001-01-9	CO[C@H]1C[C@H](OC2[C@H](C)OC(C[C@@H]2OC)O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(C5)O[C@H](C5CCCCC5)[C@@H](C)C=C2)[C@]34O)O[C@@H](C)[C@@H]1O	QLFZZSKTJWDQOS-CYHFSSRLSA-N	Launched
doripenem	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	BRD-K45319714-002-01-9, BRD-K45319714-002-03-5, BRD-K45319714-002-02-7, BRD-K20901660-002-03-3	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O, C[C@H](O)[C@H]1[C@@H]2[C@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O	AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-VFZPANTDSA-N, AVAACINZEOAHHE-PPQVSCAHSA-N	Launched
dorzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	intraocular pressure, glaucoma	BRD-K71075609-003-01-0	CCN[C@@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	IAVUPMFITXYVAF-POYBYMJQSA-N	Launched
dosulepin	norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K54759182-003-08-0	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	Launched
dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB			BRD-K85402309-406-01-8, BRD-K85402309-043-01-9, BRD-K85402309-389-03-2, BRD-K85402309-389-04-0, BRD-K85402309-001-07-4, BRD-K85402309-001-06-6	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N, PIQCTGMSNWUMAF-UHFFFAOYSA-N	Phase 3
doxapram	potassium channel blocker	KCNK3, KCNK9	pulmonary, neurology/psychiatry	respiratory depression, central nervous system depression, acute hypercapnia (AHC)	BRD-A46179541-311-02-0, BRD-A46179541-311-03-8	CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1, CCN1CC(CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1	XFDJYSQDBULQSI-UHFFFAOYSA-N, XFDJYSQDBULQSI-UHFFFAOYSA-N	Launched
doxazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	BRD-A13188892-066-21-5, BRD-A13188892-066-22-3	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1	RUZYUOTYCVRMRZ-UHFFFAOYSA-N, RUZYUOTYCVRMRZ-UHFFFAOYSA-N	Launched
doxepin	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HRH2, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, KCNH2, SLC6A2, SLC6A4	neurology/psychiatry	depression, anxiety	BRD-K37694030-003-12-7, BRD-K37694030-003-11-9	CN(C)CC\C=C1\c2ccccc2COc2ccccc12, CN(C)CC\C=C1\c2ccccc2COc2ccccc12	ODQWQRRAPPTVAG-BOPFTXTBSA-N, ODQWQRRAPPTVAG-BOPFTXTBSA-N	Launched
doxercalciferol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	BRD-K82928892-001-02-5, BRD-K07234650-001-01-4	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@@H](O)C[C@H](O)C1=C, CC(C)[C@H](C)\C=C\[C@@H](C)[C@@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1\C[C@H](O)C[C@H](O)C1=C	HKXBNHCUPKIYDM-ZKVKAWQFSA-N, HKXBNHCUPKIYDM-YXIGCUTJSA-N	Launched
doxifluridine	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	BRD-A68537732-001-03-6, BRD-K83057217-001-01-2	C[C@H]1OC(C(O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, C[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ZWAOHEXOSAUJHY-IRKUJEHTSA-N, ZWAOHEXOSAUJHY-YQHTUYAKSA-N	Launched
doxofylline	adenosine receptor antagonist	ADORA1, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma	BRD-K70507123-001-09-7, BRD-K70507123-001-08-9	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O, Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	HWXIGFIVGWUZAO-UHFFFAOYSA-N, HWXIGFIVGWUZAO-UHFFFAOYSA-N	Launched
doxorubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilms tumor, breast cancer, ovarian cancer, Hodgkins lymphoma, bladder cancer, multiple myeloma	BRD-K92093830-003-30-8, BRD-K92093830-003-31-6, BRD-K92093830-003-33-2, BRD-A52530684-001-02-9, BRD-K61468417-003-01-1	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](OC5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-TZSSRYMLSA-N, AOJJSUZBOXZQNB-TZSSRYMLSA-N, AOJJSUZBOXZQNB-TZSSRYMLSA-N, AOJJSUZBOXZQNB-BLSUDJMZSA-N, AOJJSUZBOXZQNB-HEKDSCCBSA-N	Launched
doxycycline	metalloproteinase inhibitor	MMP8	dental	periodontitis	BRD-A08545410-311-03-4, BRD-A08545410-003-07-8, BRD-A08545410-311-01-8, BRD-A36632888-003-01-6, BRD-A08545410-003-06-0	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@H]1[C@H]2[C@@H](O)[C@H]3[C@@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12, C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12	VXVNYCRICCVPTD-MULYGRJNSA-N, VXVNYCRICCVPTD-MULYGRJNSA-N, VXVNYCRICCVPTD-MULYGRJNSA-N, VXVNYCRICCVPTD-NBPHXEHFSA-N, VXVNYCRICCVPTD-MULYGRJNSA-N	Launched
doxycycline-hyclate	bacterial 30S ribosomal subunit inhibitor		dental	periodontitis	BRD-K06273313-001-07-9, BRD-K06273313-001-08-7, BRD-M28128163-003-01-7	CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N, CC(C)C[C@H](NC(=O)[C@@H]1O[C@H]1C(O)=O)C(=O)NCCCCN=C(N)N, CCO.C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12.C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12	LTLYEAJONXGNFG-HBNTYKKESA-N, LTLYEAJONXGNFG-HBNTYKKESA-N, OQQMRKYWJNJBBI-AIDNFEPSSA-N	Launched
doxylamine	histamine receptor antagonist	CHRM1, HRH1	neurology/psychiatry	sedative	BRD-A44008656-036-25-8, BRD-A44008656-036-24-1	CN(C)CCOC(C)(c1ccccc1)c1ccccn1, CN(C)CCOC(C)(c1ccccc1)c1ccccn1	HCFDWZZGGLSKEP-UHFFFAOYSA-N, HCFDWZZGGLSKEP-UHFFFAOYSA-N	Launched
DPC-681	HIV protease inhibitor				BRD-K37087535-001-01-1	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1	PNIFFZXGBAYVMQ-RKKDRKJOSA-N	Phase 1
DPCPX	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K01824921-001-18-5	CCCn1c2[nH]c(nc2c(=O)n(CCC)c1=O)C1CCCC1	FFBDFADSZUINTG-UHFFFAOYSA-N	Phase 1
DPI-201106	sodium channel activator	ADRB2			BRD-A64553394-001-04-4	OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1	BYBYHCOEAFHGJL-UHFFFAOYSA-N	Phase 2
DPO-1	potassium channel blocker	KCNA5			BRD-K99922388-001-02-0	CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	BPCNGVCAHAIZEE-COPCDDAFSA-N	Preclinical
DPPE	histamine receptor antagonist	ABCB1, HRH1			BRD-K80315159-051-02-0	CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	NFIXBCVWIPOYCD-UHFFFAOYSA-N	Phase 3
DR-2313	PARP inhibitor	PARP1, PARP3			BRD-K94920105-001-03-9	Cc1nc(=O)c2CSCCc2[nH]1	HRYKZAKEAVZGJD-UHFFFAOYSA-N	Preclinical
DRF053-(R)	CDK inhibitor	CSNK1A1			BRD-K25486274-300-01-0	CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	LWANFAFTTOKZAX-QGZVFWFLSA-N	Preclinical
drofenine			neurology/psychiatry	spasms	BRD-A22267103-003-13-1	CCN(CC)CCOC(=O)C(C1CCCCC1)c1ccccc1	AGJBLWCLQCKRJP-UHFFFAOYSA-N	Launched
droloxifene	selective estrogen receptor modulator (SERM)	ESR1			BRD-K38477637-001-01-0	CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1	ZQZFYGIXNQKOAV-OCEACIFDSA-N	Phase 3
dromostanolone-propionate	androgen receptor modulator	AR	oncology	breast cancer	BRD-A38706605-001-01-2	CCC(=O)OC1CCC2C3CCC4CC(=O)C(C)CC4(C)C3CCC12C	NOTIQUSPUUHHEH-UHFFFAOYSA-N	Launched
dronedarone	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	BRD-K05524748-003-04-4	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	Launched
droperidol	dopamine receptor antagonist	ADRA1A, DRD2, DRD3, DRD4, HTR2A	gastroenterology	nausea, vomiting	BRD-K97158071-001-18-1, BRD-K97158071-001-17-3	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O, Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O	RMEDXOLNCUSCGS-UHFFFAOYSA-N, RMEDXOLNCUSCGS-UHFFFAOYSA-N	Launched
dropropizine	antitussive		pulmonary	cough suppressant	BRD-A29349577-001-24-8, BRD-A29349577-001-23-0, BRD-A29349577-001-22-2	OCC(O)CN1CCN(CC1)c1ccccc1, OCC(O)CN1CCN(CC1)c1ccccc1, OCC(O)CN1CCN(CC1)c1ccccc1	PTVWPYVOOKLBCG-UHFFFAOYSA-N, PTVWPYVOOKLBCG-UHFFFAOYSA-N, PTVWPYVOOKLBCG-UHFFFAOYSA-N	Launched
drospirenone	mineralocorticoid receptor antagonist	AR, NR3C2, PGR	endocrinology	contraceptive	BRD-K04394237-001-03-7, BRD-A00938334-001-01-3, BRD-K04394237-001-04-5, BRD-K70875526-001-01-8	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CCC3C([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)C1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1, C[C@]12CC[C@@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@]21CCC(=O)O1	METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-GGORKCOASA-N, METQSPRSQINEEU-HXCATZOESA-N, METQSPRSQINEEU-OIBOXIMKSA-N	Launched
drotaverine	phosphodiesterase inhibitor	CACNA1C, PDE4A	obstetrics/gynecology	labor induction	BRD-K14658796-003-01-6, BRD-K14658796-001-01-0	CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC, CCOc1ccc(\C=C2\NCCc3cc(OCC)c(OCC)cc23)cc1OCC	OMFNSKIUKYOYRG-DEDYPNTBSA-N, OMFNSKIUKYOYRG-DEDYPNTBSA-N	Launched
droxicam	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K17219082-001-01-1, BRD-K17219082-001-02-9	CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O, CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O	OEHFRZLKGRKFAS-UHFFFAOYSA-N, OEHFRZLKGRKFAS-UHFFFAOYSA-N	Launched
droxidopa	norepinephrine precursor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH	cardiology, neurology/psychiatry	hypertension, Parkinsons Disease" "BRD-K20372197-001-02-3, BRD-K20372197-001-03-1" "N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O, N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O" "QXWYKJLNLSIPIN-JGVFFNPUSA-N, QXWYKJLNLSIPIN-JGVFFNPUSA-N" "Launched"
"911" "droxinostat" "HDAC inhibitor" "HDAC6, HDAC8" "" "" "BRD-K11558771-001-13-9" "Cc1cc(Cl)ccc1OCCCC(=O)NO" "JHSXDAWGLCZYSM-UHFFFAOYSA-N" "Preclinical"
"912" "DS2-(806622)" "" "" "" "" "BRD-K09619578-001-01-3" "Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1" "AZKMWHRDICVYEI-UHFFFAOYSA-N" "Preclinical"
"913" "DU-728" "structural glycoprotein antagonist" "ITGA2B, ITGB3" "" "" "BRD-K08859203-001-01-9" "N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O" "NNRFRJQMBSBXGO-CIUDSAMLSA-N" "Phase 1"
"914" "duloxetine" "norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)" "HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4" "neurology/psychiatry" "depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy" "BRD-K71103788-003-12-0, BRD-K71103788-003-11-2" "CNCC[C@H](Oc1cccc2ccccc12)c1cccs1, CNCC[C@H](Oc1cccc2ccccc12)c1cccs1" "ZEUITGRIYCTCEM-KRWDZBQOSA-N, ZEUITGRIYCTCEM-KRWDZBQOSA-N" "Launched"
"915" "DUP-697" "cyclooxygenase inhibitor" "PTGS2" "" "" "BRD-K06221026-001-06-8" "CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1" "AJFTZWGGHJXZOB-UHFFFAOYSA-N" "Phase 1"
"916" "dutasteride" "5 alpha reductase inhibitor" "SRD5A1, SRD5A2" "urology" "benign prostatic hyperplasia (BPH)" "BRD-K28984613-001-01-5" "C[C@]12CC[C@@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F" "JWJOTENAMICLJG-UUJLXMGASA-N" "Launched"
"917" "DVD-111" "" "" "" "" "BRD-K22520627-001-01-7" "CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1" "PJNSMUBMSNAEEN-AWEZNQCLSA-N" "Phase 2"
"918" "dyclonine" "sodium channel blocker" "SCN10A, SCN5A" "neurology/psychiatry" "local anesthetic" "BRD-K72259270-003-25-6, BRD-K72259270-003-23-1, BRD-K72259270-003-26-4, BRD-K72259270-003-24-9" "CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1, CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1" "BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N, BZEWSEKUUPWQDQ-UHFFFAOYSA-N" "Launched"
"919" "dydrogesterone" "progesterone receptor agonist" "PGR" "obstetrics/gynecology" "infertility" "BRD-A86597857-001-01-1, BRD-K68620903-001-09-8, BRD-K27038879-001-01-0" "CC(=O)[C@H]1CCC2C3C=CC4=CC(=O)CC[C@@]4(C)C3CC[C@]12C, CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C, CC(=O)[C@@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@H]3CC[C@]12C" "JGMOKGBVKVMRFX-ZYUAVDRCSA-N, JGMOKGBVKVMRFX-HQZYFCCVSA-N, JGMOKGBVKVMRFX-HQZQWKOLSA-N" "Launched"
"920" "dynasore" "dynamin inhibitor" "DNM1, DNM1L, DNM2" "" "" "BRD-K87718015-001-02-7, BRD-K87718015-001-01-9" "Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O, Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O" "SYNDQCRDGGCQRZ-VXLYETTFSA-N, SYNDQCRDGGCQRZ-VXLYETTFSA-N" "Preclinical"
"921" "dyphylline" "adenosine receptor antagonist, phosphodiesterase inhibitor" "ADORA1, ADORA2A, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B" "pulmonary" "asthma, bronchitis, emphysema" "BRD-A00827783-001-24-6, BRD-A00827783-001-23-8" "Cn1c2ncn(CC(O)CO)c2c(=O)n(C)c1=O, Cn1c2ncn(CC(O)CO)c2c(=O)n(C)c1=O" "KSCFJBIXMNOVSH-UHFFFAOYSA-N, KSCFJBIXMNOVSH-UHFFFAOYSA-N" "Launched"
"922" "DY131" "estrogen-related receptor agonist" "ESRRB, ESRRG" "" "" "BRD-K58343622-001-01-6" "CCN(CC)c1ccc(cc1)\C=N\NC(=O)c1ccc(O)cc1" "WLKOCYWYAWBGKY-CPNJWEJPSA-N" "Preclinical"
"923" "D609" "phospholipase inhibitor" "" "" "" "BRD-A77118605-237-08-7, BRD-A77118605-237-07-9, BRD-A77118605-237-06-1" "SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21, SC(=S)OC1CC2CC1C1CCCC21" "PWLXJBSAUKKGCM-UHFFFAOYSA-N, PWLXJBSAUKKGCM-UHFFFAOYSA-N, PWLXJBSAUKKGCM-UHFFFAOYSA-N" "Preclinical"
"924" "E-2012" "gamma secretase modulator" "APH1B" "" "" "BRD-K50564936-001-01-6, BRD-K69144501-001-01-1" "COc1cc(ccc1-n1cnc(C)c1)\C=C1/CCCN([C@@H](C)c2ccc(F)cc2)C1=O, CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OC" "PUOAETJYKQITMO-LANLRWRYSA-N, QWDCYFDDFPWISL-JEBPEJKESA-N" "Phase 1"
"925" "E-4031" "potassium channel blocker" "KCNH1, KCNH2" "" "" "BRD-K41713976-300-02-6" "Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1" "SRUISGSHWFJION-UHFFFAOYSA-N" "Phase 1"
"926" "ebastine" "histamine receptor antagonist" "CYP3A4, HRH1" "allergy" "allergic rhinitis, urticaria" "BRD-K13314656-001-01-0" "CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1" "MJJALKDDGIKVBE-UHFFFAOYSA-N" "Launched"
"927" "EBPC" "aldose reductase inhibitor" "AKR1B1" "" "" "BRD-A96485169-001-14-3" "CCOC(=O)C1CN(Cc2ccccc2)C(=O)C1=O" "FQMSSTZJKSWSMP-UHFFFAOYSA-N" "Preclinical"
"928" "ebrotidine" "histamine receptor antagonist" "HRH2" "" "" "BRD-K22421059-001-02-3, BRD-K22421059-001-01-5" "NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1, NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1" "ZQHFZHPUZXNPMF-UHFFFAOYSA-N, ZQHFZHPUZXNPMF-UHFFFAOYSA-N" "Withdrawn"
"929" "ebselen" "cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor" "ALB" "" "" "BRD-K29359156-001-30-1" "O=c1n([se]c2ccccc12)-c1ccccc1" "DYEFUKCXAQOFHX-UHFFFAOYSA-N" "Phase 2/Phase 3"
"930" "EC-23" "retinoid receptor agonist" "RARA, RARB, RARG" "" "" "BRD-K81004638-001-01-7" "CC1(C)CCC(C)(C)c2cc(ccc12)C" "" ""
"931" "ecabapide" "" "" "" "" "BRD-K47371940-001-01-6" "CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1" "JTAGHJPZEDNHHA-UHFFFAOYSA-N" "Phase 3"
"932" "ecabet" "gastrin inhibitor, urease inhibitor" "NOXO1" "ophthalmology" "dry eye syndrome" "BRD-K03353589-236-01-4" "CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O" "IWCWQNVIUXZOMJ-MISYRCLQSA-N" "Launched"
"933" "ecamsule-triethanolamine" "" "" "dermatology" "skin protectant, sunscreen lotion" "BRD-A47953250-001-01-7" "CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/c1ccc(cc1)\C=C1\C2CCC(CS(O)(=O)=O)(C1=O)C2(C)C" "HEAHZSUCFKFERC-AXPXABNXSA-N" "Launched"
"934" "echinomycin" "DNA intercalating agent" "" "" "" "BRD-A68969091-001-12-7" "CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1" "AUJXLBOHYWTPFV-UHFFFAOYSA-N" "Phase 2"
"935" "econazole" "lanosterol demethylase inhibitor, sterol demethylase inhibitor" "CYP51A1, NPY1R, NPY2R, TRPM2, TRPV5" "infectious disease" "tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis" "BRD-A51820102-008-28-9, BRD-A51820102-008-27-1" "Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1" "LEZWWPYKPKIXLL-UHFFFAOYSA-N, LEZWWPYKPKIXLL-UHFFFAOYSA-N" "Launched"
"936" "ectoine-zwitterion" "" "" "" "" "BRD-K60902958-001-01-9" "OC(=O)[C@@H]1CCNC(=C)N1" "FPZMPGPGYQUWQS-YFKPBYRVSA-N" "Preclinical"
"937" "edaravone" "nootropic agent" "BCL2" "neurology/psychiatry" "stroke" "BRD-K35458079-001-33-1, BRD-K35458079-001-29-9, BRD-K35458079-001-27-3, BRD-K35458079-001-28-1, BRD-K35458079-001-31-5" "CC1=NN(C(=O)C1)c1ccccc1, CC1=NN(C(=O)C1)c1ccccc1, CC1=NN(C(=O)C1)c1ccccc1, CC1=NN(C(=O)C1)c1ccccc1, CC1=NN(C(=O)C1)c1ccccc1" "QELUYTUMUWHWMC-UHFFFAOYSA-N, QELUYTUMUWHWMC-UHFFFAOYSA-N, QELUYTUMUWHWMC-UHFFFAOYSA-N, QELUYTUMUWHWMC-UHFFFAOYSA-N, QELUYTUMUWHWMC-UHFFFAOYSA-N" "Launched"
"938" "edelfosine" "phospholipase inhibitor" "" "" "" "BRD-A30403214-001-03-3" "CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC" "MHFRGQHAERHWKZ-HHHXNRCGSA-O" "Phase 2"
"939" "editol" "" "" "" "" "BRD-A78588743-001-03-4" "CC(O)CN(CCN(CC(C)O)CC(C)O)CC(C)O" "NSOXQYCFHDMMGV-UHFFFAOYSA-N" "Preclinical"
"940" "edoxaban" "coagulation factor inhibitor" "F10" "neurology/psychiatry, hematology, cardiology" "stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)" "BRD-K29322660-001-01-9" "CN(C)C(=O)[C@@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@H](C1)NC(=O)c1nc2CCN(C)Cc2s1" "HGVDHZBSSITLCT-KMFMINBZSA-N" "Launched"
"941" "edoxudine" "DNA directed DNA polymerase inhibitor" "" "infectious disease" "virus herpes simplex (HSV)" "BRD-K86892782-001-17-0" "CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O" "XACKNLSZYYIACO-DJLDLDEBSA-N" "Launched"
"942" "edrophonium" "acetylcholinesterase inhibitor" "ACHE, BCHE" "neurology/psychiatry" "myasthenia gravis" "BRD-K81128206-003-24-4" "CC[N+](C)(C)c1cccc(O)c1" "VWLHWLSRQJQWRG-UHFFFAOYSA-O" "Launched"
"943" "EDTMP" "chelating agent" "" "" "" "BRD-K54542929-001-01-7" "OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O" "NFDRPXJGHKJRLJ-UHFFFAOYSA-N" "Preclinical"
"944" "efaproxiral" "haemoglobin oxygen release stimulant" "HBA1, HBB" "" "" "BRD-K37355418-236-01-6" "Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1" "BNFRJXLZYUTIII-UHFFFAOYSA-N" "Phase 3"
"945" "efaroxan" "adrenergic receptor antagonist" "ADORA2A" "" "" "BRD-A10739734-003-10-6, BRD-A10739734-003-09-8" "CCC1(Cc2ccccc2O1)C1=NCCN1, CCC1(Cc2ccccc2O1)C1=NCCN1" "RATZLMXRALDSJW-UHFFFAOYSA-N, RATZLMXRALDSJW-UHFFFAOYSA-N" "Phase 2"
"946" "efatutazone" "PPAR receptor agonist" "PPARG" "" "" "BRD-A24560335-300-01-2" "Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N" "JCYNMRJCUYVDBC-UHFFFAOYSA-N" "Phase 2"
"947" "efavirenz" "HIV protease inhibitor" "CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K40758068-001-08-2" "FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C" "" ""
"948" "efinaconazole" "lanosterol demethylase inhibitor" "CYP51A1" "infectious disease" "onychomycosis" "BRD-A30774155-001-01-2" "C[C@@H](N1CCC(=C)CC1)C(O)(Cn1cncn1)c1ccc(F)cc1F" "NFEZZTICAUWDHU-IKJXHCRLSA-N" "Launched"
"949" "eflornithine" "ornithine decarboxylase inhibitor" "ARG2, ODC1" "dermatology" "facial hair reduction" "BRD-A96292436-003-16-1" "NCCCC(N)(C(F)F)C(O)=O" "VLCYCQAOQCDTCN-UHFFFAOYSA-N" "Launched"
"950" "efloxate" "vasodilator" "" "" "" "BRD-K55166090-001-09-0" "CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1" "ZVXBAHLOGZCFTP-UHFFFAOYSA-N" "Preclinical"
"951" "efonidipine-monoethanolate" "L-type calcium channel blocker, T-type calcium channel blocker" "CACNA1C, CACNA1G" "" "" "BRD-A39845846-003-01-2" "CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1" "NSVFSAJIGAJDMR-UHFFFAOYSA-N" "Launched"
"952" "EGF816" "EGFR inhibitor" "EGFR" "" "" "BRD-K22514639-001-05-7, BRD-K22514639-001-04-0" "CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12, CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12" "IOMMMLWIABWRKL-WUTDNEBXSA-N, IOMMMLWIABWRKL-WUTDNEBXSA-N" "Phase 2"
"953" "eglumetad" "glutamate receptor agonist" "GRM2, GRM3, GRM6, GRM8" "" "" "BRD-K65359424-001-02-1, BRD-K65359424-001-01-3" "N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O" "VTAARTQTOOYTES-RGDLXGNYSA-N, VTAARTQTOOYTES-RGDLXGNYSA-N" "Phase 2"
"954" "EG00229" "neuropilin receptor antagonist" "NRP1" "" "" "BRD-K50653584-001-01-2, BRD-K50653584-019-01-4" "NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O, NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O" "ZWWMEDURALZMEV-NSHDSACASA-N, ZWWMEDURALZMEV-NSHDSACASA-N" "Preclinical"
"955" "EHop-016" "Ras GTPase inhibitor" "RAC1, RAC3" "" "" "BRD-K32289541-001-01-0" "CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12" "AFTZZRFCMOAFCR-UHFFFAOYSA-N" "Preclinical"
"956" "EIT-hydrobromide" "nitric oxide synthase inhibitor" "NOS2, NOS3" "" "" "BRD-K81623406-004-08-3" "CCSC(N)=N" "VFIZBHJTOHUOEK-UHFFFAOYSA-N" "Preclinical"
"957" "EI1" "histone lysine methyltransferase inhibitor" "EZH2" "" "" "BRD-K91535048-001-01-2" "CCC(CC)n1ccc2c(cc(cc12)C" "" ""
"958" "elacridar" "P glycoprotein inhibitor" "ABCB1" "" "" "BRD-K88807631-001-01-3" "COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC" "OSFCMRGOZNQUSW-UHFFFAOYSA-N" "Phase 1"
"959" "elactocin" "exportin antagonist" "XPO1" "" "" "BRD-K63876426-001-01-6" "CCC(\C=C\[C@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(C)=C\[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C\C(C)=C\C(O)=O" "YACHGFWEQXFSBS-ZNDZZNGASA-N" "Phase 1"
"960" "elafibranor" "PPAR receptor agonist" "PPARA, PPARD" "" "" "BRD-K03165895-001-01-9" "CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1" "AFLFKFHDSCQHOL-IZZDOVSWSA-N" "Phase 3"
"961" "elagolix" "gonadotropin releasing factor hormone receptor antagonist" "GNRHR" "" "" "BRD-K55808645-001-01-4" "COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O" "HEAUOKZIVMZVQL-VWLOTQADSA-N" "Phase 3"
"962" "elbasvir" "HCV inhibitor" "" "infectious disease" "hepatitis C" "BRD-K09735259-001-01-3" "COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C" "BVAZQCUMNICBAQ-PZHYSIFUSA-N" "Launched"
"963" "elemene" "VEGFR inhibitor" "" "" "" "BRD-K79565391-001-01-8" "CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C" "OPFTUNCRGUEPRZ-RBSFLKMASA-N" "Phase 2"
"964" "elesclomol" "oxidative stress inducer" "HSPA1A" "" "" "BRD-K82135108-001-04-3" "CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1" "BKJIXTWSNXCKJH-UHFFFAOYSA-N" "Phase 3"
"965" "eletriptan" "serotonin receptor agonist" "HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7" "neurology/psychiatry" "migraine headache" "BRD-K30652337-004-02-1, BRD-K30652337-001-01-9, BRD-K30652337-004-01-3" "CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12, CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12" "PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N, PWVXXGRKLHYWKM-LJQANCHMSA-N" "Launched"
"966" "eliglustat" "Glycosyl transferase inhibitor" "UGCG" "hematology" "Gaucher disease, Gaucher disease" "BRD-M75840137-046-01-1, BRD-K86410485-001-01-5" "CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1" "SXVBURQVABOIKZ-HPHKMOBKSA-N, FJZZPCZKBUKGGU-AUSIDOKSSA-N" "Launched"
"967" "elinogrel" "purinergic receptor antagonist" "P2RY12" "" "" "BRD-K59271229-001-01-5" "CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F" "LGSDFTPAICUONK-UHFFFAOYSA-N" "Phase 2"
"968" "eliprodil" "glutamate receptor antagonist" "GRIN1, GRIN2B" "" "" "BRD-A61392169-001-02-7" "OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1" "GGUSQTSTQSHJAH-UHFFFAOYSA-N" "Phase 3"
"969" "ellagic-acid" "glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor" "CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK" "" "" "BRD-K30466858-001-10-4, BRD-K30466858-001-09-6, BRD-K30466858-001-08-8" "Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O, Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O" "AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N, AFSDNFLWKVMVRB-UHFFFAOYSA-N" "Phase 2"
"970" "ELN-441958" "bradykinin receptor antagonist" "BDKRB1" "" "" "BRD-K50699835-001-01-2" "Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1" "ARYQHSWJGHCGJS-UHFFFAOYSA-N" "Preclinical"
"971" "eltanolone" "membrane integrity inhibitor" "GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2" "" "" "BRD-K18172896-001-02-5" "CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C" "AURFZBICLPNKBZ-SYBPFIFISA-N" "Phase 3"
"972" "eltoprazine" "serotonin receptor agonist" "HTR1A, HTR1B" "" "" "BRD-K86171477-001-01-3, BRD-K86171477-001-03-9, BRD-K86171477-001-02-1" "C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12, C1CN(CCN1)c1cccc2OCCOc12" "WVLHGCRWEHCIOT-UHFFFAOYSA-N, WVLHGCRWEHCIOT-UHFFFAOYSA-N, WVLHGCRWEHCIOT-UHFFFAOYSA-N" "Phase 2"
"973" "eltrombopag" "thrombopoietin receptor agonist" "MPL" "hematology, infectious disease" "anemia, hepatitis C, thrombocytopenia" "BRD-K40496271-001-03-3, BRD-K40496271-396-01-1, BRD-K40496271-001-02-5" "CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1, CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1" "XDXWLKQMMKQXPV-HPNDGRJYSA-N, XDXWLKQMMKQXPV-HPNDGRJYSA-N, XDXWLKQMMKQXPV-HPNDGRJYSA-N" "Launched"
"974" "eluxadoline" "opioid receptor modulator" "OPRD1, OPRK1, OPRM1" "gastroenterology" "irritable bowel syndrome" "BRD-K39560679-001-01-1" "COc1ccc(CN([C@@H](C)c2ncc([nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O" "QFNHIDANIVGXPE-FNZWTVRRSA-N" "Launched"
"975" "elvitegravir" "HIV integrase inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K54472332-001-03-4" "COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C" "JUZYLCPPVHEVSV-LJQANCHMSA-N" "Launched"
"976" "embelin" "HCV inhibitor, XIAP inhibitor" "XIAP" "" "" "BRD-K86727142-001-12-4, BRD-K86727142-001-11-6, BRD-K86727142-001-13-2" "CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O, CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O" "FNQDSLSOLMXCMU-UHFFFAOYSA-N, FNQDSLSOLMXCMU-UHFFFAOYSA-N, FNQDSLSOLMXCMU-UHFFFAOYSA-N" "Preclinical"
"977" "EMD-1214063" "hepatocyte growth factor receptor inhibitor" "MET" "" "" "BRD-K97963946-001-01-3" "CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C" "" ""
"978" "EMD-386088" "serotonin receptor agonist" "HTR6" "" "" "BRD-K47659338-003-02-8" "Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1" "BPPGPYJBCVXILI-UHFFFAOYSA-N" "Preclinical"
"979" "EMD-53998" "phosphodiesterase inhibitor" "TNNC1" "" "" "BRD-A65248799-001-01-7" "COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)SC1C" "IZLRMTJLQCLMKF-UHFFFAOYSA-N" "Phase 1"
"980" "EMD-66684" "angiotensin receptor antagonist" "AGTR1" "" "" "BRD-K88759641-003-02-8" "CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1" "CQVJTTOZTTVVBK-UHFFFAOYSA-N" "Preclinical"
"981" "emedastine" "histamine receptor antagonist" "HRH1" "ophthalmology" "conjunctivitis" "BRD-K15010214-364-02-7, BRD-K15010214-364-01-9" "CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1, CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1" "KBUZBQVCBVDWKX-UHFFFAOYSA-N, KBUZBQVCBVDWKX-UHFFFAOYSA-N" "Launched"
"982" "emetine" "protein synthesis inhibitor" "RPS2" "" "" "BRD-A25687296-300-04-3, BRD-K03067624-001-02-3" "CC[C@H]1CN2CCc3cc(OC)c(OC)cc3C2C[C@@H]1CC1NCCc2cc(OC)c(OC)cc12, CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12" "AUVVAXYIELKVAI-VXNUJMKFSA-N, AUVVAXYIELKVAI-CKBKHPSWSA-N" "Phase 2"
"983" "emodin" "11-beta hydroxysteroid dehydrogenase inhibitor" "CSNK2A1" "" "" "BRD-K58685305-001-20-4" "Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1" "RHMXXJGYXNZAPX-UHFFFAOYSA-N" "Preclinical"
"984" "emorfazone" "antiinflammatory agent, cyclooxygenase inhibitor" "" "dental" "mouth inflammation" "BRD-K90629600-001-01-4" "CCOc1c(cnn(C)c1=O)N1CCOCC1" "URJQOOISAKEBKW-UHFFFAOYSA-N" "Launched"
"985" "emoxipin" "" "" "" "" "BRD-K28982731-001-01-6" "CCc1nc(C)ccc1O" "JPGDYIGSCHWQCC-UHFFFAOYSA-N" "Phase 2"
"986" "empagliflozin" "sodium/glucose cotransporter inhibitor" "SLC5A1, SLC5A2" "endocrinology" "diabetes mellitus" "BRD-K53765467-001-02-1" "OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1" "OBWASQILIWPZMG-QZMOQZSNSA-N" "Launched"
"987" "emtricitabine" "nucleoside reverse transcriptase inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K61452026-001-04-6" "Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1" "XQSPYNMVSIKCOC-NTSWFWBYSA-N" "Launched"
"988" "enalapril" "angiotensin converting enzyme inhibitor" "ACE" "cardiology" "hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)" "BRD-K57545991-050-23-1, BRD-K57545991-050-24-9" "CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O" "GBXSMTUPTTWBMN-XIRDDKMYSA-N, GBXSMTUPTTWBMN-XIRDDKMYSA-N" "Launched"
"989" "enalaprilat" "angiotensin converting enzyme inhibitor" "ACE" "cardiology" "hypertension" "BRD-K99447003-335-04-1, BRD-K99447003-335-03-3, BRD-K99447003-335-05-8, BRD-K99447003-335-02-5" "C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O" "LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N, LZFZMUMEGBBDTC-QEJZJMRPSA-N" "Launched"
"990" "enasidenib" "isocitrate dehydrogenase inhibitor" "IDH1" "" "" "BRD-K70601687-001-01-3" "CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F" "DYLUUSLLRIQKOE-UHFFFAOYSA-N" "Phase 3"
"991" "enbucrilate" "" "" "dermatology" "skin lacerations, tissue adhesive" "BRD-K66918327-001-01-3" "CCCCOC(=O)C(=C)C" "" ""
"992" "enciprazine" "GABA receptor modulator" "GABRA1" "" "" "BRD-A62197763-001-01-1" "COc1ccccc1N1CCN(CC(O)COc2cc(OC)c(OC)c(OC)c2)CC1" "KSQCNASWXSCJTD-UHFFFAOYSA-N" "Phase 3"
"993" "endo-IWR-1" "PARP inhibitor" "TNKS, TNKS2" "" "" "BRD-K61314889-001-05-1, BRD-K61314889-001-04-4" "O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O, O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O" "ZGSXEXBYLJIOGF-ALFLXDJESA-N, ZGSXEXBYLJIOGF-ALFLXDJESA-N" "Preclinical"
"994" "endoxifen" "estrogen receptor antagonist" "ESR1" "" "" "BRD-K91486246-003-01-4, BRD-K62752296-003-01-3" "CC\C(=C(\c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1, CC\C(c1ccccc1)=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1" "MHJBZVSGOZTKRH-OCOZRVBESA-N, MHJBZVSGOZTKRH-IZHYLOQSSA-N" "Phase 2"
"995" "enflurane" "membrane permeability inhibitor" "ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, KCNN4" "" "" "BRD-A51831848-001-01-7" "FC(F)OC(F)(F)C(F)Cl" "JPGQOUSTVILISH-UHFFFAOYSA-N" "Launched"
"996" "enilconazole" "sterol demethylase inhibitor" "CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2" "infectious disease" "skin infections" "BRD-A11776908-065-01-5" "Clc1ccc(C(Cn2ccnc2)OCC=C)c(Cl)c1" "PZBPKYOVPCNPJY-UHFFFAOYSA-N" "Launched"
"997" "eniluracil" "dihydropyrimidine dehydrogenase inhibitor" "AOX1, DPYD, XDH" "" "" "BRD-K26425819-001-01-3" "Oc1ncc(C" "" ""
"998" "enisamium-iodide" "" "" "" "" "BRD-K10029415-005-06-9" "C[n+]1ccc(cc1)C(=O)NCc1ccccc1" "QOEJDHLJOKRPJG-UHFFFAOYSA-O" "Launched"
"999" "ENMD-2076" "Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor" "AURKA, FLT3, KDR, PDGFRA, PTK2, SRC" "" "" "BRD-K68488863-001-04-9" "CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1" "BLQYVHBZHAISJM-CMDGGOBGSA-N" "Phase 2"
"1000" "enocitabine" "DNA synthesis inhibitor" "CMPK1, RRM1, TYMS" "" "" "BRD-K32007074-001-01-1, BRD-A77582494-001-01-3" "CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1, CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)C(O)[C@H]2O)c(=O)n1" "SAMRUMKYXPVKPA-VFKOLLTISA-N, SAMRUMKYXPVKPA-MJYRGXJLSA-N" "Launched"
"1001" "enoxacin" "topoisomerase inhibitor" "TOP2A" "infectious disease" "urinary tract infections, gonorrhea" "BRD-K78113049-001-16-2, BRD-K78113049-001-17-0, BRD-K78113049-001-15-4" "CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1" "IDYZIJYBMGIQMJ-UHFFFAOYSA-N, IDYZIJYBMGIQMJ-UHFFFAOYSA-N, IDYZIJYBMGIQMJ-UHFFFAOYSA-N" "Launched"
"1002" "enoximone" "phosphodiesterase inhibitor" "PDE3A" "cardiology" "congestive heart failure" "BRD-K21152241-001-07-3" "CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C" "ZJKNESGOIKRXQY-UHFFFAOYSA-N" "Launched"
"1003" "enoxolone" "gap junction modulator" "HSD11B1" "gastroenterology, otolaryngology" "peptic ulcer disease (PUD), common cold" "BRD-K80535353-001-01-4, BRD-A20200672-001-05-5" "C[C@]12CC[C@@](C)(C[C@@H]1C1=CC(=O)[C@H]3[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O, C[C@]12CC[C@@](C)(C[C@H]1C1=CC(=O)C3[C@@]4(C)CC[C@H](O)C(C)(C)C4CC[C@@]3(C)[C@]1(C)CC2)C(O)=O" "MPDGHEJMBKOTSU-AOLSMHRZSA-N, MPDGHEJMBKOTSU-VOPRYAMFSA-N" "Launched"
"1004" "enprofylline" "phosphodiesterase inhibitor" "ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B" "" "" "BRD-K35007173-001-07-5" "CCCn1c2nc[nH]c2c(=O)[nH]c1=O" "SIQPXVQCUCHWDI-UHFFFAOYSA-N" "Phase 3"
"1005" "enrofloxacin" "bacterial DNA gyrase inhibitor" "" "infectious disease" "gram-negative bacterial infections, gram-negative bacterial infections" "BRD-K76534306-001-22-7, BRD-K76534306-001-21-9" "CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1, CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1" "SPFYMRJSYKOXGV-UHFFFAOYSA-N, SPFYMRJSYKOXGV-UHFFFAOYSA-N" "Launched"
"1006" "entacapone" "catechol O methyltransferase inhibitor" "COMT" "neurology/psychiatry" "Parkinsons Disease	BRD-K83636919-001-05-5, BRD-K83636919-001-04-8, BRD-K83636919-001-03-0	CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O, CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O, CCN(CC)C(=O)C(\C#N)=C\c1cc(O)c(O)c(c1)[N+]([O-])=O	JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N, JRURYQJSLYLRLN-BJMVGYQFSA-N	Launched
entecavir	DNA replication inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	BRD-K08206212-002-01-0	Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1	QDGZDCVAUDNJFG-FXQIFTODSA-N	Launched
entinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC9			BRD-K77908580-001-09-6, BRD-K77908580-001-10-4	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	INVTYAOGFAGBOE-UHFFFAOYSA-N, INVTYAOGFAGBOE-UHFFFAOYSA-N	Phase 3
entrectinib	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	ALK, NTRK1, NTRK2, NTRK3, ROS1			BRD-K39009484-001-01-4	CN1CCN(CC1)c1ccc(C(=O)Nc2n[nH]c3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1	HAYYBYPASCDWEQ-UHFFFAOYSA-N	Phase 2
enzalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	BRD-K56851771-001-06-8	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	WXCXUHSOUPDCQV-UHFFFAOYSA-N	Launched
enzastaurin	PKC inhibitor	AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG			BRD-K79404599-001-09-3	Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12	AXRCEOKUDYDWLF-UHFFFAOYSA-N	Phase 3
EN460	endoplasmic reticulum oxidation inhibitor	ERO1A			BRD-K86063171-001-02-9	OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F	RSLFQCNAOMQAIH-WJDWOHSUSA-N	Preclinical
EO-1428	p38 MAPK inhibitor	MAPK11, MAPK14			BRD-K42452249-001-02-5, BRD-K42452249-001-03-3	Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl, Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	HDCLCHNAEZNGNV-UHFFFAOYSA-N, HDCLCHNAEZNGNV-UHFFFAOYSA-N	Preclinical
epacadostat	indoleamine 2,3-dioxygenase inhibitor	IDO1			BRD-K67385813-001-01-5, BRD-A15458132-001-01-9	NS(=O)(=O)NCCNC1=NONC\1=C(/Nc1ccc(F)c(Br)c1)[N+][O-], NS(=O)(=O)NCCNc1nonc1C(Nc1ccc(F)c(Br)c1)[N+][O-]	YPBKTZBXSBLTDK-PKNBQFBNSA-N, ILXMXVFOSIVPSY-UHFFFAOYSA-N	Phase 3
epalrestat	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	BRD-K98054437-001-09-9, BRD-K98054437-001-08-1, BRD-K98054437-001-11-5	CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1, CC(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N, CHNUOJQWGUIOLD-NFZZJPOKSA-N	Launched
eperezolid	bacterial 30S ribosomal subunit inhibitor				BRD-K47554101-001-01-2	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	SIMWTRCFFSTNMG-AWEZNQCLSA-N	Phase 1
eperisone	acetylcholine receptor antagonist	CYP2J2	neurology/psychiatry	amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury	BRD-A04252265-003-01-4	CCc1ccc(cc1)C(=O)C(C)CN1CCCCC1	SQUNAWUMZGQQJD-UHFFFAOYSA-N	Launched
ephedrine	adrenergic receptor agonist	ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	BRD-K45014108-003-01-8	CN[C@@H](C)[C@H](O)c1ccccc1	KWGRBVOPPLSCSI-WPRPVWTQSA-N	Launched
ephedrine-(racemic)	adrenergic receptor agonist	ADRA1A, ADRA2A	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	BRD-A54236247-003-04-3	CNC(C)C(O)c1ccccc1	KWGRBVOPPLSCSI-UHFFFAOYSA-N	Launched
epiandrosterone	steroid	G6PD			BRD-K42756753-001-01-9	C[C@]12CC[C@@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-DBQFFBIKSA-N	Preclinical
epicatechin-gallate-(-)	bacterial DNA gyrase inhibitor	BACE1, FASN			BRD-K50660797-001-05-1, BRD-K50660797-001-04-4	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	LSHVYAFMTMFKBA-TZIWHRDSSA-N, LSHVYAFMTMFKBA-TZIWHRDSSA-N	Phase 2
epigallocatechin-gallate-(-)	bacterial DNA gyrase inhibitor	ELANE, EP300, FASN, KAT2B, MMP14, MMP2			BRD-K55591206-001-20-7, BRD-K55591206-001-18-1, BRD-K55591206-001-19-9	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1, Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N, WMBWREPUVVBILR-WIYYLYMNSA-N	Phase 2/Phase 3
epinastine	histamine receptor antagonist	ADRA1A, ADRA2A, HRH1, HRH2, HTR2A, HTR7	ophthalmology	conjunctivitis	BRD-A98990573-003-01-3	NC1=NCC2N1c1ccccc1Cc1ccccc21	WHWZLSFABNNENI-UHFFFAOYSA-N	Launched
epinephrine	adrenergic receptor agonist, neurotransmitter	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	BRD-K63126190-003-01-6, BRD-K63126190-046-03-1, BRD-K63126190-046-02-3, BRD-K63126190-001-03-6, BRD-K63126190-001-04-4, BRD-K63126190-001-05-1	CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1, CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N, UCTWMZQNUQWSLP-VIFPVBQESA-N	Launched
epinephrine-(racemic)	carbonic anhydrase activator		cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	BRD-A07765530-001-05-6, BRD-A07765530-001-06-4	CNCC(O)c1ccc(O)c(O)c1, CNCC(O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-UHFFFAOYSA-N, UCTWMZQNUQWSLP-UHFFFAOYSA-N	Launched
epirizole	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K39339537-001-21-0	COc1cc(C)nn1-c1nc(C)cc(OC)n1	RHAXSHUQNIEUEY-UHFFFAOYSA-N	Launched
epirubicin	topoisomerase inhibitor	CHD1, TOP2A	oncology	breast cancer	BRD-K56844688-003-01-2, BRD-K04548931-003-13-2	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-SQGPBGNMSA-N, AOJJSUZBOXZQNB-VTZDEGQISA-N	Launched
epitiostanol	androgen receptor agonist	AR			BRD-K02314383-001-01-3	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O	OBMLHUPNRURLOK-XGRAFVIBSA-N	Launched
eplerenone	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure, hypertension	BRD-K19761926-001-03-6, BRD-K19761926-001-02-8, BRD-K82139003-001-01-7	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13, COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@]23O[C@H]2C[C@@]2(C)[C@@H](CC[C@]22CCC(=O)O2)[C@H]13	JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-VWBFHTRKSA-N, JUKPWJGBANNWMW-RZVCPIHASA-N	Launched
epomediol	cholesterol inhibitor	CYP7A1			BRD-A59329714-001-01-5	CC1(C)OC2(C)C(O)CC1CC2O	JSNQSLSBBZFGBM-UHFFFAOYSA-N	Launched
epoprostenol	prostacyclin analog	P2RY12, PTGER1, PTGER4, PTGIR, PTGIS	cardiology	hypertension	BRD-K64054020-001-03-5	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	KAQKFAOMNZTLHT-OZUDYXHBSA-N	Launched
epothilone-a	microtubule stabilizing agent				BRD-K87031376-001-01-0	C[C@H]1CCC[C@H]2O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	HESCAJZNRMSMJG-RANUMCTHSA-N	Preclinical
epothilone-b	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B			BRD-K68164687-001-01-6	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@@H](OC(=O)C[C@@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	QXRSDHAAWVKZLJ-AXCXJGFASA-N	Phase 3
epothilone-d	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, TUBB4A, TUBB4B			BRD-K52762805-001-01-2	C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	XOZIUKBZLSUILX-GIQCAXHBSA-N	Phase 2
eprazinone	mucolytic agent		pulmonary	bronchospasm	BRD-A72212290-300-02-2, BRD-A72212290-300-01-4	CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1, CCOC(CN1CCN(CC(C)C(=O)c2ccccc2)CC1)c1ccccc1	BSHWLCACYCVCJE-UHFFFAOYSA-N, BSHWLCACYCVCJE-UHFFFAOYSA-N	Launched
eprinomectin	benzodiazepine receptor agonist		infectious disease	gastrointestinal roundworms, lungworms	BRD-A91366704-001-01-9	CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C	ZKWQQXZUCOBISE-WIDYHQJMSA-N	Launched
eprobemide	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	BRD-K17979676-001-01-2	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	YYFGRAGNYHYWEZ-UHFFFAOYSA-N	Launched
eprodisate	antiamyloidogenic agent, amyloid protein inhibitor	SAA1			BRD-K11463116-304-03-5, BRD-K11463116-304-02-7, BRD-K11463116-304-01-9	OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O, OS(=O)(=O)CCCS(O)(=O)=O	MGNVWUDMMXZUDI-UHFFFAOYSA-N, MGNVWUDMMXZUDI-UHFFFAOYSA-N, MGNVWUDMMXZUDI-UHFFFAOYSA-N	Phase 3
eprosartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	BRD-K67977190-066-03-1, BRD-K67977190-066-02-3	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O, CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	OROAFUQRIXKEMV-LDADJPATSA-N, OROAFUQRIXKEMV-LDADJPATSA-N	Launched
eptifibatide	platelet aggregation inhibitor	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	BRD-A90547603-001-02-5	NC(=N)NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O	CZKPOZZJODAYPZ-UHFFFAOYSA-N	Launched
EPZ-5676	histone lysine methyltransferase inhibitor	DOT1L			BRD-K26531771-001-01-4, BRD-K63457253-001-01-3	CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1, CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)C1C[C@H](CCc2nc3cc(ccc3[nH]2)C(C)(C)C)C1	LXFOLMYKSYSZQS-LURJZOHASA-N, LXFOLMYKSYSZQS-JTBNCTPPSA-N	Phase 1
EPZ004777	histone lysine methyltransferase inhibitor	DOT1L			BRD-K69070623-001-01-1, BRD-K69070623-003-01-7, BRD-K69070623-001-02-9	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12, CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	WXRGFPHDRFQODR-ICLZECGLSA-N, WXRGFPHDRFQODR-ICLZECGLSA-N, WXRGFPHDRFQODR-ICLZECGLSA-N	Preclinical
EPZ005687	histone lysine methyltransferase inhibitor	EZH2			BRD-K57754230-001-02-7	Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1	ZOIBZSZLMJDVDQ-UHFFFAOYSA-N	Preclinical
EPZ011989	histone lysine methyltransferase inhibitor	EZH2			BRD-K87468701-001-01-0	CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1	XQFINGFCBFHOPE-WXUXXXNLSA-N	Preclinical
EPZ015666	protein arginine N-methyltransferase inhibitor	PRMT5			BRD-K70446295-001-01-7	O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1	ZKXZLIFRWWKZRY-KRWDZBQOSA-N	Preclinical
EPZ020411	protein arginine N-methyltransferase inhibitor	PRMT6			BRD-K33586289-003-02-8, BRD-K33586289-003-01-0	CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1, CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1	QMDKVNSQXPVCRD-RQNOJGIXSA-N, QMDKVNSQXPVCRD-RQNOJGIXSA-N	Preclinical
equilin	estrogen receptor agonist	HSD17B1			BRD-A88080608-001-04-2	CC12CCC3C(=CCc4cc(O)ccc34)C1CCC2=O	WKRLQDKEXYKHJB-UHFFFAOYSA-N	Preclinical
equol	estrogen receptor agonist	ESR1, ESR2			BRD-K54847683-001-04-0, BRD-K54847683-001-03-2	Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1, Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	ADFCQWZHKCXPAJ-GFCCVEGCSA-N, ADFCQWZHKCXPAJ-GFCCVEGCSA-N	Launched
ER-27319	mediator release inhibitor, SYK inhibitor	SYK			BRD-K11927976-050-02-9	Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	CFPDEQBPNROZDC-UHFFFAOYSA-N	Preclinical
erastin	ion channel antagonist	VDAC2			BRD-A25004090-001-09-2, BRD-A25004090-001-08-4	CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1, CCOc1ccccc1-n1c(=O)c2ccccc2nc1C(C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1	BKQFRNYHFIQEKN-UHFFFAOYSA-N, BKQFRNYHFIQEKN-UHFFFAOYSA-N	Preclinical
erbstatin-analog	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			BRD-K35573744-001-06-8	COC(=O)\C=C\c1cc(O)ccc1O	BQCNSTFWSKOWMA-GORDUTHDSA-N	Preclinical
ercalcitriol	vitamin D receptor agonist	VDR			BRD-K84163249-001-01-9	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	ZGLHBRQAEXKACO-XJRQOBMKSA-N	Phase 1
erdafitinib	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4			BRD-K84868168-001-01-0	COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	OLAHOMJCDNXHFI-UHFFFAOYSA-N	Phase 2
erdosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections	BRD-A05515753-001-04-0, BRD-A05515753-001-03-2, BRD-A05515753-001-02-4	OC(=O)CSCC(=O)NC1CCSC1=O, OC(=O)CSCC(=O)NC1CCSC1=O, OC(=O)CSCC(=O)NC1CCSC1=O	QGFORSXNKQLDNO-UHFFFAOYSA-N, QGFORSXNKQLDNO-UHFFFAOYSA-N, QGFORSXNKQLDNO-UHFFFAOYSA-N	Launched
ergocalciferol	vitamin analog	VDR	endocrinology, orthopedics	hypoparathyroidism, rickets, hypophosphatemia	BRD-K56155962-001-12-1, BRD-A87199639-001-04-4, BRD-K05243578-001-01-6, BRD-K56155962-001-11-3	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)C1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@H](O)CCC1=C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	MECHNRXZTMCUDQ-RKHKHRCZSA-N, MECHNRXZTMCUDQ-CIFSABHRSA-N, MECHNRXZTMCUDQ-PNXBIAHGSA-N, MECHNRXZTMCUDQ-RKHKHRCZSA-N	Launched
ergonovine	adrenergic receptor agonist, serotonin receptor agonist	ADRA1A, HTR1E	hematology	postpartum hemorrhage (PPH)	BRD-A26387268-050-04-4	CC(CO)NC(=O)C1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34	WVVSZNPYNCNODU-FWXSHLFISA-N	Launched
ergosterol	vitamin D precursor				BRD-K09161066-001-01-5, BRD-K03039262-001-03-7	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C, CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	DNVPQKQSNYMLRS-UYLSPUCXSA-N, DNVPQKQSNYMLRS-APGDWVJJSA-N	Preclinical
ergotamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, DRD1, DRD2, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, SLC6A2	neurology/psychiatry	migraine headache	BRD-A43227343-046-01-4	CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)C3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	XCGSFFUVFURLIX-WSHJXIHDSA-N	Launched
ERK5-IN-1	MAP kinase inhibitor	MAPK7			BRD-K64857848-001-06-4	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1	DDTPGANIPBKTNU-UHFFFAOYSA-N	Preclinical
erlotinib	EGFR inhibitor	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	BRD-K70401845-003-09-6, BRD-K70401845-001-15-7	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	AAKJLRGGTJKAMG-UHFFFAOYSA-N, AAKJLRGGTJKAMG-UHFFFAOYSA-N	Launched
ertapenem	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, urinary tract infections, gynecologic infections, postpartum endomyometritis	BRD-A40472231-304-01-7, BRD-A40472231-304-02-5	C[C@@H](O)C1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O, C[C@@H](O)C1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O	JUZNIMUFDBIJCM-YZLSNGRKSA-N, JUZNIMUFDBIJCM-YZLSNGRKSA-N	Launched
erteberel	estrogen receptor agonist	ESR1, ESR2			BRD-K80608265-001-01-6	Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	XIESSJVMWNJCGZ-VKJFTORMSA-N	Phase 2
ertugliflozin	sodium/glucose cotransporter inhibitor	SLC5A2			BRD-K10071630-001-01-0	CCOc1ccc(Cc2cc(ccc2Cl)[C@@]23OC[C@@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1	MCIACXAZCBVDEE-VNXMGFANSA-N	Phase 3
erythritol					BRD-K79315489-001-08-6, BRD-K79315489-001-07-8	OC[C@H](O)[C@H](O)CO, OC[C@H](O)[C@H](O)CO	UNXHWFMMPAWVPI-ZXZARUISSA-N, UNXHWFMMPAWVPI-ZXZARUISSA-N	Launched
erythromycin	NFkB pathway inhibitor	MLNR	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	BRD-K63550407-001-12-7, BRD-K05127550-001-02-1, BRD-A20485507-001-01-2, BRD-K63550407-028-04-7	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@@](C)(OC)[C@H](O)[C@@H](C)O2)[C@H](C)[C@@H](O[C@H]2OC(C)C[C@H]([C@H]2O)N(C)C)[C@@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	ULGZDMOVFRHVEP-RWJQBGPGSA-N, ULGZDMOVFRHVEP-WAZPLXRZSA-N, ULGZDMOVFRHVEP-IKHZKFQISA-N, ULGZDMOVFRHVEP-RWJQBGPGSA-N	Launched
erythromycin-estolate	bacterial 50S ribosomal subunit inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	BRD-K39746403-084-04-9	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	TYQXKHPOXXXCTP-CSLYCKPJSA-N	Launched
erythromycin-ethylsuccinate	cytochrome P450 inhibitor, protein synthesis inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	BRD-K51677086-001-12-0, BRD-K13846766-001-01-8, BRD-K51677086-001-13-8	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C, CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	NSYZCCDSJNWWJL-YXOIYICCSA-N, NSYZCCDSJNWWJL-NYWHKKSUSA-N, NSYZCCDSJNWWJL-YXOIYICCSA-N	Launched
erythrosine	coloring agent				BRD-K14920963-304-02-7	OC(=O)c1ccccc1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	LAINPTZBIXYTIZ-UHFFFAOYSA-N	Preclinical
esaprazole					BRD-K92426617-001-06-3, BRD-K92426617-001-05-5	O=C(CN1CCNCC1)NC1CCCCC1, O=C(CN1CCNCC1)NC1CCCCC1	RTFADALJKSFJDZ-UHFFFAOYSA-N, RTFADALJKSFJDZ-UHFFFAOYSA-N	Phase 2
escin	nitric oxide synthase stimulant		dermatology	varicose veins	BRD-A90796352-001-04-7	C\C=C(\C)C(=O)O[C@@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CCC4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)C5CC[C@@]34C)C2CC1(C)C	AXNVHPCVMSNXNP-LGWBRZJHSA-N	Launched
escitalopram	selective serotonin reuptake inhibitor (SSRI)	ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD)	BRD-K70301876-034-14-5, BRD-K70301876-034-13-7	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1, CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	WSEQXVZVJXJVFP-FQEVSTJZSA-N, WSEQXVZVJXJVFP-FQEVSTJZSA-N	Launched
esculin	antioxidant				BRD-K36270037-001-01-7	OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@@H](O)[C@@H](O)[C@@H]1O	XHCADAYNFIFUHF-JSFFLRCESA-N	Phase 1
eseroline-(-)	acetylcholinesterase inhibitor	OPRD1, OPRM1			BRD-K13629382-051-06-6	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21	HKGWQUVGHPDEBZ-OLZOCXBDSA-N	Preclinical
ESI-09	EPAC inhibitor	RAPGEF3, RAPGEF4			BRD-K77139516-001-02-2, BRD-K77139516-001-01-4	CC(C)(C)c1cc(no1)C(=O)C(\C#N)=N\Nc1cccc(Cl)c1, CC(C)(C)c1cc(no1)C(=O)C(\C#N)=N\Nc1cccc(Cl)c1	DXEATJQGQHDURZ-DEDYPNTBSA-N, DXEATJQGQHDURZ-DEDYPNTBSA-N	Preclinical
eslicarbazepine-acetate	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K61237927-001-01-7	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	QIALRBLEEWJACW-INIZCTEOSA-N	Launched
esmolol	adrenergic receptor antagonist	ADRB1	cardiology	ventricular tachycardia (VT), hypertension	BRD-A07395371-003-10-0	COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1	AQNDDEOPVVGCPG-UHFFFAOYSA-N	Launched
esomeprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)	BRD-K61443506-239-01-6, BRD-K61443506-236-02-0, BRD-K61443506-237-01-0	COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C, COc1ccc2[nH]c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N, SUBDBMMJDZJVOS-DEOSSOPVSA-N	Launched
estetrol	selective estrogen receptor modulator (SERM)	ESR1			BRD-K75445017-001-01-1	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	AJIPIJNNOJSSQC-NYLIRDPKSA-N	Phase 3
estradiol	estrogen receptor agonist	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	BRD-A18917088-001-04-9, BRD-K60633875-001-01-0, BRD-K18910433-001-36-6	C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2O, C[C@]12CC[C@@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	VOXZDWNPVJITMN-PAOLREHBSA-N, VOXZDWNPVJITMN-RZFLPCETSA-N, VOXZDWNPVJITMN-ZBRFXRBCSA-N	Launched
estradiol-acetate	estrogen receptor agonist	ESR1	endocrinology, obstetrics/gynecology	menopause, vaginal atrophy	BRD-K53319039-001-01-8	CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1	FHXBMXJMKMWVRG-SLHNCBLASA-N	Launched
estradiol-benzoate	contraceptive agent	ESR1			BRD-A74765037-001-01-1	C[C@]12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CC[C@@H]2O	UYIFTLBWAOGQBI-YSHINGEJSA-N	Preclinical
estradiol-cypionate	estrogen receptor agonist	ESR1	endocrinology	hypoestrogenism, menopause	BRD-A91452556-001-04-0	C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@H]2OC(=O)CCC1CCCC1	UOACKFBJUYNSLK-OCTSOESTSA-N	Launched
estradiol-valerate	estrogen receptor agonist	ESR1	oncology, endocrinology, obstetrics/gynecology	prostate cancer, hypoestrogenism, menopause, vaginal atrophy	BRD-A39747742-001-04-3, BRD-K12790232-001-01-5	CCCCC(=O)O[C@H]1CCC2C3CCc4cc(O)ccc4C3CC[C@]12C, CCCCC(=O)O[C@@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@@H]3CC[C@]12C	RSEPBGGWRJCQGY-ZZSVNSIZSA-N, RSEPBGGWRJCQGY-FPQOSCNCSA-N	Launched
estramustine	DNA alkylating agent	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	BRD-A70858459-001-01-7	C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O	FRPJXPJMRWBBIH-ZZSVNSIZSA-N	Launched
estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	BRD-K00077635-304-01-2	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	ADFOJJHRTBFFOF-RBRWEJTLSA-N	Launched
estriol	estrogen receptor agonist	ESR1, ESR2	endocrinology, obstetrics/gynecology, infectious disease	menopause, vaginal atrophy, urinary tract infections	BRD-A18620900-001-05-2, BRD-K03411175-001-01-8, BRD-A63433173-001-02-1, BRD-K17016787-001-13-4	C[C@]12CCC3C(CCc4cc(O)ccc34)C1C[C@@H](O)[C@@H]2O, C[C@]12CC[C@@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@H]2O, CC12CCC3C(CCc4cc(O)ccc34)C1C[C@H](O)[C@@H]2O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	PROQIPRRNZUXQM-YDGSGPMOSA-N, PROQIPRRNZUXQM-ZKZVPCBQSA-N, PROQIPRRNZUXQM-WRECPOHLSA-N, PROQIPRRNZUXQM-ZXXIGWHRSA-N	Launched
estrone	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2			BRD-A37959677-001-04-5, BRD-K81839095-001-25-1, BRD-K15236393-001-01-1	C[C@]12CCC3C(CCc4cc(O)ccc34)C1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O, C[C@]12CC[C@@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	DNXHEGUUPJUMQT-GUZDXLFXSA-N, DNXHEGUUPJUMQT-CBZIJGRNSA-N, DNXHEGUUPJUMQT-DFGXFYAUSA-N	Launched
estropipate	estrogen receptor agonist	ESR1, ESR2	orthopedics, endocrinology, obstetrics/gynecology	osteoporosis, menopause, vaginal atrophy, hypoestrogenism	BRD-A22143024-231-03-8	C[C@]12CCC3C(CCc4cc(OS(O)(=O)=O)ccc34)C1CCC2=O	JKKFKPJIXZFSSB-GUZDXLFXSA-N	Launched
eszopiclone	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO	neurology/psychiatry	insomnia	BRD-K29220403-001-10-8	CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)c2nccnc12)c1ccc(Cl)cn1	GBBSUAFBMRNDJC-INIZCTEOSA-N	Launched
etacrynic-acid	sodium/potassium/chloride transporter inhibitor	ATP1A1, SLC12A1	cardiology, gastroenterology, nephrology, rheumatology	hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome	BRD-K63630713-001-25-8	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	AVOLMBLBETYQHX-UHFFFAOYSA-N	Launched
etafenone	calcium channel blocker				BRD-K84971356-001-01-4	CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1	OEGDFSLNGABBKJ-UHFFFAOYSA-N	Launched
etamsylate	haemostatic agent		hematology	hemorrhage	BRD-K71055333-224-06-6, BRD-K71055333-224-05-8	Oc1ccc(O)c(c1)S(O)(=O)=O, Oc1ccc(O)c(c1)S(O)(=O)=O	IKQCSJBQLWJEPU-UHFFFAOYSA-N, IKQCSJBQLWJEPU-UHFFFAOYSA-N	Launched
etanidazole	bacterial cell wall synthesis inhibitor				BRD-K96042922-001-09-8	OCCNC(=O)Cn1ccnc1[N+]([O-])=O	WCDWBPCFGJXFJZ-UHFFFAOYSA-N	Phase 3
etazolate	phosphodiesterase inhibitor	GABRB3, PDE4A			BRD-K64755930-003-03-2	CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	OPQRBXUBWHDHPQ-UHFFFAOYSA-N	Phase 2
ETC-1002	AMPK inhibitor	ACLY			BRD-K63177377-001-01-8	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	HYHMLYSLQUKXKP-UHFFFAOYSA-N	Phase 3
ETC-159	porcupine inhibitor, beta catenin inhibitor	PORCN			BRD-K54264768-001-01-2	Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O	QTRXIFVSTWXRJJ-UHFFFAOYSA-N	Phase 1
etebenecid	uricosuric blocker				BRD-K24443618-001-10-2	CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O	UACOQEQOBAQRDQ-UHFFFAOYSA-N	Preclinical
eterobarb	anticonvulsant				BRD-K64834129-001-19-6	CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1	DACOQFZGGLCXMA-UHFFFAOYSA-N	Phase 2
ethacizin	anticonvulsant		cardiology	ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)	BRD-K10667240-001-01-7	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1	PQXGNJKJMFUPPM-UHFFFAOYSA-N	Launched
ethacridine-lactate-monohydrate	DNA intercalating agent				BRD-K24715592-406-02-1, BRD-K24715592-043-02-2, BRD-K24715592-406-01-3	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1, CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N, CIKWKGFPFXJVGW-UHFFFAOYSA-N	Preclinical
ethambutol	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	BRD-K93231391-300-06-4, BRD-K93231391-300-05-6	CC[C@@H](CO)NCCN[C@@H](CC)CO, CC[C@@H](CO)NCCN[C@@H](CC)CO	AEUTYOVWOVBAKS-UWVGGRQHSA-N, AEUTYOVWOVBAKS-UWVGGRQHSA-N	Launched
ethamivan	respiratory stimulant				BRD-K38055836-001-21-1	CCN(CC)C(=O)c1ccc(O)c(OC)c1	BQJODPIMMWWMFC-UHFFFAOYSA-N	Preclinical
ethanolamine-oleate	immunostimulant	F12, FABP4, FFAR1, FFAR4, PLD2	gastroenterology	esophageal varices	BRD-M75061779-001-01-2	NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O	KGWDUNBJIMUFAP-KVVVOXFISA-N	Launched
ethaverine	calcium channel blocker		neurology/psychiatry	muscle relaxant, spasms	BRD-K36756879-003-08-7	CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	ZOWYFYXTIWQBEP-UHFFFAOYSA-N	Launched
ethenzamide	analgesic agent		neurology/psychiatry, endocrinology, otolaryngology	headache, fever, common cold	BRD-K88308881-001-06-8	CCOc1ccccc1C(N)=O	SBNKFTQSBPKMBZ-UHFFFAOYSA-N	Launched
ethimizol					BRD-K19672466-001-02-3	CCn1cnc(C(=O)NC)c1C(=O)NC	RYRFAMRQBZNEPX-UHFFFAOYSA-N	Phase 1
ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2, NR1I2	endocrinology	contraceptive	BRD-A02367930-001-04-5, BRD-K42555202-001-01-2, BRD-K48195008-001-17-3	C[C@]12CCC3C(CCc4cc(O)ccc34)C1CC[C@@]2(O)C#C, C[C@]12CC[C@@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@]2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	BFPYWIDHMRZLRN-OQPPHWFISA-N, BFPYWIDHMRZLRN-LJDSDSDDSA-N, BFPYWIDHMRZLRN-SLHNCBLASA-N	Launched
ethionamide	mycolic synthesis inhibitor		infectious disease	tuberculosis	BRD-K51207550-001-23-0, BRD-K51207550-001-22-2	CCc1cc(ccn1)C(S)=N, CCc1cc(ccn1)C(S)=N	AEOCXXJPGCBFJA-UHFFFAOYSA-N, AEOCXXJPGCBFJA-UHFFFAOYSA-N	Launched
ethisterone	progestogen hormone	TYR			BRD-A29111201-001-04-8, BRD-K03981224-001-19-3, BRD-K00456604-001-01-7	CC12CCC3C(CCC4=CC(=O)CCC34C)C1CCC2(O)C#C, C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C, C[C@]12CC[C@@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C#C	CHNXZKVNWQUJIB-UHFFFAOYSA-N, CHNXZKVNWQUJIB-CEGNMAFCSA-N, CHNXZKVNWQUJIB-QMFSVNIWSA-N	Launched
ethopabate	antiprotozoal agent		infectious disease	coccidiosis	BRD-K02475039-001-01-0	CCOc1cc(NC(C)=O)ccc1C(=O)OC	GOVWOKSKFSBNGD-UHFFFAOYSA-N	Launched
ethosuximide	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	epilepsy	BRD-A99633051-001-08-8, BRD-A99633051-001-07-0	CCC1(C)CC(=O)NC1=O, CCC1(C)CC(=O)NC1=O	HAPOVYFOVVWLRS-UHFFFAOYSA-N, HAPOVYFOVVWLRS-UHFFFAOYSA-N	Launched
ethotoin	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-A30205217-001-12-0, BRD-A30205217-001-11-2	CCN1C(=O)NC(C1=O)c1ccccc1, CCN1C(=O)NC(C1=O)c1ccccc1	SZQIFWWUIBRPBZ-UHFFFAOYSA-N, SZQIFWWUIBRPBZ-UHFFFAOYSA-N	Launched
ethoxyquin	antioxidant				BRD-K56792340-001-13-2	CCOc1ccc2NC(C)(C)C=C(C)c2c1	DECIPOUIJURFOJ-UHFFFAOYSA-N	Preclinical
ethoxzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9	ophthalmology, gastroenterology	glaucoma, duodenal ulcer disease	BRD-K18131774-001-17-6, BRD-K18131774-001-18-4	CCOc1ccc2nc(sc2c1)S(N)(=O)=O, CCOc1ccc2nc(sc2c1)S(N)(=O)=O	OUZWUKMCLIBBOG-UHFFFAOYSA-N, OUZWUKMCLIBBOG-UHFFFAOYSA-N	Launched
ethyl-paraben					BRD-K02464583-001-02-2	CCOC(=O)c1ccc(O)cc1	NUVBSKCKDOMJSU-UHFFFAOYSA-N	Preclinical
ethyl-pyruvate	tumor necrosis factor production inhibitor	HMGB1, TNF			BRD-K47738867-001-01-5	CCOC(=O)C(C)=O	XXRCUYVCPSWGCC-UHFFFAOYSA-N	Phase 2
ethyl-vanillin					BRD-K82104468-001-05-0	CCOc1cc(C=O)ccc1O	CBOQJANXLMLOSS-UHFFFAOYSA-N	Preclinical
ethyl-2-(carbamoyloxy)benzoate					BRD-K21892374-001-01-6	CCOC(=O)c1ccccc1OC(N)=O	JFMIIMPCFQKAAD-UHFFFAOYSA-N	Phase 1
ethylenediaminetetraacetic-acid	PKC inhibitor		neurology/psychiatry	metal toxicity	BRD-K82603084-408-01-1	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	KCXVZYZYPLLWCC-UHFFFAOYSA-N	Launched
ethylnorepinephrine	bronchodilator				BRD-A68509429-003-03-9	CCC(N)C(O)c1ccc(O)c(O)c1	LENNRXOJHWNHSD-UHFFFAOYSA-N	Preclinical
ethynodiol-diacetate		ESR1, PGR	endocrinology	contraceptive	BRD-K46331928-001-06-6, BRD-K46331928-001-05-8, BRD-K06056310-001-01-4	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1, CC(=O)O[C@H]1CC[C@@H]2[C@@H]3CC[C@@]4(C)[C@@H](CC[C@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1	ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-KIEAKMPYSA-N, ONKUMRGIYFNPJW-OUTQORHZSA-N	Launched
eticlopride	dopamine receptor antagonist	DRD2, DRD3, DRD4			BRD-K50417881-003-17-4	CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	AADCDMQTJNYOSS-LBPRGKRZSA-N	Preclinical
etidronic-acid	bone resorption inhibitor	ATP6V1A, PTPRS	endocrinology, orthopedics	Pagets disease, heterotopic ossification" "BRD-K37949327-304-06-1, BRD-K37949327-001-07-1, BRD-K37949327-001-06-3" "CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O, CC(O)(P(O)(O)=O)P(O)(O)=O" "DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N, DBVJJBKOTRCVKF-UHFFFAOYSA-N" "Launched"
"1007" "etifenin" "renal function diagnostic agent" "" "" "" "BRD-K63979671-001-10-1" "CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O" "WNIDXAKKFOKNEF-UHFFFAOYSA-N" "Preclinical"
"1008" "etifoxine" "GABA receptor modulator" "GABRA1, GABRA2, GABRA3, GABRA5" "neurology/psychiatry" "anxiety" "BRD-A60821666-003-01-2, BRD-A60821666-003-02-0" "CCNC1=Nc2ccc(Cl)cc2C(C)(O1)c1ccccc1, CCNC1=Nc2ccc(Cl)cc2C(C)(O1)c1ccccc1" "IBYCYJFUEJQSMK-UHFFFAOYSA-N, IBYCYJFUEJQSMK-UHFFFAOYSA-N" "Launched"
"1009" "etilefrine" "adrenergic receptor agonist" "ADRA1A, ADRB1" "neurology/psychiatry, otolaryngology, endocrinology, pulmonary" "headache, nasal congestion, fever, cough suppressant, common cold" "BRD-A09925278-003-05-6" "CCNCC(O)c1cccc(O)c1" "SQVIAVUSQAWMKL-UHFFFAOYSA-N" "Launched"
"1010" "etilevodopa" "dopamine receptor agonist" "DRD3" "" "" "BRD-K90982969-001-01-2, BRD-K90982969-003-01-8" "CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1" "NULMGOSOSZBEQL-QMMMGPOBSA-N, NULMGOSOSZBEQL-QMMMGPOBSA-N" "Phase 3"
"1011" "etizolam" "benzodiazepine receptor agonist" "GABRA1" "neurology/psychiatry" "insomnia, anxiety" "BRD-K68232413-001-01-2" "CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl" "VMZUTJCNQWMAGF-UHFFFAOYSA-N" "Launched"
"1012" "etodolac" "cyclooxygenase inhibitor" "PTGS1, PTGS2, RXRA" "rheumatology" "osteoarthritis, rheumatoid arthritis" "BRD-A74667430-001-23-6, BRD-K36911961-001-01-6" "CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12, CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12" "NNYBQONXHNTVIJ-UHFFFAOYSA-N, NNYBQONXHNTVIJ-KRWDZBQOSA-N" "Launched"
"1013" "etofenamate" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "neurology/psychiatry, rheumatology" "muscle pain, joint pain" "BRD-K73541271-001-03-6" "OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F" "XILVEPYQJIOVNB-UHFFFAOYSA-N" "Launched"
"1014" "etofibrate" "PPAR receptor agonist" "PPARA" "endocrinology" "hypertriglyceridemia" "BRD-K49338325-001-03-4" "CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1" "XXRVYAFBUDSLJX-UHFFFAOYSA-N" "Launched"
"1015" "etofylline" "adenosine receptor antagonist" "ADORA1" "pulmonary" "asthma, bronchitis" "BRD-K83064458-001-23-0" "Cn1c2ncn(CCO)c2c(=O)n(C)c1=O" "NWPRCRWQMGIBOT-UHFFFAOYSA-N" "Launched"
"1016" "etofylline-clofibrate" "platelet aggregation inhibitor" "PPARA" "" "" "BRD-K49840922-001-05-1" "Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O" "KYAKGJDISSNVPZ-UHFFFAOYSA-N" "Launched"
"1017" "etomidate" "GABA receptor modulator" "ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ" "neurology/psychiatry" "general anaesthetic" "BRD-A54880345-001-20-9, BRD-K55055802-001-08-6, BRD-K55055802-001-09-4" "CCOC(=O)c1cncn1C(C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1, CCOC(=O)c1cncn1[C@H](C)c1ccccc1" "NPUKDXXFDDZOKR-UHFFFAOYSA-N, NPUKDXXFDDZOKR-LLVKDONJSA-N, NPUKDXXFDDZOKR-LLVKDONJSA-N" "Launched"
"1018" "etomoxir" "carnitine palmitoyltransferase inhibitor" "CPT1A" "" "" "BRD-K32405725-001-02-8" "CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1" "DZLOHEOHWICNIL-QGZVFWFLSA-N" "Phase 2"
"1019" "etonogestrel" "progesterone receptor agonist" "ESR1, PGR" "endocrinology" "contraceptive" "BRD-A08302182-001-01-7" "CCC12CC(=C)C3C(CCC4=CC(=O)CCC34)C1CC[C@@]2(O)C" "" ""
"1020" "etoposide" "topoisomerase inhibitor" "TOP2A, TOP2B" "oncology" "non-small cell lung cancer (NSCLC)" "BRD-K37798499-001-25-6, BRD-A33280134-001-04-7, BRD-K37798499-001-18-1, BRD-K37798499-001-21-5, BRD-K37798499-001-22-3" "COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(OC2O[C@@H]3COC(C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12" "VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-GEGAHKOSSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N, VJJPUSNTGOMMGY-MRVIYFEKSA-N" "Launched"
"1021" "etoposide-phosphate" "topoisomerase inhibitor" "TOP2A" "oncology" "testicular carcinoma, small cell lung cancer" "BRD-K72533376-001-01-2" "COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12" "LIQODXNTTZAGID-OCBXBXKTSA-N" "Launched"
"1022" "etoricoxib" "cyclooxygenase inhibitor" "PTGS2" "rheumatology" "rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis" "BRD-K54770957-001-04-3" "Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O" "MNJVRJDLRVPLFE-UHFFFAOYSA-N" "Launched"
"1023" "etosalamide" "anti-inflammatory agent" "" "" "" "BRD-K60914966-001-01-4" "CCOCCOc1ccccc1C(N)=O" "XBNRCMFFZFCWMH-UHFFFAOYSA-N" "Preclinical"
"1024" "etoxybamide" "" "" "" "" "BRD-K51364817-001-01-4" "OCCCC(=O)NCCO" "MFHPPMMWHSHDSI-UHFFFAOYSA-N" "Phase 2"
"1025" "ETP-46464" "ATR kinase inhibitor" "" "" "" "BRD-K24556407-001-02-3" "CC(C)(C" "" ""
"1026" "etravirine" "non-nucleoside reverse transcriptase inhibitor" "CYP2C19, CYP2C9, CYP3A4" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K74717603-001-02-2" "Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C" "" ""
"1027" "etretinate" "protein synthesis inhibitor" "RARA, RARB, RARG, RXRA, RXRB, RXRG" "" "" "BRD-K49076555-001-01-5, BRD-K49076555-001-04-9, BRD-K49076555-001-03-1" "CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\c1c(C)cc(OC)c(C)c1C, CCOC(=O)\C=C(C)\C=C\C=C(C)\C=C\c1c(C)cc(OC)c(C)c1C" "HQMNCQVAMBCHCO-DJRRULDNSA-N, HQMNCQVAMBCHCO-DJRRULDNSA-N, HQMNCQVAMBCHCO-DJRRULDNSA-N" "Withdrawn"
"1028" "eucalyptol" "acetylcholinesterase inhibitor" "ACHE" "dental" "gingivitis" "BRD-K15671046-001-03-6, BRD-K29996876-001-09-3" "C[C@@]12CC[C@@H](CC1)C(C)(C)O2, CC12CCC(CC1)C(C)(C)O2" "WEEGYLXZBRQIMU-WAAGHKOSSA-N, WEEGYLXZBRQIMU-UHFFFAOYSA-N" "Launched"
"1029" "eucatropine" "acetylcholine receptor antagonist" "" "" "" "BRD-A37942872-003-20-6" "CC1CC(CC(C)(C)N1C)OC(=O)C(O)c1ccccc1" "QSAVEGSLJISCDF-UHFFFAOYSA-N" "Preclinical"
"1030" "eugenol" "androgen receptor antagonist" "AR" "dental" "toothache" "BRD-K32977963-001-05-0" "COc1cc(CC=C)ccc1O" "RRAFCDWBNXTKKO-UHFFFAOYSA-N" "Launched"
"1031" "EUK-134" "catalase stimulant" "APP, SOD2" "" "" "BRD-K19741031-001-01-4, BRD-K19741031-001-02-2" "COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12, COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12" "QCAWBJDECIOVBU-UHFFFAOYSA-K, QCAWBJDECIOVBU-UHFFFAOYSA-K" "Preclinical"
"1032" "eupatilin" "mucus protecting agent" "" "" "" "BRD-K47031502-001-02-4, BRD-K47031502-001-01-6" "COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1, COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1" "DRRWBCNQOKKKOL-UHFFFAOYSA-N, DRRWBCNQOKKKOL-UHFFFAOYSA-N" "Launched"
"1033" "evacetrapib" "cholesteryl ester transfer protein inhibitor" "CETP" "" "" "BRD-K16551357-001-03-2, BRD-K16551357-001-02-4" "Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1, Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1" "IHIUGIVXARLYHP-YBXDKENTSA-N, IHIUGIVXARLYHP-YBXDKENTSA-N" "Phase 3"
"1034" "evans-blue" "glutamate receptor negative allosteric modulator" "GRIA1, PTPN1" "" "" "BRD-K24548560-342-02-1" "Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(c(C)c1)\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O" "COXVTLYNGOIATD-HVMBLDELSA-N" "Launched"
"1035" "evatanepag" "prostaglandin inhibitor" "PTGER2, PTGER4" "" "" "BRD-K11452913-001-01-9" "CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1" "WOHRHWDYFNWPNG-UHFFFAOYSA-N" "Phase 2"
"1036" "everolimus" "mTOR inhibitor" "MTOR" "oncology, neurology/psychiatry, genetics, urology" "breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma" "BRD-K13154216-001-01-3, BRD-K13154216-001-03-9" "CO[C@@H]1C[C@H](C[C@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO" "HKVAMNSJSFKALM-MUKRYTAKSA-N, HKVAMNSJSFKALM-MUKRYTAKSA-N" "Launched"
"1037" "evodiamine" "ATPase inhibitor, TRPV agonist" "TRPV1" "" "" "BRD-A68631409-001-06-2, BRD-A68631409-001-05-4" "CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12, CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12" "TXDUTHBFYKGSAH-UHFFFAOYSA-N, TXDUTHBFYKGSAH-UHFFFAOYSA-N" "Preclinical"
"1038" "EVP-6124" "acetylcholine receptor agonist" "CHRNA7" "" "" "BRD-K71603915-003-01-8" "Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2" "SSRDSYXGYPJKRR-ZDUSSCGKSA-N" "Phase 3"
"1039" "EVP4593" "NFkB pathway inhibitor" "" "" "" "BRD-K68395654-001-06-4, BRD-K68395654-001-03-1, BRD-K68395654-001-05-6" "Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1, Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1" "IBAKVEUZKHOWNG-UHFFFAOYSA-N, IBAKVEUZKHOWNG-UHFFFAOYSA-N, IBAKVEUZKHOWNG-UHFFFAOYSA-N" "Preclinical"
"1040" "EW-7197" "TGF beta receptor inhibitor" "ACVR1B, TGFBR1" "" "" "BRD-K74396648-001-01-4" "Cc1cccc(n1)-c1[nH]c(CNc2ccccc2F)nc1-c1ccc2ncnn2c1" "FJCDSQATIJKQKA-UHFFFAOYSA-N" "Phase 1"
"1041" "EX-527" "SIRT inhibitor" "SIRT1" "" "" "BRD-A73908300-001-09-1, BRD-A73908300-001-06-7" "NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21, NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21" "FUZYTVDVLBBXDL-UHFFFAOYSA-N, FUZYTVDVLBBXDL-UHFFFAOYSA-N" "Phase 2"
"1042" "exalamide" "membrane permeability inhibitor" "" "" "" "BRD-K12609457-001-03-1" "CCCCCCOc1ccccc1C(N)=O" "CKSJXOVLXUMMFF-UHFFFAOYSA-N" "Launched"
"1043" "examorelin" "growth hormone releasing factor agonist" "GHRHR, GHSR" "" "" "BRD-K35304636-001-01-0" "C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O" "RVWNMGKSNGWLOL-GIIHNPQRSA-N" "Phase 2"
"1044" "exatecan-mesylate" "topoisomerase inhibitor" "TOP1" "" "" "BRD-K92150287-066-01-2, BRD-K92150287-066-02-0" "CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45" "ZVYVPGLRVWUPMP-FYSMJZIKSA-N, ZVYVPGLRVWUPMP-FYSMJZIKSA-N" "Phase 3"
"1045" "exemestane" "aromatase inhibitor" "CYP19A1" "oncology" "breast cancer" "BRD-A73741725-001-02-8, BRD-K35247444-001-01-3" "C[C@]12CCC3C(CC(=C)C4=CC(=O)C=C[C@]34C)C1CCC2=O, C[C@@]12CC[C@@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O" "BFYIZQONLCFLEV-VQIOPMHJSA-N, BFYIZQONLCFLEV-RHVZCBDQSA-N" "Launched"
"1046" "exenatide" "GLP receptor agonist" "GLP1R" "endocrinology" "diabetes mellitus" "BRD-K05505104-001-01-1" "CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O" "HRPOQXWQRXFQTM-XWLPCZSASA-N" "Launched"
"1047" "exherin" "cadherin antagonist" "CDH2" "" "" "BRD-K81795818-019-01-4" "CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O" "FQVLRGLGWNWPSS-BXBUPLCLSA-N" "Phase 2"
"1048" "exifone" "nootropic agent" "TYR" "" "" "BRD-K65716359-001-04-7, BRD-K65716359-001-02-1" "Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O, Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O" "XEDWWPGWIXPVRQ-UHFFFAOYSA-N, XEDWWPGWIXPVRQ-UHFFFAOYSA-N" "Withdrawn"
"1049" "exisulind" "phosphodiesterase inhibitor" "PDE5A" "" "" "BRD-K37708699-001-01-4" "CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)(=O)=O" "MVGSNCBCUWPVDA-MFOYZWKCSA-N" "Phase 3"
"1050" "EXO-1" "ARF inhibitor" "" "" "" "BRD-K78633253-001-10-3" "COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1" "KIAPWMKFHIKQOZ-UHFFFAOYSA-N" "Preclinical"
"1051" "ezatiostat" "glutathione transferase inhibitor" "GSTP1" "" "" "BRD-K98963219-001-01-2" "CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1" "GWEJFLVSOGNLSS-WPFOTENUSA-N" "Phase 2"
"1052" "ezetimibe" "cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist" "ANPEP, NPC1L1, SOAT1" "endocrinology, metabolism" "hyperlipidemia, hypercholesterolemia, sitosterolemia" "BRD-K42260897-001-07-6, BRD-K32180660-001-01-6, BRD-A41519720-001-04-8" "O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, O[C@@H](CC[C@@H]1[C@@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1, OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1" "OLNTVTPDXPETLC-XPWALMASSA-N, OLNTVTPDXPETLC-VJBWXMMDSA-N, OLNTVTPDXPETLC-OJVMETQDSA-N" "Launched"
"1053" "ezutromid" "utrophin enhancer" "UTRN" "" "" "BRD-K25570267-001-01-4" "CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1" "WRIPKYOZKAJHRL-UHFFFAOYSA-N" "Phase 2"
"1054" "E7449" "PARP inhibitor" "PARP1, PARP2, TNKS, TNKS2" "" "" "BRD-K05444225-001-02-5, BRD-K05444225-001-01-7" "O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23, O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23" "JLFSBHQQXIAQEC-UHFFFAOYSA-N, JLFSBHQQXIAQEC-UHFFFAOYSA-N" "Phase 1/Phase 2"
"1055" "F-11440" "serotonin receptor agonist" "HTR1A" "" "" "BRD-K87948281-001-01-9" "Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O" "NMYAHEULKSYAPP-UHFFFAOYSA-N" "Phase 2"
"1056" "fadrozole" "aromatase inhibitor" "CYP11B1, CYP19A1" "oncology" "breast cancer" "BRD-A25619068-003-03-4" "N" "" ""
"1057" "fagomine" "glucosidase inhibitor" "GLB1" "" "" "BRD-K61536264-001-01-3" "OC[C@H]1NCC[C@@H](O)[C@@H]1O" "YZNNBIPIQWYLDM-HSUXUTPPSA-N" "Phase 2"
"1058" "falecalcitriol" "vitamin D receptor agonist" "VDR" "endocrinology" "hyperparathyroidism" "BRD-K08251020-001-01-0" "C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C" "XPYGGHVSFMUHLH-UUSULHAXSA-N" "Launched"
"1059" "famciclovir" "DNA polymerase inhibitor" "" "dental, infectious disease" "cold sore, genitial herpes, shingles" "BRD-K45033733-001-12-2, BRD-K45033733-001-11-4" "CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O, CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O" "GGXKWVWZWMLJEH-UHFFFAOYSA-N, GGXKWVWZWMLJEH-UHFFFAOYSA-N" "Launched"
"1060" "famotidine" "histamine receptor antagonist" "HRH2" "gastroenterology" "heartburn" "BRD-K00673382-001-18-9, BRD-K00673382-001-17-1" "NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1, NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1" "XUFQPHANEAPEMJ-UHFFFAOYSA-N, XUFQPHANEAPEMJ-UHFFFAOYSA-N" "Launched"
"1061" "famprofazone" "cyclooxygenase inhibitor" "" "" "" "BRD-A08255417-001-14-7, BRD-A08255417-001-13-9" "CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C, CC(Cc1ccccc1)N(C)Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C" "GNUXVOXXWGNPIV-UHFFFAOYSA-N, GNUXVOXXWGNPIV-UHFFFAOYSA-N" "Preclinical"
"1062" "fananserin" "dopamine receptor antagonist, serotonin receptor antagonist" "HTR2A" "" "" "BRD-K08998509-001-03-2, BRD-K08998509-001-02-4" "Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1, Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1" "VGIGHGMPMUCLIQ-UHFFFAOYSA-N, VGIGHGMPMUCLIQ-UHFFFAOYSA-N" "Phase 2"
"1063" "fanetizole" "neutrophil superoxide production" "" "" "" "BRD-K60798049-001-03-8" "C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1" "WEEYMMXMBFJUAI-UHFFFAOYSA-N" "Phase 3"
"1064" "farnesyl-thiosalicylic-acid-amide" "Ras GTPase inhibitor" "HRAS" "" "" "BRD-K14590126-001-01-6" "CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O" "GZTMFRUGZMZCRD-CFBAGHHKSA-N" "Phase 1"
"1065" "faropenem" "lactamase inhibitor" "" "infectious disease, pulmonary, otolaryngology" "pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis" "BRD-A49622760-001-01-9" "CC(O)C1C2SC(C3CCCO3)=C(N2C1=O)C(O)=O" "HGGAKXAHAYOLDJ-UHFFFAOYSA-N" "Launched"
"1066" "faropenem-medoxomil" "lactamase inhibitor" "" "otolaryngology, infectious disease, pulmonary" "sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections" "BRD-K59045783-001-01-1, BRD-K59045783-001-02-9" "C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C, C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C" "JQBKWZPHJOEQAO-DVPVEWDBSA-N, JQBKWZPHJOEQAO-DVPVEWDBSA-N" "Launched"
"1067" "fasudil" "rho associated kinase inhibitor" "PKIA, PRKACA, ROCK1, ROCK2" "neurology/psychiatry" "cerebral vasospasm" "BRD-K76617868-003-14-3, BRD-K76617868-003-11-9, BRD-K76617868-001-05-5, BRD-K76617868-003-10-1" "O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12, O=S(=O)(N1CCCNCC1)c1cccc2cnccc12" "NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N, NGOGFTYYXHNFQH-UHFFFAOYSA-N" "Launched"
"1068" "favipiravir" "RNA polymerase inhibitor" "" "" "" "BRD-K04264130-001-01-4" "NC(=O)c1nc(F)cnc1O" "ZCGNOVWYSGBHAU-UHFFFAOYSA-N" "Phase 3"
"1069" "FCE-22250" "DNA directed DNA polymerase inhibitor" "" "" "" "BRD-A10991937-001-01-1" "COC1\C=C\OC2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)c(O)c2c(O)c3C" "JEGGQYICWGMXOZ-GMPMKFSHSA-N" "Phase 1"
"1070" "fdcyd" "DNA methyltransferase inhibitor" "" "" "" "BRD-K18157228-001-01-7" "Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1" "IDYKCXHJJGMAEV-RRKCRQDMSA-N" "Phase 2"
"1071" "febuxostat" "xanthine oxidase inhibitor" "XDH" "nephrology" "hyperuricemia" "BRD-K48367671-001-05-9, BRD-K48367671-001-06-7" "CC(C)COc1ccc(cc1C" "" ""
"1072" "felbamate" "glutamate receptor antagonist" "GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B" "neurology/psychiatry" "epilepsy" "BRD-K99107520-001-25-8, BRD-K99107520-001-24-1, BRD-K99107520-001-23-3" "NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1, NC(=O)OCC(COC(N)=O)c1ccccc1" "WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N, WKGXYQFOCVYPAC-UHFFFAOYSA-N" "Launched"
"1073" "felbinac" "cyclooxygenase inhibitor" "CTSL" "rheumatology, neurology/psychiatry" "rheumatoid arthritis, muscle pain" "BRD-K91740057-001-19-8" "OC(=O)Cc1ccc(cc1)-c1ccccc1" "QRZAKQDHEVVFRX-UHFFFAOYSA-N" "Launched"
"1074" "felbinac-ethyl" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "" "" "BRD-K26404903-001-01-5" "CCOC(=O)Cc1ccc(cc1)-c1ccccc1" "NPPJLSILDPVHCM-UHFFFAOYSA-N" "Launched"
"1075" "felodipine" "calcium channel blocker" "CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2, CALM1, CFTR, NR3C2, PDE1A, PDE1B, TNNC1, TNNC2" "cardiology" "hypertension" "BRD-A30815329-001-10-5, BRD-A30815329-001-08-9" "CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC" "RZTAMFZIAATZDJ-UHFFFAOYSA-N, RZTAMFZIAATZDJ-UHFFFAOYSA-N" "Launched"
"1076" "fenaclon" "" "" "" "" "BRD-K08791496-001-01-0" "ClCCC(=O)NCCc1ccccc1" "BITWVVLBVUMFHU-UHFFFAOYSA-N" "Preclinical"
"1077" "fenbendazole" "tubulin polymerization inhibitor" "TUBB" "infectious disease" "gastrointestinal parasites, gastrointestinal roundworms" "BRD-K51318897-001-15-3, BRD-K51318897-001-14-6" "COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1, COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1" "HDDSHPAODJUKPD-UHFFFAOYSA-N, HDDSHPAODJUKPD-UHFFFAOYSA-N" "Launched"
"1078" "fenbufen" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "" "" "BRD-K12513978-001-24-1" "OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1" "ZPAKPRAICRBAOD-UHFFFAOYSA-N" "Launched"
"1079" "fenclonine-(+/-)" "tryptophan hydroxylase inhibitor" "PAH, TPH1, TPH2" "" "" "BRD-A81615860-003-01-7" "NC(Cc1ccc(Cl)cc1)C(O)=O" "NIGWMJHCCYYCSF-UHFFFAOYSA-N" "Preclinical"
"1080" "fendiline" "calcium channel blocker" "HTR2B" "" "" "BRD-A71033472-003-23-9" "CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1" "NMKSAYKQLCHXDK-UHFFFAOYSA-N" "Preclinical"
"1081" "fenigam" "benzodiazepine receptor agonist" "GABBR1, GABBR2" "neurology/psychiatry" "posttraumatic stress disorder, anxiety, depression" "BRD-A66920069-001-01-3" "NCC(CC(O)=O)c1ccccc1" "DAFOCGYVTAOKAJ-UHFFFAOYSA-N" "Launched"
"1082" "fenipentol" "choleretic agent" "" "gastroenterology" "bile stimulation" "BRD-A66284731-001-02-0" "CCCCC(O)c1ccccc1" "OVGORFFCBUIFIA-UHFFFAOYSA-N" "Launched"
"1083" "fenobam" "glutamate receptor antagonist" "GRM5" "" "" "BRD-K41160163-001-06-8" "CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1" "DWPQODZAOSWNHB-UHFFFAOYSA-N" "Phase 2"
"1084" "fenofibrate" "PPAR receptor agonist" "MMP25, PPARA" "endocrinology" "hypercholesterolemia, hypertriglyceridemia" "BRD-K50388907-001-30-4, BRD-K50388907-001-29-6" "CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1, CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1" "YMTINGFKWWXKFG-UHFFFAOYSA-N, YMTINGFKWWXKFG-UHFFFAOYSA-N" "Launched"
"1085" "fenofibric-acid" "cytochrome P450 inhibitor" "CLCN1, PPARA" "cardiology" "dyslipidemia" "BRD-K30213273-001-01-6" "CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O" "MQOBSOSZFYZQOK-UHFFFAOYSA-N" "Launched"
"1086" "fenoldopam" "dopamine receptor agonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD4, DRD5" "cardiology" "hypertension" "BRD-A50684349-003-02-9, BRD-A50684349-066-11-7" "Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12, Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12" "TVURRHSHRRELCG-UHFFFAOYSA-N, TVURRHSHRRELCG-UHFFFAOYSA-N" "Launched"
"1087" "fenoprofen" "prostaglandin inhibitor" "PTGS1, PTGS2, SLC5A8" "rheumatology" "rheumatoid arthritis, osteoarthritis" "BRD-A81129465-001-03-8, BRD-A81129465-238-01-0, BRD-A81129465-001-04-6" "CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1, CC(C(O)=O)c1cccc(Oc2ccccc2)c1" "RDJGLLICXDHJDY-UHFFFAOYSA-N, RDJGLLICXDHJDY-UHFFFAOYSA-N, RDJGLLICXDHJDY-UHFFFAOYSA-N" "Launched"
"1088" "fenoterol" "adrenergic receptor agonist" "ADRB1, ADRB2, ADRB3" "" "" "BRD-A97104540-004-15-0" "CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1" "LSLYOANBFKQKPT-UHFFFAOYSA-N" "Withdrawn"
"1089" "fenoverine" "acetylcholine receptor antagonist" "" "neurology/psychiatry" "spasms" "BRD-K77564118-001-03-1" "O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12" "UBAJTZKNDCEGKL-UHFFFAOYSA-N" "Launched"
"1090" "fenoxaprop-p-ethyl" "" "NOS2, NOS3" "" "" "BRD-K44777569-001-01-7" "CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1" "PQKBPHSEKWERTG-LLVKDONJSA-N" "Preclinical"
"1091" "fenretinide" "apoptosis stimulant, retinoid receptor agonist" "RARA" "" "" "BRD-K89085489-001-23-2, BRD-K89085489-001-19-0, BRD-K89085489-001-22-4" "CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1" "AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N, AKJHMTWEGVYYSE-FXILSDISSA-N" "Phase 3"
"1092" "fenspiride" "bronchodilator" "" "pulmonary, otolaryngology" "asthma, otitis, sinusitis, rhinopharyngitis, laryngitis" "BRD-K26739552-003-15-4, BRD-K26739552-003-14-7" "O=C1NCC2(CCN(CCc3ccccc3)CC2)O1, O=C1NCC2(CCN(CCc3ccccc3)CC2)O1" "FVNFBBAOMBJTST-UHFFFAOYSA-N, FVNFBBAOMBJTST-UHFFFAOYSA-N" "Launched"
"1093" "fenthion" "cholinesterase inhibitor" "" "" "" "BRD-K67217586-001-08-0" "COP(=S)(OC)Oc1ccc(SC)c(C)c1" "PNVJTZOFSHSLTO-UHFFFAOYSA-N" "Launched"
"1094" "fentiazac" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "neurology/psychiatry, rheumatology" "muscle pain, joint pain" "BRD-K16077845-001-06-1" "OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1" "JIEKMACRVQTPRC-UHFFFAOYSA-N" "Launched"
"1095" "fenticonazole" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "vulvovaginal candidiasis" "BRD-A33697453-008-02-4" "Clc1ccc(C(Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1" "ZCJYUTQZBAIHBS-UHFFFAOYSA-N" "Launched"
"1096" "FERb-033" "EGFR inhibitor" "ERBB2" "" "" "BRD-K61642990-001-01-0" "O\N=C\c1ccc(-c2ccc(O)c(F)c2)c(Cl)c1O" "LRRMQNGSYOUANY-OMCISZLKSA-N" "Preclinical"
"1097" "ferrostatin-1" "ferroptosis inhibitor" "" "" "" "BRD-K97375133-001-03-9, BRD-K97375133-001-02-1, BRD-K97375133-001-01-3" "CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1, CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1" "UJHBVMHOBZBWMX-UHFFFAOYSA-N, UJHBVMHOBZBWMX-UHFFFAOYSA-N, UJHBVMHOBZBWMX-UHFFFAOYSA-N" "Preclinical"
"1098" "ferulic-acid" "antioxidant" "CA1, CA12, CA14, CA2, CA4, CA6, CA9" "" "" "BRD-K66295376-001-13-1, BRD-K66295376-001-12-3, BRD-K66295376-236-01-8" "COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O, COc1cc(\C=C\C(O)=O)ccc1O" "KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N, KSEBMYQBYZTDHS-HWKANZROSA-N" "Phase 2"
"1099" "fesoterodine" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "urology" "urinary incontinence" "BRD-K46731503-051-04-0, BRD-K46731503-050-01-8" "CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C" "DCCSDBARQIPTGU-HSZRJFAPSA-N, DCCSDBARQIPTGU-HSZRJFAPSA-N" "Launched"
"1100" "fexaramine" "FXR agonist" "NR1H4" "" "" "BRD-K08864679-001-02-2" "COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1" "VLQTUNDJHLEFEQ-KGENOOAVSA-N" "Preclinical"
"1101" "fexinidazole" "" "" "" "" "BRD-K37069697-001-01-3" "CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1" "MIWWSGDADVMLTG-UHFFFAOYSA-N" "Phase 2/Phase 3"
"1102" "fexofenadine" "histamine receptor antagonist" "HRH1" "allergy" "allergic rhinitis, urticaria" "BRD-A73368467-003-17-6, BRD-A73368467-003-16-8, BRD-A73368467-003-18-4" "CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1" "RWTNPBWLLIMQHL-UHFFFAOYSA-N, RWTNPBWLLIMQHL-UHFFFAOYSA-N, RWTNPBWLLIMQHL-UHFFFAOYSA-N" "Launched"
"1103" "FG-2216" "hypoxia inducible factor prolyl hydroxylase inhibitor" "EGLN1, EGLN2, HIF1A" "" "" "BRD-K56807945-001-01-2" "OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O" "OUQVKRKGTAUJQA-UHFFFAOYSA-N" "Phase 2"
"1104" "FG-4592" "hypoxia inducible factor prolyl hydroxylase inhibitor" "EGLN2" "" "" "BRD-K14385366-001-04-4, BRD-K14385366-001-02-8" "Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12, Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12" "YOZBGTLTNGAVFU-UHFFFAOYSA-N, YOZBGTLTNGAVFU-UHFFFAOYSA-N" "Phase 3"
"1105" "FG-7142" "GABA benzodiazepine site receptor inverse agonist" "" "" "" "BRD-K61951118-001-07-9" "CNC(=O)c1cc2c(cn1)[nH]c1ccccc21" "QMCOPDWHWYSJSA-UHFFFAOYSA-N" "Preclinical"
"1106" "FGIN-1-27" "inositol monophosphatase inhibitor" "TSPO" "" "" "BRD-K09778810-001-10-6" "CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1" "VUWXAQFLTSBUDB-UHFFFAOYSA-N" "Preclinical"
"1107" "FGIN-1-43" "benzodiazepine receptor agonist" "TSPO" "" "" "BRD-K66093087-001-03-1" "CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1" "XTZUPNNVXIMWAR-UHFFFAOYSA-N" "Preclinical"
"1108" "FH1" "hepatocyte function enhancer" "" "" "" "BRD-K44777625-001-03-5" "CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1" "OEXMNSOPAKOPEF-UHFFFAOYSA-N" "Preclinical"
"1109" "fiacitabine" "DNA synthesis inhibitor" "" "" "" "BRD-K07160047-001-01-3" "Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F" "GIMSJJHKKXRFGV-BYPJNBLXSA-N" "Phase 2"
"1110" "fidarestat" "aldose reductase inhibitor" "AKR1B1" "" "" "BRD-A63752151-001-01-2" "NC(=O)C1CC2(NC(=O)NC2=O)c2cc(F)ccc2O1" "WAAPEIZFCHNLKK-UHFFFAOYSA-N" "Phase 3"
"1111" "fidaxomicin" "RNA polymerase inhibitor" "" "gastroenterology" "diarrhea" "BRD-K57371763-001-01-7" "CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O" "ZVGNESXIJDCBKN-MHDOWYNASA-N" "Launched"
"1112" "filanesib" "kinesin inhibitor, kinesin-like spindle protein inhibitor" "KIF11" "" "" "BRD-K37379014-001-02-0, BRD-K37379014-001-01-2" "CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F" "LLXISKGBWFTGEI-FQEVSTJZSA-N, LLXISKGBWFTGEI-FQEVSTJZSA-N" "Phase 3"
"1113" "filgotinib" "JAK inhibitor" "JAK1, JAK2, JAK3, TYK2" "" "" "BRD-K16803204-001-01-6" "O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1" "RIJLVEAXPNLDTC-UHFFFAOYSA-N" "Phase 2"
"1114" "fimasartan" "angiotensin receptor antagonist" "AGTR1" "cardiology" "hypertension, congestive heart failure, hypertension, congestive heart failure" "BRD-K21586122-001-01-9, BRD-K76786967-001-01-7" "CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCC=C1NC(C)=C(CC(=S)N(C)C)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1" "AMEROGPZOLAFBN-UHFFFAOYSA-N, ZCVMXWPQAQXWFO-UHFFFAOYSA-N" "Launched"
"1115" "finafloxacin" "bacterial DNA gyrase inhibitor" "" "infectious disease, pulmonary" "intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis" "BRD-K98384930-003-01-5" "OC(=O)c1cn(C2CC2)c2c(C" "" ""
"1116" "finasteride" "5 alpha reductase inhibitor" "AKR1D1, SRD5A1, SRD5A2" "endocrinology" "androgenetic alopecia" "BRD-A83081521-001-02-3, BRD-K37882277-001-01-7" "CC(C)(C)NC(=O)[C@H]1CCC2C3CCC4NC(=O)C=C[C@]4(C)C3CC[C@]12C, CC(C)(C)NC(=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@@H]3CC[C@]12C" "DBEPLOCGEIEOCV-BYQKQGHSSA-N, DBEPLOCGEIEOCV-LBEDSLCJSA-N" "Launched"
"1117" "fingolimod" "immunosuppressant, sphingosine phosphate receptor agonist" "S1PR1, S1PR5" "neurology/psychiatry" "multiple sclerosis" "BRD-K88025533-003-04-1, BRD-K88025533-003-03-3" "CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1, CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1" "KKGQTZUTZRNORY-UHFFFAOYSA-N, KKGQTZUTZRNORY-UHFFFAOYSA-N" "Launched"
"1118" "fipexide" "psychoactive drug" "" "" "" "BRD-K37688416-003-13-1" "Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1" "BFUJHVVEMMWLHC-UHFFFAOYSA-N" "Withdrawn"
"1119" "fipronil" "chloride channel blocker, GABA gated chloride channel blocker" "" "" "" "BRD-A50675702-001-07-1" "Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C" "" ""
"1120" "firategrast" "integrin antagonist" "ITGA4" "" "" "BRD-K17513304-001-01-9" "CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(O)=O)cc2)c(OC)c1" "YLFZHHDVRSYTKT-NRFANRHFSA-N" "Phase 2"
"1121" "firocoxib" "cyclooxygenase inhibitor" "PTGS2" "rheumatology" "osteoarthritis" "BRD-K09090523-001-02-1" "CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O" "FULAPETWGIGNMT-UHFFFAOYSA-N" "Launched"
"1122" "fisetin" "Aurora kinase inhibitor" "CDK6, FASN" "" "" "BRD-K31836715-001-06-8, BRD-K31836715-001-05-0" "Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O" "XHEFDIBZLJXQHF-UHFFFAOYSA-N, XHEFDIBZLJXQHF-UHFFFAOYSA-N" "Preclinical"
"1123" "FIT" "opioid receptor agonist" "OPRD1" "" "" "BRD-K17896185-001-02-0" "CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1" "VDKBIFPJULZUPU-UHFFFAOYSA-N" "Preclinical"
"1124" "FK-33-824" "opioid receptor agonist" "OPRM1" "" "" "BRD-A01907367-001-01-7" "C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CCS(C)=O" "HYZHONGSQNXMPH-WFZMTUIASA-N" "Phase 2"
"1125" "FK-3311" "cyclooxygenase inhibitor" "PTGS2" "" "" "BRD-K38350380-001-01-8" "CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1" "DIIYLGZNZGPXRR-UHFFFAOYSA-N" "Phase 2"
"1126" "FK-866" "niacinamide phosphoribosyltransferase inhibitor" "NAMPT" "" "" "BRD-K58550667-001-08-7" "O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1" "KPBNHDGDUADAGP-VAWYXSNFSA-N" "Phase 2"
"1127" "FK-888" "tachykinin antagonist" "TACR1, TACR2" "" "" "BRD-K83508485-001-03-5, BRD-K83508485-001-02-7" "CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12, CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12" "BFNKQTIJVFGCKQ-PDJGWCFMSA-N, BFNKQTIJVFGCKQ-PDJGWCFMSA-N" "Phase 2"
"1128" "FK-962" "somatostatin receptor agonist" "" "" "" "BRD-K80607346-001-01-1" "CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1" "VBHVOHJOTMCSBQ-UHFFFAOYSA-N" "Phase 2"
"1129" "flavin-adenine-dinucleotide" "" "ACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ERO1LB, FDXR, GCDH, GFER, GSR, IL4I1, IVD, MAOA, MAOB, NOS1, NQO1, NQO2, POR, TXNRD1, XDH" "" "" "BRD-A86545589-001-01-5" "Cc1cc2nc3c(nc(=O)[nH]c3=O)n(CC(O)C(O)C(O)COP(O)(=O)OP(O)(=O)OCC3OC(C(O)C3O)n3cnc4c(N)ncnc34)c2cc1C" "VWWQXMAJTJZDQX-UHFFFAOYSA-N" "Preclinical"
"1130" "flavoxate" "acetylcholine receptor antagonist" "CHRM1, CHRM2" "urology" "urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis" "BRD-K47639036-003-06-6" "Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1" "SPIUTQOUKAMGCX-UHFFFAOYSA-N" "Launched"
"1131" "flecainide" "sodium channel blocker" "KCNA5, KCNA7, SCN4A, SCN5A" "cardiology" "ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias" "BRD-A09472452-015-23-4, BRD-A09472452-015-22-6" "FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1, FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1" "DJBNUMBKLMJRSA-UHFFFAOYSA-N, DJBNUMBKLMJRSA-UHFFFAOYSA-N" "Launched"
"1132" "fleroxacin" "topoisomerase inhibitor" "" "infectious disease, gastroenterology" "gonorrhea, enteritis, diarrhea, respiratory tract infections" "BRD-K61717546-001-05-0, BRD-K61717546-001-04-3" "CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O" "XBJBPGROQZJDOJ-UHFFFAOYSA-N, XBJBPGROQZJDOJ-UHFFFAOYSA-N" "Launched"
"1133" "FLI-06" "notch signaling inhibitor" "" "" "" "BRD-A44500574-001-02-6, BRD-A44500574-001-03-4, BRD-A44500574-001-01-8" "CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1, CC1=C(C(c2ccc(cc2)[N+]([O-])=O)C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1" "SWWVFYHSSOWZMF-UHFFFAOYSA-N, SWWVFYHSSOWZMF-UHFFFAOYSA-N, SWWVFYHSSOWZMF-UHFFFAOYSA-N" "Preclinical"
"1134" "flibanserin" "serotonin receptor agonist" "DRD4, HTR1A, HTR2A" "neurology/psychiatry" "hypoactive sexual desire disorder" "BRD-K33637378-001-01-7" "FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1" "PPRRDFIXUUSXRA-UHFFFAOYSA-N" "Launched"
"1135" "flindokalner" "potassium channel agonist" "KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5" "" "" "BRD-K56740996-001-01-3, BRD-K56740996-001-02-1" "COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F, COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F" "ULYONBAOIMCNEH-HNNXBMFYSA-N, ULYONBAOIMCNEH-HNNXBMFYSA-N" "Phase 3"
"1136" "floctafenine" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "neurology/psychiatry" "pain relief" "BRD-A23418262-001-01-5" "OCC(O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F" "APQPGQGAWABJLN-UHFFFAOYSA-N" "Launched"
"1137" "flopropione" "serotonin receptor antagonist" "HTR1A" "neurology/psychiatry" "spasms" "BRD-K43383936-001-05-2, BRD-K43383936-001-04-5" "CCC(=O)c1c(O)cc(O)cc1O, CCC(=O)c1c(O)cc(O)cc1O" "PTHLEKANMPKYDB-UHFFFAOYSA-N, PTHLEKANMPKYDB-UHFFFAOYSA-N" "Launched"
"1138" "florfenicol" "protein synthesis inhibitor" "" "pulmonary" "bovine respiratory disease (BRD)" "BRD-A30886737-001-02-9, BRD-K11298197-001-12-0" "CS(=O)(=O)c1ccc(cc1)C(O)[C@H](CF)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl" "AYIRNRDRBQJXIF-RGURZIINSA-N, AYIRNRDRBQJXIF-NXEZZACHSA-N" "Launched"
"1139" "flosequinan" "phosphodiesterase inhibitor" "" "" "" "BRD-A79643124-001-01-9" "Cn1cc(S(C)=O)c(=O)c2ccc(F)cc12" "UYGONJYYUKVHDD-UHFFFAOYSA-N" "Withdrawn"
"1140" "floxuridine" "DNA synthesis inhibitor" "TYMS" "oncology" "colorectal cancer" "BRD-K73088654-001-01-9, BRD-A03757454-001-03-4" "OC[C@H]1O[C@@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O, OC[C@H]1OC(C[C@H]1O)n1cc(F)c(=O)[nH]c1=O" "ODKNJVUHOIMIIZ-XVMARJQXSA-N, ODKNJVUHOIMIIZ-CQMSUOBXSA-N" "Launched"
"1141" "flubendazole" "tubulin polymerization inhibitor" "TUBB" "infectious disease" "gastrointestinal parasites" "BRD-K86003836-001-10-5, BRD-K86003836-001-09-7" "COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1ccc(F)cc1" "CPEUVMUXAHMANV-UHFFFAOYSA-N, CPEUVMUXAHMANV-UHFFFAOYSA-N" "Launched"
"1142" "flucloxacillin" "bacterial cell wall synthesis inhibitor" "" "infectious disease, otolaryngology, dermatology, gastroenterology" "gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia" "BRD-A13650332-236-09-6, BRD-K27871792-236-01-0" "Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)C(N2C1=O)C(O)=O)-c1c(F)cccc1Cl, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl" "UIOFUWFRIANQPC-SNVMCYLTSA-N, UIOFUWFRIANQPC-JKIFEVAISA-N" "Launched"
"1143" "fluconazole" "sterol demethylase inhibitor" "CYP51A1" "infectious disease" "esophageal candidiasis, meningitis" "BRD-K05977355-001-19-0, BRD-K05977355-001-23-2, BRD-K05977355-001-18-2" "OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F, OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F" "RFHAOTPXVQNOHP-UHFFFAOYSA-N, RFHAOTPXVQNOHP-UHFFFAOYSA-N, RFHAOTPXVQNOHP-UHFFFAOYSA-N" "Launched"
"1144" "flucytosine" "other antifungal" "DNMT1" "infectious disease" "bacterial septicemia, endocarditis, urinary tract infections, meningitis" "BRD-K82143716-001-19-9, BRD-K82143716-001-20-7" "Nc1nc(=O)[nH]cc1F, Nc1nc(=O)[nH]cc1F" "XRECTZIEBJDKEO-UHFFFAOYSA-N, XRECTZIEBJDKEO-UHFFFAOYSA-N" "Launched"
"1145" "fludarabine" "ribonucleotide reductase inhibitor" "ADA, RRM1, RRM2" "hematologic malignancy" "chronic lymphocytic leukemia (CLL)" "BRD-K66788707-001-14-3, BRD-K51927012-001-02-9" "Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@H]1O[C@H](CO)[C@@H](O)[C@@H]1O" "HBUBKKRHXORPQB-FJFJXFQQSA-N, HBUBKKRHXORPQB-ICKFSKTQSA-N" "Launched"
"1146" "fludarabine-phosphate" "ribonucleotide reductase inhibitor" "DCK, POLA1, POLD1, POLE, RRM1, RRM2, RRM2B" "hematologic malignancy" "chronic lymphocytic leukemia (CLL)" "BRD-K71106091-001-06-1, BRD-K71106091-001-09-5, BRD-K71106091-001-05-3" "Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O, Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O" "GIUYCYHIANZCFB-FJFJXFQQSA-N, GIUYCYHIANZCFB-FJFJXFQQSA-N, GIUYCYHIANZCFB-FJFJXFQQSA-N" "Launched"
"1147" "fludrocortisone-acetate" "" "AR, NR3C1, NR3C2" "endocrinology" "Addisons disease, adrenogenital syndrome	BRD-A38749782-001-04-1, BRD-K06408664-001-02-7	CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	SYWHXTATXSMDSB-JORUCDAYSA-N, SYWHXTATXSMDSB-GSLJADNHSA-N	Launched
fludroxycortide	glucocorticoid receptor agonist	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	BRD-A49765801-001-04-1	CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	POPFMWWJOGLOIF-KYSSJFEUSA-N	Launched
flufenamic-acid	chloride channel blocker	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5			BRD-K44067360-001-30-3, BRD-K44067360-001-29-5	OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	LPEPZBJOKDYZAD-UHFFFAOYSA-N, LPEPZBJOKDYZAD-UHFFFAOYSA-N	Preclinical
flumatinib	Bcr-Abl kinase inhibitor	ABL1, PDGFRB			BRD-K68870568-066-01-5	CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	BJCJYEYYYGBROF-UHFFFAOYSA-N	Phase 3
flumazenil	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	sedative	BRD-K98769987-001-23-7, BRD-K98769987-001-22-9, BRD-K98769987-001-21-1	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21, CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N, OFBIFZUFASYYRE-UHFFFAOYSA-N	Launched
flumecinol					BRD-A44181516-001-01-8	CCC(O)(c1ccccc1)c1cccc(c1)C(F)(F)F	DVASNQYQOZHAJN-UHFFFAOYSA-N	Launched
flumequine	topoisomerase inhibitor		infectious disease	urinary tract infections	BRD-A69777949-001-24-2, BRD-A69777949-001-25-9	CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O	DPSPPJIUMHPXMA-UHFFFAOYSA-N, DPSPPJIUMHPXMA-UHFFFAOYSA-N	Launched
flumetasone	glucocorticoid receptor agonist	NR3C1	otolaryngology, infectious disease	otitis, ear infections	BRD-A01346607-001-04-2	C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	WXURHACBFYSXBI-DRBBXQFKSA-N	Launched
flumethasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	BRD-K09237689-001-01-0	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	WXURHACBFYSXBI-TYZSNXFESA-N	Launched
flumethazone-pivalate	glucocorticoid receptor agonist	NR3C1, SERPINA6			BRD-A50064262-001-04-7	C[C@@H]1CC2C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C	JWRMHDSINXPDHB-DCPWPRNHSA-N	Preclinical
flumexadol					BRD-A43518428-001-02-7, BRD-A43518428-001-01-9	FC(F)(F)c1cccc(c1)C1CNCCO1, FC(F)(F)c1cccc(c1)C1CNCCO1	GXPYCYWPUGKQIJ-UHFFFAOYSA-N, GXPYCYWPUGKQIJ-UHFFFAOYSA-N	Preclinical
flunarizine	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1	neurology/psychiatry, cardiology	migraine headache, vertigo, peripheral artery disease (PAD)	BRD-K29582677-300-10-6, BRD-K29582677-300-09-8, BRD-K29582677-300-08-0	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1, Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N, SMANXXCATUTDDT-QPJJXVBHSA-N	Launched
flunisolide	cytochrome P450 inhibitor	NR3C1	allergy	allergic rhinitis	BRD-A65449987-001-10-4	CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO	XSFJVAJPIHIPKU-CCRGDLLISA-N	Launched
flunixin-meglumin	prostanoid receptor antagonist				BRD-K99984802-100-13-5, BRD-K99984802-100-12-7	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F, Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	NOOCSNJCXJYGPE-UHFFFAOYSA-N, NOOCSNJCXJYGPE-UHFFFAOYSA-N	Launched
fluocinolone-acetonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	BRD-A15297126-001-04-3, BRD-A77824596-001-04-0, BRD-K95627890-001-01-2	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1CC1C3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C, CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO, CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@]4(F)[C@H](O)C[C@]3(C)[C@]2(O1)C(=O)CO	WJOHZNCJWYWUJD-UUTDCOIBSA-N, FEBLZLNTKCEFIT-AHVBUMMWSA-N, FEBLZLNTKCEFIT-FWFSREQTSA-N	Launched
fluocinonide	glucocorticoid receptor agonist	NR3C1, SERPINA6, SMO	dermatology	seborrheic dermatitis, eczema	BRD-K68865937-001-01-6	CC(=O)OCC(=O)[C@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]21C	WJOHZNCJWYWUJD-REMSQOBTSA-N	Launched
fluorescein		SLC22A6	ophthalmology	ophthalmology diagnostic	BRD-K21913543-001-02-4	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	GNBHRKFJIUUOQI-UHFFFAOYSA-N	Launched
fluorometholone	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation	BRD-A13133631-001-04-0	C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12	FAOZLTXFLGPHNG-KXWDGVDDSA-N	Launched
fluorometholone-acetate		NR3C1	ophthalmology	eye inflammation	BRD-K02528732-001-02-4, BRD-K02528732-001-01-6	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12	YRFXGQHBPBMFHW-SBTZIJSASA-N, YRFXGQHBPBMFHW-SBTZIJSASA-N	Launched
fluoromethylcholine					BRD-K51199656-003-01-4	C[N+](C)(CF)CCO	PBVFROWIWWGIFK-UHFFFAOYSA-N	Launched
fluoxetine	selective serotonin reuptake inhibitor (SSRI)	ANO1, HTR2B, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder	BRD-A31159102-003-30-4, BRD-A31159102-003-29-6, BRD-A31159102-003-28-8	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1, CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	RTHCYVBBDHJXIQ-UHFFFAOYSA-N, RTHCYVBBDHJXIQ-UHFFFAOYSA-N, RTHCYVBBDHJXIQ-UHFFFAOYSA-N	Launched
fluoxymesterone	androgen receptor modulator	AR, ESR1, NR3C1, PRLR	endocrinology	hypogonadism	BRD-K24255045-001-05-3	C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	YLRFCQOZQXIBAB-RBZZARIASA-N	Launched
flupentixol	dopamine receptor antagonist	ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A	neurology/psychiatry	schizophrenia, depression	BRD-K70487031-001-02-8	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	NJMYODHXAKYRHW-DVZOWYKESA-N	Launched
fluphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	BRD-K55127134-300-11-2	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	PLDUPXSUYLZYBN-UHFFFAOYSA-N	Launched
fluphenazine-decanoate	dopamine receptor antagonist	DRD2, HTR1B, HTR4	neurology/psychiatry	schizophrenia	BRD-K27898013-001-01-4	CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	VIQCGTZFEYDQMR-UHFFFAOYSA-N	Launched
flupirtine	glutamate receptor antagonist	ADRA2A, KCNQ1, KCNQ2	neurology/psychiatry	pain relief	BRD-K50720187-051-03-1, BRD-K50720187-050-08-2, BRD-K50720187-051-02-3	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N, CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N, JUUFBMODXQKSTD-UHFFFAOYSA-N	Launched
fluprazine	serotonin receptor agonist	HTR1A, HTR1B			BRD-K44091134-001-01-9	NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F	CHQKHXJPWDSTPY-UHFFFAOYSA-N	Phase 1
flurbiprofen-(+/-)	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-A86044036-001-26-5, BRD-A86044036-001-27-3	CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1, CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-UHFFFAOYSA-N, SYTBZMRGLBWNTM-UHFFFAOYSA-N	Launched
flurbiprofen-(S)-(+)	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K69907333-001-10-6, BRD-K69907333-001-07-2	C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1, C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-JTQLQIEISA-N, SYTBZMRGLBWNTM-JTQLQIEISA-N	Launched
flurofamide	urease inhibitor				BRD-K67445247-001-03-9, BRD-K67445247-001-02-1	NP(N)(=O)NC(=O)c1ccc(F)cc1, NP(N)(=O)NC(=O)c1ccc(F)cc1	QWZFVMCWPLMLTL-UHFFFAOYSA-N, QWZFVMCWPLMLTL-UHFFFAOYSA-N	Preclinical
flurothyl					BRD-K14763542-001-02-3	FC(F)(F)COCC(F)(F)F	KGPPDNUWZNWPSI-UHFFFAOYSA-N	Preclinical
fluroxene	local anesthetic				BRD-K56908511-001-01-2	FC(F)(F)COC=C	DLEGDLSLRSOURQ-UHFFFAOYSA-N	Preclinical
fluspirilene	dopamine receptor antagonist	CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia	BRD-K77947974-001-16-3	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	QOYHHIBFXOOADH-UHFFFAOYSA-N	Launched
flutamide	androgen receptor antagonist	AHR, AR	oncology	prostate cancer	BRD-K28307902-001-21-7, BRD-K28307902-001-20-9	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	MKXKFYHWDHIYRV-UHFFFAOYSA-N, MKXKFYHWDHIYRV-UHFFFAOYSA-N	Launched
fluticasone-propionate	glucocorticoid receptor agonist	NR3C1, NR3C2, PGR, PLA2G4A	dermatology	corticosteroid-responsive dermatoses	BRD-K62310379-001-10-5, BRD-K40517875-001-01-0, BRD-A45538101-001-01-9	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)SCF, CCC(=O)O[C@@]1([C@H](C)CC2C3CC(F)C4=CC(=O)C=C[C@]4(C)C3(F)[C@@H](O)C[C@]12C)C(=O)SCF	WMWTYOKRWGGJOA-CENSZEJFSA-N, WMWTYOKRWGGJOA-HCAVUHQRSA-N, WMWTYOKRWGGJOA-HLJZTEGPSA-N	Launched
flutrimazole	sterol demethylase inhibitor		infectious disease	mycosis	BRD-A00218260-001-03-4	Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1	QHMWCHQXCUNUAK-UHFFFAOYSA-N	Launched
fluvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	BRD-K66296774-236-11-3, BRD-K66296774-236-10-5, BRD-K66296774-001-07-9	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12, CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N, FJLGEFLZQAZZCD-MCBHFWOFSA-N	Launched
fluvoxamine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	BRD-K53517854-051-01-4, BRD-K53517854-050-20-6, BRD-K53517854-050-21-4	COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN, COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN, COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN	CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N, CJOFXWAVKWHTFT-XSFVSMFZSA-N	Launched
fmoc-l-leucine	PPAR receptor agonist				BRD-K15327298-001-05-5	CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	CBPJQFCAFFNICX-IBGZPJMESA-N	Phase 2
folic-acid	folate receptor ligand	FOLR2, FOLR3, SLC19A1, SLC46A1	hematology	megaloblastic anemia	BRD-K18673820-001-15-5	Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1	OVBPIULPVIDEAO-LBPRGKRZSA-N	Launched
fomepizole	alcohol dehydrogenase inhibitor	ADH1A, ADH1B, ADH1C, AKR1A1, CAT	critical care	poison antidote	BRD-K56810756-001-03-0, BRD-K56810756-003-07-7	Cc1cn[nH]c1, Cc1cn[nH]c1	RIKMMFOAQPJVMX-UHFFFAOYSA-N, RIKMMFOAQPJVMX-UHFFFAOYSA-N	Launched
fomocaine	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	BRD-K44942188-001-09-1	C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	CVHGCWVMTZWGAY-UHFFFAOYSA-N	Launched
foretinib	VEGFR inhibitor	FLT1, FLT4, KDR, MET			BRD-K03449891-001-08-6	COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	CXQHYVUVSFXTMY-UHFFFAOYSA-N	Phase 2
formestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	BRD-A87468186-001-01-6, BRD-A26503646-001-16-6	C[C@]12CC[C@@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O, C[C@]12CC[C@H]3[C@@H](CCC4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O	ZMEULISFKSVRLQ-YYMBHICASA-N, ZMEULISFKSVRLQ-AZXRADLDSA-N	Launched
formononetin	alcohol dehydrogenase inhibitor	ADH1C, SLC5A2			BRD-K55567017-001-12-3	COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	HKQYGTCOTHHOMP-UHFFFAOYSA-N	Preclinical
formoterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	BRD-K54006094-051-03-3, BRD-K54006094-051-01-7, BRD-K54006094-051-02-5	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1, COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N, BPZSYCZIITTYBL-ORAYPTAESA-N	Launched
forodesine	purinergic receptor antagonist	PNP			BRD-K16505263-003-02-9, BRD-K16505263-003-01-1	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O, OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	IWKXDMQDITUYRK-KUBHLMPHSA-N, IWKXDMQDITUYRK-KUBHLMPHSA-N	Phase 2
foropafant	platelet activating factor receptor antagonist	PTAFR			BRD-K57774929-001-01-3	CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C	VVBFISAUNSXQGZ-UHFFFAOYSA-N	Phase 3
forskolin	adenylyl cyclase activator	ADCY2, ADCY5, GNAS			BRD-K09602097-001-13-6, BRD-K62498766-001-01-8	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C, CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@@H](O)[C@]2(C)[C@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	OHCQJHSOBUTRHG-KGGHGJDLSA-N, OHCQJHSOBUTRHG-NOAPGGELSA-N	Launched
fosamprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K59110290-238-01-7	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	MLBVMOWEQCZNCC-OEMFJLHTSA-N	Launched
fosaprepitant-dimeglumine	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	BRD-K23848629-401-03-7, BRD-K23848629-401-04-5, BRD-K23848629-401-02-9	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N, BARDROPHSZEBKC-OITMNORJSA-N	Launched
fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	CDH5			BRD-K06814349-304-02-7, BRD-K06814349-304-01-9	COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1	WDOGQTQEKVLZIJ-WAYWQWQTSA-N, WDOGQTQEKVLZIJ-WAYWQWQTSA-N	Phase 3
foscarnet	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)	BRD-K85146014-314-06-2, BRD-K85146014-314-07-0, BRD-K85146014-314-05-4	OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O, OC(=O)P(O)(O)=O	ZJAOAACCNHFJAH-UHFFFAOYSA-N, ZJAOAACCNHFJAH-UHFFFAOYSA-N, ZJAOAACCNHFJAH-UHFFFAOYSA-N	Launched
fosfestrol	synthetic estrogen	ESR1, ESR2	oncology	prostate cancer	BRD-K20801936-001-01-9	CC\C(c1ccc(OP(O)(O)=O)cc1)=C(\CC)c1ccc(OP(O)(O)=O)cc1	NLORYLAYLIXTID-ISLYRVAYSA-N	Launched
fosfomycin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	BRD-K48461310-234-01-3, BRD-A10652366-238-04-1	C[C@H]1O[C@H]1P(O)(O)=O, CC1OC1P(O)(O)=O	YMDXZJFXQJVXBF-GBXIJSLDSA-N, YMDXZJFXQJVXBF-UHFFFAOYSA-N	Launched
fosfosal	phosphodiesterase inhibitor	PTGS1, PTGS2			BRD-K28687144-001-08-7, BRD-K28687144-001-07-9	OC(=O)c1ccccc1OP(O)(O)=O, OC(=O)c1ccccc1OP(O)(O)=O	FFKUDWZICMJVPA-UHFFFAOYSA-N, FFKUDWZICMJVPA-UHFFFAOYSA-N	Launched
fosfructose	fructose diphosphate stimulant	PKLR			BRD-A19086570-314-01-0	O[C@@H]1[C@@H](COP(O)(O)=O)OC(O)(COP(O)(O)=O)[C@H]1O	RNBGYGVWRKECFJ-VRPWFDPXSA-N	Phase 3
fosinopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	BRD-A51382177-236-04-8, BRD-A51382177-236-03-0	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C, CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C	BIDNLKIUORFRQP-AJTMIRJTSA-N, BIDNLKIUORFRQP-AJTMIRJTSA-N	Launched
fosinoprilat	angiotensin converting enzyme inhibitor	ACE			BRD-A33506612-001-01-2	OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(O)(=O)CCCCc1ccccc1)C1CCCCC1	WOIWWYDXDVSWAZ-RTWAWAEBSA-N	Launched
fosphenytoin	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy, seizures	BRD-K53809807-304-02-4, BRD-K53809807-304-01-6	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1, OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	XWLUWCNOOVRFPX-UHFFFAOYSA-N, XWLUWCNOOVRFPX-UHFFFAOYSA-N	Launched
fostamatinib	SYK inhibitor	RET, SYK			BRD-K20285085-001-07-1, BRD-K85178109-001-03-1, BRD-K20285085-074-03-7, BRD-K20285085-074-04-5, BRD-K85178109-001-02-3	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC, COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	NHHQJBCNYHBUSI-UHFFFAOYSA-N, GKDRMWXFWHEQQT-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, NHHQJBCNYHBUSI-UHFFFAOYSA-N, GKDRMWXFWHEQQT-UHFFFAOYSA-N	Phase 3
fotemustine	thioredoxin inhibitor	TXNRD1	oncology	melanoma	BRD-A62893078-001-01-5	CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)[N+][O-]	YAKWPXVTIGTRJH-UHFFFAOYSA-N	Launched
foxy-5	WNT5a peptide mimetic	WNT5A			BRD-K13005598-001-02-3	CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	WFZPJYYCTSHDJI-ATIWLJMLSA-N	Phase 1
FPA-124	AKT inhibitor				BRD-M17926088-001-01-3	Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O	HZRXQEVFXXQYFS-VBPDOGLUSA-L	Preclinical
FPH1-(BRD-6125)	hepatocyte function enhancer				BRD-K61250484-001-02-3	Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	WAOBCCBUTHNTFO-UHFFFAOYSA-N	Preclinical
FPL-12495	glutamate receptor antagonist				BRD-A09368919-001-01-7	CC(N)(Cc1ccccc1)c1ccccc1	JINQHBRSXWQJAZ-UHFFFAOYSA-N	Phase 1
FPL-55712	leukotriene receptor antagonist				BRD-A96456596-001-02-2	CCCc1c(OCC(O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O	LMQBMWHHGVZWMR-UHFFFAOYSA-N	Phase 1
FPL-62064	cyclooxygenase inhibitor, lipoxygenase inhibitor				BRD-K59875992-001-01-8	COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1	WKLGNFJHVJIZPK-UHFFFAOYSA-N	Phase 2
FPL-64176	calcium channel activator	CACNA1C, CACNA1S			BRD-K78959463-001-13-2	COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	MDMWHKZANMNXTF-UHFFFAOYSA-N	Preclinical
FPS-ZM1	RAGE receptor antagonist	AGER			BRD-K87691185-001-01-2	Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1	XDFKWGIBQMHSOH-UHFFFAOYSA-N	Preclinical
FR-122047	cyclooxygenase inhibitor				BRD-K30990140-003-02-4	COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	UBHKJRYGKOSQDJ-UHFFFAOYSA-N	Preclinical
FR-139317	endothelin receptor antagonist	EDNRA			BRD-K19318328-001-01-3	CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	LIOKMIQQPDDTNO-UPRLRBBYSA-N	Phase 1
FR-180204	MAP kinase inhibitor	MAPK1, MAPK3			BRD-K68756823-001-07-1	Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	XVECMUKVOMUNLE-UHFFFAOYSA-N	Preclinical
FRAX486	serine/threonine kinase inhibitor	PAK1, PAK2, PAK3, PAK4			BRD-K57243773-001-01-6, BRD-K57243773-001-02-4	CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O, CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O	DHKFOIHIUYFSOF-UHFFFAOYSA-N, DHKFOIHIUYFSOF-UHFFFAOYSA-N	Preclinical
frentizole	immunosuppressant				BRD-K07202345-001-19-4	COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	JHBWYQRKOUBPCA-UHFFFAOYSA-N	Phase 1
frovatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D	neurology/psychiatry	migraine headache	BRD-K08255599-365-01-1	CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O	XPSQPHWEGNHMSK-SECBINFHSA-N	Launched
fruquintinib	VEGFR inhibitor	KDR			BRD-K70504253-001-01-3	CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12	BALLNEJQLSTPIO-UHFFFAOYSA-N	Phase 3
ftaxilide					BRD-K05724540-001-08-5	Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O	LLECMGGNFBKPRH-UHFFFAOYSA-N	Preclinical
ftorafur	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	BRD-K99383816-001-03-5, BRD-K99383816-001-02-7	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O, Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	WFWLQNSHRPWKFK-ZCFIWIBFSA-N, WFWLQNSHRPWKFK-ZCFIWIBFSA-N	Launched
fudosteine	mucolytic agent		pulmonary	chest congestion	BRD-K54838207-001-03-8, BRD-K54838207-001-02-0	N[C@@H](CSCCCO)C(O)=O, N[C@@H](CSCCCO)C(O)=O	KINWYTAUPKOPCQ-YFKPBYRVSA-N, KINWYTAUPKOPCQ-YFKPBYRVSA-N	Launched
fulvestrant	estrogen receptor antagonist	ESR1, ESR2, GPER1	oncology	breast cancer	BRD-A03249105-001-01-9, BRD-A52958897-001-01-7, BRD-A50947932-001-01-9	C[C@]12CC[C@H]3C([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@@]12CC[C@@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31, C[C@]12CCC3C(C1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31	VWUXBMIQPBEWFH-LQKBAPIOSA-N, VWUXBMIQPBEWFH-BQMFAUAUSA-N, VWUXBMIQPBEWFH-AGNISOLISA-N	Launched
fumagillin	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	BRD-A99367815-001-01-5, BRD-A99367815-001-03-1	CO[C@@H]1[C@@H](CC[C@]2(CO2)C1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O, CO[C@@H]1[C@@H](CC[C@]2(CO2)C1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O	NGGMYCMLYOUNGM-ZVVCMXCESA-N, NGGMYCMLYOUNGM-ZVVCMXCESA-N	Launched
furaltadone	bacterial DNA inhibitor				BRD-A67514145-003-06-6, BRD-A67514145-003-05-8, BRD-A67514145-001-02-9	[O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(CN3CCOCC3)OC2=O)o1	YVQVOQKFMFRVGR-VGOFMYFVSA-N, YVQVOQKFMFRVGR-VGOFMYFVSA-N, YVQVOQKFMFRVGR-VGOFMYFVSA-N	Launched
furazolidone	bacterial DNA inhibitor		gastroenterology, infectious disease	diarrhea, enteritis, cholera	BRD-K11756522-001-09-9	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	PLHJDBGFXBMTGZ-WEVVVXLNSA-N	Launched
furegrelate	thromboxane synthase inhibitor	TBXAS1			BRD-K55529781-236-03-8	OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1	VHWFITPGPFLBGT-UHFFFAOYSA-N	Phase 1
furosemide	diuretic	CA2, GPR35, SLC12A1, SLC12A2	cardiology, rheumatology	edema, hypertension, congestive heart failure, nephrotic syndrome	BRD-K78010432-001-21-5, BRD-K78010432-001-20-7	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl, NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	ZZUFCTLCJUWOSV-UHFFFAOYSA-N, ZZUFCTLCJUWOSV-UHFFFAOYSA-N	Launched
fursultiamine	vitamin B				BRD-A71157293-003-10-0	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCC1CCCO1	JTLXCMOFVBXEKD-FOWTUZBSSA-N	Launched
fusidic-acid	bacterial 30S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	BRD-A06935312-001-04-3	C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O	IECPWNUMDGFDKC-FRVBXGIOSA-N	Launched
F351	TGF beta receptor inhibitor	TGFB1			BRD-K41267922-001-01-4	Cc1ccc(=O)n(c1)-c1ccc(O)cc1	NETTXQJYJRFTFS-UHFFFAOYSA-N	Phase 2
g-caryophyllene	acetylcholinesterase inhibitor	ACHE			BRD-K26878113-001-01-6	C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1	NPNUFJAVOOONJE-GFUGXAQUSA-N	Preclinical
G-1	G protein-coupled receptor agonist	GPER1			BRD-K62696033-001-01-4	CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br	VHSVKVWHYFBIFJ-HKZYLEAXSA-N	Preclinical
G-15	estrogen receptor antagonist	GPER1			BRD-M30288325-001-01-4	Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12.Brc1cc2OCOc2cc1[C@@H]1Nc2ccccc2[C@@H]2C=CC[C@H]12	LBBDCJLRQXMUAE-FWHYVADDSA-N	Preclinical
GABA-linoleamide	benzodiazepine receptor agonist				BRD-K46254452-001-01-5	CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O	YGFYZZQGVSUXJE-HZJYTTRNSA-N	Phase 2
gabapentin	calcium channel blocker	ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	infectious disease, neurology/psychiatry	virus herpes simplex (HSV), shingles, seizures, restless leg syndrome	BRD-K62737565-001-09-5, BRD-K62737565-001-10-3, BRD-K62737565-003-02-6	NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1	UGJMXCAKCUNAIE-UHFFFAOYSA-N, UGJMXCAKCUNAIE-UHFFFAOYSA-N, UGJMXCAKCUNAIE-UHFFFAOYSA-N	Launched
gabapentin-enacarbil	adrenergic receptor agonist	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8	neurology/psychiatry	restless leg syndrome, postherpetic neuralgia	BRD-A86665761-001-01-1	CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1	TZDUHAJSIBHXDL-UHFFFAOYSA-N	Launched
gabazine	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2			BRD-K79905821-004-03-6	COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	ACVGNKYJVGNLIL-UHFFFAOYSA-N	Preclinical
gabexate	serine protease inhibitor	PRSS1, TPSAB1	gastroenterology	pancreatitis	BRD-K59256312-066-15-7, BRD-K59256312-066-13-2, BRD-K59256312-066-14-0, BRD-K59256312-066-16-5	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1, CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N, YKGYIDJEEQRWQH-UHFFFAOYSA-N	Launched
gaboxadol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3			BRD-K89104321-003-15-5, BRD-K89104321-003-14-8	Oc1noc2CNCCc12, Oc1noc2CNCCc12	ZXRVKCBLGJOCEE-UHFFFAOYSA-N, ZXRVKCBLGJOCEE-UHFFFAOYSA-N	Phase 3
gadobutrol	radiopaque medium		radiology	MRI contrast agent	BRD-A67181951-001-01-2	OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2	ZPDFIIGFYAHNSK-FUISWZMFSA-K	Launched
gadodiamide	radiopaque medium		radiology	MRI contrast agent	BRD-K38140108-002-01-2	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	HZHFFEYYPYZMNU-UHFFFAOYSA-K	Launched
gadopentetic-acid	contrast agent		radiology	contrast agent	BRD-K25106841-001-01-2	OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	IZOOGPBRAOKZFK-UHFFFAOYSA-K	Launched
gadoterate-meglumine	radiopaque medium		radiology	MRI contrast agent	BRD-K11099631-001-08-4, BRD-K11099631-001-07-6	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1, OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	WDLRUFUQRNWCPK-UHFFFAOYSA-N, WDLRUFUQRNWCPK-UHFFFAOYSA-N	Launched
gadoteridol	radiopaque medium		radiology	MRI contrast agent	BRD-M87846614-001-02-9, BRD-A72401848-001-01-4	[Gd+3].CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1, CC(O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3	DPNNNPAKRZOSMO-UHFFFAOYSA-N, DPNNNPAKRZOSMO-UHFFFAOYSA-K	Launched
galantamine	acetylcholinesterase inhibitor	ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG	neurology/psychiatry	senile dementia	BRD-K49481516-004-18-3, BRD-K49481516-001-01-5	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24, COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24	ASUTZQLVASHGKV-JDFRZJQESA-N, ASUTZQLVASHGKV-JDFRZJQESA-N	Launched
galeterone	androgen receptor modulator	AR, CYP17A1			BRD-A07986123-001-02-8	C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@]34C)C1CC=C2n1cnc2ccccc12	PAFKTGFSEFKSQG-BLYLLKCRSA-N	Phase 3
gallamine-triethiodide	acetylcholine receptor antagonist	ACHE, CHRM2, CHRNA1, CHRNA2	neurology/psychiatry	muscle relaxant	BRD-K43106192-320-11-8, BRD-K43106192-320-09-2, BRD-K43106192-320-10-0	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC, CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N, OZLPUNFFCJDMJD-UHFFFAOYSA-N	Launched
gallic-acid	beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP			BRD-K77345217-001-05-0	OC(=O)c1cc(O)c(O)c(O)c1	LNTHITQWFMADLM-UHFFFAOYSA-N	Preclinical
gallium-triquinolin-8-olate					BRD-K46648676-001-01-8	O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12	KWQNQSDKCINQQP-UHFFFAOYSA-K	Phase 1
gallopamil	L-type calcium channel blocker	ATP2A2	cardiology	hypertension, cardiac arrythmia	BRD-A52922642-001-03-7	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC	XQLWNAFCTODIRK-UHFFFAOYSA-N	Launched
gambogic-acid	caspase activator	BCL2			BRD-K08542803-001-01-5, BRD-A76999758-001-01-1	CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@@H]6CC(C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C	GEZHEQNLKAOMCA-RRZNCOCZSA-N, GEZHEQNLKAOMCA-UOONSFDBSA-N	Phase 2
gamma-aminobutyric-acid	benzodiazepine receptor agonist	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1			BRD-K77245796-003-01-6	NCCCC(O)=O	BTCSSZJGUNDROE-UHFFFAOYSA-N	Preclinical
gamma-linolenic-acid	cyclooxygenase inhibitor, prostanoid receptor agonist	PTGS1, PTGS2			BRD-K18059238-001-10-4, BRD-K18059238-001-13-8, BRD-K18059238-001-11-2	CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O, CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	VZCCETWTMQHEPK-QNEBEIHSSA-N, VZCCETWTMQHEPK-QNEBEIHSSA-N, VZCCETWTMQHEPK-QNEBEIHSSA-N	Phase 2
ganaxolone	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			BRD-K28217197-001-01-4	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PGTVWKLGGCQMBR-FLBATMFCSA-N	Phase 3
ganciclovir	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	BRD-K22662435-001-19-1, BRD-K22662435-001-18-3, BRD-K22662435-001-17-5	Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1, Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1	IRSCQMHQWWYFCW-UHFFFAOYSA-N, IRSCQMHQWWYFCW-UHFFFAOYSA-N, IRSCQMHQWWYFCW-UHFFFAOYSA-N	Launched
ganetespib	HSP inhibitor	HSP90AA1			BRD-K38852836-001-02-1	CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	RVAQIUULWULRNW-UHFFFAOYSA-N	Phase 3
ganglioside-gm1					BRD-A30703952-201-01-2	CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(OC4OC(CO)C(O)C(O)C4O)C3NC(C)=O)C(OC3(CC(O)C(NC(C)=O)C(O3)C(O)C(O)CO)C(O)=O)C2O)C(O)C1O)[C@H](O)\C=C\CCCCCCCCCCCCC	QPJBWNIQKHGLAU-MRSLTSNLSA-N	Phase 2
garenoxacin	topoisomerase inhibitor	TOP2A	infectious disease	respiratory tract infections	BRD-K77038618-356-01-3	C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1	NJDRXTDGYFKORP-LLVKDONJSA-N	Launched
gastrodin					BRD-K81613478-001-01-8	OC[C@@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	PUQSUZTXKPLAPR-OBPIAQAESA-N	Phase 2
gatifloxacin	bacterial DNA gyrase inhibitor				BRD-A74980173-001-11-9, BRD-A74980173-213-01-1	COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	XUBOMFCQGDBHNK-UHFFFAOYSA-N, XUBOMFCQGDBHNK-UHFFFAOYSA-N	Withdrawn
gavestinel	glutamate receptor antagonist	GLRB			BRD-K81981783-236-02-9, BRD-K81981783-236-01-1	OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1, OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	WZBNEZWCNKUOSM-VOTSOKGWSA-N, WZBNEZWCNKUOSM-VOTSOKGWSA-N	Phase 3
GBR-12783	dopamine uptake inhibitor				BRD-K92015269-300-01-2	C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	XFBDGHFDKJITGC-JLHYYAGUSA-N	Preclinical
GBR-12935	dopamine uptake inhibitor	AGTR1, SLC6A3			BRD-K50135270-300-02-3	C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	RAQPOZGWANIDQT-UHFFFAOYSA-N	Preclinical
GBR-13069	dopamine uptake inhibitor	SLC6A3			BRD-K92577649-300-01-2	Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	DASHZBBQOARCMQ-QPJJXVBHSA-N	Preclinical
GDC-0068	AKT inhibitor	AKT1, AKT2, AKT3, PRKG1			BRD-K71480163-001-01-4	CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	GRZXWCHAXNAUHY-AHRSYUTCSA-N	Phase 2
GDC-0152	XIAP inhibitor	BIRC2, BIRC3, BIRC7, XIAP			BRD-K68938568-001-01-7	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	WZRFLSDVFPIXOV-LRQRDZAKSA-N	Phase 1
GDC-0349	Pim kinase inhibitor	PIK3CA			BRD-K43187018-001-03-3, BRD-K43187018-001-02-5	CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1, CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	RGJOJUGRHPQXGF-INIZCTEOSA-N, RGJOJUGRHPQXGF-INIZCTEOSA-N	Phase 1
GDC-0623	MEK inhibitor				BRD-K46908090-001-02-2, BRD-K46908090-001-01-4, BRD-K46908090-001-03-0	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F, OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N, RFWVETIZUQEJEF-UHFFFAOYSA-N	Phase 1
GDC-0810	selective estrogen receptor destabilizer	ESR1			BRD-K61923022-001-02-4	CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl	BURHGPHDEVGCEZ-KJGLQBJMSA-N	Phase 2
GDC-0834	Brutons tyrosine kinase (BTK) inhibitor" "BTK" "" "" "BRD-A30984645-001-01-5"
"1148" "CN1CCN(C)C(=O)C1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1" "CDOOFZZILLRUQH-UHFFFAOYSA-N" "Phase 1" "" "" "" "" "" ""
"1149" "GDC-0879" "RAF inhibitor" "BRAF" "" "" "BRD-K67578145-001-10-5, BRD-K67578145-001-09-7, BRD-K14399170-001-01-7" "OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N/O)c1, OCCn1cc(c(n1)-c1ccncc1)-c1ccc2c(CC\C2=N\O)c1" "DEZZLWQELQORIU-RELWKKBWSA-N, DEZZLWQELQORIU-RELWKKBWSA-N, DEZZLWQELQORIU-PYCFMQQDSA-N" "Preclinical"
"1150" "GDC-0941" "PI3K inhibitor" "PIK3CA, PIK3CB, PIK3CD, PIK3CG" "" "" "BRD-K52911425-001-09-8" "CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1" "LHNIIDJUOCFXAP-UHFFFAOYSA-N" "Phase 2"
"1151" "GDC-0980" "mTOR inhibitor, PI3K inhibitor" "FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK" "" "" "BRD-K23228615-001-03-6, BRD-K23228615-001-02-8" "C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1" "YOVVNQKCSKSHKT-HNNXBMFYSA-N, YOVVNQKCSKSHKT-HNNXBMFYSA-N" "Phase 2"
"1152" "GDC-0994" "MAP kinase inhibitor" "MAPK1, MAPK3" "" "" "BRD-A20830788-001-01-9" "Cn1nccc1Nc1nccc(n1)-c1ccn(C(CO)c2ccc(Cl)c(F)c2)c(=O)c1" "RZUOCXOYPYGSKL-UHFFFAOYSA-N" "Phase 1"
"1153" "gedunin" "HSP inhibitor" "HSP90AA1" "" "" "BRD-K02703275-001-07-5" "CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1" "YJXDGWUNRYLINJ-BHAPSIHVSA-N" "Preclinical"
"1154" "gefitinib" "EGFR inhibitor" "EGFR" "oncology" "non-small cell lung cancer (NSCLC)" "BRD-K64052750-001-17-5, BRD-K64052750-001-16-7, BRD-K64052750-001-23-3, BRD-K64052750-001-22-5" "COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1" "XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N, XGALLCVXEZPNRQ-UHFFFAOYSA-N" "Launched"
"1155" "geldanamycin" "HSP inhibitor" "HSP90AA1, HSP90AB1" "" "" "BRD-K43570081-001-02-4, BRD-K82847623-001-01-5" "CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@@H]1C[C@@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H]1O)C2=O" "QTQAWLPCGQOSGP-PHLMVCJGSA-N, QTQAWLPCGQOSGP-ZOYSHEHLSA-N" "Preclinical"
"1156" "gemcadiol" "antilipemic" "" "" "" "BRD-K43890836-001-01-6" "CC(C)(CO)CCCCCCC(C)(C)CO" "DJKWDKJYFYUEBQ-UHFFFAOYSA-N" "Phase 2"
"1157" "gemcitabine" "ribonucleotide reductase inhibitor" "CMPK1, RRM1, RRM2, TYMS" "oncology" "ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer" "BRD-K11238904-003-01-9, BRD-K15108141-001-08-2, BRD-K15108141-001-06-6" "Nc1ccn([C@@H]2O[C@@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1, Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1" "SDUQYLNIPVEERB-UBKIQSJTSA-N, SDUQYLNIPVEERB-QPPQHZFASA-N, SDUQYLNIPVEERB-QPPQHZFASA-N" "Launched"
"1158" "gemcitabine-elaidate" "DNA synthesis inhibitor, apoptosis inhibitor" "CMPK1, RRM1, TYMS" "" "" "BRD-K09456915-001-01-2" "CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O" "HESSNRGIEVBPRB-QDDPNBLJSA-N" "Phase 1"
"1159" "gemfibrozil" "lipoprotein lipase activator" "LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1" "endocrinology, cardiology" "hyperlipidemia, coronary heart disease" "BRD-K11129031-001-27-5, BRD-K11129031-001-26-7" "Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1, Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1" "HEMJJKBWTPKOJG-UHFFFAOYSA-N, HEMJJKBWTPKOJG-UHFFFAOYSA-N" "Launched"
"1160" "gemifloxacin" "bacterial DNA gyrase inhibitor" "" "pulmonary, infectious disease" "bronchitis, pneumonia" "BRD-A40787240-066-04-6" "CO\N=C1/CN(CC1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1" "ZRCVYEYHRGVLOC-HYARGMPZSA-N" "Launched"
"1161" "genipin" "choleretic agent" "" "" "" "BRD-K28824103-001-02-8, BRD-K70886785-001-01-1" "COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@H](O)[C@H]2[C@@H]1CC=C2CO" "AZKVWQKMDGGDSV-BCMRRPTOSA-N, AZKVWQKMDGGDSV-ZOFUNIGCSA-N" "Preclinical"
"1162" "geniposide" "GLP receptor agonist" "GLP1R" "" "" "BRD-K57275767-001-02-4, BRD-K35205465-001-01-5" "COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO, COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@@H](O)[C@H]2O)[C@@H]2[C@@H]1CC=C2CO" "IBFYXTRXDNAPMM-BVTMAQQCSA-N, IBFYXTRXDNAPMM-TYYARJOLSA-N" "Preclinical"
"1163" "geniposidic-acid" "cyclooxygenase inhibitor" "" "" "" "BRD-K02342990-001-01-9, BRD-K73771095-001-02-5" "OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O" "ZJDOESGVOWAULF-PMCVATQOSA-N, ZJDOESGVOWAULF-OGJQONSISA-N" "Preclinical"
"1164" "genistein" "tyrosine kinase inhibitor" "CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5" "" "" "BRD-K43797669-001-30-4, BRD-K43797669-001-29-6, BRD-K43797669-001-28-8" "Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O, Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O" "TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N, TZBJGXHYKVUXJN-UHFFFAOYSA-N" "Phase 2/Phase 3"
"1165" "gentamycin" "bacterial 50S ribosomal subunit inhibitor" "HSPA8, LRP2" "infectious disease, critical care" "bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis" "BRD-A89445950-001-01-6, BRD-M10279501-065-05-9" "CNC(C)[C@@H]1CC[C@@H](N)[C@@H](OC2[C@@H](N)C[C@@H](N)[C@H](OC3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@@H](CC[C@H]3N)[C@@H](C)N)[C@@H]2O)OC[C@]1(C)O.CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1" "CEAZRRDELHUEMR-VVSHQIECSA-N, NPEFREDMMVQEPL-YJSGWBGLSA-N" "Launched"
"1166" "gentiopicrin" "glutamate receptor downregulator" "GRIN2B" "" "" "BRD-K33131085-001-07-2" "OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O" "DUAGQYUORDTXOR-GPQRQXLASA-N" "Phase 3"
"1167" "genz-123346" "glucosylceramidase inhibitor" "UGCG" "" "" "BRD-K70693421-001-01-1, BRD-K70693421-001-02-9" "CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1, CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1" "JMNXWOFCUJJYEO-HYBUGGRVSA-N, JMNXWOFCUJJYEO-HYBUGGRVSA-N" "Preclinical"
"1168" "genz-644282" "topoisomerase inhibitor" "TOP1" "" "" "BRD-K99475619-001-01-2" "CNCCn1c2c(cnc3cc4OCOc4cc23)c2cc(OC)c(OC)cc2c1=O" "BAORCAMWLWRZQG-UHFFFAOYSA-N" "Phase 1"
"1169" "gepefrine" "adrenergic receptor agonist" "" "cardiology" "hypotension" "BRD-A04447196-001-01-8" "CC(N)Cc1cccc(O)c1" "WTDGMHYYGNJEKQ-UHFFFAOYSA-N" "Launched"
"1170" "gepon" "" "" "" "" "BRD-A56754222-001-01-2" "CC(C)[C@@H](NC(=O)C(NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)C(CCC(O)=O)NC(=O)[C@H](N)C(C)O)C(C)O)C(=O)N[C@H](CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NC(CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O" "HTQONPPEZULJKY-CXRHXLISSA-N" "Phase 1"
"1171" "geranyl-farnesylacetate" "mucin production enhancer" "" "" "" "BRD-K02780233-001-01-7, BRD-K02780233-001-02-5" "CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C, CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C" "ZPACYDRSPFRDHO-ROBAGEODSA-N, ZPACYDRSPFRDHO-ROBAGEODSA-N" "Phase 2"
"1172" "gestodene" "contraceptive agent" "" "endocrinology" "contraceptive" "BRD-K81077266-001-01-2" "CC[C@]12CC[C@@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@]2(O)C" "" ""
"1173" "gestrinone" "progesterone receptor antagonist" "AR, ESR1, PGR" "obstetrics/gynecology" "endometriosis" "BRD-K97472745-001-01-8" "CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C" "" ""
"1174" "GF109203X" "PKC inhibitor" "PDPK1, PIM1, PRKCI, PRKCZ" "" "" "BRD-K31342827-001-15-3, BRD-K31342827-001-13-8" "CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12, CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12" "QMGUOJYZJKLOLH-UHFFFAOYSA-N, QMGUOJYZJKLOLH-UHFFFAOYSA-N" "Preclinical"
"1175" "GGTI-298" "GGTase inhibitor" "CDKN1A" "" "" "BRD-K19669037-001-01-1" "COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12" "XVWPFYDMUFBHBF-CLOONOSVSA-N" "Preclinical"
"1176" "gidazepam" "GABA benzodiazepine site receptor agonist" "" "" "" "BRD-K22588750-001-07-0" "NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1" "XLGCMZLSEXRBSG-UHFFFAOYSA-N" "Launched"
"1177" "gilteritinib" "FLT3 inhibitor" "FLT3" "" "" "BRD-K72280606-001-01-2" "CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1" "GYQYAJJFPNQOOW-UHFFFAOYSA-N" "Phase 3"
"1178" "gimeracil" "dihydropyrimidine dehydrogenase inhibitor" "DPYD" "oncology" "gastric adenocarcinoma" "BRD-K35687421-001-03-3, BRD-K35687421-001-02-5" "Oc1cc(=O)[nH]cc1Cl, Oc1cc(=O)[nH]cc1Cl" "ZPLQIPFOCGIIHV-UHFFFAOYSA-N, ZPLQIPFOCGIIHV-UHFFFAOYSA-N" "Launched"
"1179" "ginkgolide-a" "GABA receptor antagonist" "GLRA1, GLRB" "" "" "BRD-A94702766-001-01-7" "C[C@@H]1C(=O)O[C@H]2CC34[C@H]5C[C@@H](C(C)(C)C)C33[C@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O" "FPUXKXIZEIDQKW-VTPWKYHPSA-N" "Preclinical"
"1180" "ginkgolide-b" "platelet activating factor receptor antagonist" "GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B" "" "" "BRD-A59001851-001-01-3, BRD-A82395837-001-01-9" "C[C@@H]1C(=O)O[C@H]2[C@H](O)C34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@]4(C(=O)O5)[C@@]12O, C[C@H]1C(=O)O[C@H]2[C@@H](O)C34[C@@H]5C[C@@H](C(C)(C)C)C33[C@H](O)C(=O)O[C@H]3O[C@]4(C(=O)O5)[C@@]12O" "SQOJOAFXDQDRGF-IWNUMIARSA-N, SQOJOAFXDQDRGF-DJCNAJSISA-N" "Phase 3"
"1181" "ginsenoside-c-k" "NFkB pathway inhibitor, nitric oxide synthase inhibitor" "PTGS2" "" "" "BRD-K01942833-001-01-8" "CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C" "FVIZARNDLVOMSU-IRFFNABBSA-N" "Preclinical"
"1182" "ginsenoside-rd" "calcium channel blocker" "" "" "" "BRD-A84810646-001-01-6" "CC(C)=CCCC(C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C" "RLDVZILFNVRJTL-HIOAYSDNSA-N" "Phase 3"
"1183" "ginsenoside-rg3" "angiogenesis inhibitor, apoptosis stimulant" "KCNH2" "" "" "BRD-A44511856-001-01-4" "CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C" "RWXIFXNRCLMQCD-QIRRTGJGSA-N" "Launched"
"1184" "givinostat" "HDAC inhibitor" "HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9" "" "" "BRD-K13810148-311-03-2" "CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1" "YALNUENQHAQXEA-UHFFFAOYSA-N" "Phase 2"
"1185" "GKT137831" "NADPH oxidase inhibitor" "NOX1, NOX4" "" "" "BRD-K79710622-001-02-9, BRD-K79710622-001-01-1" "CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12, CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12" "RGYQPQARIQKJKH-UHFFFAOYSA-N, RGYQPQARIQKJKH-UHFFFAOYSA-N" "Phase 2"
"1186" "GK921" "transglutaminase inhibitor" "TGM2" "" "" "BRD-K38272302-001-01-9" "C(CN1CCCC1)Oc1nc2cccnc2nc1C" "" ""
"1187" "glafenine" "DeltaF508-CFTR Correctors" "CFTR" "" "" "BRD-A38076815-003-10-3, BRD-A38076815-001-04-0" "OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12, OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12" "GWOFUCIGLDBNKM-UHFFFAOYSA-N, GWOFUCIGLDBNKM-UHFFFAOYSA-N" "Withdrawn"
"1188" "glasdegib" "hedgehog pathway inhibitor" "SMO" "" "" "BRD-K34341643-001-01-4" "CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C" "" ""
"1189" "gliclazide" "ATP channel blocker, insulin secretagogue" "ABCC8, VEGFA" "endocrinology" "diabetes mellitus" "BRD-A61154809-001-15-9, BRD-A61154809-001-16-7, BRD-A61154809-001-14-2" "Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1" "BOVGTQGAOIONJV-UHFFFAOYSA-N, BOVGTQGAOIONJV-UHFFFAOYSA-N, BOVGTQGAOIONJV-UHFFFAOYSA-N" "Launched"
"1190" "glimepiride" "insulin secretagogue" "ABCC8, KCNJ1, KCNJ11" "endocrinology" "diabetes mellitus" "BRD-K34776109-001-16-6, BRD-K34776109-001-15-8, BRD-K34776109-001-14-1" "CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O, CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O" "WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N, WIGIZIANZCJQQY-RUCARUNLSA-N" "Launched"
"1191" "glipizide" "sulfonylurea" "ABCC8, KCNJ10, KCNJ11, PPARG" "endocrinology" "diabetes mellitus, hyperglycemia" "BRD-K12219985-001-26-1, BRD-K12219985-001-25-3" "Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1" "ZJJXGWJIGJFDTL-UHFFFAOYSA-N, ZJJXGWJIGJFDTL-UHFFFAOYSA-N" "Launched"
"1192" "gliquidone" "sulfonylurea" "ABCC8, KCNJ10, KCNJ8" "endocrinology" "diabetes mellitus" "BRD-K80396088-001-12-0" "COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C" "LLJFMFZYVVLQKT-UHFFFAOYSA-N" "Launched"
"1193" "GLPG0492" "androgen receptor modulator" "AR" "" "" "BRD-K15893360-001-01-8" "CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C" "" ""
"1194" "GLPG0492-R-enantiomer" "androgen receptor modulator" "AR" "" "" "BRD-K04643927-001-01-6" "CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C" "" ""
"1195" "glucaric-acid" "" "" "" "" "BRD-K60150658-432-01-5" "O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O" "DSLZVSRJTYRBFB-LLEIAEIESA-N" "Phase 1"
"1196" "gluconolactone" "" "LCT" "" "" "BRD-K04288422-001-04-4" "OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O" "PHOQVHQSTUBQQK-KLVWXMOXSA-N" "Launched"
"1197" "glucosamine" "glycosylated protein precursor" "IFNG, IL1B, MMP9, NFKB2, TNF" "neurology/psychiatry, rheumatology" "muscle pain, rheumatoid arthritis, joint pain, backache" "BRD-K29918010-003-04-1" "N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O" "MSWZFWKMSRAUBD-QZABAPFNSA-N" "Launched"
"1198" "glutamine-(l)" "" "CTPS1, GLUL, GPRC6A, PPAT" "gastroenterology, dental, neurology/psychiatry, rheumatology" "diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohns disease, anxiety, insomnia	BRD-K83896451-001-07-5, BRD-K83896451-001-06-7	N[C@@H](CCC(N)=O)C(O)=O, N[C@@H](CCC(N)=O)C(O)=O	ZDXPYRJPNDTMRX-VKHMYHEASA-N, ZDXPYRJPNDTMRX-VKHMYHEASA-N	Launched
glutathione	antioxidant	ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12			BRD-K69346723-001-04-8	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	RWSXRVCMGQZWBV-WDSKDSINSA-N	Phase 3
glutathione-monoisopropyl-ester	lipid peroxidase inhibitor				BRD-K58937086-001-01-4, BRD-K58937086-001-02-2	CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O, CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	MVNCPACIPXNJIW-IUCAKERBSA-N, MVNCPACIPXNJIW-IUCAKERBSA-N	Phase 2
gly-gln					BRD-K85066592-001-01-6	NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	PNMUAGGSDZXTHX-BYPYZUCNSA-N	Phase 2
glyburide	ATP channel blocker, insulin secretagogue, sulfonylurea	ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1	endocrinology	diabetes mellitus, hyperglycemia	BRD-K36927236-001-32-6, BRD-K36927236-001-31-8, BRD-K36927236-001-30-0	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1, COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N, ZNNLBTZKUZBEKO-UHFFFAOYSA-N	Launched
glycerol-monolaurate	beta lactamase inhibitor				BRD-A10773072-001-03-4	CCCCCCCCCCCC(=O)OCC(O)CO	ARIWANIATODDMH-UHFFFAOYSA-N	Launched
glycitein	tumor necrosis factor release inhibitor	TNF			BRD-K78303961-001-02-3	COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O	DXYUAIFZCFRPTH-UHFFFAOYSA-N	Phase 3
glycopyrrolate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	BRD-A81233518-004-16-1	C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)c1ccccc1	ANGKOCUUWGHLCE-UHFFFAOYSA-N	Launched
GMX1778	NAMPT inhibitor	NAMPT			BRD-K69832040-001-01-9	Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1	BOIPLTNGIAPDBY-UHFFFAOYSA-N	Phase 1/Phase 2
GNF-2	Bcr-Abl kinase inhibitor	ABL1, BCR			BRD-K97056771-001-14-9, BRD-K97056771-001-13-1	NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1, NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	WEVYNIUIFUYDGI-UHFFFAOYSA-N, WEVYNIUIFUYDGI-UHFFFAOYSA-N	Preclinical
GNTI	opioid receptor antagonist	OPRK1, OPRM1			BRD-K64748124-300-01-7	NC(=N)Nc1ccc2[nH]c3c(C[C@@]4(O)[C@H]5Cc6ccc(O)c7O[C@@H]3[C@]4(CCN5CC3CC3)c67)c2c1	VLNHDKDBGWXJEE-GYHUNEDQSA-N	Preclinical
go-6983	protein kinase inhibitor	PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ			BRD-K36984403-001-03-5, BRD-K36984403-001-02-7	COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1, COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1	LLJJDLHGZUOMQP-UHFFFAOYSA-N, LLJJDLHGZUOMQP-UHFFFAOYSA-N	Preclinical
golgicide-a	ARF inhibitor	GBF1			BRD-A53244165-001-01-6	Fc1cc(F)c2NC([C@H]3CC=C[C@@H]3c2c1)c1cccnc1	NJZHEQOUHLZCOX-VORVDWIASA-N	Preclinical
golvatinib	VEGFR inhibitor	KDR, MET			BRD-K69001009-001-02-8	CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	UQRCJCNVNUFYDX-UHFFFAOYSA-N	Phase 2
gonadorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR, GNRHR2	obstetrics/gynecology	cystic ovaries, reproductive synchrony	BRD-K96874295-015-01-0	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	XLXSAKCOAKORKW-AQJXLSMYSA-N	Launched
goserelin-acetate	gonadotropin releasing factor hormone receptor agonist	GNRHR, LHCGR	oncology, obstetrics/gynecology	prostate cancer, breast cancer, endometriosis	BRD-K99504665-001-01-2	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	BLCLNMBMMGCOAS-URPVMXJPSA-N	Launched
gossypol	BCL inhibitor, MCL1 inhibitor	BCL2			BRD-K19295594-015-14-3, BRD-K19295594-015-13-5, BRD-K19295594-015-12-7, BRD-K19295594-001-15-0, BRD-K19295594-001-16-8	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O, CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N, QBKSWRVVCFFDOT-UHFFFAOYSA-N	Phase 2
GPI-1046	FKBP inhibitor	FKBP1A			BRD-K44869961-001-01-6	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1	OQAHHWOPVDDWHD-INIZCTEOSA-N	Preclinical
GPR120-modulator-1	G protein-coupled receptor modulator	FFAR4			BRD-K19409553-001-01-6	Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O	FONSSTYHKIFEBM-UHFFFAOYSA-N	Preclinical
GP1a	cannabinoid receptor agonist	CNR2			BRD-K65285700-001-02-3	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	FNOMTMVRTBHRET-UHFFFAOYSA-N	Preclinical
GP2a	cannabinoid receptor agonist	CNR2			BRD-K34608650-001-02-4	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	SPEFJYZGXZENAF-UHFFFAOYSA-N	Preclinical
GR-103691	dopamine receptor antagonist	DRD3			BRD-K50891186-001-04-4	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1	JARNORYOPMINDY-UHFFFAOYSA-N	Preclinical
GR-113808	serotonin receptor antagonist	HTR4			BRD-K49945136-001-10-0	Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	MOZPSIXKYJUTKI-UHFFFAOYSA-N	Preclinical
GR-127935	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			BRD-K11911061-003-11-9	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	YDBCEBYHYKAFRX-UHFFFAOYSA-N	Preclinical
GR-135531	melatonin receptor agonist				BRD-K83023055-001-02-7	COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	MPZVHKLZCUEJFO-UHFFFAOYSA-N	Preclinical
GR-144053	integrin antagonist	ITGA2B, ITGB3			BRD-K12120659-305-02-2	NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	QGEGSJUSWLLZLH-UHFFFAOYSA-N	Preclinical
GR-159897	tachykinin antagonist	TAC1, TACR2			BRD-K52394958-001-02-7	COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	BANYJBHWTOJQDU-GDLZYMKVSA-N	Preclinical
GR-235	estrogen receptor agonist, FXR antagonist, progesterone receptor agonist	NR1H4			BRD-K26674531-001-02-1	C\C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	WDXRGPWQVHZTQJ-OSJVMJFVSA-N	Launched
GR-79236	adenosine receptor agonist	ADORA1, ADORA2A			BRD-K40578143-001-02-6	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	GYWXTRVEUURNEW-TVDBPQCTSA-N	Phase 1
gramicidin	bacterial permeability inducer		infectious disease	first-aid antibiotic	BRD-A52977603-001-01-2	CC(C)CC(NC(=O)C(C)NC(=O)CNC(=O)C(NC=O)C(C)C)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCCO	ZWCXYZRRTRDGQE-UHFFFAOYSA-N	Launched
gramine	norepinephrine reputake inhibitor				BRD-K26005076-001-12-8	CN(C)Cc1c[nH]c2ccccc12	OCDGBSUVYYVKQZ-UHFFFAOYSA-N	Preclinical
granisetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	BRD-A10967948-003-06-3, BRD-A10967948-003-05-5	CN1C2CCCC1CC(C2)NC(=O)c1nn(C)c2ccccc12, CN1C2CCCC1CC(C2)NC(=O)c1nn(C)c2ccccc12	MFWNKCLOYSRHCJ-UHFFFAOYSA-N, MFWNKCLOYSRHCJ-UHFFFAOYSA-N	Launched
grapiprant	prostaglandin inhibitor	PTGER4	rheumatology	osteoarthritis	BRD-K62050508-001-01-0	CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1	HZVLFTCYCLXTGV-UHFFFAOYSA-N	Launched
grazoprevir	HCV inhibitor				BRD-K24943235-001-01-3, BRD-K24943235-237-01-3	COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C, COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	OBMNJSNZOWALQB-NCQNOWPTSA-N, OBMNJSNZOWALQB-NCQNOWPTSA-N	Launched
griseofulvin	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm, tinea pedis	BRD-K12423485-001-01-7, BRD-K08273968-001-16-6	COc1cc(OC)c(Cl)c2O[C@@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12, COc1cc(OC)c(Cl)c2O[C@]3([C@H](C)CC(=O)C=C3OC)C(=O)c12	DDUHZTYCFQRHIY-CQLKUDPESA-N, DDUHZTYCFQRHIY-RBHXEPJQSA-N	Launched
GR125487	serotonin receptor antagonist	HTR4			BRD-K62594868-082-08-6	COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	SSPCCAYAIDNNJX-UHFFFAOYSA-N	Preclinical
GR46611	serotonin receptor agonist	HTR1D			BRD-K98155362-001-07-7	COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	LBVZWEWTNUDWNS-YRNVUSSQSA-N	Preclinical
GS-39783	GABA receptor modulator	GABBR1			BRD-K75478907-001-02-3	CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	GSGVDKOCBKBMGG-UHFFFAOYSA-N	Preclinical
GS-6201	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K68453341-001-01-1	CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1	KOYXXLLNCXWUNF-UHFFFAOYSA-N	Phase 1
GS-9620	toll-like receptor agonist	TLR7			BRD-K73585091-001-02-3, BRD-K73585091-001-01-5	CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1, CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	VFOKSTCIRGDTBR-UHFFFAOYSA-N, VFOKSTCIRGDTBR-UHFFFAOYSA-N	Phase 2
GS-9973	syk inhibitor	SYK			BRD-K76719364-001-02-5, BRD-K76719364-001-04-1, BRD-K76719364-001-01-7	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1, C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3cn[nH]c3c2)cc1	XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N, XSMSNFMDVXXHGJ-UHFFFAOYSA-N	Phase 2
GSK-J1	histone demethylase inhibitor	KDM6B			BRD-K32847255-001-01-1	OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	AVZCPICCWKMZDT-UHFFFAOYSA-N	Preclinical
GSK-J2	histone demethylase inhibitor				BRD-K82484347-001-01-2	OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	LJIFOCRGDDQFJF-UHFFFAOYSA-N	Preclinical
GSK-J4	histone lysine demethylase inhibitor	KDM6A, KDM6B			BRD-K98203492-003-04-1	CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	WBKCKEHGXNWYMO-UHFFFAOYSA-N	Preclinical
GSK-0660	PPAR receptor antagonist	PPARD			BRD-K98684188-001-02-9	COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	NDFKBGWLUHKMFY-UHFFFAOYSA-N	Preclinical
GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	GSK3A, GSK3B			BRD-K04923131-001-15-4, BRD-K04923131-001-14-7	O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12, O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12	DDLZLOKCJHBUHD-UJZLGWIISA-N, DDLZLOKCJHBUHD-UJZLGWIISA-N	Preclinical
GSK1059615	PI3K inhibitor	PIK3CG			BRD-K06750613-001-07-3, BRD-K06750613-001-04-0	O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1, O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1	QDITZBLZQQZVEE-YBEGLDIGSA-N, QDITZBLZQQZVEE-YBEGLDIGSA-N	Phase 1
GSK1070916	Aurora kinase inhibitor	AURKA, AURKB, AURKC, CYP2D6, CYP3A4			BRD-K36740062-001-06-6	CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	QTBWCSQGBMPECM-UHFFFAOYSA-N	Phase 1
GSK1292263	glucose dependent insulinotropic receptor agonist	GRPR			BRD-K60341624-001-02-2	CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	AYJRTVVIBJSSKN-UHFFFAOYSA-N	Phase 2
GSK163090	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D			BRD-K69669039-001-01-8	Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1	ANGUXJDGJCHGOG-UHFFFAOYSA-N	Phase 2
GSK1838705A	insulin growth factor receptor inhibitor	ALK, IGF1R, INSR, RPS6KA1			BRD-K06749501-001-05-4, BRD-K06749501-001-03-9, BRD-K06749501-001-02-1	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12, CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N, HZTYDQRUAWIZRE-UHFFFAOYSA-N	Preclinical
GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	IGF1R, INSR			BRD-K04833372-001-06-2	CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	MOSKATHMXWSZTQ-UHFFFAOYSA-N	Preclinical
GSK2110183	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K25412176-001-01-9	Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	AFJRDFWMXUECEW-LBPRGKRZSA-N	Phase 2
GSK2126458	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K07972848-001-02-0	COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	CGBJSGAELGCMKE-UHFFFAOYSA-N	Phase 1
GSK2190915	lipoxygenase inhibitor	ALOX5AP			BRD-K15691453-236-01-6	CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1	DFQGDHBGRSTTHX-UHFFFAOYSA-N	Phase 2
GSK2256294A	epoxide hydolase inhibitor	EPHX2			BRD-K62738477-001-01-7	CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1	LQHDJQIMETZMPH-ZBFHGGJFSA-N	Phase 1
GSK2330672	bile acid transporter inhibitor	SLC10A2			BRD-K05858796-001-01-7	CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1	CZGVOBIGEBDYTP-VSGBNLITSA-N	Phase 2
GSK256066	phosphodiesterase inhibitor	PDE4A			BRD-K37590257-001-02-8	COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	JFHROPTYMMSOLG-UHFFFAOYSA-N	Phase 2
GSK2606414	protein kinase inhibitor	EIF2AK3, MYLK2			BRD-K81689258-001-03-0, BRD-K81689258-001-02-2	Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12, Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	SIXVRXARNAVBTC-UHFFFAOYSA-N, SIXVRXARNAVBTC-UHFFFAOYSA-N	Preclinical
GSK2636771	PI3K inhibitor	PIK3CB			BRD-K49215523-001-05-9, BRD-K49215523-001-04-2	Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O, Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	XTKLTGBKIDQGQL-UHFFFAOYSA-N, XTKLTGBKIDQGQL-UHFFFAOYSA-N	Phase 2
GSK2656157	PERK inhibitor				BRD-K41104902-001-01-3	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	PRWSIEBRGXYXAJ-UHFFFAOYSA-N	Preclinical
GSK2801	bromodomain inhibitor	BAZ2A, BAZ2B			BRD-K48062199-001-01-8	CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O	KHWCPNJRJCNVRI-UHFFFAOYSA-N	Preclinical
GSK2816126	histone lysine methyltransferase inhibitor	EZH2			BRD-K21867462-001-03-7, BRD-K21867462-001-02-9	CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O, CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	FKSFKBQGSFSOSM-QFIPXVFZSA-N, FKSFKBQGSFSOSM-QFIPXVFZSA-N	Phase 1
GSK2830371	protein phosphatase inhibitor	PPM1D			BRD-K17472821-001-01-2, BRD-K17472821-001-02-0	Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1, Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	IVDUVEGCMXCMSO-FQEVSTJZSA-N, IVDUVEGCMXCMSO-FQEVSTJZSA-N	Preclinical
GSK2838232	HIV gag inhibitor				BRD-K08398903-001-01-1	CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1	MEOWKUXNVNJAMY-PZFKGGKESA-N	Phase 1
GSK2879552	histone lysine demethylase inhibitor	KDM1A			BRD-K09223495-001-01-4	OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1	LRULVYSBRWUVGR-FCHUYYIVSA-N	Phase 1
GSK3787	PPAR receptor antagonist	PPARD			BRD-K03155172-001-02-2	FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	JFUIMTGOQCQTPF-UHFFFAOYSA-N	Preclinical
GSK429286A	rho associated kinase inhibitor	ROCK1			BRD-A10523515-001-11-1, BRD-A10523515-001-07-9	CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F, CC1=C(C(CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2cn[nH]c2cc1F	OLIIUAHHAZEXEX-UHFFFAOYSA-N, OLIIUAHHAZEXEX-UHFFFAOYSA-N	Preclinical
GSK461364	PLK inhibitor	PLK1			BRD-K92428232-001-10-6	C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	ZHJGWYRLJUCMRT-QGZVFWFLSA-N	Phase 1
GSK503	histone lysine methyltransferase inhibitor	EZH2			BRD-K72293620-001-01-7	CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	HRDQQHUKUIKFHT-UHFFFAOYSA-N	Preclinical
GSK650394	serum/glucocorticoid regulated kinase inhibitor	SGK1, SGK2			BRD-K14991967-001-04-2, BRD-K14991967-001-02-6, BRD-K14991967-001-03-4	OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1, OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N, WVSBGSNVCDAMCF-UHFFFAOYSA-N	Preclinical
GSK690693	AKT inhibitor	AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX			BRD-K25325018-001-05-6, BRD-K25325018-001-02-3	CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N, CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	KGPGFQWBCSZGEL-ZDUSSCGKSA-N, KGPGFQWBCSZGEL-ZDUSSCGKSA-N	Phase 1
GSK923295	centromere associated protein inhibitor	CENPE			BRD-K89015388-001-01-7	CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	WHMXDBPHBVLYRC-OFVILXPXSA-N	Phase 1
GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	CSF1R, FLT3, KIT, PDGFRB			BRD-K16664969-001-03-3	c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21	DZQLVVLATXPWBK-UHFFFAOYSA-N	Preclinical
GTS21	cholinergic receptor agonist	CHRNA7			BRD-K14235254-001-01-2	COc1ccc(\C=C2CCCN=C/2c2cccnc2)c(OC)c1	RPYWXZCFYPVCNQ-RVDMUPIBSA-N	Phase 1/Phase 2
guacetisal	immunosuppressant				BRD-K00739965-001-01-9	COc1ccccc1OC(=O)c1ccccc1OC(C)=O	HSJFYRYGGKLQBT-UHFFFAOYSA-N	Launched
guaiacol	local anesthetic	CA2			BRD-K96282009-001-08-8	COc1ccccc1O	LHGVFZTZFXWLCP-UHFFFAOYSA-N	Launched
guaifenesin	expectorant		pulmonary	cough suppressant	BRD-A90515964-001-16-5, BRD-A90515964-001-15-7	COc1ccccc1OCC(O)CO, COc1ccccc1OCC(O)CO	HSRJKNPTNIJEKV-UHFFFAOYSA-N, HSRJKNPTNIJEKV-UHFFFAOYSA-N	Launched
guanaben-acetate	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	BRD-K62736196-015-11-0, BRD-K56800335-015-04-9, BRD-K62736196-015-10-2, BRD-K62736196-015-09-4	NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C/c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl, NC(=N)N\N=C\c1c(Cl)cccc1Cl	WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-PQMHYQBVSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N, WDZVGELJXXEGPV-YIXHJXPBSA-N	Launched
guanadrel	adrenergic inhibitor	SLC6A2	cardiology	hypertension	BRD-A14262390-065-01-8	NC(=N)NCC1COC2(CCCCC2)O1	HPBNRIOWIXYZFK-UHFFFAOYSA-N	Launched
guanethidine	adrenergic inhibitor	SLC6A2	cardiology	hypertension	BRD-K62676709-065-05-5, BRD-K62676709-001-01-9	NC(=N)NCCN1CCCCCCC1, NC(=N)NCCN1CCCCCCC1	ACGDKVXYNVEAGU-UHFFFAOYSA-N, ACGDKVXYNVEAGU-UHFFFAOYSA-N	Launched
guanfacine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	BRD-K32830106-001-02-6, BRD-K32830106-003-20-4, BRD-K32830106-003-21-2	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl, NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	INJOMKTZOLKMBF-UHFFFAOYSA-N, INJOMKTZOLKMBF-UHFFFAOYSA-N, INJOMKTZOLKMBF-UHFFFAOYSA-N	Launched
guanidine	HSP inhibitor	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	BRD-K76037122-001-02-5, BRD-K76037122-001-01-7	NC(N)=N, NC(N)=N	ZRALSGWEFCBTJO-UHFFFAOYSA-N, ZRALSGWEFCBTJO-UHFFFAOYSA-N	Launched
guanidinoethyldisulfide-bicarbonate	nitric oxide synthase inhibitor	NOS2			BRD-K69191882-065-01-6	NC(N)=NCCSSCCN=C(N)N	IRMTXMJNHRISQH-UHFFFAOYSA-N	Phase 2
guanidinopropionic-acid	creatine kinase inhibitor	CKM			BRD-K50781608-001-02-1	NC(N)=NCCC(O)=O	KMXXSJLYVJEBHI-UHFFFAOYSA-N	Phase 2
guanosine		PNP			BRD-K92976206-001-01-5	Nc1nc2n(cnc2c(=O)[nH]1)[C@@H]1O[C@@H](CO)[C@@H](O)[C@H]1O	NYHBQMYGNKIUIF-HAVMAKPUSA-N	Preclinical
guvacine	GABA uptake inhibitor	SLC6A1, SLC6A11, SLC6A12, SLC6A13			BRD-K01980392-003-11-6	OC(=O)C1=CCCNC1	QTDZOWFRBNTPQR-UHFFFAOYSA-N	Preclinical
GW-0742	PPAR receptor agonist	PPARD			BRD-K82983861-001-04-3, BRD-K82983861-001-05-0	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	HWVNEWGKWRGSRK-UHFFFAOYSA-N, HWVNEWGKWRGSRK-UHFFFAOYSA-N	Preclinical
GW-1100	G protein-coupled receptor agonist	FFAR1			BRD-K23614267-001-01-2	CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1	PTPNCCWOTBBVJR-UHFFFAOYSA-N	Preclinical
GW-1929	PPAR receptor agonist	PPARG			BRD-A15415227-003-02-9	CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1	QTQMRBZOBKYXCG-UHFFFAOYSA-N	Preclinical
GW-2580	cFMS kinase inhibitor	CSF1R			BRD-K24242599-001-02-8	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1	MYQAUKPBNJWPIE-UHFFFAOYSA-N	Preclinical
GW-311616	leukocyte elastase inhibitor, elastase inhibitor	ELANE			BRD-K37864785-001-01-0	CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O	NDNKNUMSTIMSHQ-URZKGLGPSA-N	Phase 1
GW-3965	LXR agonist	NR1H2, NR1H3			BRD-K33818169-003-04-6, BRD-K33818169-003-03-8	OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1, OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	NAXSRXHZFIBFMI-UHFFFAOYSA-N, NAXSRXHZFIBFMI-UHFFFAOYSA-N	Preclinical
GW-405833	cannabinoid receptor agonist	CNR2			BRD-K10705233-001-02-2	COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	FSFZRNZSZYDVLI-UHFFFAOYSA-N	Preclinical
GW-4064	FXR agonist	NR1H4			BRD-K88186167-001-04-8, BRD-K88186167-001-05-5	CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl, CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	BYTNEISLBIENSA-MDZDMXLPSA-N, BYTNEISLBIENSA-MDZDMXLPSA-N	Preclinical
GW-441756	growth factor receptor inhibitor	NTRK1			BRD-K41312087-001-02-7, BRD-K41312087-001-01-9	Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12, Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	NXNQLECPAXXYTR-LCYFTJDESA-N, NXNQLECPAXXYTR-LCYFTJDESA-N	Preclinical
GW-501516	PPAR receptor agonist	PPARA, PPARD			BRD-K14880289-001-03-0, BRD-K14880289-001-02-2	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F, Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	YDBLKRPLXZNVNB-UHFFFAOYSA-N, YDBLKRPLXZNVNB-UHFFFAOYSA-N	Phase 2
GW-5074	RAF inhibitor, leucine rich repeat kinase inhibitor	NTRK1, RAF1			BRD-K93653303-001-01-1, BRD-K07859598-001-13-8, BRD-K07859598-001-12-0	Oc1c(Br)cc(\C=C2\C(=O)Nc3ccc(I)cc23)cc1Br, Oc1c(Br)cc(cc1Br)\C=C1/C(=O)Nc2ccc(I)cc12, Oc1c(Br)cc(cc1Br)\C=C1/C(=O)Nc2ccc(I)cc12	LMXYVLFTZRPNRV-XCVCLJGOSA-N, LMXYVLFTZRPNRV-KMKOMSMNSA-N, LMXYVLFTZRPNRV-KMKOMSMNSA-N	Preclinical
GW-583340	EGFR inhibitor	EGFR, ERBB2			BRD-K79930101-300-04-5, BRD-K79930101-300-03-7	CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	MNNXRVSQOABRRP-UHFFFAOYSA-N, MNNXRVSQOABRRP-UHFFFAOYSA-N	Preclinical
GW-6471	PPAR receptor antagonist	PPARA			BRD-K20828910-001-02-0, BRD-K20828910-001-01-2	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F, CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	TYEFSRMOUXWTDN-DYQICHDWSA-N, TYEFSRMOUXWTDN-DYQICHDWSA-N	Preclinical
GW-7647	PPAR receptor agonist	PPARA			BRD-K96263742-001-14-8	CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	PKNYXWMTHFMHKD-UHFFFAOYSA-N	Preclinical
GW-788388	ALK tyrosine kinase receptor inhibitor	LCK, MAPK14, TGFBR1			BRD-K78086729-001-02-7	O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	SAGZIBJAQGBRQA-UHFFFAOYSA-N	Preclinical
GW-803430	melanin inhibitor	KCNH2, MCHR1			BRD-K65576800-001-01-6	COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1	MWULMTACIBZPGN-UHFFFAOYSA-N	Phase 1
GW-842166	cannabinoid receptor agonist	CNR2			BRD-K26823213-001-02-9	FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	TWQYWUXBZHPIIV-UHFFFAOYSA-N	Phase 2
GW-843682X	PLK inhibitor	PLK1, PLK3			BRD-K90382497-001-10-7, BRD-K90382497-001-13-1	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC, COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	JSKUWFIZUALZLX-UHFFFAOYSA-N, JSKUWFIZUALZLX-UHFFFAOYSA-N	Preclinical
GW-9508	free fatty acid receptor agonist, G protein-coupled receptor agonist	FFAR1, FFAR4			BRD-K71534238-001-10-0, BRD-K71534238-001-11-8	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1, OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	DGENZVKCTGIDRZ-UHFFFAOYSA-N, DGENZVKCTGIDRZ-UHFFFAOYSA-N	Preclinical
GW-9662	PPAR receptor antagonist	NCOA2, PPARG, RXRA			BRD-K93258693-001-17-3, BRD-K93258693-001-16-5	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	DNTSIBUQMRRYIU-UHFFFAOYSA-N, DNTSIBUQMRRYIU-UHFFFAOYSA-N	Preclinical
GYKI-52466	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K24240364-003-08-8	CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1	LFBZZHVSGAHQPP-UHFFFAOYSA-N	Preclinical
gynostemma-extract	calcium channel modulator				BRD-K58775955-001-02-4, BRD-K75189747-001-01-2	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C, CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O)[C@@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	ZTQSADJAYQOCDD-HUGMCNGHSA-N, ZTQSADJAYQOCDD-UAQOTDPRSA-N	Preclinical
GZD824	Bcr-Abl kinase inhibitor	ABL1, BCR			BRD-K35329391-334-01-7	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4[nH]ncc4c3)cc2C(F)(F)F)CC1	TZKBVRDEOITLRB-UHFFFAOYSA-N	Preclinical
G007-LK	tankyrase inhibitor	TNKS, TNKS2			BRD-K12198961-001-01-8	CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl	HIWVLHPKZNBSBE-OUKQBFOZSA-N	Preclinical
H-89	PKA inhibitor	GSG2, PKIA, PRKACA			BRD-K27737647-300-03-0, BRD-K27737647-300-08-9, BRD-K27737647-300-04-8	Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1, Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N, ZKZXNDJNWUTGDK-NSCUHMNNSA-N	Preclinical
HA-1004	calcium channel blocker				BRD-K05434375-001-06-5	NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12	MZNDNBFMSVMUCX-UHFFFAOYSA-N	Phase 2
HA-14-1	BCL inhibitor	BCL2			BRD-A13807286-001-07-0	CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(N)=C1C(=O)OCC	SXJDCULZDFWMJC-UHFFFAOYSA-N	Preclinical
HA-966-(R)-(+)	glutamate receptor agonist	GRIA1			BRD-K58046914-001-03-8	N[C@@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-GSVOUGTGSA-N	Preclinical
HA-966-(S)-(-)	glutamate receptor antagonist	GRIA1			BRD-K41304947-001-03-2	N[C@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-VKHMYHEASA-N	Preclinical
halazone					BRD-K68091065-001-04-7	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl	XPDVQPODLRGWPL-UHFFFAOYSA-N	Launched
halcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-A88138582-001-04-8, BRD-K64408465-001-01-9	CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C)C4(F)C(O)CC3(C)[C@@]2(O1)C(=O)CCl, CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@]4(F)[C@H](O)C[C@]3(C)[C@]2(O1)C(=O)CCl	MUQNGPZZQDCDFT-RLDTZFIDSA-N, MUQNGPZZQDCDFT-MUQQULFASA-N	Launched
halobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	BRD-K65877271-001-01-8	CCC(=O)O[C@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)CCl	BDSYKGHYMJNPAB-MUYQOBDSSA-N	Launched
halofantrine	antimalarial agent	KCNH2, KCNN4	infectious disease	malaria	BRD-A51964809-003-12-6	CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F	FOHHNHSLJDZUGQ-UHFFFAOYSA-N	Launched
halofuginone	collagenase inhibitor	COL1A1, MMP2	rheumatology	scleroderma	BRD-K54247840-004-01-3	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	LVASCWIMLIKXLA-CABCVRRESA-N	Launched
halopemide	phospholipase inhibitor	PLD1, PLD2			BRD-K50055394-001-03-6	Oc1nc2cc(Cl)ccc2n1C1CCN(CCNC(=O)c2ccc(F)cc2)CC1	NBHPRWLFLUBAIE-UHFFFAOYSA-N	Phase 2
haloperidol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1	neurology/psychiatry	schizophrenia, Tourettes disorder" "BRD-K67783091-001-26-1, BRD-K67783091-003-07-7, BRD-K67783091-001-25-3" "OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1, OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1" "LNEPOXFFQSENCJ-UHFFFAOYSA-N, LNEPOXFFQSENCJ-UHFFFAOYSA-N, LNEPOXFFQSENCJ-UHFFFAOYSA-N" "Launched"
"1199" "haloperidol-decanoate" "psychoactive drug" "DRD2, DRD3, DRD4, HTR2A" "neurology/psychiatry" "schizophrenia" "BRD-K80859331-001-01-5" "CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1" "GUTXTARXLVFHDK-UHFFFAOYSA-N" "Launched"
"1200" "haloprogin" "other antifungal" "" "infectious disease" "tinea pedis" "BRD-K13238168-001-02-0" "Clc1cc(Cl)c(OCC" "" ""
"1201" "halothane" "glutamate receptor antagonist" "ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GNG2, GRIN2A, GRIN3A, GRIN3B, KCNJ3, KCNJ6, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9, KCNMA1, KCNN4, MT-ND1, NPSR1, RHO" "neurology/psychiatry" "general anaesthetic" "BRD-A20550616-001-02-9" "FC(F)(F)C(Cl)Br" "BCQZXOMGPXTTIC-UHFFFAOYSA-N" "Launched"
"1202" "harmane" "monoamine oxidase inhibitor" "MAOA, MAOB" "" "" "BRD-K12630395-001-14-9" "Cc1nccc2c3ccccc3[nH]c12" "PSFDQSOCUJVVGF-UHFFFAOYSA-N" "Preclinical"
"1203" "harringtonine" "protein synthesis inhibitor" "" "" "" "BRD-K96358241-001-01-9" "COC(=O)C[C@@](O)(CCC(C)(C)O)C(=O)O[C@H]1[C@@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC" "HAVJATCHLFRDHY-JZTSUELASA-N" "Phase 3"
"1204" "HA14-1" "BCL inhibitor" "BCL2" "" "" "BRD-K18163608-001-05-6, BRD-K18163608-001-02-3" "CCOC(=O)[C@@H](C" "" ""
"1205" "HC-030031" "TRPA1 channel blocker" "TRPA1" "" "" "BRD-K73815512-001-02-5" "CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1" "HEQDZPHDVAOBLN-UHFFFAOYSA-N" "Phase 1"
"1206" "HEMADO" "" "ADORA1, ADORA2A, ADORA2B, ADORA3" "" "" "BRD-K34672903-001-01-7" "CCCCC" "" ""
"1207" "hematoporphyrin" "" "" "neurology/psychiatry" "depression, psychosis, psychosis, depression" "BRD-A44995766-001-02-6, BRD-A44995766-300-03-0" "CC(O)c1c(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(O)=O)c(CCC(O)=O)c4C)c(C)c3C(C)O, CC(O)c1c(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(O)=O)c(CCC(O)=O)c4C)c(C)c3C(C)O" "UJKPHYRXOLRVJJ-UHFFFAOYSA-N, UJKPHYRXOLRVJJ-UHFFFAOYSA-N" "Launched"
"1208" "hematoxylin" "" "" "" "" "BRD-K78342372-001-03-2, BRD-K78342372-001-02-4" "Oc1cc2C[C@@]3(O)COc4c(ccc(O)c4O)[C@H]3c2cc1O, Oc1cc2C[C@@]3(O)COc4c(ccc(O)c4O)[C@H]3c2cc1O" "WZUVPPKBWHMQCE-XJKSGUPXSA-N, WZUVPPKBWHMQCE-XJKSGUPXSA-N" "Preclinical"
"1209" "hemin" "enzyme inducer" "" "hematology, cardiology" "acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT)" "BRD-M75036822-003-01-7" "[Fe+3].Cc1c(CCC(O)=O)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C=C)c5C)c(C=C)c4C)c(C)c3CCC(O)=O" "VSTBFMUUCAUPAF-UHFFFAOYSA-N" "Launched"
"1210" "hemoglobin-modulators-1" "hemoglobin modulator" "" "" "" "BRD-K43639297-001-01-9" "CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O" "FWCVZAQENIZVMY-UHFFFAOYSA-N" "Phase 3"
"1211" "hemomex-s" "" "PPARG" "" "" "BRD-K15231341-001-01-5" "CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C" "SHCBCKBYTHZQGZ-CJPZEJHVSA-N" "Launched"
"1212" "heptaminol" "vasoconstrictor" "" "cardiology" "hypotension" "BRD-A32988684-003-08-7" "CC(N)CCCC(C)(C)O" "LREQLEBVOXIEOM-UHFFFAOYSA-N" "Launched"
"1213" "HER2-Inhibitor-1" "EGFR inhibitor" "" "" "" "BRD-K89709433-001-02-8" "Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1" "QVMNYGOVNWWFKF-UHFFFAOYSA-N" "Preclinical"
"1214" "hesperadin" "Aurora kinase inhibitor" "AURKB" "" "" "BRD-K58122457-001-02-2, BRD-K58122457-003-01-0" "CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1, CCS(=O)(=O)Nc1ccc2NC(=O)\C(c2c1)=C(/Nc1ccc(CN2CCCCC2)cc1)c1ccccc1" "GLDSKRNGVVYJAB-DQSJHHFOSA-N, GLDSKRNGVVYJAB-DQSJHHFOSA-N" "Preclinical"
"1215" "hesperetin" "ACAT inhibitor" "DGAT1, MTTP, SOAT1, SOAT2" "" "" "BRD-K30553453-001-13-2" "COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1" "AIONOLUJZLIMTK-AWEZNQCLSA-N" "Launched"
"1216" "hesperidin" "flavanone glycoside" "CACNA1B" "" "" "BRD-K93633846-001-01-7, BRD-K43382661-001-01-4, BRD-K43382661-001-02-2" "COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1, COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1" "QUQPHWDTPGMPEX-REDIAKJPSA-N, QUQPHWDTPGMPEX-NCHMBKKRSA-N, QUQPHWDTPGMPEX-NCHMBKKRSA-N" "Launched"
"1217" "hetacillin" "bacterial cell wall synthesis inhibitor" "" "obstetrics/gynecology" "mastitis" "BRD-A27828834-237-04-4" "CC1(C)S[C@@H]2C(N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O" "DXVUYOAEDJXBPY-HCYBMXRASA-N" "Launched"
"1218" "hexachlorophene" "potassium channel activator" "GLUD1, SDHD" "infectious disease" "gram-positive bacterial infections" "BRD-K99792991-001-34-9" "Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl" "ACGUYXCXAPNIKK-UHFFFAOYSA-N" "Launched"
"1219" "hexamethonium" "cholinergic receptor antagonist" "CHRNA2, CHRNA3, CHRNA4, CHRNA6" "" "" "BRD-K10598093-303-07-9, BRD-K10598093-303-06-1, BRD-K10598093-303-05-3" "C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C, C[N+](C)(C)CCCCCC[N+](C)(C)C" "VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N, VZJFGSRCJCXDSG-UHFFFAOYSA-N" "Preclinical"
"1220" "hexamethylenebisacetamide" "AKT inhibitor, differentiation inducer, NFKB pathway inhibitor" "AKT1" "" "" "BRD-K04710043-001-17-8" "CC(=O)NCCCCCCNC(C)=O" "BNQSTAOJRULKNX-UHFFFAOYSA-N" "Phase 2"
"1221" "hexaminolevulinate" "" "" "radiology" "diagnostic agent" "BRD-K73753850-003-01-6" "CCCCCCOC(=O)CCC(=O)CN" "RYQOILLJDKPETL-UHFFFAOYSA-N" "Launched"
"1222" "hexasodium-phytate" "" "" "" "" "BRD-K70007857-001-01-7" "OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O" "IMQLKJBTEOYOSI-GPIVLXJGSA-N" "Phase 2"
"1223" "hexestrol" "synthetic estrogen" "AKR1C1, ESR1, ESR2" "" "" "BRD-K69253806-001-03-8, BRD-K69253806-001-02-0, BRD-A01078468-001-14-8" "CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1, CCC(C(CC)c1ccc(O)cc1)c1ccc(O)cc1" "PBBGSZCBWVPOOL-HDICACEKSA-N, PBBGSZCBWVPOOL-HDICACEKSA-N, PBBGSZCBWVPOOL-UHFFFAOYSA-N" "Launched"
"1224" "hexetidine" "local anesthetic" "" "otolaryngology, infectious disease, dental, gastroenterology" "pharyngitis, meningitis, laryngitis, gingivitis, ulcerative colitis" "BRD-A18605525-001-12-4, BRD-A18605525-001-13-2" "CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1, CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1" "DTOUUUZOYKYHEP-UHFFFAOYSA-N, DTOUUUZOYKYHEP-UHFFFAOYSA-N" "Launched"
"1225" "hexonic-acid" "" "" "" "" "BRD-A63267145-001-01-0" "OCC(O)C(O)C(O)C(O)C(O)=O" "RGHNJXZEOKUKBD-UHFFFAOYSA-N" "Preclinical"
"1226" "hexoprenaline" "adrenergic receptor agonist" "ADRB2" "pulmonary" "asthma" "BRD-A33894669-065-01-9" "OC(CNCCCCCCNCC(O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1" "OXLZNBCNGJWPRV-UHFFFAOYSA-N" "Launched"
"1227" "hexylcaine" "sodium channel blocker" "SCN10A, SCN5A" "neurology/psychiatry" "local anesthetic" "BRD-A97730597-003-11-5" "CC(CNC1CCCCC1)OC(=O)c1ccccc1" "DKLKMKYDWHYZTD-UHFFFAOYSA-N" "Launched"
"1228" "hexylene-glycol" "" "AKR1C3, CTPS1, DLG4, HSP90AA1, NOS3, PGF, PLA2G1B, PTPN1, SELP" "" "" "BRD-A14234430-001-01-4" "CC(O)CC(C)(C)O" "SVTBMSDMJJWYQN-UHFFFAOYSA-N" "Preclinical"
"1229" "hexylresorcinol" "local anesthetic" "TYR" "infectious disease" "skin infections, first-aid antiseptic" "BRD-K99946902-001-07-5" "CCCCCCc1ccc(O)cc1O" "WFJIVOKAWHGMBH-UHFFFAOYSA-N" "Launched"
"1230" "higenamine" "adrenergic receptor agonist" "ADRB2" "" "" "BRD-A55204514-003-01-2" "Oc1ccc(CC2NCCc3cc(O)c(O)cc23)cc1" "WZRCQWQRFZITDX-UHFFFAOYSA-N" "Phase 1"
"1231" "hippuric-acid" "" "" "" "" "BRD-K62914667-001-13-9" "OC(=O)CNC(=O)c1ccccc1" "QIAFMBKCNZACKA-UHFFFAOYSA-N" "Preclinical"
"1232" "histamine" "histamine receptor agonist" "HRH1, HRH2, HRH3, HRH4" "allergy" "allergic rhinitis" "BRD-K01674964-300-06-3, BRD-K01674964-300-08-9, BRD-K01674964-300-07-1, BRD-K01674964-316-01-0, BRD-K01674964-001-19-0" "NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1, NCCc1c[nH]cn1" "NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N, NTYJJOPFIAHURM-UHFFFAOYSA-N" "Launched"
"1233" "HKI-357" "EGFR inhibitor" "EGFR" "" "" "BRD-K58811567-001-01-9, BRD-K58811567-001-02-7" "CCOc1cc2ncc(C" "" ""
"1234" "HLCL-61" "protein arginine N-methyltransferase inhibitor" "PRMT5" "" "" "BRD-K73746696-003-01-8" "CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12" "FIOIJUCPVZEPFX-UHFFFAOYSA-N" "Preclinical"
"1235" "HMN-214" "PLK inhibitor" "CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET" "" "" "BRD-K70511574-001-06-9" "COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1" "OCKHRKSTDPOHEN-BQYQJAHWSA-N" "Phase 1"
"1236" "homatropine" "acetylcholine receptor antagonist" "CES1, CHRM1" "ophthalmology" "pupil dilation" "BRD-A09539288-004-04-4" "CN1C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1" "ZTVIKZXZYLEVOL-FGZQJIAISA-N" "Launched"
"1237" "homatropine-bromide" "acetylcholine receptor antagonist" "" "ophthalmology" "uveal tract inflammation" "BRD-A35196708-004-01-9" "CN1[C@@H]2CC[C@@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1" "ZTVIKZXZYLEVOL-HCYNLOQUSA-N" "Launched"
"1238" "homatropine-methylbromide" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "ophthalmology" "uveal tract inflammation" "BRD-A43999749-004-04-1" "C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1" "WKWOJBUWWZTUQV-JWMHWRSXSA-N" "Launched"
"1239" "homidium" "" "" "" "" "BRD-K28354016-004-11-7" "CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12" "QTANTQQOYSUMLC-UHFFFAOYSA-O" "Preclinical"
"1240" "homochlorcyclizine" "antihistamine" "HRH1" "allergy" "allergic rhinitis" "BRD-A22769835-300-05-7" "CN1CCCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1" "WEUCDJCFJHYFRL-UHFFFAOYSA-N" "Launched"
"1241" "homoharringtonine" "protein synthesis inhibitor" "RPL3" "hematologic malignancy" "chronic myeloid leukemia (CML)" "BRD-K76674262-001-03-3" "COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC" "HYFHYPWGAURHIV-JFIAXGOJSA-N" "Launched"
"1242" "homoquinolinic-acid" "glutamate receptor agonist" "GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D" "" "" "BRD-K30519779-001-03-1" "OC(=O)Cc1cccnc1C(O)=O" "HQPMJFFEXJELOQ-UHFFFAOYSA-N" "Preclinical"
"1243" "homosalate" "HSP inducer" "" "" "" "BRD-A34751532-001-06-9" "CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O" "WSSJONWNBBTCMG-UHFFFAOYSA-N" "Preclinical"
"1244" "homoveratrylamine" "dopamine analog" "" "" "" "BRD-K59570838-003-01-9" "COc1ccc(CCN)cc1OC" "ANOUKFYBOAKOIR-UHFFFAOYSA-N" "Preclinical"
"1245" "honokiol" "AKT inhibitor" "ALOX5, PTGS1, PTGS2" "" "" "BRD-K98493452-001-14-9" "Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O" "FVYXIJYOAGAUQK-UHFFFAOYSA-N" "Phase 3"
"1246" "hordenine" "" "" "" "" "BRD-K93631643-001-03-2, BRD-K93631643-001-02-4" "CN(C)CCc1ccc(O)cc1, CN(C)CCc1ccc(O)cc1" "KUBCEEMXQZUPDQ-UHFFFAOYSA-N, KUBCEEMXQZUPDQ-UHFFFAOYSA-N" "Preclinical"
"1247" "HQK-1001" "" "" "" "" "BRD-K44963273-001-06-9" "CCC(C)(C)C(O)=O" "VUAXHMVRKOTJKP-UHFFFAOYSA-N" "Phase 2"
"1248" "HTMT" "histamine receptor agonist" "HRH4" "" "" "BRD-A66435872-332-01-8" "CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1" "PMKJGGBYYNEYPA-UHFFFAOYSA-N" "Preclinical"
"1249" "huperzine-a" "acetylcholinesterase inhibitor" "ACHE" "" "" "BRD-K45888792-001-03-6, BRD-K97618845-001-03-1, BRD-K45888792-001-02-8" "C\C=C1\[C@@H]2Cc3nc(O)ccc3[C@@]1(N)CC(C)=C2, CC=C1[C@@H]2Cc3nc(O)ccc3[C@@]1(N)CC(C)=C2, C\C=C1\[C@@H]2Cc3nc(O)ccc3[C@@]1(N)CC(C)=C2" "ZRJBHWIHUMBLCN-SEQYCRGISA-N, ZRJBHWIHUMBLCN-ZUZCIYMTSA-N, ZRJBHWIHUMBLCN-SEQYCRGISA-N" "Phase 2"
"1250" "hyaluronic-acid" "" "C1QBP, CD44, HABP2, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, NCAN, VCAN" "rheumatology, urology" "osteoarthritis, interstitial cystitis (IC)" "BRD-K59788572-236-01-3" "CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O" "WCDDVEOXEIYWFB-VXORFPGASA-N" "Launched"
"1251" "hycanthone" "RNA synthesis inhibitor" "" "infectious disease" "schistosomiasis" "BRD-K50406511-001-26-0" "CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12" "MFZWMTSUNYWVBU-UHFFFAOYSA-N" "Launched"
"1252" "hydralazine" "vasodilator" "AOC3, P4HA1" "cardiology" "hypertension" "BRD-K82103381-003-09-4, BRD-K82103381-003-08-6, BRD-K82103381-003-07-8, BRD-K82103381-003-06-0" "NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12, NNc1nncc2ccccc12" "RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N, RPTUSVTUFVMDQK-UHFFFAOYSA-N" "Launched"
"1253" "hydrastinine" "haemostatic agent" "" "" "" "BRD-A57900429-003-05-8, BRD-A57900429-003-06-6" "CN1CCc2cc3OCOc3cc2C1O, CN1CCc2cc3OCOc3cc2C1O" "YOJQZPVUNUQTDF-UHFFFAOYSA-N, YOJQZPVUNUQTDF-UHFFFAOYSA-N" "Preclinical"
"1254" "hydrochlorothiazide" "thiazide diuretic" "CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3" "cardiology" "hypertension, congestive heart failure" "BRD-K13078532-001-28-4, BRD-K13078532-001-27-6" "NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl, NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl" "JZUFKLXOESDKRF-UHFFFAOYSA-N, JZUFKLXOESDKRF-UHFFFAOYSA-N" "Launched"
"1255" "hydrocortisone" "glucocorticoid receptor agonist" "" "dermatology, neurology/psychiatry" "eczema, psoriasis, seborrheic dermatitis, itching" "BRD-A75172220-001-04-0, BRD-K97571677-001-01-9" "C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12C[C@@H](O)[C@@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C(=O)CO" "JYGXADMDTFJGBT-YDAVOWJHSA-N, JYGXADMDTFJGBT-KYWYDSBTSA-N" "Launched"
"1256" "hydrocortisone-acetate" "glucocorticoid receptor agonist" "NR3C1, NR3C2" "dermatology" "corticosteroid-responsive dermatoses" "BRD-A65767837-001-04-4" "CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C" "ALEXXDVDDISNDU-KPYZGQEZSA-N" "Launched"
"1257" "hydrocortisone-butyrate" "glucocorticoid receptor agonist" "NR3C1" "dermatology" "corticosteroid-responsive dermatoses, eczema" "BRD-K99199077-001-16-1, BRD-A34508879-001-04-9" "CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO, CCCC(=O)O[C@@]1(CCC2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO" "BMCQMVFGOVHVNG-TUFAYURCSA-N, BMCQMVFGOVHVNG-ZNBJZEBJSA-N" "Launched"
"1258" "hydrocortisone-hemisuccinate" "" "" "" "" "BRD-A07000685-001-04-4" "C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O" "VWQWXZAWFPZJDA-PILPDLGISA-N" "Phase 2/Phase 3"
"1259" "hydrocortisone-phosphate" "" "ANXA1, NOS2, NR3C1" "pulmonary, gastroenterology, hematologic malignancy, ophthalmology" "asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis" "BRD-A46186775-369-02-0" "CC12C[C@H](O)C3C(CCC4=CC(=O)CCC34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O" "BGSOJVFOEQLVMH-QVABZINDSA-N" "Launched"
"1260" "hydrocortisone-valerate" "glucocorticoid receptor agonist" "" "dermatology" "corticosteroid-responsive dermatoses" "BRD-A25143711-001-02-2" "CCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO" "FZCHYNWYXKICIO-BXLKFAEVSA-N" "Launched"
"1261" "hydroflumethiazide" "sodium/potassium/chloride transporter inhibitor" "ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3" "cardiology, gastroenterology, rheumatology, nephrology" "edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension" "BRD-K36862742-001-25-6" "NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F" "DMDGGSIALPNSEE-UHFFFAOYSA-N" "Launched"
"1262" "hydroquinidine" "antiarrhythmic" "" "cardiology" "cardiac arrythmia" "BRD-A06390036-001-04-6" "CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12" "LJOQGZACKSYWCH-NBGVHYBESA-N" "Launched"
"1263" "hydroquinone" "melanin inhibitor" "TYR" "dermatology" "dyschromia" "BRD-K11227669-001-07-8, BRD-K11227669-001-08-6" "Oc1ccc(O)cc1, Oc1ccc(O)cc1" "QIGBRXMKCJKVMJ-UHFFFAOYSA-N, QIGBRXMKCJKVMJ-UHFFFAOYSA-N" "Launched"
"1264" "hydroxyamphetamine" "trace amine associated receptor agonist" "TAAR1" "ophthalmology" "mydriasis" "BRD-A80871782-004-06-9" "CC(N)Cc1ccc(O)cc1" "GIKNHHRFLCDOEU-UHFFFAOYSA-N" "Launched"
"1265" "hydroxychloroquine" "antimalarial agent" "TLR7, TLR9" "infectious disease" "malaria" "BRD-A99117172-065-05-7, BRD-A99117172-065-04-0" "CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12, CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12" "XXSMGPRMXLTPCZ-UHFFFAOYSA-N, XXSMGPRMXLTPCZ-UHFFFAOYSA-N" "Launched"
"1266" "hydroxyfasudil" "rho associated kinase inhibitor" "PKIA, PRKACA, ROCK1" "" "" "BRD-K77793136-003-03-0" "Oc1nccc2c(cccc12)S(=O)(=O)N1CCCNCC1" "ZAVGJDAFCZAWSZ-UHFFFAOYSA-N" "Preclinical"
"1267" "hydroxyprogesterone" "progesterone receptor agonist" "PGR" "obstetrics/gynecology" "spontaneous preterm birth" "BRD-A39791822-001-05-1" "CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C" "DBPWSSGDRRHUNT-AYUYWISESA-N" "Launched"
"1268" "hydroxyprogesterone-acetate" "progesterone receptor agonist" "PGR" "" "" "BRD-K92902018-001-01-9" "CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O" "VTHUYJIXSMGYOQ-KOORYGTMSA-N" "Launched"
"1269" "hydroxypropyl-beta-cyclodextrin" "" "" "" "" "BRD-A01412266-001-01-0" "CC(O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COCC(C)O)O[C@H](O[C@@H]4[C@@H](COCC(C)O)O[C@H](O[C@@H]5[C@@H](COCC(C)O)O[C@H](O[C@@H]6[C@@H](COCC(C)O)O[C@H](O[C@@H]7[C@@H](COCC(C)O)O[C@H](O[C@@H]8[C@@H](COCC(C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O" "ODLHGICHYURWBS-LKONHMLTSA-N" "Phase 2"
"1270" "hydroxystilbamidine" "" "" "" "" "BRD-K62186992-334-02-8" "NC(=N)c1ccc(cc1)\C=C\c1ccc(cc1O)C(N)=N" "TUESWZZJYCLFNL-DAFODLJHSA-N" "Launched"
"1271" "hydroxytoluic-acid" "" "" "" "" "BRD-K75608666-001-08-3" "Cc1cccc(C(O)=O)c1O" "WHSXTWFYRGOBGO-UHFFFAOYSA-N" "Preclinical"
"1272" "hydroxyurea" "ribonucleotide reductase inhibitor" "RRM1, RRM2, RRM2B" "hematologic malignancy, oncology" "chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)" "BRD-K51747290-001-13-1, BRD-K51747290-001-15-6, BRD-K51747290-001-12-3" "NC(=O)NO, NC(=O)NO, NC(=O)NO" "VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N, VSNHCAURESNICA-UHFFFAOYSA-N" "Launched"
"1273" "hydroxyzine" "antihistamine" "HRH1" "neurology/psychiatry, allergy, dermatology" "anxiety, urticaria, itching, dermatosis, anxiety, urticaria, itching, dermatosis" "BRD-A62428732-300-06-3, BRD-A62428732-096-10-9" "OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1, OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1" "ZQDWXGKKHFNSQK-UHFFFAOYSA-N, ZQDWXGKKHFNSQK-UHFFFAOYSA-N" "Launched"
"1274" "hygromycin-b" "polypeptide synthesis inhibitor" "" "" "" "BRD-A26049141-001-01-2" "CN[C@@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3OC4(O[C@@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@@H]4O)[C@@H]1O" "GRRNUXAQVGOGFE-RVILPDFOSA-N" "Preclinical"
"1275" "hymecromone" "monoamine oxidase inhibitor" "MAOA, MAOB" "" "" "BRD-K46424862-001-14-1, BRD-K46424862-001-15-8" "Cc1cc(=O)oc2cc(O)ccc12, Cc1cc(=O)oc2cc(O)ccc12" "HSHNITRMYYLLCV-UHFFFAOYSA-N, HSHNITRMYYLLCV-UHFFFAOYSA-N" "Phase 2"
"1276" "hyodeoxycholic-acid" "atherosclerosis formation inhibitor" "" "" "" "BRD-K49031386-001-01-5" "C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C" "DGABKXLVXPYZII-MAMIRMHXSA-N" "Phase 1"
"1277" "hyoscyamine" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4" "gastroenterology, urology, neurology/psychiatry, allergy" "peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis" "BRD-A78303415-001-04-3, BRD-A97674763-001-01-8" "CN1C2CC[C@@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1, CN1C2CCC1CC(C2)OC(=O)[C@H](CO)c1ccccc1" "RKUNBYITZUJHSG-QGAIPKOMSA-N, RKUNBYITZUJHSG-LGGPCSOHSA-N" "Launched"
"1278" "hypericin" "tyrosine kinase inhibitor" "" "" "" "BRD-K29673530-001-05-4" "Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O" "BTXNYTINYBABQR-UHFFFAOYSA-N" "Phase 2"
"1279" "hyperin" "aldose reductase inhibitor" "ACE, AKR1B1" "" "" "BRD-A63780829-001-11-4" "OCC1OC(Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)C(O)C(O)C1O" "OVSQVDMCBVZWGM-UHFFFAOYSA-N" "Preclinical"
"1280" "hypoestoxide" "IKK inhibitor" "IKBKB, IL1B, TNF" "" "" "BRD-A51571244-001-01-9" "CC(=O)O[C@H]1CC2(C)OC2CCC2(C)OC2CC2CC(=O)C(=C)C1C2(C)C" "HNPAHGHFONBTLV-UOAZVOCOSA-N" "Phase 1"
"1281" "hypoxanthine" "PARP inhibitor" "PNP" "" "" "BRD-K03739921-001-06-8" "O=c1[nH]cnc2nc[nH]c12" "FDGQSTZJBFJUBT-UHFFFAOYSA-N" "Preclinical"
"1282" "I-BET-762" "bromodomain inhibitor" "BRD2, BRD3, BRD4" "" "" "BRD-K08109215-001-06-4" "CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12" "AAAQFGUYHFJNHI-SFHVURJKSA-N" "Phase 2"
"1283" "I-BET151" "bromodomain inhibitor" "BRD2, BRD3, BRD4" "" "" "BRD-K36363294-001-04-2" "COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C" "VUVUVNZRUGEAHB-CYBMUJFWSA-N" "Preclinical"
"1284" "I-BRD9" "bromodomain inhibitor" "BRD9" "" "" "BRD-K04972057-001-01-1" "CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1" "WRUWGLUCNBMGPS-UHFFFAOYSA-N" "Preclinical"
"1285" "I-BZA" "" "" "" "" "BRD-K14762862-001-01-9" "CCN(CC)CCNC(=O)c1ccc(I)cc1" "HRVWCNMOEFNEON-UHFFFAOYSA-N" "Phase 2"
"1286" "I-BZA2" "" "" "" "" "BRD-K71698503-003-01-6" "CCN(CC)CCNC(=O)c1ccccc1I" "WNSWOZIBBVUJBI-UHFFFAOYSA-N" "Phase 3"
"1287" "IB-MECA" "adenosine receptor agonist" "ADORA1, ADORA2A, ADORA2B, ADORA3" "" "" "BRD-K31135544-001-07-0" "CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12" "HUJXGQILHAUCCV-MOROJQBDSA-N" "Phase 3"
"1288" "ibandronate" "bone resorption inhibitor" "FDPS" "orthopedics" "osteoporosis" "BRD-K08681769-323-05-2, BRD-K08681769-323-04-5, BRD-K08681769-323-03-7" "CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O" "MPBVHIBUJCELCL-UHFFFAOYSA-N, MPBVHIBUJCELCL-UHFFFAOYSA-N, MPBVHIBUJCELCL-UHFFFAOYSA-N" "Launched"
"1289" "IBC-293" "hydroxycarboxylic acid receptor agonist" "HCAR3" "" "" "BRD-K15196155-001-02-3" "CC(C)n1nnc2cc(ccc12)C(O)=O" "RUTVRAJKELSHCC-UHFFFAOYSA-N" "Preclinical"
"1290" "ibotenic-acid" "glutamate receptor agonist" "GRIN1" "" "" "BRD-A04628621-001-02-6" "NC(C(O)=O)c1cc(O)no1" "IRJCBFDCFXCWGO-UHFFFAOYSA-N" "Phase 1"
"1291" "ibrolipim" "lipoprotein lipase activator" "LPL" "" "" "BRD-K62490786-001-01-1" "CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C" "" ""
"1292" "ibrutinib" "Brutons tyrosine kinase (BTK) inhibitor	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstroms macroglobulinemia (WM)" "BRD-K70301465-001-02-6, BRD-K70301465-001-05-9" "Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C" "XYFPWWZEPKGCCK-GOSISDBHSA-N, XYFPWWZEPKGCCK-GOSISDBHSA-N" "Launched" "" "" ""
"1293" "ibudilast" "leukotriene receptor antagonist, phosphodiesterase inhibitor" "IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A" "pulmonary, neurology/psychiatry" "asthma, stroke" "BRD-K16444452-001-09-1" "CC(C)C(=O)c1c(nn2ccccc12)C(C)C" "ZJVFLBOZORBYFE-UHFFFAOYSA-N" "Launched"
"1294" "ibuprofen" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental" "headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache" "BRD-A17655518-001-24-4, BRD-A17655518-001-23-6" "CC(C)Cc1ccc(cc1)C(C)C(O)=O, CC(C)Cc1ccc(cc1)C(C)C(O)=O" "HEFNNWSXXWATRW-UHFFFAOYSA-N, HEFNNWSXXWATRW-UHFFFAOYSA-N" "Launched"
"1295" "ibuprofen-(s)" "cyclooxygenase inhibitor" "ASIC1, BCL2, CFTR, FABP2, PLAT, PPARG, PTGS1, PTGS2, SLC5A8, THBD" "" "" "BRD-K14965640-001-12-4" "CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O" "HEFNNWSXXWATRW-JTQLQIEISA-N" "Preclinical"
"1296" "ibuprofen-lysine" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "cardiology" "patent ductus arteriosus (PDA)" "BRD-M64062803-001-03-9, BRD-M64062803-001-02-1" "NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)C(C)C(O)=O, NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)C(C)C(O)=O" "IHHXIUAEPKVVII-ZSCHJXSPSA-N, IHHXIUAEPKVVII-ZSCHJXSPSA-N" "Launched"
"1297" "ibuprofen-piconol" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "" "" "BRD-A75224450-001-02-4, BRD-A75224450-001-01-6" "CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1, CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1" "ACEWLPOYLGNNHV-UHFFFAOYSA-N, ACEWLPOYLGNNHV-UHFFFAOYSA-N" "Launched"
"1298" "ibutamoren" "growth hormone secretagogue receptor agonist" "GHR, GHSR" "" "" "BRD-K44771174-066-01-0" "CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1" "UMUPQWIGCOZEOY-JOCHJYFZSA-N" "Phase 2"
"1299" "ibutilide" "potassium channel blocker" "CACNA1C, CACNA2D1, CACNB1, CACNG1, KCNH2, KCNH6, KCNH7, KCNJ11, KCNK1, KCNK6" "cardiology" "atrial fibrillation (AF)" "BRD-A74391928-051-02-1, BRD-A74391928-051-01-3" "CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1, CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1" "ALOBUEHUHMBRLE-UHFFFAOYSA-N, ALOBUEHUHMBRLE-UHFFFAOYSA-N" "Launched"
"1300" "icariin" "phosphodiesterase inhibitor" "PDE5A" "" "" "BRD-A88583207-001-01-6, BRD-A06210771-001-02-9" "COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(OC3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1OC1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O, COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(OC3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1OC1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O" "TZJALUIVHRYQQB-AAPRGGRSSA-N, TZJALUIVHRYQQB-XGYHSCOOSA-N" "Phase 3"
"1301" "icaritin" "PPAR receptor antagonist" "PDE5A" "" "" "BRD-K24476327-001-01-3" "COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O" "TUUXBSASAQJECY-UHFFFAOYSA-N" "Phase 2"
"1302" "icatibant-acetate" "bradykinin receptor antagonist" "ANPEP, BDKRB2" "cardiology" "angioedema" "BRD-K63772874-001-02-2, BRD-K63772874-001-01-4" "N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O, N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O" "QURWXBZNHXJZBE-SKXRKSCCSA-N, QURWXBZNHXJZBE-SKXRKSCCSA-N" "Launched"
"1303" "ICG-001" "beta-catenin inhibitor" "CTNNB1" "" "" "BRD-K94455792-001-01-8" "Oc1ccc(C[C@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1" "HQWTUOLCGKIECB-LOYHVIPDSA-N" "Preclinical"
"1304" "ICI-162846" "histamine receptor antagonist" "HRH2" "" "" "BRD-K11071038-001-01-7" "NC(=O)CCCCn1ccc(n1)\N=C(/N)NCC(F)(F)F" "ALCSGJCIESECFD-UHFFFAOYSA-N" "Phase 1"
"1305" "ICI-192605" "thromboxane receptor antagonist" "TBXA2R" "" "" "BRD-K59433843-001-01-7" "OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl" "WHUIENZXNGAHQI-GKZDNZBASA-N" "Phase 2"
"1306" "ICI-199441" "opioid receptor agonist" "CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R" "" "" "BRD-K73290745-003-02-6" "CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1" "AEJOEPSMZCEYJN-HXUWFJFHSA-N" "Preclinical"
"1307" "ICI-63197" "phosphodiesterase inhibitor" "" "" "" "BRD-K52219182-001-02-4" "CCCn1c2nc(N)nn2cc(C)c1=O" "UQDVRVNMIJAGRK-UHFFFAOYSA-N" "Preclinical"
"1308" "ICI-89406" "adrenergic receptor antagonist" "ADRB1, ADRB2" "" "" "BRD-A03359064-001-02-3" "OC(CNCCNC(=O)Nc1ccccc1)COc1ccccc1C" "" ""
"1309" "icilin" "TRPV agonist" "TRPA1, TRPM8" "" "" "BRD-K48869804-001-09-6" "Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O" "RCEFMOGVOYEGJN-UHFFFAOYSA-N" "Phase 1"
"1310" "icomucret" "mucin production enhancer" "LTB4R2" "" "" "BRD-K41234004-001-03-1" "CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O" "JSFATNQSLKRBCI-VAEKSGALSA-N" "Phase 3"
"1311" "icosapent" "platelet aggregation inhibitor" "ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1" "endocrinology" "hypertriglyceridemia" "BRD-K47192521-001-05-4" "CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O" "JAZBEHYOTPTENJ-JLNKQSITSA-N" "Launched"
"1312" "icotinib" "EGFR inhibitor" "EGFR" "oncology" "non-small cell lung cancer (NSCLC)" "BRD-K31698212-001-02-9" "C" "" ""
"1313" "IC261" "casein kinase inhibitor" "CSNK1A1, CSNK1D, CSNK1E, CSNK1G2" "" "" "BRD-K09638361-001-02-2" "COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1" "JBJYTZXCZDNOJW-JLHYYAGUSA-N" "Preclinical"
"1314" "ID-1101" "insulin sensitizer" "INS" "" "" "BRD-K90305467-001-01-3" "C[C@H](O)[C@H](C)[C@H](N)C(O)=O" "OSCCDBFHNMXNME-YUPRTTJUSA-N" "Phase 1"
"1315" "ID-8" "" "" "" "" "BRD-K39166528-001-01-0" "COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12" "VVZNWYXIOADGSW-UHFFFAOYSA-N" "Preclinical"
"1316" "idalopirdine" "serotonin receptor antagonist" "HTR6" "" "" "BRD-K79102359-003-01-6" "FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1" "YBAWYTYNMZWMMJ-UHFFFAOYSA-N" "Phase 3"
"1317" "idarubicin" "topoisomerase inhibitor" "TOP2A" "hematologic malignancy" "acute myeloid leukemia (AML)" "BRD-K69650333-003-13-2, BRD-K63126143-003-01-4" "C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O, C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O" "XDXDZDZNSLXDNA-TZNDIEGXSA-N, XDXDZDZNSLXDNA-ULDMCBLESA-N" "Launched"
"1318" "idasanutlin" "MDM inhibitor" "MDM2, TP53" "" "" "BRD-K62627508-001-01-5" "COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C" "" ""
"1319" "idazoxan" "adrenergic receptor antagonist" "ADRA2A" "" "" "BRD-A18696154-003-22-6, BRD-A18696154-003-21-8" "C1CN=C(N1)C1COc2ccccc2O1, C1CN=C(N1)C1COc2ccccc2O1" "HPMRFMKYPGXPEP-UHFFFAOYSA-N, HPMRFMKYPGXPEP-UHFFFAOYSA-N" "Phase 3"
"1320" "idebenone" "calcium channel modulator" "" "neurology/psychiatry, ophthalmology" "Alzheimers disease, Friedreichs ataxia, Leber hereditary optic neuropathy (LHON)" "BRD-K37516142-001-10-5, BRD-K37516142-001-09-7, BRD-K37516142-001-11-3" "COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O, COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O" "JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N, JGPMMRGNQUBGND-UHFFFAOYSA-N" "Launched"
"1321" "idelalisib" "PI3K inhibitor" "PIK3CA, PIK3CB, PIK3CD, PIK3CG" "hematologic malignancy" "chronic lymphocytic leukemia (CLL)" "BRD-K60866521-001-07-1" "CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1" "IFSDAJWBUCMOAH-HNNXBMFYSA-N" "Launched"
"1322" "idoxuridin" "DNA synthesis inhibitor" "" "infectious disease" "virus herpes simplex (HSV)" "BRD-A85439007-001-01-6" "OCC1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O" "XQFRJNBWHJMXHO-REJBHVJUSA-N" "Launched"
"1323" "idoxuridine" "DNA directed DNA polymerase inhibitor" "" "infectious disease" "virus herpes simplex (HSV)" "BRD-K76634210-001-12-1" "OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O" "XQFRJNBWHJMXHO-RRKCRQDMSA-N" "Launched"
"1324" "IDRA-21" "glutamate receptor positive allosteric modulator" "GRIA1, GRIA2, GRIA3, GRIA4" "" "" "BRD-A14344385-001-03-2" "CC1Nc2ccc(Cl)cc2S(=O)(=O)N1" "VZRNTCHTJRLTMU-UHFFFAOYSA-N" "Preclinical"
"1325" "idramantone" "" "" "" "" "BRD-A57877027-001-01-7" "OC12CC3CC(C1)C(=O)C(C3)C2" "TZBDEVBNMSLVKT-UHFFFAOYSA-N" "Preclinical"
"1326" "idronoxil" "XIAP inhibitor" "ENOX2, SPHK1" "" "" "BRD-K74671368-001-01-8" "Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1" "ZZUBHVMHNVYXRR-UHFFFAOYSA-N" "Phase 3"
"1327" "IEM1460" "glutamate receptor antagonist" "GRIA2" "" "" "BRD-K13829090-303-02-9" "C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2" "IWYZMMIPAJDJBN-UHFFFAOYSA-N" "Preclinical"
"1328" "IEM1754" "glutamate receptor antagonist" "GRIA1" "" "" "BRD-K80060353-303-03-9, BRD-K80060353-303-02-1" "NCCCCCNCC12CC3CC(CC(C3)C1)C2, NCCCCCNCC12CC3CC(CC(C3)C1)C2" "UWWMQHVWAYFCDT-UHFFFAOYSA-N, UWWMQHVWAYFCDT-UHFFFAOYSA-N" "Preclinical"
"1329" "ifenprodil" "adrenergic receptor antagonist, glutamate receptor antagonist" "GRIN1, GRIN2B" "" "" "BRD-A24191444-046-03-9, BRD-A24191444-046-02-1, BRD-A24191444-046-01-3, BRD-A24191444-045-10-6" "CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1, CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1" "UYNVMODNBIQBMV-UHFFFAOYSA-N, UYNVMODNBIQBMV-UHFFFAOYSA-N, UYNVMODNBIQBMV-UHFFFAOYSA-N, UYNVMODNBIQBMV-UHFFFAOYSA-N" "Launched"
"1330" "ifosfamide" "DNA alkylating agent" "CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1" "oncology, urology" "testicular carcinoma, hemorrhagic cystitis" "BRD-A67097164-001-18-7, BRD-A67097164-001-17-9" "ClCCNP1(=O)OCCCN1CCCl, ClCCNP1(=O)OCCCN1CCCl" "HOMGKSMUEGBAAB-UHFFFAOYSA-N, HOMGKSMUEGBAAB-UHFFFAOYSA-N" "Launched"
"1331" "igmesine" "sigma receptor agonist" "SIGMAR1" "" "" "BRD-A48376327-003-01-5" "CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1" "VCZSWYIFCKGTJI-JLHYYAGUSA-N" "Phase 2"
"1332" "iguratimod" "cyclooxygenase inhibitor, NFkB pathway inhibitor" "PTGS2" "rheumatology" "rheumatoid arthritis" "BRD-K15426076-001-01-2" "CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1" "ANMATWQYLIFGOK-UHFFFAOYSA-N" "Launched"
"1333" "IKK-16" "IKK inhibitor" "IKBKB" "" "" "BRD-K14618467-001-04-6, BRD-K14618467-003-03-4, BRD-K14618467-003-02-6" "O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1" "BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N, BWZJBXAPRCVCKQ-UHFFFAOYSA-N" "Preclinical"
"1334" "IKK-2-inhibitor" "IKK inhibitor, SYK inhibitor" "IKBKB" "" "" "BRD-K26373640-001-07-7, BRD-K26373640-001-05-1, BRD-K26373640-001-06-9" "NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1, NC(=O)c1sc(cc1N)-c1ccsc1" "BMUACLADCKCNKZ-UHFFFAOYSA-N, BMUACLADCKCNKZ-UHFFFAOYSA-N, BMUACLADCKCNKZ-UHFFFAOYSA-N" "Preclinical"
"1335" "IKK-2-inhibitor-V" "IKK inhibitor, NFkB pathway inhibitor" "IKBKB" "" "" "BRD-K74305673-001-06-2, BRD-K74305673-001-07-0" "Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F, Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F" "CHILCFMQWMQVAL-UHFFFAOYSA-N, CHILCFMQWMQVAL-UHFFFAOYSA-N" "Phase 1"
"1336" "ilepcimide" "anticonvulsant" "" "" "" "BRD-K43873574-001-01-8" "O=C(C=Cc1ccc2OCOc2c1)N1CCCCC1" "BLPUOQGPBJPXRL-UHFFFAOYSA-N" "Phase 3"
"1337" "ilomastat" "matrix metalloprotease inhibitor" "ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9" "" "" "BRD-K51662849-001-08-8, BRD-K51662849-001-05-4" "CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO, CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO" "NITYDPDXAAFEIT-DYVFJYSZSA-N, NITYDPDXAAFEIT-DYVFJYSZSA-N" "Phase 3"
"1338" "iloperidone" "dopamine receptor antagonist, serotonin receptor antagonist" "ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7" "neurology/psychiatry" "schizophrenia" "BRD-K48722833-001-07-6" "COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O" "XMXHEBAFVSFQEX-UHFFFAOYSA-N" "Launched"
"1339" "iloprost" "platelet aggregation inhibitor, prostanoid receptor agonist" "PDE4A, PDE4B, PDE4C, PDE4D, PLAT, PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R" "pulmonary" "pulmonary arterial hypertension (PAH)" "BRD-A45664787-001-04-8" "CC" "" ""
"1340" "imatinib" "Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor" "ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET" "hematologic malignancy, oncology" "chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)" "BRD-K92723993-001-06-7, BRD-K92723993-066-22-7, BRD-K92723993-001-12-5" "CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1" "KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N, KTUFNOKKBVMGRW-UHFFFAOYSA-N" "Launched"
"1341" "imeglimin" "gluconeogenesis inhibitor" "" "" "" "BRD-K55822903-003-01-8" "C[C@@H]1N=C(N)NC(=N1)N(C)C" "GFICWFZTBXUVIG-SCSAIBSYSA-N" "Phase 2"
"1342" "imetit" "histamine receptor agonist" "HRH3, HRH4" "" "" "BRD-K33183200-303-02-4" "NC(=N)SCCc1c[nH]cn1" "PEHSVUKQDJULKE-UHFFFAOYSA-N" "Preclinical"
"1343" "imexon" "apoptosis stimulant, ribonucleotide reductase inhibitor" "RRM1, RRM2" "" "" "BRD-A78195072-001-06-2" "N=C1NC(=O)N2CC12" "BIXBBIPTYBJTRY-UHFFFAOYSA-N" "Phase 2"
"1344" "imidacloprid" "acetylcholine receptor antagonist" "CHRFAM7A" "" "" "BRD-K76609936-001-08-4" "[O-][N+](=O)NC1=NCCN1Cc1ccc(Cl)nc1" "YWTYJOPNNQFBPC-UHFFFAOYSA-N" "Launched"
"1345" "imidafenacin" "acetylcholine receptor antagonist" "CHRM1, CHRM3" "neurology/psychiatry" "spasms, spasms" "BRD-K29626940-001-01-5, BRD-K29626940-001-02-3" "Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1, Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1" "SQKXYSGRELMAAU-UHFFFAOYSA-N, SQKXYSGRELMAAU-UHFFFAOYSA-N" "Launched"
"1346" "imidapril" "angiotensin converting enzyme inhibitor" "ACE" "cardiology" "hypertension, congestive heart failure" "BRD-K34332569-001-01-3" "CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](CN(C)C1=O)C(O)=O" "KLZWOWYOHUKJIG-CWRNSKLLSA-N" "Launched"
"1347" "imidurea" "other antibiotic" "" "" "" "BRD-A65444648-001-11-4" "OCN1C(NC(=O)NCNC(=O)NC2N(CO)C(=O)NC2=O)C(=O)NC1=O" "ZCTXEAQXZGPWFG-UHFFFAOYSA-N" "Preclinical"
"1348" "imiloxan" "adrenergic receptor antagonist" "ADRA2A, ADRA2B" "" "" "BRD-A10903566-003-07-7" "CCn1ccnc1CC1COc2ccccc2O1" "UXABARREKCJULM-UHFFFAOYSA-N" "Phase 1"
"1349" "imipenem" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis" "BRD-K23200955-002-02-3, BRD-K23200955-002-01-5" "C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O" "ZSKVGTPCRGIANV-ZXFLCMHBSA-N, ZSKVGTPCRGIANV-ZXFLCMHBSA-N" "Launched"
"1350" "imipramine" "norepinephrine reputake inhibitor, serotonin reuptake inhibitor" "ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4" "neurology/psychiatry, urology" "depression, nocturnal enuresis" "BRD-K38436528-003-26-1, BRD-K38436528-003-27-9, BRD-K38436528-003-25-3" "CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12, CN(C)CCCN1c2ccccc2CCc2ccccc12" "BCGWQEUPMDMJNV-UHFFFAOYSA-N, BCGWQEUPMDMJNV-UHFFFAOYSA-N, BCGWQEUPMDMJNV-UHFFFAOYSA-N" "Launched"
"1351" "imiquimod" "interferon inducer, toll-like receptor agonist" "TLR7, TLR8" "dermatology, infectious disease, oncology" "actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)" "BRD-K26657438-001-17-8, BRD-K26657438-001-15-2, BRD-K26657438-003-01-8" "CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12" "DOUYETYNHWVLEO-UHFFFAOYSA-N, DOUYETYNHWVLEO-UHFFFAOYSA-N, DOUYETYNHWVLEO-UHFFFAOYSA-N" "Launched"
"1352" "immepip" "histamine receptor agonist" "HRH3, HRH4" "" "" "BRD-K25906698-303-02-7" "C(C1CCNCC1)c1c[nH]cn1" "MCNGUYXRBCIGOV-UHFFFAOYSA-N" "Preclinical"
"1353" "immethridine" "histamine receptor agonist" "HRH3" "" "" "BRD-K49519092-303-03-0, BRD-K49519092-303-02-2" "C(c1cnc[nH]1)c1ccncc1, C(c1cnc[nH]1)c1ccncc1" "DFVSGZHJSIEEQQ-UHFFFAOYSA-N, DFVSGZHJSIEEQQ-UHFFFAOYSA-N" "Phase 1"
"1354" "impentamine" "histamine receptor antagonist" "HRH3" "" "" "BRD-K20049318-303-02-1" "NCCCCCc1cnc[nH]1" "MZCJWLAXZRFUPI-UHFFFAOYSA-N" "Preclinical"
"1355" "IMREG-1" "" "" "" "" "BRD-K00926464-001-01-8" "N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O" "HIINQLBHPIQYHN-JTQLQIEISA-N" "Phase 3"
"1356" "INC-280" "c-Met inhibitor" "MET" "" "" "BRD-K81016934-001-02-0" "CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1" "LIOLIMKSCNQPLV-UHFFFAOYSA-N" "Phase 2"
"1357" "INCA-6" "calcineurin inhibitor" "NFATC1" "" "" "BRD-K33308633-001-02-4" "O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12" "GCHPUOHXXCNSQL-UHFFFAOYSA-N" "Preclinical"
"1358" "INCB-003284" "CC chemokine receptor antagonist" "" "" "" "BRD-K28059174-334-01-2" "COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F" "NXZNYBUBXWWKCP-JMOWIOHXSA-N" "Phase 2"
"1359" "INCB-024360" "indoleamine 2,3-dioxygenase inhibitor" "IDO1" "" "" "BRD-K79450420-001-01-8, BRD-K22356203-001-01-8" "NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O, Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1" "FBKMWOJEPMPVTQ-UHFFFAOYSA-N, HGXSLPIXNPASGZ-UHFFFAOYSA-N" "Phase 2"
"1360" "INCB-3284" "CC chemokine receptor antagonist" "CCR2" "" "" "BRD-K67628093-001-01-9" "COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F" "NXZNYBUBXWWKCP-DNRQZRRGSA-N" "Phase 2"
"1361" "indacaterol" "adrenergic receptor agonist" "ADRB1, ADRB2" "pulmonary" "chronic obstructive pulmonary disease (COPD)" "BRD-K89208535-051-01-5" "CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12" "QZZUEBNBZAPZLX-QFIPXVFZSA-N" "Launched"
"1362" "indalpine" "selective serotonin reuptake inhibitor (SSRI)" "SLC6A4" "" "" "BRD-K64973364-001-01-4" "C(Cc1c[nH]c2ccccc12)C1CCNCC1" "SADQVAVFGNTEOD-UHFFFAOYSA-N" "Withdrawn"
"1363" "indapamide" "thiazide diuretic" "KCNE1, KCNQ1, SLC12A3" "cardiology" "hypertension, congestive heart failure" "BRD-A95869247-001-26-9, BRD-A95869247-001-25-1" "CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O, CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O" "NDDAHWYSQHTHNT-UHFFFAOYSA-N, NDDAHWYSQHTHNT-UHFFFAOYSA-N" "Launched"
"1364" "indatraline" "norepinephrine transporter inhibitor" "MAOA, MAOB" "" "" "BRD-K01649396-003-07-1" "CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1" "SVFXPTLYMIXFRX-XJKSGUPXSA-N" "Preclinical"
"1365" "indeloxazine" "norepinephrine reuptake inhibitor, serotonin reuptake inhibitor" "" "" "" "BRD-A59747053-003-01-3" "C(Oc1cccc2C=CCc12)C1CNCCO1" "MADRVGBADLFHMO-UHFFFAOYSA-N" "Withdrawn"
"1366" "indibulin" "tubulin polymerization inhibitor" "" "" "" "BRD-K74057757-001-01-9" "Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1" "SOLIIYNRSAWTSQ-UHFFFAOYSA-N" "Phase 1/Phase 2"
"1367" "indinavir" "HIV protease inhibitor" "CYP3A4, CYP3A5, CYP3A7" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K33226500-001-01-0" "CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12" "CBVCZFGXHXORBI-PXQQMZJSSA-N" "Launched"
"1368" "indiplon" "benzodiazepine receptor agonist" "GABRA1" "" "" "BRD-K90948141-001-01-4" "CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1" "CBIAWPMZSFFRGN-UHFFFAOYSA-N" "Phase 3"
"1369" "indirubin" "CDK inhibitor, glycogen synthase kinase inhibitor" "CDK1, CDK5, GSK3A" "" "" "BRD-K17894950-001-14-3" "O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O" "CRDNMYFJWFXOCH-YPKPFQOOSA-N" "Phase 2/Phase 3"
"1370" "indirubin-3-monoxime" "CDK inhibitor, glycogen synthase kinase inhibitor" "CDK1, CDK2, CDK5, CDK5R1, GSK3B" "" "" "BRD-K19136521-001-08-9" "O\N=C1c2ccccc2NC/1=C1\C(=O)Nc2ccccc12" "HBDSHCUSXQATPO-BGBJRWHRSA-N" "Preclinical"
"1371" "indisulam" "CDK inhibitor" "CA1, CA12, CA14, CA2, CA6, CA7, CA9" "" "" "BRD-K17610631-001-03-3" "NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12" "SETFNECMODOHTO-UHFFFAOYSA-N" "Phase 2"
"1372" "indium(iii)-isopropoxide" "" "" "" "" "BRD-M08274809-001-01-7" "[In].CC(C)O.CC(C)O.CC(C)O" "JUUUERJZVKCDOT-UHFFFAOYSA-N" "Preclinical"
"1373" "indobufen" "cyclooxygenase inhibitor, platelet aggregation inhibitor" "PTGS1, PTGS2" "hematology" "thrombosis" "BRD-A16296925-001-01-3" "CCC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O" "AYDXAULLCROVIT-UHFFFAOYSA-N" "Launched"
"1374" "indocyanine-green" "contrast agent" "SLCO1B1" "" "" "BRD-K80762071-236-02-5, BRD-K80762071-236-01-7" "CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12, CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12" "BDBMLMBYCXNVMC-UHFFFAOYSA-O, BDBMLMBYCXNVMC-UHFFFAOYSA-O" "Launched"
"1375" "indole-3-carbinol" "aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor" "AHR" "" "" "BRD-K01815685-001-15-5" "OCc1c[nH]c2ccccc12" "IVYPNXXAYMYVSP-UHFFFAOYSA-N" "Phase 2/Phase 3"
"1376" "indole-3-pyrubate" "melatonin receptor agonist" "" "" "" "BRD-K09109825-001-07-3" "OC(=O)C(=O)Cc1c[nH]c2ccccc12" "RSTKLPZEZYGQPY-UHFFFAOYSA-N" "Phase 2"
"1377" "indomethacin" "cyclooxygenase inhibitor" "GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1" "rheumatology, orthopedics" "rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis" "BRD-K57222227-001-30-1, BRD-K57222227-001-29-3, BRD-K57222227-001-28-5" "COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1, COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1" "CGIGDMFJXJATDK-UHFFFAOYSA-N, CGIGDMFJXJATDK-UHFFFAOYSA-N, CGIGDMFJXJATDK-UHFFFAOYSA-N" "Launched"
"1378" "indoprofen" "cyclooxygenase inhibitor, prostanoid receptor antagonist" "CXCR1, CXCR2, PTGS1, PTGS2" "" "" "BRD-A44090213-001-25-6" "CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O" "RJMIEHBSYVWVIN-UHFFFAOYSA-N" "Withdrawn"
"1379" "indoramin" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C" "urology, cardiology" "benign prostatic hyperplasia (BPH), hypertension" "BRD-K76953762-001-08-5" "O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1" "JXZZEXZZKAWDSP-UHFFFAOYSA-N" "Launched"
"1380" "indoximod" "indoleamine 2,3-dioxygenase inhibitor" "IDO1" "" "" "BRD-K93255255-001-02-1" "Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12" "ZADWXFSZEAPBJS-SNVBAGLBSA-N" "Phase 2"
"1381" "ingenol-mebutate" "PKC activator" "PRKCA, PRKCB, PRKCD, PRKCE, PRKCG" "dermatology" "actinic keratosis (AK)" "BRD-K93779381-001-01-9" "C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C" "VDJHFHXMUKFKET-WDUFCVPESA-N" "Launched"
"1382" "INH1" "Hec1 inhibitor" "NDC80" "" "" "BRD-K70177501-003-01-4" "Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1" "JPMOKRWIYQGMJL-UHFFFAOYSA-N" "Preclinical"
"1383" "inimur" "other antifungal" "" "" "" "BRD-A71407503-001-02-6, BRD-A71407503-001-01-8" "CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1, CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1" "SRQKTCXJCCHINN-NYYWCZLTSA-N, SRQKTCXJCCHINN-NYYWCZLTSA-N" "Launched"
"1384" "iniparib" "PARP inhibitor" "PARP1" "" "" "BRD-K11153516-001-05-5" "NC(=O)c1ccc(I)c(c1)[N+]([O-])=O" "MDOJTZQKHMAPBK-UHFFFAOYSA-N" "Phase 3"
"1385" "inosine" "neurotrophic agent" "PARP1, PNP" "" "" "BRD-K79612754-001-19-1, BRD-A28787076-001-04-8, BRD-K14210676-001-01-5" "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(O)ncnc12, OC[C@H]1OC([C@H](O)[C@@H]1O)n1cnc2c1nc[nH]c2=O, OC[C@H]1O[C@@H]([C@H](O)[C@@H]1O)n1cnc2c1nc[nH]c2=O" "UGQMRVRMYYASKQ-KQYNXXCUSA-N, UGQMRVRMYYASKQ-VTHZCTBJSA-N, UGQMRVRMYYASKQ-CRKDRTNXSA-N" "Launched"
"1386" "inositol" "insulin sensitizer" "CDIPT, GBA" "" "" "BRD-K52618540-001-09-9" "O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O" "CDAISMWEOUEBRE-GPIVLXJGSA-N" "Launched"
"1387" "inositol-hexanicotinate" "" "" "dermatology, cardiology, rheumatology, neurology/psychiatry" "statis dermatitis, claudication, Raynauds disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)	BRD-K82800842-001-01-9	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	MFZCIDXOLLEMOO-GYSGTQPESA-N	Launched
INS316	purinergic receptor antagonist				BRD-A29125379-314-01-7	OC1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H](C1O)n1ccc(=O)[nH]c1=O	PGAVKCOVUIYSFO-AYZDMWBASA-N	Phase 2
INT-747	FXR agonist				BRD-K30968378-001-01-9	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	ZXERDUOLZKYMJM-ZWECCWDJSA-N	Phase 3
INT-767	FXR agonist	GPBAR1			BRD-K33067152-236-01-1	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	XGIYOABXZNJOHV-APIYUPOTSA-N	Phase 1
integrin-antagonist-1	integrin antagonist	ITGAV, ITGB6			BRD-K88165431-003-01-4	Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCC2=CC=C3CCCN=C3N2)C1)CC(O)=O	ZMXBIIQMSGOIRZ-RCZVLFRGSA-N	Phase 1
iobenguane	antineoplastic agent		oncology, cardiology, endocrinology	neuroblastoma, congestive heart failure, pheochromocytoma	BRD-K43860855-065-11-9, BRD-K43860855-065-10-1	NC(=N)NCc1cccc(I)c1, NC(=N)NCc1cccc(I)c1	PDWUPXJEEYOOTR-UHFFFAOYSA-N, PDWUPXJEEYOOTR-UHFFFAOYSA-N	Launched
iocetamic-acid	radiopaque medium		radiology	contrast agent	BRD-A37492983-001-10-3	CC(CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O	GSVQIUGOUKJHRC-UHFFFAOYSA-N	Launched
iodipamide	radiopaque medium	ALB	radiology	contrast agent	BRD-K67261995-001-11-7	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	FFINMCNLQNTKLU-UHFFFAOYSA-N	Launched
iodixanol	radiopaque medium		radiology	contrast agent	BRD-A08660406-001-05-9	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	NBQNWMBBSKPBAY-UHFFFAOYSA-N	Launched
iodoantipyrine					BRD-K69216798-001-01-9	Cc1c(I)c(=O)n(-c2ccccc2)n1C	ZZOBLCHCPLOXCE-UHFFFAOYSA-N	Preclinical
iododexetimide	acetylcholine receptor antagonist				BRD-A46813902-001-01-6	Ic1ccc(CN2CCC(CC2)C2(CCC(=O)NC2=O)c2ccccc2)cc1	WJLRTFJPHDSXAF-UHFFFAOYSA-N	Phase 2
iodophenpropit	histamine receptor antagonist	HRH3, HRH4			BRD-K51918615-303-02-9	Ic1ccc(CCNC(=N)SCCCc2c[nH]cn2)cc1	UBHYDQAARZKHEZ-UHFFFAOYSA-N	Preclinical
iodoquinol	antiseptic		infectious disease	amebiasis	BRD-K75855670-001-14-2	Oc1c(I)cc(I)c2cccnc12	UXZFQZANDVDGMM-UHFFFAOYSA-N	Launched
iohexol	radiopaque medium		radiology	contrast agent	BRD-A60217728-001-11-2	CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	NTHXOOBQLCIOLC-UHFFFAOYSA-N	Launched
iopamidol	radiopaque medium		radiology	contrast agent	BRD-K75868704-001-05-3	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	XQZXYNRDCRIARQ-LURJTMIESA-N	Launched
iopanic-acid	thyroid hormone inhibitor				BRD-A42628519-001-12-4	CCC(Cc1c(I)cc(I)c(N)c1I)C(O)=O	OIRFJRBSRORBCM-UHFFFAOYSA-N	Preclinical
iopodic-acid			radiology	contrast agent	BRD-K51956333-001-03-8	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	YQNFBOJPTAXAKV-OMCISZLKSA-N	Launched
iopromide	radiopaque medium		radiology	contrast agent	BRD-A72075775-001-11-2, BRD-A72075775-001-10-4	COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I, COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I	DGAIEPBNLOQYER-UHFFFAOYSA-N, DGAIEPBNLOQYER-UHFFFAOYSA-N	Launched
iothalamic-acid-d3	radiopaque medium				BRD-K98250023-001-01-0	CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	UXIGWFXRQKWHHA-UHFFFAOYSA-N	Preclinical
ioversol	radiopaque medium		radiology	contrast agent	BRD-A65818372-001-05-3	OCCN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I	AMDBBAQNWSUWGN-UHFFFAOYSA-N	Launched
IOWH032	CFTR channel antagonist	CFTR			BRD-K84892605-001-01-1	Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	DSFNLJXHXBIKDS-UHFFFAOYSA-N	Phase 2
ioxaglic-acid	radiopaque medium		radiology	contrast agent	BRD-K79124250-001-08-9	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	TYYBFXNZMFNZJT-UHFFFAOYSA-N	Launched
ioxilan	radiopaque medium		radiology	angiography	BRD-A09370961-001-01-0	CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I	UUMLTINZBQPNGF-UHFFFAOYSA-N	Launched
IOX1	histone demethylase inhibitor	EGLN1, KDM3A, KDM4C, KDM6B			BRD-K70751730-001-10-4	OC(=O)c1ccc(O)c2ncccc12	JGRPKOGHYBAVMW-UHFFFAOYSA-N	Preclinical
IOX2	hypoxia inducible factor inhibitor	EGLN1, KDM2A, KDM5C			BRD-K98251413-001-04-0	OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	CAOSCCRYLYQBES-UHFFFAOYSA-N	Preclinical
IPA-3	p21 activated kinase inhibitor	PAK1			BRD-K38727704-001-03-2, BRD-K38727704-001-02-4, BRD-K38727704-001-01-6	Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12, Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	RFAXLXKIAKIUDT-UHFFFAOYSA-N, RFAXLXKIAKIUDT-UHFFFAOYSA-N, RFAXLXKIAKIUDT-UHFFFAOYSA-N	Preclinical
IPAG					BRD-K82421491-001-02-6	Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	UUKPIWYXWLJPJF-UHFFFAOYSA-N	Preclinical
IPI-145	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K93468883-001-02-0	C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	SJVQHLPISAIATJ-ZDUSSCGKSA-N	Phase 3
ipidacrine	acetylcholinesterase inhibitor	ACHE			BRD-K66896231-001-08-1	Nc1c2CCCc2nc2CCCCc12	YLUSMKAJIQOXPV-UHFFFAOYSA-N	Phase 3
ipragliflozin-l-proline	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	BRD-K51247865-001-01-2	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	AHFWIQIYAXSLBA-RQXATKFSSA-N	Launched
ipratropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	BRD-A96060515-004-01-6, BRD-A65721754-004-02-8, BRD-A05352148-004-03-8	CC(C)[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(CO)c1ccccc1, CC(C)[N+]1(C)C2CCC1C[C@H](C2)OC(=O)C(CO)c1ccccc1, CC(C)[N+]1(C)C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1	OEXHQOGQTVQTAT-QQLIVEQCSA-N, OEXHQOGQTVQTAT-AZCHJOIVSA-N, OEXHQOGQTVQTAT-UHFFFAOYSA-N	Launched
ipriflavone	bone resorption inhibitor		orthopedics	osteoporosis	BRD-K93618743-001-21-0, BRD-K93618743-001-20-2	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O, CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	SFBODOKJTYAUCM-UHFFFAOYSA-N, SFBODOKJTYAUCM-UHFFFAOYSA-N	Launched
iproniazid	monoamine oxidase inhibitor	MAOA, MAOB			BRD-K88568253-011-19-9	CC(C)NNC(=O)c1ccncc1	NYMGNSNKLVNMIA-UHFFFAOYSA-N	Withdrawn
ipsapirone	serotonin receptor agonist	HTR1A			BRD-K90574421-001-03-5	O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	TZJUVVIWVWFLCD-UHFFFAOYSA-N	Phase 3
irbesartan	angiotensin receptor antagonist	AGTR1, JUN, SLC10A1	cardiology, nephrology	hypertension, diabetic nephropathy	BRD-K60038276-001-09-0, BRD-K60038276-001-08-2	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1	YOSHYTLCDANDAN-UHFFFAOYSA-N, YOSHYTLCDANDAN-UHFFFAOYSA-N	Launched
irinotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	colorectal cancer	BRD-K08547377-003-07-3, BRD-K08547377-394-03-5, BRD-K08547377-003-05-7, BRD-K72035773-001-01-7, BRD-K08547377-001-04-4, BRD-K08547377-003-04-0	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-MGBGTMOVSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N, UWKQSNNFCGGAFS-XIFFEERXSA-N	Launched
IRL-2500	endothelin receptor antagonist	EDNRB			BRD-K98357249-001-02-9	CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	UZDORQWMYRRLQV-JHOUSYSJSA-N	Preclinical
irosustat	steroid sulfatase inhibitor	CA2, STS			BRD-K87777313-001-02-2	NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1	DSLPMJSGSBLWRE-UHFFFAOYSA-N	Phase 2
irsogladine	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	BRD-K74195153-050-12-1, BRD-K74195153-001-04-1	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl, Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	ATCGGEJZONJOCL-UHFFFAOYSA-N, ATCGGEJZONJOCL-UHFFFAOYSA-N	Launched
isamoltane	adrenergic receptor antagonist	HTR1A, HTR1B			BRD-A26845397-051-01-9	CC(C)NCC(O)COc1ccccc1-n1cccc1	XVTVPGKWYHWYAD-UHFFFAOYSA-N	Phase 1
isavuconazole	cytochrome P450 inhibitor	CYP3A4			BRD-A17009129-001-01-3	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)C(O)(Cn1cncn1)c1cc(F)ccc1F	DDFOUSQFMYRUQK-XLEXHMCLSA-N	Phase 3
isaxonine	nerve growth factor agonist				BRD-K95957366-001-02-6	CC(C)Nc1ncccn1	FTCYIGBVOHNHCD-UHFFFAOYSA-N	Withdrawn
isbufylline	phosphodiesterase inhibitor				BRD-K06762493-001-08-1	CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	WHUWQSQEVISUMC-UHFFFAOYSA-N	Phase 2
isepamicin	protein synthesis inhibitor		infectious disease	pneumonia, peritonitis	BRD-K74759733-065-01-4, BRD-K74759733-001-01-9	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	UDIIBEDMEYAVNG-ZKFPOVNWSA-N, UDIIBEDMEYAVNG-ZKFPOVNWSA-N	Launched
isobutamben	local anesthetic				BRD-K96714749-001-01-0	CC(C)COC(=O)c1ccc(N)cc1	PUYOAVGNCWPANW-UHFFFAOYSA-N	Preclinical
isobutyramide	gene expression stimulant	HBE1, HBG1			BRD-K54057105-001-01-2	CC(C)C(N)=O	WFKAJVHLWXSISD-UHFFFAOYSA-N	Phase 2
isocarboxazid	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	BRD-K93332168-001-11-5, BRD-K93332168-001-10-7	Cc1cc(no1)C(=O)NNCc1ccccc1, Cc1cc(no1)C(=O)NNCc1ccccc1	XKFPYPQQHFEXRZ-UHFFFAOYSA-N, XKFPYPQQHFEXRZ-UHFFFAOYSA-N	Launched
isoconazole	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	BRD-A93353767-008-02-2	Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1	MPIPASJGOJYODL-UHFFFAOYSA-N	Launched
isodibut	aldehyde reductase inhibitor				BRD-K60241851-001-11-9, BRD-K60241851-001-10-1	OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23, OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	ZHXRDXTYPCPBTI-UHFFFAOYSA-N, ZHXRDXTYPCPBTI-UHFFFAOYSA-N	Phase 2
isoetharine	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	bronchospasm, asthma	BRD-A24587114-066-23-3, BRD-A24587114-066-22-5, BRD-A24587114-066-21-7	CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1, CCC(NC(C)C)C(O)c1ccc(O)c(O)c1	HUYWAWARQUIQLE-UHFFFAOYSA-N, HUYWAWARQUIQLE-UHFFFAOYSA-N, HUYWAWARQUIQLE-UHFFFAOYSA-N	Launched
isofloxythepin	dopamine receptor antagonist				BRD-A07704283-001-01-3	CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1	XDBMBHVYXPBOPL-UHFFFAOYSA-N	Phase 2
isoflupredone-acetate		NR3C1			BRD-K29173907-001-09-2	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C	ZOCUOMKMBMEYQV-GSLJADNHSA-N	Preclinical
isoflurane	inhaled anaesthetic	ATP2C1, ATP5D, CALM1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	BRD-A31564021-001-01-8	FC(F)OC(Cl)C(F)(F)F	PIWKPBJCKXDKJR-UHFFFAOYSA-N	Launched
isoflurophate	cholinesterase inhibitor	ACHE, BCHE	ophthalmology	glaucoma	BRD-K56575995-001-03-0, BRD-K56575995-001-02-2	CC(C)OP(F)(=O)OC(C)C, CC(C)OP(F)(=O)OC(C)C	MUCZHBLJLSDCSD-UHFFFAOYSA-N, MUCZHBLJLSDCSD-UHFFFAOYSA-N	Launched
isoguvacine	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			BRD-K66480997-003-10-0	OC(=O)C1=CCNCC1	KRVDMABBKYMBHG-UHFFFAOYSA-N	Preclinical
isoleucine		ACADSB, BCAT1, BCAT2, IARS, IARS2			BRD-A02232681-001-01-8	CCC(C)C(N)C(O)=O	AGPKZVBTJJNPAG-UHFFFAOYSA-N	Launched
isoliquiritigenin	guanylate cyclase activator	GABBR1			BRD-K33583600-001-16-1	Oc1ccc(cc1)\C=C\C(=O)c1ccc(O)cc1O	DXDRHHKMWQZJHT-FPYGCLRLSA-N	Preclinical
isometheptene-mucate		ADRA1A, SLC18A2	neurology/psychiatry	headache	BRD-A64743628-001-01-5	CNC(C)CCC=C(C)C	XVQUOJBERHHONY-UHFFFAOYSA-N	Launched
isoniazid	FABI inhibitor	CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4	infectious disease	tuberculosis	BRD-K87202646-001-33-4, BRD-K87202646-001-32-6	NNC(=O)c1ccncc1, NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched
isopentyl-4-methoxycinnamate			dermatology	sunscreen lotion	BRD-K37851352-001-01-0	COc1ccc(cc1)\C=C\C(=O)OCCC(C)C	UBNYRXMKIIGMKK-RMKNXTFCSA-N	Launched
isoprenaline	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3, MAPK1, PIK3R1, PIK3R2, PIK3R3	cardiology, pulmonary	bradycardia, heart block, asthma	BRD-A04322457-003-17-9, BRD-A04322457-003-16-1, BRD-A04322457-003-15-3, BRD-A04322457-003-18-7	CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1, CC(C)NCC(O)c1ccc(O)c(O)c1	JWZZKOKVBUJMES-UHFFFAOYSA-N, JWZZKOKVBUJMES-UHFFFAOYSA-N, JWZZKOKVBUJMES-UHFFFAOYSA-N, JWZZKOKVBUJMES-UHFFFAOYSA-N	Launched
isopropamide-iodide	acetylcholine receptor antagonist	CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD), gastrointestinal acidosis	BRD-K14127446-005-22-7	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	JTPUMZTWMWIVPA-UHFFFAOYSA-O	Launched
isopropyl-myristate			dermatology	cosmetic	BRD-K13409143-001-01-9	CCCCCCCCCCCCCC(=O)OC(C)C	AXISYYRBXTVTFY-UHFFFAOYSA-N	Launched
isopropyl-palmitate	cosmetic moisturizer		dermatology	cosmetic	BRD-K30758549-001-01-8	CCCCCCCCCCCCCCCC(=O)OC(C)C	XUGNVMKQXJXZCD-UHFFFAOYSA-N	Launched
isosorbide	nitric oxide stimulant		cardiology	angina pectoris, coronary artery disease (CAD)	BRD-K47178855-001-02-6, BRD-K57344138-001-01-2, BRD-K47178855-001-01-8	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]12, O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	KLDXJTOLSGUMSJ-JGWLITMVSA-N, KLDXJTOLSGUMSJ-FBXFSONDSA-N, KLDXJTOLSGUMSJ-JGWLITMVSA-N	Launched
isosorbide-dinitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1	cardiology	angina pectoris, coronary artery disease (CAD)	BRD-K55853390-001-12-4, BRD-K55853390-001-13-2	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O, [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	MOYKHGMNXAOIAT-JGWLITMVSA-N, MOYKHGMNXAOIAT-JGWLITMVSA-N	Launched
isosorbide-mononitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	angina pectoris, coronary artery disease (CAD)	BRD-K82225283-001-03-1	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	YWXYYJSYQOXTPL-SLPGGIOYSA-N	Launched
isosteviol					BRD-A96529864-001-01-3	C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)C3CC2	KFVUFODCZDRVSS-LBWIARQKSA-N	Phase 2
isotiquimide					BRD-A02933148-001-01-8	Cc1ccnc2C(CCCc12)C(N)=S	PWPWEYFVLITGNU-UHFFFAOYSA-N	Phase 1
isotretinoin	retinoid receptor agonist	RARA, RARB, RARG	dermatology	acne vulgaris (AV)	BRD-K76723084-001-24-0, BRD-K95366153-001-02-7, BRD-K76723084-001-23-2, BRD-K76723084-001-22-4	CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C/C(O)=O, CC(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C/C(O)=O, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C/C(O)=O, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C/C(O)=O	SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-CDMOMSTLSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N, SHGAZHPCJJPHSC-XFYACQKRSA-N	Launched
isovaleramide	alcohol dehydrogenase inhibitor				BRD-K90069354-001-03-7, BRD-K90069354-001-02-9, BRD-K90069354-001-04-5, BRD-K90069354-001-01-1	CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O, CC(C)CC(N)=O	SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N, SANOUVWGPVYVAV-UHFFFAOYSA-N	Phase 2
isoxepac	anti-inflammatory agent				BRD-K92116564-001-01-4	OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1	QFGMXJOBTNZHEL-UHFFFAOYSA-N	Phase 2
isoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A75552914-001-15-0, BRD-A75552914-001-16-8	CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O	SPTMROWPYQRZSX-UHFFFAOYSA-N, SPTMROWPYQRZSX-UHFFFAOYSA-N	Withdrawn
isoxsuprine	adrenergic receptor agonist	ADRB2	rheumatology, cardiology	Raynauds disease, arteriosclerosis, Buergers disease	BRD-A16700644-003-04-4	CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1	BMUKKTUHUDJSNZ-JRSKDTKFSA-N	Launched
ispinesib	kinesin inhibitor	KIF11			BRD-K64881305-001-05-2, BRD-K64881305-001-03-7	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	QJZRFPJCWMNVAV-HHHXNRCGSA-N, QJZRFPJCWMNVAV-HHHXNRCGSA-N	Phase 2
isradipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2	cardiology	hypertension	BRD-A90799790-001-19-9, BRD-A90799790-001-16-5, BRD-A90799790-001-17-3	COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C	HMJIYCCIJYRONP-UHFFFAOYSA-N, HMJIYCCIJYRONP-UHFFFAOYSA-N, HMJIYCCIJYRONP-UHFFFAOYSA-N	Launched
ISRIB	eukaryotic translation initiation factor inhibitor, PERK inhibitor	EIF2A, EIF2AK3			BRD-K12826175-001-02-4	Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1	HJGMCDHQPXTGAV-IYARVYRRSA-N	Preclinical
istaroxime	ATPase inhibitor	ATP1A1			BRD-K95412502-003-01-5	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	MPYLDWFDPHRTEG-PAAYLBSLSA-N	Phase 2
istradefylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3	neurology/psychiatry	Parkinsons Disease, dyskinesia" "BRD-K87774949-001-04-7, BRD-K87774949-001-03-9, BRD-K87774949-001-05-4" "CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O, CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O" "IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N, IQVRBWUUXZMOPW-PKNBQFBNSA-N" "Launched"
"1388" "itacitinib" "JAK inhibitor" "JAK1" "" "" "BRD-K67482377-001-01-8" "Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC" "" ""
"1389" "ITI214" "phosphodiesterase inhibitor" "PDE1A" "" "" "BRD-K77987496-011-01-9" "CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O" "BBIPVJCGIASXJB-PKTZIBPZSA-N" "Phase 1"
"1390" "itopride" "dopamine receptor antagonist" "CHRM3, DRD2" "gastroenterology, neurology/psychiatry" "dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia" "BRD-K96740444-001-02-1" "COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1" "QQQIECGTIMUVDS-UHFFFAOYSA-N" "Launched"
"1391" "itraconazole" "cytochrome P450 inhibitor" "CYP51A1" "infectious disease" "onychomycosis, histoplasmosis, blastomycosis, aspergillosis" "BRD-A23067620-001-04-1, BRD-A23067620-300-01-3, BRD-A23067620-001-03-3" "CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O, CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O" "VHVPQPYKVGDNFY-ZPGVKDDISA-N, VHVPQPYKVGDNFY-ZPGVKDDISA-N, VHVPQPYKVGDNFY-ZPGVKDDISA-N" "Launched"
"1392" "ITX3" "GEF inhibitor" "TRIO" "" "" "BRD-K36515744-001-02-7" "Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1" "SJMYMKPBODEZSH-DEDYPNTBSA-N" "Preclinical"
"1393" "IU1" "ubiquitin C-terminal hydrolase inhibitor" "USP14" "" "" "BRD-K45841694-001-11-7, BRD-K45841694-001-10-9" "Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1, Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1" "JUWDSDKJBMFLHE-UHFFFAOYSA-N, JUWDSDKJBMFLHE-UHFFFAOYSA-N" "Preclinical"
"1394" "ivabradine" "HCN channel antagonist, potassium channel blocker, sodium channel blocker" "HCN1, HCN3, HCN4" "cardiology" "angina pectoris" "BRD-K31385749-003-01-3" "COc1cc2C[C@@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC" "ACRHBAYQBXXRTO-NRFANRHFSA-N" "Launched"
"1395" "ivacaftor" "CFTR channel potentiator" "CFTR" "pulmonary" "cystic fibrosis" "BRD-K52818472-001-02-2" "CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C" "PURKAOJPTOLRMP-UHFFFAOYSA-N" "Launched"
"1396" "ivermectin" "benzodiazepine receptor agonist" "CHRNA7, GABRB3, GLRA3, P2RX7" "infectious disease" "gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies" "BRD-A48570745-001-02-9, BRD-K85554912-001-06-3, BRD-K85554912-001-05-5, BRD-K71544586-001-01-6" "CCC(C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](OC3C[C@H](OC)C(O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2, CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@H](C(=O)O1)[C@]34O)O2" "AZSNMRSAGSSBNP-ONDMGMIHSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-XPNPUAGNSA-N, AZSNMRSAGSSBNP-TYECJXEWSA-N" "Launched"
"1397" "ivosidenib" "isocitrate dehydrogenase inhibitor" "IDH1" "" "" "BRD-K93073858-001-01-1" "Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C" "" ""
"1398" "IWP-L6" "porcupine inhibitor" "PORCN" "" "" "BRD-K53234107-001-01-6" "O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1" "QESQGTFWEQMCMH-UHFFFAOYSA-N" "Preclinical"
"1399" "ixabepilone" "microtubule stabilizing agent" "TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8" "oncology" "breast cancer" "BRD-K03601870-001-01-2" "C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1" "FABUFPQFXZVHFB-PVYNADRNSA-N" "Launched"
"1400" "ixazomib" "proteasome inhibitor" "" "hematologic malignancy" "multiple myeloma" "BRD-K78659596-001-03-9" "CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O" "MXAYKZJJDUDWDS-LBPRGKRZSA-N" "Launched"
"1401" "ixazomib-citrate" "proteasome inhibitor" "" "hematologic malignancy" "multiple myeloma" "BRD-A66419424-001-02-4" "CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)CC(CC(O)=O)(O1)C(O)=O" "YTXSYWAKVMZICI-PVCZSOGJSA-N" "Launched"
"1402" "JAK3-inhibitor-V" "JAK inhibitor" "JAK3" "" "" "BRD-K95676198-001-05-9" "C=CC(=O)c1ccc2ccccc2c1" "FOTCGZPFSUWZBN-UHFFFAOYSA-N" "Preclinical"
"1403" "JDTic" "opioid receptor antagonist" "OPRK1" "" "" "BRD-K95837862-300-01-7" "CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1" "ZLVXBBHTMQJRSX-VMGNSXQWSA-N" "Phase 1"
"1404" "JIB04" "histone lysine demethylase inhibitor" "KDM4E" "" "" "BRD-K76180386-001-01-6, BRD-K76180386-001-02-4" "Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1, Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1" "YHHFKWKMXWRVTJ-OQKWZONESA-N, YHHFKWKMXWRVTJ-OQKWZONESA-N" "Preclinical"
"1405" "JK-184" "hedgehog pathway inhibitor" "" "" "" "BRD-K38860038-001-01-2" "CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1" "ROYXIPOUVGDTAO-UHFFFAOYSA-N" "Preclinical"
"1406" "JLK-6" "gamma secretase inhibitor" "PSEN1" "" "" "BRD-K22010301-001-04-6" "COc1oc(=O)c2cc(N)ccc2c1Cl" "AMDGKLWVCUXONP-UHFFFAOYSA-N" "Preclinical"
"1407" "JNJ-10191584" "histamine receptor antagonist" "HRH4" "" "" "BRD-K15086322-050-01-3" "CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1" "MOIWSUQWIOVGRH-UHFFFAOYSA-N" "Preclinical"
"1408" "JNJ-16259685" "glutamate receptor antagonist" "GRM1" "" "" "BRD-K25596805-001-01-8" "CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1" "QOTAQTRFJWLFCR-XFHMXUHZSA-N" "Preclinical"
"1409" "JNJ-1661010" "FAAH inhibitor" "FAAH" "" "" "BRD-K47376733-001-08-1" "O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1" "BHBOSTKQCZEAJM-UHFFFAOYSA-N" "Preclinical"
"1410" "JNJ-17203212" "TRPV antagonist" "TRPV1" "" "" "BRD-K51770398-001-01-9" "FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1" "JFRYYGVYCWYIDQ-UHFFFAOYSA-N" "Preclinical"
"1411" "JNJ-26481585" "HDAC inhibitor" "HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2" "" "" "BRD-K83837640-001-04-8" "Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12" "PAWIYAYFNXQGAP-UHFFFAOYSA-N" "Phase 2"
"1412" "JNJ-26990990" "anticonvulsant" "" "" "" "BRD-K24864897-001-01-0" "NS(=O)(=O)NCc1csc2ccccc12" "AWSKBQNOSRREEY-UHFFFAOYSA-N" "Phase 2"
"1413" "JNJ-37822681" "dopamine receptor antagonist" "DRD2" "" "" "BRD-K31802667-001-01-9" "Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F" "UVUYWJWYRLJHEN-UHFFFAOYSA-N" "Phase 2"
"1414" "JNJ-38877605" "tyrosine kinase inhibitor" "MET" "" "" "BRD-K02123250-001-06-7" "Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1" "JRWCBEOAFGHNNU-UHFFFAOYSA-N" "Phase 1"
"1415" "JNJ-40411813" "glutamate receptor positive allosteric modulator" "GRM2" "" "" "BRD-K55029398-001-01-6" "CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O" "HYOGJHCDLQSAHX-UHFFFAOYSA-N" "Phase 2"
"1416" "JNJ-42041935" "hypoxia inducible factor prolyl hydroxylase inhibitor" "PDK2" "" "" "BRD-K01036220-001-01-0" "OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1" "FXHHASJVTYRJHH-UHFFFAOYSA-N" "Preclinical"
"1417" "JNJ-42165279" "FAAH inhibitor" "FAAH" "" "" "BRD-K70330032-001-01-1" "FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1" "YWGYNGCRVZLMCS-UHFFFAOYSA-N" "Phase 2"
"1418" "JNJ-63533054" "G protein-coupled receptor agonist" "GPR139" "" "" "BRD-K19482962-001-01-8" "C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1" "MWDVCHRYCKXEBY-LBPRGKRZSA-N" "Preclinical"
"1419" "JNJ-7706621" "CDK inhibitor" "AURKA, AURKB, CDK1, CDK2" "" "" "BRD-K11636097-001-03-1" "Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F" "KDKUVYLMPJIGKA-UHFFFAOYSA-N" "Preclinical"
"1420" "JNJ-7777120" "histamine receptor antagonist" "HRH4" "" "" "BRD-K17774839-001-02-9" "CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1" "HUQJRYMLJBBEDO-UHFFFAOYSA-N" "Preclinical"
"1421" "josamycin" "bacterial 50S ribosomal subunit inhibitor" "" "pulmonary" "bronchitis" "BRD-K25837718-001-03-8" "CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC(=O)CC(C)C)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C)OC(C)=O" "UKNSBNVKSFTZOJ-NGVXBBESSA-N" "Launched"
"1422" "JQ1-(+)" "bromodomain inhibitor" "BRD4, BRDT" "" "" "BRD-K54606188-001-13-1" "Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1" "DNVXATUJJDPFDM-KRWDZBQOSA-N" "Preclinical"
"1423" "JTC-801" "opioid receptor antagonist" "OPRL1" "" "" "BRD-K17705806-003-04-4, BRD-K17705806-003-03-6" "CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1, CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1" "VTGBZWHPJFMTKS-UHFFFAOYSA-N, VTGBZWHPJFMTKS-UHFFFAOYSA-N" "Phase 2"
"1424" "JTE-013" "lysophospholipid receptor antagonist" "P2RY10, S1PR2" "" "" "BRD-K43330982-001-02-3" "CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12" "RNSLRQNDXRSASX-UHFFFAOYSA-N" "Preclinical"
"1425" "JTE-607" "cytokine production inhibitor" "IL10, IL1B, IL6, TNF" "" "" "BRD-K81405859-300-01-4, BRD-K81405859-300-02-2" "CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O, CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O" "IPSSXIMJJXSJQB-FQEVSTJZSA-N, IPSSXIMJJXSJQB-FQEVSTJZSA-N" "Phase 2"
"1426" "JTE-907" "cannabinoid receptor inverse agonist" "CNR2" "" "" "BRD-K63150726-001-02-1" "CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12" "GRAJFFFXJYFVOC-UHFFFAOYSA-N" "Phase 1"
"1427" "JW-74" "WNT signaling inhibitor, tankyrase inhibitor" "TNKS, TNKS2" "" "" "BRD-K75664313-001-02-6" "COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1" "KRIKILRRJCIWNB-UHFFFAOYSA-N" "Preclinical"
"1428" "JX-401" "p38 MAPK inhibitor" "MAPK14" "" "" "BRD-K05464208-001-05-7" "COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1" "OMGLGPKQUFSRNN-UHFFFAOYSA-N" "Preclinical"
"1429" "JZL-184" "monoacylglucerol lipase inhibitor" "MGLL" "" "" "BRD-K45446451-001-05-0" "OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1" "SEGYOKHGGFKMCX-UHFFFAOYSA-N" "Preclinical"
"1430" "K-MAP" "" "" "" "" "BRD-A45906415-001-01-9" "OCC1OC(Nc2ccc(cc2)C(O)=O)C(O)C(O)C1O" "VXMVXDITZWJXJN-UHFFFAOYSA-N" "Phase 2"
"1431" "K-Ras(G12C)-inhibitor-12" "K-ras inhibitor" "KRAS" "" "" "BRD-K90756851-001-01-1" "Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C" "JFIFBWVNHLXJFY-UHFFFAOYSA-N" "Preclinical"
"1432" "K-Ras(G12C)-inhibitor-6" "K-ras inhibitor" "" "" "" "BRD-K26305185-001-02-1, BRD-K26305185-001-01-3" "SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl, SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl" "ZPXCEHMKUTXHRZ-UHFFFAOYSA-N, ZPXCEHMKUTXHRZ-UHFFFAOYSA-N" "Preclinical"
"1433" "k-strophanthidin" "ATPase inhibitor" "ATP1A1" "" "" "BRD-A55312468-001-04-7" "C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1" "ODJLBQGVINUMMR-VJHNTTCYSA-N" "Phase 2"
"1434" "K-247" "" "" "" "" "BRD-A74648924-001-02-3" "OCC1OC(Nc2ccc(cc2)C(O)=O)C(O)C1O" "QNUBRHYSSHJWDH-UHFFFAOYSA-N" "Phase 1"
"1435" "K-858" "kinesin-like spindle protein inhibitor" "KIF11" "" "" "BRD-A67748489-001-10-0" "CC(=O)NC1=NN(C(C)=O)C(C)(S1)c1ccccc1" "JEFVYQYZCAVNTP-UHFFFAOYSA-N" "Preclinical"
"1436" "kaempferol" "bone resorption inhibitor, estrogen-related receptor inverse agonist" "AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1" "" "" "BRD-K12807006-001-19-3, BRD-K12807006-001-18-5, BRD-K12807006-001-17-7" "Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O" "IYRMWMYZSQPJKC-UHFFFAOYSA-N, IYRMWMYZSQPJKC-UHFFFAOYSA-N, IYRMWMYZSQPJKC-UHFFFAOYSA-N" "Preclinical"
"1437" "kainic-acid" "kainate receptor agonist" "GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5" "" "" "BRD-K52459018-001-09-1" "CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O" "VLSMHEGGTFMBBZ-OOZYFLPDSA-N" "Preclinical"
"1438" "kakonein" "GABA receptor antagonist, serotonin receptor antagonist" "" "" "" "BRD-A07815743-001-01-1" "OCC1OC(C(O)C(O)C1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O" "HKEAFJYKMMKDOR-UHFFFAOYSA-N" "Phase 2"
"1439" "kanamycin" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K08327065-065-04-3, BRD-A53533407-065-04-9" "NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O, NC[C@H]1O[C@H](OC2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O" "SBUJHOSQTJFQJX-NOAMYHISSA-N, SBUJHOSQTJFQJX-BTALVITBSA-N" "Launched"
"1440" "KB-R7943" "sodium/calcium exchange inhibitor" "SLC8A1, TRPC3, TRPC5, TRPC6" "" "" "BRD-K17743697-066-03-6" "NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1" "UMJUNUMSJDTYTM-UHFFFAOYSA-N" "Preclinical"
"1441" "KBG" "neprilysin inhibitor" "MME" "" "" "BRD-A00376169-001-01-6" "OC1O[C@@H]2COC(O[C@H]2[C@H](O)[C@H]1O)c1ccccc1" "FOLRUCXBTYDAQK-SFZUHQLGSA-N" "Phase 2"
"1442" "KD-023" "ACAT inhibitor" "ACACA, ACACB" "" "" "BRD-K71164191-001-01-0" "CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O" "CZRCFAOMWRAFIC-UHFFFAOYSA-N" "Phase 2"
"1443" "KD025" "rho associated kinase inhibitor" "ROCK2" "" "" "BRD-K88506063-001-01-8" "CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3[nH]ncc3c2)c2ccccc2n1" "GKHIVNAUVKXIIY-UHFFFAOYSA-N" "Phase 2"
"1444" "kenpaullone" "CDK inhibitor, glycogen synthase kinase inhibitor" "CCNB1, CDK1, CDK5, GSK3B" "" "" "BRD-K37312348-001-15-0" "Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1" "QQUXFYAWXPMDOE-UHFFFAOYSA-N" "Preclinical"
"1445" "ketanserin" "serotonin receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2" "cardiology" "hypertension" "BRD-K49671696-045-08-5, BRD-K49671696-046-01-8, BRD-K49671696-001-05-4" "Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1, Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1" "FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N, FPCCSQOGAWCVBH-UHFFFAOYSA-N" "Launched"
"1446" "ketoconazole" "sterol demethylase inhibitor" "AR, CYP19A1, CYP21A2, KCNA10" "dermatology" "seborrheic dermatitis" "BRD-A38350138-001-04-9, BRD-K29113274-001-27-5, BRD-K29113274-001-28-3, BRD-K29113274-001-26-7" "CC(=O)N1CCN(CC1)c1ccc(OCC2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1" "XMAYWYJOQHXEEK-NASUQTAISA-N, XMAYWYJOQHXEEK-OZXSUGGESA-N, XMAYWYJOQHXEEK-OZXSUGGESA-N, XMAYWYJOQHXEEK-OZXSUGGESA-N" "Launched"
"1447" "ketoprofen" "cyclooxygenase inhibitor" "CXCR1, PTGS1, PTGS2, SLC5A8" "rheumatology" "rheumatoid arthritis, osteoarthritis" "BRD-A97739905-001-26-5, BRD-A97739905-001-25-7" "CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1, CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1" "DKYWVDODHFEZIM-UHFFFAOYSA-N, DKYWVDODHFEZIM-UHFFFAOYSA-N" "Launched"
"1448" "ketorolac" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "" "" "BRD-A40639672-001-01-9, BRD-A40639672-234-18-0, BRD-A40639672-234-17-2" "OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1, OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1, OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1" "OZWKMVRBQXNZKK-UHFFFAOYSA-N, OZWKMVRBQXNZKK-UHFFFAOYSA-N, OZWKMVRBQXNZKK-UHFFFAOYSA-N" "Launched"
"1449" "ketotifen" "histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor" "HRH1, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE8B, PGD" "neurology/psychiatry" "itching" "BRD-K28936863-051-33-0, BRD-K28936863-051-32-2, BRD-K28936863-051-31-4" "CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12, CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12, CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12" "ZCVMWBYGMWKGHF-UHFFFAOYSA-N, ZCVMWBYGMWKGHF-UHFFFAOYSA-N, ZCVMWBYGMWKGHF-UHFFFAOYSA-N" "Launched"
"1450" "kevetrin" "p53 activator" "" "" "" "BRD-K61339991-003-01-8" "NC(=N)SCCCC" "" ""
"1451" "KF-38789" "P selectin inhibitor" "SELP" "" "" "BRD-A54927599-001-16-9" "COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1" "NHFIAAAMCYVRIW-UHFFFAOYSA-N" "Preclinical"
"1452" "KH-CB19" "CDC inhibitor" "CLK1, CLK3, DYRK1A" "" "" "BRD-K01673854-001-02-1" "CCOC(=O)c1c(\C(=C/N)C" "" ""
"1453" "khellin" "vasodilator" "" "" "" "BRD-K80353807-001-25-3, BRD-K80353807-001-24-6" "COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12, COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12" "HSMPDPBYAYSOBC-UHFFFAOYSA-N, HSMPDPBYAYSOBC-UHFFFAOYSA-N" "Phase 2"
"1454" "KHK-IN-1" "hexokinase inhibitor" "KHK" "" "" "BRD-K84605263-003-01-6" "CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1" "HFLMLZKGLUEWBU-UHFFFAOYSA-N" "Preclinical"
"1455" "KI-16425" "lysophosphatidic acid receptor antagonist" "LPAR1, LPAR3" "" "" "BRD-A25569250-001-03-3" "CC(OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl" "LLIFMNUXGDHTRO-UHFFFAOYSA-N" "Preclinical"
"1456" "KI-8751" "KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "KDR" "" "" "BRD-K47150025-001-05-3, BRD-K47150025-001-09-5, BRD-K47150025-001-06-1" "COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC, COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC" "LFKQSJNCVRGFCC-UHFFFAOYSA-N, LFKQSJNCVRGFCC-UHFFFAOYSA-N, LFKQSJNCVRGFCC-UHFFFAOYSA-N" "Preclinical"
"1457" "kifunensine" "mannosidase inhibitor" "MAN1B1, MAN2A1" "" "" "BRD-K02898090-001-02-7" "OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12" "OIURYJWYVIAOCW-PQMKYFCFSA-N" "Phase 1"
"1458" "kinetin" "cell division inducer" "" "dermatology" "sunburn" "BRD-K65667145-001-14-0" "C(Nc1ncnc2[nH]cnc12)c1ccco1" "QANMHLXAZMSUEX-UHFFFAOYSA-N" "Launched"
"1459" "ki16198" "lipoprotein antagonist" "LPA" "" "" "BRD-A94323479-001-02-8" "COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)OC(C)c1ccccc1Cl" "HHVJBROTJWPHHX-UHFFFAOYSA-N" "Preclinical"
"1460" "KML29" "monoacylglucerol lipase inhibitor" "MGLL" "" "" "BRD-K46734292-001-03-6" "OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1" "SXHQLPHDBLTFPM-UHFFFAOYSA-N" "Preclinical"
"1461" "KN-62" "calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist" "AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1" "" "" "BRD-A81177136-001-12-7" "CN(C(Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12" "RJVLFQBBRSMWHX-UHFFFAOYSA-N" "Preclinical"
"1462" "KN-93" "calcium/calmodulin dependent protein kinase inhibitor" "CAMK2A" "" "" "BRD-K93480852-003-01-0, BRD-K93480852-001-05-5, BRD-K93480852-001-06-3" "COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1, COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1" "LLLQTDSSHZREGW-AATRIKPKSA-N, LLLQTDSSHZREGW-AATRIKPKSA-N, LLLQTDSSHZREGW-AATRIKPKSA-N" "Preclinical"
"1463" "Ko143" "BCRP inhibitor" "ABCB1, ABCC1" "" "" "BRD-K64642496-001-03-2" "COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O" "NXNRAECHCJZNRF-JBACZVJFSA-N" "Preclinical"
"1464" "KP-1212" "" "" "" "" "BRD-K46690591-001-01-2" "NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1" "LAOLDMMWVYDDID-HSUXUTPPSA-N" "Phase 2"
"1465" "KPT-185" "exportin antagonist" "XPO1" "" "" "BRD-K71467466-001-02-3" "COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1" "NLNGWFLRRRYNIL-PLNGDYQASA-N" "Preclinical"
"1466" "KPT-276" "exportin antagonist" "XPO1" "" "" "BRD-K75352575-001-01-3" "FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(n1)\C=C/C(=O)N1CC(F)(F)C1" "JCHAWRDHMUSLMM-UPHRSURJSA-N" "Preclinical"
"1467" "KRN-633" "VEGFR inhibitor" "FLT1, FLT4, KDR" "" "" "BRD-K90993449-001-02-7" "CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl" "VPBYZLCHOKSGRX-UHFFFAOYSA-N" "Preclinical"
"1468" "KT-433" "uricosuric agent" "" "" "" "BRD-K66437909-001-01-0" "CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1" "XSDFWTIKVXKOGJ-UHFFFAOYSA-N" "Phase 2"
"1469" "ku-0063794" "mTOR inhibitor" "MTOR" "" "" "BRD-K67566344-001-08-3, BRD-K67566344-001-07-5" "COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1, COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1" "RFSMUFRPPYDYRD-CALCHBBNSA-N, RFSMUFRPPYDYRD-CALCHBBNSA-N" "Preclinical"
"1470" "KU-55933" "ATM kinase inhibitor" "ATM, PRKDC" "" "" "BRD-K25311561-001-10-7, BRD-K25311561-001-09-9" "O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1, O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1" "XRKYMMUGXMWDAO-UHFFFAOYSA-N, XRKYMMUGXMWDAO-UHFFFAOYSA-N" "Preclinical"
"1471" "KU-60019" "ATM kinase inhibitor" "ATM" "" "" "BRD-K36016295-001-05-2, BRD-K36016295-001-04-5" "C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1, C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1" "SCELLOWTHJGVIC-BGYRXZFFSA-N, SCELLOWTHJGVIC-BGYRXZFFSA-N" "Preclinical"
"1472" "kuromanin" "ribosyl cyclase inhibitor" "CD38" "" "" "BRD-K51337109-003-01-3" "OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O" "RKWHWFONKJEUEF-GQUPQBGVSA-O" "Preclinical"
"1473" "KU14R" "imidazoline receptor antagonist" "" "" "" "BRD-A38747044-001-02-3" "CCC1(Cc2ccccc2O1)c1ncc[nH]1" "JCWVNNMJXQJVNC-UHFFFAOYSA-N" "Preclinical"
"1474" "KW-2449" "Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor" "ABL1, AURKA, AURKB, FLT3" "" "" "BRD-K21718444-001-06-8" "O=C(N1CCNCC1)c1ccc(cc1)\C=C\c1n[nH]c2ccccc12" "YYLKKYCXAOBSRM-JXMROGBWSA-N" "Phase 1"
"1475" "KW-2478" "HSP inhibitor" "" "" "" "BRD-K41213548-001-02-0" "CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC" "VFUXSYAXEKYYMB-UHFFFAOYSA-N" "Phase 1/Phase 2"
"1476" "KX2-391" "src inhibitor, tubulin polymerization inhibitor" "SRC" "" "" "BRD-K29968218-001-03-2" "O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1" "HUNGUWOZPQBXGX-UHFFFAOYSA-N" "Phase 2"
"1477" "kynurenic-acid" "glutamate receptor antagonist" "GPR35, GRIN1, GRIN2A, GRIN2B" "" "" "BRD-K85872723-001-15-9" "OC(=O)c1cc(O)c2ccccc2n1" "HCZHHEIFKROPDY-UHFFFAOYSA-N" "Preclinical"
"1478" "KY02111" "Wnt pathway inhibitor" "DKK1" "" "" "BRD-K13302470-001-02-7" "COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC" "LXFKEVQQSKQXPR-UHFFFAOYSA-N" "Preclinical"
"1479" "K02288" "bone morphogenic protein inhibitor" "BMP1" "" "" "BRD-K58568447-001-02-9, BRD-K58568447-001-03-7, BRD-K58568447-001-01-1" "COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1, COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1" "CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N, CJLMANFTWLNAKC-UHFFFAOYSA-N" "Preclinical"
"1480" "K145" "sphingosine kinase inhibitor" "SPHK2" "" "" "BRD-K12106308-003-01-9" "CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1" "MPZXLTZVPUSTFY-SOFYXZRVSA-N" "Preclinical"
"1481" "L-(+)-Rhamnose-Monohydrate" "" "" "" "" "BRD-A86354194-002-01-7" "C[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O" "SHZGCJCMOBCMKK-CBPJZXOFSA-N" "Preclinical"
"1482" "L-alanine" "" "" "" "" "BRD-K25125382-001-02-5" "C[C@H](N)C(O)=O" "QNAYBMKLOCPYGJ-REOHCLBHSA-N" "Launched"
"1483" "L-Arginine" "nitric oxide precursor" "ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4" "cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology" "congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold" "BRD-K76811153-003-01-3" "N[C@H](CCCNC(N)=N)C(O)=O" "ODKSFYDXXFIFQN-SCSAIBSYSA-N" "Launched"
"1484" "L-Ascorbyl-6-palmitate" "" "" "" "" "BRD-A45419686-001-03-1, BRD-A45419686-001-02-3, BRD-A14985772-001-03-3" "CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)C1O, CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC(=O)C(=O)C1O" "CYJPUZLKFAUFHF-PRZWFREHSA-N, CYJPUZLKFAUFHF-PRZWFREHSA-N, CYJPUZLKFAUFHF-CNBHCMJISA-N" "Preclinical"
"1485" "L-asparagine" "" "ASNS, ASRGL1, NARS, NARS2, SLC1A5, SLC38A3" "" "" "BRD-K06665116-001-02-6" "N[C@@H](CC(N)=O)C(O)=O" "DCXYFEDJOCDNAF-REOHCLBHSA-N" "Phase 3"
"1486" "L-asparagine-n-hydroxy" "" "" "" "" "BRD-K82178523-001-01-6" "N[C@@H](CC(=O)NO)C(O)=O" "ZBYVTTSIVDYQSO-REOHCLBHSA-N" "Preclinical"
"1487" "L-Aspartic-Acid" "metallic radical formation stimulant" "ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13" "" "" "BRD-K97163964-001-04-1, BRD-K97163964-001-03-3" "N[C@@H](CC(O)=O)C(O)=O, N[C@@H](CC(O)=O)C(O)=O" "CKLJMWTZIZZHCS-REOHCLBHSA-N, CKLJMWTZIZZHCS-REOHCLBHSA-N" "Launched"
"1488" "L-Citrulline" "nitric oxide stimulant" "ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6" "cardiology, urology" "hypertension, erectile dysfunction" "BRD-A12237696-001-04-2" "NC(CCCNC(N)=O)C(O)=O" "RHGKLRLOHDJJDR-UHFFFAOYSA-N" "Launched"
"1489" "L-cysteine" "" "CARS, CARS2, CBS, CDO-1, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NFS1, SLC19A3" "" "" "BRD-K00795468-001-02-1" "N[C@@H](CS)C(O)=O" "XUJNEKJLAYXESH-REOHCLBHSA-N" "Launched"
"1490" "L-Cysteinesulfinic-acid" "glutamate receptor agonist" "GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2" "" "" "BRD-A25800195-001-02-2" "N[C@@H](CS(O)=O)C(O)=O" "ADVPTQAUNPRNPO-REOHCLBHSA-N" "Preclinical"
"1491" "L-Cystine" "" "CTNS, SLC3A1, SLC7A11, SLC7A9" "" "" "BRD-K99679910-001-02-3, BRD-A15397381-001-02-5" "N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O, NC(CSSCC(N)C(O)=O)C(O)=O" "LEVWYRKDKASIDU-IMJSIDKUSA-N, LEVWYRKDKASIDU-UHFFFAOYSA-N" "Launched"
"1492" "L-ergothioneine" "free radical scavenger" "" "" "" "BRD-K26341917-001-01-3" "C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O" "SSISHJJTAXXQAX-ZETCQYMHSA-O" "Phase 2"
"1493" "L-glutamic-acid" "glutamate receptor agonist" "AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT" "" "" "BRD-K62309135-001-05-2" "N[C@@H](CCC(O)=O)C(O)=O" "WHUUTDBJXJRKMK-VKHMYHEASA-N" "Launched"
"1494" "L-Hydroxyproline" "" "" "" "" "BRD-A12454076-001-01-9" "OC1CNC(C1)C(O)=O" "PMMYEEVYMWASQN-UHFFFAOYSA-N" "Launched"
"1495" "L-leucine" "" "BCAT1, BCAT2, LARS, LARS2, LCMT1, LCMT2" "" "" "BRD-K12853841-001-02-2" "CC(C)C[C@H](N)C(O)=O" "ROHFNLRQFUQHCH-YFKPBYRVSA-N" "Phase 3"
"1496" "L-lysine" "serotonin receptor agonist" "GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4" "" "" "BRD-K86016185-001-01-3" "NCCCC[C@H](N)C(O)=O" "KDXKERNSBIXSRK-YFKPBYRVSA-N" "Phase 2"
"1497" "L-methionine" "voltage-gated calcium channel ligand" "" "" "" "BRD-K06502269-001-02-6" "CSCC[C@H](N)C(O)=O" "FFEARJCKVFRZRR-BYPYZUCNSA-N" "Launched"
"1498" "L-mimosine" "dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor" "DBH, EIF5A" "" "" "BRD-K98151021-001-01-2" "N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O" "BLYDGIISUNWHLF-YFKPBYRVSA-N" "Preclinical"
"1499" "L-monomethylarginine" "nitric oxide synthase inhibitor" "NOS1, NOS2" "" "" "BRD-K20946707-001-01-9" "CN[C@@H](CCCNC(N)=N)C(O)=O" "NTWVQPHTOUKMDI-YFKPBYRVSA-N" "Phase 3"
"1500" "L-NAME" "nitric oxide synthase inhibitor" "NOS3" "" "" "BRD-K33141550-003-05-7" "COC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O" "KCWZGJVSDFYRIX-YFKPBYRVSA-N" "Phase 2/Phase 3"
"1501" "L-NIL" "nitric oxide synthase inhibitor" "NOS1, NOS2, NOS3" "" "" "BRD-K60036103-003-01-6" "CC(=N)NCCCC[C@H](N)C(O)=O" "ONYFNWIHJBLQKE-ZETCQYMHSA-N" "Preclinical"
"1502" "L-proline" "glutamate receptor agonist" "EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7" "" "" "BRD-K01666412-001-02-0" "OC(=O)[C@@H]1CCCN1" "ONIBWKKTOPOVIA-BYPYZUCNSA-N" "Launched"
"1503" "L-Quisqualic-acid" "glutamate receptor agonist" "FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8" "" "" "BRD-K92404805-001-07-0" "N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O" "ASNFTDCKZKHJSW-REOHCLBHSA-N" "Preclinical"
"1504" "L-Theanine" "glutamate receptor antagonist" "" "" "" "BRD-A08715367-001-01-7" "CCNC(=O)CCC(N)C(O)=O" "DATAGRPVKZEWHA-UHFFFAOYSA-N" "Launched"
"1505" "L-threonine" "" "TARS, TARS2, THNSL1" "" "" "BRD-K75508643-001-02-6" "C[C@@H](O)[C@H](N)C(O)=O" "AYFVYJQAPQTCCC-GBXIJSLDSA-N" "Phase 2"
"1506" "L-152804" "neuropeptide receptor antagonist" "NPY5R" "" "" "BRD-A42553870-001-14-3" "CC1(C)CC(=O)C(C2c3ccccc3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1" "XQDXIHYKAGHZRX-UHFFFAOYSA-N" "Preclinical"
"1507" "L-161982" "prostanoid receptor antagonist" "PTGER4" "" "" "BRD-K39733634-001-02-6" "CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C" "MMDNKTXNUZFVKD-UHFFFAOYSA-N" "Preclinical"
"1508" "L-165041" "PPAR receptor agonist" "PPARD" "" "" "BRD-K98372770-001-08-2" "CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(C(C)=O)c1O" "HBBVCKCCQCQCTJ-UHFFFAOYSA-N" "Preclinical"
"1509" "L-168049" "glucagon receptor antagonist" "GCGR" "" "" "BRD-K18036262-001-02-8" "CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1" "HHBOWXZOLYQFNY-UHFFFAOYSA-N" "Preclinical"
"1510" "L-365260" "CCK receptor antagonist" "CCKAR, CCKBR, KCNQ1" "" "" "BRD-K34277641-001-01-2" "CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1" "KDFQABSFVYLGPM-QFIPXVFZSA-N" "Phase 2"
"1511" "L-368899" "oxytocin receptor antagonist" "AVPR1A, AVPR2, OXTR" "" "" "BRD-A43930669-003-02-8" "Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C" "MWIASLNTAGRGGA-WVJGRJQASA-N" "Phase 1"
"1512" "L-655240" "thromboxane receptor antagonist" "PTGES" "" "" "BRD-K89402695-001-02-3" "Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12" "JLPYLHLUHJOPNL-UHFFFAOYSA-N" "Phase 1"
"1513" "L-670596" "prostanoid receptor antagonist" "" "" "" "BRD-A85472596-001-02-2" "CS(=O)(=O)c1ccc(Cn2c3C(CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1" "GMJWAIMJHBTYPD-UHFFFAOYSA-N" "Preclinical"
"1514" "L-689560" "glutamate receptor antagonist" "GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D" "" "" "BRD-K74284736-001-02-3" "OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1" "UCKHICKHGAOGAP-UONOGXRCSA-N" "Preclinical"
"1515" "L-690330" "inositol monophosphatase inhibitor" "IMPA1" "" "" "BRD-K28470988-001-04-6" "CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O" "JKOCAAWWDVHWKB-UHFFFAOYSA-N" "Preclinical"
"1516" "L-693403" "sigma receptor agonist, sigma receptor antagonist" "DRD2, SIGMAR1" "" "" "BRD-K83322645-050-01-9" "C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1" "GSXJSGMDWKPVBY-UHFFFAOYSA-N" "Preclinical"
"1517" "L-694247" "serotonin receptor agonist" "HTR1A, HTR1B, HTR1D" "" "" "BRD-K18816859-001-02-2" "CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1" "HKXMQLISPYELRD-UHFFFAOYSA-N" "Preclinical"
"1518" "L-701252" "glutamate receptor antagonist" "GRIN1" "" "" "BRD-K10176267-001-03-3" "Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12" "MXEFWCFPCLDOOG-UHFFFAOYSA-N" "Preclinical"
"1519" "L-701324" "glutamate receptor antagonist" "GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D" "" "" "BRD-K08109516-001-07-8" "Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12" "FLVRDMUHUXVRET-UHFFFAOYSA-N" "Preclinical"
"1520" "L-733060" "tachykinin antagonist" "TACR1" "" "" "BRD-K15791587-003-02-5" "FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F" "FCDRFVCGMLUYPG-ROUUACIJSA-N" "Preclinical"
"1521" "L-741742" "dopamine receptor antagonist" "DRD3, DRD4, SCN1A, SCN3A" "" "" "BRD-K13211965-003-02-8" "Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1" "QDMAKDIDFJTXEL-UHFFFAOYSA-N" "Preclinical"
"1522" "L-745870" "dopamine receptor antagonist" "DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7" "" "" "BRD-K05528470-305-02-2" "Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1" "OGJGQVFWEPNYSB-UHFFFAOYSA-N" "Preclinical"
"1523" "L-755507" "adrenergic receptor agonist" "ADRB1, ADRB2, ADRB3" "" "" "BRD-K39359968-001-01-8" "CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1" "NYYJKMXNVNFOFQ-MHZLTWQESA-N" "Preclinical"
"1524" "L-778123" "farnesyltransferase inhibitor" "FNTA, FNTB, PGGT1B" "" "" "BRD-K10958118-003-01-5" "Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C" "" ""
"1525" "labetalol" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2" "cardiology" "hypertension" "BRD-A07440155-003-25-4" "CC(CCc1ccccc1)NCC(O)c1ccc(O)c(c1)C(N)=O" "SGUAFYQXFOLMHL-UHFFFAOYSA-N" "Launched"
"1526" "lacidipine" "calcium channel blocker" "CACNA1C" "cardiology" "hypertension" "BRD-K43586850-001-02-9" "CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC" "GKQPCPXONLDCMU-CCEZHUSRSA-N" "Launched"
"1527" "lacitol" "osmosis stimulant" "" "gastroenterology" "constipation" "BRD-A34513497-002-02-3, BRD-K40787673-001-01-3" "OC[C@H](O)[C@@H](O)C(O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO, OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO" "VQHSOMBJVWLPSR-HWCAIPQBSA-N, VQHSOMBJVWLPSR-JVCRWLNRSA-N" "Launched"
"1528" "lacosamide" "collapsin response mediator protein inhibitor, collapsin response mediator protein stimulant, sodium channel blocker" "SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "seizures" "BRD-K68232650-001-02-2" "COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1" "VPPJLAIAVCUEMN-GFCCVEGCSA-N" "Launched"
"1529" "lactulose" "laxative" "" "gastroenterology" "portal-systemic encephalopathy (PSE)" "BRD-K77258318-001-04-6" "OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O" "JCQLYHFGKNRPGE-FCVZTGTOSA-N" "Launched"
"1530" "lafutidine" "histamine receptor antagonist" "HRH2" "gastroenterology" "duodenal ulcer disease, peptic ulcer disease (PUD)" "BRD-A67516570-001-02-8" "O=C(CS(=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1" "KMZQAVXSMUKBPD-DJWKRKHSSA-N" "Launched"
"1531" "lamivudine" "nucleoside reverse transcriptase inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B" "BRD-K02992638-001-11-8, BRD-A02309928-001-04-1" "Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1, Nc1ccn(C2CSC(CO)O2)c(=O)n1" "JTEGQNOMFQHVDC-NKWVEPMBSA-N, JTEGQNOMFQHVDC-UHFFFAOYSA-N" "Launched"
"1532" "lamotrigine" "serotonin receptor antagonist, sodium channel blocker" "SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "epilepsy, bipolar disorder" "BRD-K93460210-001-23-7, BRD-K93460210-001-22-9" "Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl, Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl" "PYZRQGJRPPTADH-UHFFFAOYSA-N, PYZRQGJRPPTADH-UHFFFAOYSA-N" "Launched"
"1533" "lanatoside-c" "cardiac glycoside" "" "" "" "BRD-A64242993-001-05-6" "C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)C(CCC3C2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1" "JAYAGJDXJIDEKI-YBYZECQXSA-N" "Preclinical"
"1534" "landiolol" "adrenergic receptor antagonist" "ADRB1" "cardiology" "cardiac arrythmia" "BRD-K86436199-003-01-3" "CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1" "WMDSZGFJQKSLLH-RBBKRZOGSA-N" "Launched"
"1535" "lanoconazole" "sterol demethylase inhibitor" "" "infectious disease" "fungal infection" "BRD-A54275602-001-01-0" "Clc1ccccc1C1CS\C(S1)=C(\C" "" ""
"1536" "lansoprazole" "ATPase inhibitor" "ATP4A, ATP4B" "gastroenterology" "heartburn" "BRD-A49172652-001-27-1, BRD-A49172652-001-26-3, BRD-A49172652-001-28-9" "Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1, Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1" "MJIHNNLFOKEZEW-UHFFFAOYSA-N, MJIHNNLFOKEZEW-UHFFFAOYSA-N, MJIHNNLFOKEZEW-UHFFFAOYSA-N" "Launched"
"1537" "lapatinib" "EGFR inhibitor" "EGFR, ERBB2" "oncology" "breast cancer" "BRD-K19687926-379-07-4, BRD-K19687926-001-04-1, BRD-K19687926-001-10-8" "CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1" "BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N, BCFGMOOMADDAQU-UHFFFAOYSA-N" "Launched"
"1538" "lappaconite" "sodium channel blocker" "" "" "" "BRD-A05906449-004-01-1" "CCN1C[C@@]2(CC[C@@H](OC)[C@@]34[C@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@H](C[C@H]23)C14)OC(=O)c1ccccc1NC(C)=O" "NWBWCXBPKTTZNQ-BBLNFATASA-N" "Phase 2"
"1539" "laquinimod" "immunosuppressant" "CXCL2" "" "" "BRD-K60918217-001-03-8, BRD-K60918217-001-02-0" "CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1, CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1" "GKWPCEFFIHSJOE-UHFFFAOYSA-N, GKWPCEFFIHSJOE-UHFFFAOYSA-N" "Phase 3"
"1540" "laropiprant" "prostanoid receptor antagonist" "PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R" "cardiology" "cholesterol" "BRD-K48894757-001-01-8" "CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12" "NXFFJDQHYLNEJK-CYBMUJFWSA-N" "Launched"
"1541" "lasalocid" "bacterial permeability inducer" "" "infectious disease" "coccidiosis" "BRD-A72711497-236-03-8" "CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O" "BBMULGJBVDDDNI-YFGMYPSKSA-N" "Launched"
"1542" "lasofoxifene" "selective estrogen receptor modulator (SERM)" "ESR1, ESR2" "orthopedics, oncology" "osteoporosis, breast cancer" "BRD-M93148412-001-01-8" "O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1" "INEHJXCWEVNEDZ-LUDNRVPPSA-N" "Launched"
"1543" "latamoxef" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections, gram-negative bacterial infections" "BRD-K40831222-304-06-2, BRD-K40831222-304-04-7, BRD-K40831222-304-05-4" "CO[C@]1(NC(=O)[C@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O, CO[C@]1(NC(=O)[C@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O, CO[C@]1(NC(=O)[C@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O" "JWCSIUVGFCSJCK-LIUKBUMOSA-N, JWCSIUVGFCSJCK-LIUKBUMOSA-N, JWCSIUVGFCSJCK-LIUKBUMOSA-N" "Launched"
"1544" "latanoprost" "prostanoid receptor agonist" "PTGFR" "ophthalmology" "ocular hypertension, glaucoma" "BRD-K10961822-001-05-1" "CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1" "GGXICVAJURFBLW-CEYXHVGTSA-N" "Launched"
"1545" "latrepirdine" "glutamate receptor antagonist" "HRH1, HTR6" "" "" "BRD-K55703048-300-01-6, BRD-K55703048-001-07-7" "CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1, CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1" "JNODQFNWMXFMEV-UHFFFAOYSA-N, JNODQFNWMXFMEV-UHFFFAOYSA-N" "Phase 3"
"1546" "latrunculin-b" "actin polymerization inhibitor" "ACTA1, MKL1, SPIRE2" "" "" "BRD-K61292460-001-02-3" "C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1" "NSHPHXHGRHSMIK-JRIKCGFMSA-N" "Phase 1"
"1547" "lauric-acid" "bacterial permeability inducer" "GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4" "" "" "BRD-K67375056-001-07-9" "CCCCCCCCCCCC(O)=O" "POULHZVOKOAJMA-UHFFFAOYSA-N" "Phase 3"
"1548" "lauric-diethanolamide" "" "" "" "" "BRD-K11548689-001-01-6" "CCCCCCCCCCCC(=O)N(CCO)CCO" "AOMUHOFOVNGZAN-UHFFFAOYSA-N" "Preclinical"
"1549" "laurocapram" "" "" "" "" "BRD-K35698076-001-01-2" "CCCCCCCCCCCCN1CCCCCC1=O" "AXTGDCSMTYGJND-UHFFFAOYSA-N" "Phase 3"
"1550" "lazabemide" "monoamine oxidase inhibitor" "MAOB" "" "" "BRD-K51486818-003-02-8" "NCCNC(=O)c1ccc(Cl)cn1" "JZXRLKWWVNUZRB-UHFFFAOYSA-N" "Phase 3"
"1551" "LB-100" "protein phosphatase inhibitor" "" "" "" "BRD-A73709786-001-02-1, BRD-A73709786-001-01-3" "CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O, CN1CCN(CC1)C(=O)C1C2CCC(O2)C1C(O)=O" "JUQMLSGOTNKJKI-UHFFFAOYSA-N, JUQMLSGOTNKJKI-UHFFFAOYSA-N" "Phase 1"
"1552" "LB42708" "farnesyltransferase inhibitor" "" "" "" "BRD-K18834913-001-02-9, BRD-K18834913-001-01-1" "Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1, Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1" "GUUIRIMAQGOLHT-UHFFFAOYSA-N, GUUIRIMAQGOLHT-UHFFFAOYSA-N" "Preclinical"
"1553" "LCL-161" "XIAP inhibitor" "BIRC2, XIAP" "" "" "BRD-K08248804-001-01-8" "CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1" "UFPFGVNKHCLJJO-SSKFGXFMSA-N" "Phase 2"
"1554" "LCQ908" "diacylglycerol O acyltransferase inhibitor" "DGAT1" "" "" "BRD-K20008181-001-01-3" "OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1" "GXALXAKNHIROPE-QAQDUYKDSA-N" "Phase 3"
"1555" "LCZ696" "angiotensin receptor antagonist" "" "cardiology" "angioedema, hypotension" "BRD-M31057929-001-01-2, BRD-M42331949-431-01-3" "CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)[C@@H](C(C)C)C(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)[C@@H](C(C)C)C(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)[C@@H](C(C)C)C(O)=O" "XTKIDERFOUYBDE-QEPKIHTBSA-N, CZEVQIRNFRBGNT-WSFJVKDJSA-N" "Launched"
"1556" "LDC1267" "protein tyrosine kinase inhibitor" "AXL, MERTK, TYRO3" "" "" "BRD-K44715996-001-01-0" "CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C" "ISPBCAXOSOLFME-UHFFFAOYSA-N" "Preclinical"
"1557" "LDN-212854" "bone morphogenic protein inhibitor" "ABL1, ACVR1, RIPK2" "" "" "BRD-K59831625-001-02-4, BRD-K59831625-001-01-6" "C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12, C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12" "BBDGBGOVJPEFBT-UHFFFAOYSA-N, BBDGBGOVJPEFBT-UHFFFAOYSA-N" "Preclinical"
"1558" "LDN-57444" "ubiquitin C-terminal hydrolase inhibitor" "" "" "" "BRD-K94485812-001-01-1, BRD-K94485812-001-02-9" "CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12, CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12" "OPQRFPHLZZPCCH-LTGZKZEYSA-N, OPQRFPHLZZPCCH-LTGZKZEYSA-N" "Preclinical"
"1559" "LDN193189" "bone morphogenic protein inhibitor" "ACVR1, BMPR1A" "" "" "BRD-K04853698-376-01-4" "C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12" "CDOVNWNANFFLFJ-UHFFFAOYSA-N" "Preclinical"
"1560" "LE-135" "retinoid receptor agonist" "RARB" "" "" "BRD-K06593056-001-04-8" "CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C" "YZZAIQOVMHVWBS-UHFFFAOYSA-N" "Preclinical"
"1561" "ledipasvir" "HCV inhibitor" "" "infectious disease" "hepatitis C" "BRD-K05446112-001-01-8" "COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1ncc([nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C" "VRTWBAAJJOHBQU-KMWAZVGDSA-N" "Launched"
"1562" "leflunomide" "dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor" "AHR, DHODH, PTK2B" "rheumatology" "rheumatoid arthritis" "BRD-K78692225-001-24-5, BRD-K78692225-001-23-7, BRD-K78692225-001-22-9" "Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F, Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F" "VHOGYURTWQBHIL-UHFFFAOYSA-N, VHOGYURTWQBHIL-UHFFFAOYSA-N, VHOGYURTWQBHIL-UHFFFAOYSA-N" "Launched"
"1563" "lemborexant" "orexin receptor antagonist" "HCRTR1, HCRTR2" "" "" "BRD-K78666663-001-01-6" "Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1" "MUGXRYIUWFITCP-PGRDOPGGSA-N" "Phase 3"
"1564" "lenalidomide" "anticancer agent" "CDH5, CRBN, PTGS2, TNF, TNFSF11" "hematologic malignancy" "multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)" "BRD-A17883755-001-06-1" "Nc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O" "GOTYRUGSSMKFNF-UHFFFAOYSA-N" "Launched"
"1565" "lenvatinib" "FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "FLT4, KDR" "oncology" "thyroid cancer" "BRD-K39974922-001-04-3" "COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O" "WOSKHXYHFSIKNG-UHFFFAOYSA-N" "Launched"
"1566" "lercanidipine" "calcium channel blocker" "CACNA2D1, CACNG1" "cardiology" "hypertension" "BRD-A18992208-003-02-7" "COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1" "ZDXUKAKRHYTAKV-UHFFFAOYSA-N" "Launched"
"1567" "lerisetron" "serotonin receptor antagonist" "HTR3A" "" "" "BRD-K62398570-300-01-2" "C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1" "PWWDCRQZITYKDV-UHFFFAOYSA-N" "Phase 3"
"1568" "lersivirine" "non-nucleoside reverse transcriptase inhibitor" "" "" "" "BRD-K03289534-001-01-4" "CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C" "" ""
"1569" "lesinurad" "uric acid diuretic" "SLC22A12" "rheumatology" "gout" "BRD-K75024268-001-01-0" "OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12" "FGQFOYHRJSUHMR-UHFFFAOYSA-N" "Launched"
"1570" "lestaurtinib" "FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor" "FLT3, NTRK1" "" "" "BRD-A27376179-001-01-3" "C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13" "UIARLYUEJFELEN-DMVVYWCZSA-N" "Phase 3"
"1571" "leteprinim" "nerve growth factor agonist" "" "" "" "BRD-K21612934-001-01-1" "OC(=O)c1ccc(NC(=O)CCn2cnc3c(O)ncnc23)cc1" "JMPOIZCOJJMTHI-UHFFFAOYSA-N" "Phase 2"
"1572" "letermovir" "CMV terminase inhibitor" "" "" "" "BRD-K94288301-001-01-7" "COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F" "FWYSMLBETOMXAG-QHCPKHFHSA-N" "Phase 3"
"1573" "letosteine" "mucolytic agent" "" "pulmonary, infectious disease" "bronchitis, pneumonia" "BRD-A32597168-001-03-6" "CCOC(=O)CSCCC1NC(CS1)C(O)=O" "IKOCLISPVJZJEA-UHFFFAOYSA-N" "Launched"
"1574" "letrozole" "aromatase inhibitor" "CYP19A1" "oncology" "breast cancer" "BRD-K88789588-001-14-9" "N" "" ""
"1575" "leucomethylene-blue" "nitric oxide production inhibitor, tau aggregation inhibitor" "MAPT" "" "" "BRD-K27460187-334-01-8" "CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C" "QTWZICCBKBYHDM-UHFFFAOYSA-N" "Phase 3"
"1576" "leucovorin" "folate receptor ligand" "TYMS" "oncology" "osteosarcoma" "BRD-A75919782-399-03-4, BRD-A75919782-399-02-6, BRD-A75919782-238-08-3" "Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1, Nc1nc(=O)c2N(C=O)C(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1" "VVIAGPKUTFNRDU-ABLWVSNPSA-N, VVIAGPKUTFNRDU-ABLWVSNPSA-N, VVIAGPKUTFNRDU-ABLWVSNPSA-N" "Launched"
"1577" "leucylleucine-methyl-ester" "" "" "" "" "BRD-K81136890-003-01-6" "COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C" "AJMOLNFDYWTVQW-QWRGUYRKSA-N" "Phase 2"
"1578" "leuprolide" "gonadotropin releasing factor hormone receptor agonist" "GNRHR" "oncology" "prostate cancer" "BRD-K26323068-001-01-8" "CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1" "GFIJNRVAKGFPGQ-LIJARHBVSA-N" "Launched"
"1579" "levalbuterol" "adrenergic receptor agonist" "ADRB2" "pulmonary" "bronchospasm" "BRD-K34469523-003-03-0" "CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1" "NDAUXUAQIAJITI-LBPRGKRZSA-N" "Launched"
"1580" "levallorphan" "opioid antagonist" "CHRNA2, OPRM1" "pulmonary" "respiratory depression" "BRD-K30634073-046-01-0" "Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1" "OZYUPQUCAUTOBP-QXAKKESOSA-N" "Launched"
"1581" "levamisole" "acetylcholine receptor agonist" "ALPL, ALPPL2, CHRNA3" "" "" "BRD-K73107279-003-12-5, BRD-K73107279-003-11-7" "C1CN2C[C@@H](N=C2S1)c1ccccc1, C1CN2C[C@@H](N=C2S1)c1ccccc1" "HLFSDGLLUJUHTE-SNVBAGLBSA-N, HLFSDGLLUJUHTE-SNVBAGLBSA-N" "Withdrawn"
"1582" "levcromakalim" "potassium channel activator" "KCNJ5, KCNJ8" "" "" "BRD-K24526313-001-17-7, BRD-K24526313-001-18-5, BRD-M89827113-001-01-5" "CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C" "" ""
"1583" "levetiracetam" "calcium channel blocker" "CACNA1B, SCN1A, SV2A" "neurology/psychiatry" "seizures" "BRD-K49404994-001-10-9, BRD-K49404994-001-11-7, BRD-K49404994-001-09-1" "CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O, CC[C@H](N1CCCC1=O)C(N)=O" "HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N, HPHUVLMMVZITSG-LURJTMIESA-N" "Launched"
"1584" "levo-phencynonate" "acetylcholine receptor antagonist" "CHRM1" "" "" "BRD-A64698388-003-01-7" "CN1CC2CCCC(C1)C2OC(=O)C(O)(C1CCCC1)c1ccccc1" "ROZOEEGFKDFEFP-UHFFFAOYSA-N" "Launched"
"1585" "levobunolol" "adrenergic receptor antagonist" "ADRB1, ADRB2, ADRB3" "ophthalmology" "glaucoma, ocular hypertension" "BRD-K31812033-003-11-0, BRD-K31812033-003-10-2" "CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12, CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12" "IXHBTMCLRNMKHZ-LBPRGKRZSA-N, IXHBTMCLRNMKHZ-LBPRGKRZSA-N" "Launched"
"1586" "levobunolol-(+)" "adrenergic receptor antagonist" "" "" "" "BRD-K73323637-003-10-9" "CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12" "IXHBTMCLRNMKHZ-GFCCVEGCSA-N" "Preclinical"
"1587" "levobunolol-(+/-)" "adrenergic receptor antagonist" "" "" "" "BRD-A46876182-003-02-8" "CC(C)(C)NCC(O)COc1cccc2C(=O)CCCc12" "IXHBTMCLRNMKHZ-UHFFFAOYSA-N" "Preclinical"
"1588" "levocabastine" "histamine receptor antagonist" "HRH1, NTSR2" "ophthalmology" "conjunctivitis" "BRD-K33453211-003-11-5" "C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C" "" ""
"1589" "levocarnitine" "" "" "endocrinology" "carnitine deficiency" "BRD-K59647213-001-10-5, BRD-K59647213-001-09-7" "C[N+](C)(C)C[C@H](O)CC(O)=O, C[N+](C)(C)C[C@H](O)CC(O)=O" "PHIQHXFUZVPYII-ZCFIWIBFSA-O, PHIQHXFUZVPYII-ZCFIWIBFSA-O" "Launched"
"1590" "levocarnitine-propionate" "carnitine palmitoyltransferase inhibitor" "CRAT" "neurology/psychiatry, endocrinology" "peripheral neuropathy, carnitine deficiency" "BRD-K84366268-003-01-0" "CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C" "UFAHZIUFPNSHSL-MRVPVSSYSA-O" "Launched"
"1591" "levocetirizine" "histamine receptor antagonist" "HRH1" "allergy" "allergic rhinitis, urticaria" "BRD-K27184429-300-01-3" "OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1" "ZKLPARSLTMPFCP-OAQYLSRUSA-N" "Launched"
"1592" "levodopa" "dopamine precursor" "DRD1, DRD2, DRD3, DRD4, DRD5, GPR143" "neurology/psychiatry" "Parkinsons Disease	BRD-K34730807-001-17-6, BRD-K34730807-001-16-8, BRD-K34730807-001-15-0	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O, N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	WTDRDQBEARUVNC-LURJTMIESA-N, WTDRDQBEARUVNC-LURJTMIESA-N, WTDRDQBEARUVNC-LURJTMIESA-N	Launched
levodropropizine	antitussive		pulmonary	cough suppressant	BRD-K83551379-001-01-8, BRD-K60537263-001-01-3	OC[C@@H](O)CN1CCN(CC1)c1ccccc1, OC[C@H](O)CN1CCN(CC1)c1ccccc1	PTVWPYVOOKLBCG-ZDUSSCGKSA-N, PTVWPYVOOKLBCG-CYBMUJFWSA-N	Launched
levofloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, otolaryngology, pulmonary, urology	pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague	BRD-K09471561-001-18-2, BRD-K88565300-001-01-7	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, C[C@@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	GSDSWSVVBLHKDQ-JTQLQIEISA-N, GSDSWSVVBLHKDQ-SNVBAGLBSA-N	Launched
levomenol			neurology/psychiatry, infectious disease	spasms, skin infections	BRD-K62751771-001-01-3	CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1	RGZSQWQPBWRIAQ-CABCVRRESA-N	Launched
levomenthol		OPRK1, TRPA1, TRPM8, TRPV3	neurology/psychiatry	pain relief	BRD-K50329370-001-08-2, BRD-A54393207-001-03-6, BRD-K50329370-001-09-0	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CC(C)C1CCC(C)CC1O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NOOLISFMXDJSKH-KXUCPTDWSA-N, NOOLISFMXDJSKH-UHFFFAOYSA-N, NOOLISFMXDJSKH-KXUCPTDWSA-N	Launched
levomepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C	neurology/psychiatry, gastroenterology	psychosis, schizophrenia, bipolar disorder, nausea, insomnia	BRD-K35559145-001-01-3, BRD-K35559145-050-08-5	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1, COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	VRQVVMDWGGWHTJ-CQSZACIVSA-N, VRQVVMDWGGWHTJ-CQSZACIVSA-N	Launched
levomequitazine	histamine receptor antagonist	HRH1			BRD-A67616246-001-07-9	C(C1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12	HOKDBMAJZXIPGC-UHFFFAOYSA-N	Phase 2
levonordefrin	vasodilator	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, SLC6A2	hematology	hemorrhage	BRD-K02976377-001-07-4, BRD-K02976377-001-08-2	C[C@H](N)[C@H](O)c1ccc(O)c(O)c1, C[C@H](N)[C@H](O)c1ccc(O)c(O)c1	GEFQWZLICWMTKF-CDUCUWFYSA-N, GEFQWZLICWMTKF-CDUCUWFYSA-N	Launched
levonorgestrel	estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist	AR, ESR1, PGR, SRD5A1	endocrinology	contraceptive	BRD-K10086084-001-02-7, BRD-K35189033-001-26-1, BRD-K10086084-001-01-9	CC[C@]12CC[C@@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@]2(O)C#C, CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C, CC[C@]12CC[C@@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@]2(O)C#C	WWYNJERNGUHSAO-MFHSYZQISA-N, WWYNJERNGUHSAO-XUDSTZEESA-N, WWYNJERNGUHSAO-MFHSYZQISA-N	Launched
levopropoxyphene	antitussive	OPRD1, OPRK1, OPRM1	pulmonary	cough suppressant	BRD-A54635441-078-09-1	CCC(=O)OC(Cc1ccccc1)(C(C)CN(C)C)c1ccccc1	XLMALTXPSGQGBX-UHFFFAOYSA-N	Launched
levosimendan	calcium sensitizer	KCNJ11, KCNJ8, PDE3A, TNNC1	cardiology	congestive heart failure	BRD-K03095347-001-06-1, BRD-K03095347-001-05-3	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1, C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1	WHXMKTBCFHIYNQ-SECBINFHSA-N, WHXMKTBCFHIYNQ-SECBINFHSA-N	Launched
levosulpiride	dopamine receptor antagonist	CA1, CA12, CA7, DRD2, DRD3	neurology/psychiatry, gastroenterology, urology	schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)	BRD-K51671335-001-10-6, BRD-K51671335-001-09-8	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	BGRJTUBHPOOWDU-NSHDSACASA-N, BGRJTUBHPOOWDU-NSHDSACASA-N	Launched
levothyroxine	thyroid hormone stimulant	THRA, THRB	endocrinology	myxedema coma	BRD-K30685142-001-17-0, BRD-K30685142-001-15-4, BRD-K30685142-001-16-2, BRD-K30685142-001-14-7	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N, XUIIKFGFIJCVMT-LBPRGKRZSA-N	Launched
LFM-A13	Brutons tyrosine kinase (BTK) inhibitor" "BTK" "" "" "BRD-A30655177-001-14-0"
"1593" "CC(=O)C(C" "" "" "" "" "" "" "" ""
"1594" "LGK-974" "porcupine inhibitor" "PORCN" "" "" "BRD-K16810791-001-01-0" "Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C" "XXYGTCZJJLTAGH-UHFFFAOYSA-N" "Phase 2"
"1595" "LGX818" "RAF inhibitor" "BRAF" "" "" "BRD-A56085258-001-01-8" "COC(=O)NC(C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C" "CMJCXYNUCSMDBY-UHFFFAOYSA-N" "Phase 3"
"1596" "LH846" "casein kinase inhibitor" "CSNK1D" "" "" "BRD-K47409078-001-02-6, BRD-K47409078-001-01-8" "Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl, Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl" "DYHAMRNAHTWYKY-UHFFFAOYSA-N, DYHAMRNAHTWYKY-UHFFFAOYSA-N" "Preclinical"
"1597" "licarbazepine" "voltage-gated sodium channel blocker" "SCN5A" "" "" "BRD-A22642447-001-01-9" "NC(=O)N1c2ccccc2CC(O)c2ccccc12" "BMPDWHIDQYTSHX-UHFFFAOYSA-N" "Phase 3"
"1598" "licochalcone-a" "topoisomerase inhibitor" "PTPN1" "" "" "BRD-K26011976-001-01-0" "COc1cc(O)c(cc1C=CC(=O)c1ccc(O)cc1)C(C)(C)C=C" "KAZSKMJFUPEHHW-UHFFFAOYSA-N" "Phase 3"
"1599" "licofelone" "cyclooxygenase inhibitor, lipoxygenase inhibitor" "ALOX5, PLA2G2E, PTGS2" "" "" "BRD-K08439945-001-01-3, BRD-K08439945-001-03-9, BRD-K08439945-001-02-1" "CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1, CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1" "UAWXGRJVZSAUSZ-UHFFFAOYSA-N, UAWXGRJVZSAUSZ-UHFFFAOYSA-N, UAWXGRJVZSAUSZ-UHFFFAOYSA-N" "Phase 3"
"1600" "lidamidine" "adrenergic receptor agonist" "" "gastroenterology" "diarrhea" "BRD-K68693535-001-03-4" "CNC(=N)NC(=O)Nc1c(C)cccc1C" "RRHJHSBDJDZUGL-UHFFFAOYSA-N" "Launched"
"1601" "lidocaine" "histamine receptor agonist" "EGFR, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry, dermatology, hematology" "itching, eczema, hemorrhage" "BRD-K52662033-003-21-2, BRD-K52662033-001-19-0" "CCN(CC)CC(=O)Nc1c(C)cccc1C, CCN(CC)CC(=O)Nc1c(C)cccc1C" "NNJVILVZKWQKPM-UHFFFAOYSA-N, NNJVILVZKWQKPM-UHFFFAOYSA-N" "Launched"
"1602" "lidoflazine" "calcium channel blocker" "SCN1A, SCN3A, SLC29A1" "" "" "BRD-K62996583-001-10-3" "Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1" "ZBIAKUMOEKILTF-UHFFFAOYSA-N" "Launched"
"1603" "ligustilide" "tumor necrosis factor production inhibitor" "TNF" "" "" "BRD-K48875051-001-01-0" "CCC\C=C1OC(=O)C2=C/1CCC=C2" "IQVQXVFMNOFTMU-FLIBITNWSA-N" "Preclinical"
"1604" "limaprost-alfadex" "prostanoid receptor agonist" "PTGER1" "cardiology" "claudication" "BRD-K25015158-001-02-0, BRD-K25015158-001-01-2" "CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O, CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O" "OJZYRQPMEIEQFC-UAWLTFRCSA-N, OJZYRQPMEIEQFC-UAWLTFRCSA-N" "Launched"
"1605" "limonin" "HIV protease inhibitor" "" "" "" "BRD-K64094723-001-01-5" "CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@@H]3O[C@@]123)c1ccoc1" "KBDSLGBFQAGHBE-YGLKJFJQSA-N" "Preclinical"
"1606" "linaclotide" "guanylate cyclase activator" "GUCY2C" "gastroenterology" "irritable bowel syndrome, constipation" "BRD-A55468767-001-01-1" "C[C@@H](O)C1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CSSC[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2" "KXGCNMMJRFDFNR-IURAOCFRSA-N" "Launched"
"1607" "linagliptin" "dipeptidyl peptidase inhibitor" "DPP4" "endocrinology" "diabetes mellitus" "BRD-K96550715-001-04-2, BRD-K96550715-001-02-6, BRD-K96550715-003-01-4, BRD-K96550715-001-03-4" "CC" "" ""
"1608" "linalool" "anticonvulsant" "" "" "" "BRD-A43082461-001-06-3" "CC(C)=CCCC(C)(O)C=C" "CDOSHBSSFJOMGT-UHFFFAOYSA-N" "Phase 1"
"1609" "lincomycin" "bacterial 30S ribosomal subunit inhibitor" "" "gastroenterology" "enteritis" "BRD-K81447180-003-21-4, BRD-K08033334-003-04-3, BRD-K99816398-003-01-0" "CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O, CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O" "OJMMVQQUTAEWLP-HZUSHKNOSA-N, OJMMVQQUTAEWLP-LPSAIEBYSA-N, OJMMVQQUTAEWLP-IASOXNGFSA-N" "Launched"
"1610" "lindane" "" "GABRB1, GLRA1, GLRA2, GLRA3, GLRB" "infectious disease" "scabies" "BRD-K93814253-001-05-0, BRD-K93814253-001-04-3" "Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl, Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl" "JLYXXMFPNIAWKQ-GNIYUCBRSA-N, JLYXXMFPNIAWKQ-GNIYUCBRSA-N" "Launched"
"1611" "linezolid" "bacterial 50S ribosomal subunit inhibitor" "MAOA, MAOB" "infectious disease" "pneumonia, skin infections" "BRD-K66876909-001-12-6, BRD-K66876909-001-11-8" "CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1, CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1" "TYZROVQLWOKYKF-ZDUSSCGKSA-N, TYZROVQLWOKYKF-ZDUSSCGKSA-N" "Launched"
"1612" "linifanib" "PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK" "" "" "BRD-K99749624-001-07-0" "Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1" "MPVGZUGXCQEXTM-UHFFFAOYSA-N" "Phase 3"
"1613" "linoleic-acid" "oxidative stress inducer" "FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8" "" "" "BRD-K08973992-001-06-2" "CCCCC\C=C/C\C=C/CCCCCCCC(O)=O" "OYHQOLUKZRVURQ-HZJYTTRNSA-N" "Phase 3"
"1614" "linopirdine" "potassium channel blocker" "KCNQ2, KCNQ3, KCNQ4, KCNQ5" "" "" "BRD-K59332007-300-02-7" "O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1" "YEJCDKJIEMIWRQ-UHFFFAOYSA-N" "Phase 3"
"1615" "linsidomine" "nitric oxide donor" "" "urology" "erectile dysfunction" "BRD-K72922393-003-15-2, BRD-K86344238-003-03-8" "N=c1c[n+]([n-]o1)N1CCOCC1, Nc1c[n+](no1)N1CCOCC1" "FKDHHVKWGRFRTG-UHFFFAOYSA-N, XZYRDNUZENBYFI-UHFFFAOYSA-N" "Launched"
"1616" "linsitinib" "IGF-1 inhibitor" "IGF1R, INSR, INSRR" "" "" "BRD-K86118762-001-01-8, BRD-K86118762-001-05-9" "C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12" "PKCDDUHJAFVJJB-VLZXCDOPSA-N, PKCDDUHJAFVJJB-VLZXCDOPSA-N" "Phase 3"
"1617" "liothyronine" "thyroid hormone stimulant" "THRA, THRB" "endocrinology" "hypothyroidism, myxedema coma" "BRD-K89152108-236-07-6, BRD-K89152108-236-06-8, BRD-K89152108-236-05-0" "N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O, N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O" "AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N, AUYYCJSJGJYCDS-LBPRGKRZSA-N" "Launched"
"1618" "liothyronine-(isomer)" "" "" "" "" "BRD-K46428823-001-02-5" "N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O" "AUYYCJSJGJYCDS-GFCCVEGCSA-N" "Preclinical"
"1619" "lipoamide" "" "" "" "" "BRD-A14440173-001-03-4" "NC(=O)CCCCC1CCSS1" "FCCDDURTIIUXBY-UHFFFAOYSA-N" "Preclinical"
"1620" "liraglutide" "GLP receptor agonist" "GLP1R" "endocrinology" "weight-loss aid, diabetes mellitus" "BRD-A48274390-001-01-8" "CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O" "YSDQQAXHVYUZIW-UHFFFAOYSA-N" "Launched"
"1621" "liranaftate" "fungal squalene epoxidase inhibitor" "" "infectious disease" "fungal infection" "BRD-K35775715-001-03-1" "COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1" "VPHPQNGOVQYUMG-UHFFFAOYSA-N" "Launched"
"1622" "lirimilast" "phosphodiesterase inhibitor" "" "" "" "BRD-K31339321-001-03-6" "CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl" "YPFLFUJKZDAXRA-UHFFFAOYSA-N" "Phase 2"
"1623" "lisadimate" "topical sunscreen agent" "" "dermatology" "sunscreen lotion" "BRD-A76533773-001-01-9" "Nc1ccc(cc1)C(=O)OCC(O)CO" "WHQOKFZWSDOTQP-UHFFFAOYSA-N" "Launched"
"1624" "lisinopril" "angiotensin converting enzyme inhibitor" "ACE, ACE2" "cardiology, endocrinology" "hypertension, congestive heart failure, diabetes mellitus" "BRD-K67966701-001-12-4, BRD-K67966701-001-11-6, BRD-K67966701-001-10-8" "NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O, NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O" "RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N, RLAWWYSOJDYHDC-BZSNNMDCSA-N" "Launched"
"1625" "lisofylline" "interleukin receptor antagonist, STAT inhibitor" "" "" "" "BRD-A05334458-001-02-8" "CC(O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O" "NSMXQKNUPPXBRG-UHFFFAOYSA-N" "Phase 2"
"1626" "lisuride" "dopamine receptor agonist" "ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6" "neurology/psychiatry" "Parkinsons Disease	BRD-K67943528-050-01-4	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34	BKRGVLQUQGGVSM-KBXCAEBGSA-N	Launched
lithium-acetoacetate					BRD-K73234506-235-02-1	CC(=O)CC(O)=O	WDJHALXBUFZDSR-UHFFFAOYSA-N	Preclinical
lithium-citrate			neurology/psychiatry	bipolar disorder, depression	BRD-M41245765-001-05-9, BRD-M41245765-001-03-4, BRD-M41245765-001-04-2	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O, [Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	PTYJGLZVOMGTRG-UHFFFAOYSA-N, PTYJGLZVOMGTRG-UHFFFAOYSA-N, PTYJGLZVOMGTRG-UHFFFAOYSA-N	Launched
lithocholic-acid	FXR antagonist, vitamin D receptor agonist	GPBAR1, NR1H4, NR1I2, VDR			BRD-K04497194-001-02-1	C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	SMEROWZSTRWXGI-JKTPOEMPSA-N	Preclinical
litronesib	kinesin-like spindle protein inhibitor	KIF11			BRD-K83029223-001-01-3	CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1	YVAFBXLHPINSIK-QHCPKHFHSA-N	Phase 2
lixivaptan	vasopressin receptor antagonist	AVPR2			BRD-K59391348-001-01-7	Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1	PPHTXRNHTVLQED-UHFFFAOYSA-N	Phase 3
LMI070	survival motor neuron protein modulator	SMN1			BRD-K08532119-001-01-5	CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1	STWTUEAWRAIWJG-UHFFFAOYSA-N	Phase 1/Phase 2
LM11A-31	neurotrophic agent	NGFR			BRD-A04649065-001-01-7	CCC(C)C(N)C(=O)NCCN1CCOCC1	YNMUTYLWSRFTPX-UHFFFAOYSA-N	Phase 1
lobeline	acetylcholine receptor antagonist	CHRNA10, CHRNA9, SLC18A2	neurology/psychiatry	smoking cessation	BRD-K66206289-003-21-3, BRD-A65243462-003-04-4, BRD-K66206289-003-20-5, BRD-M82226456-065-01-7	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1C(CC(O)c2ccccc2)CCCC1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1, CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1.CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	MXYUKLILVYORSK-HBMCJLEFSA-N, MXYUKLILVYORSK-UHFFFAOYSA-N, MXYUKLILVYORSK-HBMCJLEFSA-N, ZLKSFXYIUFVQRH-NPAAHEPDSA-N	Launched
lobendazole	anthelmintic agent				BRD-K15834839-001-02-3	CCOC(=O)Nc1nc2ccccc2[nH]1	OKOVSTKGUBOSTB-UHFFFAOYSA-N	Preclinical
lobenzarit	immunosuppressant		rheumatology	rheumatoid arthritis	BRD-K55847762-304-01-7	OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O	UGDPYGKWIHHBMB-UHFFFAOYSA-N	Launched
lodoxamide	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	BRD-K66937583-001-01-2	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	RVGLGHVJXCETIO-UHFFFAOYSA-N	Launched
lofemizole	cyclooxygenase inhibitor				BRD-K06388517-001-01-2	Cc1nc[nH]c1-c1ccc(Cl)cc1	MBKWNJVQSFBLQI-UHFFFAOYSA-N	Phase 3
lofepramine	norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)	HTR1A, SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K82147103-003-05-6, BRD-K82147103-001-02-7	CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1, CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1	SAPNXPWPAUFAJU-UHFFFAOYSA-N, SAPNXPWPAUFAJU-UHFFFAOYSA-N	Launched
lofexidine	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	opioid withdrawal	BRD-A02990301-003-06-6, BRD-A02990301-003-05-8	CC(Oc1c(Cl)cccc1Cl)C1=NCCN1, CC(Oc1c(Cl)cccc1Cl)C1=NCCN1	KSMAGQUYOIHWFS-UHFFFAOYSA-N, KSMAGQUYOIHWFS-UHFFFAOYSA-N	Launched
lomefloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease	respiratory tract infections, urinary tract infections	BRD-A75850590-213-01-0, BRD-A75850590-003-09-8	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12, CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12	ZEKZLJVOYLTDKK-UHFFFAOYSA-N, ZEKZLJVOYLTDKK-UHFFFAOYSA-N	Launched
lomeguatrib	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			BRD-K27955832-001-02-9	Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	JUJPKFNFCWJBCX-UHFFFAOYSA-N	Phase 2
lomerizine	calcium channel blocker	CACNA1B, SCN5A	neurology/psychiatry	migraine headache	BRD-K62858456-001-01-8, BRD-K62858456-300-01-4	COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC, COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	JQSAYKKFZOSZGJ-UHFFFAOYSA-N, JQSAYKKFZOSZGJ-UHFFFAOYSA-N	Launched
lometrexol	glycinamide ribonucleotide formyltransferase inhibitor	GART, MTHFD1			BRD-K66036108-001-01-9	Nc1nc(O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2n1	ZUQBAQVRAURMCL-DOMZBBRYSA-N	Phase 2
lomitapide	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	BRD-K92213669-001-01-3	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	MBBCVAKAJPKAKM-UHFFFAOYSA-N	Launched
lomustine	DNA synthesis inhibitor	STMN4	hematologic malignancy, oncology	Hodgkins lymphoma, brain tumors" "BRD-K51768138-001-09-1, BRD-K51768138-001-04-2, BRD-K51768138-001-05-9, BRD-K51768138-001-07-5" "[O-][N+]N(CCCl)C(=O)NC1CCCCC1, [O-][N+]N(CCCl)C(=O)NC1CCCCC1, [O-][N+]N(CCCl)C(=O)NC1CCCCC1, [O-][N+]N(CCCl)C(=O)NC1CCCCC1" "GQYIWUVLTXOXAJ-UHFFFAOYSA-N, GQYIWUVLTXOXAJ-UHFFFAOYSA-N, GQYIWUVLTXOXAJ-UHFFFAOYSA-N, GQYIWUVLTXOXAJ-UHFFFAOYSA-N" "Launched"
"1627" "lonafarnib" "farnesyltransferase inhibitor" "FNTA, HRAS, KRAS, NRAS" "" "" "BRD-K41599323-001-02-3" "NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1" "DHMTURDWPRKSOA-RUZDIDTESA-N" "Phase 3"
"1628" "lonidamine" "glucokinase inhibitor" "GCK" "" "" "BRD-K78513633-001-15-7, BRD-K78513633-001-14-0, BRD-K78513633-001-13-2" "OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12, OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12" "WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N, WDRYRZXSPDWGEB-UHFFFAOYSA-N" "Launched"
"1629" "loperamide" "opioid receptor agonist" "CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC" "gastroenterology" "diarrhea" "BRD-K61250553-003-32-2, BRD-K61250553-003-30-6, BRD-K61250553-003-29-8" "CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1, CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1" "RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N, RDOIQAHITMMDAJ-UHFFFAOYSA-N" "Launched"
"1630" "lopinavir" "HIV protease inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K99451608-001-07-3" "CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1" "KJHKTHWMRKYKJE-SUGCFTRWSA-N" "Launched"
"1631" "loracarbef" "bacterial cell wall synthesis inhibitor" "" "infectious disease, otolaryngology, pulmonary" "ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections" "BRD-K28935038-001-02-2, BRD-A04915500-002-01-3" "N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1, N[C@@H](C(=O)NC1C2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1" "JAPHQRWPEGVNBT-UTUOFQBUSA-N, JAPHQRWPEGVNBT-MOENNCHZSA-N" "Launched"
"1632" "loratadine" "histamine receptor antagonist" "HRH1" "allergy, neurology/psychiatry" "allergic rhinitis, itching" "BRD-K82795137-001-26-2, BRD-K82795137-001-25-4, BRD-K82795137-001-24-7" "CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12, CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12" "JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N, JCCNYMKQOSZNPW-UHFFFAOYSA-N" "Launched"
"1633" "lorazepam" "benzodiazepine receptor agonist" "GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO" "neurology/psychiatry" "status epilepticus" "BRD-A11990600-001-03-4" "OC1N=C(c2ccccc2Cl)c2cc(Cl)ccc2NC1=O" "DIWRORZWFLOCLC-UHFFFAOYSA-N" "Launched"
"1634" "lorcaserin" "serotonin receptor agonist" "HTR2A, HTR2B, HTR2C" "endocrinology" "obesity" "BRD-K55013654-003-02-3" "C[C@H]1CNCCc2ccc(Cl)cc12" "XTTZERNUQAFMOF-QMMMGPOBSA-N" "Launched"
"1635" "loreclezole" "benzodiazepine receptor agonist" "GABRB2, GABRB3" "" "" "BRD-K09659835-003-01-4" "Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl" "XGLHZTBDUXXHOM-WMZJFQQLSA-N" "Phase 2"
"1636" "lorediplon" "GABA receptor modulator" "GABRA1" "" "" "BRD-K42066335-001-01-0" "CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1" "NQPOCLFSADOXBR-UHFFFAOYSA-N" "Phase 2"
"1637" "lorglumide" "CCK receptor antagonist" "CCKAR, CCKBR" "" "" "BRD-A29854054-236-12-6" "CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1" "IEKOTSCYBBDIJC-UHFFFAOYSA-N" "Phase 1"
"1638" "lorlatinib" "ALK tyrosine kinase receptor inhibitor" "ALK" "" "" "BRD-K99879819-001-02-1" "C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C" "" ""
"1639" "lornoxicam" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "rheumatology, neurology/psychiatry" "osteoarthritis, sciata" "BRD-A90551241-001-10-8, BRD-A90551241-001-09-0" "CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2sc(Cl)cc2S1(=O)=O" "QOFQTBTZCJVITI-UHFFFAOYSA-N, QOFQTBTZCJVITI-UHFFFAOYSA-N" "Launched"
"1640" "losartan" "angiotensin receptor antagonist" "AGTR1" "cardiology, nephrology" "hypertension, diabetic nephropathy" "BRD-K76205745-237-16-5, BRD-K76205745-237-18-1, BRD-K76205745-001-06-6" "CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1, CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1" "PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N, PSIFNNKUMBGKDQ-UHFFFAOYSA-N" "Launched"
"1641" "losmapimod" "p38 MAPK inhibitor" "MAPK14" "" "" "BRD-K56195681-001-01-0" "Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1" "KKYABQBFGDZVNQ-UHFFFAOYSA-N" "Phase 3"
"1642" "loteprednol" "glucocorticoid receptor agonist, phospholipase inhibitor" "NR3C1" "ophthalmology" "conjunctivitis" "BRD-K39983086-001-06-1, BRD-K43659793-001-01-6" "CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl, CCOC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@H](O)C[C@]12C)C(=O)OCCl" "DMKSVUSAATWOCU-HROMYWEYSA-N, DMKSVUSAATWOCU-GJOKDQRHSA-N" "Launched"
"1643" "lovastatin" "HMGCR inhibitor" "HDAC2, HMGCR, ITGAL, NR1I2" "cardiology, endocrinology" "coronary heart disease, myocardial infarction, hypercholesterolemia" "BRD-K09416995-001-40-7, BRD-K09416995-001-39-9, BRD-K09416995-001-38-1, BRD-K74251557-001-01-0" "CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12" "PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-BXMDZJJMSA-N, PCZOHLXUXFIOCF-KMAFYUSPSA-N" "Launched"
"1644" "loxapine" "dopamine receptor antagonist, serotonin receptor antagonist" "ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4" "neurology/psychiatry" "schizophrenia" "BRD-K39915878-036-24-4, BRD-K39915878-036-25-1" "CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12, CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12" "XJGVXQDUIWGIRW-UHFFFAOYSA-N, XJGVXQDUIWGIRW-UHFFFAOYSA-N" "Launched"
"1645" "loxistatin-acid" "cysteine peptidase inhibitor" "CTSB" "" "" "BRD-K21937671-001-09-2, BRD-A44872635-001-01-8" "CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O, CC(C)CCNC(=O)C(CC(C)C)NC(=O)C1OC1C(O)=O" "SCMSYZJDIQPSDI-SRVKXCTJSA-N, SCMSYZJDIQPSDI-UHFFFAOYSA-N" "Preclinical"
"1646" "LOXO-101" "tropomyosin receptor kinase inhibitor" "NTRK1, NTRK2, NTRK3" "" "" "BRD-K36574127-001-01-3" "O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F" "NYNZQNWKBKUAII-KBXCAEBGSA-N" "Phase 2"
"1647" "loxoprofen" "cyclooxygenase inhibitor, prostanoid receptor antagonist" "PTGS2" "neurology/psychiatry" "pain relief" "BRD-A43082555-001-02-9, BRD-A43082555-001-01-1" "CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1, CC(C(O)=O)c1ccc(CC2CCCC2=O)cc1" "YMBXTVYHTMGZDW-UHFFFAOYSA-N, YMBXTVYHTMGZDW-UHFFFAOYSA-N" "Launched"
"1648" "LPA2-antagonist-1" "lysophosphatidic acid receptor antagonist" "LPAR2" "" "" "BRD-K32322923-001-01-7" "C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12" "BPRNMVDTWIHULJ-AWEZNQCLSA-N" "Preclinical"
"1649" "LRRK2-IN-1" "leucine rich repeat kinase inhibitor" "LRRK2" "" "" "BRD-K01436366-001-22-2, BRD-K01436366-001-20-6" "COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1" "IWMCPJZTADUIFX-UHFFFAOYSA-N, IWMCPJZTADUIFX-UHFFFAOYSA-N" "Preclinical"
"1650" "LTA" "" "" "" "" "BRD-K52914072-001-01-5" "N=C(Nc1ccccc1)c1cccs1" "RCORNHOUCUDCAC-UHFFFAOYSA-N" "Phase 2"
"1651" "LTB4" "leukocyte activator" "LTB4R, LTB4R2" "" "" "BRD-K53124401-001-03-8" "CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O" "VNYSSYRCGWBHLG-AMOLWHMGSA-N" "Phase 2"
"1652" "lubiprostone" "chloride channel activator" "CLCN2" "gastroenterology" "constipation, irritable bowel syndrome" "BRD-K33814251-001-01-4, BRD-K58693165-001-01-7" "CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O, CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@H]1CCCCCCC(O)=O" "DBVFKLAGQHYVGQ-BFYDXBDKSA-N, DBVFKLAGQHYVGQ-ZMSDIMECSA-N" "Launched"
"1653" "lucitanib" "FGFR inhibitor, VEGFR inhibitor" "FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET" "" "" "BRD-K31309378-001-01-5" "CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12" "CUDVHEFYRIWYQD-UHFFFAOYSA-N" "Phase 2"
"1654" "lufenuron" "chitin inhibitor" "" "infectious disease" "flea control" "BRD-A71774530-001-05-9" "FC(C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl" "PWPJGUXAGUPAHP-UHFFFAOYSA-N" "Launched"
"1655" "luliconazole" "sterol demethylase inhibitor" "" "infectious disease" "tinea pedis, tinea cruris, tinea corporis" "BRD-K71058253-001-01-9" "Clc1ccc([C@@H]2CS\C(S2)=C(\C" "" ""
"1656" "lumacaftor" "CFTR channel agonist" "CFTR" "pulmonary" "cystic fibrosis" "BRD-K69236721-001-02-7" "Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O" "UFSKUSARDNFIRC-UHFFFAOYSA-N" "Launched"
"1657" "lumateperone" "serotonin receptor antagonist, dopamine receptor modulator" "DRD2, HTR2A" "" "" "BRD-K10031916-075-01-3" "CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23" "HOIIHACBCFLJET-SFTDATJTSA-N" "Phase 3"
"1658" "lumefantrine" "antimalarial agent" "ATP1A1" "infectious disease" "malaria" "BRD-A58804007-001-01-4, BRD-A05926236-001-03-8" "CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1\C2=C/c1ccc(Cl)cc1, CCCCN(CCCC)CC(O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12" "DYLGFOYVTXJFJP-MFKUBSTISA-N, DYLGFOYVTXJFJP-MYYYXRDXSA-N" "Launched"
"1659" "lumiracoxib" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "" "" "BRD-K26901728-001-06-2, BRD-K26901728-001-05-4" "Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1, Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1" "KHPKQFYUPIUARC-UHFFFAOYSA-N, KHPKQFYUPIUARC-UHFFFAOYSA-N" "Withdrawn"
"1660" "lupanine" "sodium channel blocker" "INS" "" "" "BRD-A92826379-001-01-5" "O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3" "JYIJIIVLEOETIQ-RFPFOJJUSA-N" "Phase 1"
"1661" "lurasidone" "dopamine receptor antagonist, serotonin receptor antagonist" "ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7" "neurology/psychiatry" "schizophrenia" "BRD-K51143828-003-03-1" "O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12" "PQXKDMSYBGKCJA-CVTJIBDQSA-N" "Launched"
"1662" "lutein" "antioxidant" "" "ophthalmology" "macular degeneration, cataracts, retinitis pigmentosa (RP)" "BRD-K16742848-001-02-6, BRD-K16742848-001-01-8" "CC(\C=C\C=C(C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C, CC(\C=C\C=C(C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C" "KBPHJBAIARWVSC-RGZFRNHPSA-N, KBPHJBAIARWVSC-RGZFRNHPSA-N" "Launched"
"1663" "luteolin" "glucosidase inhibitor" "TOP1" "" "" "BRD-K05236810-001-19-0" "Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1" "IQPNAANSBPBGFQ-UHFFFAOYSA-N" "Phase 2"
"1664" "luzindole" "melatonin receptor antagonist" "MTNR1A, MTNR1B" "" "" "BRD-K67013324-001-03-1" "CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12" "WVVXBPKOIZGVNS-UHFFFAOYSA-N" "Preclinical"
"1665" "LXR-623" "LXR agonist" "AR, NR1H2, NR1H3, NR1I2, NR3C1" "" "" "BRD-K54520417-001-01-2" "Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F" "KYWWJENKIMRJBI-UHFFFAOYSA-N" "Phase 1"
"1666" "LX1031" "tryptophan hydroxylase inhibitor" "TPH1" "" "" "BRD-K32101625-001-01-6" "COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F" "XNMUICFMGGQSMZ-WIOPSUGQSA-N" "Phase 2"
"1667" "LX7101" "LIM kinase inhibitor, rho associated kinase inhibitor" "LIMK2, ROCK1, ROCK2" "" "" "BRD-K21038058-001-01-9" "CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1" "PWPNYABQEOGNNC-UHFFFAOYSA-N" "Phase 1/Phase 2"
"1668" "lycopene" "free radical scavenger" "" "" "" "BRD-K37083340-001-02-3" "CC(C)=CCC\C(C)=C\C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C=C(/C)CCC=C(C)C" "OAIJSZIZWZSQBC-GYZMGTAESA-N" "Phase 3"
"1669" "lylamine" "cannabinoid receptor agonist" "CNR1" "" "" "BRD-K62289640-003-02-7" "CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1" "JVVXZOOGOGPDRZ-SLFFLAALSA-N" "Preclinical"
"1670" "lymecycline" "bacterial 50S ribosomal subunit inhibitor" "" "dermatology" "acne vulgaris (AV)" "BRD-A15750551-001-01-1" "CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O" "DZTKAWPWXGIREW-UINNQTPFSA-N" "Launched"
"1671" "lynestrenol" "progestogen hormone" "" "endocrinology" "contraceptive" "BRD-K39707084-001-04-1, BRD-K39707084-001-05-8" "C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C" "" ""
"1672" "lypressin" "vasopressin receptor agonist" "AVPR1A, AVPR1B, AVPR2" "" "" "BRD-K93331255-001-02-0" "NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O" "BJFIDCADFRDPIO-DZCXQCEKSA-N" "Launched"
"1673" "LY2090314" "glycogen synthase kinase inhibitor" "GSK3B" "" "" "BRD-K78055238-001-01-8" "Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1" "HRJWTAWVFDCTGO-UHFFFAOYSA-N" "Phase 2"
"1674" "LY2109761" "TGF beta receptor inhibitor" "TGFBR1, TGFBR2" "" "" "BRD-K47557313-001-02-7" "C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c(nn2CCCc12)-c1ccccn1" "IHLVSLOZUHKNMQ-UHFFFAOYSA-N" "Preclinical"
"1675" "LY2140023" "glutamate receptor agonist" "GRM3" "" "" "BRD-K49519144-001-04-6, BRD-K49519144-001-03-8" "N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O" "AVDUGNCTZRCAHH-MDASVERJSA-N, AVDUGNCTZRCAHH-MDASVERJSA-N" "Phase 3"
"1676" "LY215490" "glutamate receptor antagonist" "GRIA1, GRIA2, GRIA3, GRIA4, GRIK1" "" "" "BRD-K34313798-001-01-6" "OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1" "ZXFRFPSZAKNPQQ-YTWAJWBKSA-N" "Phase 1"
"1677" "LY2157299" "TGF beta receptor inhibitor" "TGFBR1" "" "" "BRD-K78118466-001-03-3" "Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O" "IVRXNBXKWIJUQB-UHFFFAOYSA-N" "Phase 2/Phase 3"
"1678" "LY2183240" "FAAH inhibitor, FAAH reuptake inhibitor" "FAAH" "" "" "BRD-K37865504-001-04-1" "CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1" "GZNIYOXWFCDBBJ-UHFFFAOYSA-N" "Preclinical"
"1679" "LY2228820" "p38 MAPK inhibitor" "MAPK14" "" "" "BRD-K59227464-334-02-4, BRD-K59227464-334-03-2" "CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C, CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1[nH]c(nc1-c1ccc(F)cc1)C(C)(C)C" "XPPBBJCBDOEXDN-UHFFFAOYSA-N, XPPBBJCBDOEXDN-UHFFFAOYSA-N" "Phase 2"
"1680" "LY223982" "leukotriene receptor antagonist" "LTB4R" "" "" "BRD-K35367061-001-01-1" "COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1" "SYZSSLLFRVDRHL-QPJJXVBHSA-N" "Phase 2"
"1681" "LY225910" "CCK receptor antagonist" "CCKBR" "" "" "BRD-K33864865-001-02-5" "CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O" "KUECXUACQOYKNB-UHFFFAOYSA-N" "Preclinical"
"1682" "LY231617" "lipid peroxidase inhibitor" "" "" "" "BRD-K85804405-003-01-3" "CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C" "WQNYIWJBDGLKEB-UHFFFAOYSA-N" "Preclinical"
"1683" "LY2334737" "antitumor agent, ribonucleotide reductase inhibitor" "" "" "" "BRD-K04993719-001-01-7" "CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1" "MEOYFIHNRBNEPI-UXIGCNINSA-N" "Phase 1"
"1684" "LY2365109" "Glycine transporter 1 inhibitor" "SLC6A9" "" "" "BRD-K13888115-003-02-2" "CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O" "FKPLJWGRBCQLTL-UHFFFAOYSA-N" "Preclinical"
"1685" "LY2452473" "androgen receptor modulator" "AR" "" "" "BRD-K90171280-001-01-4" "CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C" "" ""
"1686" "LY255283" "leukotriene receptor antagonist" "LTB4R, LTB4R2" "" "" "BRD-K92492521-001-02-9" "CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1" "WCGXJPFHTHQNJL-UHFFFAOYSA-N" "Preclinical"
"1687" "LY2584702" "ribosomal protein inhibitor" "RPS6KB1" "" "" "BRD-K21833260-075-01-1, BRD-K21833260-075-02-9" "Cn1cc(nc1C1CCN(CC1)c1ncnc2[nH]ncc12)-c1ccc(F)c(c1)C(F)(F)F, Cn1cc(nc1C1CCN(CC1)c1ncnc2[nH]ncc12)-c1ccc(F)c(c1)C(F)(F)F" "FYXRSVDHGLUMHB-UHFFFAOYSA-N, FYXRSVDHGLUMHB-UHFFFAOYSA-N" "Phase 1"
"1688" "LY2603618" "CHK inhibitor" "CHEK1" "" "" "BRD-K14109347-001-05-9, BRD-K14109347-001-03-4" "Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1" "SYYBDNPGDKKJDU-ZDUSSCGKSA-N, SYYBDNPGDKKJDU-ZDUSSCGKSA-N" "Phase 2"
"1689" "LY2606368" "CHK inhibitor" "CHEK1" "" "" "BRD-K20463415-300-01-4, BRD-K20463415-001-01-8" "COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C" "" ""
"1690" "LY2608204" "glucokinase activator" "GCK" "" "" "BRD-K12068470-001-02-5, BRD-K69247090-001-01-9" "O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1, O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1" "QIIVJLHCZUTGSD-CUBQBAPOSA-N, QIIVJLHCZUTGSD-YWEHKCAJSA-N" "Phase 2"
"1691" "LY2784544" "JAK inhibitor" "JAK2, JAK3" "" "" "BRD-K25630527-001-03-8" "Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1" "SQSZANZGUXWJEA-UHFFFAOYSA-N" "Phase 2"
"1692" "LY2801653" "MET inhibitor" "MET" "" "" "BRD-K18961567-001-01-1" "Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1" "QHADVLVFMKEIIP-UHFFFAOYSA-N" "Phase 2"
"1693" "LY2811376" "beta-secretase inhibitor" "BACE1" "" "" "BRD-K94534639-001-02-5" "C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1" "MJQMRGWYPNIERM-HNNXBMFYSA-N" "Phase 1"
"1694" "LY2835219" "CDK inhibitor" "CDK4, CDK6" "" "" "BRD-K33622447-066-01-9" "CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1" "UZWDCWONPYILKI-UHFFFAOYSA-N" "Phase 3"
"1695" "LY2857785" "CDK inhibitor" "CDK9" "" "" "BRD-K15382985-001-01-7" "CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1" "LHIUZPIDLZYPRL-MXVIHJGJSA-N" "Preclinical"
"1696" "LY2874455" "FGFR antagonist" "FGFR1, FGFR2, FGFR3, FGFR4, KDR" "" "" "BRD-K17203476-001-01-9" "C[C@@H](Oc1ccc2[nH]nc(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl" "GKJCVYLDJWTWQU-CXLRFSCWSA-N" "Phase 1"
"1697" "LY288513" "CCK receptor antagonist" "CCKBR" "" "" "BRD-K24675965-001-04-1" "Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1" "LMUQHXHWJWQXSD-PMACEKPBSA-N" "Preclinical"
"1698" "LY2886721" "beta-secretase inhibitor" "BACE1" "" "" "BRD-K17953908-001-01-7" "NC1=N[C@]2(COC[C@@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F" "NIDRNVHMMDAAIK-MGNBDDOMSA-N" "Phase 1/Phase 2"
"1699" "LY294002" "mTOR inhibitor, PI3K inhibitor, DNA dependent protein kinase inhibitor, phosphodiesterase inhibitor, PLK inhibitor" "AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1" "" "" "BRD-K27305650-001-16-6, BRD-K27305650-003-02-2" "O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1, O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1" "CZQHHVNHHHRRDU-UHFFFAOYSA-N, CZQHHVNHHHRRDU-UHFFFAOYSA-N" "Preclinical"
"1700" "LY2979165" "glutamate receptor agonist" "GRM2" "" "" "BRD-K68220839-413-02-8, BRD-K68220839-413-01-0" "C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O, C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O" "BBGHHIUQOKQCBW-LDZWZCGGSA-N, BBGHHIUQOKQCBW-LDZWZCGGSA-N" "Phase 1"
"1701" "LY3000328" "cathepsin inhibitor" "CTSS" "" "" "BRD-K21070437-001-01-4" "CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1" "NDEBZCZEAVMSQF-GOTSBHOMSA-N" "Phase 1"
"1702" "LY3009120" "RAF inhibitor" "BRAF, RAF1" "" "" "BRD-K38385169-001-04-5, BRD-K38385169-001-03-7" "CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C, CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C" "HHCBMISMPSAZBF-UHFFFAOYSA-N, HHCBMISMPSAZBF-UHFFFAOYSA-N" "Phase 1"
"1703" "LY3023414" "PI3K inhibitor, mTOR inhibitor" "MTOR" "" "" "BRD-K82967180-001-01-6" "CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O" "ACCFLVVUVBJNGT-AWEZNQCLSA-N" "Phase 2"
"1704" "LY303511" "casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor" "BRD2, BRD3, BRD4" "" "" "BRD-K22385716-001-02-5" "O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1" "NGAGMBNBKCDCDJ-UHFFFAOYSA-N" "Preclinical"
"1705" "LY310762" "serotonin receptor antagonist" "HTR1D" "" "" "BRD-K41194171-003-09-7" "CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12" "KDXISMANFPJVJY-UHFFFAOYSA-N" "Preclinical"
"1706" "LY320135" "cannabinoid receptor antagonist" "CNR1" "" "" "BRD-K78637815-001-02-2" "COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C" "" ""
"1707" "LY344864" "serotonin receptor agonist" "HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7" "" "" "BRD-K95899059-003-02-8" "CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1" "GKWHICIUSVVNGX-MRXNPFEDSA-N" "Preclinical"
"1708" "LY364947" "TGF beta receptor inhibitor, p38 MAPK inhibitor" "TGFBR1" "" "" "BRD-K06234293-001-04-2, BRD-K06234293-001-03-4" "c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1, c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1" "IBCXZJCWDGCXQT-UHFFFAOYSA-N, IBCXZJCWDGCXQT-UHFFFAOYSA-N" "Preclinical"
"1709" "LY393558" "serotonin receptor antagonist" "HTR1B, HTR1D, HTR2A, HTR2B" "" "" "BRD-K08534264-001-01-4" "CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O" "QUSLYAPLTMMCFE-UHFFFAOYSA-N" "Preclinical"
"1710" "LY411575" "gamma secretase inhibitor" "" "" "" "BRD-K20013301-001-02-6" "C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O" "ULSSJYNJIZWPSB-CVRXJBIPSA-N" "Preclinical"
"1711" "LY450108" "glutamate receptor modulator" "" "" "" "BRD-K54538117-001-01-7" "C[C@@H](CNS(=O)(=O)C(C)C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1" "ACOXQYLJOQAHST-ZDUSSCGKSA-N" "Phase 1"
"1712" "LY456236" "glutamate receptor antagonist" "GRM1" "" "" "BRD-K87696786-003-04-4" "COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1" "XPJOMFBGKIABQW-UHFFFAOYSA-N" "Preclinical"
"1713" "m-Chlorophenylbiguanide" "" "HTR3A, HTR3B" "" "" "BRD-K36965586-003-08-8" "NC(=N)NC(=N)Nc1cccc(Cl)c1" "DIHXJZHAIHGSAW-UHFFFAOYSA-N" "Preclinical"
"1714" "m-THP" "" "" "" "" "BRD-K91147684-001-01-5" "Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2" "ZUELZXZJXUXJCH-UHFFFAOYSA-N" "Phase 1"
"1715" "M-14157" "ATP-sensitive potassium channel antagonist" "KCNQ1" "" "" "BRD-A96977263-001-03-7" "CCCCCC(O)CCCC(O)=O" "LMHJFKYQYDSOQO-UHFFFAOYSA-N" "Phase 2"
"1716" "m-3M3FBS" "" "PLCB2, PLCB3, PLCD1, PLCG1, PLCG2" "" "" "BRD-K09635314-001-03-4" "Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F" "ZIIUUSVHCHPIQD-UHFFFAOYSA-N" "Preclinical"
"1717" "M-344" "HDAC inhibitor" "" "" "" "BRD-K45528773-001-07-2, BRD-K45528773-001-06-4" "CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO, CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO" "MXWDSZWTBOCWBK-UHFFFAOYSA-N, MXWDSZWTBOCWBK-UHFFFAOYSA-N" "Preclinical"
"1718" "mabuprofen" "cyclooxygenase inhibitor" "" "neurology/psychiatry" "pain relief" "BRD-A93683007-001-01-9" "CC(C)Cc1ccc(cc1)C(C)C(=O)NCCO" "JVGUNCHERKJFCM-UHFFFAOYSA-N" "Launched"
"1719" "mabuterol" "adrenergic receptor agonist" "ADRB2" "" "" "BRD-A13116749-003-01-6" "CC(C)(C)NCC(O)c1cc(Cl)c(N)c(c1)C(F)(F)F" "JSJCTEKTBOKRST-UHFFFAOYSA-N" "Launched"
"1720" "macelignan" "antioxidant, antiinflammatory agent" "" "" "" "BRD-K94948151-001-07-4" "COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O" "QDDILOVMGWUNGD-UONOGXRCSA-N" "Preclinical"
"1721" "macitentan" "endothelin receptor antagonist" "EDNRA, EDNRB" "endocrinology" "contraceptive" "BRD-K48812570-001-03-1, BRD-K48812570-001-02-3" "CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1, CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1" "JGCMEBMXRHSZKX-UHFFFAOYSA-N, JGCMEBMXRHSZKX-UHFFFAOYSA-N" "Launched"
"1722" "madrasin" "cell splicing inhibitor" "" "" "" "BRD-K48905682-001-11-1" "COc1ccc2c(C)nc(Nc3nc(C)c(C)c(O)n3)nc2c1" "QQJIYKXTEMDJFM-UHFFFAOYSA-N" "Preclinical"
"1723" "mafenide" "carbonic anhydrase inhibitor" "CA12, CA14, CA2, CA4, CA6, CA9" "infectious disease" "first-aid antibiotic, skin infections" "BRD-K30649484-003-13-7" "NCc1ccc(cc1)S(N)(=O)=O" "TYMRLRRVMHJFTF-UHFFFAOYSA-N" "Launched"
"1724" "magnolol" "PPAR receptor agonist" "GABRA1, PPARG" "" "" "BRD-K26168087-001-09-7" "Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O" "VVOAZFWZEDHOOU-UHFFFAOYSA-N" "Preclinical"
"1725" "malathion" "cholinesterase inhibitor" "ACHE, BCHE" "infectious disease" "lice" "BRD-A01976766-001-06-8, BRD-A01976766-001-04-3" "CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC, CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC" "JXSJBGJIGXNWCI-UHFFFAOYSA-N, JXSJBGJIGXNWCI-UHFFFAOYSA-N" "Launched"
"1726" "malic-acid" "" "CS, ME2, PKD2L1" "" "" "BRD-A18396475-001-15-3" "OC(CC(O)=O)C(O)=O" "BJEPYKJPYRNKOW-UHFFFAOYSA-N" "Launched"
"1727" "malotilate" "protein synthesis stimulant" "" "gastroenterology" "hepatic cirrhosis" "BRD-K97884852-001-05-4" "CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1" "YPIQVCUJEKAZCP-UHFFFAOYSA-N" "Launched"
"1728" "maltobionic-acid" "matrix metalloprotease inhibitor" "" "dermatology" "cosmetic" "BRD-K01624185-001-05-7" "OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O" "JYTUSYBCFIZPBE-AMTLMPIISA-N" "Launched"
"1729" "mandelic-acid" "" "" "" "" "BRD-A91448670-001-06-4" "OC(C(O)=O)c1ccccc1" "IWYDHOAUDWTVEP-UHFFFAOYSA-N" "Launched"
"1730" "mangafodipir" "contrast agent" "" "radiology" "contrast agent" "BRD-K57365211-314-01-4, BRD-A81339141-314-01-6" "Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12, Cc1ncc(COP(O)(O)=O)c2C[N+]34CC[N+]56CC(=O)O[Mn]35(OC(=O)C4)(Oc12)Oc1c(C)ncc(COP(O)(O)=O)c1C6" "CXFKOLCMCRBYPL-UHFFFAOYSA-L, NJHZOXLWSHPJPK-UHFFFAOYSA-J" "Launched"
"1731" "manidipine" "calcium channel blocker" "CACNA1C, CACNA1D" "cardiology" "hypertension" "BRD-A90695733-001-08-2, BRD-A90695733-001-07-4, BRD-A90695733-300-02-1, BRD-A90695733-001-06-6" "COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1" "ANEBWFXPVPTEET-UHFFFAOYSA-N, ANEBWFXPVPTEET-UHFFFAOYSA-N, ANEBWFXPVPTEET-UHFFFAOYSA-N, ANEBWFXPVPTEET-UHFFFAOYSA-N" "Launched"
"1732" "mannitol-D" "diuretic" "" "neurology/psychiatry, ophthalmology, gastroenterology" "intracranial pressure, intraocular pressure, constipation" "BRD-K66035042-001-11-9, BRD-K30374899-001-09-3" "OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO" "FBPFZTCFMRRESA-JGWLITMVSA-N, FBPFZTCFMRRESA-KVTDHHQDSA-N" "Launched"
"1733" "maprotiline" "norepinephrine reputake inhibitor, tricyclic antidepressant" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2C, HTR7, SLC6A2" "neurology/psychiatry" "depression, dysthymic disorder" "BRD-K25433859-003-25-4, BRD-K25433859-003-23-9, BRD-K25433859-003-24-7" "CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21, CNCCCC12CCC(c3ccccc13)c1ccccc21" "QSLMDECMDJKHMQ-UHFFFAOYSA-N, QSLMDECMDJKHMQ-UHFFFAOYSA-N, QSLMDECMDJKHMQ-UHFFFAOYSA-N" "Launched"
"1734" "maraviroc" "CC chemokine receptor antagonist" "CCR5" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-A04352665-001-05-3" "CC(C)c1nnc(C)n1C1CC2CCC(C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1" "GSNHKUDZZFZSJB-ILVMPNSOSA-N" "Launched"
"1735" "marbofloxacin" "bacterial DNA gyrase inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K71926323-001-14-6, BRD-K71926323-001-13-8, BRD-K71926323-001-12-0" "CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O, CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O" "BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N, BPFYOAJNDMUVBL-UHFFFAOYSA-N" "Launched"
"1736" "maribavir" "cytomegalovirus inhibitor, protein kinase inhibitor" "PYGM" "" "" "BRD-K59524082-001-01-3" "CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O" "KJFBVJALEQWJBS-XUXIUFHCSA-N" "Phase 3"
"1737" "marimastat" "matrix metalloprotease inhibitor" "MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9" "" "" "BRD-K21396683-001-04-8" "CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C" "OCSMOTCMPXTDND-OUAUKWLOSA-N" "Phase 3"
"1738" "maropitant" "neurokinin receptor antagonist" "TACR1" "gastroenterology" "vomiting" "BRD-K76594255-001-01-6" "COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C" "OMPCVMLFFSQFIX-CONSDPRKSA-N" "Launched"
"1739" "masitinib" "KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor" "FGFR3, KIT, PDGFRA, PDGFRB" "dermatology" "mastocytoma" "BRD-K71035033-001-08-9, BRD-K71035033-001-07-1" "CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1" "WJEOLQLKVOPQFV-UHFFFAOYSA-N, WJEOLQLKVOPQFV-UHFFFAOYSA-N" "Launched"
"1740" "masoprocol" "lipoxygenase inhibitor" "ALOX5" "dermatology" "actinic keratosis (AK)" "BRD-A87130939-001-07-9" "CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1" "HCZKYJDFEPMADG-UHFFFAOYSA-N" "Launched"
"1741" "matrine" "opioid receptor agonist" "OPRK1" "" "" "BRD-K25312248-001-01-5" "O=C1CCC[C@@H]2[C@@H]3CCCN4CCC[C@H](CN12)[C@@H]34" "ZSBXGIUJOOQZMP-COMQUAJESA-N" "Phase 2"
"1742" "mavoglurant" "glutamate receptor antagonist" "GRM5" "" "" "BRD-K07790550-001-01-6" "COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C" "" ""
"1743" "maxacalcitol" "vitamin D receptor agonist" "VDR" "endocrinology" "hyperparathyroidism" "BRD-K81332461-001-01-4" "[2H]C([2H])([2H])C(O)(CCO[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C)C([2H])([2H])[2H]" "DTXXSJZBSTYZKE-OXMAATCFSA-N" "Launched"
"1744" "maytansinol-isobutyrate" "" "" "" "" "BRD-K15898725-001-01-7" "CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2" "OPQNCARIZFLNLF-JBHFWYGFSA-N" "Preclinical"
"1745" "mazindol" "dopamine reuptake inhibitor, selective serotonin reuptake inhibitor (SSRI)" "SLC6A2, SLC6A3, SLC6A4" "genetics" "duchenne muscular dystrophy (DMD)" "BRD-A68464583-001-02-5" "OC1(N2CCN=C2c2ccccc12)c1ccc(Cl)cc1" "ZPXSCAKFGYXMGA-UHFFFAOYSA-N" "Launched"
"1746" "MBX-2982" "glucose dependent insulinotropic receptor agonist" "GPR119" "" "" "BRD-K32218650-001-01-6" "CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1" "NFTMKHWBOINJGM-UHFFFAOYSA-N" "Phase 2"
"1747" "MC-1" "" "AADAT, ABAT, AGXT, AGXT2, ALAS1, AZIN2, BCAT1, BCAT2, CBS, CCBL1, CCBL2, CSAD, CTH, DDC, FTCD, GAD1, GAD2, GADL1, GCAT, GLDC, GOT1, GOT2, GPT, GPT2, HDC, IGSF10, KYNU, MOCOS, NFS1, OAT, ODC1, PDXDC1, PDXP, PHYKPL, PNPO, PROSC, PSAT1, PYGB, PYGL, PYGM, SCLY, SDS, SDSL, SEPSECS, SGPL1, SHMT1, SHMT2, SPTLC1, SPTLC2, SPTLC3, SRR, TAT, THNSL1" "" "" "BRD-K50712474-001-02-7, BRD-K50712474-002-02-5" "Cc1ncc(COP(O)(O)=O)c(C=O)c1O, Cc1ncc(COP(O)(O)=O)c(C=O)c1O" "NGVDGCNFYWLIFO-UHFFFAOYSA-N, NGVDGCNFYWLIFO-UHFFFAOYSA-N" "Phase 3"
"1748" "MCC950" "NOD like receptor inhibitor" "NLRP3" "" "" "BRD-K55418700-001-02-2" "CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12" "HUUSXLKCTQDPGL-UHFFFAOYSA-N" "Preclinical"
"1749" "McN-5652-(+/-)" "selective serotonin reuptake inhibitor (SSRI)" "" "" "" "BRD-K31168993-001-02-8" "CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12" "YVKDUIAAPBKHMJ-MOPGFXCFSA-N" "Preclinical"
"1750" "mCPP" "serotonin receptor agonist" "HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6" "" "" "BRD-K75844781-003-08-0" "Clc1cccc(c1)N1CCNCC1" "VHFVKMTVMIZMIK-UHFFFAOYSA-N" "Phase 2"
"1751" "MC1568" "HDAC inhibitor" "HDAC2" "" "" "BRD-K24031866-001-03-9, BRD-K24031866-001-02-1, BRD-K24031866-001-01-3" "Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1, Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1" "QQDIFLSJMFDTCQ-FIFLTTCUSA-N, QQDIFLSJMFDTCQ-FIFLTTCUSA-N, QQDIFLSJMFDTCQ-FIFLTTCUSA-N" "Preclinical"
"1752" "MD-920" "NFkB pathway inhibitor" "AADACL2" "" "" "BRD-K92758126-001-18-8" "C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O" "IXORZMNAPKEEDV-OBDJNFEBSA-N" "Phase 1"
"1753" "mdivi-1" "dynamin inhibitor" "DNM1" "" "" "BRD-K61128465-001-10-7, BRD-K61128465-001-09-9" "COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O, COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O" "NZJKEVWTYMOYOR-UHFFFAOYSA-N, NZJKEVWTYMOYOR-UHFFFAOYSA-N" "Preclinical"
"1754" "MDL-11939" "serotonin receptor antagonist" "HTR2A, HTR2B, HTR2C" "" "" "BRD-A62057054-001-03-1" "OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1" "AXNGJCOYCMDPQG-UHFFFAOYSA-N" "Phase 2"
"1755" "MDL-27531" "glycine receptor agonist" "" "" "" "BRD-K50888640-001-01-6" "Cn1c(nnc1S(C)(=O)=O)-c1ccccc1" "DPGDRICHXKQXEN-UHFFFAOYSA-N" "Preclinical"
"1756" "MDL-29951" "glutamate receptor antagonist" "FBP1" "" "" "BRD-K59753853-001-02-3" "OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O" "KNBSYZNKEAWABY-UHFFFAOYSA-N" "Preclinical"
"1757" "MDL-72832" "serotonin receptor agonist" "HTR1A" "" "" "BRD-A17453586-003-02-3" "O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1" "HCVRCHQFYYZPHT-UHFFFAOYSA-N" "Preclinical"
"1758" "MDL-73005EF" "serotonin receptor antagonist" "HTR1A" "" "" "BRD-A50764878-003-02-8" "O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1" "BVMYCHKQPGEOSI-UHFFFAOYSA-N" "Phase 1"
"1759" "MDMS" "DNA inhibitor" "" "" "" "BRD-K70840370-001-01-9" "CS(=O)(=O)OCOS(C)(=O)=O" "IQLZWWDXNXZGPK-UHFFFAOYSA-N" "Phase 2"
"1760" "mebendazole" "tubulin polymerization inhibitor" "TUBA1A, TUBB, TUBB4B" "infectious disease" "pinworm, whipworm, hookworm, ascariasis" "BRD-K77987382-001-13-2" "COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1" "OPXLLQIJSORQAM-UHFFFAOYSA-N" "Launched"
"1761" "mebeverine" "acetylcholine receptor antagonist" "CHRM1" "gastroenterology" "irritable bowel syndrome" "BRD-A09467419-003-22-4" "CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1" "VYVKHNNGDFVQGA-UHFFFAOYSA-N" "Launched"
"1762" "mebhydrolin" "antihistamine" "" "allergy" "allergic rhinitis, urticaria" "BRD-K29713308-001-01-7" "CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1" "FQQIIPAOSKSOJM-UHFFFAOYSA-N" "Launched"
"1763" "mebicar" "anxiolytic" "" "neurology/psychiatry" "anxiety" "BRD-K76606751-001-01-7" "CN1C2C(N(C)C1=O)N(C)C(=O)N2C" "XIUUSFJTJXFNGH-UHFFFAOYSA-N" "Launched"
"1764" "mebrofenin" "" "" "radiology" "diagnostic agent" "BRD-K96691275-001-01-2" "Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br" "MHPZZZZLAQGTHT-UHFFFAOYSA-N" "Launched"
"1765" "mecamylamine" "acetylcholine receptor antagonist" "CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7" "cardiology" "hypertension" "BRD-A20119038-003-07-8" "CNC1(C)C2CCC(C2)C1(C)C" "IMYZQPCYWPFTAG-UHFFFAOYSA-N" "Launched"
"1766" "mecarbinate" "" "" "" "" "BRD-K28405228-001-06-7" "CCOC(=O)c1c(C)n(C)c2ccc(O)cc12" "YTBNTDMBGXAOCG-UHFFFAOYSA-N" "Preclinical"
"1767" "mechlorethamine" "DNA inhibitor" "" "hematologic malignancy, hematology, infectious disease, oncology" "Hodgkins lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma	BRD-K12829205-001-04-8, BRD-K12829205-003-04-4, BRD-K12829205-003-03-6, BRD-K12829205-003-02-8	CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl, CN(CCCl)CCCl	HAWPXGHAZFHHAD-UHFFFAOYSA-N, HAWPXGHAZFHHAD-UHFFFAOYSA-N, HAWPXGHAZFHHAD-UHFFFAOYSA-N, HAWPXGHAZFHHAD-UHFFFAOYSA-N	Launched
meclinertant	neurotensin receptor antagonist	NTSR1, NTSR2			BRD-K25075681-001-02-0	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O	DYLJVOXRWLXDIG-UHFFFAOYSA-N	Phase 2/Phase 3
meclizine	constitutive androstane receptor (CAR) agonist	HRH1, NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	BRD-A50311610-300-10-4, BRD-A50311610-300-09-6	Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1, Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1	OCJYIGYOJCODJL-UHFFFAOYSA-N, OCJYIGYOJCODJL-UHFFFAOYSA-N	Launched
meclocycline-sulfosalicylate	bacterial 50S ribosomal subunit inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	BRD-A07600638-060-06-0, BRD-A07600638-060-05-2, BRD-A07600638-060-04-5	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O	YKYBWGJKLYMCFI-KCDYASHQSA-N, YKYBWGJKLYMCFI-KCDYASHQSA-N, YKYBWGJKLYMCFI-KCDYASHQSA-N	Launched
meclofenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2	rheumatology, neurology/psychiatry, endocrinology	joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)	BRD-K50398167-236-22-7	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	SBDNJUWAMKYJOX-UHFFFAOYSA-N	Launched
meclofenoxate	nootropic agent		neurology/psychiatry	senile dementia, Alzheimers disease" "BRD-K10314788-003-12-7" "CN(C)CCOC(=O)COc1ccc(Cl)cc1" "XZTYGFHCIAKPGJ-UHFFFAOYSA-N" "Launched"
"1768" "mecysteine" "analgesic agent" "" "pulmonary" "chest congestion" "BRD-A77473570-003-04-2" "COC(=O)C(N)CS" "MCYHPZGUONZRGO-UHFFFAOYSA-N" "Launched"
"1769" "medetomidine" "adrenergic receptor agonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C" "neurology/psychiatry" "sedative" "BRD-A21607826-003-05-1, BRD-K18423410-003-02-5, BRD-K18423410-001-02-9, BRD-A21607826-003-04-4, BRD-A21607826-003-06-9" "CC(c1c[nH]cn1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, C[C@H](c1cnc[nH]1)c1cccc(C)c1C, CC(c1c[nH]cn1)c1cccc(C)c1C, CC(c1c[nH]cn1)c1cccc(C)c1C" "CUHVIMMYOGQXCV-UHFFFAOYSA-N, CUHVIMMYOGQXCV-NSHDSACASA-N, CUHVIMMYOGQXCV-NSHDSACASA-N, CUHVIMMYOGQXCV-UHFFFAOYSA-N, CUHVIMMYOGQXCV-UHFFFAOYSA-N" "Launched"
"1770" "medica-16" "ATP citrase lyase inhibitor" "FFAR1" "" "" "BRD-K92908289-001-01-8" "CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O" "HYSMCRNFENOHJH-UHFFFAOYSA-N" "Phase 2"
"1771" "medorinone" "" "" "" "" "BRD-K40715924-001-01-1" "Cc1nccc2[nH]c(=O)ccc12" "OCCZJXAHSUCJSA-UHFFFAOYSA-N" "Phase 1"
"1772" "medronic-acid" "bone resorption inhibitor" "" "radiology" "skeletal imaging agent" "BRD-K94072573-001-09-9" "OP(O)(=O)CP(O)(O)=O" "MBKDYNNUVRNNRF-UHFFFAOYSA-N" "Launched"
"1773" "medroxyprogesterone" "progesterone receptor agonist" "ESR1, PGR" "endocrinology" "contraceptive" "BRD-K99615199-001-18-5" "C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12" "FRQMUZJSZHZSGN-HBNHAYAOSA-N" "Launched"
"1774" "medroxyprogesterone-acetate" "progesterone receptor agonist" "" "endocrinology" "contraceptive" "BRD-A61221616-001-04-3, BRD-K44848460-001-01-6" "C[C@H]1CC2C3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CCC2[C@@]2(C)CCC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@H]2[C@@]2(C)CCC(=O)C=C12" "PSGAAPLEWMOORI-GDXVCIIOSA-N, PSGAAPLEWMOORI-BJRKDMOKSA-N" "Launched"
"1775" "medrysone" "glucocorticoid receptor agonist" "NR3C1" "ophthalmology" "conjunctivitis, episcleritis" "BRD-A20126139-001-04-2, BRD-A59014912-001-01-3" "C[C@H]1CC2C3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)CCC(=O)C=C12, C[C@H]1CC2C3CCC(C(C)=O)C3(C)CC(O)C2C2(C)CCC(=O)C=C12" "GZENKSODFLBBHQ-IENIWFQZSA-N, GZENKSODFLBBHQ-CHMAHDFQSA-N" "Launched"
"1776" "mefenamic-acid" "cyclooxygenase inhibitor" "KCNQ1, PTGS1, PTGS2, TRPM3" "endocrinology" "primary dysmenorrhea (PD)" "BRD-K92778217-001-32-7, BRD-K92778217-001-31-9" "Cc1cccc(Nc2ccccc2C(O)=O)c1C, Cc1cccc(Nc2ccccc2C(O)=O)c1C" "HYYBABOKPJLUIN-UHFFFAOYSA-N, HYYBABOKPJLUIN-UHFFFAOYSA-N" "Launched"
"1777" "mefexamide" "psychoactive drug" "" "" "" "BRD-K20655524-003-12-0" "CCN(CC)CCNC(=O)COc1ccc(OC)cc1" "HUNIPYLVUPMFCZ-UHFFFAOYSA-N" "Preclinical"
"1778" "mefloquine" "adenosine receptor antagonist, hemoglobin antagonist" "ADORA2A, HBA1" "infectious disease" "malaria" "BRD-A89585551-003-16-6" "OC(C1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F" "XEEQGYMUWCZPDN-UHFFFAOYSA-N" "Launched"
"1779" "megestrol-acetate" "progesterone receptor agonist" "NR3C1, PGR" "neurology/psychiatry, endocrinology" "anorexia, cachexia" "BRD-K19507340-001-22-1, BRD-A35989968-001-04-2, BRD-K29344105-001-01-6" "CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O, CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC12C)C(C)=O, CC(=O)O[C@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)=O" "RQZAXGRLVPAYTJ-GQFGMJRRSA-N, RQZAXGRLVPAYTJ-VSUSFZLSSA-N, RQZAXGRLVPAYTJ-RYOCMHIPSA-N" "Launched"
"1780" "meglitinide" "potassium channel blocker" "CCR2" "" "" "BRD-K51324732-001-01-0" "COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O" "SWLAMJPTOQZTAE-UHFFFAOYSA-N" "Phase 2"
"1781" "meglumine" "excipient" "" "" "" "BRD-K28595280-001-04-5, BRD-K28595280-001-05-2, BRD-K28595280-001-03-7" "CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO" "MBBZMMPHUWSWHV-BDVNFPICSA-N, MBBZMMPHUWSWHV-BDVNFPICSA-N, MBBZMMPHUWSWHV-BDVNFPICSA-N" "Launched"
"1782" "meglutol" "HMGCR inhibitor" "HMGCR" "" "" "BRD-K00495673-001-05-2" "CC(O)(CC(O)=O)CC(O)=O" "NPOAOTPXWNWTSH-UHFFFAOYSA-N" "Launched"
"1783" "meisoindigo" "STAT inhibitor" "STAT3" "" "" "BRD-K14529030-001-01-9" "CN1C(=O)\C(c2ccccc12)=C1\C(=O)Nc2ccccc12" "QNOCRUSVMMAKSC-CCEZHUSRSA-N" "Phase 3"
"1784" "MEK1-2-inhibitor" "MEK inhibitor" "MAP2K2" "" "" "BRD-K12244279-001-05-8, BRD-K12244279-001-04-1" "N\C(Sc1ccc(N)cc1)=C(\C" "" ""
"1785" "MEK162" "MEK inhibitor" "MAP2K1, MAP2K2" "" "" "BRD-K82244583-001-01-3" "Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO" "ACWZRVQXLIRSDF-UHFFFAOYSA-N" "Phase 3"
"1786" "melatonin" "melatonin receptor agonist, nitric oxide synthase inhibitor" "ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB" "neurology/psychiatry" "sleep cycle support" "BRD-K97530723-001-20-9, BRD-K97530723-001-19-1" "COc1ccc2[nH]cc(CCNC(C)=O)c2c1, COc1ccc2[nH]cc(CCNC(C)=O)c2c1" "DRLFMBDRBRZALE-UHFFFAOYSA-N, DRLFMBDRBRZALE-UHFFFAOYSA-N" "Launched"
"1787" "meldonium" "gamma butyrobetaine hydroxylase inhibitor" "BBOX1" "cardiology" "coronary artery disease (CAD)" "BRD-K79392608-335-01-8" "C[N+](C)(C)NCCC(O)=O" "PVBQYTCFVWZSJK-UHFFFAOYSA-O" "Launched"
"1788" "melengestrol-acetate" "progesterone receptor agonist" "" "" "" "BRD-A42746051-001-02-9" "CC(=O)O[C@]1(C(C)=O)C(=C)CC2C3C=C(C)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C" "UDKABVSQKJNZBH-PQQMIVRBSA-N" "Preclinical"
"1789" "melevodopa" "dopamine precursor, dopamine receptor agonist" "DDC" "neurology/psychiatry" "Parkinsons Disease	BRD-K18749874-003-08-9, BRD-A25827085-001-01-0	COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1, COC(=O)C(N)Cc1ccc(O)c(O)c1	XBBDACCLCFWBSI-ZETCQYMHSA-N, XBBDACCLCFWBSI-UHFFFAOYSA-N	Launched
meloxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	BRD-A84174393-236-07-1, BRD-A84174393-323-07-7, BRD-A84174393-001-34-3	CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O	ZAHQBPYQBHTECE-UHFFFAOYSA-N, ZAHQBPYQBHTECE-UHFFFAOYSA-N, ZAHQBPYQBHTECE-UHFFFAOYSA-N	Launched
melperone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	psychosis	BRD-K92984783-003-05-7	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	DKMFBWQBDIGMHM-UHFFFAOYSA-N	Launched
melphalan	DNA alkylating agent, DNA inhibitor		hematologic malignancy	multiple myeloma	BRD-K87827419-001-16-8, BRD-K87827419-001-14-3	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O, N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	SGDBTWWWUNNDEQ-LBPRGKRZSA-N, SGDBTWWWUNNDEQ-LBPRGKRZSA-N	Launched
melphalan-n-oxide	hypoxia inducible factor inhibitor	HIF1A			BRD-K36394566-300-01-0	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	GSKQMLGAUOTSKT-LBPRGKRZSA-N	Phase 1
meluadrine					BRD-A07164067-001-01-2	CC(C)(C)NCC(O)c1ccc(O)cc1Cl	LIXBJWRFCNRAPA-UHFFFAOYSA-N	Preclinical
memantine	glutamate receptor antagonist	CHRFAM7A, DRD2, GRIN1, GRIN2A, GRIN2B, GRIN3A, HTR3A	neurology/psychiatry	Alzheimers disease, senile dementia" "BRD-A79803969-003-18-7, BRD-A79803969-003-16-1, BRD-A79803969-003-17-9" "CC12CC3CC(C)(C1)CC(N)(C3)C2, CC12CC3CC(C)(C1)CC(N)(C3)C2, CC12CC3CC(C)(C1)CC(N)(C3)C2" "BUGYDGFZZOZRHP-UHFFFAOYSA-N, BUGYDGFZZOZRHP-UHFFFAOYSA-N, BUGYDGFZZOZRHP-UHFFFAOYSA-N" "Launched"
"1790" "menadione" "mitochondrial DNA polymerase inhibitor, phosphatase inhibitor" "AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1" "gastroenterology, neurology/psychiatry, dermatology, rheumatology" "ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis" "BRD-K78126613-001-28-5, BRD-K78126613-001-29-3, BRD-K78126613-001-27-7" "CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O, CC1=CC(=O)c2ccccc2C1=O" "MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N, MJVAVZPDRWSRRC-UHFFFAOYSA-N" "Launched"
"1791" "menadione-bisulfite" "vitamin K" "GGCX, VKORC1, VKORC1L1" "" "" "BRD-A19777893-236-01-9" "CC1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O" "WIXFIQKTHUVFDI-UHFFFAOYSA-N" "Phase 2"
"1792" "menatetrenone" "bone resorption inhibitor" "" "orthopedics" "osteoporosis" "BRD-K75864342-001-14-2" "CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O" "DKHGMERMDICWDU-GHDNBGIDSA-N" "Launched"
"1793" "menbutone" "" "" "gastroenterology" "bile stimulation" "BRD-K53852914-001-01-8" "COc1ccc(C(=O)CCC(O)=O)c2ccccc12" "FHGJSJFIQNQBCK-UHFFFAOYSA-N" "Launched"
"1794" "mepacrine" "cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator" "PLA2G1B, PLA2G4A, PLA2G6, PLCL1" "infectious disease" "giardiasis" "BRD-A45889380-300-07-1, BRD-A45889380-300-08-9, BRD-A45889380-300-06-3" "CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12, CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12, CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12" "GPKJTRJOBQGKQK-UHFFFAOYSA-N, GPKJTRJOBQGKQK-UHFFFAOYSA-N, GPKJTRJOBQGKQK-UHFFFAOYSA-N" "Launched"
"1795" "meparfylon" "" "" "" "" "BRD-A11662333-001-03-3" "CCC(C)(O)C" "" ""
"1796" "mepazine" "MALT1 inhibitor (JH)" "MALT1" "" "" "BRD-A82772293-001-03-2" "CN1CCCC(CN2c3ccccc3Sc3ccccc23)C1" "CBHCDHNUZWWAPP-UHFFFAOYSA-N" "Phase 2"
"1797" "mepenzolate" "acetylcholine receptor antagonist" "CHRM1, CHRM3" "gastroenterology" "peptic ulcer disease (PUD)" "BRD-A62421304-004-18-9, BRD-A62421304-004-17-1" "C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1, C[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1" "GKNPSSNBBWDAGH-UHFFFAOYSA-N, GKNPSSNBBWDAGH-UHFFFAOYSA-N" "Launched"
"1798" "mephenesin" "muscle relaxant" "" "neurology/psychiatry" "muscle relaxant" "BRD-A55469827-001-07-4" "Cc1ccccc1OCC(O)CO" "JWDYCNIAQWPBHD-UHFFFAOYSA-N" "Launched"
"1799" "mephentermine" "adrenergic receptor agonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3" "cardiology" "hypotension" "BRD-K18194590-065-08-0" "CNC(C)(C)Cc1ccccc1" "RXQCGGRTAILOIN-UHFFFAOYSA-N" "Launched"
"1800" "mephenytoin" "hydantoin antiepileptic" "SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "seizures" "BRD-A83937277-001-10-5" "CCC1(NC(=O)N(C)C1=O)c1ccccc1" "GMHKMTDVRCWUDX-UHFFFAOYSA-N" "Launched"
"1801" "mepiroxol" "" "" "" "" "BRD-K78299798-001-02-2, BRD-K78299798-001-03-0" "OCc1ccc[n+]([O-])c1, OCc1ccc[n+]([O-])c1" "LQYJAVWWKTWWKN-UHFFFAOYSA-N, LQYJAVWWKTWWKN-UHFFFAOYSA-N" "Preclinical"
"1802" "mepivacaine" "potassium channel blocker, sodium channel blocker" "SCN10A" "neurology/psychiatry" "local anesthetic" "BRD-A03216249-003-24-3, BRD-A03216249-003-23-5" "CN1CCCCC1C(=O)Nc1c(C)cccc1C, CN1CCCCC1C(=O)Nc1c(C)cccc1C" "INWLQCZOYSRPNW-UHFFFAOYSA-N, INWLQCZOYSRPNW-UHFFFAOYSA-N" "Launched"
"1803" "meprednisone" "" "NR3C1" "" "" "BRD-K79233274-001-01-5, BRD-K18207669-001-02-4" "C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3C(=O)C[C@]2(C)[C@]1(O)C(=O)CO, C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO" "PIDANAQULIKBQS-KRPOLQELSA-N, PIDANAQULIKBQS-RNUIGHNZSA-N" "Launched"
"1804" "meprobamate" "" "GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ" "neurology/psychiatry" "anxiety" "BRD-K19180152-001-02-6" "CCCC(C)(COC(N)=O)COC(N)=O" "NPPQSCRMBWNHMW-UHFFFAOYSA-N" "Launched"
"1805" "meprylcaine" "local anesthetic" "" "" "" "BRD-K65417056-003-10-1" "CCCNC(C)(C)COC(=O)c1ccccc1" "VXJABHHJLXLNMP-UHFFFAOYSA-N" "Preclinical"
"1806" "meptazinol" "opioid receptor agonist" "BCHE" "neurology/psychiatry" "pain relief" "BRD-A02710418-003-12-6, BRD-A02710418-003-11-8" "CCC1(CCCCN(C)C1)c1cccc(O)c1, CCC1(CCCCN(C)C1)c1cccc(O)c1" "JLICHNCFTLFZJN-UHFFFAOYSA-N, JLICHNCFTLFZJN-UHFFFAOYSA-N" "Launched"
"1807" "mepyramine" "histamine receptor antagonist" "HRH1" "otolaryngology, obstetrics/gynecology" "common cold, menstrual pain" "BRD-K97564742-050-32-7, BRD-K97564742-050-31-9, BRD-K97564742-051-02-8" "COc1ccc(cc1)CN(CCN(C)C)c1ccccn1, COc1ccc(cc1)CN(CCN(C)C)c1ccccn1, COc1ccc(cc1)CN(CCN(C)C)c1ccccn1" "YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N, YECBIJXISLIIDS-UHFFFAOYSA-N" "Launched"
"1808" "mequinol" "" "TYR" "dermatology" "skin depigmentation" "BRD-K45216060-001-11-8, BRD-K45216060-001-10-0, BRD-K45216060-001-09-2" "COc1ccc(O)cc1, COc1ccc(O)cc1, COc1ccc(O)cc1" "NWVVVBRKAWDGAB-UHFFFAOYSA-N, NWVVVBRKAWDGAB-UHFFFAOYSA-N, NWVVVBRKAWDGAB-UHFFFAOYSA-N" "Launched"
"1809" "merbarone" "topoisomerase inhibitor" "TOP2A" "" "" "BRD-K45152786-001-08-4" "O=C(Nc1ccccc1)C1C(=O)NC(=S)NC1=O" "JARCFMKMOFFIGZ-UHFFFAOYSA-N" "Phase 2"
"1810" "merbromin" "antiseptic" "" "infectious disease" "first-aid antiseptic" "BRD-K21771665-304-04-2" "O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12" "OHCFGBLQZMYRTR-UHFFFAOYSA-M" "Launched"
"1811" "mercaptopurine" "immunosuppressant, protein synthesis inhibitor, purine antagonist" "HPRT1, IMPDH1, IMPDH2, PPAT" "hematologic malignancy" "acute lymphoblastic leukemia (ALL)" "BRD-K91601245-001-13-8, BRD-K91601245-001-12-0" "S=c1[nH]cnc2nc[nH]c12, S=c1[nH]cnc2nc[nH]c12" "GLVAUDGFNGKCSF-UHFFFAOYSA-N, GLVAUDGFNGKCSF-UHFFFAOYSA-N" "Launched"
"1812" "mercaptosuccinic-acid" "" "" "" "" "BRD-A43435802-001-02-0, BRD-A43435802-001-01-2" "OC(=O)CC(S)C(O)=O, OC(=O)CC(S)C(O)=O" "NJRXVEJTAYWCQJ-UHFFFAOYSA-N, NJRXVEJTAYWCQJ-UHFFFAOYSA-N" "Launched"
"1813" "mericitabine" "HCV inhibitor" "" "" "" "BRD-K69726595-001-01-2" "CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C" "MLESJYFEMSJZLZ-MAAOGQSESA-N" "Phase 2"
"1814" "merimepodib" "inosine monophosphate dehydrogenase inhibitor" "IMPDH1" "" "" "BRD-K09372874-001-01-0" "COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1" "JBPUGFODGPKTDW-SFHVURJKSA-N" "Phase 2"
"1815" "meropenem" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections, intra-abdominal infections, meningitis" "BRD-A18115130-001-03-0, BRD-A18115130-001-02-2, BRD-K01612348-001-11-4, BRD-A53925737-001-01-9" "CC(O)C1C2C(C)C(SC3CNC(C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O, CC(O)C1C2C(C)C(SC3CNC(C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O, C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O" "DMJNNHOOLUXYBV-UHFFFAOYSA-N, DMJNNHOOLUXYBV-UHFFFAOYSA-N, DMJNNHOOLUXYBV-PQTSNVLCSA-N, DMJNNHOOLUXYBV-JSEGGCCYSA-N" "Launched"
"1816" "mesalazine" "cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist" "ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2" "gastroenterology" "ulcerative colitis, inflammatory bowel disease" "BRD-K28849549-001-13-4, BRD-K28849549-001-12-6, BRD-K28849549-001-11-8" "Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O, Nc1ccc(O)c(c1)C(O)=O" "KBOPZPXVLCULAV-UHFFFAOYSA-N, KBOPZPXVLCULAV-UHFFFAOYSA-N, KBOPZPXVLCULAV-UHFFFAOYSA-N" "Launched"
"1817" "mesna" "antioxidant" "" "urology" "hemorrhagic cystitis" "BRD-K49954789-001-02-9, BRD-K49954789-001-01-1, BRD-K49954789-001-03-7" "OS(=O)(=O)CCS, OS(=O)(=O)CCS, OS(=O)(=O)CCS" "ZNEWHQLOPFWXOF-UHFFFAOYSA-N, ZNEWHQLOPFWXOF-UHFFFAOYSA-N, ZNEWHQLOPFWXOF-UHFFFAOYSA-N" "Launched"
"1818" "mesoridazine" "dopamine receptor antagonist" "DRD2, HTR2A" "neurology/psychiatry" "schizophrenia" "BRD-A14395271-074-17-8, BRD-A14395271-074-16-0, BRD-A14395271-074-18-6" "CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O, CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O" "SLVMESMUVMCQIY-UHFFFAOYSA-N, SLVMESMUVMCQIY-UHFFFAOYSA-N, SLVMESMUVMCQIY-UHFFFAOYSA-N" "Launched"
"1819" "mestinon" "cholinesterase inhibitor" "ACHE, BCHE" "neurology/psychiatry" "myasthenia gravis" "BRD-K69688083-004-23-1, BRD-K69688083-004-22-3" "CN(C)C(=O)Oc1ccc[n+](C)c1, CN(C)C(=O)Oc1ccc[n+](C)c1" "RVOLLAQWKVFTGE-UHFFFAOYSA-N, RVOLLAQWKVFTGE-UHFFFAOYSA-N" "Launched"
"1820" "mestranol" "estrogen receptor agonist" "ESR1" "endocrinology" "contraceptive" "BRD-A14798026-001-02-6, BRD-K92042497-001-01-4" "COc1ccc2C3CC[C@@]4(C)C(CC[C@@]4(O)C" "" ""
"1821" "mesulergine" "dopamine receptor agonist" "HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7" "" "" "BRD-K91336023-003-01-0" "CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1" "JLVHTNZNKOSCNB-YSVLISHTSA-N" "Phase 2"
"1822" "meta-cresyl-acetate" "" "" "" "" "BRD-K33442414-001-02-6" "CC(=O)Oc1cccc(C)c1" "OTGAHJPFNKQGAE-UHFFFAOYSA-N" "Preclinical"
"1823" "metacetamol" "analgesic agent" "" "" "" "BRD-K16474819-001-09-6" "CC(=O)Nc1cccc(O)c1" "QLNWXBAGRTUKKI-UHFFFAOYSA-N" "Preclinical"
"1824" "metacresol" "" "INS" "" "" "BRD-K22518984-001-01-8" "Cc1cccc(O)c1" "RLSSMJSEOOYNOY-UHFFFAOYSA-N" "Launched"
"1825" "metafolin" "" "AMT" "" "" "BRD-K28580965-238-01-3, BRD-K28580965-238-02-1" "CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2nc(N)[nH]c(=O)c12, CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2nc(N)[nH]c(=O)c12" "ZNOVTXRBGFNYRX-STQMWFEESA-N, ZNOVTXRBGFNYRX-STQMWFEESA-N" "Launched"
"1826" "metamizole" "cyclooxygenase inhibitor, opioid receptor agonist" "PTGS1" "" "" "BRD-K76812510-236-14-8" "CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O" "LVWZTYCIRDMTEY-UHFFFAOYSA-N" "Withdrawn"
"1827" "metaphit" "phencyclidine receptor acylator" "" "" "" "BRD-K95701999-001-02-3" "S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1" "FGSGBQAQSPSRJK-UHFFFAOYSA-N" "Preclinical"
"1828" "metaproterenol" "adrenergic receptor agonist" "ADRB2" "pulmonary" "bronchospasm, asthma, bronchitis, emphysema" "BRD-A07780951-001-08-9, BRD-A07780951-065-10-0, BRD-A07780951-065-09-2" "CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1, CC(C)NCC(O)c1cc(O)cc(O)c1" "LMOINURANNBYCM-UHFFFAOYSA-N, LMOINURANNBYCM-UHFFFAOYSA-N, LMOINURANNBYCM-UHFFFAOYSA-N" "Launched"
"1829" "metaraminol" "adrenergic receptor agonist" "ADRA1A" "cardiology" "hypotension" "BRD-K96253961-046-05-6, BRD-K96253961-046-03-1, BRD-K96253961-046-04-9" "C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1, C[C@H](N)[C@H](O)c1cccc(O)c1" "WXFIGDLSSYIKKV-RCOVLWMOSA-N, WXFIGDLSSYIKKV-RCOVLWMOSA-N, WXFIGDLSSYIKKV-RCOVLWMOSA-N" "Launched"
"1830" "metatinib" "Bcr-Abl kinase inhibitor" "ABL1, BCR" "" "" "BRD-K27182532-001-02-3" "Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl" "PDYXPCKITKHFOZ-UHFFFAOYSA-N" "Phase 1"
"1831" "metaxalone" "muscle relaxant" "" "neurology/psychiatry" "muscle pain" "BRD-A94709349-001-08-3" "Cc1cc(C)cc(OCC2CNC(=O)O2)c1" "IMWZZHHPURKASS-UHFFFAOYSA-N" "Launched"
"1832" "metazosin" "adrenergic receptor antagonist" "ADRA1A" "" "" "BRD-A78277353-001-01-9" "COC(C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1" "YEOTYALSMRNXLJ-UHFFFAOYSA-N" "Phase 2"
"1833" "metenkephalin" "immunostimulant" "OPRD1" "" "" "BRD-A38218502-001-01-2" "CSCCC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(N)Cc1ccc(O)cc1)C(O)=O" "YFGBQHOOROIVKG-UHFFFAOYSA-N" "Phase 2"
"1834" "metergoline" "dopamine receptor agonist, serotonin receptor antagonist" "HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7" "" "" "BRD-A72309220-001-04-1, BRD-K56699285-001-23-5" "CN1CC(CNC(=O)OCc2ccccc2)C[C@@H]2C1Cc1cn(C)c3cccc2c13, CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13" "WZHJKEUHNJHDLS-STDCAVTESA-N, WZHJKEUHNJHDLS-QTGUNEKASA-N" "Launched"
"1835" "metformin" "insulin sensitizer" "ACACB, PRKAB1" "endocrinology" "diabetes mellitus" "BRD-K79602928-003-19-9, BRD-K79602928-003-18-1" "CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N" "XZWYZXLIPXDOLR-UHFFFAOYSA-N, XZWYZXLIPXDOLR-UHFFFAOYSA-N" "Launched"
"1836" "methacholine" "acetylcholine receptor agonist" "CHRM2, CHRM3, CHRM4" "pulmonary" "bronchial hyperresponsiveness diagnostic" "BRD-A18056626-003-22-3" "CC(C[N+](C)(C)C)OC(C)=O" "NZWOPGCLSHLLPA-UHFFFAOYSA-N" "Launched"
"1837" "methacycline" "protein synthesis inhibitor" "" "pulmonary" "bronchitis" "BRD-A49035384-003-28-9, BRD-A27249758-003-01-7, BRD-A49035384-003-27-1" "CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@@H]1[C@@H]2[C@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O" "QNJKSUYWBCNWFI-KCDYASHQSA-N, QNJKSUYWBCNWFI-JIFCKJPSSA-N, QNJKSUYWBCNWFI-KCDYASHQSA-N" "Launched"
"1838" "methanesulfonyl-fluoride" "acetylcholinesterase inhibitor" "ACHE" "" "" "BRD-K53896891-001-01-2" "CS(F)(=O)=O" "KNWQLFOXPQZGPX-UHFFFAOYSA-N" "Phase 2"
"1839" "methantheline" "acetylcholine receptor antagonist" "CHRM1, HRH2" "gastroenterology, neurology/psychiatry, urology" "peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder" "BRD-K09859624-004-10-4" "CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12" "GZHFODJQISUKAY-UHFFFAOYSA-N" "Launched"
"1840" "methapyrilene" "histamine receptor antagonist" "HRH1" "" "" "BRD-K47323024-003-24-4, BRD-K47323024-003-25-1" "CN(C)CCN(Cc1cccs1)c1ccccn1, CN(C)CCN(Cc1cccs1)c1ccccn1" "HNJJXZKZRAWDPF-UHFFFAOYSA-N, HNJJXZKZRAWDPF-UHFFFAOYSA-N" "Withdrawn"
"1841" "metharbital" "GABA receptor modulator" "CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2" "neurology/psychiatry" "epilepsy" "BRD-K88143662-001-01-5" "CCC1(CC)C(=O)NC(=O)N(C)C1=O" "FWJKNZONDWOGMI-UHFFFAOYSA-N" "Launched"
"1842" "methazolamide" "carbonic anhydrase inhibitor" "CA1, CA12, CA14, CA2, CA4, CA7" "ophthalmology" "glaucoma, intraocular pressure" "BRD-K13356952-001-27-7, BRD-K13356952-001-25-1, BRD-K13356952-001-26-9" "CC(=O)N=c1sc(nn1C)S(N)(=O)=O, CC(=O)N=c1sc(nn1C)S(N)(=O)=O, CC(=O)N=c1sc(nn1C)S(N)(=O)=O" "FLOSMHQXBMRNHR-UHFFFAOYSA-N, FLOSMHQXBMRNHR-UHFFFAOYSA-N, FLOSMHQXBMRNHR-UHFFFAOYSA-N" "Launched"
"1843" "methenamine" "bacterial DNA inhibitor" "" "infectious disease" "urinary tract infections" "BRD-K30114692-001-15-9, BRD-K30114692-001-16-7" "C1N2CN3CN1CN(C2)C3, C1N2CN3CN1CN(C2)C3" "VKYKSIONXSXAKP-UHFFFAOYSA-N, VKYKSIONXSXAKP-UHFFFAOYSA-N" "Launched"
"1844" "methiazole" "anthelmintic agent" "" "" "" "BRD-K02764365-001-13-6" "COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1" "SXJIZQPZESTWLD-UHFFFAOYSA-N" "Preclinical"
"1845" "methicillin" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-K34388247-236-09-0, BRD-K34388247-236-08-2" "COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O" "RJQXTJLFIWVMTO-TYNCELHUSA-N, RJQXTJLFIWVMTO-TYNCELHUSA-N" "Launched"
"1846" "methimazole" "antithyroid agent" "TPO" "endocrinology" "hyperthyroidism" "BRD-K54416256-001-19-9, BRD-K54416256-001-18-1" "Cn1cc[nH]c1=S, Cn1cc[nH]c1=S" "PMRYVIKBURPHAH-UHFFFAOYSA-N, PMRYVIKBURPHAH-UHFFFAOYSA-N" "Launched"
"1847" "methionine" "" "BHMT, BHMT2, METAP2, MTR, MTRR" "" "" "BRD-A39515206-001-01-9" "CSCCC(N)C(O)=O" "FFEARJCKVFRZRR-UHFFFAOYSA-N" "Launched"
"1848" "methiopril" "angiotensin converting enzyme inhibitor" "ACE" "" "" "BRD-A32172948-001-07-6" "CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O" "JHFOAISYWJRTIM-UHFFFAOYSA-N" "Phase 2"
"1849" "methocarbamol" "muscle relaxant" "CA1" "neurology/psychiatry" "muscle relaxant" "BRD-A31521121-001-26-4, BRD-A31521121-001-25-6" "COc1ccccc1OCC(O)COC(N)=O, COc1ccccc1OCC(O)COC(N)=O" "GNXFOGHNGIVQEH-UHFFFAOYSA-N, GNXFOGHNGIVQEH-UHFFFAOYSA-N" "Launched"
"1850" "methoprene-(s)" "" "" "" "" "BRD-K34591242-001-04-3" "COC(C)(C)CCC[C@H](C)C\C=C\C(C)=C\C(=O)OC(C)C" "NFGXHKASABOEEW-GYMWBFJFSA-N" "Preclinical"
"1851" "methotrexate" "dihydrofolate reductase inhibitor" "DHFR" "oncology, hematologic malignancy, dermatology, rheumatology" "gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis" "BRD-K59456551-001-22-6, BRD-A55424491-001-19-9, BRD-K59456551-001-20-0, BRD-K59456551-001-19-2" "CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O" "FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-UHFFFAOYSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N, FBOZXECLQNJBKD-ZDUSSCGKSA-N" "Launched"
"1852" "methoxamine" "adrenergic receptor agonist" "ADRA1A, ADRA1B, ADRA1D" "cardiology" "hypotension" "BRD-A39189014-003-22-7, BRD-A39189014-003-21-9" "COc1ccc(OC)c(c1)C(O)C(C)N, COc1ccc(OC)c(c1)C(O)C(C)N" "WJAJPNHVVFWKKL-UHFFFAOYSA-N, WJAJPNHVVFWKKL-UHFFFAOYSA-N" "Launched"
"1853" "methoxsalen" "DNA synthesis inhibitor" "CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4" "dermatology" "psoriasis" "BRD-K63430059-001-17-2, BRD-K63430059-001-16-4" "COc1c2occc2cc2ccc(=O)oc12, COc1c2occc2cc2ccc(=O)oc12" "QXKHYNVANLEOEG-UHFFFAOYSA-N, QXKHYNVANLEOEG-UHFFFAOYSA-N" "Launched"
"1854" "methoxyamine" "DNA repair enzyme inhibitor" "APEX1" "" "" "BRD-K79277568-003-04-7" "CON" "GMPKIPWJBDOURN-UHFFFAOYSA-N" "Phase 2"
"1855" "methoxyflurane" "membrane permeability inhibitor" "ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1" "neurology/psychiatry" "general anaesthetic" "BRD-K06152156-001-01-8" "COC(F)(F)C(Cl)Cl" "RFKMCNOHBTXSMU-UHFFFAOYSA-N" "Launched"
"1856" "methoxyphenamine" "adrenergic receptor agonist" "" "pulmonary" "asthma" "BRD-A21474126-001-01-6" "CNC(C)Cc1ccccc1OC" "OEHAYUOVELTAPG-UHFFFAOYSA-N" "Launched"
"1857" "methscopolamine" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3" "gastroenterology" "peptic ulcer disease (PUD)" "BRD-K48619321-004-16-8, BRD-A03932035-004-04-3, BRD-K05224916-004-01-1" "C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, C[N+]1(C)C2CC(CC1C1OC21)OC(=O)[C@@H](CO)c1ccccc1, C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1" "LZCOQTDXKCNBEE-IKIFYQGPSA-N, LZCOQTDXKCNBEE-RUTJIGONSA-N, LZCOQTDXKCNBEE-RGGMIXCSSA-N" "Launched"
"1858" "methsuximide" "T-type calcium channel binder" "CACNA1G, CACNA1H, CACNA1I" "neurology/psychiatry" "seizures" "BRD-A57592049-001-01-6" "CN1C(=O)CC(C)(C1=O)c1ccccc1" "AJXPJJZHWIXJCJ-UHFFFAOYSA-N" "Launched"
"1859" "methyclothiazide" "chloride reabsorption inhibitor" "CA1, CA2, CA4, SLC12A1, SLC12A3" "cardiology" "hypertension, edema" "BRD-A95340155-001-09-7" "CN1C(CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O" "CESYKOGBSMNBPD-UHFFFAOYSA-N" "Launched"
"1860" "methyl-aminolevulinate" "oxidizing agent" "FCGR1A, FECH" "dermatology" "actinic keratosis (AK)" "BRD-K01292611-003-17-8" "COC(=O)CCC(=O)CN" "YUUAYBAIHCDHHD-UHFFFAOYSA-N" "Launched"
"1861" "methyl-nicotinate" "" "" "" "" "BRD-K10132944-001-01-1, BRD-K10132944-001-02-9" "COC(=O)c1cccnc1, COC(=O)c1cccnc1" "YNBADRVTZLEFNH-UHFFFAOYSA-N, YNBADRVTZLEFNH-UHFFFAOYSA-N" "Phase 2"
"1862" "methyl-salicylate" "" "" "endocrinology, neurology/psychiatry" "fever, pain relief" "BRD-K10103010-001-01-1" "COC(=O)c1ccccc1O" "OSWPMRLSEDHDFF-UHFFFAOYSA-N" "Launched"
"1863" "methylatropine-nitrate" "acetylcholine receptor antagonist" "CHRM1" "" "" "BRD-A52460047-001-01-3" "C[N+]1(C)C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1" "PIPAJLPNWZMYQA-UHFFFAOYSA-N" "Preclinical"
"1864" "methylbenzethonium-chloride" "other antibiotic" "" "" "" "BRD-K46531780-003-18-9" "Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C" "UQOOPIMXBSPVJI-UHFFFAOYSA-N" "Preclinical"
"1865" "methyldopa" "adrenergic receptor agonist" "ADRA2A, ADRA2B, ADRA2C, DDC" "cardiology" "hypertension" "BRD-K48578705-001-17-6, BRD-K48578705-001-16-8, BRD-K48578705-001-14-3, BRD-K48578705-001-15-0" "C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O, C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O" "CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N, CJCSPKMFHVPWAR-JTQLQIEISA-N" "Launched"
"1866" "methyldopate" "" "" "cardiology" "hypertension" "BRD-K82259334-003-02-7" "CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1" "SVEBYYWCXTVYCR-LBPRGKRZSA-N" "Launched"
"1867" "methylene-blue" "guanylyl cyclase inhibitor, nitric oxide production inhibitor" "ACHE" "hematology" "methemoglobinemia" "BRD-K16406336-311-02-0, BRD-K54770538-003-14-6" "CN(C)c1ccc2nc3ccc(cc3[s+]c2c1)N(C)C, CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C" "RBTBFTRPCNLSDE-UHFFFAOYSA-N, RBTBFTRPCNLSDE-UHFFFAOYSA-N" "Launched"
"1868" "methylergometrine" "dopamine receptor antagonist, serotonin receptor antagonist" "DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C" "hematology, neurology/psychiatry" "postpartum hemorrhage (PPH), migraine headache" "BRD-K34685430-050-12-5, BRD-K34685430-050-11-7" "CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34, CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34" "UNBRKDKAWYKMIV-QWQRMKEZSA-N, UNBRKDKAWYKMIV-QWQRMKEZSA-N" "Launched"
"1869" "methyllycaconitine" "acetylcholine receptor antagonist" "CHRNA7" "" "" "BRD-A29043702-048-01-4" "CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@](O)([C@@H](OC)C23)[C@H]14" "XLTANAWLDBYGFU-VGISAMKQSA-N" "Preclinical"
"1870" "methylnaltrexone" "opioid receptor antagonist" "OPRD1, OPRK1, OPRM1" "gastroenterology" "constipation" "BRD-K33732501-004-01-0" "C[N@@+]1(CC2CC2)CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@@]3(O)CCC4=O)ccc5O" "JVLBPIPGETUEET-RESYIPQXSA-O" "Launched"
"1871" "methylparaben" "other antifungal" "" "dermatology" "cosmetic" "BRD-K78321730-001-10-8" "COC(=O)c1ccc(O)cc1" "LXCFILQKKLGQFO-UHFFFAOYSA-N" "Launched"
"1872" "methylphenidate" "dopamine-norepinephrine reuptake inhibitor" "SLC6A2, SLC6A3, SLC6A4" "neurology/psychiatry" "attention-deficit/hyperactivity disorder (ADHD), narcolepsy" "BRD-A19585813-003-03-3" "COC(=O)C(C1CCCCN1)c1ccccc1" "DUGOZIWVEXMGBE-UHFFFAOYSA-N" "Launched"
"1873" "methylprednisolone" "glucocorticoid receptor agonist" "NR3C1" "endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology" "hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis" "BRD-A53176877-001-04-3, BRD-K99443616-001-01-3" "C[C@H]1CC2C3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12, C[C@H]1C[C@H]2[C@@H]3CC[C@@](O)(C(=O)CO)[C@@]3(C)C[C@@H](O)[C@H]2[C@@]2(C)C=CC(=O)C=C12" "VHRSUDSXCMQTMA-IETLARDKSA-N, VHRSUDSXCMQTMA-DTOSWALXSA-N" "Launched"
"1874" "methylprednisolone-aceponate" "anti-inflammatory agent, glucocorticoid receptor agonist" "NR3C1" "endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology" "congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia" "BRD-K24452555-001-01-7" "CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O" "DALKLAYLIPSCQL-YPYQNWSCSA-N" "Launched"
"1875" "methylprednisolone-sodium-succinate" "glucocorticoid receptor agonist" "" "endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry" "hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis" "BRD-A45044890-236-02-3" "C[C@H]1CC2C3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)C2[C@@]2(C)C=CC(=O)C=C12" "IMBXEJJVJRTNOW-RCSGDJEUSA-N" "Launched"
"1876" "methylthiouracil" "" "" "endocrinology" "hyperthyroidism" "BRD-K11900042-001-14-4, BRD-K11900042-001-13-6" "Cc1cc(=O)[nH]c(=S)[nH]1, Cc1cc(=O)[nH]c(=S)[nH]1" "HWGBHCRJGXAGEU-UHFFFAOYSA-N, HWGBHCRJGXAGEU-UHFFFAOYSA-N" "Launched"
"1877" "methysergide" "serotonin receptor antagonist" "HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7" "neurology/psychiatry" "headache" "BRD-K35941380-050-27-9" "CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34" "KPJZHOPZRAFDTN-ZRGWGRIASA-N" "Launched"
"1878" "meticrane" "diuretic" "" "cardiology" "edema" "BRD-K58265391-001-12-7, BRD-K58265391-001-11-9" "Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O, Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O" "FNQQBFNIYODEMB-UHFFFAOYSA-N, FNQQBFNIYODEMB-UHFFFAOYSA-N" "Launched"
"1879" "metipranolol" "adrenergic receptor antagonist" "ADRB1, ADRB2" "" "" "BRD-A99388803-001-01-5" "CC(C)NCC(O)COc1cc(C)c(OC(C)=O)c(C)c1C" "BQIPXWYNLPYNHW-UHFFFAOYSA-N" "Withdrawn"
"1880" "metirosine" "tyrosine hydroxylase inhibitor" "TH" "cardiology" "hypertension" "BRD-K83766205-001-03-8" "C[C@](N)(Cc1ccc(O)cc1)C(O)=O" "NHTGHBARYWONDQ-JTQLQIEISA-N" "Launched"
"1881" "metitepine" "anti-HCVE2" "HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7" "" "" "BRD-A07932845-050-15-8, BRD-A07932845-066-11-3" "CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1, CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1" "RLJFTICUTYVZDG-UHFFFAOYSA-N, RLJFTICUTYVZDG-UHFFFAOYSA-N" "Preclinical"
"1882" "metixene" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "neurology/psychiatry" "Parkinsons Disease	BRD-A33711280-003-03-1	CN1CCCC(CC2c3ccccc3Sc3ccccc23)C1	MJFJKKXQDNNUJF-UHFFFAOYSA-N	Launched
metoclopramide	dopamine receptor antagonist, serotonin receptor antagonist	CHRM1, DRD2, HTR3A, HTR3B, HTR4	gastroenterology	gastroparesis, nausea, vomiting	BRD-K75641298-003-25-0	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	TTWJBBZEZQICBI-UHFFFAOYSA-N	Launched
metocurine	acetylcholine receptor antagonist	CHRM2, CHRNA2	neurology/psychiatry	muscle relaxant	BRD-K16484091-001-01-1	COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3	JFXBEKISTKFVAB-AJQTZOPKSA-N	Launched
metolazone	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	BRD-A61793559-001-15-6, BRD-A61793559-001-16-4, BRD-A61793559-001-14-9	CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O, CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O, CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O	AQCHWTWZEMGIFD-UHFFFAOYSA-N, AQCHWTWZEMGIFD-UHFFFAOYSA-N, AQCHWTWZEMGIFD-UHFFFAOYSA-N	Launched
metoprolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	BRD-A03623303-045-09-5, BRD-A03623303-046-14-3	COCCc1ccc(OCC(O)CNC(C)C)cc1, COCCc1ccc(OCC(O)CNC(C)C)cc1	IUBSYMUCCVWXPE-UHFFFAOYSA-N, IUBSYMUCCVWXPE-UHFFFAOYSA-N	Launched
metoxibutropate	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A71725768-001-01-3	COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1	FVRWRGBTEHAPDI-UHFFFAOYSA-N	Launched
metrifonate	acetylcholinesterase inhibitor	ACHE			BRD-A22101059-001-13-0, BRD-A22101059-001-14-8	COP(=O)(OC)C(O)C(Cl)(Cl)Cl, COP(=O)(OC)C(O)C(Cl)(Cl)Cl	NFACJZMKEDPNKN-UHFFFAOYSA-N, NFACJZMKEDPNKN-UHFFFAOYSA-N	Phase 3
metrizamide	radiopaque medium		radiology	contrast agent	BRD-A45543382-001-10-0	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I	BAQCROVBDNBEEB-UBYUBLNFSA-N	Launched
metrizoic-acid	radiopaque medium		radiology	contrast agent	BRD-K99241550-001-03-5	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	GGGDNPWHMNJRFN-UHFFFAOYSA-N	Launched
metronidazole	DNA inhibitor	CYP2C9, CYP3A4	dermatology	rosacea	BRD-K52020312-001-26-8, BRD-K52020312-001-25-0	Cc1ncc(n1CCO)[N+]([O-])=O, Cc1ncc(n1CCO)[N+]([O-])=O	VAOCPAMSLUNLGC-UHFFFAOYSA-N, VAOCPAMSLUNLGC-UHFFFAOYSA-N	Launched
metyrapone	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	BRD-K46862739-001-14-3, BRD-K46862739-001-13-5	CC(C)(C(=O)c1cccnc1)c1cccnc1, CC(C)(C(=O)c1cccnc1)c1cccnc1	FJLBFSROUSIWMA-UHFFFAOYSA-N, FJLBFSROUSIWMA-UHFFFAOYSA-N	Launched
mevastatin	HMGCR inhibitor	HMGCR			BRD-K94441233-001-13-0, BRD-A83177971-001-04-0, BRD-K94441233-001-12-2, BRD-K31414443-001-01-4	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)C(CCC3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@H]3C[C@@H](O)CC(=O)O3)[C@@H]12	AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-JGKZIMKKSA-N, AJLFOPYRIVGYMJ-INTXDZFKSA-N, AJLFOPYRIVGYMJ-YUDIKBHMSA-N	Preclinical
mexeneone					BRD-K18613660-001-05-5	COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	MJVGBKJNTFCUJM-UHFFFAOYSA-N	Preclinical
mexiletine	sodium channel blocker	AHR, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	BRD-A64092382-003-18-3, BRD-A64092382-003-17-5, BRD-A64092382-003-16-7	CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C, CC(N)COc1c(C)cccc1C	VLPIATFUUWWMKC-UHFFFAOYSA-N, VLPIATFUUWWMKC-UHFFFAOYSA-N, VLPIATFUUWWMKC-UHFFFAOYSA-N	Launched
mezlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K45114938-236-01-8, BRD-K53064842-236-01-9	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O, CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	YPBATNHYBCGSSN-ZJOBFFGXSA-N, YPBATNHYBCGSSN-WSMBLCCSSA-N	Launched
ME0328	PARP inhibitor	PARP3			BRD-A63444178-001-01-5	CC(NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	QIHBWVVVRYYYRO-UHFFFAOYSA-N	Preclinical
MF-101	estrogen receptor agonist	CYP19A1, XDH			BRD-K34328244-001-01-4	Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	FURUXTVZLHCCNA-AWEZNQCLSA-N	Phase 3
MG-132	proteasome inhibitor	PSMB1			BRD-K60230970-001-17-5, BRD-K60230970-001-13-4, BRD-K60230970-001-16-7	CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O, CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N, TZYWCYJVHRLUCT-VABKMULXSA-N	Preclinical
MG-624	acetylcholine receptor antagonist	CHRNA7			BRD-K03128577-005-06-2	CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	YIMFXBPXUPTIEJ-OUKQBFOZSA-N	Preclinical
MGCD-265	VEGFR inhibitor	AXL, MET			BRD-K56277358-001-07-5	Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	UFICVEHDQUKCEA-UHFFFAOYSA-N	Preclinical
mianserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-A19661776-003-27-6, BRD-A19661776-003-26-8, BRD-A19661776-003-28-4, BRD-A19661776-003-25-0	CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21, CN1CCN2C(C1)c1ccccc1Cc1ccccc21	UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N, UEQUQVLFIPOEMF-UHFFFAOYSA-N	Launched
mibampator	glutamate receptor modulator	GRIA1			BRD-K42981054-001-01-9	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	ULRDYYKSPCRXAJ-KRWDZBQOSA-N	Phase 2
mibefradil	T-type calcium channel blocker	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4			BRD-K09549677-300-03-4	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	HBNPJJILLOYFJU-VMPREFPWSA-N	Withdrawn
micafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, peritonitis, esophageal candidiasis	BRD-A11207520-001-01-4, BRD-A06596811-236-01-7, BRD-A06596811-236-02-5	CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)NC1C[C@@H](O)[C@@H](O)NC(=O)C2[C@@H](O)[C@@H](C)CN2C(=O)C(NC(=O)C(NC(=O)C2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O, CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)NC1C[C@@H](O)[C@@H](O)NC(=O)C2[C@@H](O)[C@@H](C)CN2C(=O)C(NC(=O)C(NC(=O)C2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O	PIEUQSKUWLMALL-SICPAZHLSA-N, PIEUQSKUWLMALL-LZQXLXGFSA-N, PIEUQSKUWLMALL-LZQXLXGFSA-N	Launched
miconazole	bacterial cell wall synthesis inhibitor	KCNH2, KCNH6, KCNH7, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, NOS2, NOS3, TRPM2, TRPV5	infectious disease, neurology/psychiatry	yeast infection, itching	BRD-A82396632-008-29-0, BRD-A82396632-001-16-2, BRD-A82396632-008-28-2	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1, Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	BYBLEWFAAKGYCD-UHFFFAOYSA-N, BYBLEWFAAKGYCD-UHFFFAOYSA-N, BYBLEWFAAKGYCD-UHFFFAOYSA-N	Launched
micronomicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K18552138-001-01-8	CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	DNYGXMICFMACRA-XHEDQWPISA-N	Launched
midafotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K45163704-001-01-5	OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	VZXMZMJSGLFKQI-ABVWVHJUSA-N	Phase 3
midecamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, ear infections, skin infections	BRD-K68822425-001-01-6	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C	DMUAPQTXSSNEDD-QALJCMCCSA-N	Launched
midodrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	BRD-A79981887-003-16-4	COc1ccc(OC)c(c1)C(O)CNC(=O)CN	PTKSEFOSCHHMPD-UHFFFAOYSA-N	Launched
midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	FLT3, PRKCG			BRD-K13646352-001-03-8	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	BMGQWWVMWDBQGC-IIFHNQTCSA-N	Phase 3
mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	BRD-K37270826-001-27-6, BRD-K37270826-001-26-8, BRD-A79939557-001-01-7, BRD-K46504237-001-01-5	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C, CC#C[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](C[C@]12C)c1ccc(cc1)N(C)C	VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-GCNJZUOMSA-N, VKHAHZOOUSRJNA-YYTJNDDGSA-N, VKHAHZOOUSRJNA-ZWWPDORQSA-N	Launched
mifobate	PPAR receptor antagonist	PPARG			BRD-A72066420-001-04-5	COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC	VQHUQHAPWMNBLP-UHFFFAOYSA-N	Phase 2
miglitol	glucosidase inhibitor	GAA, GANAB, GANC, MGAM	endocrinology	diabetes mellitus	BRD-A63310107-001-04-8, BRD-K82665349-001-01-4	OCCN1C[C@@H](O)[C@@H](O)C(O)C1CO, OCCN1C[C@H](O)[C@H](O)[C@H](O)[C@H]1CO	IBAQFPQHRJAVAV-WMEPKMGJSA-N, IBAQFPQHRJAVAV-CWKFCGSDSA-N	Launched
miglustat	Glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	BRD-K33251802-001-01-3	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	UQRORFVVSGFNRO-UTINFBMNSA-N	Launched
milacemide	monoamine oxidase inhibitor	MAOB			BRD-K64338723-001-01-6	CCCCCNCC(N)=O	GJNNXIYZWIZFRH-UHFFFAOYSA-N	Phase 3
milnacipran	serotonin–norepinephrine reuptake inhibitor (SNRI)	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A4	rheumatology	fibromyalgia	BRD-A15202882-003-02-7, BRD-K02227374-003-07-1	CCN(CC)C(=O)C1(CC1CN)c1ccccc1, CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)c1ccccc1	GJJFMKBJSRMPLA-UHFFFAOYSA-N, GJJFMKBJSRMPLA-HIFRSBDPSA-N	Launched
milrinone	phosphodiesterase inhibitor	PDE2A, PDE3A, PDE3B, PDE5A	cardiology	congestive heart failure	BRD-K67080878-001-15-4, BRD-K67080878-001-16-2	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N, Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	PZRHRDRVRGEVNW-UHFFFAOYSA-N, PZRHRDRVRGEVNW-UHFFFAOYSA-N	Launched
miltefosine	membrane integrity inhibitor	PLA2G1B	infectious disease	leishmaniasis	BRD-A31811760-001-06-7	CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C	PQLXHQMOHUQAKB-UHFFFAOYSA-O	Launched
mimosine	DNA replication inhibitor	CCL2, SHMT1, SHMT2, TYR			BRD-K67642028-001-03-6	N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O	WZNJWVWKTVETCG-YFKPBYRVSA-N	Preclinical
minaprine	serotonin reuptake inhibitor	ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4			BRD-K02867583-300-08-9	Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	LDMWSLGGVTVJPG-UHFFFAOYSA-N	Withdrawn
minerval	FAAH inhibitor				BRD-A74347210-001-01-7	CCCCCCCC\C=C/CCCCCCC(O)C(O)=O	JBSOOFITVPOOSY-KTKRTIGZSA-N	Phase 1/Phase 2
minocycline	bacterial 30S ribosomal subunit inhibitor	ALOX5, CASP1, CASP3, CYCS, IL1B, MMP9, VEGFA	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	BRD-A69651145-003-10-6, BRD-A69651145-003-09-8, BRD-A69651145-003-11-4, BRD-A69651145-003-07-2, BRD-A69651145-003-08-0	CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C	ZZZRUAITSXLWBH-CSYJEMQYSA-N, ZZZRUAITSXLWBH-CSYJEMQYSA-N, ZZZRUAITSXLWBH-CSYJEMQYSA-N, ZZZRUAITSXLWBH-CSYJEMQYSA-N, ZZZRUAITSXLWBH-CSYJEMQYSA-N	Launched
minodronic-acid	bone resorption inhibitor	FDPS, GGPS1	orthopedics	osteoporosis	BRD-K89337853-001-01-1, BRD-K89337853-001-02-9	OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O	VMMKGHQPQIEGSQ-UHFFFAOYSA-N, VMMKGHQPQIEGSQ-UHFFFAOYSA-N	Launched
minoxidil	KATP activator, Kir6 channel (KATP) activator, vasodilator	ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1	endocrinology	androgenetic alopecia	BRD-K14888893-001-14-8, BRD-K06902185-003-01-7, BRD-K06902185-001-17-7, BRD-K06902185-001-16-9	Nc1cc(nc(=N)n1O)N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1, Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	ZIMGGGWCDYVHOY-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N, ZFMITUMMTDLWHR-UHFFFAOYSA-N	Launched
miocamycin	other antibiotic		infectious disease	urinary tract infections, chlamydia	BRD-K30764557-001-01-5	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C	GQNZGCARKRHPOH-RQIKCTSVSA-N	Launched
MIRA-1	apoptosis stimulant				BRD-K39706510-001-03-9	CCC(=O)OCN1C(=O)C=CC1=O	YXEWPGYLMHXLPS-UHFFFAOYSA-N	Preclinical
mirabegron	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	urology	urinary incontinence	BRD-K47949423-001-03-1, BRD-K47949423-001-02-3	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1, Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	PBAPPPCECJKMCM-IBGZPJMESA-N, PBAPPPCECJKMCM-IBGZPJMESA-N	Launched
miriplatin	DNA synthesis inhibitor		oncology	hepatocellular carcinoma (HCC)	BRD-M78068755-001-01-2	[Pt++].NC1CCCCC1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O	BGIHRZPJIYJKAZ-UHFFFAOYSA-N	Launched
mirodenafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	BRD-K82967685-300-01-2	CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	MIJFNYMSCFYZNY-UHFFFAOYSA-N	Launched
mirtazapine	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD5, HRH1, HRH3, HTR2A, HTR2B, HTR2C, HTR3A, HTR7, OPRK1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-A64977602-001-15-9, BRD-A64977602-001-14-2, BRD-A64977602-001-13-4	CN1CCN2C(C1)c1ccccc1Cc1cccnc21, CN1CCN2C(C1)c1ccccc1Cc1cccnc21, CN1CCN2C(C1)c1ccccc1Cc1cccnc21	RONZAEMNMFQXRA-UHFFFAOYSA-N, RONZAEMNMFQXRA-UHFFFAOYSA-N, RONZAEMNMFQXRA-UHFFFAOYSA-N	Launched
misonidazole					BRD-A16263897-001-06-6	COCC(O)Cn1ccnc1[N+]([O-])=O	OBBCSXFCDPPXOL-UHFFFAOYSA-N	Phase 3
misoprostol	prostanoid receptor agonist	PTGER2, PTGER3, PTGER4, PTGIR	gastroenterology	duodenal ulcer disease	BRD-A72351335-001-04-5	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	OJLOPKGSLYJEMD-URPKTTJQSA-N	Launched
mitiglinide	insulin secretagogue	ABCC8, KCNJ10, PPARG	endocrinology	diabetes mellitus	BRD-K52959329-238-01-9	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	WPGGHFDDFPHPOB-BBWFWOEESA-N	Launched
mitoflaxone	antitumor agent	VWF			BRD-K35882976-001-04-7	OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1	TZZNWMJZDWYJAZ-UHFFFAOYSA-N	Phase 2
mitomycin-c	DNA alkylating agent, DNA synthesis inhibitor		oncology	pancreatic cancer, gastric adenocarcinoma	BRD-A48237631-001-04-8	CO[C@@]12[C@@H]3NC3CN1C1=C([C@@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O	NWIBSHFKIJFRCO-CPKMXBGFSA-N	Launched
mitotane	antineoplastic agent	CYP11A1, CYP11B1, ESR1, FDX1	oncology	adrenal cortical carcinoma	BRD-A31204924-001-16-7, BRD-A31204924-001-14-2, BRD-A31204924-001-17-5, BRD-A31204924-001-13-4	ClC(Cl)C(c1ccc(Cl)cc1)c1ccccc1Cl, ClC(Cl)C(c1ccc(Cl)cc1)c1ccccc1Cl, ClC(Cl)C(c1ccc(Cl)cc1)c1ccccc1Cl, ClC(Cl)C(c1ccc(Cl)cc1)c1ccccc1Cl	JWBOIMRXGHLCPP-UHFFFAOYSA-N, JWBOIMRXGHLCPP-UHFFFAOYSA-N, JWBOIMRXGHLCPP-UHFFFAOYSA-N, JWBOIMRXGHLCPP-UHFFFAOYSA-N	Launched
mitoxantrone	topoisomerase inhibitor	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	BRD-K21680192-300-16-9, BRD-K21680192-300-14-4, BRD-K21680192-300-15-1	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12, OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N, KKZJGLLVHKMTCM-UHFFFAOYSA-N	Launched
mivacurium	acetylcholine receptor antagonist	BCHE, CHRM2, CHRM3, CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	BRD-A48465967-300-01-1	COc1cc2CC[N+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC	ILVYCEVXHALBSC-OTBYEXOQSA-N	Launched
mivobulin	microtubule inhibitor				BRD-K39576764-071-01-6	CCOC(=O)Nc1cc2NC(C)=C(Nc2c(N)n1)c1ccccc1	ZAKKIVMLUCPABA-UHFFFAOYSA-N	Preclinical
mizolastine	histamine receptor antagonist	HRH1	allergy	urticaria, allergic rhinitis	BRD-K21884483-001-03-7	CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nccc(=O)[nH]1	PVLJETXTTWAYEW-UHFFFAOYSA-N	Launched
mizoribine	immunosuppressant, inosine monophosphate dehydrogenase inhibitor	IMPDH1			BRD-K88061624-001-21-4, BRD-K88061624-001-20-6, BRD-K05218031-001-01-9	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O, NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c1O	HZQDCMWJEBCWBR-UUOKFMHZSA-N, HZQDCMWJEBCWBR-UUOKFMHZSA-N, HZQDCMWJEBCWBR-FJFJXFQQSA-N	Launched
MK-0354	niacin receptor agonist	HCAR2, HCAR3			BRD-K91405252-001-01-9	C1Cc2[nH]nc(-c3nnn[nH]3)c2C1	LTQYSJKGRPGMPO-UHFFFAOYSA-N	Phase 2
MK-0752	gamma secretase inhibitor				BRD-K18850819-001-04-6	OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1	XCGJIFAKUZNNOR-QCKZDCLWSA-N	Phase 1/Phase 2
MK-0773	androgen receptor modulator	AR			BRD-K38868394-001-01-3	CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6cccnc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O	GBEUKTWTUSPHEE-JWJWXJQQSA-N	Phase 2
MK-0812	CC chemokine receptor antagonist	CCR2			BRD-K14175878-001-01-6	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	MTMDXAIUENDNDL-RJSMDTJLSA-N	Phase 2
MK-0893	glucagon receptor antagonist	GCGR			BRD-K16732600-001-01-7	COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	DNTVJEMGHBIUMW-IBGZPJMESA-N	Phase 2
MK-1775	WEE1 kinase inhibitor	WEE1			BRD-K54256913-001-08-7	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	BKWJAKQVGHWELA-UHFFFAOYSA-N	Phase 2
MK-2048	HIV integrase inhibitor				BRD-K03128512-001-02-8, BRD-K66135050-001-01-7	CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O, CCN1C[C@@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	JSRREMIKIHJGAA-JTQLQIEISA-N, JSRREMIKIHJGAA-SNVBAGLBSA-N	Preclinical
MK-2206	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K68065987-300-09-1	NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	ULDXWLCXEDXJGE-UHFFFAOYSA-N	Phase 2
MK-2295	TRPV antagonist	TRPV1			BRD-K43316319-001-01-8	FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1	VTANGSDRFFLTSQ-UHFFFAOYSA-N	Phase 2
MK-2461	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB			BRD-K56405753-001-02-4	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	Phase 1/Phase 2
MK-2894	prostaglandin inhibitor	PTGER4			BRD-K27983781-001-01-4	Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F	QJZQFVRFJCGDKF-UHFFFAOYSA-N	Preclinical
MK-3207	calcitonin antagonist	CALCA			BRD-K66911501-003-01-2	Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	AZAANWYREOQRFB-SETSBSEESA-N	Phase 2
MK-3697	orexin receptor antagonist	HCRTR2			BRD-K95828359-001-01-0	COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	VSOUDUXMPUHJEU-UHFFFAOYSA-N	Phase 2
MK-5046	bombesin receptor agonist	BRS3, GRPR, NMBR			BRD-K03886848-001-01-8	O[C@@](Cc1nc(CC2(CC2)C(F)(F)F)c[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F	UJINBEQCDMOAHM-SFHVURJKSA-N	Preclinical
MK-5108	Aurora kinase inhibitor	AURKA, AURKB, AURKC			BRD-K53665955-001-03-0	OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F	LCVIRAZGMYMNNT-VVONHTQRSA-N	Phase 1
MK-571	leukotriene receptor antagonist	ABCC2, CYSLTR1			BRD-A73679382-236-01-8	CN(C)C(=O)CCSC(SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	AXUZQJFHDNNPFG-UXBLZVDNSA-N	Phase 2
MK-6096	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K03894385-001-01-1	C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1	NPFDWHQSDBWQLH-QZTJIDSGSA-N	Phase 2
MK-8033	c-Met inhibitor	MET			BRD-K55512740-001-01-6	Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	VMJFTOSOFDEKTM-UHFFFAOYSA-N	Phase 1
MK-8245	stearoyl-CoA desaturase inhibitor	SCD			BRD-K29656036-001-02-5	OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	UJEAABFSXKCSGI-UHFFFAOYSA-N	Phase 2
MK-8745	Aurora kinase inhibitor	AURKA			BRD-K25279140-001-01-5	Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	YCRFPWKUUNKNDN-UHFFFAOYSA-N	Preclinical
MKT-077	HSP inhibitor				BRD-K61695967-003-01-3	CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O	QLYHOWIZHHZGPV-XUTLUUPISA-N	Phase 1
MK2-IN-1	MAP kinase inhibitor	MAPKAPK2			BRD-K90316462-003-01-1	Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1	LIPNXDIBECKOMJ-UHFFFAOYSA-N	Preclinical
ML-323	ubiquitin specific protease inhibitor	USP1			BRD-K93942811-001-01-3	CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1	VUIRVWPJNKZOSS-UHFFFAOYSA-N	Preclinical
ML-9	myosin light chain kinase inhibitor	TRPC6			BRD-K68402494-003-04-3, BRD-K68402494-003-03-5	Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1, Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	OZSMSRIUUDGTEP-UHFFFAOYSA-N, OZSMSRIUUDGTEP-UHFFFAOYSA-N	Preclinical
MLN-8054	Aurora kinase inhibitor	AURKA			BRD-K83963101-001-06-9	OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1	HHFBDROWDBDFBR-UHFFFAOYSA-N	Phase 1
MLN0128	mTOR inhibitor	MTOR, PIK3CA, PIK3CD, PIK3CG			BRD-K59317601-001-05-5	CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	GYLDXIAOMVERTK-UHFFFAOYSA-N	Phase 2
MLN1117	PI3K inhibitor	PIK3CA			BRD-K73877023-001-01-9	Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1	BLGWHBSBBJNKJO-UHFFFAOYSA-N	Phase 1/Phase 2
MLN2480	RAF inhibitor				BRD-K43410529-001-02-3	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F	VWMJHAFYPMOMGF-ZCFIWIBFSA-N	Phase 1
MLN9708	proteasome inhibitor				BRD-K15203492-001-01-1	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1	MBOMYENWWXQSNW-AWEZNQCLSA-N	Phase 3
ML130	NOD1 inhibitor				BRD-K89306950-001-12-5	Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	SRFABRWQVPCPRG-UHFFFAOYSA-N	Preclinical
ML133	potassium channel blocker				BRD-K33743361-003-02-6	COc1ccc(CNCc2cccc3ccccc23)cc1	GIFYKGIODMXYNT-UHFFFAOYSA-N	Preclinical
ML161	protease-activated receptor inhibitor				BRD-K59036917-001-16-7, BRD-K59036917-001-17-5	CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1, CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	DFOVLSMXPWPCFH-UHFFFAOYSA-N, DFOVLSMXPWPCFH-UHFFFAOYSA-N	Preclinical
ML167	CLK inhibitor, DYRK inhibitor	CLK4, DYRK1B			BRD-K64835161-001-02-8	Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1	ROCFOIBAEVAOLQ-UHFFFAOYSA-N	Preclinical
ML204	transient receptor potential channel antagonist	TRPC4, TRPC5			BRD-K80021413-001-08-8	Cc1cc(nc2ccccc12)N1CCCCC1	USYRQXDHKXGTCK-UHFFFAOYSA-N	Preclinical
ML314	neurotensin agonist	NTSR1			BRD-K92606079-001-02-0	COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1	SWEOAXMICIJCQC-UHFFFAOYSA-N	Preclinical
ML324	histone lysine demethylase inhibitor	KDM4A			BRD-K25611237-001-02-1	CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1	QDBVSOZTVKXUES-UHFFFAOYSA-N	Preclinical
ML347	ALK tyrosine kinase receptor inhibitor	ACVR1, ACVRL1, BMPR1A			BRD-K33892651-001-02-4	COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	FVRYPYDPKSZGNS-UHFFFAOYSA-N	Preclinical
MM-102	WDR5/MLL interaction inhibitor				BRD-K68474068-001-01-8	CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	RZKSQRIPRKWVBU-MHZLTWQESA-N	Preclinical
MMPX	phosphodiesterase inhibitor				BRD-K56077740-001-09-2	COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	NBLBCGUCPBXKOV-UHFFFAOYSA-N	Preclinical
MM77	serotonin receptor antagonist	HTR1A			BRD-K50293352-300-02-1	COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	MQHOGPLXAXSQAJ-UHFFFAOYSA-N	Preclinical
MN-64	tankyrase inhibitor	TNKS			BRD-K16183658-001-01-4	CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1	PYTOHIUBXSJKQH-UHFFFAOYSA-N	Preclinical
MNITMT	lymphocyte inhibitor				BRD-K63151507-001-02-4	Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	NMBDIMPYACLUDE-UHFFFAOYSA-N	Preclinical
mocetinostat	HDAC inhibitor	HDAC1, HDAC11, HDAC2, HDAC3			BRD-K16485616-001-13-9, BRD-K16485616-001-12-1, BRD-K16485616-001-08-9	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1, Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N, HRNLUBSXIHFDHP-UHFFFAOYSA-N	Phase 2
moclobemide	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression, anxiety	BRD-K07237224-001-19-6	Clc1ccc(cc1)C(=O)NCCN1CCOCC1	YHXISWVBGDMDLQ-UHFFFAOYSA-N	Launched
modafinil	adrenergic receptor agonist	ADRA1B, SLC6A3	pulmonary, neurology/psychiatry	obstructive sleep apnea, shift work disorder (SWD)	BRD-A16332958-001-09-9	NC(=O)CS(=O)C(c1ccccc1)c1ccccc1	YFGHCGITMMYXAQ-UHFFFAOYSA-N	Launched
modaline					BRD-K25317177-065-01-4	Cc1nccnc1N1CCCCC1	BJHCGMHPEKLROM-UHFFFAOYSA-N	Preclinical
moexipril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology	hypertension	BRD-K34441861-003-07-0, BRD-K34441861-003-06-2, BRD-K34441861-003-05-4	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N, UWWDHYUMIORJTA-HSQYWUDLSA-N	Launched
mofegiline	monoamine oxidase inhibitor	MAOA, MAOB			BRD-K52598503-003-01-1	NC\C(CCc1ccc(F)cc1)=C\F	VXLBSYHAEKDUSU-JXMROGBWSA-N	Phase 1
mofezolac	cyclooxygenase inhibitor	PTGS1	rheumatology, orthopedics	rheumatoid arthritis, osteoporosis	BRD-K49372556-001-04-1	COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1	DJEIHHYCDCTAAH-UHFFFAOYSA-N	Launched
moguisteine	ATP-sensitive potassium channel inhibitor				BRD-A87673115-001-04-1	CCOC(=O)CC(=O)N1CCSC1COc1ccccc1OC	WSYVIAQNTFPTBI-UHFFFAOYSA-N	Phase 2
molidustat	hypoxia inducible factor inhibitor	EGLN2			BRD-K01291782-001-01-1	O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	IJMBOKOTALXLKS-UHFFFAOYSA-N	Phase 2
molindone	dopamine receptor antagonist	CHRM1, DRD2, HRH1, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	BRD-A65280694-003-13-7	CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12	KLPWJLBORRMFGK-UHFFFAOYSA-N	Launched
molsidomine	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	BRD-K63861289-001-19-6	CCOC(=O)Nc1c[n+](no1)N1CCOCC1	XLFWDASMENKTKL-UHFFFAOYSA-O	Launched
mometasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K50265942-001-01-2	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl	QLIIKPVHVRXHRI-CXSFZGCWSA-N	Launched
mometasone-furoate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-A01139232-001-01-0, BRD-K28476963-001-01-8	C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl, C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@]3(Cl)[C@H](O)C[C@]2(C)[C@]1(OC(=O)c1ccco1)C(=O)CCl	WOFMFGQZHJDGCX-NKEDMXMMSA-N, WOFMFGQZHJDGCX-RRDYVFDESA-N	Launched
monastrol	kinesin inhibitor	KIF11			BRD-A78377521-001-05-5	CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1	LOBCDGHHHHGHFA-UHFFFAOYSA-N	Preclinical
monensin	bacterial permeability inducer				BRD-A09919099-236-01-1, BRD-A61543962-236-02-6, BRD-A43972623-236-01-3	CC[C@]1(CC[C@@H](O1)[C@]1(C)CCC2(C[C@H](O)[C@@H](C)[C@H](O2)[C@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CCC(O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C, CC[C@]1(CCC(O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)C1O[C@H](C[C@@H]1C)C1O[C@@](O)(CO)[C@H](C)C[C@@H]1C	GAOZTHIDHYLHMS-ISRMXOCXSA-N, GAOZTHIDHYLHMS-YHJWYVMVSA-N, GAOZTHIDHYLHMS-SODLTBBSSA-N	Launched
monobenzone	melanin inhibitor	TYR	dermatology	skin depigmentation	BRD-K54262262-001-09-0, BRD-K54262262-001-10-8, BRD-K54262262-001-11-6, BRD-K54262262-001-12-4	Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1, Oc1ccc(OCc2ccccc2)cc1	VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N, VYQNWZOUAUKGHI-UHFFFAOYSA-N	Launched
monoctanoin			gastroenterology	gallstones	BRD-A48938994-001-14-1, BRD-A48938994-001-15-8	CCCCCCCC(=O)OCC(O)CO, CCCCCCCC(=O)OCC(O)CO	GHBFNMLVSPCDGN-UHFFFAOYSA-N, GHBFNMLVSPCDGN-UHFFFAOYSA-N	Launched
monosodium-alpha-luminol					BRD-K52559566-001-02-9, BRD-K52559566-001-01-1	Nc1cccc2c1c(=O)[nH][nH]c2=O, Nc1cccc2c1c(=O)[nH][nH]c2=O	HWYHZTIRURJOHG-UHFFFAOYSA-N, HWYHZTIRURJOHG-UHFFFAOYSA-N	Launched
monostearin					BRD-A31454688-001-01-6	CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO	VBICKXHEKHSIBG-UHFFFAOYSA-N	Preclinical
montelukast	leukotriene receptor antagonist	ALOX5, CYSLTR1	pulmonary, allergy	asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)	BRD-K69470111-236-09-7, BRD-K69470111-236-08-9, BRD-K69470111-001-01-2	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1, CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N, UCHDWCPVSPXUMX-TZIWLTJVSA-N	Launched
moprolol	adrenergic receptor antagonist		cardiology, ophthalmology, neurology/psychiatry	hypertension, glaucoma, anxiety	BRD-A51747092-003-03-0	COc1ccccc1OCC(O)CNC(C)C	LFTFGCDECFPSQD-UHFFFAOYSA-N	Launched
moracizine	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	BRD-K21548250-003-19-1	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	FUBVWMNBEHXPSU-UHFFFAOYSA-N	Launched
morantel	acetylcholine receptor agonist		infectious disease	tapeworm	BRD-K71454870-048-06-3	CN1CCCN=C1\C=C\c1sccc1C	NVEPPWDVLBMNMB-SNAWJCMRSA-N	Launched
morin	cytochrome P450 inhibitor	ADORA2A, ESR2, FASN, MCL1, SLC22A12			BRD-K11590034-002-03-4, BRD-K11590034-002-02-6	Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O, Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	YXOLAZRVSSWPPT-UHFFFAOYSA-N, YXOLAZRVSSWPPT-UHFFFAOYSA-N	Preclinical
morinidazole	other antibiotic	CYP51A1			BRD-A40546373-001-01-8	Cc1ncc(n1CC(O)CN1CCOCC1)[N+]([O-])=O	GAZGHCHCYRSPIV-UHFFFAOYSA-N	Launched
morniflumate	anti-inflammatory agent		neurology/psychiatry	pain relief	BRD-K38938675-001-01-4	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1	LDXSPUSKBDTEKA-UHFFFAOYSA-N	Launched
moroxydine	antiviral		infectious disease	influenza A virus infection	BRD-K57291914-003-09-4, BRD-K57291914-003-10-2	NC(=N)NC(=N)N1CCOCC1, NC(=N)NC(=N)N1CCOCC1	KJHOZAZQWVKILO-UHFFFAOYSA-N, KJHOZAZQWVKILO-UHFFFAOYSA-N	Launched
mosapride	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome	BRD-A39052811-048-11-0	CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1	YPELFRMCRYSPKZ-UHFFFAOYSA-N	Launched
motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT1, FLT4, KDR, KIT			BRD-K99616396-001-05-1, BRD-K99616396-316-05-3, BRD-K99616396-316-06-1, BRD-K99616396-316-04-6	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N, RAHBGWKEPAQNFF-UHFFFAOYSA-N	Phase 3
motolimod	toll-like receptor agonist	TLR8			BRD-K11785681-001-01-2	CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1	QSPOQCXMGPDIHI-UHFFFAOYSA-N	Phase 1/Phase 2
moxalactam	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, bone and joint infections, pneumonia, urinary tract infections, meningitis	BRD-A08899266-304-05-0	CO[C@]1(NC(=O)C(C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O	JWCSIUVGFCSJCK-CAVRMKNVSA-N	Launched
moxaverine	phosphodiesterase inhibitor		neurology/psychiatry	spasms	BRD-K12742203-003-01-7	CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1	MYCMTMIGRXJNSO-UHFFFAOYSA-N	Launched
moxidectin	chloride channel antagonist		infectious disease	gastrointestinal parasites	BRD-K61988078-001-01-2	CO\N=C1\C[C@]2(C[C@@H]3C[C@@H](C\C=C(C)\C[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)O[C@@H]([C@H]1C)C(\C)=C\C(C)C	YZBLFMPOMVTDJY-CBYMMZEQSA-N	Launched
moxifloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology, pulmonary, infectious disease	sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections	BRD-K66615216-003-14-8, BRD-K66615216-003-13-0	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1, COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	FABPRXSRWADJSP-MEDUHNTESA-N, FABPRXSRWADJSP-MEDUHNTESA-N	Launched
moxisylyte	adrenergic receptor antagonist				BRD-K81144366-003-19-7	CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	VRYMTAVOXVTQEF-UHFFFAOYSA-N	Withdrawn
moxonidine	imidazoline receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	BRD-K77771411-003-10-7, BRD-K77771411-001-12-7	COc1nc(C)nc(Cl)c1NC1=NCCN1, COc1nc(C)nc(Cl)c1NC1=NCCN1	WPNJAUFVNXKLIM-UHFFFAOYSA-N, WPNJAUFVNXKLIM-UHFFFAOYSA-N	Launched
mozavaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	BRD-A31095847-001-02-3	CN(C)C1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12	WRNXUQJJCIZICJ-UHFFFAOYSA-N	Launched
MPEP	glutamate receptor antagonist	GRM1, GRM4, GRM5			BRD-K60690191-001-03-3, BRD-K60690191-003-09-6	Cc1cccc(n1)C#Cc1ccccc1, Cc1cccc(n1)C#Cc1ccccc1	NEWKHUASLBMWRE-UHFFFAOYSA-N, NEWKHUASLBMWRE-UHFFFAOYSA-N	Preclinical
MPI-0479605	mitotic kinase inhibitor	TTK			BRD-K45551181-001-02-1, BRD-K45551181-001-03-9, BRD-K45551181-001-01-3	Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1, Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N, OVJBNYKNHXJGSA-UHFFFAOYSA-N	Preclinical
Mps1-IN-5	protein kinase inhibitor				BRD-K43812936-001-01-9	COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O	NRJKIOCCERLIDG-GOSISDBHSA-N	Preclinical
MR-16728	acetylcholine release enhancer				BRD-A30590053-003-02-9	O=C(NCCCN1CCCCCC1)C(C1CCCCC1)c1ccccc1	AGKAAJMNNVUNDK-UHFFFAOYSA-N	Preclinical
MR-948	thromboxane synthase inhibitor	TBXAS1			BRD-K84883208-001-01-1	OCCc1ccc(OCCn2ccnc2)cc1	LQQIZTXSZOYPPS-UHFFFAOYSA-N	Phase 1
MRK-016	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			BRD-K44022883-001-01-7	Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C	QYSYOGCIDRANAR-UHFFFAOYSA-N	Phase 1
MRK-409	benzodiazepine receptor agonist				BRD-K57416838-001-01-1	Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F	GOIFCXRIFSYPFG-UHFFFAOYSA-N	Phase 1
MRS-1220	adenosine receptor antagonist	ADORA2B, ADORA3			BRD-K37618799-001-03-0	Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	TWWFAXQOKNBUCR-UHFFFAOYSA-N	Preclinical
MRS1334	adenosine receptor antagonist	ADORA3			BRD-A06784547-001-02-6	CCOC(=O)C1=C(C)NC(c2ccccc2)=C(C1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O	QFLOJAMZLQXHFS-UHFFFAOYSA-N	Preclinical
MRS1845	calcium channel blocker				BRD-A78093359-001-06-3	CCOC(=O)C1=C(C)N(CC#C)C(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC	BITHABUTZRAUGT-UHFFFAOYSA-N	Preclinical
MRS2578	purinergic receptor antagonist	P2RY6			BRD-K91135178-001-03-9, BRD-K91135178-001-02-1	S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1, S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	QOHNRGHTJPFMSL-UHFFFAOYSA-N, QOHNRGHTJPFMSL-UHFFFAOYSA-N	Preclinical
MRS3777	adenosine receptor antagonist	ADORA2A			BRD-K10575656-034-01-0	C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2[nH]cnc12	OGCQBCHLFMBCCE-UHFFFAOYSA-N	Preclinical
MSX-122	CC chemokine receptor antagonist	CXCR4			BRD-K25143390-001-01-0	C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1	PXZXYRKDDXKDTK-UHFFFAOYSA-N	Phase 1
MTPG	glutamate receptor antagonist	GRM2, GRM3			BRD-A28329383-001-02-1	CC(N)(C(O)=O)c1ccc(cc1)-c1nnn[nH]1	OZBFBAYESADVDX-UHFFFAOYSA-N	Preclinical
mubritinib	protein tyrosine kinase inhibitor	EGFR, ERBB2			BRD-K19061412-001-02-4, BRD-K19061412-001-03-2, BRD-K19061412-001-04-0	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1, FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	ZTFBIUXIQYRUNT-MDWZMJQESA-N, ZTFBIUXIQYRUNT-MDWZMJQESA-N, ZTFBIUXIQYRUNT-MDWZMJQESA-N	Phase 1
mupirocin	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	BRD-K15262564-001-15-0, BRD-K25394084-001-01-0, BRD-K15262564-001-14-3	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@@H](O)[C@@H]1O, C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	MINDHVHHQZYEEK-HBBNESRFSA-N, MINDHVHHQZYEEK-QNVPSAJBSA-N, MINDHVHHQZYEEK-HBBNESRFSA-N	Launched
muscimol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			BRD-K60441002-001-04-8	NCc1cc(O)no1	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	Phase 1
MUT056399	FABI inhibitor				BRD-K72078047-001-01-7	CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F	QUHARGDBJJUOEB-UHFFFAOYSA-N	Phase 1
MY-5445	phosphodiesterase inhibitor, platelet aggregation inhibitor	PDE5A			BRD-K90524085-001-07-8	Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	CEHQLKSLMFIHBF-UHFFFAOYSA-N	Preclinical
mycophenolate-mofetil	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	BRD-K92428153-001-04-4, BRD-K92428153-001-05-1	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	RTGDFNSFWBGLEC-SYZQJQIISA-N, RTGDFNSFWBGLEC-SYZQJQIISA-N	Launched
mycophenolic-acid	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	BRD-K63750851-001-20-7, BRD-K63750851-001-19-9, BRD-K63750851-001-18-1	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O, COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N, HPNSFSBZBAHARI-RUDMXATFSA-N	Launched
myricetin	androgen receptor agonist, cytochrome P450 inhibitor	PIK3CG			BRD-K43149758-001-23-5, BRD-K43149758-001-22-7	Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	IKMDFBPHZNJCSN-UHFFFAOYSA-N, IKMDFBPHZNJCSN-UHFFFAOYSA-N	Preclinical
myricitrin	PKC inhibitor	NOS1, PRKCA			BRD-K29834313-001-01-4	C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](O)[C@H]1O	DCYOADKBABEMIQ-FLCVNNLFSA-N	Preclinical
myristyl-nicotinate	topical sunscreen agent				BRD-K88153212-001-01-9	CCCCCCCCCCCCCCOC(=O)c1cccnc1	TVGLGJWCZSCAEM-UHFFFAOYSA-N	Phase 1
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide					BRD-K57027742-001-01-1	Clc1ccccc1NC(=S)NNC(=S)NNC(=C)c1ccccn1	AHKBRSQVOSQELW-UHFFFAOYSA-N	Preclinical
N-(3-methoxyphenyl)prop-2-enamide					BRD-K87269850-001-01-1	COc1cccc(NC(=O)C=C)c1	YDKJSAXEBRKYLM-UHFFFAOYSA-N	Preclinical
N-(4-chlorophenyl)acrylamide					BRD-K43237107-001-01-2	Clc1ccc(NC(=O)C=C)cc1	JEPAGMKWFWQECH-UHFFFAOYSA-N	Preclinical
N-(4-Methoxyphenyl)acrylamide					BRD-K44321941-001-01-3	COc1ccc(NC(=O)C=C)cc1	YMHDGRAROYGJLT-UHFFFAOYSA-N	Preclinical
N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide	sigma receptor ligand				BRD-K78844995-001-02-6	Ic1ccc(cc1)C(=O)NCCN1CCCCC1	WCMWVYQHPUQKHW-UHFFFAOYSA-N	Preclinical
N-acetyl-D-glucosamine		B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP			BRD-K80653534-001-01-7	CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	MBLBDJOUHNCFQT-LXGUWJNJSA-N	Phase 2/Phase 3
N-acetyl-tyrosine					BRD-A24857382-001-03-4	CC(=O)NC(Cc1ccc(O)cc1)C(O)=O	CAHKINHBCWCHCF-UHFFFAOYSA-N	Launched
N-acetylcarnosine					BRD-K52523550-001-01-5	CC(=O)NCCC(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O	BKAYIFDRRZZKNF-VIFPVBQESA-N	Phase 2
N-acetylglycyl-D-glutamic-acid	glutamate receptor agonist				BRD-K28121004-001-01-1	CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	CQTYJLQESPLSOP-ZCFIWIBFSA-N	Preclinical
N-acetylmannosamine		CHIT1			BRD-A92872453-001-01-8	CC(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O	OVRNDRQMDRJTHS-PNALHPDYSA-N	Phase 1
N-acetyltryptamine	melatonin receptor agonist				BRD-K73700643-001-11-2	CC(=O)NCCc1c[nH]c2ccccc12	NVUGEQAEQJTCIX-UHFFFAOYSA-N	Preclinical
N-alpha-Methylhistamine-dihydrochloride	histamine receptor agonist	HRH4			BRD-K64422603-300-02-7	CNCCc1cnc[nH]1	PHSPJQZRQAJPPF-UHFFFAOYSA-N	Phase 3
N-benzylacrylamide					BRD-K81844417-001-01-3	C=CC(=O)NCc1ccccc1	OHLHOLGYGRKZMU-UHFFFAOYSA-N	Preclinical
N-benzylnaltrindole	opioid receptor antagonist				BRD-A33514596-003-01-2	Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1	PSPANKCQVWSVHM-OSLYBJCVSA-N	Preclinical
N-cyanopyrrolidine		CTSK			BRD-K90042229-001-01-1	N#CN1CCCC1	QJRYYOWARFCJQZ-UHFFFAOYSA-N	Preclinical
N-demethylantipyrine					BRD-K84517077-001-01-3	Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N	Preclinical
N-hydroxynicotinamide					BRD-K28030264-001-02-7	ONC(=O)c1cccnc1	IYCHDNQCHLMLJZ-UHFFFAOYSA-N	Preclinical
N-methylformamide					BRD-K33445938-001-01-8	CNC=O	ATHHXGZTWNVVOU-UHFFFAOYSA-N	Phase 2
N-methyllidocaine-iodide	antiarrhythmic medication				BRD-K60060639-005-02-2	CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C	HFRFLLYLVAKRMZ-UHFFFAOYSA-O	Preclinical
N-methylpyrrolidone					BRD-K52732207-001-01-9	CN1CCCC1=O	SECXISVLQFMRJM-UHFFFAOYSA-N	Phase 1
N-methylquipazine	serotonin receptor agonist	HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4			BRD-K62056274-332-01-8	CN1CCN(CC1)c1ccc2ccccc2n1	HOMWNUXPSJQSSU-UHFFFAOYSA-N	Preclinical
N-MPPP	opioid receptor agonist				BRD-K93806173-003-01-8	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1	OVZWUDZIAAHNFG-HXUWFJFHSA-N	Preclinical
N-oxydiethylenebenzothiazole-2-sulfenamide					BRD-K97360717-001-09-2	C1CN(CCO1)Sc1nc2ccccc2s1	MHKLKWCYGIBEQF-UHFFFAOYSA-N	Preclinical
N-phenylacrylamide					BRD-K44160053-001-01-9	C=CC(=O)Nc1ccccc1	BPCNEKWROYSOLT-UHFFFAOYSA-N	Preclinical
N-salicoylaminophenol	ribonucleotide reductase inhibitor				BRD-K39693230-001-01-2	Oc1ccc(NC(=O)c2ccccc2O)cc1	LGCMKPRGGJRYGM-UHFFFAOYSA-N	Preclinical
nabumetone	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K65146499-001-27-9, BRD-K65146499-001-26-1	COc1ccc2cc(CCC(C)=O)ccc2c1, COc1ccc2cc(CCC(C)=O)ccc2c1	BLXXJMDCKKHMKV-UHFFFAOYSA-N, BLXXJMDCKKHMKV-UHFFFAOYSA-N	Launched
nadide	electron acceptor	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2			BRD-A11132253-001-08-2	NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O	BAWFJGJZGIEFAR-NNYOXOHSSA-O	Launched
nadifloxacin	bacterial DNA gyrase inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	BRD-A24397426-001-10-4, BRD-A24397426-001-09-6	CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	JYJTVFIEFKZWCJ-UHFFFAOYSA-N, JYJTVFIEFKZWCJ-UHFFFAOYSA-N	Launched
nadolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, hypertension	BRD-A87606379-001-22-4, BRD-A87606379-001-23-2	CC(C)(C)NCC(O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12, CC(C)(C)NCC(O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12	VWPOSFSPZNDTMJ-UCWKZMIHSA-N, VWPOSFSPZNDTMJ-UCWKZMIHSA-N	Launched
NADPH		AASS, DPYD, GHSR, TXNRD1			BRD-M06409173-001-01-9	NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O	PTKRUDMLGIIORX-ITGWJZMWSA-N	Preclinical
nafadotride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			BRD-A71262238-001-08-4	CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC	IDZASIQMRGPBCQ-UHFFFAOYSA-N	Preclinical
nafamostat	serine protease inhibitor	ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7			BRD-K06674495-334-03-2, BRD-K06674495-334-04-0	NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N, NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	MQQNFDZXWVTQEH-UHFFFAOYSA-N, MQQNFDZXWVTQEH-UHFFFAOYSA-N	Launched
nafcillin	bacterial cell wall synthesis inhibitor	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	BRD-K18574842-236-17-7, BRD-K18574842-323-10-8, BRD-K96812051-323-01-2	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O, CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@H](N2C1=O)C(O)=O	GPXLMGHLHQJAGZ-JTDSTZFVSA-N, GPXLMGHLHQJAGZ-JTDSTZFVSA-N, GPXLMGHLHQJAGZ-GPMSIDNRSA-N	Launched
naftidrofuryl	adrenergic receptor antagonist		cardiology	claudication	BRD-A67862938-034-14-9	CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12	KBAFPSLPKGSANY-UHFFFAOYSA-N	Launched
naftifine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	BRD-K74141488-003-11-2, BRD-K74141488-003-10-4	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12, CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	OZGNYLLQHRPOBR-DHZHZOJOSA-N, OZGNYLLQHRPOBR-DHZHZOJOSA-N	Launched
naftopidil	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	BRD-A01787639-003-16-9, BRD-A01787639-300-08-6, BRD-A01787639-300-09-4, BRD-A01787639-001-06-4, BRD-A01787639-001-08-0, BRD-A01787639-001-07-2	COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1, COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1	HRRBJVNMSRJFHQ-UHFFFAOYSA-N, HRRBJVNMSRJFHQ-UHFFFAOYSA-N, HRRBJVNMSRJFHQ-UHFFFAOYSA-N, HRRBJVNMSRJFHQ-UHFFFAOYSA-N, HRRBJVNMSRJFHQ-UHFFFAOYSA-N, HRRBJVNMSRJFHQ-UHFFFAOYSA-N	Launched
nalbuphine	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry	pain relief	BRD-K66404838-310-01-1, BRD-A92651262-003-04-7	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45, O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5OC1[C@]2(CCN3CC1CCC1)c45	NETZHAKZCGBWSS-CEDHKZHLSA-N, NETZHAKZCGBWSS-XDWDPSITSA-N	Launched
nalfurafine	opioid receptor agonist	OPRK1, OPRM1	nephrology	uremic pruritus	BRD-K89272869-003-01-8	CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1	XGZZHZMWIXFATA-UEZBDDGYSA-N	Launched
nalidixic-acid	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	BRD-K47886988-001-21-4, BRD-K47886988-001-22-2	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12, CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	MHWLWQUZZRMNGJ-UHFFFAOYSA-N, MHWLWQUZZRMNGJ-UHFFFAOYSA-N	Launched
nalmefene	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	pulmonary	respiratory depression	BRD-A72767275-003-01-6	Oc1ccc2CC3N(CC4CC4)CCC45C(Oc1c24)C(=C)CCC35O	WJBLNOPPDWQMCH-UHFFFAOYSA-N	Launched
naloxegol	opioid receptor antagonist	OPRM1	gastroenterology	constipation	BRD-K41458421-034-01-6	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45	XNKCCCKFOQNXKV-ZRSCBOBOSA-N	Launched
naloxone	opioid receptor antagonist	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	BRD-A23195370-003-01-4, BRD-K67511046-003-14-4, BRD-K67511046-003-16-9, BRD-K67511046-003-15-1	Oc1ccc2C[C@H]3N(CC=C)CCC45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	UZHSEJADLWPNLE-IPFLSCHISA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N, UZHSEJADLWPNLE-GRGSLBFTSA-N	Launched
naloxone-benzoylhydrazone	opioid receptor antagonist	OPRK1, OPRM1			BRD-K70898774-001-03-5	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	AKXCFAYOTIEFOH-XTNAHFASSA-N	Preclinical
naltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	BRD-A66559694-003-01-8, BRD-K88172511-003-20-3, BRD-K88172511-003-19-5	Oc1ccc2C[C@H]3N(CC4CC4)CCC45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O, Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	DQCKKXVULJGBQN-PODIIYFMSA-N, DQCKKXVULJGBQN-XFWGSAIBSA-N, DQCKKXVULJGBQN-XFWGSAIBSA-N	Launched
naltriben	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			BRD-A19102171-066-01-4	Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O	ZHVWWEYETMPAMX-OOGIKFLQSA-N	Preclinical
naltrindole	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			BRD-A47342814-003-01-8	Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O	WIYUZYBFCWCCQJ-OOGIKFLQSA-N	Preclinical
Nampt-IN-1					BRD-K18280217-001-01-0	CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1	QHHSCLARESIWBH-UHFFFAOYSA-N	Preclinical
NAN-190	serotonin receptor agonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F			BRD-K69195780-004-08-4	COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	SJDOMIRMMUGQQK-UHFFFAOYSA-N	Preclinical
nanchangmycin	other antibiotic				BRD-A68478444-236-01-8	CO[C@H]1CCC(O[C@H]2CC(O[C@]3(O[C@H](C[C@@H]3C)C3O[C@@](O)(CO)[C@H](C)C[C@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C	FELYAZAWTURXNF-XRXSCDHHSA-N	Preclinical
nandrolone	imidazoline receptor agonist	AR, CYP19A1, MAOA, MAOB	hematology	anemia	BRD-K52080565-001-09-2	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@H]2O	NPAGDVCDWIYMMC-IZPLOLCNSA-N	Launched
nandrolone-decanoate	androgenic steroid	AR			BRD-K78352627-001-01-8	CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C	JKWKMORAXJQQSR-MOPIKTETSA-N	Phase 1
napabucasin	STAT inhibitor	STAT3			BRD-K22064724-001-01-8	CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	DPHUWDIXHNQOSY-UHFFFAOYSA-N	Phase 3
naphazoline	adrenergic receptor agonist	ADRA1A, ADRA2A	ophthalmology	eye irritation	BRD-K77641333-003-27-1, BRD-K77641333-003-26-3	C(C1=NCCN1)c1cccc2ccccc12, C(C1=NCCN1)c1cccc2ccccc12	CNIIGCLFLJGOGP-UHFFFAOYSA-N, CNIIGCLFLJGOGP-UHFFFAOYSA-N	Launched
naphthoquine-phosphate	antimalarial agent				BRD-K13664493-316-02-5, BRD-K13664493-316-01-7	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O, CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	VEVMYTDOWUQLGI-UHFFFAOYSA-N, VEVMYTDOWUQLGI-UHFFFAOYSA-N	Launched
napirimus	immunosuppressant				BRD-K91234829-001-01-7	Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12	CNUPQURTHORUGH-UHFFFAOYSA-N	Phase 1
naproxen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology	pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever	BRD-K59197931-001-04-5, BRD-K59197931-236-22-9, BRD-K59197931-236-21-1, BRD-K59197931-236-20-3	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O, COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N, CMWTZPSULFXXJA-VIFPVBQESA-N	Launched
narasin	antiprotozoal agent		infectious disease	coccidiosis	BRD-A25608658-001-01-1	CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)C4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O	VHKXXVVRRDYCIK-HNOFAURLSA-N	Launched
naratriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	BRD-K61337602-003-03-9, BRD-K61337602-003-02-1	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1, CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	AMKVXSZCKVJAGH-UHFFFAOYSA-N, AMKVXSZCKVJAGH-UHFFFAOYSA-N	Launched
naringenin	aromatase inhibitor, TRPV antagonist	CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1			BRD-K08832567-001-11-5	Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	FTVWIRXFELQLPI-ZDUSSCGKSA-N	Phase 1
naringeninic-acid		HCAR2, PTGR1			BRD-K87122641-001-10-7, BRD-K87122641-001-08-1	OC(=O)\C=C\c1ccc(O)cc1, OC(=O)\C=C\c1ccc(O)cc1	NGSWKAQJJWESNS-ZZXKWVIFSA-N, NGSWKAQJJWESNS-ZZXKWVIFSA-N	Phase 1
naringin	cytochrome P450 inhibitor	SLCO1A2			BRD-K80718324-001-01-2	C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@@H](O)[C@H](O)[C@H]1O	DFPMSGMNTNDNHN-OHQIONLKSA-N	Preclinical
naringin-dihydrochalcone	cytochrome P450 inhibitor				BRD-K13511380-001-01-4	C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	CWBZAESOUBENAP-WMKOAESCSA-N	Preclinical
narlaprevir	HCV inhibitor				BRD-K38287497-001-01-2	CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	RICZEKWVNZFTNZ-LFGITCQGSA-N	Phase 2/Phase 3
nastorazepide	CCK receptor antagonist	CCKBR			BRD-K17295893-001-01-0	CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	VIJCCFFEBCOOIE-JOCHJYFZSA-N	Phase 2
natamycin	fungal ergosterol inhibitor		ophthalmology, infectious disease	conjunctivitis, fungal keratosis, blepharitis	BRD-K90563805-001-02-6, BRD-K40312300-001-01-1, BRD-A00773244-001-01-3, BRD-A00398769-213-01-5, BRD-K63692151-001-01-8	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C/2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](OC2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](OC2CC3OC(O)(CC(O)C3C(O)=O)CC(O)CC3OC3\C=C\C(=O)OC(C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@H](O)[C@@H](N)[C@@H]1O	NCXMLFZGDNKEPB-FFPOYIOWSA-N, NCXMLFZGDNKEPB-UEZLWEFHSA-N, NCXMLFZGDNKEPB-DBPNMPFSSA-N, NCXMLFZGDNKEPB-ZTCXGQLRSA-N, NCXMLFZGDNKEPB-RNAPBSOWSA-N	Launched
nateglinide	insulin secretagogue	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus	BRD-K44353683-001-08-3, BRD-K44353683-001-07-5, BRD-K84658672-001-04-8	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O, CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O	OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-BRWVUGGUSA-N, OELFLUMRDSZNSF-ULQDDVLXSA-N	Launched
navarixin	CC chemokine receptor antagonist	CXCR1, CXCR2			BRD-K82850175-001-01-1	CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	RXIUEIPPLAFSDF-CYBMUJFWSA-N	Phase 2
navitoclax	BCL inhibitor	BCL2, BCL2L1, BCL2L2			BRD-K82746043-001-19-3, BRD-K82746043-001-15-1	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1	JLYAXFNOILIKPP-KXQOOQHDSA-N, JLYAXFNOILIKPP-KXQOOQHDSA-N	Phase 2
NBI-27914	corticosteroid releasing factor receptor antagonist	CRHR1			BRD-K61177364-003-02-9	CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	KNADXBVKFAUMCR-UHFFFAOYSA-N	Preclinical
NBQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B			BRD-K11796549-001-04-5, BRD-K11796549-304-01-9	NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O, NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	UQNAFPHGVPVTAL-UHFFFAOYSA-N, UQNAFPHGVPVTAL-UHFFFAOYSA-N	Preclinical
NCS-382	GABA receptor antagonist	GABBR1, GABBR2, SLC52A2			BRD-A85025557-001-02-5	OC1c2ccccc2CCC\C1=C/C(O)=O	UADPGHINQMWEAG-CSKARUKUSA-N	Preclinical
NE-100	sigma receptor antagonist	SIGMAR1			BRD-K11443721-003-01-6	CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	YBLIQJGXRLZBCZ-UHFFFAOYSA-N	Phase 2
nebivolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension	BRD-K04956647-003-02-5, BRD-K04956647-003-03-3, BRD-A53597562-003-01-2	O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1, O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1, OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1	KOHIRBRYDXPAMZ-YHBROIRLSA-N, KOHIRBRYDXPAMZ-YHBROIRLSA-N, KOHIRBRYDXPAMZ-UHFFFAOYSA-N	Launched
nebracetam	acetylcholine receptor agonist	CHRM1			BRD-A51355958-003-01-9	NCC1CN(Cc2ccccc2)C(=O)C1	LCAFGJGYCUMTGS-UHFFFAOYSA-N	Phase 3
NECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HSP90B1			BRD-K14395568-001-16-3	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	JADDQZYHOWSFJD-FLNNQWSLSA-N	Launched
necrostatin-1	RIPK inhibitor	RIPK1			BRD-A36318220-001-11-2, BRD-A36318220-001-08-8, BRD-A36318220-001-09-6	CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O, CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O, CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O	TXUWMXQFNYDOEZ-UHFFFAOYSA-N, TXUWMXQFNYDOEZ-UHFFFAOYSA-N, TXUWMXQFNYDOEZ-UHFFFAOYSA-N	Preclinical
necrostatin-2	necroptosis inhibitor, RIPK inhibitor	RIPK2			BRD-K68851986-001-01-6	CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O	WIKGAEMMNQTUGL-SNVBAGLBSA-N	Preclinical
nedaplatin	DNA inhibitor				BRD-K73469236-001-01-8	N[Pt]1(N)OCC(=O)O1	GRHLMSBCOPRFNA-UHFFFAOYSA-M	Launched
nedocromil	histamine receptor antagonist	CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR	neurology/psychiatry, ophthalmology	itching, conjunctivitis	BRD-K64716392-001-03-9, BRD-K64716392-001-02-1, BRD-K64716392-001-01-3	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O, CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	RQTOOFIXOKYGAN-UHFFFAOYSA-N, RQTOOFIXOKYGAN-UHFFFAOYSA-N, RQTOOFIXOKYGAN-UHFFFAOYSA-N	Launched
nefazodone	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4			BRD-K90789829-001-07-8, BRD-K90789829-003-12-4	CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1, CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	VRBKIVRKKCLPHA-UHFFFAOYSA-N, VRBKIVRKKCLPHA-UHFFFAOYSA-N	Withdrawn
nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	CHRM1			BRD-K65678996-001-05-5, BRD-K65678996-001-04-8	Cc1cccc(C)c1NC(=O)CN1CCCC1=O, Cc1cccc(C)c1NC(=O)CN1CCCC1=O	NGHTXZCKLWZPGK-UHFFFAOYSA-N, NGHTXZCKLWZPGK-UHFFFAOYSA-N	Phase 3
nefopam	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	BRD-A78877355-001-03-0, BRD-A78877355-003-11-9	CN1CCOC(c2ccccc2)c2ccccc2C1, CN1CCOC(c2ccccc2)c2ccccc2C1	RGPDEAGGEXEMMM-UHFFFAOYSA-N, RGPDEAGGEXEMMM-UHFFFAOYSA-N	Launched
nelarabine	DNA synthesis inhibitor, T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL)	BRD-K84466663-001-05-4	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	IXOXBSCIXZEQEQ-UHTZMRCNSA-N	Launched
nelfinavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K74117820-066-10-8	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	QAGYKUNXZHXKMR-HKWSIXNMSA-N	Launched
nemonapride	dopamine receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	BRD-M80207679-001-01-5	CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C	QCYCDKUNJFKYEI-ZVWWNKPMSA-N	Launched
nemorubicin	topoisomerase inhibitor	TOP1, TOP2A			BRD-K51911221-001-01-2	CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	CTMCWCONSULRHO-UHQPFXKFSA-N	Phase 2
neo-gilurytmal					BRD-A53539450-004-01-7	CCC[N+]12[C@H]3C[C@]45C(O)C3[C@@H](CC1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O	UAUHEPXILIZYCU-CQSZUQOFSA-N	Launched
neohesperidin					BRD-K49617926-001-01-8	COc1cc(O)cc(c1)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]3O)cc2O1	TWAZWVPPDIUVOD-IZJLPOHQSA-N	Preclinical
neohesperidin-dihydrochalcone					BRD-K33395461-001-01-0	COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	ITVGXXMINPYUHD-NGDSJZOMSA-N	Preclinical
neomycin	bacterial 30S ribosomal subunit inhibitor	CXCR4	gastroenterology, infectious disease	hepatic encephalopathy (HE), intra-abdominal infections	BRD-K71013094-326-01-8, BRD-K71013094-001-02-5	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N, PGBHMTALBVVCIT-VCIWKGPPSA-N	Launched
neomycin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	first-aid antibiotic	BRD-A93490927-326-01-7, BRD-A35132579-065-01-1, BRD-A93778806-065-02-3	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)OC(O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3OC3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)OC(O[C@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@H]2O)[C@@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)OC(O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-JZFNLLFKSA-N, PGBHMTALBVVCIT-XRYCRLCKSA-N, PGBHMTALBVVCIT-WFUHEDKOSA-N	Launched
neostigmine	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	BRD-K18922609-004-23-1, BRD-K18922609-004-24-9, BRD-K18922609-004-22-3	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C, CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N, ALWKGYPQUAPLQC-UHFFFAOYSA-N	Launched
nepafenac	cyclooxygenase inhibitor	PTGS1, PTGS2	ophthalmology	eye inflammation	BRD-K04112579-001-07-0	NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N	QEFAQIPZVLVERP-UHFFFAOYSA-N	Launched
nepicastat	dopamine beta hydroxylase inhibitor	DBH			BRD-K09126848-003-02-7, BRD-K09126848-003-01-9	NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1, NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	YZZVIKDAOTXDEB-JTQLQIEISA-N, YZZVIKDAOTXDEB-JTQLQIEISA-N	Phase 2
neratinib	EGFR inhibitor	EGFR, ERBB2, KDR			BRD-K85606544-001-09-1	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	JWNPDZNEKVCWMY-VQHVLOKHSA-N	Phase 3
nerbacadol	cyclooxygenase inhibitor				BRD-K43647122-001-01-3	Cc1oncc1C(=O)N1CCCCC1	ZWNGSOLJLMBZFZ-UHFFFAOYSA-N	Phase 3
neridronic-acid	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease, Pagets disease" "BRD-K60212747-236-01-1" "NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O" "PUUSSSIBPPTKTP-UHFFFAOYSA-N" "Launched"
"1883" "nesbuvir" "RNA polymerase inhibitor" "" "" "" "BRD-K79989959-001-01-4" "CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1" "WTDWVLJJJOTABN-UHFFFAOYSA-N" "Phase 2"
"1884" "netilmicin" "protein synthesis inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-M29626677-343-03-4, BRD-A59825838-315-02-5, BRD-A79774694-315-01-6, BRD-A79774694-315-02-4" "CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O, CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@H]1O, CCN[C@@H]1C[C@@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@@H]1O, CCN[C@@H]1C[C@@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@@H]2N)[C@H](O)[C@H]1OC1OC[C@](C)(O)[C@H](NC)[C@@H]1O" "ZPPSNKXLCHJTDP-DMOYXCCZSA-N, CIDUJQMULVCIBT-OHMMYJSPSA-N, CIDUJQMULVCIBT-JNCMTFRISA-N, CIDUJQMULVCIBT-JNCMTFRISA-N" "Launched"
"1885" "netupitant" "tachykinin antagonist" "TACR1" "gastroenterology" "nausea, vomiting" "BRD-K97428065-001-01-2" "CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1" "WAXQNWCZJDTGBU-UHFFFAOYSA-N" "Launched"
"1886" "neurodazine" "neurogenesis of non-pluripotent C2C12 myoblast inducer" "" "" "" "BRD-K22631935-001-02-7" "COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1" "FEEOFPAEDSMOTO-UHFFFAOYSA-N" "Preclinical"
"1887" "nevirapine" "non-nucleoside reverse transcriptase inhibitor" "CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K15502390-001-20-9, BRD-K15502390-001-19-1" "Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1, Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1" "NQDJXKOVJZTUJA-UHFFFAOYSA-N, NQDJXKOVJZTUJA-UHFFFAOYSA-N" "Launched"
"1888" "nexturastat-a" "HDAC inhibitor" "HDAC1, HDAC6" "" "" "BRD-K70402238-001-02-8" "CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1" "JZWXMCPARMXZQV-UHFFFAOYSA-N" "Preclinical"
"1889" "NFKB-activation-inhibitor-II" "NFkB pathway inhibitor" "RELA" "" "" "BRD-K83354763-001-06-0, BRD-K83354763-001-03-7" "Cc1ccc(NCCCc2ccccc2)c(N)c1, Cc1ccc(NCCCc2ccccc2)c(N)c1" "YMFNPBSZFWXMAD-UHFFFAOYSA-N, YMFNPBSZFWXMAD-UHFFFAOYSA-N" "Preclinical"
"1890" "NG-nitro-arginine" "nitric oxide synthase inhibitor" "NOS1, NOS2, NOS3" "" "" "BRD-K89223384-001-05-2, BRD-K89223384-001-04-5" "N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(O)=O, N[C@@H](CCCNC(=N)N[N+]([O-])=O)C(O)=O" "MRAUNPAHJZDYCK-BYPYZUCNSA-N, MRAUNPAHJZDYCK-BYPYZUCNSA-N" "Phase 1"
"1891" "NGB-2904" "dopamine receptor antagonist" "DRD3" "" "" "BRD-K05181084-003-03-7" "Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl" "YJPWVCIGSHWNON-UHFFFAOYSA-N" "Preclinical"
"1892" "NGD-94-1" "dopamine receptor antagonist" "DRD4" "" "" "BRD-K28639661-001-01-6" "C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1" "OTVQCHUIPJYASM-UHFFFAOYSA-N" "Phase 1"
"1893" "NH125" "eukaryotic translation elongation factor 2 inhibitor" "" "" "" "BRD-K70344361-005-01-4, BRD-K31086665-005-01-2" "CCCCCCCCCCCCCCCCn1cc[n+](Cc2ccccc2)c1C, CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C" "ZZXUNAFAKNKXFW-UHFFFAOYSA-N, ZZXUNAFAKNKXFW-UHFFFAOYSA-N" "Preclinical"
"1894" "niacin" "NAD precursor, vitamin B" "DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT" "endocrinology" "hypertriglyceridemia" "BRD-K60237333-001-27-1, BRD-K60237333-001-26-3, BRD-K60237333-001-28-9" "OC(=O)c1cccnc1, OC(=O)c1cccnc1, OC(=O)c1cccnc1" "PVNIIMVLHYAWGP-UHFFFAOYSA-N, PVNIIMVLHYAWGP-UHFFFAOYSA-N, PVNIIMVLHYAWGP-UHFFFAOYSA-N" "Launched"
"1895" "nialamide" "monoamine oxidase inhibitor" "COMT, MAOA, MAOB" "" "" "BRD-K12102668-001-25-5, BRD-K12102668-001-24-8" "O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1, O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1" "NOIIUHRQUVNIDD-UHFFFAOYSA-N, NOIIUHRQUVNIDD-UHFFFAOYSA-N" "Withdrawn"
"1896" "nibentan" "potassium channel blocker" "" "" "" "BRD-A85876464-001-01-5" "CCN(CC)CCCCC(NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1" "YRFYIORBFFGPPZ-UHFFFAOYSA-N" "Phase 2"
"1897" "nicaraven" "free radical scavenger" "" "" "" "BRD-A86871940-001-01-9" "CC(CNC(=O)c1cccnc1)NC(=O)c1cccnc1" "KTXBOOWDLPUROC-UHFFFAOYSA-N" "Phase 3"
"1898" "nicardipine" "calcium channel blocker" "ADORA3, ADRA1A, ADRA1B, ADRA1D, CACNA1C, CACNA1D, CACNA2D1, CACNB2, CALM1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, PDE1A, PDE1B" "cardiology" "chronic stable angina, hypertension" "BRD-A26711594-003-10-6, BRD-A26711594-003-08-0" "COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1, COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1" "ZBBHBTPTTSWHBA-UHFFFAOYSA-N, ZBBHBTPTTSWHBA-UHFFFAOYSA-N" "Launched"
"1899" "nicergoline" "adrenergic receptor antagonist" "ADRA1A" "rheumatology, neurology/psychiatry, cardiology, hematology" "Raynauds disease, migraine headache, atherosclerosis, thrombosis, Raynauds disease, migraine headache, atherosclerosis, thrombosis" "BRD-K76810206-001-07-3, BRD-K76810206-001-08-1" "CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13, CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13" "YSEXMKHXIOCEJA-FVFQAYNVSA-N, YSEXMKHXIOCEJA-FVFQAYNVSA-N" "Launched"
"1900" "niceritrol" "NAD precursor" "" "endocrinology" "hyperlipidemia" "BRD-K11256763-001-01-5" "O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1" "KUEUWHJGRZKESU-UHFFFAOYSA-N" "Launched"
"1901" "niclosamide" "DNA replication inhibitor, STAT inhibitor" "STAT3" "infectious disease" "tapeworm" "BRD-K35960502-001-20-0, BRD-K35960502-001-19-2" "Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O, Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O" "RJMUSRYZPJIFPJ-UHFFFAOYSA-N, RJMUSRYZPJIFPJ-UHFFFAOYSA-N" "Launched"
"1902" "nicorandil" "nitric oxide donor, potassium channel activator" "KCNJ11" "cardiology" "angina pectoris" "BRD-K97752965-001-16-4, BRD-K97752965-001-14-9, BRD-K97752965-001-15-6, BRD-K97752965-001-13-1" "[O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1, [O-][N+](=O)OCCNC(=O)c1cccnc1" "LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N, LBHIOVVIQHSOQN-UHFFFAOYSA-N" "Launched"
"1903" "nicotinamide" "protein synthesis stimulant" "BST1, LDHA, PARP1, SIRT5" "dermatology" "acne vulgaris (AV)" "BRD-K28912512-001-25-7, BRD-K28912512-001-23-2, BRD-K28912512-001-24-0" "NC(=O)c1cccnc1, NC(=O)c1cccnc1, NC(=O)c1cccnc1" "DFPAKSUCGFBDDF-UHFFFAOYSA-N, DFPAKSUCGFBDDF-UHFFFAOYSA-N, DFPAKSUCGFBDDF-UHFFFAOYSA-N" "Launched"
"1904" "nicotine" "acetylcholine receptor agonist" "CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1" "neurology/psychiatry" "smoking cessation" "BRD-A93695607-322-02-5, BRD-K05395900-322-05-4, BRD-A93695607-322-01-7" "CN1CCCC1c1cccnc1, CN1CCC[C@H]1c1cccnc1, CN1CCCC1c1cccnc1" "SNICXCGAKADSCV-UHFFFAOYSA-N, SNICXCGAKADSCV-JTQLQIEISA-N, SNICXCGAKADSCV-UHFFFAOYSA-N" "Launched"
"1905" "nicotinyl-alcohol-tartrate" "" "" "" "" "BRD-K76600340-045-04-9" "OCc1cccnc1" "MVQVNTPHUGQQHK-UHFFFAOYSA-N" "Launched"
"1906" "nifedipine" "calcium channel blocker" "CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3" "cardiology" "vasospastic angina, chronic stable angina" "BRD-K96354014-001-27-8, BRD-K96354014-001-17-9, BRD-K96354014-001-14-6, BRD-K96354014-001-21-1, BRD-K96354014-001-15-3" "COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC" "HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N, HYIMSNHJOBLJNT-UHFFFAOYSA-N" "Launched"
"1907" "nifekalant" "potassium channel blocker" "" "cardiology" "ventricular arrhythmias, ventricular tachycardia (VT)" "BRD-K32311154-001-01-0" "Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O" "OEBPANQZQGQPHF-UHFFFAOYSA-N" "Launched"
"1908" "nifenalol" "adrenergic receptor antagonist" "ADRB1, ADRB2" "" "" "BRD-A21280314-001-06-8" "CC(C)NCC(O)c1ccc(cc1)[N+]([O-])=O" "UAORFCGRZIGNCI-UHFFFAOYSA-N" "Launched"
"1909" "nifenazone" "analgesic agent" "" "neurology/psychiatry" "pain relief" "BRD-K47407372-001-17-1, BRD-K47407372-001-16-3" "Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C, Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C" "BRZANEXCSZCZCI-UHFFFAOYSA-N, BRZANEXCSZCZCI-UHFFFAOYSA-N" "Launched"
"1910" "niflumic-acid" "cyclooxygenase inhibitor" "ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9" "rheumatology, neurology/psychiatry" "joint pain, muscle pain" "BRD-K98763141-001-30-8, BRD-K98763141-001-29-0" "OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F, OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F" "JZFPYUNJRRFVQU-UHFFFAOYSA-N, JZFPYUNJRRFVQU-UHFFFAOYSA-N" "Launched"
"1911" "nifuroxazide" "bacterial DNA inhibitor" "" "gastroenterology" "colitis, diarrhea" "BRD-K68188368-001-11-0, BRD-K68188368-001-09-4, BRD-K68188368-001-08-6" "Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O" "YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N, YCWSUKQGVSGXJO-NTUHNPAUSA-N" "Launched"
"1912" "nifursol" "bacterial DNA inhibitor" "" "" "" "BRD-K85757157-001-01-7" "Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O" "XXUXXCZCUGIGPP-WLRTZDKTSA-N" "Launched"
"1913" "nifurtimox" "DNA inhibitor" "" "infectious disease" "Chagas disease, African trypanosomiasis" "BRD-A00100033-001-08-9" "CC1CS(=O)(=O)CCN1N=Cc1ccc(o1)[N+]([O-])=O" "ARFHIAQFJWUCFH-UHFFFAOYSA-N" "Launched"
"1914" "niguldipine-(S)-(+)" "adrenergic receptor antagonist" "ADRA1A" "" "" "BRD-K59333713-003-02-0" "COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1" "SVJMLYUFVDMUHP-XIFFEERXSA-N" "Preclinical"
"1915" "nikethamide" "immunostimulant" "" "" "" "BRD-K91544578-001-03-8" "CCN(CC)C(=O)c1cccnc1" "NCYVXEGFNDZQCU-UHFFFAOYSA-N" "Withdrawn"
"1916" "nilotinib" "Abl kinase inhibitor, Bcr-Abl kinase inhibitor" "ABL1, KIT" "hematologic malignancy" "chronic myeloid leukemia (CML)" "BRD-K81528515-001-13-8" "Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F" "HHZIURLSWUIHRB-UHFFFAOYSA-N" "Launched"
"1917" "nilutamide" "androgen receptor antagonist" "AR" "oncology" "prostate cancer" "BRD-K23566484-001-15-1, BRD-K23566484-001-14-4" "CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O" "XWXYUMMDTVBTOU-UHFFFAOYSA-N, XWXYUMMDTVBTOU-UHFFFAOYSA-N" "Launched"
"1918" "nilvadipine" "calcium channel blocker" "CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNA2D3, CACNB2" "cardiology" "hypertension, cerebral artery occlusion" "BRD-A84687895-001-04-0, BRD-A84687895-001-03-2" "COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C" "" ""
"1919" "nimesulide" "cyclooxygenase inhibitor" "LTF, PLA2G2E, PTGS1, PTGS2" "rheumatology, obstetrics/gynecology" "osteoarthritis, menstrual pain" "BRD-K76775527-001-30-2, BRD-K76775527-001-29-4, BRD-K76775527-001-28-6" "CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O, CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O" "HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N, HYWYRSMBCFDLJT-UHFFFAOYSA-N" "Launched"
"1920" "nimodipine" "calcium channel blocker" "AHR, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CFTR, NR3C2" "hematology" "hemorrhage" "BRD-A58048407-001-18-8, BRD-A58048407-001-20-4, BRD-A58048407-001-17-0" "COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C, COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C" "UIAGMCDKSXEBJQ-UHFFFAOYSA-N, UIAGMCDKSXEBJQ-UHFFFAOYSA-N, UIAGMCDKSXEBJQ-UHFFFAOYSA-N" "Launched"
"1921" "nimorazole" "bacterial DNA inhibitor" "" "oncology" "head and neck squamous cell carcinoma (HNSCC)" "BRD-K79145628-001-05-5" "[O-][N+](=O)c1cncn1CCN1CCOCC1" "MDJFHRLTPRPZLY-UHFFFAOYSA-N" "Launched"
"1922" "nimustine" "DNA alkylating agent" "" "" "" "BRD-K13240081-001-06-1, BRD-K13240081-003-06-7" "Cc1ncc(CNC(=O)N(CCCl)[N+][O-])c(N)n1, Cc1ncc(CNC(=O)N(CCCl)[N+][O-])c(N)n1" "VFEDRRNHLBGPNN-UHFFFAOYSA-N, VFEDRRNHLBGPNN-UHFFFAOYSA-N" "Launched"
"1923" "nintedanib" "FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB" "pulmonary" "idiopathic pulmonary fibrosis (IPF)" "BRD-K49075727-001-09-3, BRD-K49075727-001-08-5" "COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1, COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1" "XZXHXSATPCNXJR-ZIADKAODSA-N, XZXHXSATPCNXJR-ZIADKAODSA-N" "Launched"
"1924" "niraparib" "PARP inhibitor" "PARP1" "" "" "BRD-K54955827-001-02-2, BRD-K54955827-001-01-4" "NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1" "PCHKPVIQAHNQLW-CQSZACIVSA-N, PCHKPVIQAHNQLW-CQSZACIVSA-N" "Phase 3"
"1925" "niridazole" "phosphofructokinase inhibitor" "" "infectious disease" "schistosomiasis" "BRD-K53123955-001-10-5" "[O-][N+](=O)c1cnc(s1)N1CCNC1=O" "RDXLYGJSWZYTFJ-UHFFFAOYSA-N" "Launched"
"1926" "nisin" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-U59029435-000-01-7" "" "" "Phase 1"
"1927" "nisoldipine" "calcium channel blocker" "CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1, CACNB2" "cardiology" "hypertension" "BRD-A84465106-001-08-7, BRD-A84465106-001-06-1, BRD-A84465106-001-03-8, BRD-A84465106-001-05-3" "COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C, COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C" "VKQFCGNPDRICFG-UHFFFAOYSA-N, VKQFCGNPDRICFG-UHFFFAOYSA-N, VKQFCGNPDRICFG-UHFFFAOYSA-N, VKQFCGNPDRICFG-UHFFFAOYSA-N" "Launched"
"1928" "nisoxetine" "norepinephrine reuptake inhibitor" "SLC6A2, SLC6A3, SLC6A4" "" "" "BRD-A95696066-003-13-8" "CNCCC(Oc1ccccc1OC)c1ccccc1" "ITJNARMNRKSWTA-UHFFFAOYSA-N" "Phase 1"
"1929" "nitarsone" "" "" "dermatology" "blackhead disease" "BRD-K56707426-001-02-0, BRD-K56707426-001-01-2" "O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O, O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O" "FUUFQLXAIUOWML-UHFFFAOYSA-N, FUUFQLXAIUOWML-UHFFFAOYSA-N" "Launched"
"1930" "nitazoxanide" "pyruvate ferredoxin oxidoreductase inhibitor" "" "gastroenterology" "diarrhea" "BRD-K96471533-001-09-0, BRD-K96471533-001-08-2, BRD-K96471533-001-10-8, BRD-K96471533-001-07-4" "CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O" "YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N, YQNQNVDNTFHQSW-UHFFFAOYSA-N" "Launched"
"1931" "nitecapone" "catechol O methyltransferase inhibitor" "COMT" "" "" "BRD-K75551531-001-01-3" "CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O" "UPMRZALMHVUCIN-UHFFFAOYSA-N" "Phase 2"
"1932" "nitenpyram" "" "" "infectious disease" "flea control" "BRD-K47887731-001-01-4" "CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O" "CFRPSFYHXJZSBI-DHZHZOJOSA-N" "Launched"
"1933" "nithiamide" "bacterial DNA inhibitor" "" "" "" "BRD-K39467894-001-06-7, BRD-K39467894-001-05-9, BRD-K39467894-001-04-2" "CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O, CC(=O)Nc1ncc(s1)[N+]([O-])=O" "UJRRDDHEMZLWFI-UHFFFAOYSA-N, UJRRDDHEMZLWFI-UHFFFAOYSA-N, UJRRDDHEMZLWFI-UHFFFAOYSA-N" "Preclinical"
"1934" "nitisinone" "hydroxyphenylpyruvate dioxygenase inhibitor" "HPD" "metabolism" "tyrosinemia" "BRD-K01109406-001-04-5, BRD-K01109406-001-03-7" "[O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F, [O-][N+](=O)c1cc(ccc1C(=O)C1C(=O)CCCC1=O)C(F)(F)F" "OUBCNLGXQFSTLU-UHFFFAOYSA-N, OUBCNLGXQFSTLU-UHFFFAOYSA-N" "Launched"
"1935" "nitrendipine" "calcium channel blocker" "CACNA1C, CACNA1D, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNB2, CACNG1, KCNN4" "cardiology" "hypertension" "BRD-A02006392-001-16-4, BRD-A02006392-001-17-2, BRD-A02006392-001-15-6" "CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC, CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC" "PVHUJELLJLJGLN-UHFFFAOYSA-N, PVHUJELLJLJGLN-UHFFFAOYSA-N, PVHUJELLJLJGLN-UHFFFAOYSA-N" "Launched"
"1936" "nitrocaramiphen" "cholinergic receptor antagonist" "CHRM1" "" "" "BRD-K28453807-003-11-2" "CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O" "NSHMVLOWOAQFTP-UHFFFAOYSA-N" "Preclinical"
"1937" "nitrofurantoin" "DNA inhibitor" "" "infectious disease" "urinary tract infections, pyelonephritis" "BRD-K76927775-001-11-8, BRD-K76927775-001-10-0" "[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1, [O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1" "NXFQHRVNIOXGAQ-YCRREMRBSA-N, NXFQHRVNIOXGAQ-YCRREMRBSA-N" "Launched"
"1938" "nitrofurazone" "bacterial DNA inhibitor" "" "infectious disease" "first-aid antibiotic" "BRD-K79092138-001-11-0, BRD-K79092138-001-10-2" "NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O, NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O" "IAIWVQXQOWNYOU-FPYGCLRLSA-N, IAIWVQXQOWNYOU-FPYGCLRLSA-N" "Launched"
"1939" "nitromide" "" "" "" "" "BRD-K76381435-001-08-6" "NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O" "UUKWKUSGGZNXGA-UHFFFAOYSA-N" "Launched"
"1940" "nitrosodimethylurea" "DNA synthesis inhibitor" "" "" "" "BRD-K08927448-001-01-9" "CNC(=O)N(C)[N+][O-]" "BHMHNSQLZKUIMD-UHFFFAOYSA-N" "Preclinical"
"1941" "nitroxoline" "cathepsin inhibitor" "METAP2" "infectious disease" "urinary tract infections" "BRD-K97534525-001-23-5, BRD-K97534525-001-24-3" "Oc1ccc([N+]([O-])=O)c2cccnc12, Oc1ccc([N+]([O-])=O)c2cccnc12" "RJIWZDNTCBHXAL-UHFFFAOYSA-N, RJIWZDNTCBHXAL-UHFFFAOYSA-N" "Launched"
"1942" "nizatidine" "histamine receptor antagonist" "HRH2" "gastroenterology" "duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)" "BRD-K73589491-001-11-2, BRD-K46652470-001-09-1" "CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O, CN\C(NCCSCc1csc(CN(C)C)n1)=C\[N+]([O-])=O" "SGXXNSQHWDMGGP-IZZDOVSWSA-N, SGXXNSQHWDMGGP-WDZFZDKYSA-N" "Launched"
"1943" "nizofenone" "ion channel antagonist" "" "neurology/psychiatry" "stroke" "BRD-K84011460-051-01-7" "CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O" "WZGBZLHGOVJDET-UHFFFAOYSA-N" "Launched"
"1944" "NKP-1339" "HSP inhibitor" "" "" "" "BRD-K81645297-236-01-1" "Cl[Ru](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1" "HZRCCSSSNUKHQG-UHFFFAOYSA-J" "Phase 1"
"1945" "NLG919" "indoleamine 2,3-dioxygenase inhibitor" "IDO1" "" "" "BRD-A62133859-001-03-7, BRD-A62133859-001-02-9, BRD-A62133859-001-01-1" "OC(CC1c2ccccc2-c2cncn12)C1CCCCC1, OC(CC1c2ccccc2-c2cncn12)C1CCCCC1, OC(CC1c2ccccc2-c2cncn12)C1CCCCC1" "YTRRAUACYORZLX-UHFFFAOYSA-N, YTRRAUACYORZLX-UHFFFAOYSA-N, YTRRAUACYORZLX-UHFFFAOYSA-N" "Phase 1"
"1946" "NMDA" "glutamate receptor agonist" "GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D" "" "" "BRD-A02508087-001-02-9, BRD-K62414032-001-12-0" "CNC(CC(O)=O)C(O)=O, CN[C@H](CC(O)=O)C(O)=O" "HOKKHZGPKSLGJE-UHFFFAOYSA-N, HOKKHZGPKSLGJE-GSVOUGTGSA-N" "Preclinical"
"1947" "NMS-E973" "HSP inhibitor" "" "" "" "BRD-K58770988-001-01-8" "CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O" "YLQODGGPIHWTHR-UHFFFAOYSA-N" "Preclinical"
"1948" "NMS-P715" "protein kinase inhibitor" "" "" "" "BRD-K54170555-001-01-8" "CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21" "JFOAJUGFHDCBJJ-UHFFFAOYSA-N" "Preclinical"
"1949" "NMS-1286937" "PLK inhibitor" "FLT3, PLK1, PLK2, PLK3" "" "" "BRD-K83699324-001-01-1" "CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1" "QHLVBNKYJGBCQJ-UHFFFAOYSA-N" "Phase 1"
"1950" "NMS-873" "ATPase inhibitor" "VCP" "" "" "BRD-K26253904-001-03-1, BRD-K26253904-001-01-5" "Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O, Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O" "UJGTUKMAJVCBIS-UHFFFAOYSA-N, UJGTUKMAJVCBIS-UHFFFAOYSA-N" "Preclinical"
"1951" "NM107" "RNA polymerase inhibitor" "" "" "" "BRD-A66966115-001-01-0" "CC1(O)C(O)C(CO)OC1n1ccc(N)nc1=O" "PPUDLEUZKVJXSZ-UHFFFAOYSA-N" "Phase 2"
"1952" "NNC-05-2090" "GABA uptake inhibitor, GAT inhibitor" "SLC6A12" "" "" "BRD-K85015012-003-02-9" "COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1" "XZZYCJOGZYEPPW-UHFFFAOYSA-N" "Preclinical"
"1953" "NNC-55-0396" "T-type calcium channel blocker" "CATSPER1, CATSPER2, CATSPER3, CATSPER4" "" "" "BRD-K78122587-300-02-7" "CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1" "VHHVPDKNKPNKHY-JDXGNMNLSA-N" "Preclinical"
"1954" "NNC-63-0532" "opioid receptor agonist" "OPRL1" "" "" "BRD-K72904818-001-01-1" "COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O" "AQMPIDSGLFVVPL-UHFFFAOYSA-N" "Preclinical"
"1955" "NNC-711" "GABA uptake inhibitor" "SIGMAR1, SLC6A1" "" "" "BRD-K42221274-003-07-7" "OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1" "NGNALWDRPKNJGR-UHFFFAOYSA-N" "Preclinical"
"1956" "NO-ASA" "cyclooxygenase inhibitor" "PTGS2" "" "" "BRD-K08807999-001-02-4" "CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1" "IOJUJUOXKXMJNF-UHFFFAOYSA-N" "Phase 2"
"1957" "nobiletin" "MEK inhibitor" "MAP2K1" "" "" "BRD-K06753942-001-14-5" "COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1" "MRIAQLRQZPPODS-UHFFFAOYSA-N" "Preclinical"
"1958" "nocodazole" "tubulin polymerization inhibitor" "HPGDS" "" "" "BRD-K12539581-001-23-7, BRD-K12539581-001-22-9, BRD-K12539581-001-21-1" "COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1, COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1" "KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N, KYRVNWMVYQXFEU-UHFFFAOYSA-N" "Preclinical"
"1959" "nolatrexed" "thymidylate synthase inhibitor" "TYMS" "" "" "BRD-K36636143-001-01-0" "Cc1ccc2nc(N)nc(O)c2c1Sc1ccncc1" "XHWRWCSCBDLOLM-UHFFFAOYSA-N" "Phase 3"
"1960" "nomegestrol-acetate" "progesterone receptor agonist" "PGR" "endocrinology" "contraceptive" "BRD-K27351809-001-09-5" "CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O" "IIVBFTNIGYRNQY-YQLZSBIMSA-N" "Launched"
"1961" "nomifensine" "dopamine uptake inhibitor, noradrenaline uptake inhibitor" "DRD2, MAOA, MAOB, MPO, SLC6A2, SLC6A3" "" "" "BRD-A29644307-050-18-8, BRD-A29644307-050-17-0, BRD-A29644307-050-16-2" "CN1CC(c2ccccc2)c2cccc(N)c2C1, CN1CC(c2ccccc2)c2cccc(N)c2C1, CN1CC(c2ccccc2)c2cccc(N)c2C1" "XXPANQJNYNUNES-UHFFFAOYSA-N, XXPANQJNYNUNES-UHFFFAOYSA-N, XXPANQJNYNUNES-UHFFFAOYSA-N" "Withdrawn"
"1962" "nonivamide" "TRPV agonist" "TRPV1" "rheumatology, neurology/psychiatry" "rheumatoid arthritis, muscle pain" "BRD-K05907307-001-07-1" "CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1" "RGOVYLWUIBMPGK-UHFFFAOYSA-N" "Launched"
"1963" "nonoxynol-9" "membrane integrity inhibitor" "" "endocrinology" "contraceptive" "BRD-K88625236-001-04-2, BRD-K88625236-001-05-9" "CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1, CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1" "FBWNMEQMRUMQSO-UHFFFAOYSA-N, FBWNMEQMRUMQSO-UHFFFAOYSA-N" "Launched"
"1964" "nor-Binaltorphimine-dihydrochloride" "opioid receptor antagonist" "OPRD1, OPRK1, OPRM1" "" "" "BRD-K36381762-300-02-7" "Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O" "APSUXPSYBJVPPS-YAUKWVCOSA-N" "Preclinical"
"1965" "norcyclobenzaprine" "adrenergic receptor agonist, serotonin receptor antagonist" "" "" "" "BRD-K63165456-001-10-8" "CNCCC=C1c2ccccc2C=Cc2ccccc12" "XECQQDXTQRYYBH-UHFFFAOYSA-N" "Preclinical"
"1966" "norelgestromin" "" "PGR" "endocrinology" "contraceptive" "BRD-K42504537-001-01-6" "CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C" "" ""
"1967" "norepinephrine" "adrenergic receptor agonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2" "cardiology, allergy, neurology/psychiatry" "hypertension, urticaria, headache, seasonal affective disorder" "BRD-K87349682-347-03-8, BRD-K87349682-347-02-0, BRD-K87349682-001-04-9" "NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1, NC[C@H](O)c1ccc(O)c(O)c1" "SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N, SFLSHLFXELFNJZ-QMMMGPOBSA-N" "Launched"
"1968" "norethindrone" "progestogen hormone" "PGR" "obstetrics/gynecology" "endometriosis" "BRD-A83260288-001-01-8, BRD-K01123092-001-01-1" "C[C@]12CC[C@@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CCC2(O)C" "" ""
"1969" "norethindrone-acetate" "progesterone receptor agonist" "" "endocrinology, orthopedics, obstetrics/gynecology" "menopause, osteoporosis, vaginal atrophy" "BRD-A09349126-001-10-7" "CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C" "" ""
"1970" "norethisterone" "progesterone receptor agonist" "PGR" "endocrinology, obstetrics/gynecology" "contraceptive, menstrual pain, menopause" "BRD-A39415247-001-10-4" "C[C@]12CCC3C(CCC4=CC(=O)CC[C@H]34)C1CC[C@@]2(O)C" "" ""
"1971" "norethisterone-enanthate" "contraceptive agent" "" "endocrinology" "contraceptive" "BRD-K07625016-001-01-2" "CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C" "" ""
"1972" "noretynodrel" "progestogen hormone" "PGR" "endocrinology" "contraceptive" "BRD-A00758722-001-04-9" "C[C@]12CCC3C(CCC4=C3CCC(=O)C4)C1CC[C@@]2(O)C" "" ""
"1973" "norfloxacin" "bacterial DNA gyrase inhibitor" "TOP2A" "infectious disease, urology" "urinary tract infections, gonorrhea, prostatitis" "BRD-K11196887-001-22-0, BRD-K11196887-001-21-2, BRD-K11196887-001-20-4" "CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1" "OGJPXUAPXNRGGI-UHFFFAOYSA-N, OGJPXUAPXNRGGI-UHFFFAOYSA-N, OGJPXUAPXNRGGI-UHFFFAOYSA-N" "Launched"
"1974" "norfluoxetine" "selective serotonin reuptake inhibitor (SSRI)" "HTR2B" "" "" "BRD-A79769222-001-01-3" "NCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1" "WIQRCHMSJFFONW-UHFFFAOYSA-N" "Phase 1"
"1975" "norgestimate" "progesterone receptor agonist" "ESR1, PGR" "endocrinology" "contraceptive" "BRD-A75867198-001-01-9, BRD-A04756508-001-02-3" "CC[C@]12CC[C@H]3[C@@H](CCC4=CC(CC[C@H]34)[N+][O-])[C@@H]1CC[C@@]2(OC(C)=O)C" "" ""
"1976" "norgestrel" "progesterone receptor agonist" "PGR" "endocrinology" "contraceptive" "BRD-A14886633-001-01-6" "CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C" "" ""
"1977" "nornicotine" "acetylcholine receptor agonist" "" "" "" "BRD-A24543851-001-05-7" "C1CNC(C1)c1cccnc1" "MYKUKUCHPMASKF-UHFFFAOYSA-N" "Preclinical"
"1978" "nortriptyline" "tricyclic antidepressant" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4" "neurology/psychiatry" "depression" "BRD-K91263825-003-21-4" "CNCCC=C1c2ccccc2CCc2ccccc12" "PHVGLTMQBUFIQQ-UHFFFAOYSA-N" "Launched"
"1979" "norvancomycin" "" "" "" "" "BRD-A08791201-003-01-4" "CC(C)CC(N)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(O)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1)c(Cl)c2" "NUAQIRUAZSJTAI-UHFFFAOYSA-N" "Preclinical"
"1980" "noscapine" "bradykinin receptor antagonist, tubulin polymerization inhibitor" "SIGMAR1" "pulmonary" "cough suppressant" "BRD-K91301684-003-05-5, BRD-K91301684-003-04-8, BRD-A51393488-003-02-7" "COc1ccc2[C@@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12, COc1ccc2[C@H](OC(=O)c2c1OC)C1N(C)CCc2cc3OCOc3c(OC)c12" "AKNNEGZIBPJZJG-QZTJIDSGSA-N, AKNNEGZIBPJZJG-QZTJIDSGSA-N, AKNNEGZIBPJZJG-ZVAWYAOSSA-N" "Launched"
"1981" "NOV-002" "" "GSR, GSTM2" "" "" "BRD-K11411329-001-01-3" "N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O" "YPZRWBKMTBYPTK-USZNOCQGSA-N" "Phase 3"
"1982" "novobiocin" "bacterial DNA gyrase inhibitor" "" "obstetrics/gynecology" "mastitis" "BRD-K85307935-236-10-3, BRD-K85307935-236-09-5, BRD-K85307935-236-08-7" "CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C, CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C" "YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N, YJQPYGGHQPGBLI-KGSXXDOSSA-N" "Launched"
"1983" "NPC-01" "steroid" "" "" "" "BRD-K58277159-001-01-7" "C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O" "WSCUHXPGYUMQEX-KCZNZURUSA-N" "Phase 3"
"1984" "NPC-15199" "ICAM1 antagonist" "PPARG" "" "" "BRD-K65275554-001-04-7" "CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O" "CBPJQFCAFFNICX-LJQANCHMSA-N" "Phase 2"
"1985" "NPPB" "chloride channel blocker" "ANO1, CLCN2, CLCN7, TRPA1" "" "" "BRD-K89272762-001-12-7" "OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O" "WBSMIPAMAXNXFS-UHFFFAOYSA-N" "Preclinical"
"1986" "NPS-2143" "calcium receptor antagonist" "CASR" "" "" "BRD-K75506300-001-01-6" "CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C" "" ""
"1987" "NPY-5RA972" "neuropeptide receptor antagonist" "NPY5R" "" "" "BRD-K95600043-001-01-5" "CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12" "ZNFMHLDBJPAFEQ-UHFFFAOYSA-N" "Preclinical"
"1988" "NQDI-1" "caspase inhibitor" "CASP3" "" "" "BRD-K61918008-001-07-1" "CCOC(=O)c1c(O)nc2cccc3C(=O)c4ccccc4-c1c23" "UFJGFNHRMPMALC-UHFFFAOYSA-N" "Preclinical"
"1989" "NS-018" "JAK inhibitor" "JAK1, JAK2, JAK3, TYK2" "" "" "BRD-K21865955-003-01-5" "C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1" "UQTPDWDAYHAZNT-AWEZNQCLSA-N" "Phase 1/Phase 2"
"1990" "NS-8" "potassium channel agonist" "KCNMA1" "" "" "BRD-K22667752-001-01-3" "Cc1c([nH]c(N)c1C" "" ""
"1991" "NSC-23766" "Ras GTPase inhibitor" "" "" "" "BRD-A80213327-305-11-7, BRD-A80213327-305-08-3, BRD-A80213327-305-07-5" "CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1, CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1" "DEFBCZWQLILOJF-UHFFFAOYSA-N, DEFBCZWQLILOJF-UHFFFAOYSA-N, DEFBCZWQLILOJF-UHFFFAOYSA-N" "Preclinical"
"1992" "NSC-319726" "p53 activator" "" "" "" "BRD-K99170882-001-05-0, BRD-K99170882-001-04-3" "C\C(c1ccccn1)=N/NC(=S)N1CCC1, C\C(c1ccccn1)=N/NC(=S)N1CCC1" "XDHBUMNIQRLHGO-UKTHLTGXSA-N, XDHBUMNIQRLHGO-UKTHLTGXSA-N" "Preclinical"
"1993" "NSC-3852" "HDAC inhibitor" "HDAC1" "" "" "BRD-K13169950-001-14-4" "Oc1ccc([N+][O-])c2cccnc12" "RZWRYPGAUIOOMK-UHFFFAOYSA-N" "Preclinical"
"1994" "NSC-405020" "matrix metalloprotease inhibitor" "MMP1" "" "" "BRD-A67975844-001-01-8, BRD-A67975844-001-02-6" "CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1, CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1" "ARDYECYBETXQFD-UHFFFAOYSA-N, ARDYECYBETXQFD-UHFFFAOYSA-N" "Preclinical"
"1995" "NSC-4644" "ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor" "PYGM" "" "" "BRD-K64874225-001-04-7" "CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12" "FVWJYYTZTCVBKE-ROUWMTJPSA-N" "Phase 2"
"1996" "NSC-625987" "CDK inhibitor" "CDK2, CDK4" "" "" "BRD-K62949423-001-03-1" "COc1ccc(OC)c2c1[nH]c1ccccc1c2=S" "KFAKESMKRPNZTM-UHFFFAOYSA-N" "Preclinical"
"1997" "NSC-632839" "ubiquitin specific protease inhibitor" "SENP2, USP1, USP2, USP7" "" "" "BRD-K81197548-003-01-4" "Cc1ccc(cc1)\C=C1/CNC\C(C1=O)=C/c1ccc(C)cc1" "PKCYYPHSCUSQDK-AYKLPDECSA-N" "Preclinical"
"1998" "NSC-663284" "CDC inhibitor" "CDC25A, CDC25B, CDC25C" "" "" "BRD-K03109492-001-02-2" "ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O" "BMKPVDQDJQWBPD-UHFFFAOYSA-N" "Preclinical"
"1999" "NSC-697923" "ubiquitin-conjugating enzyme inhibitor" "UBE2N" "" "" "BRD-K20605374-001-05-4" "Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O" "GAUHIPWCDXOLCZ-UHFFFAOYSA-N" "Preclinical"
"2000" "NSC-95397" "CDC inhibitor" "CDC25A, CDC25B" "" "" "BRD-K68143200-001-11-7" "OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O" "MAASHDQFQDDECQ-UHFFFAOYSA-N" "Preclinical"
"2001" "NSC-9965" "acetylcholine receptor antagonist" "CHRNA4, CHRNB2" "" "" "BRD-K49811169-004-06-6" "CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1" "ALSKYCOJJPXPFS-BBRMVZONSA-N" "Preclinical"
"2002" "NSC5844" "CC chemokine receptor agonist" "CCR1" "" "" "BRD-K73799155-001-01-5" "C(CNc1ccnc2cc(Cl)ccc12)Nc1ccnc2cc(Cl)ccc12" "SSXYXSMMVMVYEV-UHFFFAOYSA-N" "Preclinical"
"2003" "NSI-189" "neurotrophic agent" "" "" "" "BRD-K74371986-001-01-7" "CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1" "DYTOQURYRYYNOR-UHFFFAOYSA-N" "Phase 2"
"2004" "NTNCB" "neuropeptide receptor antagonist" "NPY5R" "" "" "BRD-A40413915-003-01-2" "[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1" "ISSSVYKMIIAPTH-YGQOYYDZSA-N" "Preclinical"
"2005" "nTZDpa" "PPAR receptor agonist" "PPARG" "" "" "BRD-K54708045-001-02-1" "OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1" "VUPOTURDKDMIGQ-UHFFFAOYSA-N" "Preclinical"
"2006" "NT157" "IGF-1 inhibitor" "IGF1R" "" "" "BRD-K54098378-001-01-6" "Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O" "NIPUPOUEGOSAAO-OWOJBTEDSA-N" "Preclinical"
"2007" "NU-1025" "PARP inhibitor" "PARP1" "" "" "BRD-K48692744-001-02-0" "Cc1nc2c(O)cccc2c(=O)[nH]1" "YJDAOHJWLUNFLX-UHFFFAOYSA-N" "Preclinical"
"2008" "NU-7026" "DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor" "PRKDC" "" "" "BRD-K09537769-001-06-5, BRD-K09537769-001-04-0, BRD-K09537769-001-03-2" "O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1, O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1" "KKTZALUTXUZPSN-UHFFFAOYSA-N, KKTZALUTXUZPSN-UHFFFAOYSA-N, KKTZALUTXUZPSN-UHFFFAOYSA-N" "Preclinical"
"2009" "NU-7441" "DNA dependent protein kinase inhibitor" "PRKDC" "" "" "BRD-K00337317-001-06-6" "O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1" "JAMULYFATHSZJM-UHFFFAOYSA-N" "Preclinical"
"2010" "nuclomedone" "immunosuppressant" "" "" "" "BRD-A96466199-001-01-4" "Clc1ccc(CC2C(=O)N=C3SCCN3C2=O)cc1" "QSKVYHYMQQQAFS-UHFFFAOYSA-N" "Phase 3"
"2011" "nutlin-3" "MDM inhibitor" "MDM2, TP53" "" "" "BRD-A12230535-001-06-7, BRD-A12230535-001-11-7" "COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1, COc1ccc(C2=NC(C(N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1" "BDUHCSBCVGXTJM-UHFFFAOYSA-N, BDUHCSBCVGXTJM-UHFFFAOYSA-N" "Preclinical"
"2012" "NU6027" "CDK inhibitor" "CCNA2, CDK2" "" "" "BRD-K03294269-001-08-0" "Nc1nc(N)c([N+][O-])c(OCC2CCCCC2)n1" "DGWXOLHKVGDQLN-UHFFFAOYSA-N" "Preclinical"
"2013" "NVP-ADW742" "insulin growth factor receptor inhibitor" "IGF1R" "" "" "BRD-K15179513-001-04-2, BRD-K15179513-001-05-9, BRD-K15179513-001-03-4" "Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1, Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1" "LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N, LSFLAQVDISHMNB-AFARHQOCSA-N" "Preclinical"
"2014" "NVP-AEW541" "IGF-1 inhibitor" "IGF1R, INSR" "" "" "BRD-K24696047-001-02-3" "Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1" "AECDBHGVIIRMOI-GRGXKFILSA-N" "Preclinical"
"2015" "NVP-AUY922" "HSP inhibitor" "HSP90AA1, HSP90AB1" "" "" "BRD-K41859756-001-09-2, BRD-K41859756-001-08-4, BRD-K41859756-001-06-8" "CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O" "NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N, NDAZATDQFDPQBD-UHFFFAOYSA-N" "Phase 2"
"2016" "NVP-BEZ235" "mTOR inhibitor, PI3K inhibitor" "ATR, MTOR, PIK3CA, PIK3CD, PIK3CG" "" "" "BRD-K12184916-001-19-6, BRD-K12184916-001-15-4" "Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C" "" ""
"2017" "NVP-BGJ398" "FGFR inhibitor" "FGFR1, FGFR2, FGFR3, FGFR4, KDR" "" "" "BRD-K42728290-001-09-1, BRD-K42728290-001-08-3, BRD-K42728290-001-07-5, BRD-K42728290-001-06-7" "CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1, CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1" "QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N, QADPYRIHXKWUSV-UHFFFAOYSA-N" "Phase 2"
"2018" "NVP-BHG712" "ephrin inhibitor" "EPHB4" "" "" "BRD-K79259477-001-04-9" "Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F" "ZCCPLJOKGAACRT-UHFFFAOYSA-N" "Preclinical"
"2019" "NVP-BSK805" "JAK inhibitor" "JAK2" "" "" "BRD-K02017404-300-07-0, BRD-K02017404-300-06-2" "Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1, Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1" "IBPVXAOOVUAOKJ-UHFFFAOYSA-N, IBPVXAOOVUAOKJ-UHFFFAOYSA-N" "Preclinical"
"2020" "NVP-BVU972" "MET inhibitor" "MET" "" "" "BRD-K77943374-001-02-8" "Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1" "RNCNPRCUHHDYPC-UHFFFAOYSA-N" "Preclinical"
"2021" "NVP-DPP728" "dipeptidyl peptidase inhibitor" "DPP4" "" "" "BRD-K77396579-300-01-0" "O=C(CNCCNc1ccc(cn1)C" "" ""
"2022" "NVP-HSP990" "HSP inhibitor" "HSP90AA1, HSP90AB1" "" "" "BRD-K67915505-001-01-2" "COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1" "WSMQUUGTQYPVPD-OAHLLOKOSA-N" "Phase 1"
"2023" "NVP-TAE226" "protein tyrosine kinase inhibitor" "PTK2" "" "" "BRD-K21025364-001-05-6, BRD-K21025364-001-04-9" "CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl, CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl" "UYJNQQDJUOUFQJ-UHFFFAOYSA-N, UYJNQQDJUOUFQJ-UHFFFAOYSA-N" "Preclinical"
"2024" "NVP-TAE684" "ALK tyrosine kinase receptor inhibitor" "ALK, INSR" "" "" "BRD-K50140147-001-10-1" "COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1" "QQWUGDVOUVUTOY-UHFFFAOYSA-N" "Preclinical"
"2025" "NVP-TNKS656" "tankyrase inhibitor" "TNKS2" "" "" "BRD-K87454346-001-01-1" "COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc3CCOCc3c(=O)[nH]2)CC1" "DYGBNAYFDZEYBA-UHFFFAOYSA-N" "Preclinical"
"2026" "NVP-231" "ceramidase inhibitor" "CERK" "" "" "BRD-K01573278-001-02-1" "O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1" "MVSSJPGNLQPWSW-UHFFFAOYSA-N" "Preclinical"
"2027" "NXY-059" "free radical scavenger" "" "" "" "BRD-K46133855-304-03-8, BRD-K46133855-304-02-0" "CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O, CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O" "OVTCHWSLKGENKP-GHXNOFRVSA-N, OVTCHWSLKGENKP-GHXNOFRVSA-N" "Phase 3"
"2028" "nystatin" "fungal ergosterol inhibitor" "" "infectious disease" "esophageal candidiasis, skin infections, yeast infection" "BRD-K82677637-001-01-0, BRD-A78080706-001-04-5, BRD-K25770965-001-01-5, BRD-K45107378-001-01-7, BRD-K33243830-001-01-6" "C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@H]1OC(OC2CC3O[C@@](O)(CC(O)C3C(O)=O)CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)C(C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O, C[C@@H]1O[C@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@H](O)[C@H](N)[C@H]1O, C[C@@H]1O[C@H](O[C@@H]2C[C@@H]3O[C@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@H](O)[C@H](N)[C@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C/CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O" "VQOXZBDYSJBXMA-QEKUPDCNSA-N, VQOXZBDYSJBXMA-VNGPISPUSA-N, VQOXZBDYSJBXMA-VHFLTRTASA-N, VQOXZBDYSJBXMA-NSTZTQKZSA-N, VQOXZBDYSJBXMA-ILCQKZOOSA-N" "Launched"
"2029" "N20C" "glutamate receptor antagonist" "" "" "" "BRD-K41143549-003-02-4" "NC(=O)CNCCC(c1ccccc1)c1ccccc1" "BYGXICRJQZKUPA-UHFFFAOYSA-N" "Preclinical"
"2030" "N6-cyclopentyladenosine" "adenosine receptor agonist" "ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1" "" "" "BRD-K60150510-001-15-6" "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12" "SQMWSBKSHWARHU-SDBHATRESA-N" "Preclinical"
"2031" "N6-methyladenosine" "" "" "" "" "BRD-K81807412-001-10-6" "CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O" "VQAYFKKCNSOZKM-IOSLPCCCSA-N" "Preclinical"
"2032" "N6022" "alcohol dehydrogenase inhibitor" "ADH5" "" "" "BRD-K82522873-001-01-1" "Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O" "YVPGZQLRPAGKLA-UHFFFAOYSA-N" "Phase 1/Phase 2"
"2033" "o-acetyl-L-serine" "" "PTGS1" "" "" "BRD-K63247785-001-01-5" "CC(=O)OC[C@H](N)C(O)=O" "VZXPDPZARILFQX-BYPYZUCNSA-N" "Preclinical"
"2034" "o-mercapto-benzoic-acid" "" "" "" "" "BRD-K36998189-001-03-5" "OC(=O)c1ccccc1S" "NBOMNTLFRHMDEZ-UHFFFAOYSA-N" "Preclinical"
"2035" "O-1918" "cannabinoid receptor antagonist" "" "" "" "BRD-K18316707-001-02-7" "COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C" "ICHJMVMWPKLUKT-JKSUJKDBSA-N" "Preclinical"
"2036" "o-3M3FBS" "phospholipase activator" "" "" "" "BRD-K46384212-001-02-9" "Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F" "SKJJIFRWCCSXGL-UHFFFAOYSA-N" "Preclinical"
"2037" "OAC1" "Oct activator" "" "" "" "BRD-K10878147-001-02-2" "O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1" "HWJRIFZDXJKJJN-UHFFFAOYSA-N" "Preclinical"
"2038" "OAC2" "Oct activator" "POU5F1" "" "" "BRD-K18305454-001-07-4" "O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1" "JCAFGYWSIWYMOX-UHFFFAOYSA-N" "Preclinical"
"2039" "obatoclax" "BCL inhibitor" "BCL2" "" "" "BRD-K15600710-066-05-8, BRD-K15600710-066-04-1" "COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1" "RFTSSZJZXOSICM-GRSHGNNSSA-N, RFTSSZJZXOSICM-GRSHGNNSSA-N" "Phase 3"
"2040" "obeticholic-acid" "FXR agonist" "NR1H4" "" "" "BRD-A75838038-001-01-4" "CCC1C(O)C2C3CCC(C(C)CCC(O)=O)C3(C)CCC2C2(C)CCC(O)CC12" "ZXERDUOLZKYMJM-UHFFFAOYSA-N" "Phase 3"
"2041" "obidoxime" "cholinesterase reactivator" "ACHE" "critical care, neurology/psychiatry" "poison antidote, nerve gas poisoning" "BRD-K33588785-001-01-9" "O\N=C\c1cc[n+](COC[n+]2ccc(cc2)\C=N\O)cc1" "HIGRLDNHDGYWQJ-UHFFFAOYSA-P" "Launched"
"2042" "ochromycinone" "STAT inhibitor" "STAT3" "" "" "BRD-K92524032-001-02-1" "C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21" "ZAWXOCUFQSQDJS-VIFPVBQESA-N" "Phase 1"
"2043" "ocinaplon" "GABA receptor modulator" "GABRA1, GABRA2, GABRA3, GABRA5" "" "" "BRD-K92581468-001-01-6" "O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1" "OQJFBUOFGHPMSR-UHFFFAOYSA-N" "Phase 3"
"2044" "OCO-1112" "cholesterol inhibitor" "" "" "" "BRD-K22097830-001-01-9" "CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O" "ODLDHXPJRGNTPC-UHFFFAOYSA-N" "Phase 2"
"2045" "octadecan-1-ol" "" "" "" "" "BRD-K20501889-001-02-0" "CCCCCCCCCCCCCCCCCCO" "GLDOVTGHNKAZLK-UHFFFAOYSA-N" "Preclinical"
"2046" "octamethyltrisiloxane" "" "" "" "" "BRD-K73201113-001-01-3" "C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C" "CXQXSVUQTKDNFP-UHFFFAOYSA-N" "Preclinical"
"2047" "octenidine" "membrane integrity inhibitor" "" "" "" "BRD-K04568635-300-01-4" "CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1" "ZVXNYZWXUADSRV-UHFFFAOYSA-N" "Launched"
"2048" "octinoxate" "" "" "dermatology" "sunscreen lotion" "BRD-K19972289-001-01-4" "CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1" "YBGZDTIWKVFICR-NRMKIYEFSA-N" "Launched"
"2049" "octisalate" "" "" "dermatology" "sunscreen lotion" "BRD-K95161686-001-02-8" "CCCC[C@@H](CC)COC(=O)c1ccccc1O" "FMRHJJZUHUTGKE-GFCCVEGCSA-N" "Launched"
"2050" "octocrylene" "" "" "dermatology" "sunscreen lotion" "BRD-K39023557-001-01-7" "CCCC[C@@H](CC)COC(=O)C(C" "" ""
"2051" "octodrine" "antitumor agent" "" "" "" "BRD-A37873789-001-01-9" "CC(C)CCCC(C)N" "QNIVIMYXGGFTAK-UHFFFAOYSA-N" "Preclinical"
"2052" "octopamine" "trace amine associated receptor agonist" "F10, TAAR1" "" "" "BRD-A14240607-003-26-1, BRD-A14240607-003-27-9, BRD-A14240607-003-25-3, BRD-A14240607-003-24-6" "NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1, NCC(O)c1ccc(O)cc1" "QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N, QHGUCRYDKWKLMG-UHFFFAOYSA-N" "Preclinical"
"2053" "octreotide" "somatostatin receptor agonist" "SSTR1, SSTR2, SSTR3, SSTR5" "gastroenterology, endocrinology, oncology" "diarrhea, acromegaly, carcinoid tumors" "BRD-A64173453-015-02-3, BRD-A64173453-015-01-5" "CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1, CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)Cc2ccccc2)C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1" "DEQANNDTNATYII-UHFFFAOYSA-N, DEQANNDTNATYII-UHFFFAOYSA-N" "Launched"
"2054" "OC000459" "CRTH receptor antagonist" "PTGDR2" "" "" "BRD-K36463073-001-03-9, BRD-K36463073-001-02-1, BRD-K36463073-001-01-3" "Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O, Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O" "FATGTHLOZSXOBC-UHFFFAOYSA-N, FATGTHLOZSXOBC-UHFFFAOYSA-N, FATGTHLOZSXOBC-UHFFFAOYSA-N" "Phase 2"
"2055" "odanacatib" "cathepsin inhibitor" "CTSK" "" "" "BRD-K22822991-001-02-3" "CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C" "" ""
"2056" "ODM-201" "androgen receptor antagonist" "AR" "" "" "BRD-A01259528-001-01-9, BRD-A44971162-001-01-9" "CC(Cn1ccc(n1)-c1ccc(C" "" ""
"2057" "ODQ" "guanylyl cyclase inhibitor" "GUCY1A2, GUCY1A3, GUCY1B3" "" "" "BRD-K26015241-001-03-6" "O=c1onc2cnc3ccccc3n12" "LZMHWZHOZLVYDL-UHFFFAOYSA-N" "Preclinical"
"2058" "ofloxacin" "bacterial DNA gyrase inhibitor" "TOP2A" "infectious disease, otolaryngology, gastroenterology, endocrinology" "respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections" "BRD-A24228527-213-01-9, BRD-A24228527-001-31-5" "CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O, CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O" "GSDSWSVVBLHKDQ-UHFFFAOYSA-N, GSDSWSVVBLHKDQ-UHFFFAOYSA-N" "Launched"
"2059" "OG-L002" "histone lysine demethylase inhibitor" "KDM1A" "" "" "BRD-A46597779-001-01-5, BRD-K26349472-001-01-3" "NC1CC1c1ccc(cc1)-c1cccc(O)c1, N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1" "DSOJSZXQRJGBCW-UHFFFAOYSA-N, DSOJSZXQRJGBCW-CABCVRRESA-N" "Preclinical"
"2060" "oglemilast" "phosphodiesterase inhibitor" "" "" "" "BRD-K92303087-001-01-6" "CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1" "OKFDRAHPFKMAJH-UHFFFAOYSA-N" "Phase 2"
"2061" "olanzapine" "dopamine receptor antagonist, serotonin receptor antagonist" "ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7" "neurology/psychiatry" "schizophrenia, bipolar disorder" "BRD-K18895904-001-17-9, BRD-K18895904-001-16-1, BRD-K18895904-001-15-3" "CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12, CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12" "KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N, KVWDHTXUZHCGIO-UHFFFAOYSA-N" "Launched"
"2062" "olaparib" "PARP inhibitor" "PARP1, PARP2" "oncology" "ovarian cancer" "BRD-K02113016-001-15-4, BRD-K02113016-001-19-6" "Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1" "FDLYAMZZIXQODN-UHFFFAOYSA-N, FDLYAMZZIXQODN-UHFFFAOYSA-N" "Launched"
"2063" "OLDA" "TRPV agonist" "GPR119" "" "" "BRD-K95523387-001-09-6" "CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1" "QQBPLXNESPTPNU-KTKRTIGZSA-N" "Preclinical"
"2064" "oleamide" "cannabinoid receptor agonist" "HTR7, PLA2G2A" "" "" "BRD-K06644925-001-03-0" "CCCCCCCC\C=C/CCCCCCCC(N)=O" "FATBGEAMYMYZAF-KTKRTIGZSA-N" "Preclinical"
"2065" "oleandrin" "Na/K-ATPase inhibitor" "" "" "" "BRD-K98006098-001-01-6" "CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O" "JLPDBLFIVFSOCC-XYXFTTADSA-N" "Phase 1"
"2066" "oleanolic-acid" "G protein-coupled receptor agonist" "GPBAR1" "" "" "BRD-K90647725-001-07-3, BRD-K90647725-001-06-5" "CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O, CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O" "MIJYXULNPSFWEK-GTOFXWBISA-N, MIJYXULNPSFWEK-GTOFXWBISA-N" "Preclinical"
"2067" "oleoylethanolamide" "cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist" "CNR1, GPR119, GPR55, PPARA" "" "" "BRD-K66956375-001-11-3" "CCCCCCCC\C=C/CCCCCCCC(=O)NCCO" "BOWVQLFMWHZBEF-KTKRTIGZSA-N" "Preclinical"
"2068" "olesoxime" "apoptosis stimulant" "" "" "" "BRD-K18210059-001-01-8" "CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O" "QNTASHOAVRSLMD-SIWSWZRQSA-N" "Phase 2/Phase 3"
"2069" "oleuropein" "estrogen receptor agonist" "GPER1" "" "" "BRD-A00842753-001-01-9" "COC(=O)C1=COC(OC2OC(CO)C(O)C(O)C2O)\C(=C/C)C1CC(=O)OCCc1ccc(O)c(O)c1" "RFWGABANNQMHMZ-DXNYSGJVSA-N" "Phase 2"
"2070" "oligomycin-a" "ATP synthase inhibitor, ATPase inhibitor" "ATP5A1" "" "" "BRD-K52536804-001-01-1" "CC[C@@H]1CC[C@@H]2O[C@@]3(CC[C@@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C\[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C/C=C\1)[C@@H]2C" "MNULEGDCPYONBU-PNZMTSLHSA-N" "Preclinical"
"2071" "olmesartan" "angiotensin receptor antagonist" "AGTR1" "cardiology" "hypertension" "BRD-K83144676-001-09-5, BRD-K83144676-001-08-7, BRD-K83144676-001-06-1, BRD-K83144676-001-07-9" "CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O, CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O" "VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N, VTRAEEWXHOVJFV-UHFFFAOYSA-N" "Launched"
"2072" "olmesartan-medoxomil" "angiotensin receptor antagonist" "AGTR1" "cardiology" "hypertension" "BRD-K78485176-001-07-8, BRD-K78485176-001-06-0" "CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1, CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1" "UQGKUQLKSCSZGY-UHFFFAOYSA-N, UQGKUQLKSCSZGY-UHFFFAOYSA-N" "Launched"
"2073" "olmutinib" "EGFR inhibitor, Brutons tyrosine kinase (BTK) inhibitor	BTK, EGFR			BRD-K60421517-001-01-4	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	FDMQDKQUTRLUBU-UHFFFAOYSA-N	Launched
olomoucine	CDK inhibitor	CDK1, CDK2, CDK5, MAPK1			BRD-K82731415-001-07-0	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	GTVPOLSIJWJJNY-UHFFFAOYSA-N	Preclinical
olopatadine	histamine receptor antagonist	HRH1, S100A1, S100A12, S100A13, S100A2, S100B	ophthalmology	conjunctivitis	BRD-K06625472-003-01-6	CN(C)CC\C=C1/c2ccccc2COc2ccc(CC(O)=O)cc12	JBIMVDZLSHOPLA-QGMBQPNBSA-N	Launched
olprinone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	BRD-K20745393-003-01-0	Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N	JPAWFIIYTJQOKW-UHFFFAOYSA-N	Launched
olsalazine	cyclooxygenase inhibitor	IFNG, TPMT	gastroenterology	ulcerative colitis	BRD-K57853941-304-02-5, BRD-K57853941-304-03-3	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O, OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	QQBDLJCYGRGAKP-FOCLMDBBSA-N, QQBDLJCYGRGAKP-FOCLMDBBSA-N	Launched
oltipraz	nuclear factor erythroid derived, like (NRF2) activator	ANG			BRD-K86972824-001-02-2, BRD-K86972824-001-01-4	Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1	CKNAQFVBEHDJQV-UHFFFAOYSA-N, CKNAQFVBEHDJQV-UHFFFAOYSA-N	Phase 3
olvanil	TRPV agonist	CNR1, GPR119, TRPV1			BRD-K31560319-001-01-5	CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	OPZKBPQVWDSATI-KHPPLWFESA-N	Preclinical
omadacycline	bacterial 30S ribosomal subunit inhibitor				BRD-A72591750-066-01-1	CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(CNCC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C	OVIWLBQFYMOVOF-NPGXJKJDSA-N	Phase 3
omarigliptin	dipeptidyl peptidase inhibitor	DPP4			BRD-K14171291-001-01-4	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	MKMPWKUAHLTIBJ-ISTRZQFTSA-N	Launched
ombitasvir	HCV inhibitor		infectious disease	hepatitis C	BRD-K11072003-001-01-6	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1	PIDFDZJZLOTZTM-KHVQSSSXSA-N	Launched
OMDM-2	FAAH inhibitor	GPR119			BRD-K48830578-001-01-9	CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	ICDMLAQPOAVWNH-HAAQQRBASA-N	Preclinical
omecamtiv-mecarbil	cardiac myosin activator	MYBPC3			BRD-K36680103-001-01-6	COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	RFUBTTPMWSKEIW-UHFFFAOYSA-N	Phase 2
omega-(4-Iodophenyl)pentadecanoic acid					BRD-K53156781-001-01-4	OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1	YAONEUNUMVOKNQ-UHFFFAOYSA-N	Preclinical
omega-3-acid-esters	cholesterol inhibitor				BRD-K31139048-001-03-2, BRD-K31139048-001-02-4	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC, CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	SSQPWTVBQMWLSZ-AAQCHOMXSA-N, SSQPWTVBQMWLSZ-AAQCHOMXSA-N	Launched
omeprazole	ATPase inhibitor	ATP4A, CLCN2	gastroenterology	heartburn	BRD-A55962179-001-22-1, BRD-A55962179-001-23-9, BRD-A55962179-001-24-7, BRD-A55962179-001-21-3	COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C, COc1ccc2nc([nH]c2c1)S(=O)Cc1ncc(C)c(OC)c1C	SUBDBMMJDZJVOS-UHFFFAOYSA-N, SUBDBMMJDZJVOS-UHFFFAOYSA-N, SUBDBMMJDZJVOS-UHFFFAOYSA-N, SUBDBMMJDZJVOS-UHFFFAOYSA-N	Launched
omeprazole-magnesium	proton pump inhibitor	ATP4A, ATP4B	gastroenterology	gastroesophageal reflux disease (GERD), heartburn	BRD-A56892734-001-09-4	COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)S(=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)S(=O)Cc1ncc(C)c(OC)c1C	KWORUUGOSLYAGD-UHFFFAOYSA-N	Launched
omeprazole-sulfide	ATPase inhibitor				BRD-K69035426-001-01-3	COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1	XURCIPRUUASYLR-UHFFFAOYSA-N	Phase 1
ON-01500	apoptosis stimulant				BRD-K55790047-001-01-8	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1	KUTAVMCJCVADGZ-BQYQJAHWSA-N	Preclinical
oncrasin-1	apoptosis stimulant				BRD-K43449605-001-01-0	Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	ZDRQMXCSSAPUMM-UHFFFAOYSA-N	Preclinical
ONC201	AKT inhibitor, MAP kinase inhibitor	TNFSF10			BRD-K58529924-001-01-5	Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O	VLULRUCCHYVXOH-UHFFFAOYSA-N	Phase 2
ondansetron	serotonin receptor antagonist	HTR1A, HTR1B, HTR3A, HTR3B, HTR4, OPRM1	gastroenterology	nausea, vomiting	BRD-A19736161-001-06-7, BRD-A19736161-003-14-7, BRD-A19736161-001-05-9	Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C, Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C, Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C	FELGMEQIXOGIFQ-UHFFFAOYSA-N, FELGMEQIXOGIFQ-UHFFFAOYSA-N, FELGMEQIXOGIFQ-UHFFFAOYSA-N	Launched
ONO-4059	Brutons tyrosine kinase (BTK) inhibitor" "BTK" "" "" "BRD-A13689093-001-01-8" "Nc1ncnc2n(C3CCCN(C3)C(=O)C=C)c(=O)n(-c3ccc(Oc4ccccc4)cc3)c12" "KSUDUUBCXJUFRL-UHFFFAOYSA-N" "Phase 1"
"2074" "ONO-4817" "matrix metalloprotease inhibitor" "MMP8" "" "" "BRD-K58894520-001-01-1" "CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1" "HDWWQELUBWGQGA-WMZOPIPTSA-N" "Phase 1"
"2075" "ONX-0914" "proteasome inhibitor" "" "" "" "BRD-K60446698-001-01-2" "COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@]2(C)CO2)cc1" "WQAVPPWWLLVGFK-FRDWYVIJSA-N" "Preclinical"
"2076" "ON123300" "CDK inhibitor" "CDK4, NUAK1, PDGFRB" "" "" "BRD-K88554883-001-01-6" "CN1CCN(CC1)c1ccc(Nc2ncc3cc(C" "" ""
"2077" "OPC-21268" "vasopressin receptor antagonist" "AVPR1A, AVPR2, OXTR" "" "" "BRD-K19426040-001-01-1" "CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12" "KSNUCNRMDYJBKT-UHFFFAOYSA-N" "Phase 1"
"2078" "opicapone" "catechol O methyltransferase inhibitor" "COMT" "" "" "BRD-K66192203-001-02-2, BRD-K66192203-001-01-4" "Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O" "ASOADIZOVZTJSR-UHFFFAOYSA-N, ASOADIZOVZTJSR-UHFFFAOYSA-N" "Phase 3"
"2079" "opipramol" "sigma receptor agonist" "" "neurology/psychiatry" "generalized anxiety disorder (GAD)" "BRD-K43786866-300-02-3" "OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1" "YNZFUWZUGRBMHL-UHFFFAOYSA-N" "Launched"
"2080" "oprozomib" "proteasome inhibitor" "" "" "" "BRD-A36331462-001-02-1" "COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1" "SWZXEVABPLUDIO-QNLBTCDKSA-N" "Phase 1/Phase 2"
"2081" "OR-486" "catechol O methyltransferase inhibitor" "COMT" "" "" "BRD-K18602506-001-08-0" "Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O" "VDCDWNDTNSWDFJ-UHFFFAOYSA-N" "Preclinical"
"2082" "orantinib" "FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB" "" "" "BRD-K55966568-001-09-6, BRD-K55966568-001-05-4, BRD-K55966568-001-06-2" "Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O, Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O" "NHFDRBXTEDBWCZ-ZROIWOOFSA-N, NHFDRBXTEDBWCZ-ZROIWOOFSA-N, NHFDRBXTEDBWCZ-ZROIWOOFSA-N" "Phase 3"
"2083" "orbifloxacin" "bacterial DNA gyrase inhibitor" "" "infectious disease" "urinary tract infections" "BRD-K63001556-001-09-6, BRD-K63001556-001-08-8, BRD-K68153448-001-01-9" "C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1" "QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-DTORHVGOSA-N, QIPQASLPWJVQMH-RKDXNWHRSA-N" "Launched"
"2084" "ORE1001" "angiotensin converting enzyme inhibitor" "ACE2" "" "" "BRD-K67068943-001-01-0" "CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O" "NTCCRGGIJNDEAB-IRXDYDNUSA-N" "Phase 1/Phase 2"
"2085" "Org-12962" "serotonin receptor agonist" "HTR2A, HTR2B, HTR2C" "" "" "BRD-K07409305-001-01-1" "FC(F)(F)c1ccc(nc1Cl)N1CCNCC1" "QZYYPQAYSFBKPW-UHFFFAOYSA-N" "Phase 2"
"2086" "org-26576" "glutamate receptor modulator" "" "" "" "BRD-K40002998-001-01-5" "O=C1N2CCC[C@H]2COc2ncccc12" "FIKUEZUFASUKAH-QMMMGPOBSA-N" "Phase 2"
"2087" "org-27569" "cannabinoid receptor modulator" "CNR1" "" "" "BRD-K57597776-001-01-2" "CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1" "AHFZDNYNXFMRFQ-UHFFFAOYSA-N" "Preclinical"
"2088" "org-9768" "adrenergic receptor antagonist" "ADRA2A" "" "" "BRD-K41434598-003-01-9" "CC1(CN)Cc2ccccc2C1" "JOLKQWPKJFRPOU-UHFFFAOYSA-N" "Phase 1"
"2089" "oridonin" "BCL inhibitor" "BCL2" "" "" "BRD-A09838294-001-02-2, BRD-A99499647-001-01-0" "CC1(C)CC[C@H](O)[C@]23CO[C@](O)([C@@H](O)[C@H]12)[C@@]12[C@H](O)[C@@H](CCC31)C(=C)C2=O, CC1(C)CC[C@H](O)[C@@]23CO[C@](O)([C@H](O)[C@H]12)[C@]12[C@H](O)[C@@H](CCC31)C(=C)C2=O" "SDHTXBWLVGWJFT-CAYOSMHYSA-N, SDHTXBWLVGWJFT-QVKMGZASSA-N" "Preclinical"
"2090" "oritavancin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "skin infections" "BRD-A33352494-316-01-6" "CNC(CC(C)C)C(=O)NC1C(O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)C(OC5CC(C)(N)C(O)C(C)O5)C5NC(=O)C(NC(=O)C4NC(=O)C(CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1C(NC5=O)C(O)=O)c3OC1OC(CO)C(O)C(O)C1OC1CC(C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)C(O)C(C)O1)c(Cl)c2" "VHFGEBVPHAGQPI-UHFFFAOYSA-N" "Launched"
"2091" "orlistat" "lipase inhibitor" "CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP" "endocrinology" "weight-loss aid" "BRD-K63343048-001-13-0, BRD-K63343048-001-12-2, BRD-K94062100-001-04-3" "CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O, CCCCCCCCCCC[C@@H](C[C@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H](CC(C)C)NC=O" "AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-FWEHEUNISA-N, AHLBNYSZXLDEJQ-GWMMUDDPSA-N" "Launched"
"2092" "ornidazole" "antiprotozoal agent" "" "infectious disease" "protozoan infection" "BRD-A42759514-001-21-3, BRD-A42759514-001-20-5, BRD-A42759514-001-19-7" "Cc1ncc(n1CC(O)CCl)[N+]([O-])=O, Cc1ncc(n1CC(O)CCl)[N+]([O-])=O, Cc1ncc(n1CC(O)CCl)[N+]([O-])=O" "IPWKIXLWTCNBKN-UHFFFAOYSA-N, IPWKIXLWTCNBKN-UHFFFAOYSA-N, IPWKIXLWTCNBKN-UHFFFAOYSA-N" "Launched"
"2093" "ornithine" "NFkB pathway modulator" "ARG1, ARG2, GATM, GPRC6A, OAT, OAZ1, OAZ2, OAZ3, OTC, SLC25A15, SLC25A2, SLC7A1, SLC7A2, SLC7A3, SLC7A4" "" "" "BRD-A13561534-003-02-0" "NCCCC(N)C(O)=O" "AHLPHDHHMVZTML-UHFFFAOYSA-N" "Launched"
"2094" "orotic-acid" "" "DHODH" "" "" "BRD-K32572029-001-05-1, BRD-K32572029-001-04-4" "OC(=O)c1cc(=O)[nH]c(=O)[nH]1, OC(=O)c1cc(=O)[nH]c(=O)[nH]1" "PXQPEWDEAKTCGB-UHFFFAOYSA-N, PXQPEWDEAKTCGB-UHFFFAOYSA-N" "Phase 2"
"2095" "orphanin-fq" "opioid receptor agonist" "OPRL1, OPRM1" "" "" "BRD-K05717154-001-01-1" "CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O" "PULGYDLMFSFVBL-SMFNREODSA-N" "Phase 1"
"2096" "orphenadrine" "acetylcholine receptor antagonist" "GRIN1, GRIN2D, GRIN3A, GRIN3B, HRH1, SCN10A, SLC6A2" "neurology/psychiatry" "muscle pain" "BRD-A53576514-048-14-3, BRD-A53576514-048-13-5" "CN(C)CCOC(c1ccccc1)c1ccccc1C, CN(C)CCOC(c1ccccc1)c1ccccc1C" "QVYRGXJJSLMXQH-UHFFFAOYSA-N, QVYRGXJJSLMXQH-UHFFFAOYSA-N" "Launched"
"2097" "orteronel" "androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor" "CYP17A1" "" "" "BRD-K00674894-001-01-4" "CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12" "OZPFIJIOIVJZMN-GOSISDBHSA-N" "Phase 3"
"2098" "ORY-1001" "histone lysine demethylase inhibitor" "KDM1A" "" "" "BRD-K59711701-300-02-1, BRD-K59711701-300-01-3" "NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1, NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1" "ALHBJBCQLJZYON-PFSRBDOWSA-N, ALHBJBCQLJZYON-PFSRBDOWSA-N" "Phase 1/Phase 2"
"2099" "oseltamivir-carboxylate" "neuraminidase inhibitor" "" "infectious disease" "influenza A virus infection" "BRD-K93767137-001-01-1" "CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O" "NENPYTRHICXVCS-YNEHKIRRSA-N" "Launched"
"2100" "oseltamivir-phosphate" "neuraminidase inhibitor" "CES1, NEU1, NEU2" "infectious disease" "influenza A virus infection" "BRD-K76011241-011-02-5, BRD-K76011241-001-01-8, BRD-K76011241-001-02-6" "CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1" "VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N, VSZGPKBBMSAYNT-RRFJBIMHSA-N" "Launched"
"2101" "osemozotan" "serotonin receptor agonist" "HTR1A" "" "" "BRD-K60371362-001-01-7" "C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1" "MEEQBDCQPIZMLY-HNNXBMFYSA-N" "Phase 2/Phase 3"
"2102" "OSI-027" "mTOR inhibitor" "MTOR" "" "" "BRD-K87124298-001-04-2, BRD-K87124298-001-03-4" "COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12, COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12" "JROFGZPOBKIAEW-HAQNSBGRSA-N, JROFGZPOBKIAEW-HAQNSBGRSA-N" "Phase 1"
"2103" "OSI-420" "EGFR inhibitor" "EGFR" "" "" "BRD-K73309154-003-02-8" "COCCOc1cc2ncnc(Nc3cccc(c3)C" "" ""
"2104" "OSI-930" "KIT inhibitor, VEGFR inhibitor" "KDR, KIT" "" "" "BRD-K25340465-001-11-1, BRD-K25340465-001-07-9" "FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1, FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1" "FGTCROZDHDSNIO-UHFFFAOYSA-N, FGTCROZDHDSNIO-UHFFFAOYSA-N" "Phase 1"
"2105" "osimertinib" "EGFR inhibitor" "EGFR" "oncology" "non-small cell lung cancer (NSCLC)" "BRD-K42805893-001-04-9" "COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12" "DUYJMQONPNNFPI-UHFFFAOYSA-N" "Launched"
"2106" "ospemifene" "selective estrogen receptor modulator (SERM)" "ESR1, ESR2" "obstetrics/gynecology, endocrinology" "vaginal atrophy, dyspareunia, menopause" "BRD-K44184170-001-01-7" "OCCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1" "LUMKNAVTFCDUIE-VHXPQNKSSA-N" "Launched"
"2107" "ostarine" "androgen receptor modulator" "AR" "" "" "BRD-K29735307-001-02-9" "C[C@](O)(COc1ccc(cc1)C" "" ""
"2108" "osthol" "calcium channel blocker" "" "" "" "BRD-K78294846-001-12-4" "COc1ccc2ccc(=O)oc2c1CC=C(C)C" "MBRLOUHOWLUMFF-UHFFFAOYSA-N" "Preclinical"
"2109" "OT-R-antagonist-1" "oxytocin receptor antagonist" "AVPR1A, OXTR" "" "" "BRD-K42009284-001-01-1" "CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1" "IBXGJPAYWMFXSF-UEEONYLUSA-N" "Preclinical"
"2110" "otamixaban" "coagulation factor inhibitor" "F10" "" "" "BRD-K80082640-001-01-0" "COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1" "PFGVNLZDWRZPJW-OPAMFIHVSA-N" "Phase 3"
"2111" "otenzepad" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "" "" "BRD-A00520476-001-07-4" "CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12" "UBRKDAVQCKZSPO-UHFFFAOYSA-N" "Phase 3"
"2112" "otilonium" "acetylcholine receptor antagonist" "CACNA1C" "gastroenterology" "irritable bowel syndrome" "BRD-K85337334-004-02-6" "CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC" "NQHNLNLJPDMBFN-UHFFFAOYSA-O" "Launched"
"2113" "OTS167" "maternal embryonic leucine zipper kinase inhibitor" "MELK" "" "" "BRD-K53417444-003-03-1" "CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O" "DKZYXHCYPUVGAF-JCNLHEQBSA-N" "Phase 1"
"2114" "OTS514" "TOPK inhibitor" "" "" "" "BRD-K38018935-001-01-1" "C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12" "OETLNMOJNONWOY-LBPRGKRZSA-N" "Preclinical"
"2115" "OTX015" "bromodomain inhibitor" "BRD2, BRD3, BRD4" "" "" "BRD-K43471985-001-03-0, BRD-K43471985-001-05-5" "Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1, Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1" "GNMUEVRJHCWKTO-FQEVSTJZSA-N, GNMUEVRJHCWKTO-FQEVSTJZSA-N" "Phase 1/Phase 2"
"2116" "ouabain" "ATPase inhibitor" "ATP1A1" "cardiology" "hypertension, cardiac arrythmia" "BRD-A68930007-331-01-6, BRD-K92158972-331-01-3, BRD-K33277808-001-01-2" "C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)C4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)C4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O, C[C@H]1O[C@@H](O[C@@H]2C[C@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O" "LPMXVESGRSUGHW-XPXORLBYSA-N, LPMXVESGRSUGHW-VQCSFJQRSA-N, LPMXVESGRSUGHW-VGFRVVOQSA-N" "Launched"
"2117" "oxacillin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "staphylococcal infections" "BRD-K96786677-323-02-0, BRD-A66481418-236-04-0, BRD-K71213463-323-01-4" "Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)NC1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1, Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@H](N2C1=O)C(O)=O)-c1ccccc1" "UWYHMGVUTGAWSP-JKIFEVAISA-N, UWYHMGVUTGAWSP-XLGXCUCASA-N, UWYHMGVUTGAWSP-CKEIUWERSA-N" "Launched"
"2118" "oxacyclohexadecan-2-one" "protein kinase inhibitor" "" "" "" "BRD-K36982194-001-01-6" "O=C1CCCCCCCCCCCCCCO1" "FKUPPRZPSYCDRS-UHFFFAOYSA-N" "Preclinical"
"2119" "oxaliplatin" "DNA inhibitor" "" "oncology" "colorectal cancer" "BRD-K78960041-001-05-7, BRD-A20035137-001-01-3, BRD-K78960041-001-02-4, BRD-K78960041-001-03-2" "O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(NC3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O, O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O" "DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BLJHELNISA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L, DWAFYCQODLXJNR-BNTLRKBRSA-L" "Launched"
"2120" "oxaloacetate" "glutamate release inhibitor" "CS, SPR" "" "" "BRD-K61279411-001-02-0" "OC(=O)CC(=O)C(O)=O" "KHPXUQMNIQBQEV-UHFFFAOYSA-N" "Phase 2/Phase 3"
"2121" "oxandrolone" "androgen receptor agonist" "AR" "endocrinology" "weight-gain aid" "BRD-K92467929-001-01-1" "C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C" "QSLJIVKCVHQPLV-PEMPUTJUSA-N" "Launched"
"2122" "oxantel" "anthelmintic agent" "" "" "" "BRD-K66019333-096-02-0" "CN1CCCN=C1\C=C\c1cccc(O)c1" "VRYKTHBAWRESFI-VOTSOKGWSA-N" "Phase 3"
"2123" "oxaprozin" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "rheumatology" "osteoarthritis, rheumatoid arthritis" "BRD-K25394294-001-14-9, BRD-K25394294-001-13-1" "OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1, OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1" "OFPXSFXSNFPTHF-UHFFFAOYSA-N, OFPXSFXSNFPTHF-UHFFFAOYSA-N" "Launched"
"2124" "oxatomide" "histamine receptor antagonist" "HRH1" "allergy" "allergic rhinitis" "BRD-K02079473-001-01-3" "O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1" "BAINIUMDFURPJM-UHFFFAOYSA-N" "Launched"
"2125" "oxazepam" "GABA benzodiazepine site receptor agonist" "GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3" "neurology/psychiatry" "anxiety" "BRD-A50049929-001-01-9" "OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O" "ADIMAYPTOBDMTL-UHFFFAOYSA-N" "Launched"
"2126" "oxcarbazepine" "sodium channel blocker" "SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "seizures" "BRD-K04196797-001-25-1, BRD-K04196797-001-24-4, BRD-K04196797-001-23-6" "NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12, NC(=O)N1c2ccccc2CC(=O)c2ccccc12" "CTRLABGOLIVAIY-UHFFFAOYSA-N, CTRLABGOLIVAIY-UHFFFAOYSA-N, CTRLABGOLIVAIY-UHFFFAOYSA-N" "Launched"
"2127" "oxelaidin" "antitussive" "" "pulmonary" "cough suppressant" "BRD-K17977438-048-02-4, BRD-K17977438-048-04-0, BRD-K17977438-048-03-2" "CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1, CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1" "IQADUMSPOQKAAO-UHFFFAOYSA-N, IQADUMSPOQKAAO-UHFFFAOYSA-N, IQADUMSPOQKAAO-UHFFFAOYSA-N" "Launched"
"2128" "oxethazaine" "local anesthetic" "" "neurology/psychiatry" "local anesthetic" "BRD-K56940463-001-13-8, BRD-K56940463-001-14-6" "CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1, CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1" "FTLDJPRFCGDUFH-UHFFFAOYSA-N, FTLDJPRFCGDUFH-UHFFFAOYSA-N" "Launched"
"2129" "oxfendazole" "anthelmintic agent" "" "infectious disease" "lungworms, tapeworm, gastrointestinal roundworms" "BRD-A33447119-001-10-8, BRD-A33447119-001-11-6" "COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1, COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1" "BEZZFPOZAYTVHN-UHFFFAOYSA-N, BEZZFPOZAYTVHN-UHFFFAOYSA-N" "Launched"
"2130" "oxfenicine" "carnitine palmitoyltransferase inhibitor" "CPT1A, CPT1B" "" "" "BRD-A86525947-001-01-4, BRD-K30373577-001-01-1" "NC(C(O)=O)c1ccc(O)cc1, N[C@@H](C(O)=O)c1ccc(O)cc1" "LJCWONGJFPCTTL-UHFFFAOYSA-N, LJCWONGJFPCTTL-SSDOTTSWSA-N" "Phase 1"
"2131" "oxibendazole" "tubulin polymerization inhibitor" "TUBB, TUBB4B" "infectious disease" "strongyles" "BRD-K52075715-001-06-7, BRD-K52075715-001-07-5" "CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1, CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1" "RAOCRURYZCVHMG-UHFFFAOYSA-N, RAOCRURYZCVHMG-UHFFFAOYSA-N" "Launched"
"2132" "oxiconazole" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "tinea pedis, tinea cruris, tinea corporis" "BRD-K56104152-008-04-1" "Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1" "QRJJEGAJXVEBNE-HKOYGPOVSA-N" "Launched"
"2133" "oxidopamine" "neurotoxin" "" "" "" "BRD-K41809988-003-09-3" "NCCc1cc(O)c(O)cc1O" "DIVDFFZHCJEHGG-UHFFFAOYSA-N" "Preclinical"
"2134" "oxiniacic-acid" "" "" "" "" "BRD-K20417253-001-01-9" "OC(=O)c1ccc[n+]([O-])c1" "FJCFFCXMEXZEIM-UHFFFAOYSA-N" "Preclinical"
"2135" "oxiperomide" "dopamine receptor antagonist" "" "" "" "BRD-K78096648-001-05-7" "Oc1nc2ccccc2n1C1CCN(CCOc2ccccc2)CC1" "NVDBBGBUTKLRSN-UHFFFAOYSA-N" "Phase 2"
"2136" "oxiracetam" "acetylcholine receptor agonist" "" "" "" "BRD-K50677762-001-01-5" "NC(=O)CN1C[C@H](O)CC1=O" "IHLAQQPQKRMGSS-SCSAIBSYSA-N" "Launched"
"2137" "oxolamine" "antitussive" "" "pulmonary" "cough suppressant" "BRD-K42596464-048-11-9" "CCN(CC)CCc1nc(no1)-c1ccccc1" "IDCHQQSVJAAUQQ-UHFFFAOYSA-N" "Launched"
"2138" "oxolinic-acid" "bacterial DNA gyrase inhibitor" "" "" "" "BRD-K73394555-237-01-1" "CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12" "KYGZCKSPAKDVKC-UHFFFAOYSA-N" "Preclinical"
"2139" "oxonic-acid" "uricase inhibitor" "" "" "" "BRD-K31468676-237-01-8, BRD-K31468676-237-02-6" "OC(=O)c1nc(=O)[nH]c(=O)[nH]1, OC(=O)c1nc(=O)[nH]c(=O)[nH]1" "RYYCJUAHISIHTL-UHFFFAOYSA-N, RYYCJUAHISIHTL-UHFFFAOYSA-N" "Preclinical"
"2140" "oxotremorine-m" "acetylcholine receptor agonist" "CHRM1, CHRM2, CHRM3, CHRM4" "" "" "BRD-K01942991-005-08-2" "C[N+](C)(C)CC" "" ""
"2141" "oxotremorine-sesquifumarate" "cholinergic receptor agonist" "CHRM1, CHRM2, CHRM3, CHRM4" "" "" "BRD-K21936341-051-03-2" "O=C1CCCN1CC" "" ""
"2142" "oxprenolol" "adrenergic receptor antagonist" "ADRB1, ADRB2" "cardiology" "angina pectoris, hypertension, cardiac arrythmia" "BRD-A43671941-003-11-9" "CC(C)NCC(O)COc1ccccc1OCC=C" "CEMAWMOMDPGJMB-UHFFFAOYSA-N" "Launched"
"2143" "oxtriphylline" "adenosine receptor antagonist" "ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE4A, PDE4B, PDE5A" "pulmonary" "asthma, chronic obstructive pulmonary disease (COPD), bronchospasm" "BRD-K97799481-205-01-9" "Cn1c2nc[nH]c2c(=O)n(C)c1=O" "ZFXYFBGIUFBOJW-UHFFFAOYSA-N" "Launched"
"2144" "oxybenzone" "lipase inhibitor" "LIPE" "dermatology" "sunscreen lotion" "BRD-K59037100-001-14-7" "COc1ccc(C(=O)c2ccccc2)c(O)c1" "DXGLGDHPHMLXJC-UHFFFAOYSA-N" "Launched"
"2145" "oxybuprocaine" "local anesthetic" "SCN10A" "neurology/psychiatry" "local anesthetic" "BRD-K04185004-003-13-5, BRD-K04185004-003-11-9, BRD-K04185004-003-12-7" "CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC, CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC" "CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N, CMHHMUWAYWTMGS-UHFFFAOYSA-N" "Launched"
"2146" "oxybutynin" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3" "urology" "urinary incontinence" "BRD-A65013509-003-24-4, BRD-A65013509-001-02-4, BRD-A65013509-003-23-6" "CCN(CC)CC" "" ""
"2147" "oxyclozanide" "" "" "infectious disease" "fascioliasis" "BRD-K07283971-001-01-3" "Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl" "JYWIYHUXVMAGLG-UHFFFAOYSA-N" "Launched"
"2148" "oxyfedrine" "adrenergic receptor agonist" "" "cardiology" "angina pectoris" "BRD-K73027814-003-01-0" "COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1" "GDYUVHBMFVMBAF-LIRRHRJNSA-N" "Launched"
"2149" "oxymatrine" "" "" "" "" "BRD-A57833392-001-01-7" "[O-][N+]12CCC[C@@H]3CN4[C@H](CCCC4=O)[C@H](CCC1)[C@@H]23" "XVPBINOPNYFXID-WEFVWUPKSA-N" "Launched"
"2150" "oxymetazoline" "adrenergic receptor agonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C" "otolaryngology" "nasal congestion" "BRD-K16195444-003-26-0, BRD-K16195444-003-24-5, BRD-K16195444-003-25-2" "Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C" "WYWIFABBXFUGLM-UHFFFAOYSA-N, WYWIFABBXFUGLM-UHFFFAOYSA-N, WYWIFABBXFUGLM-UHFFFAOYSA-N" "Launched"
"2151" "oxymetholone" "androgen receptor agonist" "AR" "hematology" "anemia" "BRD-A16767899-001-01-5, BRD-A23637604-001-04-1" "C[C@@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)C(C[C@]4(C)[C@@H]3CC[C@]12C)C=O, C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)C(C[C@]4(C)[C@H]3CC[C@]12C)C=O" "DLZUBMGMHUNDLF-YDSVGGFZSA-N, DLZUBMGMHUNDLF-CVSXEEBHSA-N" "Launched"
"2152" "oxyphenbutazone" "cyclooxygenase inhibitor" "PLA2G2E, PTGS1, PTGS2" "" "" "BRD-A33749298-001-18-3" "CCCCC1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1" "HFHZKZSRXITVMK-UHFFFAOYSA-N" "Withdrawn"
"2153" "oxyphencyclimine" "cholinergic receptor antagonist" "CHRM1, CHRM2, CHRM3" "gastroenterology" "peptic ulcer disease (PUD)" "BRD-A58193911-003-18-7" "CN1CCCN=C1COC(=O)C(O)(C1CCCCC1)c1ccccc1" "DUDKAZCAISNGQN-UHFFFAOYSA-N" "Launched"
"2154" "oxyphenonium" "cholinergic receptor antagonist" "CHRM1" "gastroenterology" "peptic ulcer disease (PUD)" "BRD-A14208071-004-19-8" "CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1" "GFRUPHOKLBPHTQ-UHFFFAOYSA-N" "Launched"
"2155" "oxypurinol" "xanthine oxidase inhibitor" "XDH" "" "" "BRD-K31841515-001-07-8" "O=c1[nH]c2n[nH]cc2c(=O)[nH]1" "HXNFUBHNUDHIGC-UHFFFAOYSA-N" "Phase 2/Phase 3"
"2156" "oxyquinoline" "chelating agent" "METAP2" "dermatology" "cosmetic" "BRD-K66808046-065-03-7" "Oc1cccc2cccnc12" "MCJGNVYPOGVAJF-UHFFFAOYSA-N" "Launched"
"2157" "oxytetracycline" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease, urology" "chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease" "BRD-A22740840-335-06-5, BRD-A22740840-003-06-9, BRD-A22740840-002-07-9, BRD-A78694248-335-01-6, BRD-A56621826-001-01-3, BRD-A22740840-001-08-9, BRD-A22740840-001-09-7" "CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@@H]1[C@@H]2[C@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4C3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O" "TUEWQXNXQFRUTK-NWGWHKHOSA-N, TUEWQXNXQFRUTK-NWGWHKHOSA-N, TUEWQXNXQFRUTK-NWGWHKHOSA-N, TUEWQXNXQFRUTK-VPLBJLOBSA-N, TUEWQXNXQFRUTK-PIZKLEGOSA-N, TUEWQXNXQFRUTK-NWGWHKHOSA-N, TUEWQXNXQFRUTK-NWGWHKHOSA-N" "Launched"
"2158" "oxytocin" "oxytocin receptor agonist" "AVPR1A, AVPR1B, AVPR2, OXTR" "obstetrics/gynecology" "labor induction" "BRD-K25243230-001-01-2, BRD-A80365673-001-01-1" "CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O, CC[C@H](C)C1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O" "XNOPRXBHLZRZKH-DSZYJQQASA-N, XNOPRXBHLZRZKH-OMTOYRQASA-N" "Launched"
"2159" "ozagrel" "thromboxane synthase inhibitor" "TBXAS1" "neurology/psychiatry" "stroke" "BRD-K53061490-003-13-9, BRD-K53061490-001-02-6, BRD-K53061490-003-14-7" "OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1, OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1" "SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N, SHZKQBHERIJWAO-AATRIKPKSA-N" "Launched"
"2160" "ozanimod" "sphingosine 1 phosphate receptor agonist" "S1PR1" "" "" "BRD-K46625559-001-01-8" "CC(C)Oc1ccc(cc1C" "" ""
"2161" "ozolinone" "diuretic" "" "" "" "BRD-A72297358-001-01-8" "CN1C(=O)C(S\C1=C/C(O)=O)N1CCCCC1" "NQFBZYYUAFJYNS-FPLPWBNLSA-N" "Phase 3"
"2162" "O6-Benzylguanine" "O6-alkylguanine-DNA alkyltransferase inhibitor" "MGMT" "" "" "BRD-K92041145-001-09-5" "Nc1nc(OCc2ccccc2)c2[nH]cnc2n1" "KRWMERLEINMZFT-UHFFFAOYSA-N" "Phase 3"
"2163" "p-dimethylinamyl-benzoate" "" "" "" "" "BRD-K42336459-001-01-7" "CCCCCOC(=O)c1ccc(cc1)N(C)C" "LXTZRIBXKVRLOA-UHFFFAOYSA-N" "Preclinical"
"2164" "PA-824" "nitric oxide donor" "FASN" "" "" "BRD-K96671969-001-03-1" "[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1" "ZLHZLMOSPGACSZ-NSHDSACASA-N" "Phase 3"
"2165" "PAC-1" "caspase activator" "CASP3" "" "" "BRD-K92991072-001-04-9, BRD-K92991072-001-05-6" "Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1, Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1" "YQNRVGJCPCNMKT-LFVJCYFKSA-N, YQNRVGJCPCNMKT-LFVJCYFKSA-N" "Phase 1"
"2166" "paclitaxel" "tubulin polymerization inhibitor" "BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1" "oncology" "ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)" "BRD-A28746609-001-11-5, BRD-A63610676-001-14-1, BRD-A28746609-001-10-7" "CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)C3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)C3[C@@]4(CO[C@@H]4C[C@@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)C3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1" "RCINICONZNJXQF-VAZQATRQSA-N, RCINICONZNJXQF-WLUSQHPBSA-N, RCINICONZNJXQF-VAZQATRQSA-N" "Launched"
"2167" "PACOCF3" "phospholipase inhibitor" "PLA2G4A" "" "" "BRD-K05677083-001-05-4" "CCCCCCCCCCCCCCCC(=O)C(F)(F)F" "MAHYXYTYTLCTQD-UHFFFAOYSA-N" "Preclinical"
"2168" "pacritinib" "FLT3 inhibitor, JAK inhibitor" "FLT3, JAK1, JAK2, JAK3" "" "" "BRD-K19034817-001-04-8, BRD-K19034817-001-01-4, BRD-K19034817-001-02-2" "C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3, C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3" "HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N, HWXVIOGONBBTBY-ONEGZZNKSA-N" "Phase 3"
"2169" "paeoniflorin" "anticonvulsant" "" "" "" "BRD-K83631119-001-02-1, BRD-K77265172-001-01-2" "C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O, C[C@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O" "YKRGDOXKVOZESV-WRJNSLSBSA-N, YKRGDOXKVOZESV-DZTHUXFRSA-N" "Preclinical"
"2170" "paeonol" "anti-inflammatory agent" "" "" "" "BRD-K94239562-001-05-5" "COc1ccc(C(C)=O)c(O)c1" "UILPJVPSNHJFIK-UHFFFAOYSA-N" "Preclinical"
"2171" "pafuramidine" "DNA synthesis inhibitor" "" "" "" "BRD-K68805147-001-01-8" "CONC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(=N)NOC" "UKOQVLAXCBRRGH-UHFFFAOYSA-N" "Phase 3"
"2172" "palbociclib" "CDK inhibitor" "CDK4, CDK6" "oncology" "breast cancer" "BRD-K51313569-003-03-3, BRD-K51313569-001-07-8" "CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O" "AHJRHEGDXFFMBM-UHFFFAOYSA-N, AHJRHEGDXFFMBM-UHFFFAOYSA-N" "Launched"
"2173" "palifosfamide" "DNA alkylating agent" "" "" "" "BRD-K12047401-001-01-5" "OP(=O)(NCCCl)NCCCl" "BKCJZNIZRWYHBN-UHFFFAOYSA-N" "Phase 3"
"2174" "paliperidone" "dopamine receptor antagonist, serotonin receptor antagonist" "ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CYP2D6, CYP3A4, CYP3A5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1D, HTR2A, HTR2C" "neurology/psychiatry" "schizophrenia" "BRD-K00665454-001-02-2, BRD-A99888680-001-03-8, BRD-K00665454-001-01-4" "Cc1nc2[C@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2C(O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2[C@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12" "PMXMIIMHBWHSKN-LJQANCHMSA-N, PMXMIIMHBWHSKN-UHFFFAOYSA-N, PMXMIIMHBWHSKN-LJQANCHMSA-N" "Launched"
"2175" "palmatine-chloride" "dopamine synthesis inhibitor" "CYP3A4" "" "" "BRD-K58466253-003-14-0" "COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC" "QUCQEUCGKKTEBI-UHFFFAOYSA-N" "Preclinical"
"2176" "palmitoleic-acid" "" "" "" "" "BRD-K91356052-001-04-0" "CCCCCC\C=C/CCCCCCCC(O)=O" "SECPZKHBENQXJG-FPLPWBNLSA-N" "Preclinical"
"2177" "palmitoylcarnitine" "protein kinase inhibitor" "" "" "" "BRD-A77577770-003-08-9" "CCCCCCCCCCCCCCCC(=O)OC(CC(O)=O)C[N+](C)(C)C" "XOMRRQXKHMYMOC-UHFFFAOYSA-O" "Preclinical"
"2178" "palmitoylethanolamide" "cannabinoid receptor agonist" "CNR2, GPR119, GPR55" "" "" "BRD-K68095457-001-10-1, BRD-K68095457-001-11-9" "CCCCCCCCCCCCCCCC(=O)NCCO, CCCCCCCCCCCCCCCC(=O)NCCO" "HXYVTAGFYLMHSO-UHFFFAOYSA-N, HXYVTAGFYLMHSO-UHFFFAOYSA-N" "Launched"
"2179" "palomid-529" "AKT inhibitor, mTOR inhibitor" "MTOR" "" "" "BRD-A50998626-001-02-1" "COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1" "YEAHTLOYHVWAKW-UHFFFAOYSA-N" "Phase 1"
"2180" "palonosetron" "serotonin receptor antagonist" "HTR3A" "gastroenterology" "nausea, vomiting" "BRD-K08924299-003-06-1" "O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2" "CPZBLNMUGSZIPR-NVXWUHKLSA-N" "Launched"
"2181" "palosuran" "urotensin receptor antagonist" "UTS2R" "" "" "BRD-K07682953-001-01-8" "Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1" "WYJCYXOCHXWTHG-UHFFFAOYSA-N" "Phase 2"
"2182" "palovarotene" "retinoid receptor agonist" "RARG" "" "" "BRD-K83794243-001-01-8" "CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12" "YTFHCXIPDIHOIA-DHZHZOJOSA-N" "Phase 2"
"2183" "pamabrom" "diuretic" "" "gastroenterology" "bloating" "BRD-M67659203-001-01-9" "CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O" "ATOTUUBRFJHZQG-UHFFFAOYSA-N" "Launched"
"2184" "pamidronate" "bone resorption inhibitor" "FDPS" "endocrinology, oncology, hematologic malignancy" "hypercalcemia, Pagets disease, breast cancer, multiple myeloma	BRD-K58513245-304-03-5, BRD-K58513245-304-02-7	NCCC(O)(P(O)(O)=O)P(O)(O)=O, NCCC(O)(P(O)(O)=O)P(O)(O)=O	WRUUGTRCQOWXEG-UHFFFAOYSA-N, WRUUGTRCQOWXEG-UHFFFAOYSA-N	Launched
pancuronium	acetylcholine receptor antagonist	CHRM2, CHRM3, CHRNA1, CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	BRD-K50817623-303-05-7, BRD-K25166838-303-01-1	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	GVEAYVLWDAFXET-XGHATYIMSA-N, GVEAYVLWDAFXET-LGWARUMUSA-N	Launched
panobinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	BRD-K02130563-001-12-2, BRD-K02130563-001-11-4, BRD-K02130563-001-14-8	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N, FPOHNWQLNRZRFC-ZHACJKMWSA-N	Launched
pantethine	coenzyme A precursor				BRD-K68764924-001-03-2, BRD-K68764924-001-04-0, BRD-A76244192-001-02-4	CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO, CC(C)(CO)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO	DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-ROUUACIJSA-N, DJWYOLJPSHDSAL-UHFFFAOYSA-N	Launched
pantoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome	BRD-A22380646-236-05-8, BRD-A22380646-236-06-6, BRD-A22380646-001-05-6	COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC, COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC, COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC	IQPSEEYGBUAQFF-UHFFFAOYSA-N, IQPSEEYGBUAQFF-UHFFFAOYSA-N, IQPSEEYGBUAQFF-UHFFFAOYSA-N	Launched
pantothenic-acid	coenzyme A precursor				BRD-K29392254-001-03-0, BRD-K29392254-001-02-2, BRD-K29392254-236-01-6	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O, CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	GHOKWGTUZJEAQD-ZETCQYMHSA-N, GHOKWGTUZJEAQD-ZETCQYMHSA-N, GHOKWGTUZJEAQD-ZETCQYMHSA-N	Launched
papaverine	phosphodiesterase inhibitor	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	BRD-K15567136-003-27-2	COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	XQYZDYMELSJDRZ-UHFFFAOYSA-N	Launched
para-toluenesulfonamide		CA12, CA2, CA6, CA9			BRD-K62412084-001-07-1	Cc1ccc(cc1)S(N)(=O)=O	LMYRWZFENFIFIT-UHFFFAOYSA-N	Phase 3
paracetamol	cyclooxygenase inhibitor	FAAH, PTGS1, PTGS2, TRPV1	neurology/psychiatry, endocrinology	pain relief, fever	BRD-K41524689-001-23-5, BRD-K41524689-001-22-7	CC(=O)Nc1ccc(O)cc1, CC(=O)Nc1ccc(O)cc1	RZVAJINKPMORJF-UHFFFAOYSA-N, RZVAJINKPMORJF-UHFFFAOYSA-N	Launched
parachlorophenol	antiinfective drug				BRD-K40992116-001-09-7	Oc1ccc(Cl)cc1	WXNZTHHGJRFXKQ-UHFFFAOYSA-N	Launched
paramethadione	anticonvulsant	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	BRD-A22128695-001-02-6, BRD-A22128695-001-03-4	CCC1(C)OC(=O)N(C)C1=O, CCC1(C)OC(=O)N(C)C1=O	VQASKUSHBVDKGU-UHFFFAOYSA-N, VQASKUSHBVDKGU-UHFFFAOYSA-N	Launched
paraxanthine	adenosine receptor antagonist				BRD-K24084088-001-11-3	Cn1cnc2[nH]c(=O)n(C)c(=O)c12	QUNWUDVFRNGTCO-UHFFFAOYSA-N	Phase 1
parbendazole	tubulin polymerization inhibitor	TUBB			BRD-K02407574-001-09-7	CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1	YRWLZFXJFBZBEY-UHFFFAOYSA-N	Preclinical
pardoprunox	serotonin receptor agonist, dopamine receptor agonist	DRD2, DRD3, DRD4, HTR1A, HTR7			BRD-K11851476-003-01-7	CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	YVPUUUDAZYFFQT-UHFFFAOYSA-N	Phase 3
parecoxib	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	BRD-K13800121-001-01-5	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	TZRHLKRLEZJVIJ-UHFFFAOYSA-N	Launched
parethoxycaine	local anesthetic				BRD-K54799382-003-08-4	CCOc1ccc(cc1)C(=O)OCCN(CC)CC	OWWVHQUOYSPNNE-UHFFFAOYSA-N	Preclinical
pargyline	monoamine oxidase inhibitor	MAOA, MAOB	cardiology	hypertension	BRD-K83597974-003-22-2	CN(CC#C)Cc1ccccc1	DPWPWRLQFGFJFI-UHFFFAOYSA-N	Launched
paricalcitol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperthyroidism	BRD-K60585088-001-01-5	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1	BPKAHTKRCLCHEA-UBFJEZKGSA-N	Launched
paritaprevir	HCV inhibitor		infectious disease	hepatitis C	BRD-K89920762-001-01-4	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1	UAUIUKWPKRJZJV-QPLHLKROSA-N	Launched
paromomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	BRD-K36524108-065-04-0, BRD-A20920572-065-04-7, BRD-K25359791-065-01-2, BRD-M40700687-001-01-8, BRD-K36524108-065-03-2	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)OC(O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@@H](N)[C@H]3O[C@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, C.NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	UOZODPSAJZTQNH-LSWIJEOBSA-N, UOZODPSAJZTQNH-FHJRSJOZSA-N, UOZODPSAJZTQNH-YEPBGTAESA-N, OYJABWUHUYVDMJ-UDXJMMFXSA-N, UOZODPSAJZTQNH-LSWIJEOBSA-N	Launched
paroxetine	selective serotonin reuptake inhibitor (SSRI)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder	BRD-K37991163-003-13-4, BRD-K37991163-003-14-2, BRD-K37991163-050-18-4	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1, Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N, AHOUBRCZNHFOSL-YOEHRIQHSA-N	Launched
paroxypropione	gonadotropin inhibitor				BRD-K07441213-001-18-9	CCC(=O)c1ccc(O)cc1	RARSHUDCJQSEFJ-UHFFFAOYSA-N	Launched
parthenolide	NFkB pathway inhibitor				BRD-K98548675-001-05-9	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	KTEXNACQROZXEV-SLXBATTESA-N	Phase 1
parthenolide-(-)	NFkB pathway inhibitor	HDAC1			BRD-K34851558-001-02-3	C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	KTEXNACQROZXEV-QLIGOWBFSA-N	Preclinical
parthenolide-(alternate-stereo)	NFkB pathway inhibitor	IKBKB, RELA			BRD-K28120222-001-08-4	C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1	KTEXNACQROZXEV-PVLRGYAZSA-N	Preclinical
pasiniazid	cyclooxygenase inhibitor		infectious disease	tuberculosis	BRD-K87202646-061-04-9, BRD-K87202646-061-05-6	NNC(=O)c1ccncc1, NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N, QRXWMOHMRWLFEY-UHFFFAOYSA-N	Launched
pasireotide	somatostatin receptor agonist	SSTR1, SSTR2, SSTR3, SSTR5	endocrinology	Cushings syndrome, acromegaly" "BRD-K59715032-362-01-4" "NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1" "VMZMNAABQBOLAK-DBILLSOUSA-N" "Launched"
"2185" "pazopanib" "KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3" "oncology" "renal cell carcinoma (RCC), soft tissue sarcoma (STS)" "BRD-K74514084-001-03-9, BRD-K74514084-003-09-2" "CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1" "CUIHSIWYWATEQL-UHFFFAOYSA-N, CUIHSIWYWATEQL-UHFFFAOYSA-N" "Launched"
"2186" "pazufloxacin" "topoisomerase inhibitor" "" "infectious disease" "pneumonia, peritonitis, bacterial septicemia" "BRD-K66412701-066-01-6" "C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1" "XAGMUUZPGZWTRP-ZETCQYMHSA-N" "Launched"
"2187" "PCA-4248" "platelet activating factor receptor antagonist" "PTAFR" "" "" "BRD-A29289453-001-04-7" "COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1" "DHCNAWNKZMNTIS-UHFFFAOYSA-N" "Phase 1"
"2188" "PCI-24781" "HDAC inhibitor" "HDAC1, HDAC2, HDAC3, HDAC6" "" "" "BRD-K12867552-001-04-7" "CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO" "MAUCONCHVWBMHK-UHFFFAOYSA-N" "Phase 1/Phase 2"
"2189" "PCI-34051" "HDAC inhibitor" "HDAC1, HDAC10, HDAC6, HDAC8" "" "" "BRD-K88742110-001-08-7, BRD-K88742110-001-07-9" "COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1, COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1" "AJRGHIGYPXNABY-UHFFFAOYSA-N, AJRGHIGYPXNABY-UHFFFAOYSA-N" "Preclinical"
"2190" "PCO-400" "potassium channel activator" "KCNJ8" "" "" "BRD-K52721684-001-03-0" "CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C" "" ""
"2191" "PD-0325901" "MEK inhibitor" "MAP2K1" "" "" "BRD-K49865102-001-08-4" "OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F" "SUDAHWBOROXANE-SECBINFHSA-N" "Phase 2"
"2192" "PD-102807" "acetylcholine receptor antagonist" "CHRM4" "" "" "BRD-A89337244-001-02-9" "CCOC(=O)c1c(C)[nH]c2ccc3OC4N(CCc5cc(OC)ccc45)Cc3c12" "VDDUJINYXKGZLV-UHFFFAOYSA-N" "Preclinical"
"2193" "PD-118057" "potassium channel activator" "KCNH2" "" "" "BRD-K34657753-001-01-9" "OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1" "ZCQOSCDABPVAFB-UHFFFAOYSA-N" "Preclinical"
"2194" "PD-123319" "angiotensin antagonist" "AGTR2" "" "" "BRD-K34713073-001-01-3, BRD-K34713073-362-01-9" "CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C, CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C" "YSTVFDAKLDMYCR-NDEPHWFRSA-N, YSTVFDAKLDMYCR-NDEPHWFRSA-N" "Phase 1"
"2195" "PD-128907" "dopamine receptor agonist" "DRD2, DRD3" "" "" "BRD-K38797369-003-01-1, BRD-K62456038-003-07-1, BRD-K20260086-001-01-6" "CCCN1CCO[C@@H]2[C@@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21, CCCN1CCO[C@H]2[C@@H]1COc1ccc(O)cc21" "YOILXOMTHPUMRG-JSGCOSHPSA-N, YOILXOMTHPUMRG-TZMCWYRMSA-N, YOILXOMTHPUMRG-GXTWGEPZSA-N" "Preclinical"
"2196" "PD-153035" "EGFR inhibitor" "EGFR, KDR" "" "" "BRD-K26603252-003-04-9" "COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC" "LSPANGZZENHZNJ-UHFFFAOYSA-N" "Phase 1"
"2197" "PD-156707" "endothelin receptor antagonist" "EDNRA, EDNRB" "" "" "BRD-K13826399-236-01-7" "COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1" "OFCTYBMKKTVKCR-QQTULTPQSA-N" "Preclinical"
"2198" "PD-158780" "EGFR inhibitor" "EGFR" "" "" "BRD-K48735772-001-03-0" "CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1" "KFHMLBXBRCITHF-UHFFFAOYSA-N" "Preclinical"
"2199" "PD-160170" "neuropeptide receptor antagonist" "NPY1R" "" "" "BRD-K12079898-001-02-6" "CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O" "YUVNGBZROXQYQH-UHFFFAOYSA-N" "Preclinical"
"2200" "PD-161570" "FGFR inhibitor" "FGFR1" "" "" "BRD-K97152684-001-01-9" "CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl" "MKVMEJKNLUWFSQ-UHFFFAOYSA-N" "Preclinical"
"2201" "PD-166793" "collagenase inhibitor, metalloproteinase inhibitor" "MMP13, MMP2, MMP3" "" "" "BRD-K60984070-001-01-0" "CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O" "GJOCABIDMCKCEG-INIZCTEOSA-N" "Preclinical"
"2202" "PD-168077" "dopamine receptor agonist" "DRD2" "" "" "BRD-K47761761-050-07-8" "Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C" "" ""
"2203" "PD-168393" "EGFR inhibitor" "EGFR, ERBB2, SRC" "" "" "BRD-K17702546-001-03-2" "Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1" "HTUBKQUPEREOGA-UHFFFAOYSA-N" "Preclinical"
"2204" "PD-173074" "FGFR inhibitor, VEGFR inhibitor" "FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB" "" "" "BRD-K97764662-001-20-7, BRD-K97764662-001-17-3" "CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1, CCN(CC)CCCCNc1ncc2cc(-c3cc(OC)cc(OC)c3)c(NC(=O)NC(C)(C)C)nc2n1" "DXCUKNQANPLTEJ-UHFFFAOYSA-N, DXCUKNQANPLTEJ-UHFFFAOYSA-N" "Preclinical"
"2205" "PD-184352" "MEK inhibitor" "MAP2K1, MAP3K1, MAP3K2" "" "" "BRD-K05104363-001-10-0" "Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F" "GFMMXOIFOQCCGU-UHFFFAOYSA-N" "Phase 2"
"2206" "PD-198306" "MAP kinase inhibitor, MEK inhibitor" "MAP2K1, MAP2K2" "" "" "BRD-K88677950-001-03-9" "Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1" "UHAXDAKQGVISBZ-UHFFFAOYSA-N" "Preclinical"
"2207" "PD-318088" "MEK inhibitor" "MAP2K1" "" "" "BRD-A57798112-001-03-7" "OCC(O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F" "XXSSGBYXSKOLAM-UHFFFAOYSA-N" "Preclinical"
"2208" "PD-407824" "PKC inhibitor" "WEE1" "" "" "BRD-K82823804-001-04-1, BRD-K82823804-001-05-8" "Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1, Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1" "IAUZTOZLTFSMIE-UHFFFAOYSA-N, IAUZTOZLTFSMIE-UHFFFAOYSA-N" "Preclinical"
"2209" "PD-81723" "adenosine receptor agonist" "ADORA1" "" "" "BRD-K77951111-001-04-5" "Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C" "KKDKAWKYGCUOGR-UHFFFAOYSA-N" "Preclinical"
"2210" "PD-98059" "MEK inhibitor" "AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1" "" "" "BRD-K62810658-001-15-5, BRD-K62810658-001-12-2, BRD-K62810658-001-11-4" "COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N, COc1cccc(-c2cc(=O)c3ccccc3o2)c1N" "QFWCYNPOPKQOKV-UHFFFAOYSA-N, QFWCYNPOPKQOKV-UHFFFAOYSA-N, QFWCYNPOPKQOKV-UHFFFAOYSA-N" "Preclinical"
"2211" "PDE10-IN-1" "phosphodiesterase inhibitor" "PDE10A" "" "" "BRD-K38145871-001-01-8" "Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1" "ZLHNYULRKIEGAY-HZPDHXFCSA-N" "Preclinical"
"2212" "PD1-PDL-inhibitor-1" "programmed death ligand inhibitor" "CD274" "" "" "BRD-K04032780-001-01-8" "COc1cc(OCc2cccc(-c3ccccc3)c2C)cc(OC)c1CN1CCCC[C@H]1C(O)=O" "ZBOYJODMIAUJHH-SANMLTNESA-N" "Preclinical"
"2213" "peficitinib" "JAK inhibitor" "JAK1, JAK2, JAK3" "" "" "BRD-A59435073-001-01-5, BRD-K21225231-001-01-2" "NC(=O)c1cnc2[nH]ccc2c1NC1C2CC3CC1CC(O)(C3)C2, NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2" "DREIJXJRTLTGJC-UHFFFAOYSA-N, DREIJXJRTLTGJC-ZKVNVPQCSA-N" "Phase 3"
"2214" "pefloxacin" "bacterial DNA gyrase inhibitor" "TOP2A" "infectious disease, urology" "gastrointestinal infections, urethritis, gonorrhea, urinary tract infections" "BRD-K55034111-066-17-1, BRD-K55034111-066-16-3" "CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1, CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1" "FHFYDNQZQSQIAI-UHFFFAOYSA-N, FHFYDNQZQSQIAI-UHFFFAOYSA-N" "Launched"
"2215" "pelanserin" "serotonin receptor antagonist" "HTR2A" "" "" "BRD-K96436774-001-01-8" "O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1" "WPKPLSFHHBBLRY-UHFFFAOYSA-N" "Phase 2"
"2216" "pelitinib" "EGFR inhibitor" "EGFR" "" "" "BRD-K08799216-001-05-3" "CCOc1cc2ncc(C" "" ""
"2217" "pemetrexed" "dihydrofolate reductase inhibitor, thymidylate synthase inhibitor" "ATIC, DHFR, GART, TYMS" "oncology" "non-small cell lung cancer (NSCLC), mesothelioma" "BRD-K32842773-434-01-8, BRD-K32842773-304-04-7, BRD-M18147244-437-01-2, BRD-K55395145-304-01-5, BRD-K32842773-304-03-9" "Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1.Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1, Nc1nc2[nH]cc(CCc3ccc(cc3)C(=O)N[C@H](CCC(O)=O)C(O)=O)c2c(=O)[nH]1, Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1" "WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N, WOPFJTZIQBVJPY-CHNGVTQJSA-N, WBXPDJSOTKVWSJ-CYBMUJFWSA-N, WBXPDJSOTKVWSJ-ZDUSSCGKSA-N" "Launched"
"2218" "pemirolast" "mediator release inhibitor" "HRH1" "pulmonary" "asthma" "BRD-K31731454-237-02-5, BRD-K31731454-237-03-3" "Cc1cccn2c1ncc(-c1nnn[nH]1)c2=O, Cc1cccn2c1ncc(-c1nnn[nH]1)c2=O" "HIANJWSAHKJQTH-UHFFFAOYSA-N, HIANJWSAHKJQTH-UHFFFAOYSA-N" "Launched"
"2219" "pempidine" "ganglionic blocker" "" "cardiology" "hypertension" "BRD-K71075093-045-14-7" "CN1C(C)(C)CCCC1(C)C" "XULIXFLCVXWHRF-UHFFFAOYSA-N" "Launched"
"2220" "penbutolol" "adrenergic receptor antagonist" "ADRB1, ADRB2, HTR1A, HTR1B" "cardiology" "hypertension" "BRD-K55705469-065-01-0" "CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1" "KQXKVJAGOJTNJS-HNNXBMFYSA-N" "Launched"
"2221" "penciclovir" "DNA directed DNA polymerase inhibitor" "" "dental" "cold sore" "BRD-K47780086-001-07-9, BRD-K47780086-001-06-1, BRD-K47780086-001-08-7" "Nc1nc(O)c2ncn(CCC(CO)CO)c2n1, Nc1nc(O)c2ncn(CCC(CO)CO)c2n1, Nc1nc(O)c2ncn(CCC(CO)CO)c2n1" "JNTOCHDNEULJHD-UHFFFAOYSA-N, JNTOCHDNEULJHD-UHFFFAOYSA-N, JNTOCHDNEULJHD-UHFFFAOYSA-N" "Launched"
"2222" "penfluridol" "T-type calcium channel blocker" "CACNA1G" "neurology/psychiatry" "schizophrenia" "BRD-K15409150-001-05-8, BRD-K15409150-001-07-4" "OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F, OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F" "MDLAAYDRRZXJIF-UHFFFAOYSA-N, MDLAAYDRRZXJIF-UHFFFAOYSA-N" "Launched"
"2223" "penicillamine-(D)" "chelating agent" "" "metabolism, rheumatology, nephrology" "Wilsons disease, rheumatoid arthritis, cystinuria	BRD-K17518951-001-04-8, BRD-K17518951-001-03-0	CC(C)(S)[C@@H](N)C(O)=O, CC(C)(S)[C@@H](N)C(O)=O	VVNCNSJFMMFHPL-VKHMYHEASA-N, VVNCNSJFMMFHPL-VKHMYHEASA-N	Launched
penicillamine-(racemic)					BRD-A16376407-213-01-1	CC(C)(S)C(N)C(O)=O	VVNCNSJFMMFHPL-UHFFFAOYSA-N	Preclinical
penicillin-v-potassium	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever	BRD-K43966364-237-04-8	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	BPLBGHOLXOTWMN-MBNYWOFBSA-N	Launched
pentacosanoic-acid					BRD-K48996094-001-01-3	CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O	MWMPEAHGUXCSMY-UHFFFAOYSA-N	Preclinical
pentagastrin	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic, anacidity diagnostic, gastric hypersecretion diagnostic	BRD-K78789465-001-01-6, BRD-K78789465-001-02-4	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O, CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	NEYNJQRKHLUJRU-DZUOILHNSA-N, NEYNJQRKHLUJRU-DZUOILHNSA-N	Launched
pentamidine	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	BRD-K13183738-317-10-2, BRD-K13183738-300-02-5	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1, NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	XDRYMKDFEDOLFX-UHFFFAOYSA-N, XDRYMKDFEDOLFX-UHFFFAOYSA-N	Launched
pentetic-acid	chelating agent	PGD			BRD-K40621224-001-06-7	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	QPCDCPDFJACHGM-UHFFFAOYSA-N	Phase 2
pentobarbital	barbiturate antiepileptic, GABA receptor modulator	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B			BRD-A44448661-001-04-8	CCCC(C)C1(CC)C(=O)NC(=O)NC1=O	WEXRUCMBJFQVBZ-UHFFFAOYSA-N	Withdrawn
pentolinium	cholinergic receptor antagonist	CHRNA10, CHRNA3, CHRNA4, CHRNB4	cardiology	hypertension	BRD-K44942604-346-05-4, BRD-K44942604-346-04-7	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1, C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	XSBSKEQEUFOSDD-UHFFFAOYSA-N, XSBSKEQEUFOSDD-UHFFFAOYSA-N	Launched
pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	BRD-K91543828-001-02-0, BRD-A17154931-001-01-5	OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12, OC[C@H]1O[C@H](CC1O)n1cnc2[C@H](O)CNC=Nc12	FPVKHBSQESCIEP-JQCXWYLXSA-N, FPVKHBSQESCIEP-FUZJYRNYSA-N	Launched
pentoxifylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF	cardiology	claudication	BRD-K57569181-001-27-5, BRD-K57569181-001-26-7	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O, CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	BYPFEZZEUUWMEJ-UHFFFAOYSA-N, BYPFEZZEUUWMEJ-UHFFFAOYSA-N	Launched
pentylenetetrazol	GABA receptor antagonist				BRD-K57718010-001-11-9, BRD-K57718010-001-12-7, BRD-K57718010-001-10-1	C1CCc2nnnn2CC1, C1CCc2nnnn2CC1, C1CCc2nnnn2CC1	CWRVKFFCRWGWCS-UHFFFAOYSA-N, CWRVKFFCRWGWCS-UHFFFAOYSA-N, CWRVKFFCRWGWCS-UHFFFAOYSA-N	Withdrawn
pepstatin	aspartic protease inhibitor	CTSB, CTSD, CTSL, REN			BRD-K13571841-001-14-4	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	FAXGPCHRFPCXOO-LXTPJMTPSA-N	Preclinical
peramivir	neuraminidase inhibitor		infectious disease	influenza A virus infection	BRD-K00519864-341-03-3, BRD-K00519864-341-02-5	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O, CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	XRQDFNLINLXZLB-CKIKVBCHSA-N, XRQDFNLINLXZLB-CKIKVBCHSA-N	Launched
perampanel	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	seizures	BRD-K41438959-001-01-7	O=c1c(cc(cn1-c1ccccc1)-c1ccccn1)-c1ccccc1C#N	PRMWGUBFXWROHD-UHFFFAOYSA-N	Launched
perchlozone			infectious disease	tuberculosis	BRD-K86435560-001-01-0	NC(=S)NN=Cc1ccncc1	QTSJJDIDTYFLFC-UHFFFAOYSA-N	Launched
peretinoin	retinoid receptor agonist	RXRA			BRD-K99431849-001-01-7	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(C)=C\C(O)=O	UUBHZHZSIKRVIV-KCXSXWJSSA-N	Phase 3
perfluamine					BRD-K16758059-001-01-8	FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F	JAJLKEVKNDUJBG-UHFFFAOYSA-N	Launched
perflubron	contrast agent		radiology	contrast agent	BRD-K92988025-001-01-9	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	WTWWXOGTJWMJHI-UHFFFAOYSA-N	Launched
perfluorodecalin			dermatology	cosmetic	BRD-K55401595-001-01-8	FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F	UWEYRJFJVCLAGH-UHFFFAOYSA-N	Launched
pergolide	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			BRD-K60770992-066-25-0, BRD-K38689957-066-01-5	CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13, CCCN1C[C@@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	YEHCICAEULNIGD-MZMPZRCHSA-N, YEHCICAEULNIGD-FDQGKXFDSA-N	Withdrawn
perhexiline	carnitine palmitoyltransferase inhibitor	CPT1A, CPT2	cardiology	angina pectoris	BRD-A19633847-050-32-1	C(C(C1CCCCC1)C1CCCCC1)C1CCCCN1	CYXKNKQEMFBLER-UHFFFAOYSA-N	Launched
perifosine	AKT inhibitor	AKT1			BRD-A89082344-001-08-7, BRD-A89082344-001-06-1, BRD-A89082344-001-07-9	CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1, CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1	SZFPYBIJACMNJV-UHFFFAOYSA-O, SZFPYBIJACMNJV-UHFFFAOYSA-O, SZFPYBIJACMNJV-UHFFFAOYSA-O	Phase 3
perillyl-alcohol	apoptosis stimulant, farnesyltransferase inhibitor	FNTA			BRD-A13323580-001-04-8, BRD-A13323580-001-05-5	CC(=C)C1CCC(CO)=CC1, CC(=C)C1CCC(CO)=CC1	NDTYTMIUWGWIMO-UHFFFAOYSA-N, NDTYTMIUWGWIMO-UHFFFAOYSA-N	Phase 2
perindopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction, coronary artery disease (CAD)	BRD-K92731339-227-04-9, BRD-A19924402-227-01-0	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC, CCCC(N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@@H]1C(O)=O)C(=O)OCC	IPVQLZZIHOAWMC-QXKUPLGCSA-N, IPVQLZZIHOAWMC-MGLUKCQKSA-N	Launched
perindoprilat	angiotensin converting enzyme inhibitor	ACE			BRD-K00768353-001-01-8	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	ODAIHABQVKJNIY-PEDHHIEDSA-N	Phase 2
permethrin		SCN1A	infectious disease	lice	BRD-A25366096-001-09-9, BRD-A25366096-001-07-3, BRD-A25366096-001-08-1	CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1, CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1, CC1(C)C(C=C(Cl)Cl)C1C(=O)OCc1cccc(Oc2ccccc2)c1	RLLPVAHGXHCWKJ-UHFFFAOYSA-N, RLLPVAHGXHCWKJ-UHFFFAOYSA-N, RLLPVAHGXHCWKJ-UHFFFAOYSA-N	Launched
perospirone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K85503079-001-02-8, BRD-K85503079-001-01-0	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12, O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	FBVFZWUMDDXLLG-HDICACEKSA-N, FBVFZWUMDDXLLG-HDICACEKSA-N	Launched
perphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry, gastroenterology	schizophrenia, nausea, vomiting	BRD-K10995081-001-27-9, BRD-K10995081-001-28-7, BRD-K10995081-001-26-1	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	RGCVKNLCSQQDEP-UHFFFAOYSA-N, RGCVKNLCSQQDEP-UHFFFAOYSA-N, RGCVKNLCSQQDEP-UHFFFAOYSA-N	Launched
peruvoside	cardiac glycoside				BRD-A72716251-001-01-5	CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O	PMTSPAGBAFCORP-WTGLOUSHSA-N	Phase 1
perzinfotel	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B			BRD-K04643877-001-03-2	OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O	BDABGOLMYNHHTR-UHFFFAOYSA-N	Phase 2
PETCM	caspase activator	CASP3			BRD-A93477898-001-04-2	OC(Cc1ccncc1)C(Cl)(Cl)Cl	NGTDJJKTGRNNAU-UHFFFAOYSA-N	Preclinical
pevonedistat	nedd activating enzyme inhibitor	NAE1, UBA3			BRD-K67844266-003-01-9	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	MPUQHZXIXSTTDU-QXGSTGNESA-N	Phase 2
pexidartinib	tyrosine kinase inhibitor	CSF1R, FLT3, KIT			BRD-K54519451-001-02-9	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1	JGWRKYUXBBNENE-UHFFFAOYSA-N	Phase 3
pexmetinib	TIE tyrosine kinase inhibitor, MAP kinase inhibitor	MAPK14, TEK			BRD-K53405000-001-02-8, BRD-K53405000-001-01-0	Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C, Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C	LNMRSSIMGCDUTP-UHFFFAOYSA-N, LNMRSSIMGCDUTP-UHFFFAOYSA-N	Phase 1
PF-02545920	phosphodiesterase inhibitor	PDE10A			BRD-K31519811-001-02-2	Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1	AZEXWHKOMMASPA-UHFFFAOYSA-N	Phase 2
PF-03049423	phosphodiesterase inhibitor	PDE5A			BRD-K07070922-001-01-4	CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1	MNLNAGRCHNMKKJ-UHFFFAOYSA-N	Phase 2
PF-03084014	gamma secretase inhibitor				BRD-K61691541-001-01-1	CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	VFCRKLWBYMDAED-REWPJTCUSA-N	Phase 2
PF-03758309	p21 activated kinase inhibitor	PAK4			BRD-K37764012-001-04-1	CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1	AYCPARAPKDAOEN-LJQANCHMSA-N	Phase 1
PF-03814735	Aurora kinase inhibitor	AURKA, AURKB			BRD-K68747584-001-02-0	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	RYYNGWLOYLRZLK-RBUKOAKNSA-N	Phase 1
PF-03882845					BRD-K51041191-001-01-4	OC(=O)c1ccc2C3=C(CCc2c1)[C@H](C1CCCC1)N(N3)c1ccc(C#N)c(Cl)c1	ONEWULDKRWPYMP-QHCPKHFHSA-N	Phase 1
PF-04136309	CC chemokine receptor antagonist				BRD-K94420399-001-01-9	O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	ZNSVOHSYDRPBGI-LXWOLXCRSA-N	Phase 2
PF-04217903	c-Met inhibitor	MET			BRD-K73319509-001-08-0	OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	PDMUGYOXRHVNMO-UHFFFAOYSA-N	Phase 1
PF-04418948	prostaglandin inhibitor	PTGER2			BRD-K54871792-001-02-2, BRD-K54871792-001-01-4	COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1, COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1	LWJGMYMNSNVCEM-UHFFFAOYSA-N, LWJGMYMNSNVCEM-UHFFFAOYSA-N	Phase 1
PF-04447943	phosphodiesterase inhibitor	PDE9A			BRD-K50031829-001-01-6	C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2n(ncc2c(=O)[nH]1)C1CCOCC1	IWXUVYOOUMLUTQ-CZUORRHYSA-N	Phase 2
PF-04457845	FAAH inhibitor	FAAH			BRD-K86816506-001-01-8	FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	BATCTBJIJJEPHM-UHFFFAOYSA-N	Phase 2
PF-04620110	diacylglycerol O acyltransferase inhibitor	DGAT1			BRD-K30550578-001-01-3	Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12	GEVVQZHMFVFGLN-HDJSIYSDSA-N	Phase 1
PF-04691502	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			BRD-K07310275-001-02-5	COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O	XDLYKKIQACFMJG-WKILWMFISA-N	Phase 2
PF-04937319	glucokinase activator	GCK			BRD-K27755542-001-01-6	CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1	MASKQITXHVYVFL-UHFFFAOYSA-N	Phase 2
PF-05190457	growth hormone secretagogue receptor inverse agonist	GHSR			BRD-K02554563-001-01-6	Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1	ZIUDADZJCKGWKR-AREMUKBSSA-N	Phase 2
PF-05212384	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			BRD-K07955840-001-04-9, BRD-K07955840-001-03-1, BRD-K07955840-001-02-3	CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1, CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	DWZAEMINVBZMHQ-UHFFFAOYSA-N, DWZAEMINVBZMHQ-UHFFFAOYSA-N, DWZAEMINVBZMHQ-UHFFFAOYSA-N	Phase 2
PF-06447475	serine/threonine kinase inhibitor	LRRK2			BRD-K83114366-001-02-8, BRD-K83114366-001-01-0	N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12, N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12	BHTWDJBVZQBRKP-UHFFFAOYSA-N, BHTWDJBVZQBRKP-UHFFFAOYSA-N	Preclinical
PF-06463922	ALK tyrosine kinase receptor inhibitor	ALK, FES, ROS1			BRD-A23124853-001-01-4	CC1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	IIXWYSCJSQVBQM-UHFFFAOYSA-N	Phase 2
PF-3274167	oxytocin receptor antagonist	AVPR1A, OXTR			BRD-K31417912-001-01-9	COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1	HNIFCPBQMKPRCX-UHFFFAOYSA-N	Phase 2
PF-3845	FAAH inhibitor	FAAH			BRD-K68997413-001-05-1	FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	NBOJHRYUGLRASX-UHFFFAOYSA-N	Preclinical
PF-4708671	ribosomal protein inhibitor	RPS6KB1			BRD-K14711741-001-02-1, BRD-K14711741-001-05-4	CCc1cncnc1N1CCN(CC1)Cc1nc2cc(ccc2[nH]1)C(F)(F)F, CCc1cncnc1N1CCN(CC1)Cc1nc2cc(ccc2[nH]1)C(F)(F)F	FBLPQCAQRNSVHB-UHFFFAOYSA-N, FBLPQCAQRNSVHB-UHFFFAOYSA-N	Preclinical
PF-477736	CHK inhibitor	CHEK1, CHEK2			BRD-K03063480-001-07-4, BRD-K03063480-001-06-6, BRD-K03063480-001-05-8	Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O, Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N, NDEXUOWTGYUVGA-LJQANCHMSA-N	Phase 1
PF-4981517	cytochrome P450 inhibitor	CYP3A4			BRD-K78318619-001-02-7	Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	WDWIMDKOXZZYHH-FQEVSTJZSA-N	Preclinical
PF-5274857	smoothened receptor antagonist	SMO			BRD-K40302533-001-02-9	Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	BBVNTTZIOTWDSV-UHFFFAOYSA-N	Preclinical
PF-562271	focal adhesion kinase inhibitor	PTK2, PTK2B			BRD-K99545815-001-06-3, BRD-K99545815-074-02-9, BRD-K99545815-003-01-0, BRD-K99545815-074-03-7	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O, CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N, MZDKLVOWGIOKTN-UHFFFAOYSA-N	Phase 1
PF-573228	focal adhesion kinase inhibitor	CDK1, CDK2, CDK7, GSK3B, IKBKB			BRD-K79239947-001-06-8, BRD-K79239947-001-07-6	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1, CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	HESLKTSGTIBHJU-UHFFFAOYSA-N, HESLKTSGTIBHJU-UHFFFAOYSA-N	Preclinical
PF-670462	casein kinase inhibitor	CSNK1D, CSNK1E			BRD-K96295391-300-01-7, BRD-K96295391-300-02-5	Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1, Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1	WUDBUIUHVNECTM-UHFFFAOYSA-N, WUDBUIUHVNECTM-UHFFFAOYSA-N	Preclinical
PF-8380	autotaxin inhibitor	ENPP2			BRD-K50865540-001-01-5	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1	JMSUDQYHPSNBSN-UHFFFAOYSA-N	Preclinical
PF-915275	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			BRD-K18289362-001-01-4	Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	ZESFDAKNYJQYKO-UHFFFAOYSA-N	Phase 1
PFI-1	bromodomain inhibitor	BRD4			BRD-K13094524-001-07-5, BRD-K13094524-001-04-2	COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1, COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	TXZPMHLMPKIUGK-UHFFFAOYSA-N, TXZPMHLMPKIUGK-UHFFFAOYSA-N	Preclinical
PFK-015	phosphofructokinase inhibitor	PFKFB3			BRD-K95573441-001-02-0, BRD-K95573441-001-01-2	O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1, O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	UJJUKZPBUMCSJZ-BQYQJAHWSA-N, UJJUKZPBUMCSJZ-BQYQJAHWSA-N	Phase 1
PFK-158	phosphofructokinase inhibitor	PFKFB3			BRD-K28010364-001-01-0	FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1	IAJOMYABKVAZCN-AATRIKPKSA-N	Phase 1
PG-9	acetylcholine receptor agonist				BRD-A70268693-050-01-2	CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1	GHDWIFTUSXQYGK-UHFFFAOYSA-N	Preclinical
PGL5001	JNK inhibitor	MAPK10, MAPK8, MAPK9			BRD-A53813595-001-02-6, BRD-A53813595-001-01-8	N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1, N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1	XCPPIJCBCWUBNT-UHFFFAOYSA-N, XCPPIJCBCWUBNT-UHFFFAOYSA-N	Phase 2
PH-797804	p38 MAPK inhibitor	MAPK11, MAPK14			BRD-K95880107-001-02-4	CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	KCAJXIDMCNPGHZ-UHFFFAOYSA-N	Phase 2
PHA-665752	c-Met inhibitor	MET			BRD-K95435023-001-08-5, BRD-K95435023-001-09-3, BRD-K55218890-001-01-8, BRD-K95435023-001-07-7	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2\C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N, OYONTEXKYJZFHA-KCOUNZPASA-N, OYONTEXKYJZFHA-SSHUPFPWSA-N	Preclinical
PHA-680632	Aurora kinase inhibitor	AURKA, AURKB, AURKC			BRD-K09443272-001-03-3	CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	OBWNXGOQPLDDPS-UHFFFAOYSA-N	Preclinical
PHA-767491	CDC inhibitor	CDK1, RPS6KB1			BRD-K50000283-001-04-4, BRD-K50000283-003-02-4	O=C1NCCc2[nH]c(cc12)-c1ccncc1, O=C1NCCc2[nH]c(cc12)-c1ccncc1	DKXHSOUZPMHNIZ-UHFFFAOYSA-N, DKXHSOUZPMHNIZ-UHFFFAOYSA-N	Preclinical
PHA-793887	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9			BRD-K64800655-001-09-0, BRD-K64800655-001-07-4	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C, CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	HUXYBQXJVXOMKX-UHFFFAOYSA-N, HUXYBQXJVXOMKX-UHFFFAOYSA-N	Phase 1
PHA-848125	CDK inhibitor, growth factor receptor inhibitor	CDK2, CDK4, CDK7, NTRK1			BRD-K60997853-001-02-3	CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	RXZMYLDMFYNEIM-UHFFFAOYSA-N	Phase 2
PHCCC	glutamate receptor agonist	GRM1, GRM4			BRD-A59709458-001-01-8	O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1	FPXPIEZPAXSELW-CYVLTUHYSA-N	Preclinical
phenacaine	local anesthetic		neurology/psychiatry	local anesthetic	BRD-K81092066-311-01-6	CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1	QXDAEKSDNVPFJG-UHFFFAOYSA-N	Launched
phenacemide	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures	BRD-K40905133-001-04-9	NC(=O)NC(=O)Cc1ccccc1	XPFRXWCVYUEORT-UHFFFAOYSA-N	Launched
phenacetin	cyclooxygenase inhibitor	PTGS1			BRD-K38323065-001-19-9, BRD-K38323065-001-18-1	CCOc1ccc(NC(C)=O)cc1, CCOc1ccc(NC(C)=O)cc1	CPJSUEIXXCENMM-UHFFFAOYSA-N, CPJSUEIXXCENMM-UHFFFAOYSA-N	Withdrawn
phenazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K46937689-001-15-0, BRD-K46937689-001-14-3	Cc1cc(=O)n(-c2ccccc2)n1C, Cc1cc(=O)n(-c2ccccc2)n1C	VEQOALNAAJBPNY-UHFFFAOYSA-N, VEQOALNAAJBPNY-UHFFFAOYSA-N	Launched
phenazopyridine	local anesthetic	SCN1A	infectious disease	urinary tract infections	BRD-K76304753-003-20-3, BRD-K76304753-003-21-1, BRD-K76304753-003-19-5	Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1, Nc1ccc(\N=N\c2ccccc2)c(N)n1	QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N, QPFYXYFORQJZEC-FOCLMDBBSA-N	Launched
phenelzine	monoamine oxidase inhibitor	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-K87024524-065-17-7, BRD-K87024524-065-18-5	NNCCc1ccccc1, NNCCc1ccccc1	RMUCZJUITONUFY-UHFFFAOYSA-N, RMUCZJUITONUFY-UHFFFAOYSA-N	Launched
phenethicillin	bacterial cell wall synthesis inhibitor				BRD-A66025870-237-06-9	CC(Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	NONJJLVGHLVQQM-JHXYUMNGSA-N	Launched
phenethyl-isothiocyanate	anticancer agent	CYP2E1			BRD-K56700933-001-03-9	S=C=NCCc1ccccc1	IZJDOKYDEWTZSO-UHFFFAOYSA-N	Phase 2
phenformin	AMPK activator	KCNJ8, PRKAA1			BRD-K11399644-003-11-3, BRD-K11399644-003-10-5, BRD-K11399644-003-09-7	NC(=N)NC(=N)NCCc1ccccc1, NC(=N)NC(=N)NCCc1ccccc1, NC(=N)NC(=N)NCCc1ccccc1	ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N, ICFJFFQQTFMIBG-UHFFFAOYSA-N	Withdrawn
phenindamine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	BRD-A33178345-001-01-4, BRD-A33178345-001-02-2	CN1CCC2=C(C1)C(c1ccccc21)c1ccccc1, CN1CCC2=C(C1)C(c1ccccc21)c1ccccc1	ISFHAYSTHMVOJR-UHFFFAOYSA-N, ISFHAYSTHMVOJR-UHFFFAOYSA-N	Launched
phenindione	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	BRD-K70592963-001-31-6, BRD-K70592963-001-29-0, BRD-K70592963-001-32-4, BRD-K70592963-001-27-4, BRD-K70592963-001-28-2	O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1, O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N, NFBAXHOPROOJAW-UHFFFAOYSA-N	Launched
pheniramine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	BRD-A23072235-050-18-5, BRD-A23072235-050-17-7	CN(C)CCC(c1ccccc1)c1ccccn1, CN(C)CCC(c1ccccc1)c1ccccn1	IJHNSHDBIRRJRN-UHFFFAOYSA-N, IJHNSHDBIRRJRN-UHFFFAOYSA-N	Launched
phenol		CA1, CA12, CA14, CA2, CA4, CA9	otolaryngology	pharyngitis	BRD-K76549667-001-04-6	Oc1ccccc1	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	Preclinical
phenolphthalein	indicator dye	UGT1A9			BRD-K19227686-001-18-6	Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	KJFMBFZCATUALV-UHFFFAOYSA-N	Withdrawn
phenolsulfonphthalein					BRD-K79892937-001-02-5	Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	BELBBZDIHDAJOR-UHFFFAOYSA-N	Launched
phenothiazine	dopamine receptor antagonist				BRD-K59597909-001-20-0, BRD-K59597909-001-17-6, BRD-K59597909-001-19-2	N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12, N1c2ccccc2Sc2ccccc12	WJFKNYWRSNBZNX-UHFFFAOYSA-N, WJFKNYWRSNBZNX-UHFFFAOYSA-N, WJFKNYWRSNBZNX-UHFFFAOYSA-N	Preclinical
phenothrin			infectious disease	lice	BRD-A22106989-001-05-0, BRD-A22106989-001-06-8	CC(C)=CC1C(C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C, CC(C)=CC1C(C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C	SBNFWQZLDJGRLK-UHFFFAOYSA-N, SBNFWQZLDJGRLK-UHFFFAOYSA-N	Launched
phenoxybenzamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, CALM1	cardiology, endocrinology	hypertension, pheochromocytoma	BRD-A67799922-003-27-8, BRD-A67799922-003-28-6, BRD-A67799922-003-26-0	CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1, CC(COc1ccccc1)N(CCCl)Cc1ccccc1	QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N, QZVCTJOXCFMACW-UHFFFAOYSA-N	Launched
phenprobamate	muscle relaxant		neurology/psychiatry	anxiety, muscle relaxant	BRD-K22009844-001-12-5	NC(=O)OCCCc1ccccc1	CAMYKONBWHRPDD-UHFFFAOYSA-N	Launched
phenprocoumon	vitamin K antagonist	VKORC1	hematology	thrombosis, pulmonary embolism (PE)	BRD-A49838158-001-01-1	CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O	DQDAYGNAKTZFIW-UHFFFAOYSA-N	Launched
phenserine	acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor	ACHE, BCHE			BRD-K46580984-001-03-6, BRD-K46580984-001-02-8	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21, CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	PBHFNBQPZCRWQP-QUCCMNQESA-N, PBHFNBQPZCRWQP-QUCCMNQESA-N	Phase 3
phensuximide	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	BRD-A18043272-001-09-9	CN1C(=O)CC(C1=O)c1ccccc1	WLWFNJKHKGIJNW-UHFFFAOYSA-N	Launched
phentermine	dopamine uptake inhibitor, serotonin reuptake inhibitor	MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	endocrinology	weight-loss aid	BRD-K96319534-003-03-9	CC(C)(N)Cc1ccccc1	DHHVAGZRUROJKS-UHFFFAOYSA-N	Launched
phentolamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	endocrinology, cardiology	pheochromocytoma, hypertension	BRD-K90333595-003-22-2, BRD-K90333595-066-17-9, BRD-K90333595-003-21-4, BRD-K90333595-066-16-1	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1, Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1	MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N, MRBDMNSDAVCSSF-UHFFFAOYSA-N	Launched
phenyl-aminosalicylate			infectious disease	tuberculosis	BRD-K73157543-001-04-1	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	DNVVZWSVACQWJE-UHFFFAOYSA-N	Launched
phenyl-salicylate	antiseptic		urology	interstitial cystitis (IC)	BRD-K44091963-001-01-5	Oc1ccccc1C(=O)Oc1ccccc1	ZQBAKBUEJOMQEX-UHFFFAOYSA-N	Launched
phenylacetylglutamine	DNA methylase inhibitor, protein synthesis inhibitor				BRD-K70592483-001-01-0	NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O	JFLIEFSWGNOPJJ-JTQLQIEISA-N	Phase 2
phenylbenzimidazole-sulfonic-acid			dermatology	sunscreen lotion	BRD-K02729857-001-01-9	OS(=O)(=O)c1ccc2[nH]c(nc2c1)-c1ccccc1	UVCJGUGAGLDPAA-UHFFFAOYSA-N	Launched
phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGIS, PTGS1, PTGS2			BRD-K10843433-001-22-7, BRD-K10843433-001-23-5, BRD-K10843433-001-21-9	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	VYMDGNCVAMGZFE-UHFFFAOYSA-N, VYMDGNCVAMGZFE-UHFFFAOYSA-N, VYMDGNCVAMGZFE-UHFFFAOYSA-N	Withdrawn
phenylbutyrate	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	BRD-K67102207-236-07-7, BRD-K67102207-236-08-5, BRD-K67102207-236-06-9	OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1, OC(=O)CCCc1ccccc1	OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N, OBKXEAXTFZPCHS-UHFFFAOYSA-N	Launched
phenylephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	otolaryngology, gastroenterology, cardiology	nasal congestion, hemorrhoids, hypotension	BRD-K73381542-003-24-2, BRD-K73381542-003-23-4, BRD-K73381542-003-22-6	CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1, CNC[C@H](O)c1cccc(O)c1	SONNWYBIRXJNDC-VIFPVBQESA-N, SONNWYBIRXJNDC-VIFPVBQESA-N, SONNWYBIRXJNDC-VIFPVBQESA-N	Launched
phenylethyl-alcohol					BRD-K42371134-001-06-6	OCCc1ccccc1	WRMNZCZEMHIOCP-UHFFFAOYSA-N	Preclinical
phenylmercuric-acetate	other antifungal				BRD-K74193284-001-04-8	CC(=O)O[Hg]c1ccccc1	XEBWQGVWTUSTLN-UHFFFAOYSA-M	Preclinical
phenylmethylsulfonyl-fluoride	serine protease inhibitor				BRD-K33422401-001-05-6, BRD-K33422401-001-06-4	FS(=O)(=O)Cc1ccccc1, FS(=O)(=O)Cc1ccccc1	YBYRMVIVWMBXKQ-UHFFFAOYSA-N, YBYRMVIVWMBXKQ-UHFFFAOYSA-N	Preclinical
phenylpiracetam	noradrenaline uptake inhibitor		neurology/psychiatry	anxiety, fatigue, depression	BRD-A65683612-001-07-7	NC(=O)CN1CC(CC1=O)c1ccccc1	LYONXVJRBWWGQO-UHFFFAOYSA-N	Launched
phenytoin	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K55930204-236-24-3, BRD-K55930204-001-20-9, BRD-K55930204-236-23-5	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1, O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	CXOFVDLJLONNDW-UHFFFAOYSA-N, CXOFVDLJLONNDW-UHFFFAOYSA-N, CXOFVDLJLONNDW-UHFFFAOYSA-N	Launched
phloretin	sodium/glucose cotransporter inhibitor	AQP9, CLCN3, SLC23A1			BRD-K15563106-001-18-0	Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1	VGEREEWJJVICBM-UHFFFAOYSA-N	Launched
phlorizin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A11, SLC5A2, SLC5A3			BRD-K24601397-001-01-1	OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@@H](O)[C@@H](O)[C@@H]1O	IOUVKUPGCMBWBT-BVJIBDCISA-N	Preclinical
phloroglucin					BRD-K00405906-001-01-9	Oc1cc(O)cc(O)c1	QCDYQQDYXPDABM-UHFFFAOYSA-N	Launched
phortress	aryl hydrocarbon receptor ligand	AHR			BRD-K74558903-300-01-5	Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1	LFDOEFHQLNGBQQ-HNNXBMFYSA-N	Phase 1
phosphatidylcholine		PCTP	infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology	hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome	BRD-U51753822-000-01-1, BRD-A10131665-001-02-0	, CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC	, JLPULHDHAOZNQI-ZTIMHPMXSA-O	Launched
PHT-427	AKT inhibitor, pyruvate dehydrogenase inhibitor	AKT2, PDPK1			BRD-K59745944-001-03-8, BRD-K59745944-001-04-6, BRD-K59745944-001-02-0	CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1, CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N, BYWWNRBKPCPJMG-UHFFFAOYSA-N	Preclinical
phthalylsulfacetamide					BRD-K77115421-001-04-2, BRD-K77115421-001-02-6, BRD-K77115421-001-03-4	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1, CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	SNWQKAWITMVCQW-UHFFFAOYSA-N, SNWQKAWITMVCQW-UHFFFAOYSA-N, SNWQKAWITMVCQW-UHFFFAOYSA-N	Preclinical
phthalylsulfathiazole	dihydropteroate synthetase inhibitor		infectious disease, gastroenterology	dysentry, colitis	BRD-K64659768-001-12-8, BRD-K64659768-001-13-6	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	PBMSWVPMRUJMPE-UHFFFAOYSA-N, PBMSWVPMRUJMPE-UHFFFAOYSA-N	Launched
PHTPP	estrogen receptor antagonist	ESR2			BRD-K76568384-001-02-2	Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	AEZPAUSGTAHLOQ-UHFFFAOYSA-N	Preclinical
physostigmine	cholinesterase inhibitor	ACHE, BCHE	cardiology, neurology/psychiatry, ophthalmology, gastroenterology	hypotension, Alzheimers disease, glaucoma, gastroparesis" "BRD-K25650355-065-02-0" "CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1" "PIJVFDBKTWXHHD-HIFRSBDPSA-N" "Launched"
"2224" "physostigmine-salicylate" "acetylcholinesterase inhibitor" "" "" "" "BRD-K25650355-059-18-9, BRD-A37052580-059-07-6" "CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1, CNC(=O)Oc1ccc2N(C)C3N(C)CC[C@@]3(C)c2c1" "PIJVFDBKTWXHHD-HIFRSBDPSA-N, PIJVFDBKTWXHHD-WUJWULDRSA-N" "Phase 3"
"2225" "phytonadione" "" "BGLAP, GGCX" "hematology" "vitamin K deficiency, anticoagulation reversal" "BRD-K76661572-001-07-6, BRD-K76661572-001-08-4" "CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O" "MBWXNTAXLNYFJB-NKFFZRIASA-N, MBWXNTAXLNYFJB-NKFFZRIASA-N" "Launched"
"2226" "phytosphingosine" "" "" "" "" "BRD-K05048137-001-03-9" "CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO" "AERBNCYCJBRYDG-KSZLIROESA-N" "Phase 1"
"2227" "PI-103" "mTOR inhibitor, PI3K inhibitor" "MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC" "" "" "BRD-K67868012-003-02-3, BRD-K67868012-001-07-6" "Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1, Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1" "TUVCWJQQGGETHL-UHFFFAOYSA-N, TUVCWJQQGGETHL-UHFFFAOYSA-N" "Preclinical"
"2228" "PI-828" "PI3K inhibitor" "" "" "" "BRD-K97365803-001-03-9, BRD-K97365803-001-02-1" "Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1, Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1" "WUKMIBOGGXMBAC-UHFFFAOYSA-N, WUKMIBOGGXMBAC-UHFFFAOYSA-N" "Preclinical"
"2229" "pibenzimol" "DNA inhibitor" "" "" "" "BRD-K17026858-001-01-2, BRD-K79132813-001-09-0" "CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1, c1ccc2[nH]c(nc2c1)-c1nc2ccccc2[nH]1" "INAAIJLSXJJHOZ-UHFFFAOYSA-N, VEZJRJGLFIXQHG-UHFFFAOYSA-N" "Phase 2"
"2230" "piboserod" "serotonin receptor antagonist" "HTR2B, HTR4" "" "" "BRD-K02750403-001-01-4, BRD-K02750403-001-02-2" "CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1, CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1" "KVCSJPATKXABRQ-UHFFFAOYSA-N, KVCSJPATKXABRQ-UHFFFAOYSA-N" "Phase 2"
"2231" "picartamide" "H+/K+-ATPase inhibitor" "ATP4A" "" "" "BRD-A71765060-001-01-4" "CNC(=S)C1(CCCS1)c1ccccn1" "ITNLONMDUMHEOK-UHFFFAOYSA-N" "Phase 2"
"2232" "piceatannol" "SYK inhibitor" "ATP5A1, ATP5B, ATP5C1, IRF3" "" "" "BRD-K91509126-001-23-6, BRD-K91509126-001-25-1, BRD-K91509126-001-24-4" "Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1, Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1, Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1" "CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N, CDRPUGZCRXZLFL-OWOJBTEDSA-N" "Preclinical"
"2233" "piclamilast" "phosphodiesterase inhibitor" "PDE4A, PDE4B, PDE4C, PDE4D" "" "" "BRD-K47642186-001-01-3" "COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl" "RRRUXBQSQLKHEL-UHFFFAOYSA-N" "Phase 2"
"2234" "picolamine" "" "" "" "" "BRD-K68653965-001-01-1" "NCc1cccnc1" "HDOUGSFASVGDCS-UHFFFAOYSA-N" "Preclinical"
"2235" "picolinic-acid" "chelating agent" "" "" "" "BRD-K01029106-001-01-4, BRD-K60612034-001-07-9, BRD-K60612034-001-08-7" "O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1, OC(=O)c1ccccn1, OC(=O)c1ccccn1" "CBDQOLKNTOMMTL-UHFFFAOYSA-K, SIOXPEMLGUPBBT-UHFFFAOYSA-N, SIOXPEMLGUPBBT-UHFFFAOYSA-N" "Phase 2"
"2236" "piconol" "" "" "" "" "BRD-K28492574-001-01-6" "OCc1ccccn1" "SHNUBALDGXWUJI-UHFFFAOYSA-N" "Preclinical"
"2237" "picotamide" "thromboxane receptor antagonist, thromboxane synthase inhibitor" "TBXA2R" "hematology" "thrombosis" "BRD-K67277431-002-10-5" "COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1" "KYWCWBXGRWWINE-UHFFFAOYSA-N" "Launched"
"2238" "picrotin" "GABA receptor antagonist" "GABRA1, GABRR1, GLRA1, GLRA2, GLRA3, GLRB" "" "" "BRD-A91822151-001-05-0" "CC(C)(O)C1C2OC(=O)C1C1(O)CC3OC33C(=O)OC2C13C" "RYEFFICCPKWYML-UHFFFAOYSA-N" "Phase 2"
"2239" "picrotoxinin" "GABA receptor antagonist" "GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B" "" "" "BRD-K36461289-001-05-8" "CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C" "PIMZUZSSNYHVCU-KBLUICEQSA-N" "Preclinical"
"2240" "pidolic-acid" "" "ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA" "dermatology" "xerosis cutis" "BRD-K57313110-001-06-8" "OC(=O)[C@@H]1CCC(=O)N1" "ODHCTXKNWHHXJC-VKHMYHEASA-N" "Launched"
"2241" "pidotimod" "interferon receptor agonist, interleukin receptor agonist" "" "infectious disease" "immune adjuvant" "BRD-K44442813-001-12-9, BRD-K44442813-001-11-1" "OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1, OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1" "UUTKICFRNVKFRG-WDSKDSINSA-N, UUTKICFRNVKFRG-WDSKDSINSA-N" "Launched"
"2242" "pifithrin-alpha" "TP53 inhibitor" "TP53" "" "" "BRD-K66874953-004-09-6, BRD-K66874953-004-07-0, BRD-K66874953-004-08-8" "Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N, Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N" "OLTZHXYLLRJLST-UHFFFAOYSA-N, OLTZHXYLLRJLST-UHFFFAOYSA-N, OLTZHXYLLRJLST-UHFFFAOYSA-N" "Preclinical"
"2243" "pifithrin-mu" "HSP inhibitor" "HSPA1A, TP53" "" "" "BRD-K96799727-001-07-4, BRD-K96799727-001-06-6, BRD-K96799727-001-05-8" "NS(=O)(=O)C" "" ""
"2244" "PIK-293" "PI3K inhibitor" "PIK3CA, PIK3CB, PIK3CD, PIK3CG" "" "" "BRD-K30977212-001-02-8" "Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O" "KQDBVHKNIYROHU-UHFFFAOYSA-N" "Preclinical"
"2245" "PIK-294" "PI3K inhibitor" "PIK3CB, PIK3CD, PIK3CG" "" "" "BRD-K50631926-001-02-3" "Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O" "WFSLJOPRIJSOJR-UHFFFAOYSA-N" "Preclinical"
"2246" "PIK-75" "DNA protein kinase inhibitor, PI3K inhibitor" "PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC" "" "" "BRD-K49371609-003-03-8" "CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O" "QTHCAAFKVUWAFI-DJKKODMXSA-N" "Preclinical"
"2247" "PIK-93" "PI3K inhibitor" "PI4KB, PIK3C3, PIK3CG" "" "" "BRD-K29395450-001-06-8" "CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO" "JFVNFXCESCXMBC-UHFFFAOYSA-N" "Preclinical"
"2248" "pikamilone" "" "" "" "" "BRD-K56691760-001-01-2" "OC(=O)CCCNC(=O)c1cccnc1" "NAJVRARAUNYNDX-UHFFFAOYSA-N" "Phase 1"
"2249" "piketoprofen" "cyclooxygenase inhibitor" "" "neurology/psychiatry" "pain relief" "BRD-A85548292-001-01-8" "CC(C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1" "ASFKKFRSMGBFRO-UHFFFAOYSA-N" "Launched"
"2250" "pilaralisib" "PI3K inhibitor" "" "" "" "BRD-K49456274-001-01-9" "COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1" "QINPEPAQOBZPOF-UHFFFAOYSA-N" "Phase 2"
"2251" "pilocarpine" "acetylcholine receptor agonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "ophthalmology, cardiology" "glaucoma, hypertension" "BRD-K85090592-008-22-7, BRD-K85090592-003-19-4, BRD-K85090592-003-18-6" "CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O, CC[C@H]1[C@@H](Cc2cncn2C)COC1=O" "QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N, QCHFTSOMWOSFHM-WPRPVWTQSA-N" "Launched"
"2252" "pilsicainide" "sodium channel blocker" "SCN5A" "cardiology" "cardiac arrythmia" "BRD-K83245588-001-01-4" "Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2" "BCQTVJKBTWGHCX-UHFFFAOYSA-N" "Launched"
"2253" "PIM-1-Inhibitor-2" "Pim kinase inhibitor" "PIM1" "" "" "BRD-K48832421-001-01-4" "Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1" "AQVFETGXIRKVAQ-UHFFFAOYSA-N" "Preclinical"
"2254" "pimavanserin" "serotonin receptor inverse agonist" "DRD2, HTR2A" "" "" "BRD-K83405785-001-01-5" "CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1" "RKEWSXXUOLRFBX-UHFFFAOYSA-N" "Launched"
"2255" "pimecrolimus" "calcineurin inhibitor" "FKBP1A, MTOR" "dermatology" "eczema" "BRD-K97729603-001-01-2" "CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](Cl)[C@@H](C1)OC" "KASDHRXLYQOAKZ-RNZHFBRZSA-N" "Launched"
"2256" "pimethixene" "antihistamine" "" "neurology/psychiatry, allergy" "attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis" "BRD-K88090157-050-10-8" "CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12" "NZLVRVYNQYGMAB-UHFFFAOYSA-N" "Launched"
"2257" "pimobendan" "calcium sensitizer, phosphodiesterase inhibitor" "PDE3A" "cardiology" "congestive heart failure" "BRD-A84575140-001-02-4" "COc1ccc(cc1)-c1nc2cc(ccc2[nH]1)C1=NNC(=O)CC1C" "GLBJJMFZWDBELO-UHFFFAOYSA-N" "Launched"
"2258" "pimonidazole" "" "" "" "" "BRD-A67521319-001-01-6" "OC(CN1CCCCC1)Cn1ccnc1[N+]([O-])=O" "WVWOOAYQYLJEFD-UHFFFAOYSA-N" "Phase 3"
"2259" "pimozide" "dopamine receptor antagonist" "CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2" "neurology/psychiatry" "Tourettes disorder	BRD-K01292756-001-25-0, BRD-K01292756-001-23-5, BRD-K01292756-001-24-3	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1, Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	YVUQSNJEYSNKRX-UHFFFAOYSA-N, YVUQSNJEYSNKRX-UHFFFAOYSA-N, YVUQSNJEYSNKRX-UHFFFAOYSA-N	Launched
pinacidil	ATP channel activator, potassium channel activator	ABCC8, ABCC9	cardiology	hypertension	BRD-A43882281-001-15-5, BRD-A43882281-001-14-8	CC(N\C(Nc1ccncc1)=N\C#N)C(C)(C)C, CC(N\C(Nc1ccncc1)=N\C#N)C(C)(C)C	IVVNZDGDKPTYHK-UHFFFAOYSA-N, IVVNZDGDKPTYHK-UHFFFAOYSA-N	Launched
pinanediol					BRD-K69885552-001-01-7	CC1(C)[C@@H]2C[C@H]1[C@@](C)(O)[C@@H](O)C2	MOILFCKRQFQVFS-BDNRQGISSA-N	Preclinical
pinaverium	T-type calcium channel blocker	CACNA1C	gastroenterology	irritable bowel syndrome	BRD-A70998768-004-01-1	COc1cc(Br)c(C[N+]2(CCOCCC3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC	DDHUTBKXLWCZCO-GFUWAVFVSA-N	Launched
pincainide	antiarrhythmic				BRD-K90727284-001-05-0	Cc1cccc(C)c1NC(=O)CN1CCCCCC1	RJOUHGWLHPOQSA-UHFFFAOYSA-N	Phase 1
pindolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR1B, HTR2A, HTR2B	cardiology	hypertension	BRD-A97701745-001-16-0, BRD-A97701745-001-15-2, BRD-A97701745-001-14-5	CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12, CC(C)NCC(O)COc1cccc2[nH]ccc12	JZQKKSLKJUAGIC-UHFFFAOYSA-N, JZQKKSLKJUAGIC-UHFFFAOYSA-N, JZQKKSLKJUAGIC-UHFFFAOYSA-N	Launched
pindolol-(-)	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A			BRD-K95598440-001-09-3	CC(C)NC[C@H](O)COc1cccc2[nH]ccc12	JZQKKSLKJUAGIC-NSHDSACASA-N	Preclinical
pinitol	gamma secretase inhibitor				BRD-A69275535-001-01-5	COC1C(O)[C@@H](O)C(O)C(O)[C@H]1O	DSCFFEYYQKSRSV-LNEVVHJTSA-N	Phase 2
pinocembrin	cytochrome P450 inhibitor	CYP1B1			BRD-K94689771-001-09-0	Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	URFCJEUYXNAHFI-ZDUSSCGKSA-N	Phase 2
pioglitazone	insulin sensitizer, PPAR receptor agonist	PPARG, TRPM3	endocrinology	diabetes mellitus	BRD-A48430263-003-17-2, BRD-A48430263-003-16-4, BRD-A48430263-001-07-7	CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1, CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1, CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1	HYAFETHFCAUJAY-UHFFFAOYSA-N, HYAFETHFCAUJAY-UHFFFAOYSA-N, HYAFETHFCAUJAY-UHFFFAOYSA-N	Launched
pipamperone	dopamine receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A	neurology/psychiatry	schizophrenia	BRD-K26801045-001-02-9	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	AXKPFOAXAHJUAG-UHFFFAOYSA-N	Launched
pipecuronium	neuromuscular blocker	CHRM2, CHRM3, CHRNA2	neurology/psychiatry	anesthetic	BRD-A21544762-303-01-5	CC(=O)OC1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1	OWWLUIWOFHMHOQ-XUCOTFPHSA-N	Launched
pipemidic-acid	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	BRD-K08999871-213-01-5	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	JOHZPMXAZQZXHR-UHFFFAOYSA-N	Launched
pipenzolate	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	BRD-A53561827-004-23-1, BRD-A53561827-004-22-3	CC[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1, CC[N+]1(C)CCCC(C1)OC(=O)C(O)(c1ccccc1)c1ccccc1	WPUKUEMZZRVAKZ-UHFFFAOYSA-N, WPUKUEMZZRVAKZ-UHFFFAOYSA-N	Launched
piperacetazine	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	BRD-K16277217-001-10-9	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	BTFMCMVEUCGQDX-UHFFFAOYSA-N	Launched
piperacillin	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia	BRD-K86873305-236-14-7, BRD-K86873305-236-16-2, BRD-A99949740-236-04-6, BRD-K67009182-236-01-6, BRD-K86873305-236-15-4	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)NC(C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2[C@H]3SC(C)(C)[C@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O, CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N, IVBHGBMCVLDMKU-UVIOZBFDSA-N, IVBHGBMCVLDMKU-IGMJJTELSA-N, IVBHGBMCVLDMKU-GXNBUGAJSA-N	Launched
piperaquine-phosphate	antimalarial agent		infectious disease	malaria	BRD-K27382019-418-01-9	Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1	UCRHFBCYFMIWHC-UHFFFAOYSA-N	Launched
piperazine	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	BRD-K13249881-001-02-3	C1CNCCN1	GLUUGHFHXGJENI-UHFFFAOYSA-N	Launched
piperazinedione	DNA synthesis inhibitor				BRD-K95941975-001-01-5	O=C1CNC(=O)CN1	BXRNXXXXHLBUKK-UHFFFAOYSA-N	Phase 2
piperidolate	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	BRD-A97479839-003-13-3	CCN1CCCC(C1)OC(=O)C(c1ccccc1)c1ccccc1	KTHVBAZBLKXIHZ-UHFFFAOYSA-N	Launched
piperine	monoamine oxidase inhibitor	MAOA, MAOB, TRPV1			BRD-K59522102-001-15-3, BRD-K59522102-001-14-6, BRD-K59522102-001-13-8	O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1, O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N, MXXWOMGUGJBKIW-YPCIICBESA-N	Phase 1
piperonyl-butoxide	cytochrome P450 inhibitor		infectious disease	lice	BRD-K76452401-001-03-6	CCCCOCCOCCOCc1cc2OCOc2cc1CCC	FIPWRIJSWJWJAI-UHFFFAOYSA-N	Launched
pipobroman	DNA alkylating agent		hematology	polycythemia vera, thrombocythemia	BRD-K15656090-001-04-0, BRD-K15656090-001-06-5	BrCCC(=O)N1CCN(CC1)C(=O)CCBr, BrCCC(=O)N1CCN(CC1)C(=O)CCBr	NJBFOOCLYDNZJN-UHFFFAOYSA-N, NJBFOOCLYDNZJN-UHFFFAOYSA-N	Launched
pipotiazine-palmitate	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, DRD2, HTR1A, HTR2A			BRD-K48429278-001-01-3	CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1	KTOYYUONFQWSMW-UHFFFAOYSA-N	Launched
piracetam	acetylcholine receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	senile dementia	BRD-K19456237-001-27-6, BRD-K19456237-001-26-8	NC(=O)CN1CCCC1=O, NC(=O)CN1CCCC1=O	GMZVRMREEHBGGF-UHFFFAOYSA-N, GMZVRMREEHBGGF-UHFFFAOYSA-N	Launched
pirarubicin	topoisomerase inhibitor	TOP2A	oncology	breast cancer	BRD-K83794624-001-03-3, BRD-K83794624-003-01-3, BRD-K83794624-001-02-5	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	KMSKQZKKOZQFFG-YXRRJAAWSA-N, KMSKQZKKOZQFFG-YXRRJAAWSA-N, KMSKQZKKOZQFFG-YXRRJAAWSA-N	Launched
pirenoxine	AGE inhibitor		ophthalmology	cataracts	BRD-K65992024-001-01-5	OC(=O)c1cc(O)c2c3nc4ccccc4oc3cc(=O)c2n1	OKPNYGAWTYOBFZ-UHFFFAOYSA-N	Launched
pirenperone	serotonin receptor antagonist	HTR2A, HTR7			BRD-K25224017-001-25-0	Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	HXCNRYXBZNHDNE-UHFFFAOYSA-N	Preclinical
pirenzepine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	BRD-K89375097-300-08-8	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	RMHMFHUVIITRHF-UHFFFAOYSA-N	Launched
piretanide	glucocorticoid receptor agonist	SLC12A1, SLC12A2	cardiology	hypertension, edema	BRD-K87990216-001-10-2	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	UJEWTUDSLQGTOA-UHFFFAOYSA-N	Launched
pirfenidone	TGF beta receptor inhibitor	FURIN, TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	BRD-K96862998-001-15-5, BRD-K96862998-001-14-8	Cc1ccc(=O)n(c1)-c1ccccc1, Cc1ccc(=O)n(c1)-c1ccccc1	ISWRGOKTTBVCFA-UHFFFAOYSA-N, ISWRGOKTTBVCFA-UHFFFAOYSA-N	Launched
piribedil	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B	neurology/psychiatry	Parkinsons Disease, dizziness" "BRD-K47936004-003-11-4" "C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1" "OQDPVLVUJFGPGQ-UHFFFAOYSA-N" "Launched"
"2260" "piricapiron" "dopamine receptor antagonist, serotonin receptor antagonist" "HTR2A" "" "" "BRD-A04203391-001-08-3" "CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O" "NCMIPRCQUMYAEC-UHFFFAOYSA-N" "Phase 2"
"2261" "pirinixic-acid" "PPAR receptor agonist" "PPARA" "" "" "BRD-K01902415-001-11-7, BRD-K01902415-001-10-9" "Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C, Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C" "SZRPDCCEHVWOJX-UHFFFAOYSA-N, SZRPDCCEHVWOJX-UHFFFAOYSA-N" "Preclinical"
"2262" "pirlindole" "monoamine oxidase inhibitor" "MAOA" "neurology/psychiatry" "depression" "BRD-A54490543-066-11-9" "Cc1ccc2n3CCNC4CCCc(c34)c2c1" "IWVRVEIKCBFZNF-UHFFFAOYSA-N" "Launched"
"2263" "piroctone-olamine" "" "" "infectious disease" "fungal infection" "BRD-A96510685-213-03-7" "CC(Cc1cc(C)cc(=O)n1O)CC(C)(C)C" "OIQJEQLSYJSNDS-UHFFFAOYSA-N" "Launched"
"2264" "pirodavir" "" "" "" "" "BRD-K22261391-001-01-2" "CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1" "KCHIOGFOPPOUJC-UHFFFAOYSA-N" "Phase 2"
"2265" "piromidic-acid" "bacterial DNA gyrase inhibitor" "" "" "" "BRD-K37682401-001-09-3, BRD-K37682401-213-01-1, BRD-K37682401-001-08-5" "CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1, CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1" "RCIMBBZXSXFZBV-UHFFFAOYSA-N, RCIMBBZXSXFZBV-UHFFFAOYSA-N, RCIMBBZXSXFZBV-UHFFFAOYSA-N" "Phase 2"
"2266" "piroxicam" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "rheumatology" "osteoarthritis, rheumatoid arthritis" "BRD-A57382968-001-29-0, BRD-A57382968-001-28-2, BRD-A57382968-001-27-4" "CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O" "MNSCVRXKDINXEY-UHFFFAOYSA-N, MNSCVRXKDINXEY-UHFFFAOYSA-N, MNSCVRXKDINXEY-UHFFFAOYSA-N" "Launched"
"2267" "piroximone" "phosphodiesterase inhibitor" "PDE3A" "" "" "BRD-K71977764-001-01-2" "CCc1[nH]c(O)nc1C(=O)c1ccncc1" "OQGWJZOWLHWFME-UHFFFAOYSA-N" "Phase 2"
"2268" "pirquinozol" "histamine release inhibitor" "" "" "" "BRD-K63651590-001-01-3" "OCc1cc2c3ccccc3[nH]c(=O)n2n1" "XLUKOGNIEDDIMV-UHFFFAOYSA-N" "Phase 1"
"2269" "PIT" "purinergic receptor antagonist" "P2RY1" "" "" "BRD-K43978949-075-02-5" "[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1" "LXEZPPZLNVOLDI-UHFFFAOYSA-N" "Preclinical"
"2270" "pitavastatin" "HMGCR inhibitor" "HMGCR" "endocrinology" "hyperlipidemia" "BRD-K75958547-238-01-0" "O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O" "VGYFMXBACGZSIL-MCBHFWOFSA-N" "Launched"
"2271" "pivagabine" "corticosteroid releasing factor receptor antagonist" "CRHR1, CRHR2" "neurology/psychiatry" "depression" "BRD-K62264492-001-01-5, BRD-K62264492-001-02-3" "CC(C)(C)C(=O)NCCCC(O)=O, CC(C)(C)C(=O)NCCCC(O)=O" "SRPNQDXRVRCTNK-UHFFFAOYSA-N, SRPNQDXRVRCTNK-UHFFFAOYSA-N" "Launched"
"2272" "pivampicillin" "bacterial cell wall synthesis inhibitor" "" "pulmonary, infectious disease" "bronchitis, pneumonia, gynecologic infections" "BRD-K32791151-001-04-0" "CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O" "ZEMIJUDPLILVNQ-ZXFNITATSA-N" "Launched"
"2273" "pivanex" "HDAC inhibitor" "HDAC1, HDAC2, HDAC3, HDAC8" "" "" "BRD-K20504455-001-01-0" "CCCC(=O)OCOC(=O)C(C)(C)C" "GYKLFBYWXZYSOW-UHFFFAOYSA-N" "Phase 2"
"2274" "pivmecillinam" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "urinary tract infections, gram-negative bacterial infections" "BRD-K67100011-003-07-1, BRD-K67100011-003-06-3, BRD-K67100011-001-01-8" "CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O, CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O" "NPGNOVNWUSPMDP-UTEPHESZSA-N, NPGNOVNWUSPMDP-UTEPHESZSA-N, NPGNOVNWUSPMDP-UTEPHESZSA-N" "Launched"
"2275" "pixantrone" "topoisomerase inhibitor" "TOP2A" "hematologic malignancy" "non-Hodgkin lymphoma (NHL)" "BRD-K48304345-332-01-6" "NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12" "PEZPMAYDXJQYRV-UHFFFAOYSA-N" "Launched"
"2276" "pizotifen" "serotonin receptor antagonist" "HTR1A, HTR2A, HTR2C" "neurology/psychiatry" "migraine headache" "BRD-K75958195-037-09-4, BRD-K75958195-037-08-6" "CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12, CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12" "FIADGNVRKBPQEU-UHFFFAOYSA-N, FIADGNVRKBPQEU-UHFFFAOYSA-N" "Launched"
"2277" "PI3K-IN-2" "PI3K inhibitor" "" "" "" "BRD-K62374002-001-01-5" "Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F" "ADGGYDAFIHSYFI-UHFFFAOYSA-N" "Phase 2"
"2278" "PI4KIII-beta-inhibitor-1" "PI4K inhibitor" "PI4K2B" "" "" "BRD-K75528696-001-01-2" "COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C" "PLUYFBRIGUAKBR-UHFFFAOYSA-N" "Preclinical"
"2279" "PJ-34" "PARP inhibitor" "EEF2, PARP1, PARP15, PARP3" "" "" "BRD-K11853856-001-02-5, BRD-K11853856-001-01-7" "CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1, CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1" "UYJZZVDLGDDTCL-UHFFFAOYSA-N, UYJZZVDLGDDTCL-UHFFFAOYSA-N" "Preclinical"
"2280" "PK-11195" "benzodiazepine receptor antagonist" "TSPO" "" "" "BRD-A41451487-001-11-2" "CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl" "RAVIZVQZGXBOQO-UHFFFAOYSA-N" "Phase 1"
"2281" "PKI-166" "EGFR inhibitor" "EGFR" "" "" "BRD-K10115470-001-01-8" "C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1" "XRYJULCDUUATMC-CYBMUJFWSA-N" "Phase 1"
"2282" "PKI-179" "mTOR inhibitor, PI3K inhibitor" "MTOR" "" "" "BRD-A28467416-002-01-0" "O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1C2CCC1COC2" "WXUUCRLKXQMWRY-UHFFFAOYSA-N" "Phase 1"
"2283" "pleconaril" "" "" "" "" "BRD-K27625831-001-02-9, BRD-K27625831-001-01-1" "Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1, Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1" "KQOXLKOJHVFTRN-UHFFFAOYSA-N, KQOXLKOJHVFTRN-UHFFFAOYSA-N" "Phase 3"
"2284" "plerixafor" "CC chemokine receptor antagonist" "ACKR3, CCR4, CXCR4" "hematologic malignancy" "non-Hodgkin lymphoma (NHL), multiple myeloma" "BRD-K33240821-001-06-2, BRD-K33240821-400-02-5, BRD-K33240821-001-03-9, BRD-K33240821-001-05-4" "C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1, C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1" "YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N, YIQPUIGJQJDJOS-UHFFFAOYSA-N" "Launched"
"2285" "plicamycin" "alcohol dehydrogenase inhibitor" "" "oncology, endocrinology" "testicular carcinoma, Pagets disease, hypercalcemia	BRD-K36368047-001-01-7	CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O	CFCUWKMKBJTWLW-BGLFSJPPSA-N	Launched
plinabulin	tubulin polymerization inhibitor				BRD-K99498722-001-02-6, BRD-K99498722-001-03-4	CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O, CC(C)(C)c1[nH]cnc1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	UNRCMCRRFYFGFX-TYPNBTCFSA-N, UNRCMCRRFYFGFX-TYPNBTCFSA-N	Phase 3
plovamer-acetate		TAT, TH, YARS, YARS2			BRD-A20781140-001-01-7	NC(Cc1ccc(O)cc1)C(O)=O	OUYCCCASQSFEME-UHFFFAOYSA-N	Phase 2
plurisin-#1	stearoyl-CoA desaturase inhibitor	SCD			BRD-K99149715-001-02-4, BRD-K99149715-001-01-6	O=C(NNc1ccccc1)c1ccncc1, O=C(NNc1ccccc1)c1ccncc1	HUDWXDLBWRHCKO-UHFFFAOYSA-N, HUDWXDLBWRHCKO-UHFFFAOYSA-N	Preclinical
PLX-4720	RAF inhibitor	BRAF, KDR			BRD-K16478699-001-09-2	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	YZDJQTHVDDOVHR-UHFFFAOYSA-N	Preclinical
PLX8394	serine/threonine kinase inhibitor	BRAF			BRD-K53723268-001-01-3	F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F	YYACLQUDUDXAPA-MRXNPFEDSA-N	Phase 1/Phase 2
PMPA	glutamate receptor antagonist	FOLH1			BRD-A74387232-001-02-5	OC(=O)CCC(CP(O)(O)=O)C(O)=O	ISEYJGQFXSTPMQ-UHFFFAOYSA-N	Preclinical
PNU-120596	acetylcholine receptor agonist	CHRNA7			BRD-K71731651-001-04-3, BRD-K71731651-001-03-5	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl, COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	CEIIEALEIHQDBX-UHFFFAOYSA-N, CEIIEALEIHQDBX-UHFFFAOYSA-N	Preclinical
PNU-142633	serotonin receptor agonist	HTR1D			BRD-K81616657-001-01-4	CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1	PNTVCCRNJOGKGA-QFIPXVFZSA-N	Phase 2
PNU-22394	serotonin receptor agonist	HTR2A, HTR2B, HTR2C, MAOA, MAOB			BRD-K16551401-003-03-4	Cn1c2CCNCCc2c2ccccc12	ZBXDOQWPGBISAR-UHFFFAOYSA-N	Phase 2
PNU-282987	cholinergic receptor agonist	CHRNA7			BRD-K28863208-001-02-0	Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	WECKJONDRAUFDD-ZDUSSCGKSA-N	Preclinical
PNU-37883	ATP-sensitive potassium channel antagonist				BRD-K12769093-003-01-3	C1CCC(CC1)N\C(N1CCOCC1)=N\C12CC3CC(CC(C3)C1)C2	GKCGWXNLOYTUNC-UHFFFAOYSA-N	Preclinical
PNU-74654	beta-catenin inhibitor	CTNNB1, TCF4			BRD-K30707190-001-04-1	Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	JJEDWBQZCRESJL-DEDYPNTBSA-N	Preclinical
PNU-89843	benzodiazepine receptor agonist	GABBR1			BRD-K84507776-003-01-4	Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1	UADIKEUOAMACNA-UHFFFAOYSA-N	Preclinical
podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	BRD-K47869605-001-32-0	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	YJGVMLPVUAXIQN-XVVDYKMHSA-N	Launched
polidocanol	local anesthetic		dermatology	varicose veins	BRD-K35798650-001-01-4	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO	ONJQDTZCDSESIW-UHFFFAOYSA-N	Launched
polydatin	ICAM1 expression inhibitor	ICAM1			BRD-K43236057-001-07-1, BRD-K94506759-001-01-9	OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@@H](O)[C@@H](O)[C@@H]1O	HSTZMXCBWJGKHG-CUYWLFDKSA-N, HSTZMXCBWJGKHG-BZAWETPFSA-N	Phase 2
polyinosine	immunostimulant	ADSSL1, HPRT1, IMPDH2, PYGM			BRD-A67531813-001-01-6	OC1C(COP(O)(O)=O)OC(C1O)n1cnc2c(O)ncnc12	GRSZFWQUAKGDAV-UHFFFAOYSA-N	Preclinical
polymyxin-b-sulfate	bacterial permeability inducer		ophthalmology	eye infection	BRD-A08641215-065-04-8	CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(Cc2ccccc2)NC(=O)C(CCN)NC1=O)C(C)O	WQVJHHACXVLGBL-UHFFFAOYSA-N	Launched
polythiazide	sodium/chloride cotransporter inhibitor	SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension	BRD-A15739803-001-01-0	CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O	CYLWJCABXYDINA-UHFFFAOYSA-N	Launched
pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor	CRBN, PTGS2, TNF	hematologic malignancy	multiple myeloma	BRD-A12994259-001-02-1	Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12	UVSMNLNDYGZFPF-UHFFFAOYSA-N	Launched
ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	BRD-K44227013-001-08-0, BRD-K44227013-001-06-4	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	PHXJVRSECIGDHY-UHFFFAOYSA-N, PHXJVRSECIGDHY-UHFFFAOYSA-N	Launched
ponesimod	sphingosine 1 phosphate receptor agonist	S1PR1			BRD-K44030614-001-01-6	CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C	LPAUOXUZGSBGDU-STDDISTJSA-N	Phase 3
posaconazole	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	BRD-K06222852-001-05-7, BRD-K06222852-001-03-2	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O, CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	RAGOYPUPXAKGKH-XAKZXMRKSA-N, RAGOYPUPXAKGKH-XAKZXMRKSA-N	Launched
potassium-canrenoate	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	BRD-K46556543-237-10-5, BRD-A29322418-237-04-0, BRD-K46556543-237-09-7	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O, C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]2(O)CCC(O)=O, C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O	PBKZPPIHUVSDNM-WNHSNXHDSA-N, PBKZPPIHUVSDNM-GMTJQTPWSA-N, PBKZPPIHUVSDNM-WNHSNXHDSA-N	Launched
potassium-iodide			pulmonary	asthma, bronchitis, emphysema	BRD-M55321172-001-02-5, BRD-M55321172-001-03-3	[K].I, [K].I	KIRAUJWBCMCUBY-UHFFFAOYSA-N, KIRAUJWBCMCUBY-UHFFFAOYSA-N	Launched
potassium-p-aminobenzoate			rheumatology, urology	scleroderma, dermatomyositis, Peyronies disease" "BRD-K58497451-237-10-7" "Nc1ccc(cc1)C(O)=O" "ALYNCZNDIQEVRV-UHFFFAOYSA-N" "Launched"
"2286" "pozanicline" "acetylcholine receptor antagonist" "CHRNA4, CHRNB2" "" "" "BRD-K79803033-300-01-3" "Cc1ncccc1OC[C@@H]1CCCN1" "YRVIKLBSVVNSHF-JTQLQIEISA-N" "Phase 2"
"2287" "poziotinib" "EGFR inhibitor" "EGFR, ERBB2, ERBB4" "" "" "BRD-K50010139-001-02-3, BRD-K50010139-001-01-5" "COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C" "LPFWVDIFUFFKJU-UHFFFAOYSA-N, LPFWVDIFUFFKJU-UHFFFAOYSA-N" "Phase 2"
"2288" "PP-1" "src inhibitor" "HCK, RET" "" "" "BRD-K47598052-001-15-8, BRD-K47598052-001-14-1" "Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C, Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C" "ZVPDNRVYHLRXLX-UHFFFAOYSA-N, ZVPDNRVYHLRXLX-UHFFFAOYSA-N" "Preclinical"
"2289" "PP-121" "protein tyrosine kinase inhibitor" "ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC" "" "" "BRD-K81801188-001-05-1, BRD-K81801188-001-02-8" "C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12, C1CCC(C1)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc12" "NVRXTLZYXZNATH-UHFFFAOYSA-N, NVRXTLZYXZNATH-UHFFFAOYSA-N" "Preclinical"
"2290" "PP-2" "src inhibitor" "ABL1, LCK, LYN, RIPK2, SRC" "" "" "BRD-K95785537-001-23-1, BRD-K95785537-001-22-3, BRD-K95785537-001-24-9" "CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12, CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12" "PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N, PBBRWFOVCUAONR-UHFFFAOYSA-N" "Preclinical"
"2291" "PPT" "estrogen receptor agonist" "ESR1" "" "" "BRD-K00312224-001-09-5" "CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1" "IOTXSIGGFRQYKW-UHFFFAOYSA-N" "Preclinical"
"2292" "PP242" "mTOR inhibitor" "MTOR, PASK" "" "" "BRD-K87112191-001-04-5, BRD-K87112191-001-05-2" "CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12, CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12" "MFAQYJIYDMLAIM-UHFFFAOYSA-N, MFAQYJIYDMLAIM-UHFFFAOYSA-N" "Preclinical"
"2293" "PQ-401" "IGF-1 inhibitor" "IGF1R" "" "" "BRD-K67537649-001-04-5, BRD-K67537649-001-03-7, BRD-K67537649-001-05-2" "COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12, COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12" "YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N, YBLWOZUPHDKFOT-UHFFFAOYSA-N" "Preclinical"
"2294" "PR-619" "DUB inhibitor" "" "" "" "BRD-K54395039-001-02-5, BRD-K54395039-001-01-7" "Nc1nc(N)c(SC" "" ""
"2295" "practolol" "adrenergic receptor antagonist" "ADRB1" "" "" "BRD-A41304429-001-17-1, BRD-A41304429-001-14-8" "CC(C)NCC(O)COc1ccc(NC(C)=O)cc1, CC(C)NCC(O)COc1ccc(NC(C)=O)cc1" "DURULFYMVIFBIR-UHFFFAOYSA-N, DURULFYMVIFBIR-UHFFFAOYSA-N" "Withdrawn"
"2296" "pralatrexate" "dihydrofolate reductase inhibitor" "DHFR, TYMS" "hematologic malignancy" "peripheral T-cell lymphoma (PTCL)" "BRD-A74914197-001-02-9" "Nc1nc(N)c2nc(CC(CC" "" ""
"2297" "pralidoxime" "acetylcholinesterase inhibitor" "ACHE, BCHE" "critical care" "organophosphate poisoning" "BRD-K84281997-003-08-4, BRD-K61327230-003-13-9, BRD-K84281997-066-03-2" "C[n+]1ccccc1\C=N\O, C[n+]1ccccc1C=NO, C[n+]1ccccc1\C=N\O" "JBKPUQTUERUYQE-UHFFFAOYSA-O, JBKPUQTUERUYQE-UHFFFAOYSA-O, JBKPUQTUERUYQE-UHFFFAOYSA-O" "Launched"
"2298" "pralidoxime-chloride" "acetylcholinesterase inhibitor" "ACHE, BCHE" "pulmonary" "respiratory depression" "BRD-K24221957-003-01-6" "C[n+]1ccccc1C[N+][O-]" "MHOAUIZFSQGCNM-UHFFFAOYSA-N" "Launched"
"2299" "pramipexole" "dopamine receptor agonist" "ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C" "neurology/psychiatry" "Parkinsons Disease	BRD-K06388322-312-02-6, BRD-K06388322-001-07-4	CCCN[C@H]1CCc2nc(N)sc2C1, CCCN[C@H]1CCc2nc(N)sc2C1	FASDKYOPVNHBLU-ZETCQYMHSA-N, FASDKYOPVNHBLU-ZETCQYMHSA-N	Launched
pramiracetam	acetylcholine receptor agonist				BRD-K21123171-001-02-9	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	ZULJGOSFKWFVRX-UHFFFAOYSA-N	Launched
pramoxine	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	BRD-K46523383-003-22-9, BRD-K46523383-003-21-1	CCCCOc1ccc(OCCCN2CCOCC2)cc1, CCCCOc1ccc(OCCCN2CCOCC2)cc1	DQKXQSGTHWVTAD-UHFFFAOYSA-N, DQKXQSGTHWVTAD-UHFFFAOYSA-N	Launched
pranidipine	calcium channel blocker	CACNA1C			BRD-A68083442-001-01-6	COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1	XTFPDGZNWTZCMF-DHZHZOJOSA-N	Phase 2
pranlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF	pulmonary	bronchospasm, asthma, bronchospasm, asthma	BRD-K97045029-001-02-7, BRD-K91497079-001-03-3	O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1, O=C(Nc1ccc2c(c1)oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1	NBQKINXMPLXUET-UHFFFAOYSA-N, UAJUXJSXCLUTNU-UHFFFAOYSA-N	Launched
pranoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	BRD-A64610707-001-05-1, BRD-A64610707-001-04-4, BRD-A64610707-001-03-6	CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1, CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1, CC(C(O)=O)c1ccc2Oc3ncccc3Cc2c1	TVQZAMVBTVNYLA-UHFFFAOYSA-N, TVQZAMVBTVNYLA-UHFFFAOYSA-N, TVQZAMVBTVNYLA-UHFFFAOYSA-N	Launched
prasterone-acetate					BRD-A20758144-001-04-5	CC(=O)O[C@H]1CC[C@]2(C)C3CC[C@@]4(C)C(CCC4=O)C3CC=C2C1	NCMZQTLCXHGLOK-KJBVPOJVSA-N	Preclinical
prasugrel	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction, acute coronary syndrome (ACS)	BRD-A83029242-001-05-3, BRD-A83029242-001-06-1, BRD-A83029242-001-07-9	CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F, CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F, CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C1CC1)c1ccccc1F	DTGLZDAWLRGWQN-UHFFFAOYSA-N, DTGLZDAWLRGWQN-UHFFFAOYSA-N, DTGLZDAWLRGWQN-UHFFFAOYSA-N	Launched
pravadoline	cyclooxygenase inhibitor	CNR1, CNR2			BRD-K46209126-001-06-4	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12	MEUQWHZOUDZXHH-UHFFFAOYSA-N	Preclinical
pravastatin	HMGCR inhibitor	HMGCR, SLCO1B1	endocrinology, cardiology	hypercholesterolemia, myocardial infarction, hyperlipidemia	BRD-K31447894-236-01-0, BRD-K60511616-236-06-3, BRD-A71816415-236-04-3	CC[C@H](C)C(=O)O[C@@H]1C[C@H](O)C=C2C=C[C@H](C)[C@@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12, CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12, CCC(C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)C12	TUZYXOIXSAXUGO-QBHFJHEUSA-N, TUZYXOIXSAXUGO-PZAWKZKUSA-N, TUZYXOIXSAXUGO-XYLZAPOUSA-N	Launched
praziquantel	anthelmintic agent		infectious disease	gastrointestinal parasites, cystic hydatid disease, schistosomiasis	BRD-A21858158-001-23-5, BRD-A21858158-001-22-7	O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1, O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1	FSVJFNAIGNNGKK-UHFFFAOYSA-N, FSVJFNAIGNNGKK-UHFFFAOYSA-N	Launched
prazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	BRD-K49111258-003-29-7, BRD-K49111258-003-28-9, BRD-K49111258-003-27-1	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N, IENZQIKPVFGBNW-UHFFFAOYSA-N	Launched
PRE-084	sigma receptor agonist	SIGMAR1			BRD-K57304726-003-06-9	O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	RQHKZUBCUZVZEF-UHFFFAOYSA-N	Preclinical
preclamol	dopamine receptor agonist	DRD2			BRD-K02908048-003-06-4	CCCN1CCC[C@@H](C1)c1cccc(O)c1	HTSNFXAICLXZMA-ZDUSSCGKSA-N	Phase 2
prednicarbate	phospholipase activator	NR3C1, PLA2G1B	dermatology, ophthalmology, neurology/psychiatry	eczema, contact dermatitis, itching	BRD-A93963402-001-01-6	CCOC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC	FNPXMHRZILFCKX-VZWGUQLYSA-N	Launched
prednisolone	glucocorticoid receptor agonist	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	BRD-K00645576-001-01-9, BRD-A27887842-001-04-0	C[C@]12C[C@@H](O)[C@@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@]2(O)C(=O)CO, C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO	OIGNJSKKLXVSLS-KYWYDSBTSA-N, OIGNJSKKLXVSLS-YDAVOWJHSA-N	Launched
prednisolone-acetate	glucocorticoid receptor agonist	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	BRD-K45664306-001-19-6, BRD-A01643550-001-04-9, BRD-K87234558-001-01-0	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@]12C, CC(=O)OCC(=O)[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@H](O)C[C@]12C	LRJOMUJRLNCICJ-JZYPGELDSA-N, LRJOMUJRLNCICJ-AUGMLKDDSA-N, LRJOMUJRLNCICJ-QGAFPSKTSA-N	Launched
prednisolone-hemisuccinate	glucocorticoid receptor agonist	NR3C1			BRD-A78391468-001-02-8	C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O	APGDTXUMTIZLCJ-PILPDLGISA-N	Preclinical
prednisolone-sodium-phosphate	glucocorticoid receptor agonist	NR3C1	allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology	allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, asthma, meningitis, psoriatic arthritis, rheumatoid arthritis	BRD-A94523291-304-02-7	C[C@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)COP(O)(O)=O	JDOZJEUDSLGTLU-YDAVOWJHSA-N	Launched
prednisolone-tebutate	anti-inflammatory agent				BRD-A53151380-001-01-2	CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@]12C	HUMXXHTVHHLNRO-VZWGUQLYSA-N	Launched
prednisone	glucocorticoid receptor agonist	HSD11B1, NR3C1	endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry	congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis	BRD-A62525898-001-05-2, BRD-K85883481-001-22-4, BRD-K60679745-001-01-1	C[C@]12CC(=O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO, C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO, C[C@]12CC(=O)[C@@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@@]2(O)C(=O)CO	XOFYZVNMUHMLCC-BDQMTFAOSA-N, XOFYZVNMUHMLCC-ZPOLXVRWSA-N, XOFYZVNMUHMLCC-PBGGHTPGSA-N	Launched
pregabalin	voltage-gated calcium channel ligand	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8	neurology/psychiatry, rheumatology	peripheral neuropathy, seizures, fibromyalgia, postherpetic neuralgia	BRD-K66786476-001-01-3, BRD-K66786476-003-01-9	CC(C)C[C@H](CN)CC(O)=O, CC(C)C[C@H](CN)CC(O)=O	AYXYPKUFHZROOJ-ZETCQYMHSA-N, AYXYPKUFHZROOJ-ZETCQYMHSA-N	Launched
pregnenolone	glutamate receptor modulator	CYP17A1, SULT2B1			BRD-K52183142-001-01-3, BRD-A35054627-001-09-7	CC(=O)[C@@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C, CC(=O)[C@H]1CCC2C3CC=C4C[C@@H](O)CC[C@]4(C)C3CC[C@]12C	ORNBQBCIOKFOEO-SPKZCENISA-N, ORNBQBCIOKFOEO-WPVPORHCSA-N	Launched
pregnenolone-succinate	GABA receptor negative allosteric modulator				BRD-A35912562-001-02-8	CC(=O)[C@H]1CCC2C3CC=C4C[C@H](CC[C@]4(C)C3CC[C@]12C)OC(=O)CCC(O)=O	OZZAYJQNMKMUSD-NNEZGNMOSA-N	Preclinical
preladenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K46290096-001-01-1	COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	DTYWJKSSUANMHD-UHFFFAOYSA-N	Phase 3
prenylamine	calcium channel blocker	CALM1, MYLK2			BRD-A10662413-043-11-2	CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1	IFFPICMESYHZPQ-UHFFFAOYSA-N	Withdrawn
presatovir	RSV fusion inhibitor				BRD-K45906612-001-01-8	Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O	GOFXWTVKPWJNGD-UWJYYQICSA-N	Phase 2
pridinol	muscle relaxant		neurology/psychiatry	muscle relaxant	BRD-K17565903-066-23-1, BRD-K17565903-066-22-3	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1, OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	RQXCLMGKHJWMOA-UHFFFAOYSA-N, RQXCLMGKHJWMOA-UHFFFAOYSA-N	Launched
prilocaine	local anesthetic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	anesthetic	BRD-A53952395-003-25-1, BRD-A53952395-001-02-4	CCCNC(C)C(=O)Nc1ccccc1C, CCCNC(C)C(=O)Nc1ccccc1C	MVFGUOIZUNYYSO-UHFFFAOYSA-N, MVFGUOIZUNYYSO-UHFFFAOYSA-N	Launched
primaquine	antimalarial agent, DNA inhibitor	KRT7, NQO2	infectious disease	malaria	BRD-A55913614-316-09-6, BRD-A55913614-316-08-8	COc1cc(NC(C)CCCN)c2ncccc2c1, COc1cc(NC(C)CCCN)c2ncccc2c1	INDBQLZJXZLFIT-UHFFFAOYSA-N, INDBQLZJXZLFIT-UHFFFAOYSA-N	Launched
PRIMA1	TP53 inhibitor	ACHE			BRD-K15318909-001-10-5	OCC1(CO)N2CCC(CC2)C1=O	RFBVBRVVOPAAFS-UHFFFAOYSA-N	Preclinical
primidone	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K32247306-001-29-4, BRD-K32247306-001-28-6, BRD-K32247306-001-27-8	CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1, CCC1(C(=O)NCNC1=O)c1ccccc1	DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N, DQMZLTXERSFNPB-UHFFFAOYSA-N	Launched
prinaberel	estrogen receptor agonist	ESR2, NCOA1			BRD-K87316765-001-01-4	Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1	MQIMZDXIAHJKQP-UHFFFAOYSA-N	Phase 2
priralfinamide	sodium channel blocker	CACNA1B			BRD-K01662324-001-01-8	C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	BHJIBOFHEFDSAU-LBPRGKRZSA-N	Phase 3
pritelivir	helicase primase inhibitor				BRD-K25204779-001-01-1	CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	IVZKZONQVYTCKC-UHFFFAOYSA-N	Phase 2
proacipimox	cholesterol inhibitor				BRD-K53605365-001-01-4	COCc1c[n+]([O-])c(C)cn1	KKKHJYGCTVKQEM-UHFFFAOYSA-N	Phase 1
proadifen	nitric oxide synthase inhibitor	NOS1			BRD-K46317332-003-18-6, BRD-K46317332-003-17-8, BRD-K46317332-003-16-0	CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1, CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	SNTQPLDRUZOSDP-UHFFFAOYSA-N, SNTQPLDRUZOSDP-UHFFFAOYSA-N, SNTQPLDRUZOSDP-UHFFFAOYSA-N	Preclinical
probenecid	uricosuric blocker	PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1	nephrology, rheumatology	hyperuricemia, gout	BRD-K95237249-001-26-5, BRD-K95237249-001-25-7	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O, CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	DBABZHXKTCFAPX-UHFFFAOYSA-N, DBABZHXKTCFAPX-UHFFFAOYSA-N	Launched
probucol	atherogenesis inhibitor	ABCA1, ABCB11, CES1	cardiology	coronary artery disease (CAD)	BRD-K72029282-001-22-0, BRD-K72029282-001-23-8	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C, CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	FYPMFJGVHOHGLL-UHFFFAOYSA-N, FYPMFJGVHOHGLL-UHFFFAOYSA-N	Launched
procainamide	sodium channel blocker	DNMT1, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	BRD-K75089421-003-24-5	CCN(CC)CCNC(=O)c1ccc(N)cc1	REQCZEXYDRLIBE-UHFFFAOYSA-N	Launched
procaine	HMGCR inhibitor	CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3	neurology/psychiatry	anesthetic	BRD-K24616672-003-20-1, BRD-K24616672-003-19-3	CCN(CC)CCOC(=O)c1ccc(N)cc1, CCN(CC)CCOC(=O)c1ccc(N)cc1	MFDFERRIHVXMIY-UHFFFAOYSA-N, MFDFERRIHVXMIY-UHFFFAOYSA-N	Launched
procarbazine	monoamine oxidase inhibitor		hematologic malignancy	Hodgkins lymphoma" "BRD-K13032584-003-19-3, BRD-K13032584-001-01-5, BRD-K13032584-003-18-5, BRD-K13032584-003-21-9" "CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C, CNNCc1ccc(cc1)C(=O)NC(C)C" "CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N, CPTBDICYNRMXFX-UHFFFAOYSA-N" "Launched"
"2300" "procaterol" "adrenergic receptor agonist" "ADRB2" "pulmonary" "asthma" "BRD-K78666826-003-01-6" "CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12" "FKNXQNWAXFXVNW-BLLLJJGKSA-N" "Launched"
"2301" "prochlorperazine" "dopamine receptor antagonist" "DRD1, DRD2, DRD3, DRD4" "gastroenterology" "nausea, vomiting" "BRD-K19352500-332-08-6, BRD-K19352500-070-12-4, BRD-K19352500-332-07-8" "CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1" "WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N, WIKYUJGCLQQFNW-UHFFFAOYSA-N" "Launched"
"2302" "procodazole" "immunostimulant" "" "" "" "BRD-K54824716-001-04-0, BRD-K54824716-001-03-2" "OC(=O)CCc1nc2ccccc2[nH]1, OC(=O)CCc1nc2ccccc2[nH]1" "XYWJNTOURDMTPI-UHFFFAOYSA-N, XYWJNTOURDMTPI-UHFFFAOYSA-N" "Preclinical"
"2303" "procyanidin-b-2" "" "" "" "" "BRD-K72093555-001-01-0, BRD-K72093555-001-02-8" "O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1, O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1" "XFZJEEAOWLFHDH-UKWJTHFESA-N, XFZJEEAOWLFHDH-UKWJTHFESA-N" "Phase 2"
"2304" "procyclidine" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4" "neurology/psychiatry" "parkinsonism, Parkinsons Disease, akathisia, dystonia	BRD-A31800922-003-25-1, BRD-A31800922-003-24-4	OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1, OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1	WYDUSKDSKCASEF-UHFFFAOYSA-N, WYDUSKDSKCASEF-UHFFFAOYSA-N	Launched
procysteine	glutathione synthase stimulant				BRD-K92413528-001-06-9	OC(=O)[C@@H]1CSC(=O)N1	BMLMGCPTLHPWPY-REOHCLBHSA-N	Phase 3
profenamine	butyrylcholinesterase inhibitor, cholinergic receptor antagonist	CHRM1, CHRM2, GRIN3A	neurology/psychiatry	Parkinsons Disease" "BRD-A16311756-003-08-5, BRD-A16311756-003-09-3" "CCN(CC)C(C)CN1c2ccccc2Sc2ccccc12, CCN(CC)C(C)CN1c2ccccc2Sc2ccccc12" "CDOZDBSBBXSXLB-UHFFFAOYSA-N, CDOZDBSBBXSXLB-UHFFFAOYSA-N" "Launched"
"2305" "proflavine-hemisulfate" "topical anesthetic" "F2" "" "" "BRD-K68408467-065-01-8" "Nc1ccc2cc3ccc(N)cc3nc2c1" "WDVSHHCDHLJJJR-UHFFFAOYSA-N" "Phase 2"
"2306" "progesterone" "progesterone receptor agonist" "CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5" "obstetrics/gynecology, endocrinology" "infertility, amenorrhea" "BRD-A67479912-001-03-4, BRD-K37762555-001-01-4" "CC(=O)[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C, CC(=O)[C@@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C" "RJKFOVLPORLFTN-OYEBDCLDSA-N, RJKFOVLPORLFTN-LEZSPFLNSA-N" "Launched"
"2307" "proglumetacin" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "neurology/psychiatry" "pain relief" "BRD-A19458515-001-01-2" "CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1" "PTXGHCGBYMQQIG-UHFFFAOYSA-N" "Launched"
"2308" "proglumide" "CCK receptor antagonist" "CCKAR, CCKBR" "" "" "BRD-A44863528-001-13-2" "CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1" "DGMKFQYCZXERLX-UHFFFAOYSA-N" "Withdrawn"
"2309" "proguanil" "dihydrofolate reductase inhibitor" "DHFR" "infectious disease" "malaria" "BRD-K28183345-003-11-4" "CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1" "SSOLNOMRVKKSON-UHFFFAOYSA-N" "Launched"
"2310" "prolylleucylglycinamide" "melanocyte-stimulating hormone release inhibitor" "" "" "" "BRD-A09911125-001-01-4" "CC(C)CC(NC(=O)C1CCCN1)C(=O)NCC(N)=O" "NOOJLZTTWSNHOX-UHFFFAOYSA-N" "Phase 2"
"2311" "promazine" "dopamine receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C" "neurology/psychiatry" "schizophrenia" "BRD-K06980535-003-26-7, BRD-K06980535-003-25-9" "CN(C)CCCN1c2ccccc2Sc2ccccc12, CN(C)CCCN1c2ccccc2Sc2ccccc12" "ZGUGWUXLJSTTMA-UHFFFAOYSA-N, ZGUGWUXLJSTTMA-UHFFFAOYSA-N" "Launched"
"2312" "promestriene" "estrogen receptor agonist" "ESR1" "endocrinology" "androgenetic alopecia" "BRD-K75097983-001-01-0" "CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC" "IUWKNLFTJBHTSD-AANPDWTMSA-N" "Launched"
"2313" "promethazine" "histamine receptor antagonist" "ADRA1A, CALM1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A" "neurology/psychiatry, allergy" "sedative, allergic rhinitis" "BRD-A46335897-003-27-8, BRD-A46335897-003-26-0" "CC(CN1c2ccccc2Sc2ccccc12)N(C)C, CC(CN1c2ccccc2Sc2ccccc12)N(C)C" "PWWVAXIEGOYWEE-UHFFFAOYSA-N, PWWVAXIEGOYWEE-UHFFFAOYSA-N" "Launched"
"2314" "pronethalol" "adrenergic receptor antagonist" "" "" "" "BRD-A87715314-003-14-4, BRD-A87715314-003-15-1" "CC(C)NCC(O)c1ccc2ccccc2c1, CC(C)NCC(O)c1ccc2ccccc2c1" "HRSANNODOVBCST-UHFFFAOYSA-N, HRSANNODOVBCST-UHFFFAOYSA-N" "Withdrawn"
"2315" "propacetamol" "cyclooxygenase inhibitor" "PTGS2" "endocrinology, neurology/psychiatry" "fever, pain relief" "BRD-K54496168-003-01-2" "CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1" "QTGAJCQTLIRCFL-UHFFFAOYSA-N" "Launched"
"2316" "propafenone" "antiarrhythmic" "ADRB1, ADRB2, KCNA5, KCNH2, SCN5A" "cardiology" "atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias" "BRD-A26334849-001-06-2, BRD-A26334849-003-23-3" "CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1, CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1" "JWHAUXFOSRPERK-UHFFFAOYSA-N, JWHAUXFOSRPERK-UHFFFAOYSA-N" "Launched"
"2317" "propagermanium" "interferon receptor agonist, CCR agonist" "CCR2" "infectious disease" "hepatitis B" "BRD-K53382462-001-02-0" "OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O" "XEABSBMNTNXEJM-UHFFFAOYSA-N" "Launched"
"2318" "propantheline" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4" "gastroenterology" "peptic ulcer disease (PUD)" "BRD-K90885812-004-24-2" "CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C" "VVWYOYDLCMFIEM-UHFFFAOYSA-N" "Launched"
"2319" "propatylnitrate" "" "" "cardiology" "angina pectoris" "BRD-K56276053-001-01-8" "CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O" "YZZCJYJBCUJISI-UHFFFAOYSA-N" "Launched"
"2320" "propentofylline" "adenosine reuptake inhibitor, phosphodiesterase inhibitor" "PDE1A" "neurology/psychiatry" "stroke" "BRD-K59273480-001-10-6" "CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12" "RBQOQRRFDPXAGN-UHFFFAOYSA-N" "Launched"
"2321" "propidium-iodide" "" "ACHE" "" "" "BRD-K14821965-302-05-2" "CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12" "ZDWVWKDAWBGPDN-UHFFFAOYSA-O" "Preclinical"
"2322" "propiolactone" "" "" "" "" "BRD-K76867903-001-03-8" "O=C1CCO1" "VEZXCJBBBCKRPI-UHFFFAOYSA-N" "Launched"
"2323" "propiverine" "acetylcholine receptor antagonist" "CHRM1" "urology" "urinary incontinence" "BRD-K91244729-003-01-3" "CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1" "QPCVHQBVMYCJOM-UHFFFAOYSA-N" "Launched"
"2324" "propofol" "benzodiazepine receptor agonist" "FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A" "neurology/psychiatry" "anesthetic" "BRD-K82255054-001-15-9, BRD-K82255054-001-17-5" "CC(C)c1cccc(C(C)C)c1O, CC(C)c1cccc(C(C)C)c1O" "OLBCVFGFOZPWHH-UHFFFAOYSA-N, OLBCVFGFOZPWHH-UHFFFAOYSA-N" "Launched"
"2325" "propoxur" "" "" "" "" "BRD-K08231299-001-08-1" "CNC(=O)Oc1ccccc1OC(C)C" "ISRUGXGCCGIOQO-UHFFFAOYSA-N" "Launched"
"2326" "propoxycaine" "local anesthetic" "" "neurology/psychiatry" "anesthetic" "BRD-K18250272-003-11-0" "CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC" "CAJIGINSTLKQMM-UHFFFAOYSA-N" "Launched"
"2327" "propranolol" "adrenergic receptor antagonist" "" "cardiology, neurology/psychiatry" "hypertension, angina pectoris, migraine headache" "BRD-A10070317-003-28-3, BRD-A10070317-003-29-1, BRD-A10070317-003-30-9" "CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12, CC(C)NCC(O)COc1cccc2ccccc12" "AQHHHDLHHXJYJD-UHFFFAOYSA-N, AQHHHDLHHXJYJD-UHFFFAOYSA-N, AQHHHDLHHXJYJD-UHFFFAOYSA-N" "Launched"
"2328" "propranolol-(R)" "adrenergic receptor antagonist" "ADRB2, ADRB3" "" "" "BRD-K92830582-003-10-5" "CC(C)NC[C@@H](O)COc1cccc2ccccc12" "AQHHHDLHHXJYJD-CQSZACIVSA-N" "Preclinical"
"2329" "propranolol-(S)" "adrenergic receptor antagonist" "ADRB1, ADRB2, ADRB3, HTR1A, HTR1B, HTR5A, SLC10A1" "" "" "BRD-K13994703-003-15-8, BRD-K13994703-003-16-6" "CC(C)NC[C@H](O)COc1cccc2ccccc12, CC(C)NC[C@H](O)COc1cccc2ccccc12" "AQHHHDLHHXJYJD-AWEZNQCLSA-N, AQHHHDLHHXJYJD-AWEZNQCLSA-N" "Preclinical"
"2330" "propyl-benzoate" "" "" "" "" "BRD-K15329706-001-01-6" "CCCOC(=O)c1ccccc1" "UDEWPOVQBGFNGE-UHFFFAOYSA-N" "Launched"
"2331" "propylene-glycol" "" "F13A1" "" "" "BRD-A19232309-001-08-6" "CC(O)CO" "DNIAPMSPPWPWGF-UHFFFAOYSA-N" "Launched"
"2332" "propylhexedrine" "adrenergic receptor agonist" "SLC18A2, TAAR1" "otolaryngology, endocrinology, allergy" "nasal congestion, fever, allergic rhinitis" "BRD-A35667010-001-01-8" "CNC(C)CC1CCCCC1" "JCRIVQIOJSSCQD-UHFFFAOYSA-N" "Launched"
"2333" "propylparaben" "" "" "" "" "BRD-K60783397-001-09-5" "CCCOC(=O)c1ccc(O)cc1" "QELSKZZBTMNZEB-UHFFFAOYSA-N" "Launched"
"2334" "propylthiouracil" "thyroid peroxidase inhibitor" "DIO1, TPO" "endocrinology" "hyperthyroidism, Graves disease, goiter	BRD-K48168960-001-19-2, BRD-K48168960-001-18-4	CCCc1cc(=O)[nH]c(=S)[nH]1, CCCc1cc(=O)[nH]c(=S)[nH]1	KNAHARQHSZJURB-UHFFFAOYSA-N, KNAHARQHSZJURB-UHFFFAOYSA-N	Launched
proquazone	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-K54339150-001-01-8	CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1	JTIGKVIOEQASGT-UHFFFAOYSA-N	Launched
proscillaridin-a			cardiology	congestive heart failure, cardiac arrythmia	BRD-A11815689-001-01-1	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)C(O)C(O)[C@H]1O	MYEJFUXQJGHEQK-BACGYGAMSA-N	Launched
protionamide			infectious disease	tuberculosis	BRD-K75360161-001-18-0, BRD-K75360161-001-17-2	CCCc1cc(ccn1)C(S)=N, CCCc1cc(ccn1)C(S)=N	VRDIULHPQTYCLN-UHFFFAOYSA-N, VRDIULHPQTYCLN-UHFFFAOYSA-N	Launched
protirelin	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	BRD-A16997652-001-02-3	NC(=O)C1CCCN1C(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1	XNSAINXGIQZQOO-UHFFFAOYSA-N	Launched
protoporphyrin-ix	heme oxygenase inhibitor	HMOX1			BRD-K26813314-001-08-5	Cc1c(CCC(O)=O)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5C=C)c(C)c4C=C)c(C)c3CCC(O)=O	KSFOVUSSGSKXFI-UHFFFAOYSA-N	Preclinical
protriptyline	tricyclic antidepressant	SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K42098891-003-20-5	CNCCCC1c2ccccc2C=Cc2ccccc12	BWPIARFWQZKAIA-UHFFFAOYSA-N	Launched
proxodolol	adrenergic receptor antagonist				BRD-A29944538-003-08-3	Cc1noc(COc2ccccc2OCC(O)CNC(C)(C)C)n1	CEDZURSVVKNCSL-UHFFFAOYSA-N	Launched
proxyfan	histamine receptor modulator	HRH3			BRD-K77171813-034-01-8	C(COCc1ccccc1)Cc1cnc[nH]1	WNWALBVQAAIULR-UHFFFAOYSA-N	Preclinical
proxymetacaine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	anesthetic	BRD-K79116891-003-15-1, BRD-K79116891-003-14-4	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC, CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	KCLANYCVBBTKTO-UHFFFAOYSA-N, KCLANYCVBBTKTO-UHFFFAOYSA-N	Launched
proxyphylline			pulmonary	asthma	BRD-A28887267-001-19-3	CC(O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	KYHQZNGJUGFTGR-UHFFFAOYSA-N	Launched
PRT062070	JAK inhibitor, syk inhibitor	SYK			BRD-K25835157-001-01-4, BRD-K25835157-001-02-2	CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1, CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	BGLPECHZZQDNCD-UHFFFAOYSA-N, BGLPECHZZQDNCD-UHFFFAOYSA-N	Phase 1
PRT062607	syk inhibitor	FGR, MAP3K9, SYK			BRD-K53734668-003-02-0, BRD-K98804570-003-01-7	N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1, N[C@@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	TXGKRVFSSHPBAJ-JKSUJKDBSA-N, TXGKRVFSSHPBAJ-HZPDHXFCSA-N	Phase 2
PRT4165	polycomb repressive complex inhibitor	PRC1			BRD-K32456483-001-02-3	O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	OMHZFEWYVFWVLI-UHFFFAOYSA-N	Preclinical
prucalopride	serotonin receptor agonist	HTR4	gastroenterology	constipation	BRD-K33681278-036-01-2, BRD-K33681278-001-02-4	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12, COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	ZPMNHBXQOOVQJL-UHFFFAOYSA-N, ZPMNHBXQOOVQJL-UHFFFAOYSA-N	Launched
prulifloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary, gastroenterology	urinary tract infections, bronchitis, diarrhea	BRD-A92341659-001-04-0, BRD-A92341659-001-03-2	CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1, CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1	PWNMXPDKBYZCOO-UHFFFAOYSA-N, PWNMXPDKBYZCOO-UHFFFAOYSA-N	Launched
pruvanserin	serotonin receptor antagonist	HTR2A, HTR2C			BRD-K43837174-003-01-3	Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	AQRLDDAFYYAIJP-UHFFFAOYSA-N	Phase 2
PRX-08066	serotonin receptor antagonist	HTR2B			BRD-K16757695-050-02-5	Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	IENZFHBNCRQMNP-UHFFFAOYSA-N	Phase 2
PSB-06126	NTPDase inhibitor	ENTPD3			BRD-K71266197-236-02-7	Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	ZHQRPIRGSWEALJ-UHFFFAOYSA-N	Preclinical
PSB-11	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA3			BRD-K10177585-003-02-4	CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1	RGDHRCXUMURWBJ-LLVKDONJSA-N	Preclinical
PSB-1115	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			BRD-K49027941-001-01-1	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	UYDRRQPGDSIMNU-UHFFFAOYSA-N	Preclinical
PSB-36	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-A70407468-001-02-0	CCCCn1c(=O)n(CCCO)c2nc([nH]c2c1=O)C12CC3CC1CC(C2)C3	CIBIXJYFYPFMTN-UHFFFAOYSA-N	Preclinical
PSI-6130	RNA polymerase inhibitor				BRD-K07798980-001-01-9	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	NYPIRLYMDJMKGW-VPCXQMTMSA-N	Phase 1
PSI-7976	HCV inhibitor				BRD-K05674516-001-01-7	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-YBSJRAAASA-N	Preclinical
PSN-375963	glucose dependent insulinotropic receptor agonist	GPR119			BRD-K25524093-003-01-7	CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	OAVLEYPTWABFLF-UHFFFAOYSA-N	Preclinical
psoralen		MAOA, MAOB	dermatology	psoriasis, eczema, vitiligo	BRD-K47264279-001-08-9	O=c1ccc2cc3ccoc3cc2o1	ZCCUUQDIBDJBTK-UHFFFAOYSA-N	Launched
PS178990	androgen receptor modulator	AR			BRD-K99092662-001-01-1	Cc1c(ccc(C#N)c1Cl)N1C(=O)[C@@H]2[C@H](O)CCN2C1=O	KEJORAMIZFOODM-PWSUYJOCSA-N	Phase 1
PT-2385	hypoxia inducible factor inhibitor	EPAS1			BRD-K20850787-001-01-6	CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12	ONBSHRSJOPSEGS-INIZCTEOSA-N	Phase 1
PTC-209	BMI-1 inhibitor				BRD-K83834509-001-02-9, BRD-K83834509-001-01-1	COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1, COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	XVOOCQSWCCRVDY-UHFFFAOYSA-N, XVOOCQSWCCRVDY-UHFFFAOYSA-N	Preclinical
pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	PTGS2			BRD-K53097745-001-01-5	COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1	VLEUZFDZJKSGMX-UHFFFAOYSA-N	Phase 2/Phase 3
PU-H71	HSP inhibitor	HSP90AA1			BRD-K36529613-001-02-6	CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	SUPVGFZUWFMATN-UHFFFAOYSA-N	Phase 1
puerarin	serotonin receptor antagonist				BRD-K89048337-001-06-9	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	HKEAFJYKMMKDOR-VPRICQMDSA-N	Phase 2
pumosetrag	serotonin receptor agonist	HTR3A, HTR4			BRD-K44164034-003-01-1	Oc1c(cnc2ccsc12)C(=O)N[C@H]1CN2CCC1CC2	AFUWQWYPPZFWCO-LBPRGKRZSA-N	Phase 2
purmorphamine	smoothened receptor agonist	SMO			BRD-K73397362-001-07-4, BRD-K73397362-001-06-6	C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12, C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	FYBHCRQFSFYWPY-UHFFFAOYSA-N, FYBHCRQFSFYWPY-UHFFFAOYSA-N	Preclinical
puromycin	protein synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			BRD-A28970875-300-04-9	COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)OC([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	RXWNCPJZOCPEPQ-DYKMBDCPSA-N	Preclinical
purvalanol-a	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC			BRD-K50836978-001-03-3, BRD-K50836978-001-02-5	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	PMXCMJLOPOFPBT-HNNXBMFYSA-N, PMXCMJLOPOFPBT-HNNXBMFYSA-N	Preclinical
purvalanol-b	tyrosine kinase inhibitor	CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2			BRD-K41564320-001-02-0, BRD-K41564320-001-03-8	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1, CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	ZKDXRFMOHZVXSG-HNNXBMFYSA-N, ZKDXRFMOHZVXSG-HNNXBMFYSA-N	Preclinical
putrescine	tissue transglutaminase inhibitor	AMD1, KCNJ4, ODC1			BRD-K75282878-300-05-3	NCCCCN	KIDHWZJUCRJVML-UHFFFAOYSA-N	Phase 2
PX-12	thioredoxin inhibitor	TXN, TXNRD1			BRD-A56592690-001-04-3	CCC(C)SSc1ncc[nH]1	BPBPYQWMFCTCNG-UHFFFAOYSA-N	Phase 2
PX-478	hypoxia inducible factor inhibitor				BRD-A26835809-300-01-3	NC(Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	GSKQMLGAUOTSKT-UHFFFAOYSA-N	Phase 1
PYM50028	neurotrophic agent				BRD-K62277907-001-01-6	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	GMBQZIIUCVWOCD-WWASVFFGSA-N	Phase 2
PYR-41	ubiquitin activating enzyme inhibitor				BRD-K66101666-001-02-3, BRD-K66101666-001-01-5	CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O, CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O	ARGIPZKQJGFSGQ-LCYFTJDESA-N, ARGIPZKQJGFSGQ-LCYFTJDESA-N	Preclinical
pyrantel	nicotinic receptor agonist		infectious disease	gastrointestinal roundworms, gastrointestinal roundworms	BRD-K82118441-001-03-7	OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O	WLJNZVDCPSBLRP-UHFFFAOYSA-N	Launched
pyrantel-pamoate	neuromuscular blocker		infectious disease	hookworm, tapeworm	BRD-K20672254-096-03-4	CN1CCCN=C1\C=C\c1cccs1	YSAUAVHXTIETRK-AATRIKPKSA-N	Launched
pyrantel-tartrate	acetylcholine receptor agonist	CHRNA1			BRD-K20672254-046-04-7, BRD-K20672254-046-03-9, BRD-K20672254-096-05-9	CN1CCCN=C1\C=C\c1cccs1, CN1CCCN=C1\C=C\c1cccs1, CN1CCCN=C1\C=C\c1cccs1	YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N, YSAUAVHXTIETRK-AATRIKPKSA-N	Preclinical
pyrazinamide	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	BRD-K28667793-001-28-1, BRD-K28667793-001-27-3	NC(=O)c1cnccn1, NC(=O)c1cnccn1	IPEHBUMCGVEMRF-UHFFFAOYSA-N, IPEHBUMCGVEMRF-UHFFFAOYSA-N	Launched
pyrazinoylguanidine	diuretic				BRD-K61693562-300-01-7	NC(=N)NC(=O)c1cnccn1	WNBSDCKJFDZMHT-UHFFFAOYSA-N	Phase 1
pyrazolanthrone	JNK inhibitor	MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK			BRD-K01567962-001-23-0, BRD-K01567962-001-24-8	O=C1c2ccccc2-c2n[nH]c3cccc1c23, O=C1c2ccccc2-c2n[nH]c3cccc1c23	ACPOUJIDANTYHO-UHFFFAOYSA-N, ACPOUJIDANTYHO-UHFFFAOYSA-N	Preclinical
pyrazoloacridine	topoisomerase inhibitor	TOP1, TOP2A			BRD-K42607789-001-01-2	COc1ccc2[nH]c3c(ccc4n(CCCN(C)C)nc(c34)c2c1)[N+]([O-])=O	HZCWPKGYTCJSEB-UHFFFAOYSA-N	Phase 2
pyrethrins					BRD-K79856453-001-01-6	CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2)C1(C)C	KKHJGHLRPBEIBW-NNRAVPRJSA-N	Launched
pyridoxal		PDXK	neurology/psychiatry	epilepsy	BRD-K76204040-001-03-8	Cc1ncc(CO)c(C=O)c1O	RADKZDMFGJYCBB-UHFFFAOYSA-N	Launched
pyridoxal-isonicotinoyl-hydrazone	apoptosis stimulant				BRD-K42019693-001-01-5	Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O	BQYIXOPJPLGCRZ-REZTVBANSA-N	Phase 2
pyridoxamine	AGE inhibitor				BRD-K96669468-300-01-1	Cc1ncc(CO)c(CN)c1O	NHZMQXZHNVQTQA-UHFFFAOYSA-N	Phase 3
pyridoxine	vitamin B	DDC, PDXK	metabolism	vitamin B6 deficiency	BRD-K14349461-003-13-1, BRD-K14349461-001-04-4	Cc1ncc(CO)c(CO)c1O, Cc1ncc(CO)c(CO)c1O	LXNHXLLTXMVWPM-UHFFFAOYSA-N, LXNHXLLTXMVWPM-UHFFFAOYSA-N	Launched
pyrimethamine	dihydrofolate reductase inhibitor	DHFR, SLC47A1	infectious disease	malaria	BRD-K88429204-001-35-1, BRD-K88429204-001-34-4, BRD-K88429204-001-33-6	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1, CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N, WKSAUQYGYAYLPV-UHFFFAOYSA-N	Launched
pyrithione-zinc	ATP synthase inhibitor	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff	BRD-K16136380-001-03-3, BRD-K16136380-001-02-5, BRD-K16136380-001-01-7	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1, O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L, KTIHEFSORPLWRR-UHFFFAOYSA-L	Launched
pyrithyldione	psychoactive drug				BRD-K36116267-001-15-3	CCC1(CC)C(=O)NC=CC1=O	NZASCBIBXNPDMH-UHFFFAOYSA-N	Withdrawn
pyritinol			rheumatology, neurology/psychiatry	rheumatoid arthritis, senile dementia	BRD-K82181219-001-04-3	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	SIXLXDIJGIWWFU-UHFFFAOYSA-N	Launched
pyronaridine	antimalarial agent				BRD-K73132780-001-01-2, BRD-K73132780-411-01-3	COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1, COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	DJUFPMUQJKWIJB-UHFFFAOYSA-N, DJUFPMUQJKWIJB-UHFFFAOYSA-N	Phase 3
pyroxamide	HDAC inhibitor	HDAC1			BRD-K11663430-001-02-3	ONC(=O)CCCCCCC(=O)Nc1cccnc1	PTJGLFIIZFVFJV-UHFFFAOYSA-N	Phase 1
pyrrolidine-dithiocarbamate	NFkB pathway inhibitor	HSD11B1, RELA			BRD-K80970344-201-08-6	SC(=S)N1CCCC1	VSWDORGPIHIGNW-UHFFFAOYSA-N	Preclinical
pyrvinium	androgen receptor antagonist				BRD-M55114534-096-01-9	CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1.CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	PVWVKJZCXALBAI-UHFFFAOYSA-N	Launched
pyrvinium-pamoate	androgen receptor antagonist	AR			BRD-M55114534-373-01-2, BRD-K39479472-096-04-7	CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1.CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1, CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	PVWVKJZCXALBAI-UHFFFAOYSA-N, QMHSXPLYMTVAMK-UHFFFAOYSA-N	Launched
P22077	ubiquitin specific protease inhibitor	USP7			BRD-K97714174-001-01-3	CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	RMAMGGNACJHXHO-UHFFFAOYSA-N	Preclinical
P276-00	CDK inhibitor	CDK1, CDK4, CDK9			BRD-K51791723-003-01-7	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	QLUYMIVVAYRECT-OCCSQVGLSA-N	Phase 2
P5091	ubiquitin specific protease inhibitor	USP7			BRD-K13606314-001-01-3	CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	LKZLGMAAKNEGCH-UHFFFAOYSA-N	Preclinical
Q-203	ATP synthase inhibitor				BRD-K59853741-001-01-9	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1	OJICYBSWSZGRFB-UHFFFAOYSA-N	Phase 1
quazinone	phosphodiesterase inhibitor	PDE3A, PDE3B			BRD-K63631219-001-01-6	Cc1c(O)nc2Nc3cccc(Cl)c3Cn12	XIXXNJFWPAVKFR-UHFFFAOYSA-N	Phase 2
quercetin	polar auxin transport inhibitor	ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1	neurology/psychiatry, allergy	fatigue, allergic rhinitis, drowsiness	BRD-K97399794-001-15-3, BRD-K97399794-001-16-1, BRD-K97399794-335-06-4, BRD-K97399794-001-14-6, BRD-K97399794-335-05-6	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O, Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N, REFJWTPEDVJJIY-UHFFFAOYSA-N	Launched
quetiapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K68867920-051-11-5, BRD-K68867920-001-11-0	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12, OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12	URKOMYMAXPYINW-UHFFFAOYSA-N, URKOMYMAXPYINW-UHFFFAOYSA-N	Launched
quiflapon	leukotriene synthesis inhibitor	ALOX5, ALOX5AP			BRD-K39503511-001-03-9	CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	NZOONKHCNQFYCI-UHFFFAOYSA-N	Phase 2
quinagolide	dopamine receptor agonist	DRD2	endocrinology	hyperprolactinemia	BRD-K02995728-003-01-9	CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC	GDFGTRDCCWFXTG-ZIFCJYIRSA-N	Launched
quinapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, angioedema	BRD-K72222507-003-17-6, BRD-K72222507-003-16-8, BRD-K72222507-003-15-0	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N, JSDRRTOADPPCHY-HSQYWUDLSA-N	Launched
quinaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, angioedema	BRD-K42317111-001-01-7	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	FLSLEGPOVLMJMN-YSSFQJQWSA-N	Launched
quinelorane	dopamine receptor agonist	DRD2, DRD3			BRD-K13261168-300-01-0	CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12	TUFADSGTJUOBEH-ZWNOBZJWSA-N	Phase 3
quinestrol	estrogen receptor agonist	ESR1	endocrinology	menopause	BRD-A16439188-001-01-1	C[C@]12CCC3C(CCc4cc(OC5CCCC5)ccc34)C1CC[C@@]2(O)C#C	PWZUUYSISTUNDW-BOSQQAFTSA-N	Launched
quinethazone	thiazide diuretic	CA1, CA2, SLC12A1, SLC12A2, SLC12A3	cardiology	hypertension	BRD-A59303141-001-10-4	CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O	AGMMTXLNIQSRCG-UHFFFAOYSA-N	Launched
quinidine	sodium channel blocker	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	BRD-K59632282-052-03-1	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-LHHVKLHASA-N	Launched
quinine	hemozoin biocrystallization inhibitor	GP9, KCNB2, KCNN4, SLC29A4	infectious disease	malaria	BRD-K99257182-310-01-6, BRD-K48278478-001-01-2	COc1ccc2nccc([C@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1, COc1ccc2nccc([C@@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-FEBSWUBLSA-N, LOUPRKONTZGTKE-AFHBHXEDSA-N	Launched
quinine-ethyl-carbonate			infectious disease	malaria	BRD-K97028990-001-04-4	CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12	NSBRKSWSLRQPJW-FRMGNDQPSA-N	Launched
quinolinic-acid	glutamate receptor agonist				BRD-K51885093-001-11-2	OC(=O)c1cccnc1C(O)=O	GJAWHXHKYYXBSV-UHFFFAOYSA-N	Preclinical
quinpirol-(-)	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C			BRD-K26548821-003-10-5	CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	Phase 2
quipazine	serotonin receptor agonist				BRD-K77925998-050-14-3, BRD-K77925998-364-01-5, BRD-K77925998-332-04-6	C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1, C1CN(CCN1)c1ccc2ccccc2n1	XRXDAJYKGWNHTQ-UHFFFAOYSA-N, XRXDAJYKGWNHTQ-UHFFFAOYSA-N, XRXDAJYKGWNHTQ-UHFFFAOYSA-N	Preclinical
quizartinib	FLT3 inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET			BRD-K93918653-001-08-9	CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	CVWXJKQAOSCOAB-UHFFFAOYSA-N	Phase 3
QX-222	sodium channel blocker				BRD-K40782193-003-02-9	Cc1cccc(C)c1NC(=O)C[N+](C)(C)C	QYUXPWDVDMSTKR-UHFFFAOYSA-O	Preclinical
QX-314	sodium channel blocker	MAPK14, TGFBR1			BRD-K56596464-004-10-7, BRD-K56596464-003-02-6	CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C, CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	PYEBKOFMWAMBFV-UHFFFAOYSA-O, PYEBKOFMWAMBFV-UHFFFAOYSA-O	Preclinical
r(-)-apomorphine	dopamine receptor agonist	DRD2, HTR5A	neurology/psychiatry	Parkinsons Disease" "BRD-K76022557-003-02-7, BRD-K76022557-001-03-9, BRD-A35931254-003-04-3" "CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31, CN1CCc2cccc-3c2C1Cc1ccc(O)c(O)c-31" "VMWNQDUVQKEIOC-CYBMUJFWSA-N, VMWNQDUVQKEIOC-CYBMUJFWSA-N, VMWNQDUVQKEIOC-UHFFFAOYSA-N" "Launched"
"2335" "R-1479" "HCV inhibitor" "" "" "" "BRD-K28442028-001-01-3" "Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1" "ODLGMSQBFONGNG-JVZYCSMKSA-N" "Phase 1"
"2336" "R-428" "AXL kinase inhibitor" "AXL" "" "" "BRD-K14870255-001-02-3" "Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1" "KXMZDGSRSGHMMK-VWLOTQADSA-N" "Phase 1"
"2337" "R-59022" "diacylglycerol kinase inhibitor, protein kinase inhibitor" "DGKA" "" "" "BRD-K54665485-001-07-9" "Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1" "MFVJXLPANKSLLD-UHFFFAOYSA-N" "Preclinical"
"2338" "R-96544" "serotonin receptor antagonist" "HTR2A" "" "" "BRD-K15588452-003-02-7" "COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1" "AFZLABYDOCWQBQ-WOJBJXKFSA-N" "Preclinical"
"2339" "rabeprazole" "ATPase inhibitor, gastrin inhibitor" "ATP4A" "gastroenterology" "gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome" "BRD-A39390670-236-10-7, BRD-A39390670-236-11-5, BRD-A39390670-236-12-3, BRD-A39390670-236-09-9" "COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C, COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C" "YREYEVIYCVEVJK-UHFFFAOYSA-N, YREYEVIYCVEVJK-UHFFFAOYSA-N, YREYEVIYCVEVJK-UHFFFAOYSA-N, YREYEVIYCVEVJK-UHFFFAOYSA-N" "Launched"
"2340" "racecadotril" "enkephalinase inhibitor" "MME" "gastroenterology" "diarrhea" "BRD-A08187463-001-12-9, BRD-A08187463-001-11-1" "CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1, CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1" "ODUOJXZPIYUATO-UHFFFAOYSA-N, ODUOJXZPIYUATO-UHFFFAOYSA-N" "Launched"
"2341" "raclopride" "dopamine receptor antagonist" "DRD2, DRD3, HTR1A" "" "" "BRD-K04111260-001-10-0" "CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC" "WAOQONBSWFLFPE-VIFPVBQESA-N" "Launched"
"2342" "ractopamine" "adrenergic receptor agonist" "" "" "" "BRD-A86414188-003-01-5, BRD-A86414188-003-02-3" "CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1, CC(CCc1ccc(O)cc1)NCC(O)c1ccc(O)cc1" "YJQZYXCXBBCEAQ-UHFFFAOYSA-N, YJQZYXCXBBCEAQ-UHFFFAOYSA-N" "Launched"
"2343" "radafaxine" "dopamine-norepinephrine reuptake inhibitor" "SLC6A3" "" "" "BRD-K13394247-003-01-4" "C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1" "RCOBKSKAZMVBHT-TVQRCGJNSA-N" "Phase 2"
"2344" "radezolid" "bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor" "" "" "" "BRD-K84683831-001-01-0" "CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cnn[nH]2)cc1" "BTTNOGHPGJANSW-IBGZPJMESA-N" "Phase 2"
"2345" "RAF265" "RAF inhibitor, VEGFR inhibitor" "BRAF" "" "" "BRD-K93123848-001-04-1" "Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12" "YABJJWZLRMPFSI-UHFFFAOYSA-N" "Phase 2"
"2346" "raloxifene" "estrogen receptor antagonist, selective estrogen receptor modulator (SERM)" "ESR1, ESR2" "orthopedics, oncology" "osteoporosis, breast cancer" "BRD-K63828191-003-32-1, BRD-K63828191-003-33-9, BRD-K63828191-003-34-7" "Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1, Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1" "GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N, GZUITABIAKMVPG-UHFFFAOYSA-N" "Launched"
"2347" "raltegravir" "HIV integrase inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K05658747-001-03-7, BRD-K05658747-001-02-9" "Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C, Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C" "CZFFBEXEKNGXKS-UHFFFAOYSA-N, CZFFBEXEKNGXKS-UHFFFAOYSA-N" "Launched"
"2348" "raltitrexed" "thymidylate synthase inhibitor" "FPGS, TYMS" "oncology" "mesothelioma" "BRD-K89839824-001-06-1, BRD-K89839824-001-05-3" "CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O" "IVTVGDXNLFLDRM-HNNXBMFYSA-N, IVTVGDXNLFLDRM-HNNXBMFYSA-N" "Launched"
"2349" "ramatroban" "prostanoid receptor antagonist" "PTGDR2, TBXA2R" "cardiology, pulmonary" "coronary artery disease (CAD), asthma" "BRD-K08586861-001-01-1" "OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1" "LDXDSHIEDAPSSA-OAHLLOKOSA-N" "Launched"
"2350" "ramelteon" "melatonin receptor agonist" "MTNR1A, MTNR1B" "neurology/psychiatry" "insomnia" "BRD-K28761891-001-10-1, BRD-K28761891-001-09-3" "CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12, CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12" "YLXDSYKOBKBWJQ-LBPRGKRZSA-N, YLXDSYKOBKBWJQ-LBPRGKRZSA-N" "Launched"
"2351" "ramifenazone" "cyclooxygenase inhibitor" "" "neurology/psychiatry, endocrinology" "pain relief, fever" "BRD-K85333151-003-13-4" "CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O" "XOZLRRYPUKAKMU-UHFFFAOYSA-N" "Launched"
"2352" "ramipril" "angiotensin converting enzyme inhibitor" "ACE" "cardiology" "hypertension" "BRD-K89348303-001-14-7, BRD-K01296542-001-01-1" "CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O, CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@@H]1C(O)=O" "HDACQVRGBOVJII-JBDAPHQKSA-N, HDACQVRGBOVJII-ONSCTEFMSA-N" "Launched"
"2353" "ramosetron" "serotonin receptor antagonist" "HTR3A" "gastroenterology" "nausea, vomiting, irritable bowel syndrome" "BRD-K85046107-003-01-2" "Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12" "NTHPAPBPFQJABD-LLVKDONJSA-N" "Launched"
"2354" "ranirestat" "aldose reductase inhibitor" "AKR1B1" "" "" "BRD-K50489389-001-01-8" "Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O" "QCVNMNYRNIMDKV-QGZVFWFLSA-N" "Phase 3"
"2355" "ranitidine" "histamine receptor antagonist" "HRH2" "gastroenterology" "heartburn" "BRD-K70505054-003-13-2, BRD-K70505054-003-12-4, BRD-K14204120-003-20-6, BRD-K70505054-003-11-6" "CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C\[N+]([O-])=O, CN\C(NCCSCc1ccc(CN(C)C)o1)=C/[N+]([O-])=O" "VMXUWOKSQNHOCA-UKTHLTGXSA-N, VMXUWOKSQNHOCA-UKTHLTGXSA-N, VMXUWOKSQNHOCA-LCYFTJDESA-N, VMXUWOKSQNHOCA-UKTHLTGXSA-N" "Launched"
"2356" "ranolazine" "sodium channel blocker" "SCN10A, SCN4A, SCN5A, SCN9A" "cardiology" "chronic stable angina" "BRD-A97674275-001-11-8, BRD-A97674275-300-03-1, BRD-A97674275-001-10-0" "COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1, COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1" "XKLMZUWKNUAPSZ-UHFFFAOYSA-N, XKLMZUWKNUAPSZ-UHFFFAOYSA-N, XKLMZUWKNUAPSZ-UHFFFAOYSA-N" "Launched"
"2357" "rapastinel" "glutamate receptor agonist" "" "" "" "BRD-K02206208-001-01-4" "C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O" "GIBQQARAXHVEGD-BSOLPCOYSA-N" "Phase 2"
"2358" "rasagiline" "monoamine oxidase inhibitor" "BCL2, MAOB" "neurology/psychiatry" "Parkinsons Disease	BRD-K58114536-066-02-7, BRD-K58114536-001-01-6, BRD-K58826770-066-01-3	C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@@H]1CCc2ccccc12, C#CCN[C@H]1CCc2ccccc12	RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-GFCCVEGCSA-N, RUOKEQAAGRXIBM-LBPRGKRZSA-N	Launched
ravoxertinib	ERK1 and ERK2 phosphorylation inhibitor	MAPK1, MAPK3			BRD-K86309810-001-01-5	Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1	RZUOCXOYPYGSKL-GOSISDBHSA-N	Phase 1
ravuconazole	sterol demethylase inhibitor				BRD-K03503561-001-01-4	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	OPAHEYNNJWPQPX-RCDICMHDSA-N	Phase 2
RBC8	Ral GTPase inhibitor	RALA, RALB			BRD-A67036568-001-01-3	COc1ccc(OC)c(c1)C1c2c(OC(N)=C1C#N)[nH]nc2-c1ccc2ccccc2c1	CLMQBVUFKIKYLU-UHFFFAOYSA-N	Preclinical
rebamipide	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD), gastritis	BRD-A15909516-001-06-6, BRD-A15909516-001-07-4	OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1, OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	ALLWOAVDORUJLA-UHFFFAOYSA-N, ALLWOAVDORUJLA-UHFFFAOYSA-N	Launched
rebastinib	Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BCR, FGR, FLT3, HCK, LYN, SRC			BRD-K76694128-001-05-0, BRD-K76694128-001-06-8, BRD-K76694128-001-04-3	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N, WVXNSAVVKYZVOE-UHFFFAOYSA-N	Phase 1
reboxetine	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	BRD-A43974499-066-02-9, BRD-M39350793-334-01-1, BRD-K77224738-066-02-7	CCOc1ccccc1OC(C1CNCCO1)c1ccccc1, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1.CCOc1ccccc1O[C@H]([C@@H]1CNCCO1)c1ccccc1, CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1	CBQGYUDMJHNJBX-UHFFFAOYSA-N, XGSCYTRLSDKRRZ-JQDMTEHVSA-N, CBQGYUDMJHNJBX-RTBURBONSA-N	Launched
refametinib	MEK inhibitor	MAP2K1, MAP2K2			BRD-K85751432-001-03-3	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	RDSACQWTXKSHJT-NSHDSACASA-N	Phase 2
regadenoson	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3	radiology	myocardial perfusion imaging (MPI)	BRD-A78341343-001-01-6	CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)C(O)C3O)c2n1	LZPZPHGJDAGEJZ-SMDQVTJXSA-N	Launched
regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	BRD-K16730910-001-07-3	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	FNHKPVJBJVTLMP-UHFFFAOYSA-N	Launched
relcovaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR			BRD-K96720755-001-02-6	COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	CEBYCSRFKCEUSW-NAYZPBBASA-N	Phase 2
relebactam	beta lactamase inhibitor				BRD-K63018010-001-01-7	OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O	SMOBCLHAZXOKDQ-ZJUUUORDSA-N	Phase 3
remacemide	glutamate receptor antagonist	GRIN1			BRD-A36074203-003-07-6	CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1	YSGASDXSLKIKOD-UHFFFAOYSA-N	Phase 3
remimazolam	benzodiazepine receptor agonist	GABBR1			BRD-K89413285-074-01-5	COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12	CYHWMBVXXDIZNZ-KRWDZBQOSA-N	Phase 3
remoxipride	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR2A, SIGMAR1			BRD-K54094468-003-11-1	CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	GUJRSXAPGDDABA-NSHDSACASA-N	Withdrawn
repaglinide	insulin secretagogue	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	BRD-K82846253-001-15-4, BRD-K82846253-001-14-7, BRD-K82846253-001-16-2	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O, CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N, FAEKWTJYAYMJKF-QHCPKHFHSA-N	Launched
reparixin	CC chemokine receptor antagonist	CXCR1, CXCR2			BRD-K58486055-001-02-7	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	KQDRVXQXKZXMHP-LLVKDONJSA-N	Phase 3
repsox	TGF beta receptor inhibitor	TGFBR1			BRD-K80480517-001-02-4	Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	LBPKYPYHDKKRFS-UHFFFAOYSA-N	Preclinical
resatorvid	toll-like receptor antagonist	TLR4			BRD-K61567297-001-01-9	CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl	LEEIJTHMHDMWLJ-CQSZACIVSA-N	Phase 3
reserpine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	cardiology	hypertension	BRD-K95921201-001-14-6, BRD-K95921201-001-15-3, BRD-K95921201-001-13-8, BRD-K95921201-001-12-0	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1, CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N, QEVHRUUCFGRFIF-MDEJGZGSSA-N	Launched
resibufogenin	Na/K-ATPase inhibitor				BRD-K25970317-001-01-6	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1	ATLJNLYIJOCWJE-CWMZOUAVSA-N	Phase 2
resiquimod	toll-like receptor agonist	TLR7, TLR8			BRD-K76210423-001-01-6, BRD-K76210423-001-02-4	CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	BXNMTOQRYBFHNZ-UHFFFAOYSA-N, BXNMTOQRYBFHNZ-UHFFFAOYSA-N	Phase 3
resminostat	HDAC inhibitor	HDAC1, HDAC3, HDAC6, HDAC8			BRD-K28822270-001-03-7, BRD-K28822270-001-01-1	CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO	FECGNJPYVFEKOD-VMPITWQZSA-N, FECGNJPYVFEKOD-VMPITWQZSA-N	Phase 2
resorcinol	phosphodiesterase inhibitor	CA12, CA14, CA2, PTGS1	dermatology	acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis	BRD-K74190368-001-04-3, BRD-K85603128-001-04-3, BRD-K85603128-001-03-5	Oc1cccc(O)c1, CC(=O)Oc1cccc(O)c1, CC(=O)Oc1cccc(O)c1	GHMLBKRAJCXXBS-UHFFFAOYSA-N, ZZPKZRHERLGEKA-UHFFFAOYSA-N, ZZPKZRHERLGEKA-UHFFFAOYSA-N	Launched
resveratrol	cytochrome P450 inhibitor, SIRT activator	CSNK2A1, NQO2, PTGS1, PTGS2			BRD-K80738081-001-46-8, BRD-K80738081-001-44-3, BRD-K80738081-001-42-7, BRD-K80738081-001-43-5	Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1, Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1	LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N, LUKBXSAWLPMMSZ-OWOJBTEDSA-N	Launched
retapamulin	protein synthesis inhibitor		infectious disease	impetigo	BRD-K17930269-001-01-8	C[C@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	STZYTFJPGGDRJD-FAJFTSBPSA-N	Launched
retaspimycin	HSP inhibitor	HSP90AA1			BRD-K67935717-003-02-8, BRD-K67935717-003-01-0	CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C, CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C	OAKGNIRUXAZDQF-TXHRRWQRSA-N, OAKGNIRUXAZDQF-TXHRRWQRSA-N	Phase 3
retigabine	potassium channel activator	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5	neurology/psychiatry	epilepsy	BRD-K89917372-001-01-2	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N	PCOBBVZJEWWZFR-UHFFFAOYSA-N	Launched
retinaldehyde			dermatology	cosmetic	BRD-K79884267-001-01-4	CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O	NCYCYZXNIZJOKI-OVSJKPMPSA-N	Launched
retinol	retinoid receptor ligand	ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG	dermatology	cosmetic, acne vulgaris (AV), keratosis	BRD-K22429181-001-14-2, BRD-K22429181-001-15-9	CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/CO, CC(\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C)=C/CO	FPIPGXGPPPQFEQ-OVSJKPMPSA-N, FPIPGXGPPPQFEQ-OVSJKPMPSA-N	Launched
retinyl-acetate					BRD-K65331431-001-06-2, BRD-K65331431-001-08-8	CC(=O)OC\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C, CC(=O)OC\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C	QGNJRVVDBSJHIZ-QHLGVNSISA-N, QGNJRVVDBSJHIZ-QHLGVNSISA-N	Launched
retinyl-palmitate					BRD-K80595380-001-09-8, BRD-K80595380-001-07-2	CCCCCCCCCCCCCCCC(=O)OC\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C, CCCCCCCCCCCCCCCC(=O)OC\C=C(C)\C=C\C=C(C)\C=C\C1=C(C)CCCC1(C)C	VYGQUTWHTHXGQB-FFHKNEKCSA-N, VYGQUTWHTHXGQB-FFHKNEKCSA-N	Launched
REV-5901	leukotriene receptor antagonist, lipoxygenase inhibitor	ALOX5			BRD-A68281735-001-18-6	CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1	JRLOEMCOOZSCQP-UHFFFAOYSA-N	Phase 2
revaprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	gastritis	BRD-A51497544-001-01-4	CC1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C	LECZXZOBEZITCL-UHFFFAOYSA-N	Launched
reversine	Aurora kinase inhibitor	AURKB, INCENP, MAP2K1			BRD-K77286328-001-03-7	C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2[nH]cnc12	ZFLJHSQHILSNCM-UHFFFAOYSA-N	Preclinical
RGB-286638	CDK inhibitor	CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9			BRD-K20986415-001-01-8, BRD-K20986415-001-02-6	COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1, COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1	XLSYZSRXVVCHLS-UHFFFAOYSA-N, XLSYZSRXVVCHLS-UHFFFAOYSA-N	Phase 1
RGFP966	HDAC inhibitor	HDAC3			BRD-K61688984-001-02-9	Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	BLVQHYHDYFTPDV-VCABWLAWSA-N	Preclinical
RG108	DNA methyltransferase inhibitor	DNMT1, DNMT3B			BRD-K89391146-001-08-0	OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	HPTXLHAHLXOAKV-INIZCTEOSA-N	Preclinical
RG1530	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2			BRD-K32942258-001-02-5, BRD-K32942258-001-01-7	COc1cc2N=C3NNC(C)=C3N=C(c3ccccc3Cl)c2cc1F, COc1cc2N=C3NNC(C)=C3N=C(c3ccccc3Cl)c2cc1F	UOVCGJXDGOGOCZ-UHFFFAOYSA-N, UOVCGJXDGOGOCZ-UHFFFAOYSA-N	Phase 1
RG2833	HDAC inhibitor	HDAC1, HDAC3			BRD-K02389548-001-04-1, BRD-K02389548-001-02-5	Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N, Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	VOPDXHFYDJAYNS-UHFFFAOYSA-N, VOPDXHFYDJAYNS-UHFFFAOYSA-N	Phase 1
RG4733	gamma secretase inhibitor	PSEN1			BRD-K22024824-001-03-7	CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	OJPLJFIFUQPSJR-INIZCTEOSA-N	Phase 2
RG7112	MDM inhibitor	MDM2			BRD-A78210457-001-01-5	CCOc1cc(ccc1C1=NC(C)(c2ccc(Cl)cc2)C(C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C	QBGKPEROWUKSBK-UHFFFAOYSA-N	Phase 1
RHC-80267	triacylglycerol lipase inhibitor	DAGLA, DAGLB			BRD-K56047318-001-06-3	O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	RXSVYGIGWRDVQC-UHFFFAOYSA-N	Preclinical
rhein		HSP90AA1			BRD-K27335680-001-10-0	OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	FCDLCPWAQCPTKC-UHFFFAOYSA-N	Phase 1
rheochrysidin	protein tyrosine kinase inhibitor	PTPN1			BRD-K67772619-001-05-1	COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	FFWOKTFYGVYKIR-UHFFFAOYSA-N	Preclinical
rhodamine-123					BRD-K47169076-003-01-6	COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12	ZWODABSNRKVFCK-UHFFFAOYSA-N	Phase 1
RI-1		RAD51			BRD-K79555887-001-01-0	ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1	MWSUIZKGNWELRF-UHFFFAOYSA-N	Preclinical
ribavirin	antiviral	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	BRD-K94397152-001-01-6, BRD-K60369935-001-15-9	NC(=O)c1ncn(n1)[C@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	IWUCXVSUMQZMFG-DJSMDIAISA-N, IWUCXVSUMQZMFG-AFCXAGJDSA-N	Launched
ribitol					BRD-K49313711-001-05-4	OC[C@H](O)[C@H](O)[C@H](O)CO	HEBKCHPVOIAQTA-ZXFHETKHSA-N	Preclinical
ribociclib	CDK inhibitor	CDK4, CDK6			BRD-K36788280-001-04-6, BRD-K36788280-001-01-2, BRD-K36788280-001-03-8	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N, RHXHGRAEPCAFML-UHFFFAOYSA-N	Phase 3
riboflavin	vitamin B2	BLVRB, RFK	gastroenterology	jaundice	BRD-K92760278-001-07-3, BRD-K70246307-001-04-1, BRD-K92760278-001-06-5	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	AUNGANRZJHBGPY-SCRDCRAPSA-N, AUNGANRZJHBGPY-MBNYWOFBSA-N, AUNGANRZJHBGPY-SCRDCRAPSA-N	Launched
riboflavin-5-phosphate-sodium		BLVRB, DHODH, DPYD, HAO1, HAO2, MT-ND1, NOS1, PNPO, POR, PPCDC, RFK, RPS6KA4, SGK1			BRD-K09229706-236-02-6, BRD-K09229706-236-01-8, BRD-K58734774-236-02-2	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C, Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)COP(O)(O)=O)c2cc1C	FVTCRASFADXXNN-SCRDCRAPSA-N, FVTCRASFADXXNN-SCRDCRAPSA-N, FVTCRASFADXXNN-MBNYWOFBSA-N	Launched
ribostamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	human immunodeficiency virus (HIV-1), human immunodeficiency virus (HIV-1)	BRD-K55188888-065-01-2, BRD-A86073102-001-01-6	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O, NCC1OC(OC2C(N)CC(N)C(O)C2OC2OC(CO)C(O)C2O)C(N)C(O)C1O	NSKGQURZWSPSBC-VVPCINPTSA-N, NSKGQURZWSPSBC-UHFFFAOYSA-N	Launched
ribostamycin-sulfate	bacterial 30S ribosomal subunit inhibitor	P4HB	infectious disease	gram-negative bacterial infections	BRD-A03826781-065-03-6	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)C2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	NSKGQURZWSPSBC-VCUPSGBRSA-N	Launched
ricinoleic-acid	prostanoid receptor agonist	PTGER3			BRD-K33682646-001-02-7	CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O	WBHHMMIMDMUBKC-QJWNTBNXSA-N	Launched
rifabutin	protein synthesis inhibitor	HSP90AA1, HSP90B1	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K30563334-001-02-9	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(c(O)c3C)c(O)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c1=NC3(CCN(CC(C)C)CC3)N=c21	AZFBLLCNOQPJGJ-NYGPAKPVSA-N	Launched
rifampin	RNA polymerase inhibitor	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	BRD-K56156786-001-01-6, BRD-A23603052-001-03-2, BRD-K66218091-001-01-2	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(C=NN4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/C(C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	JQXXHWHPUNPDRT-QDPUZLTPSA-N, JQXXHWHPUNPDRT-OUBGVEFFSA-N, JQXXHWHPUNPDRT-SBMPKVQQSA-N	Launched
rifamycin	DNA directed RNA polymerase inhibitor	SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1	infectious disease	tuberculosis, leprosy	BRD-K38512030-001-01-7	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	HJYYPODYNSCCOU-ODRIEIDWSA-N	Launched
rifamycin-sv	RNA synthesis inhibitor				BRD-K13277760-001-01-2	CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C	BZOQTGADCSFWHV-RECYQVEJSA-N	Phase 3
rifapentine	RNA polymerase inhibitor	CYP2C8, CYP2C9, CYP3A4	infectious disease	tuberculosis	BRD-K62325629-001-01-0, BRD-K42569090-001-01-8, BRD-K55889443-001-03-4	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C/O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	WDZCUPBHRAEYDL-FWNPDZDPSA-N, WDZCUPBHRAEYDL-NAFQJNKLSA-N, WDZCUPBHRAEYDL-QEDJKGLXSA-N	Launched
rifaximin	RNA synthesis inhibitor	NR1I2	gastroenterology	diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)	BRD-A62879835-001-04-2, BRD-K45512312-001-01-7	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)C(O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C, CO[C@H]1\C=C\O[C@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C	NZCRJKRKKOLAOJ-HQDKJBBOSA-N, NZCRJKRKKOLAOJ-WSTNJLQSSA-N	Launched
rigosertib	cell cycle inhibitor, PLK inhibitor	PLK1			BRD-K55187425-236-07-8, BRD-K55187425-236-05-2, BRD-K55187425-236-06-0	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N, OWBFCJROIKNMGD-BQYQJAHWSA-N	Phase 3
rilmenidine	adrenergic receptor agonist, imidazoline receptor agonist	ADRA2A	cardiology	hypertension	BRD-K01638814-011-01-4, BRD-K01638814-051-16-8	C1CC1C(NC1=NCCO1)C1CC1, C1CC1C(NC1=NCCO1)C1CC1	CQXADFVORZEARL-UHFFFAOYSA-N, CQXADFVORZEARL-UHFFFAOYSA-N	Launched
rilpivirine	non-nucleoside reverse transcriptase inhibitor	NR1I2, SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K06240250-001-01-6	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	YIBOMRUWOWDFLG-ONEGZZNKSA-N	Launched
riluzole	glutamate inhibitor	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	BRD-K21283037-001-21-5, BRD-K21283037-001-20-7, BRD-K21283037-003-11-2	Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1, Nc1nc2ccc(OC(F)(F)F)cc2s1	FTALBRSUTCGOEG-UHFFFAOYSA-N, FTALBRSUTCGOEG-UHFFFAOYSA-N, FTALBRSUTCGOEG-UHFFFAOYSA-N	Launched
rimantadine	antiviral, RNA synthesis inhibitor		infectious disease	influenza A virus infection	BRD-A75479906-003-11-1, BRD-A75479906-001-02-4	CC(N)C12CC3CC(CC(C3)C1)C2, CC(N)C12CC3CC(CC(C3)C1)C2	UBCHPRBFMUDMNC-UHFFFAOYSA-N, UBCHPRBFMUDMNC-UHFFFAOYSA-N	Launched
rimcazole	sigma receptor antagonist	SIGMAR1			BRD-K70490179-300-01-2	C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1	GUDVQJXODNJRIJ-CALCHBBNSA-N	Phase 1
rimexolone	glucocorticoid receptor agonist	NR3C1, SERPINA6	ophthalmology	anterior uveitis	BRD-K31627533-001-09-5	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C	QTTRZHGPGKRAFB-OOKHYKNYSA-N	Launched
rimonabant	cannabinoid receptor antagonist	CNR1, GPR55			BRD-K13296708-001-05-8	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	JZCPYUJPEARBJL-UHFFFAOYSA-N	Withdrawn
riociguat	guanylate cyclase stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	BRD-K84783599-001-01-0	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	WXXSNCNJFUAIDG-UHFFFAOYSA-N	Launched
riodipine	calcium channel blocker				BRD-K36379990-001-01-1	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC	AZVFIZVKGSPGPK-UHFFFAOYSA-N	Phase 2
riodoxol	other antibiotic				BRD-K48963429-001-01-9, BRD-K48963429-001-02-7	Oc1c(I)cc(I)c(O)c1I, Oc1c(I)cc(I)c(O)c1I	XKFZYVWWXHCHIX-UHFFFAOYSA-N, XKFZYVWWXHCHIX-UHFFFAOYSA-N	Launched
ripasudil	rho associated kinase inhibitor	ROCK1, ROCK2	ophthalmology	glaucoma, ocular hypertension	BRD-K53814070-310-01-3	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	QSKQVZWVLOIIEV-NSHDSACASA-N	Launched
ripazepam	benzodiazepine receptor agonist	GABRA1			BRD-K57427145-001-01-6	CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1	YFHYNLHGFKXAIQ-UHFFFAOYSA-N	Phase 2
risedronate	osteoclast inhibitor	FDPS	orthopedics, endocrinology	osteoporosis, Pagets disease" "BRD-K05185389-001-03-4, BRD-K05185389-236-05-1, BRD-K05185389-236-04-4, BRD-K05185389-001-02-6, BRD-K05185389-236-03-6" "OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O" "IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N, IIDJRNMFWXDHID-UHFFFAOYSA-N" "Launched"
"2359" "risperidone" "dopamine receptor antagonist, serotonin receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7" "neurology/psychiatry" "schizophrenia, bipolar disorder, irritability" "BRD-K53857191-001-22-7, BRD-K53857191-001-21-9" "Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12, Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12" "RAPZEAPATHNIPO-UHFFFAOYSA-N, RAPZEAPATHNIPO-UHFFFAOYSA-N" "Launched"
"2360" "RITA" "MDM inhibitor" "MDM2" "" "" "BRD-K00317371-001-06-1, BRD-K00317371-001-05-3" "OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1, OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1" "KZENBFUSKMWCJF-UHFFFAOYSA-N, KZENBFUSKMWCJF-UHFFFAOYSA-N" "Preclinical"
"2361" "ritanserin" "serotonin receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7" "" "" "BRD-K40887525-001-21-9, BRD-K40887525-001-22-7" "Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1, Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1" "JUQLTPCYUFPYKE-UHFFFAOYSA-N, JUQLTPCYUFPYKE-UHFFFAOYSA-N" "Phase 3"
"2362" "ritodrine" "adrenergic receptor agonist" "ADRB2" "obstetrics/gynecology" "premature labor" "BRD-K14003026-003-09-0, BRD-A59174698-003-18-5, BRD-K14003026-003-08-2" "C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1, CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1, C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1" "IOVGROKTTNBUGK-SJKOYZFVSA-N, IOVGROKTTNBUGK-UHFFFAOYSA-N, IOVGROKTTNBUGK-SJKOYZFVSA-N" "Launched"
"2363" "ritonavir" "HIV protease inhibitor" "CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K51485625-001-08-4" "CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1" "NCDNCNXCDXHOMX-XGKFQTDJSA-N" "Launched"
"2364" "rivanicline" "acetylcholine receptor agonist" "CHRNA4, CHRNB2, CXCL8" "" "" "BRD-K79966802-034-01-2" "CNCC\C=C\c1cccnc1" "JUOSGGQXEBBCJB-GORDUTHDSA-N" "Phase 2"
"2365" "rivaroxaban" "coagulation factor inhibitor" "F10" "neurology/psychiatry, hematology, cardiology" "stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)" "BRD-A50033377-001-02-8, BRD-K37130656-001-03-8" "Clc1ccc(s1)C(=O)NCC1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O, Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O" "KGFYHTZWPPHNLQ-UHFFFAOYSA-N, KGFYHTZWPPHNLQ-AWEZNQCLSA-N" "Launched"
"2366" "rivastigmine" "acetylcholinesterase inhibitor" "ACHE, BCHE" "neurology/psychiatry" "Alzheimers disease, Parkinsons Disease, senile dementia" "BRD-K10706131-046-03-6, BRD-K10706131-046-04-4, BRD-K10706131-046-02-8" "CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C, CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C" "XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N, XSVMFMHYUFZWBK-NSHDSACASA-N" "Launched"
"2367" "rizatriptan" "serotonin receptor agonist" "HTR1A, HTR1B, HTR1D, HTR1E, HTR1F" "neurology/psychiatry" "migraine headache" "BRD-K75699339-057-08-1, BRD-K75699339-057-09-9, BRD-K75699339-057-07-3" "CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12, CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12" "ULFRLSNUDGIQQP-UHFFFAOYSA-N, ULFRLSNUDGIQQP-UHFFFAOYSA-N, ULFRLSNUDGIQQP-UHFFFAOYSA-N" "Launched"
"2368" "RKI-1447" "rho associated kinase inhibitor" "CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2" "" "" "BRD-K19333160-001-01-3" "Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1" "GDVRVPIXWXOKQO-UHFFFAOYSA-N" "Preclinical"
"2369" "RLX" "" "" "" "" "BRD-K28773847-001-07-7" "O=c1n2CCCCCc2nc2ccccc12" "HTLIIBRHXAULMB-UHFFFAOYSA-N" "Preclinical"
"2370" "RN-1734" "TRPV antagonist" "TRPV4" "" "" "BRD-K95581532-001-01-5" "CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl" "IHYZMEAZAIFMTN-UHFFFAOYSA-N" "Preclinical"
"2371" "RN-1747" "TRPV agonist" "TRPV4" "" "" "BRD-K45519571-001-01-8" "[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1" "ZNLVYSJQUMALEO-UHFFFAOYSA-N" "Preclinical"
"2372" "Ro-04-5595" "" "GRIN2B" "" "" "BRD-A63546914-003-02-0" "COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O" "DSTWURHEHMZWEI-UHFFFAOYSA-N" "Preclinical"
"2373" "Ro-08-2750" "" "NGF" "" "" "BRD-K00486786-001-02-2" "Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O" "JDEMVNYMYPJJIM-UHFFFAOYSA-N" "Preclinical"
"2374" "Ro-10-5824" "dopamine receptor agonist" "DRD4" "" "" "BRD-K79684402-300-02-8" "Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1" "KABDATZAOUSYES-UHFFFAOYSA-N" "Preclinical"
"2375" "Ro-106-9920" "NFkB pathway inhibitor" "" "" "" "BRD-A53134341-001-03-2" "O=S(c1ccccc1)c1ccc2nnnn2n1" "JFSXSNSCPNFCDM-UHFFFAOYSA-N" "Preclinical"
"2376" "Ro-15-4513" "" "GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2" "" "" "BRD-K82823076-001-02-6" "CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]" "CFSOJZTUTOQNIA-UHFFFAOYSA-N" "Preclinical"
"2377" "Ro-19-4605" "" "GABRA1, GABRA2, GABRA3, GABRA5" "" "" "BRD-K80778372-001-02-5" "CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C" "ZIGMMUKDYCABPW-UHFFFAOYSA-N" "Preclinical"
"2378" "Ro-20-1724" "phosphodiesterase inhibitor" "PDE3A, PDE4A, PDE4B, PDE4C, PDE4D" "" "" "BRD-A07207424-001-13-2" "CCCCOc1cc(CC2CNC(=O)N2)ccc1OC" "PDMUULPVBYQBBK-UHFFFAOYSA-N" "Preclinical"
"2379" "Ro-25-6981" "" "GRIN2B" "" "" "BRD-K51541829-050-01-0" "C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1" "WVZSEUPGUDIELE-HTAPYJJXSA-N" "Preclinical"
"2380" "Ro-28-1675" "glucokinase activator" "GCK" "" "" "BRD-K21672174-001-03-0" "CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1" "NEQSWPCDHDQINX-MRXNPFEDSA-N" "Preclinical"
"2381" "Ro-48-8071" "oxidosqualene cyclase inhibitor" "LSS" "" "" "BRD-K55192287-051-01-1" "CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C" "CMYCCJYVZIMDFU-UHFFFAOYSA-N" "Preclinical"
"2382" "Ro-4987655" "MEK inhibitor" "MAP2K1" "" "" "BRD-K64538373-001-01-4" "OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F" "FIMYFEGKMOCQKT-UHFFFAOYSA-N" "Phase 1"
"2383" "Ro-5126766" "RAF inhibitor, MEK inhibitor" "BRAF, MAP2K1, MAP2K2, RAF1" "" "" "BRD-K82804538-001-01-0, BRD-K82804538-001-02-8" "CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F, CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F" "LMMJFBMMJUMSJS-UHFFFAOYSA-N, LMMJFBMMJUMSJS-UHFFFAOYSA-N" "Phase 1"
"2384" "Ro-60-0175" "" "HTR2A, HTR2B, HTR2C" "" "" "BRD-K28007504-051-01-2" "C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12" "XJJZQXUGLLXTHO-ZETCQYMHSA-N" "Preclinical"
"2385" "Ro-61-8048" "kynurenine 3-monooxygenase inhibitor" "KMO" "" "" "BRD-K12639498-001-01-3" "COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O" "NDPBMCKQJOZAQX-UHFFFAOYSA-N" "Preclinical"
"2386" "Ro-90-7501" "" "APP" "" "" "BRD-K58299615-001-03-5" "Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1" "PAGZCEHLFCJSPV-UHFFFAOYSA-N" "Preclinical"
"2387" "Ro-9187" "HCV inhibitor" "" "" "" "BRD-K57284066-001-01-6" "Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1" "ODLGMSQBFONGNG-XZMZPDFPSA-N" "Preclinical"
"2388" "rociletinib" "EGFR inhibitor" "EGFR" "" "" "BRD-K33610132-001-02-9" "COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O" "HUFOZJXAKZVRNJ-UHFFFAOYSA-N" "Phase 3"
"2389" "rocuronium" "acetylcholine receptor antagonist" "CHRM2, CHRNA2, HTR3A" "neurology/psychiatry" "anesthetic" "BRD-K58951486-004-01-5, BRD-A40127632-004-01-8" "CC(=O)O[C@@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1, CC(=O)O[C@H]1[C@H](CC2C3CCC4C[C@H](O)[C@H](C[C@]4(C)C3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1" "YXRDKMPIGHSVRX-KKBURWSNSA-N, YXRDKMPIGHSVRX-QMKYXPNJSA-N" "Launched"
"2390" "rofecoxib" "cyclooxygenase inhibitor" "ELN, PTGS2" "" "" "BRD-K21733600-001-23-2, BRD-K21733600-001-24-0, BRD-K21733600-001-14-1, BRD-K21733600-001-19-0, BRD-K21733600-001-15-8" "CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1, CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1" "RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N, RZJQGNCSTQAWON-UHFFFAOYSA-N" "Withdrawn"
"2391" "roflumilast" "phosphodiesterase inhibitor" "PDE4A, PDE4B, PDE4C, PDE4D" "pulmonary" "chronic obstructive pulmonary disease (COPD), bronchitis" "BRD-K03194791-001-04-8" "FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl" "MNDBXUUTURYVHR-UHFFFAOYSA-N" "Launched"
"2392" "rolipram" "phosphodiesterase inhibitor" "" "" "" "BRD-A34255068-001-34-5, BRD-A34255068-001-33-7, BRD-A34255068-001-32-9" "COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1" "HJORMJIFDVBMOB-UHFFFAOYSA-N, HJORMJIFDVBMOB-UHFFFAOYSA-N, HJORMJIFDVBMOB-UHFFFAOYSA-N" "Phase 3"
"2393" "rolipram-R(-)" "phosphodiesterase inhibitor" "PDE4A, PDE4B, PDE4C, PDE4D, PDE5A" "" "" "BRD-K75516118-001-03-3" "COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1" "HJORMJIFDVBMOB-LBPRGKRZSA-N" "Preclinical"
"2394" "rolipram-S(+)" "phosphodiesterase inhibitor" "" "" "" "BRD-K65856711-001-04-4, BRD-K65856711-001-03-6" "COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1, COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1" "HJORMJIFDVBMOB-GFCCVEGCSA-N, HJORMJIFDVBMOB-GFCCVEGCSA-N" "Preclinical"
"2395" "rolitetracycline" "bacterial 30S ribosomal subunit inhibitor" "" "" "" "BRD-A62336573-001-03-1, BRD-A62336573-001-02-3, BRD-A62336573-001-04-9" "CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(=O)NCN2CCCC2)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(=O)NCN2CCCC2)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(=O)NCN2CCCC2)C1=O" "PLDZOHPIBZVDLQ-KOQYWDHLSA-N, PLDZOHPIBZVDLQ-KOQYWDHLSA-N, PLDZOHPIBZVDLQ-KOQYWDHLSA-N" "Launched"
"2396" "rolziracetam" "" "" "" "" "BRD-K38564664-001-01-1" "O=C1CCC2CCC(=O)N12" "IEZDOKQWPWZVQF-UHFFFAOYSA-N" "Phase 2"
"2397" "romidepsin" "HDAC inhibitor" "HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9" "hematologic malignancy" "cutaneous T-cell lymphoma (CTCL)" "BRD-K61397605-001-03-4" "C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C" "OHRURASPPZQGQM-GCCNXGTGSA-N" "Launched"
"2398" "ronidazole" "antiprotozoal agent" "" "infectious disease" "histomoniasis, dysentry" "BRD-K94266545-001-24-1, BRD-K94266545-001-23-3" "Cn1c(COC(N)=O)ncc1[N+]([O-])=O, Cn1c(COC(N)=O)ncc1[N+]([O-])=O" "PQFRTXSWDXZRRS-UHFFFAOYSA-N, PQFRTXSWDXZRRS-UHFFFAOYSA-N" "Launched"
"2399" "ropinirole" "dopamine receptor agonist" "ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C" "neurology/psychiatry" "Parkinsons Disease, restless leg syndrome	BRD-K15933101-003-06-1, BRD-K15933101-003-07-9	CCCN(CCC)CCc1cccc2NC(=O)Cc12, CCCN(CCC)CCc1cccc2NC(=O)Cc12	UHSKFQJFRQCDBE-UHFFFAOYSA-N, UHSKFQJFRQCDBE-UHFFFAOYSA-N	Launched
ropivacaine	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	BRD-K50938786-003-11-8	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	ZKMNUMMKYBVTFN-HNNXBMFYSA-N	Launched
roquinimex	angiogenesis inhibitor, tumor necrosis factor production inhibitor				BRD-K03384561-001-02-7	CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	SGOOQMRIPALTEL-UHFFFAOYSA-N	Phase 3
rosamicin	protein synthesis inhibitor				BRD-A38799180-001-01-0	CCC1OC(=O)CC(O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC=O)CC(C)C(=O)\C=C\C2(C)OC2C1C	IUPCWCLVECYZRV-ZRDIBKRKSA-N	Phase 2
roscovitine	CDK inhibitor	CDK2, CDK9			BRD-K07691486-001-15-5, BRD-K07691486-001-19-7	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1, CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	BTIHMVBBUGXLCJ-OAHLLOKOSA-N, BTIHMVBBUGXLCJ-OAHLLOKOSA-N	Phase 2
rose-bengal	contrast agent		radiology	diagnostic agent	BRD-K33623053-304-01-7	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	VDNLFJGJEQUWRB-UHFFFAOYSA-N	Launched
rose-bengal-disodium	immunostimulant				BRD-K33623053-304-02-5	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	VDNLFJGJEQUWRB-UHFFFAOYSA-N	Phase 2
rose-bengal-lactone	coloring agent		ophthalmology	staining agent	BRD-K36163066-304-02-4	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I	IICCLYANAQEHCI-UHFFFAOYSA-N	Launched
rosiglitazone	insulin sensitizer, PPAR receptor agonist	ACSL4, FFAR1, PPARG, TRPC5, TRPM3			BRD-A97437073-050-14-5, BRD-A97437073-003-14-4, BRD-A97437073-050-13-7, BRD-A97437073-001-08-0	CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1, CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1	YASAKCUCGLMORW-UHFFFAOYSA-N, YASAKCUCGLMORW-UHFFFAOYSA-N, YASAKCUCGLMORW-UHFFFAOYSA-N, YASAKCUCGLMORW-UHFFFAOYSA-N	Withdrawn
rosmarinic-acid	GABA transaminase inhibitor	MCL1, TYR			BRD-K20313525-001-04-6	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	DOUMFZQKYFQNTF-WUTVXBCWSA-N	Launched
rosoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	BRD-K49841478-001-01-6	CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1	XBPZXDSZHPDXQU-UHFFFAOYSA-N	Launched
rostafuroxine	ATPase inhibitor	ATP1A1			BRD-K11672787-001-01-5	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	AEAPORIZZWBIEX-DTBDINHYSA-N	Phase 2
rosuvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis	BRD-K82941592-238-04-5, BRD-K82941592-238-03-7	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O, CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	BPRHUIZQVSMCRT-VEUZHWNKSA-N, BPRHUIZQVSMCRT-VEUZHWNKSA-N	Launched
rotigotine	dopamine receptor agonist	ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A	neurology/psychiatry	Parkinsons Disease, restless leg syndrome" "BRD-K91111634-001-01-2" "CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1" "KFQYTPMOWPVWEJ-INIZCTEOSA-N" "Launched"
"2400" "rotundine" "serotonin receptor agonist" "DRD1, DRD2, DRD3, HTR1A" "" "" "BRD-K35719256-001-02-6" "COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC" "AEQDJSLRWYMAQI-KRWDZBQOSA-N" "Launched"
"2401" "roxarsone" "antiprotozoal agent" "" "endocrinology" "weight-gain aid" "BRD-K22685337-001-13-4" "Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O" "XMVJITFPVVRMHC-UHFFFAOYSA-N" "Launched"
"2402" "roxatidine-acetate" "histamine receptor antagonist" "HRH2" "gastroenterology" "Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis" "BRD-K81855038-003-13-9, BRD-K81855038-003-14-7, BRD-K81855038-003-12-1" "CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1, CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1" "SMTZFNFIKUPEJC-UHFFFAOYSA-N, SMTZFNFIKUPEJC-UHFFFAOYSA-N, SMTZFNFIKUPEJC-UHFFFAOYSA-N" "Launched"
"2403" "roxithromycin" "bacterial 50S ribosomal subunit inhibitor" "ABCB1, MLNR" "infectious disease" "respiratory tract infections, urinary tract infections, skin infections" "BRD-K58211978-001-01-5, BRD-K38684403-001-04-7" "CC[C@H]1OC(=O)[C@H](C)[C@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O, CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O" "RXZBMPWDPOLZGW-IVJCFNEOSA-N, RXZBMPWDPOLZGW-XMRMVWPWSA-N" "Launched"
"2404" "RP67580" "" "" "" "" "BRD-K40767677-001-01-1" "COc1ccccc1C=C(N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1" "RQPUEHDQLXIPNI-LOSJGSFVSA-N" "Preclinical"
"2405" "RRx-001" "glucose 6-phosphate dehydrogenase inhibitor" "G6PD" "" "" "BRD-K06894065-001-01-5" "[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O" "JODKFOVZURLVTG-UHFFFAOYSA-N" "Phase 2"
"2406" "RS-0481" "immunostimulant" "" "" "" "BRD-A00055058-001-01-0" "CC(NC(=O)C1CSCN1C(=O)c1ccccc1)c1ccccc1" "MEXWLVVJOPSWLN-UHFFFAOYSA-N" "Phase 2"
"2407" "RS-100329" "adrenergic receptor antagonist" "ADRA1A, ADRA1D" "" "" "BRD-K08640512-003-02-3" "Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O" "RCOBWVAGWYRNHZ-UHFFFAOYSA-N" "Preclinical"
"2408" "RS-102221" "serotonin receptor antagonist" "HTR2A, HTR2B, HTR2C" "" "" "BRD-K87048468-003-02-7" "COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O" "HZZZZODVDSHQRG-UHFFFAOYSA-N" "Preclinical"
"2409" "RS-102895" "CCR antagonist" "CCR2" "" "" "BRD-K83063356-003-02-5" "FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1" "HIDWEYPGMLIQSN-UHFFFAOYSA-N" "Preclinical"
"2410" "RS-127445" "serotonin receptor antagonist" "HTR2A, HTR2B, HTR2C" "" "" "BRD-K90825648-001-02-0" "CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12" "ZZZQXCUPAJFVBN-UHFFFAOYSA-N" "Phase 1"
"2411" "RS-16566" "serotonin receptor antagonist" "" "" "" "BRD-K80725821-300-02-9" "CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2" "OGXMGJGFLBSEJW-HNNXBMFYSA-N" "Preclinical"
"2412" "RS-17053" "adrenergic receptor antagonist" "ADRA1A, ADRA1D" "" "" "BRD-K76840893-003-02-5" "CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1" "XLZHXAXXJVKTFM-UHFFFAOYSA-N" "Preclinical"
"2413" "RS-23597-190" "serotonin receptor antagonist" "HTR4" "" "" "BRD-K01868942-003-02-7" "COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1" "RLSGBCUXLRMTPF-UHFFFAOYSA-N" "Preclinical"
"2414" "RS-39604" "serotonin receptor antagonist" "HTR4" "" "" "BRD-K20742498-003-02-9" "COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1" "BKVIWGRFRKLFIO-UHFFFAOYSA-N" "Preclinical"
"2415" "RS-45041-190" "imidazoline receptor agonist" "" "" "" "BRD-K26160755-003-02-6" "Clc1cccc2CN(Cc12)C1=NCCN1" "IVCMOOBKRRDNHX-UHFFFAOYSA-N" "Preclinical"
"2416" "RS-504393" "CC chemokine receptor antagonist" "CCL2, CCR2" "" "" "BRD-K87510569-001-02-8" "Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1" "ODNICNWASXKNNQ-UHFFFAOYSA-N" "Preclinical"
"2417" "RS-56812" "serotonin receptor partial agonist" "HTR3A" "" "" "BRD-K20714604-003-02-9" "Cn1cc(C(=O)C(=O)N[C@H]2CN3CCC2CC3)c2ccccc12" "ZNAPADWWBWFMCQ-HNNXBMFYSA-N" "Preclinical"
"2418" "RS-67333" "serotonin receptor partial agonist" "HTR4" "" "" "BRD-K46142322-003-02-4" "CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1" "JBHLYIVFFLNISJ-UHFFFAOYSA-N" "Preclinical"
"2419" "RS-67506" "serotonin receptor partial agonist" "HTR4" "" "" "BRD-K50018155-003-02-1" "COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1" "UATDVRSFFGFTAI-UHFFFAOYSA-N" "Preclinical"
"2420" "RS-79948" "adrenergic receptor antagonist" "ADRA2A" "" "" "BRD-K86600316-003-02-0" "CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12" "UMGBFFAJXFXOIL-MNEFBYGVSA-N" "Preclinical"
"2421" "RSV604" "RSV replication inhibitor" "" "" "" "BRD-K30159788-001-01-9" "Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O" "MTPVBMVUENFFLL-HXUWFJFHSA-N" "Phase 2"
"2422" "RTA-408" "nitric oxide production inhibitor" "NFE2L2" "" "" "BRD-A96383502-001-01-3, BRD-K56211775-001-01-2" "CC(F)(F)C(=O)NC12CCC(C)(C)CC1C1C(=O)C=C3C4(C)C=C(C" "" ""
"2423" "RU-24969" "serotonin receptor agonist" "HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6" "" "" "BRD-K00234327-001-03-0, BRD-K00234327-036-05-1" "COc1ccc2[nH]cc(C3=CCNCC3)c2c1, COc1ccc2[nH]cc(C3=CCNCC3)c2c1" "KRVMLPUDAOWOGN-UHFFFAOYSA-N, KRVMLPUDAOWOGN-UHFFFAOYSA-N" "Phase 1"
"2424" "RU-28318" "cytochrome P450 inhibitor" "NR3C2" "" "" "BRD-K37687387-237-01-7" "CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12" "DNHCHRGCTVRAFT-JEHIOXJOSA-N" "Phase 2"
"2425" "RU-42173" "adrenergic receptor agonist" "ADRB2" "" "" "BRD-K85285268-003-01-1" "CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O" "ZSTCZWJCLIRCOJ-DGCLKSJQSA-N" "Phase 2"
"2426" "RU-58841" "androgen receptor antagonist" "AR" "" "" "BRD-K62762455-001-01-3" "CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C" "" ""
"2427" "rubitecan" "topoisomerase inhibitor" "TOP1" "" "" "BRD-K79821389-001-03-5" "CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O" "VHXNKPBCCMUMSW-FQEVSTJZSA-N" "Phase 3"
"2428" "rucaparib" "PARP inhibitor" "PARP1, PARP2" "" "" "BRD-K88560311-011-07-1, BRD-K88560311-011-06-3" "CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23, CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23" "HMABYWSNWIZPAG-UHFFFAOYSA-N, HMABYWSNWIZPAG-UHFFFAOYSA-N" "Phase 3"
"2429" "rucinol" "tyrosinase inhibitor" "TYR" "" "" "BRD-K61036791-001-01-6" "CCCCc1ccc(O)cc1O" "CSHZYWUPJWVTMQ-UHFFFAOYSA-N" "Phase 1"
"2430" "rufinamide" "voltage-gated sodium channel blocker" "GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "seizures" "BRD-K20079257-001-09-6" "NC(=O)c1cn(Cc2c(F)cccc2F)nn1" "POGQSBRIGCQNEG-UHFFFAOYSA-N" "Launched"
"2431" "rufloxacin" "bacterial DNA gyrase inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-K62374253-001-07-8" "CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O" "NJCJBUHJQLFDSW-UHFFFAOYSA-N" "Launched"
"2432" "rupatadine" "histamine receptor antagonist, platelet activating factor receptor antagonist" "HRH1, PTAFR" "allergy" "allergic rhinitis, urticaria" "BRD-K98004573-051-02-8" "Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1" "WUZYKBABMWJHDL-UHFFFAOYSA-N" "Launched"
"2433" "rutaecarpine" "cyclooxygenase inhibitor" "PTGS2" "" "" "BRD-K94723713-001-10-6" "O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12" "ACVGWSKVRYFWRP-UHFFFAOYSA-N" "Preclinical"
"2434" "rutin" "antioxidant, capillary stabilizing agent, nitric oxide scavenger" "AKR1C3" "rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy" "joint pain, nasal congestion, constipation, irritability, allergic rhinitis" "BRD-A76747559-001-03-1, BRD-K20482099-001-09-4, BRD-K22924152-001-01-4" "C[C@@H]1O[C@@H](OC[C@H]2OC(Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@H]1O" "IKGXIBQEEMLURG-KUKMIBIMSA-N, IKGXIBQEEMLURG-NVPNHPEKSA-N, IKGXIBQEEMLURG-MINHVLLHSA-N" "Launched"
"2435" "ruxolitinib" "JAK inhibitor" "JAK1, JAK2, JAK3, TYK2" "hematologic malignancy, hematology" "myelofibrosis, polycythemia vera" "BRD-K53972329-001-07-0" "N" "" ""
"2436" "ruxolitinib-(S)" "JAK inhibitor" "JAK1, JAK2" "" "" "BRD-K19601669-001-03-5" "N" "" ""
"2437" "RWJ-21757" "toll-like receptor agonist" "TLR7" "" "" "BRD-K00091711-001-01-2, BRD-K00091711-001-02-0" "Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1, Nc1nc2n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c(=O)n(CC=C)c2c(=O)[nH]1" "VDCRFBBZFHHYGT-IOSLPCCCSA-N, VDCRFBBZFHHYGT-IOSLPCCCSA-N" "Phase 1"
"2438" "RWJ-67657" "MAP kinase inhibitor" "MAPK14, PTGS2" "" "" "BRD-K07074923-001-01-5, BRD-K07074923-001-02-3" "OCCC" "" ""
"2439" "RX-3117" "DNA synthesis inhibitor, CDK inhibitor" "CDK2, DNMT1" "" "" "BRD-K66213167-001-01-2" "Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1" "QLLGKCJUPWYJON-HLTSFMKQSA-N" "Phase 1/Phase 2"
"2440" "RX-821002" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C" "" "" "BRD-A65597028-003-07-3" "COC1(COc2ccccc2O1)C1=NCCN1" "HQGWKNGAKBPTBX-UHFFFAOYSA-N" "Preclinical"
"2441" "ryuvidine" "histone lysine methyltransferase inhibitor" "CDK2, CDK4" "" "" "BRD-K06426971-001-03-5, BRD-K06426971-001-02-7" "Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O, Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O" "HFPLHASLIOXVGS-UHFFFAOYSA-N, HFPLHASLIOXVGS-UHFFFAOYSA-N" "Preclinical"
"2442" "R112" "syk inhibitor" "SYK" "" "" "BRD-K23902832-001-01-7" "Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1" "TVKGTSHBQZEFEE-UHFFFAOYSA-N" "Preclinical"
"2443" "R306465" "HDAC inhibitor" "" "" "" "BRD-K86687746-001-01-3" "ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1" "MUTBJZVSRNUIHA-UHFFFAOYSA-N" "Phase 1"
"2444" "R547" "CDK inhibitor" "CDK1, CDK2, CDK4, CDK7" "" "" "BRD-K52233191-001-02-4" "COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N" "JRNJNYBQQYBCLE-UHFFFAOYSA-N" "Phase 1"
"2445" "S-Isopropylisothiourea" "nitric oxide synthase inhibitor" "NOS3" "" "" "BRD-K10673031-004-02-0" "CC(C)SC(N)=N" "XSSNABKEYXKKMK-UHFFFAOYSA-N" "Preclinical"
"2446" "S-methylcysteine" "" "CTSD, MGMT" "" "" "BRD-K63123526-001-01-2" "CSC[C@H](N)C(O)=O" "IDIDJDIHTAOVLG-VKHMYHEASA-N" "Phase 1"
"2447" "S-Nitrosoglutathione" "nitric oxide stimulant" "PTPN1" "" "" "BRD-K94780074-001-06-7" "N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O" "HYHSBSXUHZOYLX-WDSKDSINSA-N" "Phase 1"
"2448" "S-Sulfo-L-cysteine-sodium-salt" "glutamate receptor agonist" "" "" "" "BRD-K59527975-236-01-8" "N[C@@H](CSS(O)(=O)=O)C(O)=O" "NOKPBJYHPHHWAN-REOHCLBHSA-N" "Preclinical"
"2449" "S-Trityl-L-cysteine" "mitotic kinesin inhibitor" "" "" "" "BRD-K09774593-001-01-7" "N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O" "DLMYFMLKORXJPO-HXUWFJFHSA-N" "Preclinical"
"2450" "S-111" "PARP inhibitor" "PARP1" "" "" "BRD-K60005752-001-01-9" "CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C" "PYXFVCFISTUSOO-HKUCOEKDSA-N" "Phase 2"
"2451" "S-14506" "serotonin receptor agonist" "HTR1A" "" "" "BRD-K46766488-003-02-0" "COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1" "IFMQODYDAUKKEN-UHFFFAOYSA-N" "Preclinical"
"2452" "saccharin" "DNA polymerase inhibitor" "CA1, CA12, CA2, CA9" "" "" "BRD-K46493214-001-06-7" "O=C1NS(=O)(=O)c2ccccc12" "CVHZOJJKTDOEJC-UHFFFAOYSA-N" "Launched"
"2453" "saclofen" "GABA receptor antagonist" "GABBR1, GABBR2, KCTD12, KCTD16, KCTD8" "" "" "BRD-A24122750-001-03-7" "NCC(CS(O)(=O)=O)c1ccc(Cl)cc1" "JYLNVJYYQQXNEK-UHFFFAOYSA-N" "Preclinical"
"2454" "sacubitril" "neprilysin inhibitor" "MME" "cardiology" "congestive heart failure" "BRD-K91456750-238-01-7, BRD-K91456750-001-01-9" "CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O, CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O" "PYNXFZCZUAOOQC-UTKZUKDTSA-N, PYNXFZCZUAOOQC-UTKZUKDTSA-N" "Launched"
"2455" "safflower-yellow" "anti-inflammatory agent" "" "" "" "BRD-A96503329-001-01-7" "OC[C@H]1OC([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)C(\C=C2/C(=O)C(C(=O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)(C3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(C(=O)\C=C\c2ccc(O)cc2)C1=O" "UHZGYDZTDCTJBO-DKEBXYRSSA-N" "Preclinical"
"2456" "safinamide" "dopamine uptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor" "MAOB" "neurology/psychiatry" "Parkinsons Disease	BRD-K92613113-066-02-7	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	NEMGRZFTLSKBAP-LBPRGKRZSA-N	Launched
safingol	PKC inhibitor	TRPM3			BRD-K93944989-001-08-0	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	OTKJDMGTUTTYMP-ZWKOTPCHSA-N	Phase 1
safranal	benzodiazepine receptor agonist	GABBR1			BRD-K90582192-001-01-9	CC1=C(C=O)C(C)(C)CC=C1	SGAWOGXMMPSZPB-UHFFFAOYSA-N	Phase 2
salazodine					BRD-K15045219-001-01-8	COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1	YFUATOCFMCWUEH-UHFFFAOYSA-N	Phase 2
salicin	anti-inflammatory agent				BRD-K64614248-001-12-3, BRD-K64614248-001-11-5	OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	NGFMICBWJRZIBI-UJPOAAIJSA-N, NGFMICBWJRZIBI-UJPOAAIJSA-N	Phase 1
salicyl-alcohol					BRD-K08493205-001-04-9	OCc1ccccc1O	CQRYARSYNCAZFO-UHFFFAOYSA-N	Preclinical
salicylamide	analgesic agent		neurology/psychiatry, endocrinology	pain relief, fever	BRD-K81130846-001-17-4	NC(=O)c1ccccc1O	SKZKKFZAGNVIMN-UHFFFAOYSA-N	Launched
salicylanilide	other antibiotic				BRD-K83036479-001-09-2, BRD-K83036479-001-08-4	Oc1ccccc1C(=O)Nc1ccccc1, Oc1ccccc1C(=O)Nc1ccccc1	WKEDVNSFRWHDNR-UHFFFAOYSA-N, WKEDVNSFRWHDNR-UHFFFAOYSA-N	Preclinical
salicylic-acid	cyclooxygenase inhibitor	AKR1C1, PTGS1, PTGS2	dermatology	acne vulgaris (AV)	BRD-K93632104-001-17-2	OC(=O)c1ccccc1O	YGSDEFSMJLZEOE-UHFFFAOYSA-N	Launched
salidroside	beta amyloid protein neurotoxicity inhibitor	APP			BRD-K66030860-001-04-4, BRD-K66030860-001-03-6	OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O, OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	ILRCGYURZSFMEG-RKQHYHRCSA-N, ILRCGYURZSFMEG-RKQHYHRCSA-N	Preclinical
salinomycin			infectious disease	coccidiosis	BRD-A46641338-001-02-3, BRD-A98605041-001-01-5, BRD-A32757659-236-04-2	CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O, CC[C@H]([C@H]1CC[C@@H](C)[C@@H](O1)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@H]1C)C(O)=O, CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1OC2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O	KQXDHUJYNAXLNZ-OTLMQKTGSA-N, KQXDHUJYNAXLNZ-XXBRCBCXSA-N, KQXDHUJYNAXLNZ-LFFGOTJKSA-N	Launched
salirasib	mTOR inhibitor	TRPA1			BRD-K98453471-001-01-7	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	WUILNKCFCLNXOK-CFBAGHHKSA-N	Phase 2
salmeterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	BRD-A01320529-104-10-1, BRD-A01320529-104-12-7, BRD-A01320529-104-11-9	OCc1cc(ccc1O)C(O)CNCCCCCCOCCCCc1ccccc1, OCc1cc(ccc1O)C(O)CNCCCCCCOCCCCc1ccccc1, OCc1cc(ccc1O)C(O)CNCCCCCCOCCCCc1ccccc1	GIIZNNXWQWCKIB-UHFFFAOYSA-N, GIIZNNXWQWCKIB-UHFFFAOYSA-N, GIIZNNXWQWCKIB-UHFFFAOYSA-N	Launched
salsolinol-1-carboxylic-acid					BRD-A49952467-001-02-4	CC1(NCCc2cc(O)c(O)cc12)C(O)=O	XHGLVMDBZZZXDP-UHFFFAOYSA-N	Preclinical
salubrinal	eukaryotic translation initiation factor inhibitor	EIF2S1			BRD-A45107007-001-05-9, BRD-A45107007-001-03-4, BRD-A45107007-001-02-6	ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12, ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12, ClC(Cl)(Cl)C(NC(=O)\C=C\c1ccccc1)NC(=S)Nc1cccc2cccnc12	LCOIAYJMPKXARU-VAWYXSNFSA-N, LCOIAYJMPKXARU-VAWYXSNFSA-N, LCOIAYJMPKXARU-VAWYXSNFSA-N	Preclinical
salvianolic-acid-B	metalloproteinase inhibitor, EGFR inhibitor	MMP9			BRD-K18898553-001-01-1	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	SNKFFCBZYFGCQN-PDVBOLEISA-N	Phase 2
salvinorin-a	opioid receptor agonist	OPRD1, OPRK1, OPRM1			BRD-K19284129-001-02-6	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	OBSYBRPAKCASQB-AGQYDFLVSA-N	Phase 1
sal003	eukaryotic translation initiation factor inhibitor	EIF2A			BRD-A45869167-001-10-0, BRD-A45869167-001-11-8	Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1, Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1	TVNBASWNLOIQML-IZZDOVSWSA-N, TVNBASWNLOIQML-IZZDOVSWSA-N	Preclinical
sanazole					BRD-K37747025-001-08-2	COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O	YKDRHKCETNMLHL-UHFFFAOYSA-N	Phase 1
sangivamycin	DNA inhibitor				BRD-A64064900-001-02-3	NC(=O)c1cn(C2OC(CO)[C@H](O)[C@@H]2O)c2ncnc(N)c12	OBZJZDHRXBKKTJ-HUNIYLEFSA-N	Phase 1
sanguinarium-chloride	apoptosis stimulant	CASP3			BRD-K66898851-003-03-3, BRD-K66898851-003-02-5	C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12, C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12	INVGWHRKADIJHF-UHFFFAOYSA-N, INVGWHRKADIJHF-UHFFFAOYSA-N	Phase 1
SANT-1	smoothened receptor antagonist	SHH, SMO			BRD-K99741577-001-01-7, BRD-K99741577-001-02-5	Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1, Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	FOORCIAZMIWALX-JJIBRWJFSA-N, FOORCIAZMIWALX-JJIBRWJFSA-N	Preclinical
SANT-2	smoothened receptor antagonist	SHH, SMO			BRD-K35781423-001-01-6	CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	VQOJFGFKIVFMDH-UHFFFAOYSA-N	Preclinical
sapropterin	phenylalanine 4-hydroxylase stimulant	NOS3, PAH, TH, TPH1	metabolism	hyperphenylalaninemia (HPA)	BRD-K36859431-300-02-3, BRD-K36859431-300-03-1	C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1, C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)nc(O)c2N1	FNKQXYHWGSIFBK-RPDRRWSUSA-N, FNKQXYHWGSIFBK-RPDRRWSUSA-N	Launched
saquinavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	BRD-A26690767-066-01-9	CC(C)(C)NC(=O)[C@@H]1CC2CCCCC2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	QWAXKHKRTORLEM-LINFGICFSA-N	Launched
SAR-245409	PI3K inhibitor	MTOR, PIK3CG			BRD-K75308783-001-07-0	COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1	HJSSPYJVWLTYHG-UHFFFAOYSA-N	Phase 1/Phase 2
saracatinib	src inhibitor	ABL1, LCK, SRC, YES1			BRD-K19540840-001-09-4	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	OUKYUETWWIPKQR-UHFFFAOYSA-N	Phase 2/Phase 3
sarafloxacin	bacterial DNA gyrase inhibitor				BRD-K08525451-003-05-2, BRD-K08525451-003-06-0	OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O, OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	XBHBWNFJWIASRO-UHFFFAOYSA-N, XBHBWNFJWIASRO-UHFFFAOYSA-N	Launched
sarcosine	Glycine transporter 1 inhibitor	SLC6A9			BRD-K51263939-001-08-6	CNCC(O)=O	FSYKKLYZXJSNPZ-UHFFFAOYSA-N	Phase 2
sari-59-801					BRD-A92448440-001-01-3	CCc1noc(C)c1-c1[nH]c2ccccc2c1C(O)CN(C)C	GMGOZCSXMVXXRS-UHFFFAOYSA-N	Phase 1
saroglitazar	PPAR receptor agonist	PPARA, PPARG			BRD-K79878800-001-01-0	CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O	MRWFZSLZNUJVQW-DEOSSOPVSA-N	Phase 3
sarpogrelate	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C	endocrinology, cardiology, rheumatology	diabetes mellitus, angina pectoris, Raynauds disease, atherosclerosis, Buergers disease	BRD-A34358106-003-01-6	COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(O)=O)c1	FFYNAVGJSYHHFO-UHFFFAOYSA-N	Launched
SAR131675	VEGFR inhibitor	FLT4			BRD-K38904395-001-02-3	CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	PFMPOBVAYMTUOX-GOSISDBHSA-N	Preclinical
SAR405838	MDM inhibitor	MDM2			BRD-A16035238-001-01-7, BRD-K86736469-001-01-3	CC(C)(C)CC1NC(C(c2cccc(Cl)c2F)C11C(=O)Nc2cc(Cl)ccc12)C(=O)NC1CCC(O)CC1, CC(C)(C)C[C@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1	IDKAKZRYYDCJDU-UHFFFAOYSA-N, IDKAKZRYYDCJDU-HEVVSWJASA-N	Phase 1
SAR407899	rho associated kinase inhibitor	ROCK1			BRD-K56912469-003-02-0, BRD-K56912469-003-01-2	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12, O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	IPEXHQGMTHOKQV-UHFFFAOYSA-N, IPEXHQGMTHOKQV-UHFFFAOYSA-N	Phase 2
sasapyrine	NFkB pathway inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	BRD-K48892307-001-04-1, BRD-K48892307-001-05-8	OC(=O)c1ccccc1OC(=O)c1ccccc1O, OC(=O)c1ccccc1OC(=O)c1ccccc1O	WVYADZUPLLSGPU-UHFFFAOYSA-N, WVYADZUPLLSGPU-UHFFFAOYSA-N	Launched
satraplatin	DNA alkylating agent				BRD-K42497885-001-01-1	CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O	JWTNVKZACPRKPF-UHFFFAOYSA-J	Phase 3
savolitinib	c-Met inhibitor	MET			BRD-K98028353-001-01-0	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1	XYDNMOZJKOGZLS-NSHDSACASA-N	Phase 2
saxagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-A82156122-001-01-9	N[C@H](C(=O)N1[C@@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2	QGJUIPDUBHWZPV-BBIKMUCQSA-N	Launched
SB-200646	serotonin receptor antagonist	HTR2B, HTR2C			BRD-K77677632-003-02-6	Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	OJZZJTLBYXHUSJ-UHFFFAOYSA-N	Preclinical
SB-202190	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			BRD-K54330070-001-15-4, BRD-K54330070-001-19-6, BRD-K54330070-001-16-2	Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1	QHKYPYXTTXKZST-UHFFFAOYSA-N, QHKYPYXTTXKZST-UHFFFAOYSA-N, QHKYPYXTTXKZST-UHFFFAOYSA-N	Preclinical
SB-203186	serotonin receptor antagonist	HTR4			BRD-K27141178-003-07-3	O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	YGKPIROTKVQCCU-UHFFFAOYSA-N	Preclinical
SB-203580	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF			BRD-A37704979-001-10-7, BRD-A37704979-003-02-0, BRD-A37704979-001-12-3, BRD-A37704979-001-09-9, BRD-A37704979-001-13-1	CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1, CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1	CDMGBJANTYXAIV-UHFFFAOYSA-N, CDMGBJANTYXAIV-UHFFFAOYSA-N, CDMGBJANTYXAIV-UHFFFAOYSA-N, CDMGBJANTYXAIV-UHFFFAOYSA-N, CDMGBJANTYXAIV-UHFFFAOYSA-N	Preclinical
SB-205384	GABA receptor modulator	GABRA3, GABRA5, GABRA6			BRD-A22707317-001-10-8	CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N	JDTZAGLGBRRCJT-UHFFFAOYSA-N	Preclinical
SB-206553	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K36395411-003-02-2	Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	QJQORSLQNXDVGE-UHFFFAOYSA-N	Preclinical
SB-216641	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			BRD-K30867024-003-03-3	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	JRNUKVFYILMMLX-UHFFFAOYSA-N	Preclinical
SB-216763	glycogen synthase kinase inhibitor	CCNA2, CDK2, GSK3A, GSK3B			BRD-K59184148-001-21-6, BRD-K59184148-001-22-4	Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12, Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12	JCSGFHVFHSKIJH-UHFFFAOYSA-N, JCSGFHVFHSKIJH-UHFFFAOYSA-N	Preclinical
SB-218078	CHK inhibitor	CHEK1			BRD-A06352508-001-05-2, BRD-A06352508-001-03-7	O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13, O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13	OTPNDVKVEAIXTI-UHFFFAOYSA-N, OTPNDVKVEAIXTI-UHFFFAOYSA-N	Preclinical
SB-218795	tachykinin antagonist	TACR3			BRD-K61097567-001-08-5	COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	IUMQXQJZIHWLIN-HSZRJFAPSA-N	Preclinical
SB-221284	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K14807180-001-02-5	CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	OQZOXHCRSXYSPM-UHFFFAOYSA-N	Preclinical
SB-222200	tachykinin antagonist	TACR3			BRD-K04414442-001-08-3	CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	MQNYRKWJSMQECI-QFIPXVFZSA-N	Preclinical
SB-225002	CC chemokine receptor antagonist	CXCR2			BRD-K61323504-001-04-0	Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	MQBZVUNNWUIPMK-UHFFFAOYSA-N	Preclinical
SB-228357	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K15424032-001-03-6	COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	RRJLJKRFFRZRAF-UHFFFAOYSA-N	Preclinical
SB-2343	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K98795921-001-01-7	CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	QYBGBLQCOOISAR-UHFFFAOYSA-N	Phase 1
SB-239063	p38 MAPK inhibitor	MAPK11, MAPK14, PTGS2			BRD-K82091397-001-03-0	COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1	ZQUSFAUAYSEREK-WKILWMFISA-N	Preclinical
SB-242235	p38 MAPK inhibitor	HSPB1, MAPK14			BRD-K19412355-001-01-0	COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	PDTYLGXVBIWRIM-UHFFFAOYSA-N	Phase 1
SB-258585	serotonin receptor antagonist	HTR6			BRD-K80639402-003-02-9	COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	BDHMSYNBSBZCAF-UHFFFAOYSA-N	Preclinical
SB-269970	serotonin receptor antagonist	HTR7			BRD-K24201553-003-11-5, BRD-K24201553-003-10-7	CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1, CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	HWKROQUZSKPIKQ-MRXNPFEDSA-N, HWKROQUZSKPIKQ-MRXNPFEDSA-N	Preclinical
SB-271046	serotonin receptor antagonist	HTR6			BRD-K82467063-001-02-7	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	LOCQRDBFWSXQQI-UHFFFAOYSA-N	Phase 1
SB-328437	CCR antagonist				BRD-K78720403-001-01-6	COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	VMFGCGRAIBLAFY-IBGZPJMESA-N	Preclinical
SB-334867	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K41567364-001-04-6	Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	AKMNUCBQGHFICM-UHFFFAOYSA-N	Preclinical
SB-366791	TRPV antagonist	TRPV1			BRD-K61536336-001-01-7	COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	RYAMDQKWNKKFHD-JXMROGBWSA-N	Preclinical
SB-408124	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K53913732-001-06-7, BRD-K53913732-001-05-9, BRD-K53913732-001-04-2	CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1, CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N, JTARFZSNUAGHRB-UHFFFAOYSA-N	Preclinical
SB-415286	glycogen synthase kinase inhibitor	GSK3A, GSK3B, RPS6KB1			BRD-K76805682-001-17-5, BRD-K76805682-001-15-9, BRD-K76805682-001-16-7	Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl, Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl	PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N, PQCXVIPXISBFPN-UHFFFAOYSA-N	Preclinical
SB-431542	TGF beta receptor inhibitor	ACVR1C, TGFBR1			BRD-K67298865-001-09-0, BRD-K67298865-001-08-2	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1, NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1	FHYUGAJXYORMHI-UHFFFAOYSA-N, FHYUGAJXYORMHI-UHFFFAOYSA-N	Preclinical
SB-505124	ALK tyrosine kinase receptor inhibitor	TGFBR1			BRD-K40109029-001-02-9	Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2OCOc2c1)C(C)(C)C	WGZOTBUYUFBEPZ-UHFFFAOYSA-N	Preclinical
SB-525334	TGF beta receptor inhibitor	TGFBR1			BRD-K37720887-001-08-6, BRD-K37720887-001-07-8	Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C, Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C	DKPQHFZUICCZHF-UHFFFAOYSA-N, DKPQHFZUICCZHF-UHFFFAOYSA-N	Preclinical
SB-590885	RAF inhibitor	BRAF			BRD-K01253243-001-03-0, BRD-K78809024-001-02-4, BRD-K78809024-001-03-2	CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N\O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1, CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2c(CC\C2=N/O)c1)-c1ccncc1	MLSAQOINCGAULQ-QLTSDVKISA-N, MLSAQOINCGAULQ-QFMPWRQOSA-N, MLSAQOINCGAULQ-QFMPWRQOSA-N	Preclinical
SB-657510	urotensin receptor antagonist	UTS2R			BRD-K95292280-001-01-3	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	KQCZCINJGIRLCD-CYBMUJFWSA-N	Preclinical
SB-683698	integrin antagonist	ITGA4, ITGAV, ITGB1, ITGB7			BRD-K24968862-001-01-0	COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	DRSJLVGDSNWQBI-SFHVURJKSA-N	Phase 1
SB-705498	TRPV antagonist	TRPV1			BRD-K65991129-001-02-9	FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	JYILLRHXRVTRSH-GFCCVEGCSA-N	Phase 2
SB-742457	serotonin receptor antagonist	HTR6			BRD-K78941306-001-03-2, BRD-K78941306-001-02-4	O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1, O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	JJZFWROHYSMCMU-UHFFFAOYSA-N, JJZFWROHYSMCMU-UHFFFAOYSA-N	Phase 3
SB-743921	kinesin-like spindle protein inhibitor	KIF11			BRD-K68532323-003-05-1, BRD-K68532323-003-02-8	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	PGXYIBJJCLWJST-MUUNZHRXSA-N, PGXYIBJJCLWJST-MUUNZHRXSA-N	Phase 1/Phase 2
SB-756050	G protein-coupled receptor agonist	GPBAR1			BRD-K45168550-001-01-9	COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	GJUFPAZNBPFNRI-UHFFFAOYSA-N	Phase 1
SB-939	HDAC inhibitor	HDAC1, HDAC10, HDAC3, HDAC4, HDAC5, HDAC9			BRD-K86797399-001-05-1, BRD-K86797399-001-04-4	CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO, CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO	JHDKZFFAIZKUCU-ZRDIBKRKSA-N, JHDKZFFAIZKUCU-ZRDIBKRKSA-N	Phase 2
SC-10	protein kinase activator	PRKCA			BRD-K05361803-001-03-9	CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	MJMJERJFCHYXEM-UHFFFAOYSA-N	Preclinical
SC-12267	dihydroorotate dehydrogenase inhibitor	IL17A			BRD-K40797222-001-01-8	COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1	XPRDUGXOWVXZLL-UHFFFAOYSA-N	Phase 2
SC-144	P glycoprotein inhibitor				BRD-K55305701-001-02-0, BRD-K55305701-001-01-2	Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21, Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	UEADAWQSJOWXBK-UHFFFAOYSA-N, UEADAWQSJOWXBK-UHFFFAOYSA-N	Preclinical
SC-19220	prostanoid receptor antagonist	PTGER1			BRD-K52512893-001-08-9	CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	KNURFLJTOUGOOQ-UHFFFAOYSA-N	Preclinical
SC-560	cyclooxygenase inhibitor	PTGS1			BRD-K14767410-001-02-3	COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	PQUGCKBLVKJMNT-UHFFFAOYSA-N	Preclinical
SC-9	protein tyrosine kinase activator	PRKCA			BRD-K25875056-001-02-0	Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	YUXMTDYHFPRPLG-UHFFFAOYSA-N	Preclinical
SCH-202676	G protein-coupled receptor modulator	CHRM1, CHRM2, DRD1, DRD2			BRD-K29562203-004-08-3	CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	FFUBTEITUNMMOK-UHFFFAOYSA-N	Preclinical
SCH-23390	dopamine receptor antagonist	DRD1, DRD5, HTR2C, KCNJ4, KCNJ6			BRD-K45435259-003-11-1	CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	GOTMKOSCLKVOGG-OAHLLOKOSA-N	Preclinical
SCH-28080	ATPase inhibitor	ATP4A			BRD-K55748775-001-02-2	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	PYKJFEPAUKAXNN-UHFFFAOYSA-N	Phase 1
SCH-58261	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K81225797-001-02-3	Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	UTLPKQYUXOEJIL-UHFFFAOYSA-N	Preclinical
SCH-900776	CHK inhibitor	CDK2, CHEK1			BRD-K75009076-001-02-1, BRD-K75009076-001-01-3	Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	GMIZZEXBPRLVIV-SECBINFHSA-N, GMIZZEXBPRLVIV-SECBINFHSA-N	Phase 2
schisandrin-b	antioxidant	ATR			BRD-K86294588-001-01-9	COc1cc2C[C@H](C)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	RTZKSTLPRTWFEV-STQMWFEESA-N	Preclinical
schisandrol-b	lipid peroxidase inhibitor				BRD-K18878288-001-06-4, BRD-K18878288-001-07-2	COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC, COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	ZWRRJEICIPUPHZ-MYODQAERSA-N, ZWRRJEICIPUPHZ-MYODQAERSA-N	Phase 3
sclareol					BRD-A23127772-001-02-3	CC(O)(CC[C@H]1[C@](C)(O)CCC2C(C)(C)CCC[C@]12C)C=C	XVULBTBTFGYVRC-ANXRZQSGSA-N	Preclinical
sclareolide	other antifungal				BRD-K35504063-001-01-7, BRD-K72925150-001-10-3	C[C@@]12CC[C@H]3C(C)(C)CCC[C@@]3(C)[C@H]1CC(=O)O2, C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	IMKJGXCIJJXALX-UAXWRAGISA-N, IMKJGXCIJJXALX-SHUKQUCYSA-N	Launched
SCMC-Lys	mucolytic agent	GSTP1			BRD-K33809398-001-01-8	N[C@@H](CSCC(O)=O)C(O)=O	GBFLZEXEOZUWRN-VKHMYHEASA-N	Launched
scopine					BRD-K75923785-001-02-5, BRD-K75923785-003-02-1	CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21, CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	FIMXSEMBHGTNKT-RZVDLVGDSA-N, FIMXSEMBHGTNKT-RZVDLVGDSA-N	Launched
scopolamine	acetylcholine receptor antagonist		neurology/psychiatry, gastroenterology	motion sickness, vomiting, nausea	BRD-A62035778-004-03-6, BRD-K89923877-004-16-2, BRD-K89923877-004-15-4	CN1C2C[C@@H](C[C@H]1[C@H]1OC21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1, CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	STECJAGHUSJQJN-WLQVYHSDSA-N, STECJAGHUSJQJN-FWXGHANASA-N, STECJAGHUSJQJN-FWXGHANASA-N	Launched
scopolamine-n-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI			BRD-A49906757-004-09-8	C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	GSYQNAMOFFWAPF-PPOBMCMBSA-N	Preclinical
SCP-1	analgesic agent				BRD-K20548681-001-01-3	Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	PUPNJSIFIXXJCH-UHFFFAOYSA-N	Phase 1
scriptaid	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			BRD-K22503835-001-11-0, BRD-K22503835-001-12-8	ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23, ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	JTDYUFSDZATMKU-UHFFFAOYSA-N, JTDYUFSDZATMKU-UHFFFAOYSA-N	Preclinical
SCS					BRD-K78496197-001-03-9	Oc1ccccc1\C=N\NC(=O)c1ccccc1O	OMCYEZUIYGPHDJ-OQLLNIDSSA-N	Preclinical
SD-169	p38 MAPK inhibitor	MAPK14			BRD-K91904471-001-02-4	NC(=O)c1ccc2[nH]ccc2c1	GQMYQEAXTITUAE-UHFFFAOYSA-N	Preclinical
SD-208	TGF beta receptor inhibitor	TGFBR1			BRD-K24566386-001-01-9, BRD-K24566386-001-03-5	Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1, Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	BERLXWPRSBJFHO-UHFFFAOYSA-N, BERLXWPRSBJFHO-UHFFFAOYSA-N	Preclinical
SDM25N	opioid receptor antagonist	OPRD1			BRD-A75769826-003-02-1	CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O	ZFMVWAWSKLAVOE-OOGIKFLQSA-N	Preclinical
SDZ-NKT-343	tachykinin antagonist	TACR1			BRD-K65820248-001-01-8	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	PCVSIMQAFWRUEC-JDXGNMNLSA-N	Phase 1
SDZ-SER-082	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K31339597-051-02-0	CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34	YASBOGFWAMXINH-TZMCWYRMSA-N	Preclinical
SDZ-WAG-994	adenosine receptor agonist	ADORA1			BRD-K39558284-001-01-2	CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	JAKAFSGZUXCHLF-LSCFUAHRSA-N	Phase 2
SDZ-205-557	serotonin receptor antagonist	HTR3A, HTR3B			BRD-K15868788-003-07-7	CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	FFNWMBDISAYHDC-UHFFFAOYSA-N	Preclinical
SDZ-21009	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A, HTR1B			BRD-A15530910-001-02-1	CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1	SJYFDORQYYEJLB-UHFFFAOYSA-N	Preclinical
SDZ-220-040	glutamate receptor antagonist	GRIN1			BRD-K82266792-001-02-1	N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O	NYZFUZCCDOSQBG-AWEZNQCLSA-N	Preclinical
SDZ-220-581	glutamate receptor antagonist	GRIN1			BRD-K27168049-001-02-8	N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	VBRJFXSFCYEZMQ-HNNXBMFYSA-N	Preclinical
se-methylselenocysteine					BRD-K74227499-001-01-1	C[Se]C[C@H](N)C(O)=O	XDSSPSLGNGIIHP-VKHMYHEASA-N	Phase 2
secalciferol	vitamin D receptor agonist	VDR	critical care	bone fracture	BRD-K02965577-001-03-4	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C	FCKJYANJHNLEEP-XRWYNYHCSA-N	Launched
seclazone	anti-inflammatory agent				BRD-A53472930-001-01-7	Clc1ccc2OC3CCON3C(=O)c2c1	XWXVKXXKKLBDDJ-UHFFFAOYSA-N	Phase 1
secnidazole	acetylcholinesterase inhibitor, microtubule inhibitor		infectious disease	protozoan infection	BRD-A70083328-001-24-3, BRD-A70083328-001-23-5, BRD-A70083328-001-22-7	CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O, CC(O)Cn1c(C)ncc1[N+]([O-])=O	KPQZUUQMTUIKBP-UHFFFAOYSA-N, KPQZUUQMTUIKBP-UHFFFAOYSA-N, KPQZUUQMTUIKBP-UHFFFAOYSA-N	Launched
secoisolariciresinol-(-)					BRD-K91733562-001-05-0	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	PUETUDUXMCLALY-HOTGVXAUSA-N	Preclinical
secoisolariciresinol-diglucoside	antioxidant				BRD-K77320845-001-01-2	COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O	SBVBJPHMDABKJV-PGCJWIIOSA-N	Phase 2
securinine	GABA receptor antagonist, TP53 activator	GABRA1			BRD-K49071277-001-04-7	O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31	SWZMSZQQJRKFBP-WZRBSPASSA-N	Preclinical
selamectin	nematocide		infectious disease	flea control	BRD-A58564983-001-04-6	CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O	AFJYYKSVHJGXSN-XUCDQRGXSA-N	Launched
selegiline	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	Parkinsons Disease" "BRD-A28545468-003-16-6" "CC(Cc1ccccc1)N(C)CC" "" ""
"2457" "selenomethionine" "" "" "" "" "BRD-A18774709-001-01-9, BRD-K74664543-213-01-2" "C[Se]CCC(N)C(O)=O, C[Se]CC[C@H](N)C(O)=O" "RJFAYQIBOAGBLC-UHFFFAOYSA-N, RJFAYQIBOAGBLC-BYPYZUCNSA-N" "Launched"
"2458" "selexipag" "platelet aggregation inhibitor, IP1 prostacyclin receptor agonist" "PTGIR" "" "" "BRD-K21191422-001-01-5" "CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1" "QXWZQTURMXZVHJ-UHFFFAOYSA-N" "Phase 3"
"2459" "selfotel" "glutamate receptor antagonist" "GRIN2A, GRIN2B, GRIN2C, GRIN2D" "" "" "BRD-K48738253-001-02-4" "OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1" "LPMRCCNDNGONCD-NTSWFWBYSA-N" "Phase 3"
"2460" "selinexor" "exportin antagonist" "XPO1" "" "" "BRD-K21361524-001-01-1" "FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1" "DEVSOMFAQLZNKR-RJRFIUFISA-N" "Phase 2/Phase 3"
"2461" "selumetinib" "MEK inhibitor" "MAP2K1" "" "" "BRD-K57080016-001-19-1, BRD-K57080016-001-15-9" "Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO" "CYOHGALHFOKKQC-UHFFFAOYSA-N, CYOHGALHFOKKQC-UHFFFAOYSA-N" "Phase 3"
"2462" "semagacestat" "gamma secretase inhibitor" "PSEN1" "" "" "BRD-K81957469-001-01-0" "CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1c2ccccc2CCN(C)C1=O" "PKXWXXPNHIWQHW-MAZHCROVSA-N" "Phase 3"
"2463" "semapimod" "cytokine production inhibitor, p38 MAPK inhibitor" "MAPK14" "" "" "BRD-K21237892-376-01-3" "NC(=N)NNC(=C)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(=C)NNC(N)=N)C(=C)NNC(N)=N)cc(c1)C(=C)NNC(N)=N" "UPKULXKXQDCEPE-UHFFFAOYSA-N" "Phase 2"
"2464" "semaxanib" "VEGFR inhibitor" "FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET" "" "" "BRD-K63504947-001-15-4, BRD-K63504947-001-17-0, BRD-K63504947-001-16-2, BRD-K63504947-001-14-7" "Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1" "WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N" "Phase 3"
"2465" "semustine" "DNA alkylating agent" "" "" "" "BRD-K13281575-001-13-4, BRD-K13281575-001-14-2" "CC1CCC(CC1)NC(=O)N(CCCl)[N+][O-], CC1CCC(CC1)NC(=O)N(CCCl)[N+][O-]" "FVLVBPDQNARYJU-UHFFFAOYSA-N, FVLVBPDQNARYJU-UHFFFAOYSA-N" "Phase 3"
"2466" "senicapoc" "intermediate conductance potassium channel blocker" "KCNN4" "" "" "BRD-K21295289-001-01-6" "NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1" "SCTZUZTYRMOMKT-UHFFFAOYSA-N" "Phase 3"
"2467" "sennoside-a" "glycoside agonist" "" "gastroenterology" "constipation" "BRD-A30370660-001-04-1" "OC[C@H]1O[C@H](Oc2cccc3C([C@H]4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5C(=O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4C(=O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O" "IPQVTOJGNYVQEO-FPJYKMGYSA-N" "Launched"
"2468" "sennoside-protonated" "" "" "" "" "BRD-A53504839-001-01-9" "OCC1OC(Oc2cccc3c(-c4c5cccc(OC6OC(CO)C(O)C(O)C6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)C(O)C(O)C1O" "QFJIQUOMKJNYLI-UHFFFAOYSA-N" "Preclinical"
"2469" "seocalcitol" "vitamin D receptor agonist" "VDR" "" "" "BRD-K28456624-001-01-1" "CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C" "LVLLALCJVJNGQQ-SEODYNFXSA-N" "Phase 3"
"2470" "SEP-227900" "D-Amino Acid Oxidase Inhibitor" "DAO" "" "" "BRD-K49504902-001-01-6" "OC(=O)c1cc2occc2[nH]1" "MMAIBGHDBYQYDI-UHFFFAOYSA-N" "Phase 1"
"2471" "seratrodast" "prostanoid receptor antagonist" "TBXA2R" "pulmonary" "asthma" "BRD-A60765580-001-01-8, BRD-A60765580-001-02-6" "CC1=C(C)C(=O)C(C(CCCCCC(O)=O)c2ccccc2)=C(C)C1=O, CC1=C(C)C(=O)C(C(CCCCCC(O)=O)c2ccccc2)=C(C)C1=O" "ZBVKEHDGYSLCCC-UHFFFAOYSA-N, ZBVKEHDGYSLCCC-UHFFFAOYSA-N" "Launched"
"2472" "serdemetan" "MDM inhibitor" "MDM2" "" "" "BRD-K65924316-001-07-2, BRD-K65924316-001-03-1" "C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1, C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1" "CEGSUKYESLWKJP-UHFFFAOYSA-N, CEGSUKYESLWKJP-UHFFFAOYSA-N" "Phase 1"
"2473" "serotonin" "growth factor receptor activator" "DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1" "neurology/psychiatry" "anxiety, depression, sleeplessness" "BRD-K38580127-003-15-4, BRD-K38580127-003-17-0, BRD-K38580127-003-16-2" "NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12, NCCc1c[nH]c2ccc(O)cc12" "QZAYGJVTTNCVMB-UHFFFAOYSA-N, QZAYGJVTTNCVMB-UHFFFAOYSA-N, QZAYGJVTTNCVMB-UHFFFAOYSA-N" "Launched"
"2474" "sertaconazole" "sterol demethylase inhibitor" "" "infectious disease" "tinea pedis" "BRD-A95939040-001-01-2" "Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1" "JLGKQTAYUIMGRK-UHFFFAOYSA-N" "Launched"
"2475" "sertindole" "dopamine receptor antagonist, serotonin receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2" "" "" "BRD-K69116396-001-04-1" "Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12" "GZKLJWGUPQBVJQ-UHFFFAOYSA-N" "Withdrawn"
"2476" "sertraline" "selective serotonin reuptake inhibitor (SSRI)" "SLC6A3, SLC6A4" "neurology/psychiatry, obstetrics/gynecology" "depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder" "BRD-K70464547-003-01-2, BRD-K82036761-003-16-1, BRD-K82036761-003-17-9" "CN[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12, CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12" "VGKDLMBJGBXTGI-YVEFUNNKSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N, VGKDLMBJGBXTGI-SJCJKPOMSA-N" "Launched"
"2477" "sesamin" "NFkB pathway inhibitor" "" "" "" "BRD-K11631773-001-10-8, BRD-K04837843-001-01-5" "C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1, C1Oc2ccc(cc2O1)[C@H]1OC[C@@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1" "PEYUIKBAABKQKQ-AFHBHXEDSA-N, PEYUIKBAABKQKQ-RYMBOPBQSA-N" "Preclinical"
"2478" "setipiprant" "prostaglandin inhibitor" "PTGDR2" "" "" "BRD-K24497734-001-01-6" "OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12" "IHAXLPDVOWLUOS-UHFFFAOYSA-N" "Phase 3"
"2479" "setiptiline" "adrenergic receptor antagonist" "HRH1, HTR2A, HTR2C" "neurology/psychiatry" "depression" "BRD-K36732695-001-01-9" "CN1CCC2=C(C1)c1ccccc1Cc1ccccc21" "GVPIXRLYKVFFMK-UHFFFAOYSA-N" "Launched"
"2480" "sevelamer" "phosphate antagonist" "" "nephrology" "chronic kidney disease (CKD)" "BRD-M22581557-003-02-5, BRD-U45393375-000-01-6" "NCC=C.ClCC1CO1, " "ZNSIZMQNQCNRBW-UHFFFAOYSA-N, " "Launched"
"2481" "sevoflurane" "membrane integrity inhibitor" "ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1" "neurology/psychiatry" "anesthetic" "BRD-K05638300-001-01-2" "FCOC(C(F)(F)F)C(F)(F)F" "DFEYYRMXOJXZRJ-UHFFFAOYSA-N" "Launched"
"2482" "SEW-2871" "lysophospholipid receptor agonist" "S1PR1" "" "" "BRD-K15601958-001-03-9" "FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F" "OYMNPJXKQVTQTR-UHFFFAOYSA-N" "Preclinical"
"2483" "SGC-CBP30" "bromodomain inhibitor" "CREBBP, EP300" "" "" "BRD-K24821794-001-01-4" "COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl" "GEPYBHCJBORHCE-SFHVURJKSA-N" "Preclinical"
"2484" "SGC-0946" "histone lysine methyltransferase inhibitor" "" "" "" "BRD-K69577666-001-01-3" "CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12" "IQCKJUKAQJINMK-HUBRGWSESA-N" "Preclinical"
"2485" "SGI-1027" "DNA methyltransferase inhibitor" "DNMT1, DNMT3A, DNMT3B" "" "" "BRD-K61228301-001-01-2" "Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1" "QSYLKMKIVWJAAK-UHFFFAOYSA-N" "Preclinical"
"2486" "SGI-1776" "Pim kinase inhibitor" "FLT3, PIM1, PIM2, PIM3" "" "" "BRD-K80700417-001-04-2" "CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1" "MHXGEROHKGDZGO-UHFFFAOYSA-N" "Phase 1"
"2487" "SGX523" "hepatocyte growth factor receptor inhibitor" "MET" "" "" "BRD-K19477839-001-07-6" "Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1" "BCZUAADEACICHN-UHFFFAOYSA-N" "Phase 1"
"2488" "shikimic-acid" "" "" "" "" "BRD-A92096630-001-02-8" "O[C@@H]1CC(=CC(O)C1O)C(O)=O" "JXOHGGNKMLTUBP-INWUZDNDSA-N" "Preclinical"
"2489" "SIB-1553A" "acetylcholine receptor agonist" "CHRNB4" "" "" "BRD-A79052425-003-01-5" "CN1CCCC1CCSc1ccc(O)cc1" "NVZGJSVPOOILDI-UHFFFAOYSA-N" "Phase 2"
"2490" "SIB-1757" "glutamate receptor antagonist" "GRM5" "" "" "BRD-K98157055-001-10-9" "Cc1ccc(O)c(N=Nc2ccccc2)n1" "LOCPVWIREQIGNQ-UHFFFAOYSA-N" "Preclinical"
"2491" "SIB-1893" "glutamate receptor antagonist" "GRM4, GRM5" "" "" "BRD-K14561059-001-05-9" "Cc1cccc(\C=C\c2ccccc2)n1" "SISOFUCTXZKSOQ-ZHACJKMWSA-N" "Preclinical"
"2492" "sibutramine" "serotonin–norepinephrine reuptake inhibitor (SNRI)" "SLC6A2, SLC6A3, SLC6A4" "" "" "BRD-A23359898-003-10-0, BRD-A23359898-003-11-8" "CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1, CC(C)CC(N(C)C)C1(CCC1)c1ccc(Cl)cc1" "UNAANXDKBXWMLN-UHFFFAOYSA-N, UNAANXDKBXWMLN-UHFFFAOYSA-N" "Withdrawn"
"2493" "SID-7969543" "steroidogenic factor antagonist" "NR5A1" "" "" "BRD-A43885598-001-08-1" "CCOC(=O)C(C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O" "KWMBIIQCLUIHDI-UHFFFAOYSA-N" "Preclinical"
"2494" "siguazodan" "phosphodiesterase inhibitor" "PDE3A" "" "" "BRD-A62071884-001-04-6" "CN\C(NC" "" ""
"2495" "sildenafil" "phosphodiesterase inhibitor" "PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3" "cardiology" "hypertension" "BRD-K79759585-048-04-8, BRD-K79759585-048-03-0" "CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1, CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1" "BNRNXUUZRGQAQC-UHFFFAOYSA-N, BNRNXUUZRGQAQC-UHFFFAOYSA-N" "Launched"
"2496" "silibinin" "cytochrome P450 inhibitor" "ALOX5" "gastroenterology" "hepatic cirrhosis" "BRD-K80353138-001-12-1, BRD-K80353138-001-13-9, BRD-K47267049-001-01-6" "COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O, COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O" "SEBFKMXJBCUCAI-HKTJVKLFSA-N, SEBFKMXJBCUCAI-HKTJVKLFSA-N, SEBFKMXJBCUCAI-YFJHUXEUSA-N" "Launched"
"2497" "silodosin" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D" "urology" "benign prostatic hyperplasia (BPH)" "BRD-K10906636-001-02-9, BRD-K10906636-001-01-1" "C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F, C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F" "PNCPYILNMDWPEY-QGZVFWFLSA-N, PNCPYILNMDWPEY-QGZVFWFLSA-N" "Launched"
"2498" "silver-sulfadiazine" "PABA antagonist" "" "critical care" "sepsis" "BRD-K68379918-001-01-1, BRD-M11664367-001-01-8" "Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1, [Ag+].Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1" "UEJSSZHHYBHCEL-UHFFFAOYSA-N, FFNALGMMTUDHGT-UHFFFAOYSA-N" "Launched"
"2499" "silymarin" "" "" "" "" "BRD-A06629414-001-03-1, BRD-A06629414-001-02-3" "COc1cc(ccc1O)C1Oc2ccc(cc2OC1CO)C1Oc2cc(O)cc(O)c2C(=O)C1O, COc1cc(ccc1O)C1Oc2ccc(cc2OC1CO)C1Oc2cc(O)cc(O)c2C(=O)C1O" "FDQAOULAVFHKBX-UHFFFAOYSA-N, FDQAOULAVFHKBX-UHFFFAOYSA-N" "Launched"
"2500" "simeprevir" "HCV inhibitor" "CYP1A2, CYP3A4" "infectious disease" "hepatitis C" "BRD-A68493689-001-01-9" "COc1ccc2c(O[C@@H]3C[C@@H]4C(C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C" "JTZZSQYMACOLNN-SNWGISBASA-N" "Launched"
"2501" "simvastatin" "HMGCR inhibitor" "HMGCR, ITGB2" "endocrinology, cardiology, neurology/psychiatry" "hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia" "BRD-K22134346-001-24-9, BRD-K22134346-001-22-3, BRD-K22134346-001-21-5, BRD-K94986873-001-01-4" "CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12, CCC(C)(C)C(=O)O[C@@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12" "RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-HGQWONQESA-N, RYMZZMVNJRMUDD-XOWITSDISA-N" "Launched"
"2502" "sinefungin" "DNA methyltransferase inhibitor, RNA synthesis inhibitor" "CARM1" "" "" "BRD-K91100918-001-03-8" "N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12" "LMXOHSDXUQEUSF-YECHIGJVSA-N" "Preclinical"
"2503" "sinomenine" "angiogenesis inhibitor" "" "" "" "BRD-K83459933-001-05-4" "COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O" "INYYVPJSBIVGPH-QHRIQVFBSA-N" "Preclinical"
"2504" "sipatrigine" "voltage-gated sodium channel blocker" "CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A" "" "" "BRD-K53195974-001-01-9" "CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl" "PDOCBJADCWMDGL-UHFFFAOYSA-N" "Phase 2"
"2505" "siponimod" "sphingosine phosphate receptor modulator" "S1PR1" "" "" "BRD-K62384160-001-02-0, BRD-K62384160-001-01-2" "CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F, CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F" "KIHYPELVXPAIDH-HNSNBQBZSA-N, KIHYPELVXPAIDH-HNSNBQBZSA-N" "Phase 3"
"2506" "siramesine" "sigma receptor antagonist" "ADRA1A, ADRA1B, ADRA1D" "" "" "BRD-K51333959-003-01-3" "Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12" "XWAONOGAGZNUSF-UHFFFAOYSA-N" "Phase 2"
"2507" "sirolimus" "mTOR inhibitor" "FGF2, FKBP1A, MTOR" "transplant, pulmonary" "organ rejection, lymphangioleiomyomatosis" "BRD-K84937637-001-13-1, BRD-K84937637-001-09-9, BRD-K84937637-001-11-5, BRD-A79768653-001-12-0" "CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O, COC1CC(CC(C)C2CC(=O)C(C)\C=C(C)\C(O)C(OC)C(=O)C(C)CC(C)\C=C\C=C\C=C(C)\C(CC3CCC(C)C(O)(O3)C(=O)C(=O)N3CCCCC3C(=O)O2)OC)CCC1O" "QFJCIRLUMZQUOT-HPLJOQBZSA-N, QFJCIRLUMZQUOT-HPLJOQBZSA-N, QFJCIRLUMZQUOT-HPLJOQBZSA-N, QFJCIRLUMZQUOT-XWBLMERNSA-N" "Launched"
"2508" "sirtinol" "SIRT inhibitor" "SIRT1, SIRT2" "" "" "BRD-A23747351-001-06-8, BRD-A23747351-001-05-0, BRD-A23747351-001-07-6" "CC(NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1, CC(NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1, CC(NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1" "UXJFDYIHRJGPFS-WPWMEQJKSA-N, UXJFDYIHRJGPFS-WPWMEQJKSA-N, UXJFDYIHRJGPFS-WPWMEQJKSA-N" "Preclinical"
"2509" "sisomicin" "protein synthesis inhibitor" "" "ophthalmology" "conjunctivitis, punctate keratitis, conjunctivitis, punctate keratitis" "BRD-A29840884-001-01-2, BRD-M47753525-343-01-2" "CNC1C(O)C(OC2C(N)CC(N)C(OC3OC(CN)=CCC3N)C2O)OCC1(C)O, CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O" "URWAJWIAIPFPJE-UHFFFAOYSA-N, GXQFWSKFVUKJCP-UNKNZERLSA-N" "Launched"
"2510" "sisomicin-sulfate" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-A68997559-065-04-5" "CN[C@@H]1C(O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O" "URWAJWIAIPFPJE-JYERGDCNSA-N" "Launched"
"2511" "sitafloxacin" "bacterial DNA gyrase inhibitor" "" "infectious disease" "buruli ulcer" "BRD-K10836013-001-01-3" "N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F" "PNUZDKCDAWUEGK-CYZMBNFOSA-N" "Launched"
"2512" "sitagliptin" "dipeptidyl peptidase inhibitor" "DPP4" "endocrinology" "diabetes mellitus" "BRD-K19416115-001-05-3, BRD-K19416115-366-02-7" "N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F, N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F" "MFFMDFFZMYYVKS-SECBINFHSA-N, MFFMDFFZMYYVKS-SECBINFHSA-N" "Launched"
"2513" "sitaxentan" "endothelin receptor antagonist" "EDNRA" "" "" "BRD-K63806092-236-04-2, BRD-K63806092-236-05-9, BRD-K63806092-236-02-6, BRD-K63806092-236-03-4" "Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl, Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl" "PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N, PHWXUGHIIBDVKD-UHFFFAOYSA-N" "Withdrawn"
"2514" "sitosterol" "" "" "" "" "BRD-K16553588-001-01-3, BRD-K79402892-001-06-7" "CC[C@H](CC[C@@H](C)[C@@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C, CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C" "KZJWDPNRJALLNS-AIEITSGWSA-N, KZJWDPNRJALLNS-VJSFXXLFSA-N" "Preclinical"
"2515" "sivelestat" "elastase inhibitor" "CELA1, ELANE" "pulmonary" "acute lung injury" "BRD-K02152879-414-02-1, BRD-K02152879-414-01-3" "CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O, CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O" "BTGNGJJLZOIYID-UHFFFAOYSA-N, BTGNGJJLZOIYID-UHFFFAOYSA-N" "Launched"
"2516" "SJ-172550" "MDM inhibitor" "MDM4" "" "" "BRD-K35945299-001-02-6" "CCOc1cc(\C=C2C(=O)N(N=C\2C)c2ccccc2)cc(Cl)c1OCC(=O)OC" "RKKFQJXGAQWHBZ-LICLKQGHSA-N" "Preclinical"
"2517" "SK&F-10047-(+)" "sigma receptor agonist" "SIGMAR1" "" "" "BRD-A47364545-003-02-6" "C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C" "LGQCVMYAEFTEFN-VUOHQMJNSA-N" "Phase 1"
"2518" "SKA-31" "potassium channel activator" "KCNN4" "" "" "BRD-K67304264-001-08-5" "Nc1nc2c(ccc3ccccc23)s1" "FECQXVPRUCCUIL-UHFFFAOYSA-N" "Preclinical"
"2519" "skepinone-l" "p38 MAPK inhibitor" "MAPK14" "" "" "BRD-K83607951-001-02-2" "OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1" "HXMGCTFLLWPVFM-GOSISDBHSA-N" "Preclinical"
"2520" "SKF-38393" "dopamine receptor agonist" "CALY, DRD1, DRD5" "" "" "BRD-A88548664-004-02-7" "Oc1cc2CCNCC(c3ccccc3)c2cc1O" "JUDKOGFHZYMDMF-UHFFFAOYSA-N" "Preclinical"
"2521" "SKF-77434" "dopamine receptor agonist" "DRD1" "" "" "BRD-A64227845-004-09-3" "Oc1cc2CCN(CC=C)CC(c3ccccc3)c2cc1O" "QBUVZVXIRYFENV-UHFFFAOYSA-N" "Preclinical"
"2522" "SKF-81297" "dopamine receptor agonist" "DRD1, DRD5" "" "" "BRD-A09828896-004-11-0" "Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1" "GHWJEDJMOVUXEC-UHFFFAOYSA-N" "Preclinical"
"2523" "SKF-83566" "dopamine receptor antagonist" "DRD1, DRD5" "" "" "BRD-A52588987-004-08-2" "CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1" "XFTVOHWWEQGXLS-UHFFFAOYSA-N" "Preclinical"
"2524" "SKF-86002" "p38 MAPK inhibitor" "ALOX5, MAPK14" "" "" "BRD-K96809896-300-02-3" "Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1" "YOELZIQOLWZLQC-UHFFFAOYSA-N" "Preclinical"
"2525" "SKF-89976A" "GABA uptake inhibitor" "SLC6A1" "" "" "BRD-A49046702-003-08-3" "OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1" "TXQKSMSLZVKQBI-UHFFFAOYSA-N" "Preclinical"
"2526" "SKF-91488" "histamine N-methyltransferase inhibitor" "HNMT" "" "" "BRD-K49776472-300-02-4" "CN(C)CCCCSC(N)=N" "UFYJLJINUGVUHO-UHFFFAOYSA-N" "Preclinical"
"2527" "SKF-96365" "calcium channel blocker" "CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2" "" "" "BRD-A72703248-003-04-9" "COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1" "HLMBXBGDBBCYII-UHFFFAOYSA-N" "Preclinical"
"2528" "SKI-II" "sphingosine kinase inhibitor" "SPHK1" "" "" "BRD-K20755323-001-07-5, BRD-K20755323-001-05-9, BRD-K20755323-001-06-7" "Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1, Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1" "ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N, ZFGXZJKLOFCECI-UHFFFAOYSA-N" "Preclinical"
"2529" "SKLB1002" "VEGFR inhibitor" "KDR" "" "" "BRD-K29895144-001-01-0" "COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC" "RQVGFDBMONQTBC-UHFFFAOYSA-N" "Preclinical"
"2530" "SLV-320" "adenosine receptor antagonist" "ADORA1, ADORA2A, ADORA2B, ADORA3" "" "" "BRD-K34445261-001-02-2, BRD-K34445261-001-01-4" "O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1, O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1" "RBZNJGHIKXAKQE-HDJSIYSDSA-N, RBZNJGHIKXAKQE-HDJSIYSDSA-N" "Phase 2"
"2531" "SM-108" "" "" "" "" "BRD-K70053378-001-01-1" "NC(=O)c1[nH]cnc1O" "UEWSIIBPZOBMBL-UHFFFAOYSA-N" "Phase 2"
"2532" "SM-164" "XIAP inhibitor" "BIRC2, BIRC3, XIAP" "" "" "BRD-K06191411-001-01-7" "CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1" "LGYDZXNSSLRFJS-IOQQVAQYSA-N" "Preclinical"
"2533" "SM-21" "sigma receptor antagonist" "PGRMC1" "" "" "BRD-A92933783-050-01-6" "CCC(Oc1ccc(Cl)cc1)C(=O)OC1CC2CCC(C1)N2C" "WTPAXDRULIZRDJ-UHFFFAOYSA-N" "Preclinical"
"2534" "SMI-4a" "Pim kinase inhibitor" "PIM1" "" "" "BRD-K70159787-001-01-1" "FC(F)(F)c1cccc(c1)\C=C1\SC(=O)NC1=O" "NGJLOFCOEOHFKQ-VMPITWQZSA-N" "Preclinical"
"2535" "SN-38" "topoisomerase inhibitor" "TOP1" "oncology" "colorectal cancer" "BRD-K89561498-001-01-7, BRD-K89561498-001-02-5" "CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12" "FJHBVJOVLFPMQE-QFIPXVFZSA-N, FJHBVJOVLFPMQE-QFIPXVFZSA-N" "Launched"
"2536" "SN-6" "sodium/calcium exchange inhibitor" "" "" "" "BRD-A14316475-001-02-3" "CCOC(=O)C1CSC(N1)Cc1ccc(OCc2ccc([N+]([O-])=O)cc2)cc1" "ZVYIJXLMBWCGHP-UHFFFAOYSA-N" "Preclinical"
"2537" "SNAP" "nitric oxide donor" "PTPN1" "" "" "BRD-A67006024-001-04-8" "CC(=O)NC(C(O)=O)C(C)(C)S[N+][O-]" "ZIIQCSMRQKCOCT-UHFFFAOYSA-N" "Phase 2"
"2538" "SNAP-5089" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D" "" "" "BRD-A21428877-003-02-7" "COC(=O)C1=C(C)NC(C)=C(C1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1" "FIIXCJGBCCCOQQ-UHFFFAOYSA-N" "Preclinical"
"2539" "SNAP-94847" "" "ADRA1A, DRD2" "" "" "BRD-K49702221-003-01-6" "CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1" "VMLZFUVIKCGATC-UHFFFAOYSA-N" "Preclinical"
"2540" "SNC-80" "" "OPRD1" "" "" "BRD-K29546239-001-02-3" "CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1" "KQWVAUSXZDRQPZ-UMTXDNHDSA-N" "Preclinical"
"2541" "SNG-1153" "selective estrogen receptor modulator (SERM)" "ESR1" "" "" "BRD-K75016267-001-01-7" "CC(C)=CCc1c(O)cc(O)c2c1oc(-c1ccc(cc1)C(F)(F)F)c(O)c2=O" "OXHMDMVBLQNMGP-UHFFFAOYSA-N" "Preclinical"
"2542" "SNS-314" "Aurora kinase inhibitor" "AURKA, AURKB, AURKC" "" "" "BRD-K71512533-066-03-6, BRD-K71512533-066-02-8" "Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1, Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1" "FAYAUAZLLLJJGH-UHFFFAOYSA-N, FAYAUAZLLLJJGH-UHFFFAOYSA-N" "Phase 1"
"2543" "SNX-2112" "HSP inhibitor" "" "" "" "BRD-K71281111-001-04-3" "CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1" "ZFVRYNYOPQZKDG-MQMHXKEQSA-N" "Phase 1"
"2544" "SNX-5422" "HSP inhibitor" "HSP90AA1" "" "" "BRD-K73197500-001-02-2, BRD-K73197500-001-03-0" "CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1, CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1" "AVDSOVJPJZVBTC-CTYIDZIISA-N, AVDSOVJPJZVBTC-CTYIDZIISA-N" "Phase 1/Phase 2"
"2545" "sobetirome" "thyroid hormone receptor agonist" "THRA, THRB" "" "" "BRD-K85406984-001-01-0, BRD-K85406984-001-02-8" "CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O, CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O" "QNAZTOHXCZPOSA-UHFFFAOYSA-N, QNAZTOHXCZPOSA-UHFFFAOYSA-N" "Phase 1"
"2546" "sobrepin" "mucolytic agent" "" "pulmonary" "chest congestion" "BRD-K58262380-001-01-0" "CC1=CC[C@H](C[C@@H]1O)C(C)(C)O" "OMDMTHRBGUBUCO-BDAKNGLRSA-N" "Launched"
"2547" "sodium-ascorbate" "" "" "" "" "BRD-A67265925-236-01-8, BRD-A67265925-236-02-6" "OC[C@H](O)[C@H]1OC(=O)C(O)C1O, OC[C@H](O)[C@H]1OC(=O)C(O)C1O" "SXZYCXMUPBBULW-FORAYFFESA-N, SXZYCXMUPBBULW-FORAYFFESA-N" "Launched"
"2548" "sodium-butyrate" "HDAC inhibitor" "BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8" "" "" "BRD-K05878375-236-06-5, BRD-K05878375-236-05-7" "CCCC(O)=O, CCCC(O)=O" "FERIUCNNQQJTOY-UHFFFAOYSA-N, FERIUCNNQQJTOY-UHFFFAOYSA-N" "Phase 2"
"2549" "sodium-danshensu" "" "" "" "" "BRD-A93699261-236-03-4, BRD-A93699261-236-02-6" "OC(Cc1ccc(O)c(O)c1)C(O)=O, OC(Cc1ccc(O)c(O)c1)C(O)=O" "PAFLSMZLRSPALU-UHFFFAOYSA-N, PAFLSMZLRSPALU-UHFFFAOYSA-N" "Preclinical"
"2550" "sodium-dodecyl-sulfate" "" "ALB, LYZ" "" "" "BRD-M58433298-001-02-4, BRD-M58433298-001-01-6" "[Na].CCCCCCCCCCCCOS(O)(=O)=O, [Na].CCCCCCCCCCCCOS(O)(=O)=O" "ISYOIFGRKUYTGX-UHFFFAOYSA-N, ISYOIFGRKUYTGX-UHFFFAOYSA-N" "Preclinical"
"2551" "sodium-glucoheptonate" "" "" "" "" "BRD-K35952844-236-01-6" "OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O" "KWMLJOLKUYYJFJ-VFUOTHLCSA-N" "Launched"
"2552" "sodium-gluconate" "" "" "" "" "BRD-K93201765-001-01-0, BRD-M54096567-001-03-5, BRD-M54096567-001-01-9" "OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O, [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O" "RGHNJXZEOKUKBD-SQOUGZDYSA-N, MPPJUDJABRMYJR-ZBHRUSISSA-N, MPPJUDJABRMYJR-ZBHRUSISSA-N" "Launched"
"2553" "sodium-gualenate" "antacid" "" "" "" "BRD-K80043866-236-01-1" "CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O" "VIZXMHCBZLGUET-UHFFFAOYSA-N" "Launched"
"2554" "sodium-monofluorophosphate" "" "PYGM" "dental" "cavities" "BRD-K99308954-304-03-2, BRD-K99308954-304-04-0, BRD-K99308954-304-02-4" "OP(O)(F)=O, OP(O)(F)=O, OP(O)(F)=O" "DWYMPOCYEZONEA-UHFFFAOYSA-N, DWYMPOCYEZONEA-UHFFFAOYSA-N, DWYMPOCYEZONEA-UHFFFAOYSA-N" "Launched"
"2555" "sodium-nitrite" "nitric oxide donor" "" "critical care" "poison antidote, cyanide poisoning" "BRD-K61230716-236-02-7, BRD-K61230716-236-03-5" "[O-][N+][O-], [O-][N+][O-]" "KYHRXPHIUFTLNH-UHFFFAOYSA-N, KYHRXPHIUFTLNH-UHFFFAOYSA-N" "Launched"
"2556" "sodium-nitroprusside" "nitric oxide donor" "" "cardiology" "hypertension, congestive heart failure" "BRD-K48526231-304-02-8, BRD-K48526231-236-01-4, BRD-K48526231-304-03-6" "[O-][N+][Fe--](C" "" ""
"2557" "sodium-orthovanadate" "" "" "" "" "BRD-K60600693-314-02-4, BRD-K60600693-314-03-2" "O[V](O)(O)=O, O[V](O)(O)=O" "WQEVDHBJGNOKKO-UHFFFAOYSA-K, WQEVDHBJGNOKKO-UHFFFAOYSA-K" "Preclinical"
"2558" "sodium-oxybate" "benzodiazepine receptor agonist" "GABRB1, HCAR1, SLC52A2" "neurology/psychiatry" "narcolepsy" "BRD-K82166906-236-02-8" "OCCCC(O)=O" "SJZRECIVHVDYJC-UHFFFAOYSA-N" "Launched"
"2559" "sodium-picosulfate" "" "" "gastroenterology" "constipation" "BRD-K77251551-304-02-9" "OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1" "UJIDKYTZIQTXPM-UHFFFAOYSA-N" "Launched"
"2560" "sodium-salicylate" "prostanoid receptor antagonist" "ASIC3, PTGS1, PTGS2" "endocrinology, neurology/psychiatry" "fever, pain relief" "BRD-K93632104-001-18-0, BRD-K93632104-001-19-8" "OC(=O)c1ccccc1O, OC(=O)c1ccccc1O" "YGSDEFSMJLZEOE-UHFFFAOYSA-N, YGSDEFSMJLZEOE-UHFFFAOYSA-N" "Launched"
"2561" "sodium-stibogluconate" "tyrosine phosphatase inhibitor" "PTPN6, TOP1" "infectious disease" "leishmaniasis" "BRD-A60786380-412-01-5" "OCC(O)C1O[Sb]2(O)(O[Sb]34(O)OC(C(O)CO)C(O3)C(O4)C(O)=O)OC1C(O2)C(O)=O" "RPOBPHCDIPHDQL-UHFFFAOYSA-L" "Launched"
"2562" "sodium-tanshinone-ii-a-sulfonate" "potassium channel activator" "" "" "" "BRD-K84798689-236-02-9" "Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O" "UJCACMLMPLLRGW-UHFFFAOYSA-N" "Phase 2"
"2563" "sodium-tetradecyl-sulfate" "" "PROC, PROS1" "dermatology" "varicose veins, varicose veins" "BRD-K84544951-236-01-0, BRD-A55664972-236-02-6" "CCCCCCCCCCCCCCOS(O)(=O)=O, CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O" "URLJMZWTXZTZRR-UHFFFAOYSA-N, GROJOWHVXQYQGN-UHFFFAOYSA-N" "Launched"
"2564" "sofalcone" "mucus protecting agent" "CBR1" "gastroenterology" "peptic ulcer disease (PUD)" "BRD-K01039503-001-01-2" "CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1" "GFWRVVCDTLRWPK-KPKJPENVSA-N" "Launched"
"2565" "sofosbuvir" "RNA polymerase inhibitor" "" "infectious disease" "hepatitis C" "BRD-K05674516-001-02-5" "CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1" "TTZHDVOVKQGIBA-YBSJRAAASA-N" "Launched"
"2566" "solamargine" "apoptosis inhibitor" "" "" "" "BRD-A65562236-001-01-2" "CC1C2C(CC3C4CC=C5CC(CCC5(C)C4CCC23C)OC2OC(CO)C(OC3OC(C)C(O)C(O)C3O)C(O)C2OC2OC(C)C(O)C(O)C2O)OC11CCC(C)CN1" "MBWUSSKCCUMJHO-UHFFFAOYSA-N" "Phase 3"
"2567" "solcitinib" "JAK inhibitor" "JAK1" "" "" "BRD-K69215269-001-01-1" "CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12" "MPYACSQFXVMWNO-UHFFFAOYSA-N" "Phase 1"
"2568" "solifenacin-succinate" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "urology" "urinary incontinence, urinary frequency" "BRD-K24723746-036-02-5, BRD-K24723746-001-01-1" "O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1, O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1" "FBOUYBDGKBSUES-VXKWHMMOSA-N, FBOUYBDGKBSUES-VXKWHMMOSA-N" "Launched"
"2569" "solithromycin" "protein synthesis inhibitor" "" "" "" "BRD-K32256160-001-01-9" "CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC" "IXXFZUPTQVDPPK-ZAWHAJPISA-N" "Phase 3"
"2570" "somantadine" "antiviral" "" "" "" "BRD-K85764479-003-01-0" "CC(C)(N)CC12CC3CC(CC(C3)C1)C2" "OWKXRDQRMTVCEX-UHFFFAOYSA-N" "Phase 1"
"2571" "somatostatin" "somatostatin receptor agonist" "OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5" "hematology" "hemorrhage" "BRD-K14681867-001-01-6" "C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N" "NHXLMOGPVYXJNR-ATOGVRKGSA-N" "Launched"
"2572" "sonidegib" "smoothened receptor antagonist" "SMO" "oncology" "basal cell carcinoma (BCC)" "BRD-K19796430-001-09-8, BRD-K19796430-001-05-6" "C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1" "VZZJRYRQSPEMTK-CALCHBBNSA-N, VZZJRYRQSPEMTK-CALCHBBNSA-N" "Launched"
"2573" "sophocarpine" "" "" "" "" "BRD-K66845263-001-03-0, BRD-K10999968-001-01-4, BRD-K66845263-001-02-2" "O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34, O=C1C=CC[C@@H]2[C@@H]3CCCN4CCC[C@@H](CN12)[C@@H]34, O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34" "AAGFPTSOPGCENQ-JLNYLFASSA-N, AAGFPTSOPGCENQ-XPCVCDNBSA-N, AAGFPTSOPGCENQ-JLNYLFASSA-N" "Phase 3"
"2574" "sorafenib" "FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor" "BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET" "oncology" "renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)" "BRD-K23984367-075-15-2, BRD-K23984367-001-07-5" "CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1" "MLDQJTXFUGDVEO-UHFFFAOYSA-N, MLDQJTXFUGDVEO-UHFFFAOYSA-N" "Launched"
"2575" "sorbic-acid" "" "" "" "" "BRD-K55892330-001-01-8" "CC=CC=CC(O)=O" "WSWCOQWTEOXDQX-UHFFFAOYSA-N" "Preclinical"
"2576" "sorbinil" "aldose reductase inhibitor" "AKR1B1" "" "" "BRD-A89164055-001-03-3" "Fc1ccc2OCCC3(NC(=O)NC3=O)c2c1" "LXANPKRCLVQAOG-UHFFFAOYSA-N" "Phase 3"
"2577" "sorbitan-monostearate" "" "" "" "" "BRD-A70197423-001-01-3" "CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O" "HVUMOYIDDBPOLL-XGKPLOKHSA-N" "Preclinical"
"2578" "sorbitol" "mucolytic agent" "" "" "" "BRD-K66035042-001-10-1, BRD-K36513555-001-02-0" "OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO" "FBPFZTCFMRRESA-JGWLITMVSA-N, FBPFZTCFMRRESA-ZXXMMSQZSA-N" "Launched"
"2579" "sotagliflozin" "sodium/glucose cotransporter inhibitor" "SLC5A1, SLC5A2" "" "" "BRD-K05850076-001-01-5" "CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1" "QKDRXGFQVGOQKS-CRSSMBPESA-N" "Phase 3"
"2580" "sotalol" "adrenergic receptor antagonist" "ADRB1, ADRB2, KCNH2" "cardiology" "atrial fibrillation (AF), ventricular arrhythmias" "BRD-A33168282-003-18-0, BRD-A33168282-003-17-2, BRD-A33168282-003-16-4" "CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1, CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1" "ZBMZVLHSJCTVON-UHFFFAOYSA-N, ZBMZVLHSJCTVON-UHFFFAOYSA-N, ZBMZVLHSJCTVON-UHFFFAOYSA-N" "Launched"
"2581" "sotrastaurin" "PKC inhibitor" "PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ" "" "" "BRD-K16761703-001-03-8" "CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1" "OAVGBZOFDPFGPJ-UHFFFAOYSA-N" "Phase 2"
"2582" "SP-420" "" "" "" "" "BRD-K23005288-001-01-8" "COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1" "YASYAEVZKXPYIZ-MRXNPFEDSA-N" "Phase 1"
"2583" "spaglumic-acid" "glutamate receptor antagonist" "GRM3" "allergy" "allergic conjunctivitis, allergic rhinitis" "BRD-K68405354-001-07-2, BRD-K68405354-001-06-4" "CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O" "OPVPGKGADVGKTG-BQBZGAKWSA-N, OPVPGKGADVGKTG-BQBZGAKWSA-N" "Launched"
"2584" "sparfloxacin" "bacterial DNA gyrase inhibitor" "TOP2A" "" "" "BRD-K07612980-001-05-3, BRD-A26423207-001-01-0, BRD-K07612980-001-04-6" "C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, CC1CN(C[C@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1, C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1" "DZZWHBIBMUVIIW-DTORHVGOSA-N, DZZWHBIBMUVIIW-IENPIDJESA-N, DZZWHBIBMUVIIW-DTORHVGOSA-N" "Withdrawn"
"2585" "sparfosate" "aspartate carbamoyltransferase inhibitor" "CA2, CA4, CAD" "" "" "BRD-A81539525-433-01-5" "OC(=O)CC(NC(=O)CP(O)(O)=O)C(O)=O" "ZZKNRXZVGOYGJT-UHFFFAOYSA-N" "Phase 3"
"2586" "sparteine-sulfate" "" "" "" "" "BRD-K32847234-065-04-6" "C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1" "SLRCCWJSBJZJBV-NMWPEEMBSA-N" "Launched"
"2587" "spectinomycin" "bacterial 30S ribosomal subunit inhibitor" "" "pulmonary" "airsacculitis, chronic respiratory disease" "BRD-K11905747-300-09-7, BRD-K11905747-300-10-5, BRD-K11905747-300-08-9, BRD-K38300715-300-01-5" "CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O, CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@@H]1O" "UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-WXKVUWSESA-N, UNFWWIHTNXNPBV-GGWBHPQESA-N" "Launched"
"2588" "spermidine" "glutamate receptor modulator" "KCNJ4, TXNRD1" "" "" "BRD-K40438880-305-06-6" "NCCCCNCCCN" "ATHGHQPFGPMSJY-UHFFFAOYSA-N" "Preclinical"
"2589" "spermine" "" "CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5" "" "" "BRD-K18375018-376-02-3" "NCCCNCCCCNCCCN" "PFNFFQXMRSDOHW-UHFFFAOYSA-N" "Preclinical"
"2590" "sphingosylphosphorylcholine" "gene expression stimulant" "GPR12" "" "" "BRD-A35379661-001-04-6" "CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C" "JLVSPVFPBBFMBE-HXSWCURESA-O" "Preclinical"
"2591" "spiperone" "dopamine receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7" "neurology/psychiatry" "schizophrenia" "BRD-K55468218-001-26-1, BRD-K55468218-003-02-8" "Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1, Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1" "DKGZKTPJOSAWFA-UHFFFAOYSA-N, DKGZKTPJOSAWFA-UHFFFAOYSA-N" "Launched"
"2592" "spiradoline" "opioid receptor agonist" "OPRK1" "" "" "BRD-K28192623-066-08-1" "CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1" "NYKCGQQJNVPOLU-ONTIZHBOSA-N" "Phase 2"
"2593" "spiramycin" "bacterial 50S ribosomal subunit inhibitor" "" "infectious disease" "toxoplasmosis, soft tissue infection" "BRD-K35824922-001-01-0, BRD-K77056640-001-01-9, BRD-K14716343-001-04-8" "CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1O[C@@H](C)[C@H](O[C@@H]2C[C@](C)(O)[C@H](O)[C@@H](C)O2)[C@H]([C@@H]1O)N(C)C, CO[C@@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1O[C@@H](C)[C@H](O[C@@H]2C[C@](C)(O)[C@H](O)[C@@H](C)O2)[C@H]([C@@H]1O)N(C)C, CO[C@H]1[C@H](O)CC(=O)O[C@@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C" "ACTOXUHEUCPTEW-JNQYENBPSA-N, ACTOXUHEUCPTEW-JUSVMKBVSA-N, ACTOXUHEUCPTEW-BOISPSKTSA-N" "Launched"
"2594" "spirobromin" "" "" "" "" "BRD-K96684644-300-01-7" "BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2" "JXEICPOBKSQAIU-UHFFFAOYSA-N" "Phase 1"
"2595" "spironolactone" "mineralocorticoid receptor antagonist" "AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG" "endocrinology, cardiology, gastroenterology, rheumatology" "hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia" "BRD-K90027355-001-13-3, BRD-A97808748-001-03-8, BRD-K30171400-001-01-2" "CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)C12, CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@H]2CC[C@@]3(C)[C@@H](CC[C@]33CCC(=O)O3)[C@H]12" "LXMSZDCAJNLERA-ZHYRCANASA-N, LXMSZDCAJNLERA-SRFJPPJVSA-N, LXMSZDCAJNLERA-ADIYBXDDSA-N" "Launched"
"2596" "spiroxatrine" "serotonin receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B" "" "" "BRD-A72483914-001-03-7" "O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1" "JVGBTTIJPBFLTE-UHFFFAOYSA-N" "Preclinical"
"2597" "spizofurone" "" "" "" "" "BRD-K94934625-001-01-5" "CC(=O)c1ccc2OC3(CC3)C(=O)c2c1" "SETMGIIITGNLAS-UHFFFAOYSA-N" "Withdrawn"
"2598" "splitomycin" "SIRT inhibitor" "SIRT1" "" "" "BRD-K27710560-001-07-5" "O=C1CCc2c(O1)ccc1ccccc21" "ISFPDBUKMJDAJH-UHFFFAOYSA-N" "Preclinical"
"2599" "SPP301" "endothelin receptor antagonist" "EDNRA" "" "" "BRD-K19203487-001-01-4" "COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1" "YBWLTKFZAOSWSM-UHFFFAOYSA-N" "Phase 3"
"2600" "SQ-109" "bacterial cell wall synthesis inhibitor" "FDFT1" "" "" "BRD-A08772153-001-02-4, BRD-A08772153-001-01-6" "CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2, CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2" "JFIBVDBTCDTBRH-UNRAVDGJSA-N, JFIBVDBTCDTBRH-UNRAVDGJSA-N" "Phase 3"
"2601" "SQ-22536" "adenylyl cyclase inhibitor" "ADCY1" "" "" "BRD-A56987319-001-12-9" "Nc1ncnc2n(cnc12)C1CCCO1" "UKHMZCMKHPHFOT-UHFFFAOYSA-N" "Preclinical"
"2602" "SR-11302" "" "" "" "" "BRD-K16229414-001-01-0" "CC(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)c1ccc(C)cc1)=C/C(O)=O" "RQANARBNMTXCDM-DKOHIBGUSA-N" "Preclinical"
"2603" "SR-2640" "leukotriene receptor antagonist" "CYSLTR1" "" "" "BRD-K62562723-003-02-7" "OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1" "LMPZHLXYBWGGNT-UHFFFAOYSA-N" "Phase 2"
"2604" "SR-27897" "CCK receptor antagonist" "CCKAR" "" "" "BRD-K35629949-001-02-0" "OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl" "ILNRQFBVVQUOLP-UHFFFAOYSA-N" "Phase 2"
"2605" "SR-3306" "JNK inhibitor" "MAPK10, MAPK8, MAPK9" "" "" "BRD-K60952143-001-01-0" "Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1" "QDMXVKKPYBGIAS-UHFFFAOYSA-N" "Preclinical"
"2606" "SR-33805" "calcium channel blocker" "" "" "" "BRD-K43002771-034-01-6" "COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC" "GCVFQRRBTCHIPK-UHFFFAOYSA-N" "Phase 1"
"2607" "SR-57227A" "serotonin receptor agonist" "HTR3A" "" "" "BRD-K09397065-003-06-1" "NC1CCN(CC1)c1cccc(Cl)n1" "WPVVMKYQOMJPIN-UHFFFAOYSA-N" "Phase 2"
"2608" "SR-59230A" "adrenergic receptor antagonist" "ADRB1, ADRB2, ADRB3" "" "" "BRD-K35430135-003-02-3" "CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12" "VFDHMSXXELYMRW-ICSRJNTNSA-N" "Preclinical"
"2609" "SR-95639A" "acetylcholine receptor agonist" "CHRM1" "" "" "BRD-K19309090-300-05-5" "C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1" "RUTYAHFAKWVMNH-UHFFFAOYSA-N" "Preclinical"
"2610" "SRC-kinase-inhibitor-I" "src inhibitor" "CSK, LCK, RIPK2" "" "" "BRD-K50495309-001-02-0" "COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC" "DMWVGXGXHPOEPT-UHFFFAOYSA-N" "Preclinical"
"2611" "SRPIN340" "serine arginine protein kinase inhibitor" "SRPK1, SRPK2" "" "" "BRD-K62621335-001-02-5, BRD-K19333160-300-01-9, BRD-K62621335-001-01-7" "FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1, Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1, FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1" "DWFGGOFPIISJIT-UHFFFAOYSA-N, GDVRVPIXWXOKQO-UHFFFAOYSA-N, DWFGGOFPIISJIT-UHFFFAOYSA-N" "Preclinical"
"2612" "SRT1720" "SIRT activator" "SIRT1" "" "" "BRD-K95926480-003-03-6" "O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1" "IASPBORHOMBZMY-UHFFFAOYSA-N" "Preclinical"
"2613" "SRT2104" "SIRT activator" "SIRT1" "" "" "BRD-K48452630-001-01-8, BRD-K48452630-001-02-6" "Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1, Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1" "LAMQVIQMVKWXOC-UHFFFAOYSA-N, LAMQVIQMVKWXOC-UHFFFAOYSA-N" "Phase 2"
"2614" "SSR128129E" "" "" "" "" "BRD-K65890018-236-01-1" "COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12" "SNMCWIDCSPHZRD-UHFFFAOYSA-N" "Preclinical"
"2615" "ST-1859" "antiamyloidogenic agent" "" "" "" "BRD-K73524797-001-01-1" "Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12" "ZPANWZBSGMDWON-UHFFFAOYSA-N" "Phase 1"
"2616" "ST-2825" "myeloid differentiation primary response inhibitor" "MYD88" "" "" "BRD-K68470841-001-01-0" "NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12" "HBLHLJXFIPCEMW-ZJSFPPFMSA-N" "Preclinical"
"2617" "ST-91" "adrenergic receptor agonist" "" "" "" "BRD-K18905250-003-02-4" "CCc1cccc(CC)c1N=C1NCCN1" "IALHTUPVRAQZFI-UHFFFAOYSA-N" "Preclinical"
"2618" "STA-5326" "interleukin synthesis inhibitor" "IL12A" "" "" "BRD-K41783120-001-02-8" "Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1" "HSKAZIJJKRAJAV-KOEQRZSOSA-N" "Phase 2"
"2619" "stanozolol" "androgen receptor agonist" "AR" "hematology" "anemia" "BRD-K46791647-001-01-2" "C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4Cc5[nH]ncc5C[C@]4(C)[C@H]3CC[C@]12C" "LKAJKIOFIWVMDJ-IYRCEVNGSA-N" "Launched"
"2620" "stattic" "" "" "" "" "BRD-K17061841-001-03-5" "[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1" "ZRRGOUHITGRLBA-UHFFFAOYSA-N" "Preclinical"
"2621" "STAT3-inhibitor-VI" "STAT inhibitor" "STAT3" "" "" "BRD-K40853697-001-17-1, BRD-K40853697-001-12-2, BRD-K40853697-001-18-9" "Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1, Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1" "HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N, HWNUSGNZBAISFM-UHFFFAOYSA-N" "Preclinical"
"2622" "stavudine" "DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-K93880783-001-26-6, BRD-A06317634-001-10-2" "Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O, Cc1cn(C2OC(CO)C=C2)c(=O)[nH]c1=O" "XNKLLVCARDGLGL-JGVFFNPUSA-N, XNKLLVCARDGLGL-UHFFFAOYSA-N" "Launched"
"2623" "stemregenin-1" "aryl hydrocarbon receptor antagonist" "AHR" "" "" "BRD-K36739687-001-03-0" "CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12" "BGFHMYJZJZLMHW-UHFFFAOYSA-N" "Preclinical"
"2624" "stepronin" "mucolytic agent" "" "" "" "BRD-A04506385-001-01-2" "CC(SC(=O)c1cccs1)C(=O)NCC(O)=O" "JNYSEDHQJCOWQU-UHFFFAOYSA-N" "Launched"
"2625" "stetaderm" "" "" "" "" "BRD-K93900986-001-15-0" "CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C" "BFZHCUBIASXHPK-QJSKAATBSA-N" "Launched"
"2626" "STF-083010" "serine/threonine kinase inhibitor" "ERN1" "" "" "BRD-K13049524-001-03-8" "Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1" "TVIVJHZHPKNDAQ-MHWRWJLKSA-N" "Preclinical"
"2627" "STF-118804" "NAMPT inhibitor" "NAMPT" "" "" "BRD-K39171998-001-01-1" "Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1" "DLFCEZOMHBPDGI-UHFFFAOYSA-N" "Preclinical"
"2628" "STF-62247" "autophagy inducer" "" "" "" "BRD-K85479953-001-12-1, BRD-K85479953-001-11-3" "Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1, Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1" "KATNUHQNJGNLPW-UHFFFAOYSA-N, KATNUHQNJGNLPW-UHFFFAOYSA-N" "Preclinical"
"2629" "stigmasterol" "" "" "" "" "BRD-K84424780-001-01-0, BRD-K41422683-001-02-2" "CC[C@H](\C=C\[C@@H](C)[C@@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C, CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C" "HCXVJBMSMIARIN-CLAUHZDRSA-N, HCXVJBMSMIARIN-PHZDYDNGSA-N" "Preclinical"
"2630" "stiripentol" "GABA uptake inhibitor" "GABRA3" "neurology/psychiatry" "epilepsy" "BRD-A72441487-001-05-7" "CC(C)(C)C(O)\C=C\c1ccc2OCOc2c1" "IBLNKMRFIPWSOY-FNORWQNLSA-N" "Launched"
"2631" "stobadine" "adrenergic receptor antagonist" "ADRA1A" "" "" "BRD-K33839500-001-01-0, BRD-A85069489-300-01-4, BRD-A85069489-001-01-8" "CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1, CN1CCC2Nc3ccc(C)cc3C2C1, CN1CCC2Nc3ccc(C)cc3C2C1" "CYJQCYXRNNCURD-DGCLKSJQSA-N, CYJQCYXRNNCURD-UHFFFAOYSA-N, CYJQCYXRNNCURD-UHFFFAOYSA-N" "Phase 2"
"2632" "streptomycin" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease" "tuberculosis" "BRD-K91768078-330-02-3, BRD-K91768078-330-01-5, BRD-A98954669-065-04-7" "CN[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@@]1(O)C=O, CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1OC1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O" "UCSJYZPVAKXKNQ-ONWXIPBKSA-N, UCSJYZPVAKXKNQ-ONWXIPBKSA-N, UCSJYZPVAKXKNQ-HUOHZKRVSA-N" "Launched"
"2633" "streptozotocin" "DNA alkylating agent" "SLC2A2" "oncology" "pancreatic cancer" "BRD-K34411947-001-12-5, BRD-K34411947-001-13-3, BRD-K34411947-001-15-8, BRD-K34411947-001-11-7, BRD-A25576662-001-02-2, BRD-K34411947-001-14-1" "CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O, CN([N+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O" "ZSJLQEPLLKMAKR-GKHCUFPYSA-N, ZSJLQEPLLKMAKR-GKHCUFPYSA-N, ZSJLQEPLLKMAKR-GKHCUFPYSA-N, ZSJLQEPLLKMAKR-GKHCUFPYSA-N, ZSJLQEPLLKMAKR-YDEIVXIUSA-N, ZSJLQEPLLKMAKR-GKHCUFPYSA-N" "Launched"
"2634" "strontium-ranelate" "bone formation stimulant, bone resorption inhibitor" "CASR" "orthopedics, rheumatology" "osteoporosis, osteoarthritis" "BRD-M65265990-001-03-0, BRD-K83146339-001-02-4, BRD-K88014802-001-02-7, BRD-K88014802-001-01-9" "[Sr].[Sr].OC(=O)CN(CC(O)=O)c1sc(C(O)=O)c(CC(O)=O)c1C" "" ""
"2635" "strychnine" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB" "" "" "BRD-A09094913-065-01-0" "O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61" "QMGVPVSNSZLJIA-OFYMUHMXSA-N" "Preclinical"
"2636" "SU-11274" "hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor" "MET" "" "" "BRD-K59067695-001-02-0" "CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C\c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1" "FPYJSJDOHRDAMT-XQNSMLJCSA-N" "Preclinical"
"2637" "SU-4312" "PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor" "KDR, PDGFRB" "" "" "BRD-K20287671-001-06-9" "CN(C)c1ccc(cc1)\C=C1/C(=O)Nc2ccccc12" "UAKWLVYMKBWHMX-PTNGSMBKSA-N" "Preclinical"
"2638" "substance-p" "neurokinin receptor antagonist" "TACR1, TACR2, TACR3" "" "" "BRD-K23106423-001-01-0" "CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O" "ADNPLDHMAVUMIW-CUZNLEPHSA-N" "Phase 1"
"2639" "succinic-acid" "" "ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE" "" "" "BRD-K45238818-001-02-6" "OC(=O)CCC(O)=O" "KDYFGRWQOYBRFD-UHFFFAOYSA-N" "Launched"
"2640" "succinylcholine-chloride" "" "CHRFAM7A, CHRM1, CHRM2, CHRM3, CHRNA1, CHRNA10" "neurology/psychiatry" "muscle relaxant" "BRD-K45497762-336-02-4, BRD-K45497762-336-01-6, BRD-K45497762-336-03-2, BRD-K45497762-300-01-2" "C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C, C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C" "AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N, AXOIZCJOOAYSMI-UHFFFAOYSA-N" "Launched"
"2641" "succinylsulfathiazole" "dihydrofolate reductase inhibitor" "DHFR" "" "" "BRD-K01950558-001-14-7" "OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1" "SKVLYVHULOWXTD-UHFFFAOYSA-N" "Phase 2"
"2642" "sucralfate" "antacid" "EGF, FGA, FGB, FGF2, FGG" "gastroenterology" "duodenal ulcer disease" "BRD-M71167108-001-01-3" "O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O" "DTULOKYBGCTCFP-QRLOXDDHSA-A" "Launched"
"2643" "sucralose" "" "" "" "" "BRD-K23414802-001-01-9, BRD-K58968598-001-02-8" "OC[C@@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl, OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl" "BAQAVOSOZGMPRM-AUVRLSKQSA-N, BAQAVOSOZGMPRM-QBMZZYIRSA-N" "Launched"
"2644" "sucrose" "" "ACTA1, ATOX1, C22orf28, LYZ" "" "" "BRD-K74724920-001-02-4" "OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O" "CZMRCDWAGMRECN-UGDNZRGBSA-N" "Launched"
"2645" "sucrose-octaacetate" "" "" "" "" "BRD-K01294196-001-01-5" "CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O" "ZIJKGAXBCRWEOL-SAXBRCJISA-N" "Preclinical"
"2646" "sudan-iv" "" "" "" "" "BRD-K65989725-001-01-3" "Cc1ccccc1N=Nc1ccc(N=Nc2c(O)ccc3ccccc23)c(C)c1" "RCTGMCJBQGBLKT-UHFFFAOYSA-N" "Preclinical"
"2647" "sufentanil" "opioid receptor modulator" "OPRD1, OPRK1, OPRM1" "neurology/psychiatry" "anesthetic" "BRD-K21547160-001-01-4" "CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1" "GGCSSNBKKAUURC-UHFFFAOYSA-N" "Launched"
"2648" "sulbactam" "beta lactamase inhibitor" "" "infectious disease" "skin infections, intra-abdominal infections, gynecologic infections" "BRD-K85679373-001-01-1, BRD-A12490291-001-01-2, BRD-K44133266-236-02-9, BRD-K85679373-236-01-3" "CC1(C)[C@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)C(N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O, CC1(C)[C@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O" "FKENQMMABCRJMK-PHDIDXHHSA-N, FKENQMMABCRJMK-LWOQYNTDSA-N, FKENQMMABCRJMK-RITPCOANSA-N, FKENQMMABCRJMK-PHDIDXHHSA-N" "Launched"
"2649" "sulbactam-pivoxil" "beta lactamase inhibitor" "" "infectious disease" "skin infections" "BRD-A63431791-001-01-9" "CC(C)(C)C(=O)OCOC(=O)C1N2C(CC2=O)S(=O)(=O)C1(C)C" "OHPVYKXTRACOSQ-UHFFFAOYSA-N" "Launched"
"2650" "sulbentine" "other antifungal" "" "" "" "BRD-K72384124-001-08-0" "S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1" "QFVAWNPSRQWSDU-UHFFFAOYSA-N" "Preclinical"
"2651" "sulbutiamine" "acetylcholine receptor antagonist" "" "neurology/psychiatry" "asthenia" "BRD-K12539416-001-01-4" "CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O" "CKHJPWQVLKHBIH-GPAWKIAZSA-N" "Launched"
"2652" "sulconazole" "sterol demethylase inhibitor" "" "infectious disease" "tinea pedis, tinea cruris, tinea corporis" "BRD-A70649075-008-30-8, BRD-A70649075-008-29-0" "Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1, Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1" "AFNXATANNDIXLG-UHFFFAOYSA-N, AFNXATANNDIXLG-UHFFFAOYSA-N" "Launched"
"2653" "sulfabenzamide" "bacterial antifolate" "" "" "" "BRD-K59983611-001-21-9" "Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1" "PBCZLFBEBARBBI-UHFFFAOYSA-N" "Launched"
"2654" "sulfacarbamide" "" "" "" "" "BRD-K13486660-001-01-0" "NC(=O)NS(=O)(=O)c1ccc(N)cc1" "WVAKABMNNSMCDK-UHFFFAOYSA-N" "Withdrawn"
"2655" "sulfacetamide" "PABA antagonist" "" "ophthalmology" "conjunctivitis" "BRD-K21520694-236-02-6, BRD-K21520694-001-21-4" "CC(=O)NS(=O)(=O)c1ccc(N)cc1, CC(=O)NS(=O)(=O)c1ccc(N)cc1" "SKIVFJLNDNKQPD-UHFFFAOYSA-N, SKIVFJLNDNKQPD-UHFFFAOYSA-N" "Launched"
"2656" "sulfachlorpyridazine" "bacterial antifolate" "" "infectious disease" "urinary tract infections" "BRD-K32021043-001-14-3" "Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1" "XOXHILFPRYWFOD-UHFFFAOYSA-N" "Launched"
"2657" "sulfadiazine" "bacterial antifolate" "" "infectious disease, ophthalmology" "malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid" "BRD-K32273377-001-17-9, BRD-K32273377-001-16-1, BRD-K32273377-001-15-3" "Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1" "SEEPANYCNGTZFQ-UHFFFAOYSA-N, SEEPANYCNGTZFQ-UHFFFAOYSA-N, SEEPANYCNGTZFQ-UHFFFAOYSA-N" "Launched"
"2658" "sulfadoxine" "dihydropteroate synthase inhibitor" "" "infectious disease" "malaria" "BRD-K55250441-001-13-0, BRD-K55250441-001-12-2" "COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC, COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC" "PJSFRIWCGOHTNF-UHFFFAOYSA-N, PJSFRIWCGOHTNF-UHFFFAOYSA-N" "Launched"
"2659" "sulfafurazole" "bacterial antifolate" "" "infectious disease" "urinary tract infections" "BRD-K50859149-001-19-5, BRD-K50859149-001-17-9, BRD-K50859149-001-18-7" "Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C, Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C" "NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N, NHUHCSRWZMLRLA-UHFFFAOYSA-N" "Launched"
"2660" "sulfaguanidine" "bacterial antifolate" "" "infectious disease" "urinary tract infections" "BRD-K45086103-001-15-5, BRD-K45086103-001-16-3, BRD-K45086103-001-14-8" "NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1, NC(=N)NS(=O)(=O)c1ccc(N)cc1" "BRBKOPJOKNSWSG-UHFFFAOYSA-N, BRBKOPJOKNSWSG-UHFFFAOYSA-N, BRBKOPJOKNSWSG-UHFFFAOYSA-N" "Launched"
"2661" "sulfamerazine" "bacterial antifolate" "" "infectious disease" "coccidiosis, cholera" "BRD-K93524252-001-23-9, BRD-K93524252-001-24-7" "Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1" "QPPBRPIAZZHUNT-UHFFFAOYSA-N, QPPBRPIAZZHUNT-UHFFFAOYSA-N" "Launched"
"2662" "sulfameter" "dihydrofolate reductase inhibitor" "DHFR" "infectious disease" "urinary tract infections" "BRD-K87492696-001-16-5, BRD-K87492696-001-15-7" "COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1, COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1" "GPTONYMQFTZPKC-UHFFFAOYSA-N, GPTONYMQFTZPKC-UHFFFAOYSA-N" "Launched"
"2663" "sulfamethazine" "PABA antagonist" "" "gastroenterology" "enteritis, enteritis" "BRD-K11640013-236-10-1, BRD-K11640013-001-15-8, BRD-K11640013-001-14-1" "Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1" "ASWVTGNCAZCNNR-UHFFFAOYSA-N, ASWVTGNCAZCNNR-UHFFFAOYSA-N, ASWVTGNCAZCNNR-UHFFFAOYSA-N" "Launched"
"2664" "sulfamethizole" "bacterial antifolate" "" "infectious disease" "urinary tract infections" "BRD-K31682896-001-24-0, BRD-K31682896-001-23-2" "Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1, Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1" "VACCAVUAMIDAGB-UHFFFAOYSA-N, VACCAVUAMIDAGB-UHFFFAOYSA-N" "Launched"
"2665" "sulfamethoxazole" "PABA antagonist" "" "infectious disease, gastroenterology" "pneumonia, enteritis, urinary tract infections" "BRD-K28494619-001-28-2, BRD-K28494619-001-27-4" "Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1, Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1" "JLKIGFTWXXRPMT-UHFFFAOYSA-N, JLKIGFTWXXRPMT-UHFFFAOYSA-N" "Launched"
"2666" "sulfamethoxypyridazine" "bacterial antifolate" "" "" "" "BRD-K00938507-001-17-8, BRD-K00938507-001-16-0" "COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1, COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1" "VLYWMPOKSSWJAL-UHFFFAOYSA-N, VLYWMPOKSSWJAL-UHFFFAOYSA-N" "Withdrawn"
"2667" "sulfametopyrazine" "PABA antagonist" "" "infectious disease" "malaria, urinary tract infections, respiratory tract infections" "BRD-K17205817-001-06-1" "COc1nccnc1NS(=O)(=O)c1ccc(N)cc1" "KXRZBTAEDBELFD-UHFFFAOYSA-N" "Launched"
"2668" "sulfamonomethoxine" "bacterial antifolate" "" "infectious disease" "urinary tract infections" "BRD-K14116214-001-09-6" "COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1" "WMPXPUYPYQKQCX-UHFFFAOYSA-N" "Launched"
"2669" "sulfamoxole" "PABA antagonist" "" "infectious disease" "urinary tract infections" "BRD-K19742012-001-02-3, BRD-K19742012-001-01-5" "Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C, Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C" "CYFLXLSBHQBMFT-UHFFFAOYSA-N, CYFLXLSBHQBMFT-UHFFFAOYSA-N" "Launched"
"2670" "sulfanilamide" "carbonic anhydrase inhibitor" "CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4" "infectious disease" "vulvovaginal candidiasis" "BRD-K02594908-001-16-4, BRD-K02594908-001-15-6" "Nc1ccc(cc1)S(N)(=O)=O, Nc1ccc(cc1)S(N)(=O)=O" "FDDDEECHVMSUSB-UHFFFAOYSA-N, FDDDEECHVMSUSB-UHFFFAOYSA-N" "Launched"
"2671" "sulfanilate-zinc" "" "" "" "" "BRD-K04254814-001-01-8" "Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1" "RIUORJCWAHCMSA-UHFFFAOYSA-L" "Preclinical"
"2672" "sulfanitran" "" "" "" "" "BRD-K76845197-001-05-4" "CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O" "GWBPFRGXNGPPMF-UHFFFAOYSA-N" "Launched"
"2673" "sulfaphenazole" "dihydropteroate synthetase inhibitor" "DHPS" "infectious disease" "urinary tract infections" "BRD-K10671814-001-14-8" "Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1" "QWCJHSGMANYXCW-UHFFFAOYSA-N" "Launched"
"2674" "sulfapyridine" "PABA antagonist" "" "" "" "BRD-K41406082-001-16-2, BRD-K41406082-001-15-4" "Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1, Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1" "GECHUMIMRBOMGK-UHFFFAOYSA-N, GECHUMIMRBOMGK-UHFFFAOYSA-N" "Launched"
"2675" "sulfaquinoxaline" "vitamin K antagonist" "" "infectious disease" "coccidiosis" "BRD-K71133585-236-14-4" "Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1" "NHZLNPMOSADWGC-UHFFFAOYSA-N" "Launched"
"2676" "sulfasalazine" "cyclooxygenase inhibitor" "ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1" "gastroenterology" "ulcerative colitis" "BRD-K10670311-001-15-5, BRD-K10670311-001-14-8" "OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1, OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1" "NCEXYHBECQHGNR-QZQOTICOSA-N, NCEXYHBECQHGNR-QZQOTICOSA-N" "Launched"
"2677" "sulfathiazole" "dihydropteroate synthase inhibitor" "" "" "" "BRD-K14705039-001-16-4, BRD-K14705039-001-15-6" "Nc1ccc(cc1)S(=O)(=O)Nc1nccs1, Nc1ccc(cc1)S(=O)(=O)Nc1nccs1" "JNMRHUJNCSQMMB-UHFFFAOYSA-N, JNMRHUJNCSQMMB-UHFFFAOYSA-N" "Launched"
"2678" "sulfinpyrazone" "uricosuric blocker" "ABCC1, ABCC2, FPR1, SLC22A12" "rheumatology" "gout" "BRD-A36217750-001-16-3" "O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1" "MBGGBVCUIVRRBF-UHFFFAOYSA-N" "Launched"
"2679" "sulfisoxazole-acetyl" "folic acid antagonist" "" "infectious disease, otolaryngology" "meningitis, urinary tract infections, otitis, trachoma" "BRD-K84810336-001-01-9" "CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1" "JFNWFXVFBDDWCX-UHFFFAOYSA-N" "Launched"
"2680" "sulforaphane" "anticancer agent, aryl hydrocarbon receptor antagonist" "NFE2L2" "" "" "BRD-A58955223-001-03-8" "CS(=O)CCCCN=C=S" "SUVMJBTUFCVSAD-UHFFFAOYSA-N" "Phase 2"
"2681" "sulindac" "cyclooxygenase inhibitor" "AKR1B1, MAPK3, PPARD, PTGDR2, PTGS1, PTGS2" "rheumatology" "osteoarthritis, rheumatoid arthritis, ankylosing spondylitis" "BRD-A13946108-001-19-7, BRD-A13946108-001-17-1, BRD-A13946108-001-16-3, BRD-A13946108-001-18-9" "CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O, CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O" "MLKXDPUZXIRXEP-MFOYZWKCSA-N, MLKXDPUZXIRXEP-MFOYZWKCSA-N, MLKXDPUZXIRXEP-MFOYZWKCSA-N, MLKXDPUZXIRXEP-MFOYZWKCSA-N" "Launched"
"2682" "sulisobenzone" "" "" "dermatology" "sunscreen lotion" "BRD-K38602774-001-03-2, BRD-K38602774-002-01-4" "COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1, COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1" "CXVGEDCSTKKODG-UHFFFAOYSA-N, CXVGEDCSTKKODG-UHFFFAOYSA-N" "Launched"
"2683" "sulmazole" "adenosine receptor antagonist" "" "" "" "BRD-A22081593-001-11-1" "COc1cc(ccc1-c1nc2ncccc2[nH]1)S(C)=O" "XMFCOYRWYYXZMY-UHFFFAOYSA-N" "Phase 1"
"2684" "sulmetozine" "gastrin inhibitor" "GAST" "gastroenterology" "peptic ulcer disease (PUD)" "BRD-K29570907-001-07-3" "COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1" "MVOUIYUWRXPNKD-UHFFFAOYSA-N" "Launched"
"2685" "suloctidil" "adrenergic receptor antagonist" "" "" "" "BRD-A34205397-001-04-5" "CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1" "BFCDFTHTSVTWOG-UHFFFAOYSA-N" "Withdrawn"
"2686" "sulphadimethoxine" "dihydropteroate synthetase inhibitor" "" "" "" "BRD-K71125014-001-27-1, BRD-K71125014-001-26-3" "COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1, COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1" "ZZORFUFYDOWNEF-UHFFFAOYSA-N, ZZORFUFYDOWNEF-UHFFFAOYSA-N" "Launched"
"2687" "sulpiride" "dopamine receptor antagonist" "" "neurology/psychiatry" "schizophrenia, schizophrenia" "BRD-A55272860-001-15-3, BRD-A55272860-001-14-6" "CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O, CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O" "BGRJTUBHPOOWDU-UHFFFAOYSA-N, BGRJTUBHPOOWDU-UHFFFAOYSA-N" "Launched"
"2688" "sumanirole" "dopamine receptor agonist" "DRD2" "" "" "BRD-K30485548-050-01-6" "CN[C@@H]1Cc2cccc3nc(O)n(C1)c23" "RKZSNTNMEFVBDT-MRVPVSSYSA-N" "Phase 3"
"2689" "sumatriptan" "serotonin receptor agonist" "HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7" "neurology/psychiatry" "migraine headache" "BRD-K50938287-036-13-8, BRD-K50938287-036-12-0, BRD-K50938287-001-09-0" "CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1, CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1" "KQKPFRSPSRPDEB-UHFFFAOYSA-N, KQKPFRSPSRPDEB-UHFFFAOYSA-N, KQKPFRSPSRPDEB-UHFFFAOYSA-N" "Launched"
"2690" "SUN-B-8155" "calcitonin agonist" "CALCR" "" "" "BRD-K36274133-001-01-2" "C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O" "SGJLINMLDNLWOS-CXUHLZMHSA-N" "Preclinical"
"2691" "sunitinib" "FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor" "" "oncology" "gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)" "BRD-K42828737-001-03-3, BRD-K42828737-044-09-0, BRD-K42828737-044-12-4, BRD-K42828737-044-10-8" "CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C" "WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N, WINHZLLDWRZWRT-ATVHPVEESA-N" "Launched"
"2692" "suplatast" "histamine release inhibitor, immunoglobulin inhibitor" "" "rheumatology" "Kimuras disease	BRD-A98427211-075-02-0, BRD-A98427211-075-05-3, BRD-A98427211-075-04-6, BRD-A98427211-075-03-8	CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1, CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1, CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1, CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1	DYZJXZOQQRXDLE-UHFFFAOYSA-O, DYZJXZOQQRXDLE-UHFFFAOYSA-O, DYZJXZOQQRXDLE-UHFFFAOYSA-O, DYZJXZOQQRXDLE-UHFFFAOYSA-O	Launched
suprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A34006693-001-15-4, BRD-A34006693-001-14-7	CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1, CC(C(O)=O)c1ccc(cc1)C(=O)c1cccs1	MDKGKXOCJGEUJW-UHFFFAOYSA-N, MDKGKXOCJGEUJW-UHFFFAOYSA-N	Withdrawn
suramin	DNA synthesis inhibitor	F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5	infectious disease	African trypanosomiasis, onchocerciasis	BRD-K70327167-348-13-4, BRD-K70327167-348-12-6	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O, Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	FIAFUQMPZJWCLV-UHFFFAOYSA-N, FIAFUQMPZJWCLV-UHFFFAOYSA-N	Launched
suritozole	GABA receptor inverse agonist	GABBR1			BRD-K98557884-001-01-6	Cn1nc(-c2cccc(F)c2)n(C)c1=S	IWDUZEHNLHFBRZ-UHFFFAOYSA-N	Phase 2
sutezolid	protein synthesis inhibitor				BRD-K86670086-001-02-5	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1	FNDDDNOJWPQCBZ-ZDUSSCGKSA-N	Phase 2
suvorexant	orexin receptor antagonist	HCRTR1, HCRTR2	neurology/psychiatry	insomnia	BRD-K94293891-001-01-3	C[C@@H]1CCN(CCN1C(=O)c1cc(C)ccc1-n1nccn1)c1nc2cc(Cl)ccc2o1	JYTNQNCOQXFQPK-MRXNPFEDSA-N	Launched
suxibuzone	cyclooxygenase inhibitor		rheumatology, neurology/psychiatry	joint pain, muscle pain	BRD-K78815826-001-14-6, BRD-K78815826-001-13-8	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1, CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	ONWXNHPOAGOMTG-UHFFFAOYSA-N, ONWXNHPOAGOMTG-UHFFFAOYSA-N	Launched
SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			BRD-K75911534-001-01-6	Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	CTNPALGJUAXMMC-HKJBKDEOSA-N	Phase 2
SU3327	JNK inhibitor	MAPK8			BRD-K32730239-001-01-0	Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	NQQBNZBOOHHVQP-UHFFFAOYSA-N	Preclinical
SU9516	CDK inhibitor	CDK1, CDK2, CDK4, CDK5			BRD-K94883909-001-17-7	COc1ccc2NC(=O)\C(=C/c3c[nH]cn3)c2c1	QNUKRWAIZMBVCU-WCIBSUBMSA-N	Preclinical
swainsonine	alpha mannosidase inhibitor	MAN2A1			BRD-K15170068-001-03-2	O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O	FXUAIOOAOAVCGD-WCTZXXKLSA-N	Phase 2
SX-011	MAP kinase inhibitor	MAPK14			BRD-K45385835-001-02-4	CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	GUTYHDCSDBBMGW-UHFFFAOYSA-N	Preclinical
SYM-2081	kainate receptor antagonist	GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2			BRD-K72106461-001-02-1	C[C@H](C[C@H](N)C(O)=O)C(O)=O	KRKRAOXTGDJWNI-DMTCNVIQSA-N	Preclinical
SYM-2206	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-A77218119-001-03-5	CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1C	OFUDZKKOKPGXOH-UHFFFAOYSA-N	Preclinical
symclosene					BRD-K33642804-001-01-1	Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O	YRIZYWQGELRKNT-UHFFFAOYSA-N	Preclinical
synephrine	adrenergic receptor agonist	ADRA1A			BRD-A04327189-003-03-3, BRD-A04327189-001-16-9, BRD-A04327189-001-15-1, BRD-A04327189-001-14-4, BRD-A04327189-003-02-5	CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1, CNCC(O)c1ccc(O)cc1	YRCWQPVGYLYSOX-UHFFFAOYSA-N, YRCWQPVGYLYSOX-UHFFFAOYSA-N, YRCWQPVGYLYSOX-UHFFFAOYSA-N, YRCWQPVGYLYSOX-UHFFFAOYSA-N, YRCWQPVGYLYSOX-UHFFFAOYSA-N	Launched
S1P1-agonist-III	sphingosine kinase inhibitor	S1PR1			BRD-K12745498-001-01-8	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	MLDQTQOMWDNTNN-UHFFFAOYSA-N	Preclinical
S18986	glutamate receptor modulator	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K02501528-001-01-1	O=S1(=O)N[C@H]2CCCN2c2ccccc12	MNTIJYGEITVWHU-SNVBAGLBSA-N	Phase 2
S26948	PPAR receptor agonist	PPARG			BRD-K48826825-001-01-8	COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	NSMJEHGOMXSLCW-UHFFFAOYSA-N	Preclinical
T-0070907	PPAR receptor antagonist	PPARG			BRD-K31843556-001-04-1, BRD-K31843556-001-03-3	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1, [O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	FRPJSHKMZHWJBE-UHFFFAOYSA-N, FRPJSHKMZHWJBE-UHFFFAOYSA-N	Preclinical
T-0156	phosphodiesterase inhibitor	PDE5A			BRD-K63516691-003-02-0	COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	JEMJAABFSYOLAP-UHFFFAOYSA-N	Preclinical
T-0901317	LXR agonist	NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB			BRD-K23383398-001-09-9, BRD-K23383398-001-08-1	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F, OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	SGIWFELWJPNFDH-UHFFFAOYSA-N, SGIWFELWJPNFDH-UHFFFAOYSA-N	Preclinical
T-5224	AP inhibitor	JUN			BRD-K84925803-001-01-9	OC(=O)CCc1cc(ccc1OCc1ccc2c(O)noc2c1)C(=O)c1ccc(OC2CCCC2)cc1O	DALCQQSLNPLQFZ-UHFFFAOYSA-N	Phase 2
T-62	adenosine receptor modulator	ADORA2A			BRD-K09001147-001-02-4, BRD-K09001147-001-01-6	Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1, Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	OTZVBZFYMFTYKH-UHFFFAOYSA-N, OTZVBZFYMFTYKH-UHFFFAOYSA-N	Phase 2
TA-01	casein kinase inhibitor, MAP kinase inhibitor	CSNK1D, CSNK1E, MAPK14			BRD-K79856806-001-01-0	Fc1ccc(cc1)-c1nc([nH]c1-c1ccncc1)-c1c(F)cccc1F	TWPJJJZCYVFUOA-UHFFFAOYSA-N	Preclinical
tabimorelin	growth hormone secretagogue receptor agonist	GHSR			BRD-K53600683-051-01-5	CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N	WURGZWOTGMLDJP-ZCYANPAGSA-N	Phase 2
tacalcitol	vitamin D receptor agonist	VDR	dermatology	psoriasis, chapped lips	BRD-K73237276-001-01-0	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C	BJYLYJCXYAMOFT-RSFVBTMBSA-N	Launched
tacedinaline	HDAC inhibitor	HDAC1			BRD-K52313696-001-12-3	CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	VAZAPHZUAVEOMC-UHFFFAOYSA-N	Phase 3
tacrine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimers disease" "BRD-K81473089-003-26-1, BRD-K81473089-003-24-6, BRD-K81473089-003-25-3" "Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12, Nc1c2CCCCc2nc2ccccc12" "YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N, YLJREFDVOIBQDA-UHFFFAOYSA-N" "Launched"
"2693" "tacrolimus" "calcineurin inhibitor" "FKBP1A" "transplant" "organ rejection" "BRD-K69608737-001-08-6, BRD-A96754982-001-01-4, BRD-K54509797-001-01-5" "CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1CC(CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC" "QJJXYPPXXYFBGM-LFZNUXCKSA-N, QJJXYPPXXYFBGM-NYOQZLQMSA-N, QJJXYPPXXYFBGM-ISLWKVMSSA-N" "Launched"
"2694" "tadalafil" "phosphodiesterase inhibitor" "PDE11A, PDE5A" "cardiology" "hypertension" "BRD-K93645900-001-11-3, BRD-K93645900-001-12-1" "CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O, CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O" "WOXKDUGGOYFFRN-IIBYNOLFSA-N, WOXKDUGGOYFFRN-IIBYNOLFSA-N" "Launched"
"2695" "tafamidis-meglumine" "transthyretin amyloid inhibitor" "TTR" "neurology/psychiatry" "familial amyloid polyneuropathy (FAP)" "BRD-K23728141-001-01-2" "OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1" "TXEIIPDJKFWEEC-UHFFFAOYSA-N" "Launched"
"2696" "tafenoquine" "antimalarial agent" "" "" "" "BRD-A78965079-036-01-8" "COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(NC(C)CCCN)c2n1" "LBHLFPGPEGDCJG-UHFFFAOYSA-N" "Phase 3"
"2697" "tagatose" "phosphorylase inhibitor" "PYGL" "" "" "BRD-K89588135-001-01-9, BRD-K18320600-001-01-9, BRD-K42064204-001-01-3, BRD-A73556557-001-06-4" "OC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O, OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO, OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO, OCC(O)C(O)C(O)C(=O)CO" "LKDRXBCSQODPBY-ARQDHWQXSA-N, BJHIKXHVCXFQLS-PQLUHFTBSA-N, BJHIKXHVCXFQLS-UYFOZJQFSA-N, BJHIKXHVCXFQLS-UHFFFAOYSA-N" "Phase 3"
"2698" "TAK-063" "phosphodiesterase inhibitor" "PDE10A" "" "" "BRD-K57155378-001-01-1" "COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1" "KVHRYLNQDWXAGI-UHFFFAOYSA-N" "Phase 2"
"2699" "TAK-220" "CC chemokine receptor antagonist" "CCR5" "" "" "BRD-K38793468-001-01-4" "CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1" "ASSJTMUEFHUKMJ-UHFFFAOYSA-N" "Phase 1"
"2700" "TAK-285" "EGFR inhibitor" "ERBB2" "" "" "BRD-K80343549-001-02-6" "CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12" "ZYQXEVJIFYIBHZ-UHFFFAOYSA-N" "Phase 1"
"2701" "TAK-593" "VEGFR inhibitor" "PDGFRA" "" "" "BRD-K67262033-001-01-0" "Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1" "DZFZXPPHBWCXPQ-UHFFFAOYSA-N" "Phase 1"
"2702" "TAK-632" "RAF inhibitor" "BRAF" "" "" "BRD-K31866293-001-01-6" "Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C" "" ""
"2703" "TAK-715" "p38 MAPK inhibitor" "MAPK14" "" "" "BRD-K52751261-001-08-7, BRD-K52751261-001-06-1" "CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1, CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1" "HEKAIDKUDLCBRU-UHFFFAOYSA-N, HEKAIDKUDLCBRU-UHFFFAOYSA-N" "Phase 2"
"2704" "TAK-733" "MEK inhibitor" "MAP2K1" "" "" "BRD-K26667523-001-03-3, BRD-K26667523-001-02-5" "Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O, Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O" "RCLQNICOARASSR-SECBINFHSA-N, RCLQNICOARASSR-SECBINFHSA-N" "Phase 1"
"2705" "TAK-875" "insulin secretagogue" "FFAR1" "" "" "BRD-K58501140-002-01-0" "Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1" "BZCALJIHZVNMGJ-HSZRJFAPSA-N" "Phase 3"
"2706" "TAK-901" "Aurora kinase inhibitor" "AURKB" "" "" "BRD-K01683783-001-02-6" "CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12" "WKDACQVEJIVHMZ-UHFFFAOYSA-N" "Phase 1"
"2707" "TAK-960" "PLK inhibitor" "PLK1" "" "" "BRD-K48059512-003-01-0, BRD-K48059512-001-01-4" "COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1, COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1" "GWRSATNRNFYMDI-UHFFFAOYSA-N, GWRSATNRNFYMDI-UHFFFAOYSA-N" "Phase 1"
"2708" "talabostat" "dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor" "DPP4" "" "" "BRD-K37419961-066-02-0, BRD-K37419961-066-01-2" "CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O, CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O" "FKCMADOPPWWGNZ-YUMQZZPRSA-N, FKCMADOPPWWGNZ-YUMQZZPRSA-N" "Phase 3"
"2709" "taladegib" "smoothened receptor antagonist" "DHH, IHH, SMO" "" "" "BRD-K50498985-001-03-3" "CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F" "SZBGQDXLNMELTB-UHFFFAOYSA-N" "Phase 2"
"2710" "talampanel" "glutamate receptor antagonist" "GRIA1, GRIA2, GRIA3, GRIA4" "" "" "BRD-K80359953-001-01-3, BRD-K80359953-001-02-1" "C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1, C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1" "JACAAXNEHGBPOQ-LLVKDONJSA-N, JACAAXNEHGBPOQ-LLVKDONJSA-N" "Phase 2"
"2711" "talarozole" "cytochrome P450 inhibitor" "CYP26A1" "" "" "BRD-A95755460-001-01-3" "CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1" "SNFYYXUGUBUECJ-UHFFFAOYSA-N" "Phase 2"
"2712" "talazoparib" "PARP inhibitor" "PARP2" "" "" "BRD-K95142244-001-01-5" "Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1" "HWGQMRYQVZSGDQ-HZPDHXFCSA-N" "Phase 3"
"2713" "talc" "" "" "" "" "BRD-M92352362-002-03-1, BRD-M92352362-002-02-3" "O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O, O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O" "XBPUDTAATCFDRE-UHFFFAOYSA-N, XBPUDTAATCFDRE-UHFFFAOYSA-N" "Launched"
"2714" "talinolol" "adrenergic receptor antagonist" "ADRB1" "cardiology" "hypertension" "BRD-A94276798-001-01-4" "CC(C)(C)NCC(O)COc1ccc(NC(=O)NC2CCCCC2)cc1" "MXFWWQICDIZSOA-UHFFFAOYSA-N" "Launched"
"2715" "talipexole" "adrenergic receptor agonist, dopamine receptor agonist" "ADRA2A, DRD2, HTR3A" "infectious disease" "genitial herpes" "BRD-K75615183-300-05-4, BRD-K75615183-300-04-7, BRD-K75615183-300-03-9" "Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1, Nc1nc2CCN(CC=C)CCc2s1" "DHSSDEDRBUKTQY-UHFFFAOYSA-N, DHSSDEDRBUKTQY-UHFFFAOYSA-N, DHSSDEDRBUKTQY-UHFFFAOYSA-N" "Launched"
"2716" "talmapimod" "p38 MAPK inhibitor" "MAPK11, MAPK14" "" "" "BRD-K17555800-003-01-5, BRD-K17555800-001-01-9" "C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C" "ZMELOYOKMZBMRB-DLBZAZTESA-N, ZMELOYOKMZBMRB-DLBZAZTESA-N" "Phase 2"
"2717" "talnetant" "tachykinin antagonist" "TACR2, TACR3" "" "" "BRD-K47095176-001-01-6" "CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1" "BIAVGWDGIJKWRM-FQEVSTJZSA-N" "Phase 2"
"2718" "talniflumate" "cyclooxygenase inhibitor" "CLCA1" "neurology/psychiatry" "pain relief" "BRD-A98378129-001-02-2" "FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1" "ANMLJLFWUCQGKZ-UHFFFAOYSA-N" "Launched"
"2719" "taltirelin" "thyrotropin releasing hormone receptor agonist" "TRHR" "neurology/psychiatry" "spinocerebellar ataxia" "BRD-K93869735-001-01-1" "CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O" "LQZAIAZUDWIVPM-SRVKXCTJSA-N" "Launched"
"2720" "taltobulin" "tubulin polymerization inhibitor" "" "" "" "BRD-K87512222-019-01-7" "CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1" "CNTMOLDWXSVYKD-PSRNMDMQSA-N" "Phase 1"
"2721" "TAME" "" "" "" "" "BRD-K72231366-001-02-3" "COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1" "FKMJXALNHKIDOD-LBPRGKRZSA-N" "Preclinical"
"2722" "tamibarotene" "retinoid receptor agonist" "RARA, RARB" "hematologic malignancy" "acute promyelocytic leukemia (APL)" "BRD-K36627727-001-05-4" "CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12" "MUTNCGKQJGXKEM-UHFFFAOYSA-N" "Launched"
"2723" "tamoxifen" "estrogen receptor antagonist, selective estrogen receptor modulator (SERM)" "EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ" "oncology" "breast cancer" "BRD-K93754473-048-21-0, BRD-K93754473-048-20-2, BRD-K93754473-048-19-4, BRD-K93754473-048-18-6" "CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1, CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1" "NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N, NKANXQFJJICGDU-QPLCGJKRSA-N" "Launched"
"2724" "tamsulosin" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D" "urology" "benign prostatic hyperplasia (BPH)" "BRD-K74339692-001-01-9" "CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O" "DRHKJLXJIQTDTD-OAHLLOKOSA-N" "Launched"
"2725" "tanaproget" "progesterone receptor agonist" "PGR" "" "" "BRD-K99604664-001-02-9, BRD-K99604664-001-01-1" "Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C" "" ""
"2726" "tandospirone" "serotonin receptor agonist" "HTR1A" "neurology/psychiatry" "generalized anxiety disorder (GAD), dysthymic disorder" "BRD-K65904673-001-01-4" "O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1" "CEIJFEGBUDEYSX-FZDBZEDMSA-N" "Launched"
"2727" "tandutinib" "FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor" "CSF1R, FLT3, KIT, PDGFD, PDGFRB" "" "" "BRD-K89162000-001-06-4, BRD-K89162000-001-07-2" "COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1, COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1" "UXXQOJXBIDBUAC-UHFFFAOYSA-N, UXXQOJXBIDBUAC-UHFFFAOYSA-N" "Phase 2"
"2728" "tanespimycin" "HSP inhibitor" "HSP90AA1" "" "" "BRD-K81473043-001-14-6, BRD-K34504123-001-01-6" "CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C/C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O" "AYUNIORJHRXIBJ-TXHRRWQRSA-N, AYUNIORJHRXIBJ-UPXYMWIDSA-N" "Phase 3"
"2729" "tangeritin" "cell cycle inhibitor" "" "" "" "BRD-K25186396-001-09-6" "COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1" "ULSUXBXHSYSGDT-UHFFFAOYSA-N" "Preclinical"
"2730" "tannic-acid" "PARG inhibitor" "ANO1" "gastroenterology" "constipation" "BRD-K67392463-001-04-8" "Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1" "LRBQNJMCXXYXIU-NRMVVENXSA-N" "Launched"
"2731" "tanshinone-i" "AP inhibitor" "IFNG" "" "" "BRD-K34073885-001-09-3, BRD-K34073885-001-07-7" "Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12" "AIGAZQPHXLWMOJ-UHFFFAOYSA-N, AIGAZQPHXLWMOJ-UHFFFAOYSA-N" "Phase 2"
"2732" "tanshinone-iia" "anti-inflammatory agent, interleukin inhibitor" "IL1B, NR1I2, TNF" "" "" "BRD-K00141480-001-15-4, BRD-K00141480-001-14-7" "Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C, Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C" "HYXITZLLTYIPOF-UHFFFAOYSA-N, HYXITZLLTYIPOF-UHFFFAOYSA-N" "Phase 2/Phase 3"
"2733" "tapentadol" "opioid receptor agonist" "HTR3A, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A4" "neurology/psychiatry" "acute pain, muscle pain" "BRD-K25699529-003-01-1, BRD-K04283354-003-01-9" "CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1, CC[C@H]([C@@H](C)CN(C)C)c1cccc(O)c1" "KWTWDQCKEHXFFR-FZMZJTMJSA-N, KWTWDQCKEHXFFR-SMDDNHRTSA-N" "Launched"
"2734" "taprenepag" "prostaglandin receptor agonist" "PTGER2" "" "" "BRD-K88854110-001-01-5" "OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1" "MFFBXYNKZHTCEY-UHFFFAOYSA-N" "Phase 2"
"2735" "tarafenacin" "acetylcholine receptor antagonist" "CHRM3" "" "" "BRD-K59390331-045-01-5" "Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1CN2CCC1CC2" "UXZDMXYRRQJIBJ-IBGZPJMESA-N" "Phase 2"
"2736" "taranabant" "cannabinoid receptor inverse agonist" "CNR1" "" "" "BRD-K35169477-001-01-9" "C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C" "" ""
"2737" "targinine" "nitric oxide synthase inhibitor" "NOS3" "" "" "BRD-K59506194-015-04-9" "CNC(=N)NCCC[C@H](N)C(O)=O" "NTNWOCRCBQPEKQ-YFKPBYRVSA-N" "Phase 3"
"2738" "tariquidar" "P glycoprotein inhibitor" "ABCB1" "" "" "BRD-K09353376-001-03-9, BRD-K09353376-001-02-1" "COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC, COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC" "LGGHDPFKSSRQNS-UHFFFAOYSA-N, LGGHDPFKSSRQNS-UHFFFAOYSA-N" "Phase 3"
"2739" "tartaric-acid" "antioxidant" "ATP6V1C1, B3GAT1, DDX6, HIF1AN, TREM1" "" "" "BRD-K36474365-001-06-6" "O[C@H]([C@@H](O)C(O)=O)C(O)=O" "FEWJPZIEWOKRBE-JCYAYHJZSA-N" "Launched"
"2740" "TAS-103" "topoisomerase inhibitor" "TOP1" "" "" "BRD-K09426783-300-01-0" "CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12" "ROWSTIYZUWEOMM-UHFFFAOYSA-N" "Phase 1"
"2741" "taselisib" "PI3K inhibitor" "PIK3CA" "" "" "BRD-K44844162-001-01-6" "CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O" "BEUQXVWXFDOSAQ-UHFFFAOYSA-N" "Phase 3"
"2742" "tasimelteon" "melatonin receptor agonist" "MTNR1A, MTNR1B" "neurology/psychiatry" "Non-24-Hour Sleep-Wake Disorder" "BRD-K62971431-001-01-9" "CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12" "PTOIAAWZLUQTIO-GXFFZTMASA-N" "Launched"
"2743" "tasisulam" "apoptosis stimulant" "" "" "" "BRD-K42495768-001-01-7" "Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1" "WWONFUQGBVOKOF-UHFFFAOYSA-N" "Phase 3"
"2744" "tasquinimod" "angiogenesis inhibitor, S100A9 inhibitor" "HDAC4" "" "" "BRD-K14653796-001-01-1" "COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12" "ONDYALNGTUAJDX-UHFFFAOYSA-N" "Phase 3"
"2745" "tasuldine" "mucolytic agent" "" "" "" "BRD-K10415035-001-04-4, BRD-K10415035-001-03-6" "C(Sc1ncccn1)c1cccnc1, C(Sc1ncccn1)c1cccnc1" "HMCTXMOKMWELFJ-UHFFFAOYSA-N, HMCTXMOKMWELFJ-UHFFFAOYSA-N" "Phase 3"
"2746" "taurine" "antioxidant" "" "neurology/psychiatry" "anxiety, irritability, sleeplessness" "BRD-K51474575-001-10-4, BRD-K51474575-001-11-2" "NCCS(O)(=O)=O, NCCS(O)(=O)=O" "XOAAWQZATWQOTB-UHFFFAOYSA-N, XOAAWQZATWQOTB-UHFFFAOYSA-N" "Launched"
"2747" "taurocholate" "G protein-coupled receptor agonist" "CEL, FABP6, SLCO1C1" "" "" "BRD-K81062487-001-05-8" "C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C" "WBWWGRHZICKQGZ-HZAMXZRMSA-N" "Phase 1"
"2748" "taurolidine" "apoptosis stimulant" "" "infectious disease" "catheter-related bloodstream infection" "BRD-K98765504-001-01-5" "O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1" "AJKIRUJIDFJUKJ-UHFFFAOYSA-N" "Launched"
"2749" "tavaborole" "leucyl-tRNA synthetase inhibitor" "" "infectious disease" "onychomycosis" "BRD-K76713213-001-02-1, BRD-K76713213-001-01-3" "OB1OCc2cc(F)ccc12, OB1OCc2cc(F)ccc12" "LFQDNHWZDQTITF-UHFFFAOYSA-N, LFQDNHWZDQTITF-UHFFFAOYSA-N" "Launched"
"2750" "taxifolin" "opioid receptor antagonist" "ADIPOR2" "" "" "BRD-K94649603-001-11-4, BRD-K94649603-001-10-6" "O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1, O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1" "CXQWRCVTCMQVQX-LSDHHAIUSA-N, CXQWRCVTCMQVQX-LSDHHAIUSA-N" "Phase 2"
"2751" "tazarotene" "retinoid receptor agonist" "RARA, RARB, RARG, RXRB" "dermatology" "cosmetic, sunscreen lotion" "BRD-K76841105-001-04-7" "CCOC(=O)c1ccc(nc1)C" "" ""
"2752" "tazemetostat" "histone lysine methyltransferase inhibitor" "EZH2" "" "" "BRD-K11215326-001-03-7, BRD-K11215326-001-02-9" "CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1, CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1" "NSQSAUGJQHDYNO-UHFFFAOYSA-N, NSQSAUGJQHDYNO-UHFFFAOYSA-N" "Phase 2"
"2753" "tazobactam" "beta lactamase inhibitor" "" "infectious disease" "pneumonia" "BRD-A18611368-001-01-5" "C[C@]1(Cn2ccnn2)C(N2C(CC2=O)S1(=O)=O)C(O)=O" "LPQZKKCYTLCDGQ-KTOWXAHTSA-N" "Launched"
"2754" "TBA-354" "" "" "" "" "BRD-K56405978-001-01-5" "[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1" "ZXSGSFMORAILEY-HNNXBMFYSA-N" "Phase 1"
"2755" "TBOA-(DL)" "excitatory amino acid transporter inhibitor" "SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7" "" "" "BRD-M77041484-001-01-8" "N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O" "CSEZCYBVEGIYNG-MFBWXLJUSA-N" "Preclinical"
"2756" "TCID" "" "" "" "" "BRD-K27536248-001-02-5, BRD-K27536248-001-01-7" "Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl, Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl" "IDLAOWFFKWRNHB-UHFFFAOYSA-N, IDLAOWFFKWRNHB-UHFFFAOYSA-N" "Preclinical"
"2757" "TCN201" "glutamate receptor antagonist" "GRIN2A" "" "" "BRD-K09787262-001-01-9" "Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1" "FYIBXBFDXNPBSF-UHFFFAOYSA-N" "Preclinical"
"2758" "TCS-359" "FLT3 inhibitor" "FLT3" "" "" "BRD-K81376179-001-06-3, BRD-K81376179-001-04-8, BRD-K81376179-001-05-5, BRD-K81376179-001-03-0" "COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O, COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O" "FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N, FSPQCTGGIANIJZ-UHFFFAOYSA-N" "Preclinical"
"2759" "TCS2002" "glycogen synthase kinase inhibitor" "GSK3B" "" "" "BRD-A50028488-001-01-6" "Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1" "RCKYSTKYIVULEK-UHFFFAOYSA-N" "Preclinical"
"2760" "TC1" "beta-secretase inhibitor" "BACE1" "" "" "BRD-A13964793-001-02-6" "OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1" "FYGREZKTJIXWIH-UHFFFAOYSA-N" "Preclinical"
"2761" "TC2559" "acetylcholine receptor agonist" "CHRNA4" "" "" "BRD-K24227647-364-01-5" "CCOc1cncc(\C=C\CCNC)c1" "HFZDMKMXPGRKCK-GQCTYLIASA-N" "Preclinical"
"2762" "tebipenem" "bacterial cell wall synthesis inhibitor" "CNR1" "infectious disease, otolaryngology" "pneumonia, otitis" "BRD-K06900071-001-01-2" "C[C@@H](O)[C@@H]1[C@@H]2[C@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C" "SNUDIPVBUUXCDG-MXYBEHONSA-N" "Launched"
"2763" "tecalcet" "calcium-sensing receptor agonist" "CASR" "" "" "BRD-K41662846-003-01-5" "COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl" "ZVQUCWXZCKWZBP-CQSZACIVSA-N" "Phase 2"
"2764" "tecastemizole" "histamine receptor antagonist" "KCNH2" "" "" "BRD-K48195801-001-01-6" "Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1" "SFOVDSLXFUGAIV-UHFFFAOYSA-N" "Phase 3"
"2765" "tecovirimat" "orthopoxvirus egress inhibitor" "" "" "" "BRD-K24312986-001-01-2" "FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O" "CSKDFZIMJXRJGH-VWLPUNTISA-N" "Phase 3"
"2766" "tedizolid" "bacterial 50S ribosomal subunit inhibitor" "" "infectious disease" "skin infections" "BRD-K59436580-001-01-7" "Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O" "XFALPSLJIHVRKE-GFCCVEGCSA-N" "Launched"
"2767" "tedizolid-phosphate" "protein synthesis inhibitor" "" "infectious disease" "skin infections" "BRD-K89121095-001-01-7, BRD-K89121095-304-01-5" "Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O, Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O" "QCGUSIANLFXSGE-GFCCVEGCSA-N, QCGUSIANLFXSGE-GFCCVEGCSA-N" "Launched"
"2768" "tegaserod" "serotonin receptor partial agonist" "HTR2A, HTR2B, HTR2C, HTR4" "" "" "BRD-K88743730-050-04-1, BRD-K88743730-050-03-3" "CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12, CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12" "IKBKZGMPCYNSLU-RGVLZGJSSA-N, IKBKZGMPCYNSLU-RGVLZGJSSA-N" "Withdrawn"
"2769" "tegobuvir" "HCV inhibitor, protease inhibitor" "" "" "" "BRD-K26701552-001-01-8" "Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1" "XBEQSQDCBSKCHJ-UHFFFAOYSA-N" "Phase 3"
"2770" "teicoplanin" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-K07712545-001-01-8" "CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl" "BJNLLBUOHPVGFT-VPMXZCLFSA-N" "Launched"
"2771" "teicoplanin-A2-1" "bacterial cell wall synthesis inhibitor" "" "" "" "BRD-A09761158-001-02-1" "CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(CC4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(OC4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl" "YMWQIYMUNZBOOV-AQQDCCNYSA-N" "Launched"
"2772" "teicoplanin-a2-3" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "gram-positive bacterial infections" "BRD-K96571715-001-01-4, BRD-U59360347-000-01-3" "CC(C)CCCCCCCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1NC(C)=O)[C@@H]1NC(=O)[C@@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl, " "FHBQKTSCJKPYIO-UBGUEUOASA-N, " "Launched"
"2773" "telaprevir" "HCV inhibitor" "CTSA, PGR" "infectious disease" "hepatitis C" "BRD-K72912098-001-02-3, BRD-K83470352-001-01-2" "CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1, CCC[C@H](NC(=O)[C@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1" "BBAWEDCPNXPBQM-GDEBMMAJSA-N, BBAWEDCPNXPBQM-WRWQEFDNSA-N" "Launched"
"2774" "telatinib" "KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "KDR" "" "" "BRD-K84564571-001-02-4" "CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1" "QFCXANHHBCGMAS-UHFFFAOYSA-N" "Phase 2"
"2775" "telbivudine" "DNA polymerase inhibitor" "TK2" "infectious disease" "hepatitis B" "BRD-K15976406-001-03-3" "Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O" "IQFYYKKMVGJFEH-CSMHCCOUSA-N" "Launched"
"2776" "telcagepant" "calcitonin antagonist" "CALCRL, RAMP1" "" "" "BRD-K91159026-001-01-7" "Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F" "CGDZXLJGHVKVIE-DNVCBOLYSA-N" "Phase 3"
"2777" "telenzepine" "acetylcholine receptor antagonist" "CHRM1" "" "" "BRD-K06147391-300-06-8, BRD-K06147391-003-03-5" "CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1, CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1" "VSWPGAIWKHPTKX-UHFFFAOYSA-N, VSWPGAIWKHPTKX-UHFFFAOYSA-N" "Phase 3"
"2778" "telithromycin" "bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor" "CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7" "infectious disease" "pneumonia" "BRD-K82240271-001-01-8, BRD-A94008949-001-01-9" "CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC, CCC1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@@H](C)[C@@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC" "LJVAJPDWBABPEJ-PNUFFHFMSA-N, LJVAJPDWBABPEJ-FXVGUYRBSA-N" "Launched"
"2779" "telmesteine" "mucolytic agent" "" "" "" "BRD-A05523972-001-01-5" "CCOC(=O)N1CSCC1C(O)=O" "XBJWOGLKABXFJE-UHFFFAOYSA-N" "Launched"
"2780" "telmisartan" "angiotensin receptor antagonist" "AGTR1, PPARG" "cardiology" "hypertension" "BRD-K73999723-001-11-3, BRD-K73999723-001-10-5" "CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C, CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C" "RMMXLENWKUUMAY-UHFFFAOYSA-N, RMMXLENWKUUMAY-UHFFFAOYSA-N" "Launched"
"2781" "telotristat" "serotonin receptor antagonist, serotonin release inhibitor" "TPH1" "" "" "BRD-K94559059-091-03-2, BRD-K63178091-001-01-1, BRD-K94559059-091-01-6, BRD-K94559059-091-02-4" "CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1, CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1" "MDSQOJYHHZBZKA-GBXCKJPGSA-N, NCLGDOBQAWBXRA-PGRDOPGGSA-N, MDSQOJYHHZBZKA-GBXCKJPGSA-N, MDSQOJYHHZBZKA-GBXCKJPGSA-N" "Phase 3"
"2782" "temazepam" "benzodiazepine receptor agonist" "GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO" "" "" "BRD-A93093700-001-02-9" "CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1" "SEQDDYPDSLOBDC-UHFFFAOYSA-N" "Withdrawn"
"2783" "temefos" "cholinesterase inhibitor" "" "" "" "BRD-K51805276-001-09-3" "COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1" "WWJZWCUNLNYYAU-UHFFFAOYSA-N" "Launched"
"2784" "temocapril" "angiotensin converting enzyme inhibitor" "ACE" "cardiology, nephrology" "hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)" "BRD-K10784860-003-02-3" "CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1" "FIQOFIRCTOWDOW-BJLQDIEVSA-N" "Launched"
"2785" "temoporfin" "radical formation stimulant" "" "oncology" "head and neck squamous cell carcinoma (HNSCC)" "BRD-K63712959-001-01-8" "Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2" "LYPFDBRUNKHDGX-UHFFFAOYSA-N" "Launched"
"2786" "temozolomide" "DNA alkylating agent" "MGMT" "oncology" "glioblastoma, astrocytoma" "BRD-K32107296-001-16-9, BRD-K32107296-001-15-1, BRD-K32107296-001-14-4" "Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O, Cn1nnc2c(ncn2c1=O)C(N)=O" "BPEGJWRSRHCHSN-UHFFFAOYSA-N, BPEGJWRSRHCHSN-UHFFFAOYSA-N, BPEGJWRSRHCHSN-UHFFFAOYSA-N" "Launched"
"2787" "tempol" "free radical scavenger" "" "" "" "BRD-K95053546-001-03-5, BRD-K95053546-001-02-7, BRD-K95053546-001-01-9" "CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O, CC1(C)CC(O)CC(C)(C)N1O" "CSGAUKGQUCHWDP-UHFFFAOYSA-N, CSGAUKGQUCHWDP-UHFFFAOYSA-N, CSGAUKGQUCHWDP-UHFFFAOYSA-N" "Phase 2"
"2788" "temsirolimus" "mTOR inhibitor" "MTOR" "oncology" "renal cell carcinoma (RCC)" "BRD-K42898655-001-01-8" "CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO" "CBPNZQVSJQDFBE-SREVRWKESA-N" "Launched"
"2789" "tenatoprazole" "ATPase inhibitor" "IDO1" "" "" "BRD-A42270467-001-04-4" "COc1ccc2[nH]c(nc2n1)S(=O)Cc1ncc(C)c(OC)c1C" "ZBFDAUIVDSSISP-UHFFFAOYSA-N" "Phase 2"
"2790" "teneligliptin" "dipeptidyl peptidase inhibitor" "DPP4" "endocrinology" "diabetes mellitus" "BRD-K48068743-001-01-6" "Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1" "WGRQANOPCQRCME-PMACEKPBSA-N" "Launched"
"2791" "tenidap" "cyclooxygenase inhibitor" "KCNJ4, PTGS1" "" "" "BRD-A87479750-001-02-7" "NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12" "IGPDWKCUDHIIRL-UHFFFAOYSA-N" "Phase 3"
"2792" "tenilsetam" "AGE inhibitor" "" "" "" "BRD-A41835910-001-02-2, BRD-A41835910-001-01-4" "O=C1NCCNC1c1cccs1, O=C1NCCNC1c1cccs1" "BBACKDMGYMXYLE-UHFFFAOYSA-N, BBACKDMGYMXYLE-UHFFFAOYSA-N" "Phase 3"
"2793" "teniposide" "topoisomerase inhibitor" "TOP2A, TOP2B" "hematologic malignancy" "acute lymphoblastic leukemia (ALL)" "BRD-A35588707-001-05-5, BRD-K10362825-001-03-4, BRD-K94631066-001-01-3" "COc1cc(cc(OC)c1O)[C@H]1[C@@H]2C(COC2=O)C(O[C@@H]2O[C@@H]3CO[C@H](OC3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12, COc1cc(cc(OC)c1O)[C@@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12" "NRUKOCRGYNPUPR-OQMCATNJSA-N, NRUKOCRGYNPUPR-QBPJDGROSA-N, NRUKOCRGYNPUPR-DKQCQWADSA-N" "Launched"
"2794" "tenofovir" "HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1), hepatitis B" "BRD-K15891719-001-05-1, BRD-K15891719-213-01-1, BRD-K15891719-001-04-4" "C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O, C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O" "SGOIRFVFHAKUTI-ZCFIWIBFSA-N, SGOIRFVFHAKUTI-ZCFIWIBFSA-N, SGOIRFVFHAKUTI-ZCFIWIBFSA-N" "Launched"
"2795" "tenofovir-alafenamide" "nucleoside reverse transcriptase inhibitor" "" "" "" "BRD-A25988899-001-01-6" "CC(C)OC(=O)C(C)NP(=O)(COC(C)Cn1cnc2c(N)ncnc12)Oc1ccccc1" "LDEKQSIMHVQZJK-UHFFFAOYSA-N" "Preclinical"
"2796" "tenofovir-disoproxil" "nucleoside reverse transcriptase inhibitor" "CYP1A2" "infectious disease" "human immunodeficiency virus (HIV-1), hepatitis B" "BRD-K61868322-051-06-4, BRD-K61868322-050-01-7" "CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C, CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C" "JFVZFKDSXNQEJW-CQSZACIVSA-N, JFVZFKDSXNQEJW-CQSZACIVSA-N" "Launched"
"2797" "tenovin-1" "SIRT inhibitor, TP53 activator" "SIRT1" "" "" "BRD-K05977823-001-04-6, BRD-K05977823-001-03-8" "CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1" "WOWJIWFCOPZFGV-UHFFFAOYSA-N, WOWJIWFCOPZFGV-UHFFFAOYSA-N" "Preclinical"
"2798" "tenovin-6" "SIRT inhibitor" "SIRT1, SIRT2, SIRT3" "" "" "BRD-K13949769-003-01-3, BRD-K13949769-001-01-7" "CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1, CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1" "BVJSXSQRIUSRCO-UHFFFAOYSA-N, BVJSXSQRIUSRCO-UHFFFAOYSA-N" "Preclinical"
"2799" "tenoxicam" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "rheumatology, orthopedics" "rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis" "BRD-A22844106-001-26-0, BRD-A22844106-001-25-2" "CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O, CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O" "OTGJPAOGHQFBMI-UHFFFAOYSA-N, OTGJPAOGHQFBMI-UHFFFAOYSA-N" "Launched"
"2800" "tenylidone" "" "" "" "" "BRD-K91298281-001-01-3" "O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1" "KHXBULXCCPIELT-DCIPZJNNSA-N" "Preclinical"
"2801" "tepoxalin" "cyclooxygenase inhibitor, lipoxygenase inhibitor" "ALOX5" "rheumatology, orthopedics" "rheumatoid arthritis, hip dysplasia" "BRD-K89714990-001-01-5" "COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1" "XYKWNRUXCOIMFZ-UHFFFAOYSA-N" "Launched"
"2802" "TEPP-46" "pyruvate kinase isozyme activator" "PKM" "" "" "BRD-A18279961-001-01-2" "Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)S(C)=O" "ZWKJWVSEDISQIS-UHFFFAOYSA-N" "Preclinical"
"2803" "teprenone" "mucus protecting agent" "" "dermatology" "cosmetic" "BRD-K11510141-001-03-4, BRD-K11510141-001-01-8, BRD-K11510141-001-02-6" "CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C, CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C" "HUCXKZBETONXFO-NJFMWZAGSA-N, HUCXKZBETONXFO-NJFMWZAGSA-N, HUCXKZBETONXFO-NJFMWZAGSA-N" "Launched"
"2804" "terameprocol" "lipoxygenase inhibitor" "BIRC5, CDK1" "" "" "BRD-K76788410-001-01-6" "COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC" "ORQFDHFZSMXRLM-IYBDPMFKSA-N" "Phase 1/Phase 2"
"2805" "terazosin" "adrenergic receptor antagonist" "ADRA1A, ADRA1B, ADRA1D, KCNH2, KCNH6, KCNH7" "urology, cardiology" "benign prostatic hyperplasia (BPH), hypertension" "BRD-A22256192-003-22-7, BRD-A22256192-310-02-8" "COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1, COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1CCCO1" "VCKUSRYTPJJLNI-UHFFFAOYSA-N, VCKUSRYTPJJLNI-UHFFFAOYSA-N" "Launched"
"2806" "terbinafine" "fungal squalene epoxidase inhibitor" "SQLE" "infectious disease" "tinea pedis, tinea cruris, tinea corporis" "BRD-K68132782-003-13-8, BRD-K68132782-003-14-6, BRD-K68132782-001-03-3" "CN(C\C=C\C" "" ""
"2807" "terbutaline" "adrenergic receptor agonist" "ADRB2" "pulmonary" "bronchospasm, bronchitis, emphysema" "BRD-M79902621-065-06-7, BRD-A50157456-065-20-6" "CC(C)(C)NCC(O)c1cc(O)cc(O)c1.CC(C)(C)NCC(O)c1cc(O)cc(O)c1, CC(C)(C)NCC(O)c1cc(O)cc(O)c1" "BPZKHKAYOKSXAK-UHFFFAOYSA-N, XWTYSIMOBUGWOL-UHFFFAOYSA-N" "Launched"
"2808" "terciprazine" "" "" "" "" "BRD-A11725667-001-01-8" "OC(COC1(CCCCC1)C" "" ""
"2809" "terconazole" "sterol demethylase inhibitor" "" "infectious disease" "vulvovaginal candidiasis" "BRD-K07400595-001-02-7, BRD-K86204871-001-16-2" "CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1, CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1" "BLSQLHNBWJLIBQ-ZEQKJWHPSA-N, BLSQLHNBWJLIBQ-OZXSUGGESA-N" "Launched"
"2810" "terfenadine" "histamine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2" "" "" "BRD-A06352418-001-25-9, BRD-A06352418-001-24-2" "CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1, CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1" "GUGOEEXESWIERI-UHFFFAOYSA-N, GUGOEEXESWIERI-UHFFFAOYSA-N" "Withdrawn"
"2811" "terguride" "dopamine receptor agonist, serotonin receptor antagonist" "ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C" "" "" "BRD-A89207210-001-01-6" "CCN(CC)C(=O)N[C@H]1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1" "JOAHPSVPXZTVEP-NXVRBGIVSA-N" "Launched"
"2812" "teriflunomide" "dihydroorotate dehydrogenase inhibitor" "DHODH" "neurology/psychiatry" "multiple sclerosis" "BRD-A42699921-001-03-6, BRD-A42699921-001-04-4, BRD-A42699921-001-02-8" "CC(=O)C(C" "" ""
"2813" "terlipressin" "vasopressin receptor agonist" "AVPR1A, AVPR1B, AVPR2" "cardiology" "hypotension" "BRD-K73451719-001-01-2" "NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O" "BENFXAYNYRLAIU-QSVFAHTRSA-N" "Launched"
"2814" "terodiline" "cholinergic receptor antagonist" "" "" "" "BRD-A33479817-003-03-7" "CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C" "UISARWKNNNHPGI-UHFFFAOYSA-N" "Phase 3"
"2815" "teroxirone" "DNA inhibitor" "" "" "" "BRD-A39935389-001-05-9" "O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1" "OUPZKGBUJRBPGC-UHFFFAOYSA-N" "Phase 1"
"2816" "terpene" "" "" "" "" "BRD-K93396439-002-01-2" "CC(C)(O)C1CCC(C)(O)CC1" "RBNWAMSGVWEHFP-UHFFFAOYSA-N" "Preclinical"
"2817" "terreic-acid-(-)" "Brutons tyrosine kinase (BTK) inhibitor	BTK			BRD-A64228451-001-08-4	CC1C(=O)[C@H]2O[C@H]2C(=O)C1=O	NYFMSQHOGRWGFD-OOEDRKFMSA-N	Preclinical
terutroban	prostanoid receptor antagonist	TBXA2R			BRD-K43975632-001-01-1	Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1	HWEOXFSBSQIWSY-MRXNPFEDSA-N	Phase 3
tesaglitazar	insulin sensitizer, PPAR receptor agonist	PPARA, PPARG			BRD-K15507868-001-03-7	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	CXGTZJYQWSUFET-IBGZPJMESA-N	Phase 3
testolactone	aromatase inhibitor	CYP19A1	oncology	breast cancer	BRD-K69636617-001-01-7	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2	BPEWUONYVDABNZ-DZBHQSCQSA-N	Launched
testosterone	androgen receptor agonist	AR	endocrinology	hypogonadism	BRD-A55393291-001-09-9	C[C@]12CCC3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@@H]2O	MUMGGOZAMZWBJJ-PPORCNLBSA-N	Launched
testosterone-enanthate	androgen receptor agonist	AR	endocrinology	hypogonadism	BRD-K89657519-001-01-8	CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	VOCBWIIFXDYGNZ-IXKNJLPQSA-N	Launched
testosterone-propionate	androgen receptor agonist	AR			BRD-A48720949-001-04-0	CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C	PDMMFKSKQVNJMI-PPRDLICTSA-N	Launched
testosterone-undecanoate	androgen receptor agonist	AR	endocrinology	hypogonadism	BRD-K70650177-001-01-7	CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C	UDSFVOAUHKGBEK-CNQKSJKFSA-N	Launched
tetrabenazine	vesicular monoamine transporter inhibitor	DRD2, SLC18A1, SLC18A2	infectious disease, neurology/psychiatry	cholera, Huntingtons disease" "BRD-K95739795-001-03-7" "COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC" "MKJIEFSOBYUXJB-HOCLYGCPSA-N" "Launched" "" "" ""
"2818" "tetracaine" "membrane integrity inhibitor" "SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "anesthetic" "BRD-K45071273-003-25-6, BRD-K45071273-003-24-9" "CCCCNc1ccc(cc1)C(=O)OCCN(C)C, CCCCNc1ccc(cc1)C(=O)OCCN(C)C" "GKCBAIGFKIBETG-UHFFFAOYSA-N, GKCBAIGFKIBETG-UHFFFAOYSA-N" "Launched"
"2819" "tetracycline" "bacterial 30S ribosomal subunit inhibitor" "PRNP" "infectious disease, dermatology" "respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis" "BRD-A34788695-003-10-2, BRD-A34788695-003-08-6, BRD-A34788695-003-12-8, BRD-A78253580-003-01-1, BRD-A34788695-003-09-4" "CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4C3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O, CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O" "MUHBBHLZPHKTTR-GWFFGYACSA-N, MUHBBHLZPHKTTR-GWFFGYACSA-N, MUHBBHLZPHKTTR-GWFFGYACSA-N, MUHBBHLZPHKTTR-WFWRUCNRSA-N, MUHBBHLZPHKTTR-GWFFGYACSA-N" "Launched"
"2820" "tetradecylthioacetic-acid" "lipid peroxidase inhibitor" "" "" "" "BRD-K47539947-001-03-7" "CCCCCCCCCCCCCCSCC(O)=O" "IPBCWPPBAWQYOO-UHFFFAOYSA-N" "Phase 2"
"2821" "tetraethylenepentamine" "superoxide dismutase inhibitor" "SOD1, SOD2" "" "" "BRD-K41298358-395-03-4, BRD-K41298358-395-02-6" "NCCNCCNCCNCCN, NCCNCCNCCNCCN" "FAGUFWYHJQFNRV-UHFFFAOYSA-N, FAGUFWYHJQFNRV-UHFFFAOYSA-N" "Phase 2/Phase 3"
"2822" "tetrahydrofolic-acid" "" "ALDH1L1, AMT, ATIC, FOLR2, FTCD, MTFMT, MTHFD1, MTHFD2, MTHFR, MTR, SHMT1, SHMT2" "" "" "BRD-A36978621-001-01-9" "Nc1nc(O)c2NC(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2n1" "MSTNYGQPCMXVAQ-KIYNQFGBSA-N" "Launched"
"2823" "tetrahydropapaverine" "" "" "" "" "BRD-A91831168-003-02-5" "COc1ccc(CC2NCCc3cc(OC)c(OC)cc23)cc1OC" "YXWQTVWJNHKSCC-UHFFFAOYSA-N" "Preclinical"
"2824" "tetrahydrouridine" "cytidine deaminase inhibitor" "CDA" "" "" "BRD-A86248581-001-01-4" "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CCC(O)NC1=O" "UCKYOOZPSJFJIZ-XVKVHKPRSA-N" "Phase 2"
"2825" "tetrahydrozoline" "adrenergic receptor agonist" "" "ophthalmology" "eye irritation" "BRD-A28856712-003-26-0, BRD-A28856712-003-25-2" "C1CN=C(N1)C1CCCc2ccccc12, C1CN=C(N1)C1CCCc2ccccc12" "BYJAVTDNIXVSPW-UHFFFAOYSA-N, BYJAVTDNIXVSPW-UHFFFAOYSA-N" "Launched"
"2826" "tetramethylthiuram-monosulfide" "" "" "" "" "BRD-K36889451-001-01-1" "CN(C)C(=S)SC(=S)N(C)C" "REQPQFUJGGOFQL-UHFFFAOYSA-N" "Preclinical"
"2827" "tetramisole" "immunostimulant" "" "infectious disease" "gastrointestinal parasites" "BRD-A46393198-003-16-6, BRD-A46393198-003-15-8" "C1CN2CC(N=C2S1)c1ccccc1, C1CN2CC(N=C2S1)c1ccccc1" "HLFSDGLLUJUHTE-UHFFFAOYSA-N, HLFSDGLLUJUHTE-UHFFFAOYSA-N" "Launched"
"2828" "tetrandrine" "calcium channel blocker" "SLC6A3" "" "" "BRD-K08078237-001-19-8, BRD-K59640580-001-07-1" "COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34, COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34" "WVTKBKWTSCPRNU-KYJUHHDHSA-N, WVTKBKWTSCPRNU-XZWHSSHBSA-N" "Preclinical"
"2829" "tetrazol-5-yl-glycine-(RS)" "glutamate receptor agonist" "GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D" "" "" "BRD-A14757586-001-03-2" "NC(C(O)=O)c1nnn[nH]1" "UKBRUIZWQZHXFL-UHFFFAOYSA-N" "Preclinical"
"2830" "tetrindole" "monoamine oxidase inhibitor" "MAOA" "" "" "BRD-A52660433-066-02-1" "C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1" "AUXCHYJDVJZEPG-UHFFFAOYSA-N" "Phase 3"
"2831" "tetroquinone" "" "" "" "" "BRD-K90177246-001-05-5" "OC1C(=O)C(=O)C(O)C(=O)C1=O" "GQPHQLHUIDOQTA-UHFFFAOYSA-N" "Preclinical"
"2832" "TG-003" "CLK inhibitor" "CLK1, CLK4, DYRK1A, DYRK1B" "" "" "BRD-K97072811-001-11-4" "CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O" "BGVLELSCIHASRV-QPEQYQDCSA-N" "Preclinical"
"2833" "TG-02" "CDK inhibitor, FLT3 inhibitor, JAK inhibitor" "CDK1, CDK2, CDK7, CDK9, FLT3, JAK2" "" "" "BRD-K14560436-001-01-4" "CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2" "VXBAJLGYBMTJCY-NSCUHMNNSA-N" "Phase 1"
"2834" "TG-100572" "src inhibitor, VEGFR inhibitor" "KDR, SRC" "" "" "BRD-K18424115-003-01-3" "Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl" "AQSSMEORRLJZLU-UHFFFAOYSA-N" "Preclinical"
"2835" "TG-100713" "PI3K inhibitor" "" "" "" "BRD-K46392623-001-02-5" "Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1" "UOORQSPLBHUQDQ-UHFFFAOYSA-N" "Preclinical"
"2836" "TG-100801" "src inhibitor, VEGFR inhibitor" "FGFR1, FLT1, KDR, SRC" "" "" "BRD-K12735121-001-01-4" "Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl" "JMGXJHWTVBGOKG-UHFFFAOYSA-N" "Phase 2"
"2837" "TG-101209" "JAK inhibitor" "JAK2, JAK3" "" "" "BRD-K39841531-001-02-1" "CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1" "JVDOKQYTTYUYDV-UHFFFAOYSA-N" "Preclinical"
"2838" "TG-101348" "FLT3 inhibitor, JAK inhibitor" "BRD4, JAK1, JAK2, JAK3, TYK2" "" "" "BRD-K12502280-001-11-4, BRD-K12502280-001-08-0" "Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C, Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C" "JOOXLOJCABQBSG-UHFFFAOYSA-N, JOOXLOJCABQBSG-UHFFFAOYSA-N" "Phase 3"
"2839" "TGR-1202" "PI3K inhibitor" "" "" "" "BRD-K52579889-001-01-9" "CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12" "IUVCFHHAEHNCFT-INIZCTEOSA-N" "Phase 3"
"2840" "TGX-221" "PI3K inhibitor" "PIK3CB, PIK3CD" "" "" "BRD-A41692738-001-10-0, BRD-A41692738-001-07-6" "CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1, CC(Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1" "CPRAGQJXBLMUEL-UHFFFAOYSA-N, CPRAGQJXBLMUEL-UHFFFAOYSA-N" "Preclinical"
"2841" "TG100-115" "PI3K inhibitor" "PIK3CA, PIK3CB, PIK3CD, PIK3CG" "" "" "BRD-K64785675-001-04-0" "Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1" "UJIAQDJKSXQLIT-UHFFFAOYSA-N" "Phase 1/Phase 2"
"2842" "TH-302" "DNA alkylating agent" "" "" "" "BRD-K20958582-001-01-4" "Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O" "UGJWRPJDTDGERK-UHFFFAOYSA-N" "Phase 3"
"2843" "thaliblastine" "DNA inhibitor" "" "" "" "BRD-K87548127-300-01-1" "COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC" "ZCTJIMXXSXQXRI-KYJUHHDHSA-N" "Phase 2"
"2844" "thalidomide" "tumor necrosis factor production inhibitor" "CRBN, FGFR2, NFKB1, ORM1, ORM2, PTGS2, TNF" "" "" "BRD-A93255169-001-28-3, BRD-A93255169-001-27-5" "O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12, O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12" "UEJJHQNACJXSKW-UHFFFAOYSA-N, UEJJHQNACJXSKW-UHFFFAOYSA-N" "Launched"
"2845" "theobromine" "phosphodiesterase inhibitor" "ADORA1, ADORA2A, PDE4B" "" "" "BRD-K34888156-213-01-4, BRD-K34888156-001-11-2" "Cn1cnc2n(C)c(=O)[nH]c(=O)c12, Cn1cnc2n(C)c(=O)[nH]c(=O)c12" "YAPQBXQYLJRXSA-UHFFFAOYSA-N, YAPQBXQYLJRXSA-UHFFFAOYSA-N" "Launched"
"2846" "theophylline" "adenosine receptor antagonist" "" "pulmonary" "asthma, emphysema, bronchitis" "BRD-K97799481-001-16-0" "Cn1c2nc[nH]c2c(=O)n(C)c1=O" "ZFXYFBGIUFBOJW-UHFFFAOYSA-N" "Launched"
"2847" "thiamet-g" "GLCNAC phosphotransferase inhibitor" "MGEA5" "" "" "BRD-K38380126-001-01-4" "CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1" "PPAIMZHKIXDJRN-FMDGEEDCSA-N" "Preclinical"
"2848" "thiamine" "vitamin B" "SLC19A2, SLC19A3, TPK1" "metabolism" "thiamine deficiency" "BRD-K95785345-300-14-8, BRD-K95785345-300-15-5" "Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N, Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N" "JZRWCGZRTZMZEH-UHFFFAOYSA-N, JZRWCGZRTZMZEH-UHFFFAOYSA-N" "Launched"
"2849" "thiamine-pyrophosphate" "" "" "" "" "BRD-A09994331-003-02-4" "Cc1c(CCOP(O)(=O)OP(O)(O)=O)sc[n+]1Cc1cnc(C)nc1N" "AYEKOFBPNLCAJY-UHFFFAOYSA-O" "Launched"
"2850" "thiamphenicol" "bacterial 50S ribosomal subunit inhibitor" "" "infectious disease" "pelvic inflammatory disease" "BRD-K79711234-001-18-3, BRD-K79711234-001-17-5" "CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl, CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl" "OTVAEFIXJLOWRX-NXEZZACHSA-N, OTVAEFIXJLOWRX-NXEZZACHSA-N" "Launched"
"2851" "thiamylal" "glutamate receptor antagonist" "GABRA1, KCNJ11, KCNJ8" "neurology/psychiatry" "sedative" "BRD-A23970436-236-04-2" "CCCC(C)C1(CC=C)C(=O)NC(S)=NC1=O" "XLOMZPUITCYLMJ-UHFFFAOYSA-N" "Launched"
"2852" "thiazovivin" "rho associated kinase inhibitor" "" "" "" "BRD-K03164761-001-02-1" "O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1" "DOBKQCZBPPCLEG-UHFFFAOYSA-N" "Preclinical"
"2853" "thiethylperazine" "dopamine receptor antagonist" "DRD1, DRD2, DRD4" "gastroenterology" "nausea" "BRD-K69600043-328-05-5" "CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1" "XCTYLCDETUVOIP-UHFFFAOYSA-N" "Launched"
"2854" "thiocolchicoside" "GABA receptor antagonist" "GABRA1, GABRB2, GABRG2, GLRA1, GLRB" "neurology/psychiatry" "muscle relaxant" "BRD-K26619122-001-02-1" "COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC" "LEQAKWQJCITZNK-AXHKHJLKSA-N" "Launched"
"2855" "thioctic-acid" "reducing agent" "ACHE, LIAS, LIPT1, PTGS2, SLC5A6" "" "" "BRD-A16347691-001-13-1" "OC(=O)CCCCC1CCSS1" "AGBQKNBQESQNJD-UHFFFAOYSA-N" "Launched"
"2856" "thiodiglycol" "" "" "" "" "BRD-K54521836-001-02-1" "OCCSCCO" "YODZTKMDCQEPHD-UHFFFAOYSA-N" "Preclinical"
"2857" "thioguanine" "purine antagonist" "IMPDH1, IMPDH2" "hematologic malignancy" "acute myeloid leukemia (AML)" "BRD-K49350383-001-13-7, BRD-K49350383-001-15-2, BRD-K49350383-001-14-5" "Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1" "WYWHKKSPHMUBEB-UHFFFAOYSA-N, WYWHKKSPHMUBEB-UHFFFAOYSA-N, WYWHKKSPHMUBEB-UHFFFAOYSA-N" "Launched"
"2858" "thiomersal" "other antibiotic" "OXCT1" "" "" "BRD-K61443650-236-13-1" "CC[Hg]Sc1ccccc1C(O)=O" "HXQVQGWHFRNKMS-UHFFFAOYSA-M" "Launched"
"2859" "thiopental" "GABA receptor antagonist" "CHRNA4, CHRNA7, FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GRIA2, GRIK2" "neurology/psychiatry" "anesthetic" "BRD-A72603112-236-04-0, BRD-A72603112-236-05-7" "CCCC(C)C1(CC)C(=O)NC(S)=NC1=O, CCCC(C)C1(CC)C(=O)NC(S)=NC1=O" "IUJDSEJGGMCXSG-UHFFFAOYSA-N, IUJDSEJGGMCXSG-UHFFFAOYSA-N" "Launched"
"2860" "thioperamide" "histamine receptor antagonist" "HRH3, HRH4" "" "" "BRD-K63874012-001-02-9" "S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1" "QKDDJDBFONZGBW-UHFFFAOYSA-N" "Preclinical"
"2861" "thiophanate" "" "" "" "" "BRD-K90168339-001-08-6" "COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC" "QGHREAKMXXNCOA-UHFFFAOYSA-N" "Preclinical"
"2862" "thioproperazine" "dopamine receptor antagonist" "ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A" "neurology/psychiatry" "schizophrenia" "BRD-K08619574-334-05-4" "CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1" "VZYCZNZBPPHOFY-UHFFFAOYSA-N" "Launched"
"2863" "thioridazine" "dopamine receptor antagonist" "ADRA1A, ADRA1B, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCNH2" "" "" "BRD-A84481105-003-31-3, BRD-A84481105-003-32-1" "CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1, CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1" "KLBQZWRITKRQQV-UHFFFAOYSA-N, KLBQZWRITKRQQV-UHFFFAOYSA-N" "Withdrawn"
"2864" "thiorphan" "membrane metalloendopeptidase inhibitor" "MME" "" "" "BRD-A56012032-001-15-5, BRD-A56012032-001-14-8" "OC(=O)CNC(=O)C(CS)Cc1ccccc1, OC(=O)CNC(=O)C(CS)Cc1ccccc1" "LJJKNPQAGWVLDQ-UHFFFAOYSA-N, LJJKNPQAGWVLDQ-UHFFFAOYSA-N" "Phase 1"
"2865" "thiostrepton" "FOXM1 inhibitor, protein synthesis inhibitor" "FOXM1" "obstetrics/gynecology" "mastitis" "BRD-A86083681-001-01-4, BRD-A51799737-001-01-0, BRD-A91347104-001-01-5, BRD-A20697603-001-07-2" "CC[C@H](C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)C1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)C(NC(=O)C3=NC(SC3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CC[C@H](C)C1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O, CCC(C)C1NC2C=Cc3c(cc(nc3C2O)C(=O)OC(C)C2NC(=O)c3csc(n3)C(NC(=O)C3CSC(=N3)\C(NC(=O)C(NC(=O)c3csc(n3)C3(CCC(=NC3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC1=O)C(C)O)=C/C)C(C)(O)C(C)O)C(C)O" "NSFFHOGKXHRQEW-HYHNWAPVSA-N, AMRSLVJUMUBRSB-NVJNIVQBSA-N, NSFFHOGKXHRQEW-FTJHWWITSA-N, NSFFHOGKXHRQEW-DVRIZHICSA-N" "Launched"
"2866" "thiotepa" "cytochrome P450 inhibitor" "CYP2B6, CYP3A4" "oncology" "breast cancer, ovarian cancer, bladder cancer" "BRD-K09631521-001-11-5, BRD-K09631521-001-09-9" "S=P(N1CC1)(N1CC1)N1CC1, S=P(N1CC1)(N1CC1)N1CC1" "FOCVUCIESVLUNU-UHFFFAOYSA-N, FOCVUCIESVLUNU-UHFFFAOYSA-N" "Launched"
"2867" "thiothixene" "dopamine receptor antagonist" "DRD1, DRD2, HRH1, HTR2A" "neurology/psychiatry" "schizophrenia" "BRD-K97309399-001-09-4" "CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C/CCN3CCN(C)CC3)c2c1" "GFBKORZTTCHDGY-UFWORHAWSA-N" "Launched"
"2868" "thiram" "" "JAK2" "ophthalmology" "contact dermatitis" "BRD-K29254801-001-14-7" "CN(C)C(=S)SSC(=S)N(C)C" "KUAZQDVKQLNFPE-UHFFFAOYSA-N" "Launched"
"2869" "thonzonium" "ATPase inhibitor" "" "" "" "BRD-K13387373-004-14-5, BRD-K13387373-004-15-2" "CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1, CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1" "IOYZYMQFUSNATM-UHFFFAOYSA-N, IOYZYMQFUSNATM-UHFFFAOYSA-N" "Launched"
"2870" "thonzylamine" "antihistamine" "" "neurology/psychiatry" "itching" "BRD-K88405679-003-03-1" "COc1ccc(CN(CCN(C)C)c2ncccn2)cc1" "GULNIHOSWFYMRN-UHFFFAOYSA-N" "Launched"
"2871" "threo-2-methylisocitrate-(DL)" "isocitrate lyase substrate" "" "" "" "BRD-M01344114-348-01-0" "CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O" "KTKGACLAXAFYNU-BWELSHISSA-N" "Preclinical"
"2872" "thymol" "GABA receptor positive allosteric modulator" "TRPA1" "" "" "BRD-K17458574-001-07-7" "CC(C)c1ccc(C)cc1O" "MGSRCZKZVOBKFT-UHFFFAOYSA-N" "Launched"
"2873" "thymol-iodide" "" "" "" "" "BRD-K36617478-001-01-5" "CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C" "SHOKWSLXDAIZPP-UHFFFAOYSA-N" "Preclinical"
"2874" "THZ1" "CDK inhibitor" "CDK7" "" "" "BRD-K66401437-001-03-3" "CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1" "OBJNFLYHUXWUPF-IZZDOVSWSA-N" "Preclinical"
"2875" "THZ1-R" "CDK inhibitor" "CDK7" "" "" "BRD-K02135007-001-01-8" "CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1" "TUERFPPIPKZNKE-UHFFFAOYSA-N" "Preclinical"
"2876" "THZ2" "CDK inhibitor" "CDK7" "" "" "BRD-K95902121-001-01-0" "CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1" "FONRCZUZCHXWBD-VGOFMYFVSA-N" "Preclinical"
"2877" "TH588" "MTH1 inhibitor" "NUDT1" "" "" "BRD-K01054709-001-01-3" "Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl" "PNMYJIOQIAEYQL-UHFFFAOYSA-N" "Preclinical"
"2878" "tiabendazole" "angiogenesis inhibitor" "" "infectious disease" "gastrointestinal roundworms, hookworm" "BRD-K77695569-001-30-0, BRD-K77695569-001-29-2" "c1nc(cs1)-c1nc2ccccc2[nH]1, c1nc(cs1)-c1nc2ccccc2[nH]1" "WJCNZQLZVWNLKY-UHFFFAOYSA-N, WJCNZQLZVWNLKY-UHFFFAOYSA-N" "Launched"
"2879" "tiagabine" "GABA uptake inhibitor" "SLC6A1" "neurology/psychiatry" "seizures" "BRD-K60160658-003-11-2" "Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C" "PBJUNZJWGZTSKL-MRXNPFEDSA-N" "Launched"
"2880" "tianeptine" "selective serotonin reuptake enhancer (SSRE)" "OPRD1, OPRK1, OPRM1" "neurology/psychiatry, pulmonary, gastroenterology" "depression, asthma, irritable bowel syndrome" "BRD-A53077924-001-01-2, BRD-A53077924-236-07-1, BRD-A53077924-236-05-5, BRD-A53077924-236-09-7, BRD-A53077924-236-06-3" "CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O, CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O" "JICJBGPOMZQUBB-UHFFFAOYSA-N, JICJBGPOMZQUBB-UHFFFAOYSA-N, JICJBGPOMZQUBB-UHFFFAOYSA-N, JICJBGPOMZQUBB-UHFFFAOYSA-N, JICJBGPOMZQUBB-UHFFFAOYSA-N" "Launched"
"2881" "tiapride" "dopamine receptor antagonist" "DRD2, DRD3" "neurology/psychiatry" "dyskinesia, abstinence from alcohol, psychosis" "BRD-K57432881-003-21-8" "CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O" "JTVPZMFULRWINT-UHFFFAOYSA-N" "Launched"
"2882" "tiaprofenic-acid" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "rheumatology" "rheumatoid arthritis" "BRD-A72988804-001-11-1, BRD-A72988804-001-10-3" "CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1, CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1" "GUHPRPJDBZHYCJ-UHFFFAOYSA-N, GUHPRPJDBZHYCJ-UHFFFAOYSA-N" "Launched"
"2883" "tiaramide" "anti-inflammatory agent" "" "pulmonary" "asthma" "BRD-K27293958-001-01-5" "OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O" "HTJXMOGUGMSZOG-UHFFFAOYSA-N" "Launched"
"2884" "tibolone" "androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist" "ESR1" "obstetrics/gynecology" "endometriosis" "BRD-A82522119-001-01-7" "C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C" "" ""
"2885" "ticagrelor" "purinergic receptor antagonist" "P2RY12" "cardiology" "acute coronary syndrome (ACS), myocardial infarction" "BRD-K44974079-001-01-3" "CCCSc1nc(N[C@@H]2C[C@@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@H](O)[C@H]3O)c2n1" "OEKWJQXRCDYSHL-MGXMICMRSA-N" "Launched"
"2886" "ticarcillin" "lactamase inhibitor" "" "infectious disease" "gram-negative bacterial infections" "BRD-A91757199-304-01-9, BRD-A55051145-304-03-2, BRD-A91757199-001-01-1, BRD-A91757199-304-02-7" "CC1(C)SC2C(NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2C1C(O)=O, CC1(C)S[C@@H]2[C@H](NC(=O)C(C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O, CC1(C)SC2C(NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2C1C(O)=O, CC1(C)SC2C(NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2C1C(O)=O" "OHKOGUYZJXTSFX-SNYNKORZSA-N, OHKOGUYZJXTSFX-IRHHVTTKSA-N, OHKOGUYZJXTSFX-SNYNKORZSA-N, OHKOGUYZJXTSFX-SNYNKORZSA-N" "Launched"
"2887" "ticlopidine" "purinergic receptor antagonist" "P2RY12" "hematology, neurology/psychiatry" "thrombosis, stroke" "BRD-K00603606-003-24-0, BRD-K00603606-003-23-2" "Clc1ccccc1CN1CCc2sccc2C1, Clc1ccccc1CN1CCc2sccc2C1" "PHWBOXQYWZNQIN-UHFFFAOYSA-N, PHWBOXQYWZNQIN-UHFFFAOYSA-N" "Launched"
"2888" "TIC10" "AKT inhibitor, TRAIL modulator" "AKT1, MAPK1" "" "" "BRD-K01115818-001-01-0, BRD-K19939891-001-05-4" "Cc1ccccc1CN1CC2=C(CCN(Cc3ccccc3)C2=O)N2CCN=C12, Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2" "DJNVPMWOJIZWOG-UHFFFAOYSA-N, RSAQARAFWMUYLL-UHFFFAOYSA-N" "Phase 2"
"2889" "tideglusib" "glycogen synthase kinase inhibitor" "GSK3B" "" "" "BRD-K81330143-001-04-8, BRD-K81330143-001-02-2" "O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1, O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1" "PMJIHLSCWIDGMD-UHFFFAOYSA-N, PMJIHLSCWIDGMD-UHFFFAOYSA-N" "Phase 2"
"2890" "tienilic-acid" "sodium/potassium/chloride transporter inhibitor, cytochrome P450 inhibitor" "CYP2C9, SLC12A1" "" "" "BRD-K34098590-001-02-1" "OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl" "AGHANLSBXUWXTB-UHFFFAOYSA-N" "Withdrawn"
"2891" "tie2-kinase-inhibitor" "TIE tyrosine kinase inhibitor" "KDR, MAPK14" "" "" "BRD-A92800748-001-05-5" "COc1ccc2cc(ccc2c1)-c1nc([nH]c1-c1ccncc1)-c1ccc(cc1)S(C)=O" "SINQIEAULQKUPD-UHFFFAOYSA-N" "Preclinical"
"2892" "tifenazoxide" "ATP-sensitive potassium channel agonist" "ABCC8, KCNJ11" "" "" "BRD-K20568871-001-01-1" "CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1" "KYSFUHHFTIGRJN-UHFFFAOYSA-N" "Phase 1"
"2893" "tigecycline" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease" "skin infections, pneumonia, intra-abdominal infections" "BRD-A34462049-001-13-5, BRD-A08915912-001-01-3, BRD-A34462049-001-12-7, BRD-A34462049-001-08-5, BRD-A34462049-001-09-3, BRD-A34462049-001-11-9" "CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C, CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(cc(NC(=O)CNC(C)(C)C)c(O)c4C(=O)C3C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O)N(C)C" "CGZOGNUFXMNYEI-UDUHKTKDSA-N, CGZOGNUFXMNYEI-GGPICEJPSA-N, CGZOGNUFXMNYEI-UDUHKTKDSA-N, CGZOGNUFXMNYEI-UDUHKTKDSA-N, CGZOGNUFXMNYEI-UDUHKTKDSA-N, CGZOGNUFXMNYEI-UDUHKTKDSA-N" "Launched"
"2894" "tiletamine" "glutamate receptor antagonist" "" "neurology/psychiatry" "anesthetic" "BRD-A30582499-003-05-1" "CCNC1(CCCCC1=O)c1cccs1" "QAXBVGVYDCAVLV-UHFFFAOYSA-N" "Launched"
"2895" "tilmicosin" "bacterial 50S ribosomal subunit inhibitor" "" "pulmonary" "bovine respiratory disease (BRD)" "BRD-K12921935-001-01-6, BRD-K26634012-001-03-1" "CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@H]1CO[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(C)=C/[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC" "JTSDBFGMPLKDCD-LRGOXBFPSA-N, JTSDBFGMPLKDCD-NXYWBGGVSA-N" "Launched"
"2896" "tilorone" "interferon inducer" "" "infectious disease, gastroenterology, neurology/psychiatry" "influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C" "BRD-K34568562-001-04-3" "CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1" "MPMFCABZENCRHV-UHFFFAOYSA-N" "Launched"
"2897" "tiludronate" "bone resorption inhibitor, osteoclast inhibitor" "ATP6V1A, MMP2, PTPN1" "orthopedics" "navicular syndrome" "BRD-K10845183-304-01-6" "OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O" "DKJJVAGXPKPDRL-UHFFFAOYSA-N" "Launched"
"2898" "timofibrate" "cholesterol inhibitor, lipase clearing factor inhibitor" "LPL" "" "" "BRD-A64406146-001-01-2" "CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSCC1C(O)=O" "QSNOWCXXECLALL-UHFFFAOYSA-N" "Phase 2"
"2899" "timolol" "adrenergic receptor antagonist" "ADRB1, ADRB2" "ophthalmology" "ocular hypertension, glaucoma" "BRD-K30421593-050-04-9, BRD-K08806317-050-29-1, BRD-K08806317-051-01-8" "CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1, CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1" "BLJRIMJGRPQVNF-SNVBAGLBSA-N, BLJRIMJGRPQVNF-JTQLQIEISA-N, BLJRIMJGRPQVNF-JTQLQIEISA-N" "Launched"
"2900" "timonacic" "antioxidant" "ANXA5" "" "" "BRD-A38592941-001-02-7" "OC(=O)C1CSCN1" "DZLNHFMRPBPULJ-UHFFFAOYSA-N" "Launched"
"2901" "tinidazole" "antiprotozoal agent" "" "infectious disease, obstetrics/gynecology" "giardiasis, amebiasis, bacterial vaginosis, trichomoniasis" "BRD-K89125793-001-27-8, BRD-K89125793-001-26-0, BRD-K89125793-001-25-2" "CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O, CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O" "HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N, HJLSLZFTEKNLFI-UHFFFAOYSA-N" "Launched"
"2902" "tioconazole" "sterol demethylase inhibitor" "CYP51A1" "infectious disease" "yeast infection" "BRD-A33084557-001-06-6, BRD-A33084557-001-07-4" "Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl, Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl" "QXHHHPZILQDDPS-UHFFFAOYSA-N, QXHHHPZILQDDPS-UHFFFAOYSA-N" "Launched"
"2903" "tioguanine" "purine antagonist" "" "" "" "BRD-K75649340-001-13-1" "Nc1nc(S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1" "OTDJAMXESTUWLO-UUOKFMHZSA-N" "Phase 2"
"2904" "tiopronin" "chelating agent, reducing agent" "" "urology" "kidney stones" "BRD-A85295731-001-06-4, BRD-A85295731-001-05-6, BRD-A85295731-001-02-3, BRD-A85295731-001-04-9, BRD-A85295731-001-03-1" "CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O, CC(S)C(=O)NCC(O)=O" "YTGJWQPHMWSCST-UHFFFAOYSA-N, YTGJWQPHMWSCST-UHFFFAOYSA-N, YTGJWQPHMWSCST-UHFFFAOYSA-N, YTGJWQPHMWSCST-UHFFFAOYSA-N, YTGJWQPHMWSCST-UHFFFAOYSA-N" "Launched"
"2905" "tiotidine" "histamine receptor antagonist" "HRH2" "" "" "BRD-K15071410-001-01-1" "CN\C(NCCSCc1csc(N=C(N)N)n1)=N/C" "" ""
"2906" "tiotropium" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3" "pulmonary" "chronic obstructive pulmonary disease (COPD), bronchitis, emphysema" "BRD-K62782754-337-02-5" "C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1" "LERNTVKEWCAPOY-DZZGSBJMSA-N" "Launched"
"2907" "tioxolone" "carbonic anhydrase inhibitor" "CA2" "" "" "BRD-K41876534-001-13-7, BRD-K41876534-001-12-9" "Oc1ccc2sc(=O)oc2c1, Oc1ccc2sc(=O)oc2c1" "SLYPOVJCSQHITR-UHFFFAOYSA-N, SLYPOVJCSQHITR-UHFFFAOYSA-N" "Preclinical"
"2908" "tipifarnib" "farnesyltransferase inhibitor" "FNTA, FNTB" "" "" "BRD-K62965247-001-04-9" "Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1" "PLHJCIYEEKOWNM-HHHXNRCGSA-N" "Phase 3"
"2909" "tipiracil" "thymidine phosphorylase inhibitor" "TYMP" "oncology" "colorectal cancer" "BRD-K11973162-003-01-8" "Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O" "QQHMKNYGKVVGCZ-UHFFFAOYSA-N" "Launched"
"2910" "tiplaxtinin" "plasminogen activator inhibitor" "SERPINE1" "" "" "BRD-K30882994-001-01-6" "OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1" "ODXQFEWQSHNQNI-UHFFFAOYSA-N" "Phase 1"
"2911" "tipranavir" "HIV protease inhibitor" "" "infectious disease" "human immunodeficiency virus (HIV-1)" "BRD-A10039652-001-01-2" "CCC[C@@]1(CCc2ccccc2)CC(=O)C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1" "MYXACKZCYFKMTE-JETRDCLMSA-N" "Launched"
"2912" "tiprenolol" "adrenergic receptor antagonist" "ADRB1, ADRB2, ADRB3" "" "" "BRD-A73566563-001-01-6" "CSc1ccccc1OCC(O)CNC(C)C" "CSUNLSYSEQIDMO-UHFFFAOYSA-N" "Phase 2"
"2913" "tiquizium" "acetylcholine receptor antagonist" "" "neurology/psychiatry" "spasms" "BRD-K77552740-004-01-0" "C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1" "ZGSDGGRVFIYKKE-OXQOHEQNSA-N" "Launched"
"2914" "tiracizine" "sodium channel blocker" "SCN5A" "" "" "BRD-K75250001-001-01-3" "CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1" "KJAMZCVTJDTESW-UHFFFAOYSA-N" "Withdrawn"
"2915" "tirapazamine" "DNA inhibitor" "" "" "" "BRD-K92968657-001-01-6, BRD-K75058612-001-01-1" "Nc1n[n+]([O-])c2ccccc2[n+]1[O-], On1c2ccccc2[n+]([O-])nc1=N" "ORYDPOVDJJZGHQ-UHFFFAOYSA-N, QVMPZNRFXAKISM-UHFFFAOYSA-N" "Phase 3"
"2916" "tirasemtiv" "troponin activator" "" "" "" "BRD-K51087630-001-01-6" "CCC(CC)n1c2nc(cnc2[nH]c1=O)C" "" ""
"2917" "tiratricol" "thyroid hormone stimulant" "THRA, THRB" "endocrinology" "Refetoff syndrome" "BRD-K61236135-001-08-2, BRD-K61236135-001-09-0" "OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1, OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1" "UOWZUVNAGUAEQC-UHFFFAOYSA-N, UOWZUVNAGUAEQC-UHFFFAOYSA-N" "Launched"
"2918" "tirofiban" "platelet aggregation inhibitor, structural glycoprotein antagonist" "ITGA2B, ITGB3" "cardiology" "myocardial infarction, refactory angina" "BRD-K37872686-003-01-9" "CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O" "COKMIXFXJJXBQG-NRFANRHFSA-N" "Launched"
"2919" "titanocene-dichloride" "apoptosis stimulant" "" "" "" "BRD-K60284353-001-01-3" "Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1" "XKLWATAZDMHTSH-UHFFFAOYSA-L" "Phase 2"
"2920" "tivantinib" "tyrosine kinase inhibitor" "MET" "" "" "BRD-K33379087-001-07-5" "O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23" "UCEQXRCJXIVODC-PMACEKPBSA-N" "Phase 3"
"2921" "tivozanib" "VEGFR inhibitor" "FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB" "" "" "BRD-K53414658-001-08-2" "COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC" "SPMVMDHWKHCIDT-UHFFFAOYSA-N" "Phase 3"
"2922" "tizanidine" "adrenergic receptor agonist" "ADRA2A, ADRA2B, ADRA2C, NISCH" "neurology/psychiatry" "spasms" "BRD-K06335600-003-20-7, BRD-K06335600-003-19-9" "Clc1ccc2nsnc2c1NC1=NCCN1, Clc1ccc2nsnc2c1NC1=NCCN1" "XFYDIVBRZNQMJC-UHFFFAOYSA-N, XFYDIVBRZNQMJC-UHFFFAOYSA-N" "Launched"
"2923" "TMC-353121" "RSV fusion inhibitor" "" "" "" "BRD-K66097663-001-01-8" "Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1" "DKORMNNYNRPTBJ-UHFFFAOYSA-N" "Phase 2"
"2924" "TMC647055" "RNA polymerase inhibitor" "" "" "" "BRD-K49659468-436-01-2" "COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O" "UOBYJVFBFSLCTQ-UHFFFAOYSA-N" "Phase 2"
"2925" "TMPH" "" "" "" "" "BRD-K49119234-003-02-6" "CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1" "PWWKJRFUJIFGGD-UHFFFAOYSA-N" "Preclinical"
"2926" "TMS" "" "" "" "" "BRD-K96233303-001-01-9" "COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1" "JDBCWSHYEQUBLW-AATRIKPKSA-N" "Preclinical"
"2927" "TNP-470" "methionine aminopeptidase inhibitor" "" "" "" "BRD-K53597484-001-02-7" "CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl" "MSHZHSPISPJWHW-PVDLLORBSA-N" "Phase 2"
"2928" "tobramycin" "bacterial 30S ribosomal subunit inhibitor" "" "infectious disease" "bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections" "BRD-K96342952-001-01-2, BRD-K05619559-001-10-1" "NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@@H]3O)[C@@H]2O)[C@@H](N)C[C@@H]1O, NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O" "NLVFBUXFDBBNBW-RJHRXKMUSA-N, NLVFBUXFDBBNBW-PBSUHMDJSA-N" "Launched"
"2929" "tocainide" "sodium channel blocker" "SCN5A" "cardiology" "cardiac arrythmia" "BRD-A92670106-003-05-4" "CC(N)C(=O)Nc1c(C)cccc1C" "BUJAGSGYPOAWEI-UHFFFAOYSA-N" "Launched"
"2930" "toceranib" "protein tyrosine kinase inhibitor" "FLT1, FLT3, KDR, PDGFRA, PDGFRB" "oncology" "cutaneous mast cell tumors, cutaneous mast cell tumors" "BRD-K62040061-001-01-0, BRD-K62040061-011-01-9" "Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1, Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1" "SRSGVKWWVXWSJT-ATVHPVEESA-N, SRSGVKWWVXWSJT-ATVHPVEESA-N" "Launched"
"2931" "tocofersolan" "antioxidant" "" "cardiology" "cerebral cholesterosis" "BRD-A39830855-001-01-6" "CC(C)CCCC(C)CCCC(C)CCCC1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1" "AOBORMOPSGHCAX-UHFFFAOYSA-N" "Launched"
"2932" "todralazine" "antihypertensive agent" "" "" "" "BRD-K68553471-003-12-3" "CCOC(=O)NNc1nncc2ccccc12" "WGZDBVOTUVNQFP-UHFFFAOYSA-N" "Launched"
"2933" "tofacitinib" "JAK inhibitor" "JAK1, JAK2, JAK3, TYK2" "rheumatology" "rheumatoid arthritis" "BRD-K36280065-048-01-2, BRD-K36280065-001-01-1" "C[C@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC" "" ""
"2934" "tofisopam" "phosphodiesterase inhibitor, cytochrome P450 inhibitor" "CYP3A4, PDE10A, PDE2A, PDE3A, PDE4A" "neurology/psychiatry" "anxiety, abstinence from alcohol" "BRD-K94830213-001-01-3" "CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12" "LOUZDJSQOFXLAP-UHFFFAOYSA-N" "Launched"
"2935" "tofogliflozin" "sodium/glucose cotransporter inhibitor" "GCK" "endocrinology" "diabetes mellitus, diabetes mellitus" "BRD-K96344439-002-02-7, BRD-K96344439-002-01-9" "CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1, CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1" "VWVKUNOPTJGDOB-BDHVOXNPSA-N, VWVKUNOPTJGDOB-BDHVOXNPSA-N" "Launched"
"2936" "tolamolol" "adrenergic receptor antagonist" "ADRB1, ADRB2, ADRB3" "" "" "BRD-A60498477-001-01-2" "Cc1ccccc1OCC(O)CNCCOc1ccc(cc1)C(N)=O" "SKQDKFOTIPJUSV-UHFFFAOYSA-N" "Phase 3"
"2937" "tolazamide" "ATP channel blocker" "ABCC8, KCNJ1, KCNJ10, KCNJ11" "endocrinology" "diabetes mellitus" "BRD-K32164935-001-30-8, BRD-K32164935-001-31-6, BRD-K32164935-001-29-0" "Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1, Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1" "OUDSBRTVNLOZBN-UHFFFAOYSA-N, OUDSBRTVNLOZBN-UHFFFAOYSA-N, OUDSBRTVNLOZBN-UHFFFAOYSA-N" "Launched"
"2938" "tolazoline" "adrenergic receptor antagonist" "ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2" "neurology/psychiatry" "reverse sedative" "BRD-K46211610-003-26-7, BRD-K46211610-003-25-9" "C(C1=NCCN1)c1ccccc1, C(C1=NCCN1)c1ccccc1" "JIVZKJJQOZQXQB-UHFFFAOYSA-N, JIVZKJJQOZQXQB-UHFFFAOYSA-N" "Launched"
"2939" "tolbutamide" "ATP channel blocker" "ABCC8, KCNJ1, KCNJ11, KCNJ8" "endocrinology" "diabetes mellitus" "BRD-K85119730-001-28-9, BRD-K85119730-001-27-1" "CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1, CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1" "JLRGJRBPOGGCBT-UHFFFAOYSA-N, JLRGJRBPOGGCBT-UHFFFAOYSA-N" "Launched"
"2940" "tolcapone" "catechol O methyltransferase inhibitor" "COMT" "" "" "BRD-K10852020-001-05-2, BRD-K10852020-001-04-5" "Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O, Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O" "MIQPIUSUKVNLNT-UHFFFAOYSA-N, MIQPIUSUKVNLNT-UHFFFAOYSA-N" "Withdrawn"
"2941" "tolfenamic-acid" "cyclooxygenase inhibitor, prostanoid receptor antagonist" "" "neurology/psychiatry" "migraine headache" "BRD-K50133271-001-18-7, BRD-K50133271-001-17-9" "Cc1c(Cl)cccc1Nc1ccccc1C(O)=O, Cc1c(Cl)cccc1Nc1ccccc1C(O)=O" "YEZNLOUZAIOMLT-UHFFFAOYSA-N, YEZNLOUZAIOMLT-UHFFFAOYSA-N" "Launched"
"2942" "tolimidone" "src activator" "LYN, SRC" "" "" "BRD-K41772907-001-01-2, BRD-K41772907-001-02-0" "Cc1cccc(Oc2cnc(=O)[nH]c2)c1, Cc1cccc(Oc2cnc(=O)[nH]c2)c1" "HJQILFPVRNHTIG-UHFFFAOYSA-N, HJQILFPVRNHTIG-UHFFFAOYSA-N" "Phase 2"
"2943" "tolmetin" "cyclooxygenase inhibitor" "PTGS1, PTGS2" "rheumatology" "rheumatoid arthritis, osteoarthritis" "BRD-K82562631-236-04-6, BRD-K82562631-325-04-7" "Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C, Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C" "UPSPUYADGBWSHF-UHFFFAOYSA-N, UPSPUYADGBWSHF-UHFFFAOYSA-N" "Launched"
"2944" "tolnaftate" "fungal squalene epoxidase inhibitor" "" "infectious disease" "tinea pedis, tinea corporis" "BRD-K44273375-001-25-0, BRD-K44273375-001-24-3" "CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1, CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1" "FUSNMLFNXJSCDI-UHFFFAOYSA-N, FUSNMLFNXJSCDI-UHFFFAOYSA-N" "Launched"
"2945" "tolonidine" "adrenergic receptor antagonist" "ADRA2A" "" "" "BRD-K82687598-001-01-6" "Cc1ccc(NC2=NCCN2)c(Cl)c1" "KWBTZIFLQYYPTH-UHFFFAOYSA-N" "Launched"
"2946" "tolonium" "" "" "hematology" "methemoglobinemia" "BRD-K94882685-003-09-2" "CN(C)c1ccc2nc3cc(C)c(N)cc3[s+]c2c1" "RQNADZJRELIICT-UHFFFAOYSA-N" "Launched"
"2947" "toloxatone" "monoamine oxidase inhibitor" "MAOA, MAOB" "neurology/psychiatry" "depression" "BRD-A67182178-001-01-7" "Cc1cccc(c1)N1CC(CO)OC1=O" "MXUNKHLAEDCYJL-UHFFFAOYSA-N" "Launched"
"2948" "tolperisone" "voltage-gated sodium channel blocker" "CYP2C19, CYP2D6" "neurology/psychiatry, infectious disease, rheumatology, cardiology" "muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynauds disease	BRD-A27732521-003-08-3, BRD-A27732521-003-07-5	CC(CN1CCCCC1)C(=O)c1ccc(C)cc1, CC(CN1CCCCC1)C(=O)c1ccc(C)cc1	FSKFPVLPFLJRQB-UHFFFAOYSA-N, FSKFPVLPFLJRQB-UHFFFAOYSA-N	Launched
tolrestat	aldose reductase inhibitor	AKR1A1, AKR1B1, AKR1B10			BRD-K85693895-001-02-9, BRD-K85693895-001-01-1	COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O, COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	LUBHDINQXIHVLS-UHFFFAOYSA-N, LUBHDINQXIHVLS-UHFFFAOYSA-N	Withdrawn
tolterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	BRD-K54316499-046-05-2, BRD-K54316499-046-04-5	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	OOGJQPCLVADCPB-HXUWFJFHSA-N, OOGJQPCLVADCPB-HXUWFJFHSA-N	Launched
toltrazuril	antiprotozoal agent		infectious disease	coccidiosis	BRD-K64514229-001-05-2, BRD-K64514229-001-04-5	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O, Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	OCINXEZVIIVXFU-UHFFFAOYSA-N, OCINXEZVIIVXFU-UHFFFAOYSA-N	Launched
tolvaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology, cardiology, gastroenterology	hyponatremia, congestive heart failure, hepatic cirrhosis	BRD-A82035391-001-02-7	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc23)c(C)c1	GYHCTFXIZSNGJT-UHFFFAOYSA-N	Launched
tomelukast	leukotriene receptor antagonist	CYSLTR1			BRD-K74765201-001-16-7	CCCc1c(OCCCCc2nnn[nH]2)ccc(C(C)=O)c1O	MWYHLEQJTQJHSS-UHFFFAOYSA-N	Phase 3
tonabersat	gap junction modulator, nitric oxide production inhibitor				BRD-K36970462-001-01-6	CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	XLIIRNOPGJTBJD-ROUUACIJSA-N	Phase 2
topiramate	carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist	CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, migraine headache	BRD-K29653726-001-14-2, BRD-K29653726-001-15-9, BRD-K29653726-001-13-4	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1, CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N, KJADKKWYZYXHBB-XBWDGYHZSA-N	Launched
topiroxostat	xanthine oxidase inhibitor	XDH	rheumatology, nephrology	gout, hyperuricemia	BRD-K77561571-001-01-1	N#Cc1cc(ccn1)-c1n[nH]c(n1)-c1ccncc1	UBVZQGOVTLIHLH-UHFFFAOYSA-N	Launched
topotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	BRD-K55696337-003-24-4, BRD-K55696337-003-22-8, BRD-K55696337-003-21-0, BRD-K55696337-003-20-2, BRD-K55696337-003-23-6	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N, UCFGDBYHRUNTLO-QHCPKHFHSA-N	Launched
torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	SLC12A1	cardiology	edema, congestive heart failure, hypertension	BRD-K30480208-001-18-5, BRD-K30480208-001-17-7	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1, CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	NGBFQHCMQULJNZ-UHFFFAOYSA-N, NGBFQHCMQULJNZ-UHFFFAOYSA-N	Launched
torcetrapib	cholesteryl ester transfer protein inhibitor	CETP			BRD-K64622987-001-01-4	CCOC(=O)N1[C@H](CC)C[C@@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	CMSGWTNRGKRWGS-WIYYLYMNSA-N	Phase 3
torcitabine	DNA polymerase inhibitor	DCK, TK2			BRD-K91822704-003-07-2	Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	CKTSBUTUHBMZGZ-SHYZEUOFSA-N	Phase 2
toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	BRD-K51350053-048-17-3, BRD-K51350053-048-16-5, BRD-K51350053-048-15-7	CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1, CN(C)CCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1	XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N, XFCLJVABOIYOMF-QPLCGJKRSA-N	Launched
torin-1	mTOR inhibitor	MTOR			BRD-K40175214-001-13-2, BRD-K40175214-001-11-6	CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1, CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	AKCRNFFTGXBONI-UHFFFAOYSA-N, AKCRNFFTGXBONI-UHFFFAOYSA-N	Preclinical
torin-2	mTOR inhibitor	MTOR			BRD-K68174511-001-06-6, BRD-K68174511-001-08-2	Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1, Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	GUXXEUUYCAYESJ-UHFFFAOYSA-N, GUXXEUUYCAYESJ-UHFFFAOYSA-N	Preclinical
tosedostat	peptidase inhibitor	ANPEP, LAP3, NPEPPS			BRD-K92241597-001-06-0, BRD-K92241597-001-09-4, BRD-K92241597-001-05-2	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1, CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N, FWFGIHPGRQZWIW-SQNIBIBYSA-N	Phase 2
tosufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	BRD-A41450521-075-10-8, BRD-A41450521-003-02-7	NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F, NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	WUWFMDMBOJLQIV-UHFFFAOYSA-N, WUWFMDMBOJLQIV-UHFFFAOYSA-N	Launched
toyocamycin	serine/threonine kinase inhibitor	ERN1			BRD-K26420709-001-01-7	Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	XOKJUSAYZUAMGJ-WOUKDFQISA-N	Phase 1
tozadenant	adenosine receptor antagonist	ADORA2A			BRD-K93045741-001-01-0	COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	XNBRWUQWSKXMPW-UHFFFAOYSA-N	Phase 3
tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	AURKA, AURKB, AURKC, LCK			BRD-K59369769-001-20-3, BRD-K59369769-001-23-7	CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	GCIKSSRWRFVXBI-UHFFFAOYSA-N, GCIKSSRWRFVXBI-UHFFFAOYSA-N	Phase 2
TP-0903	AXL kinase inhibitor	AXL			BRD-K84034737-001-01-1	CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl	YUAALFPUEOYPNX-UHFFFAOYSA-N	Preclinical
TPCA-1	IKK inhibitor	IKBKB			BRD-K51575138-001-13-2, BRD-K51575138-001-12-4	NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1, NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	SAYGKHKXGCPTLX-UHFFFAOYSA-N, SAYGKHKXGCPTLX-UHFFFAOYSA-N	Preclinical
TPPS4					BRD-K39805756-001-01-6	OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2	PBHVCRIXMXQXPD-UHFFFAOYSA-N	Phase 1
tracazolate	GABA receptor modulator	GABRA1			BRD-K34154330-003-06-4	CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	PCTRYMLLRKWXGF-UHFFFAOYSA-N	Phase 2
TRAM-34	potassium channel antagonist	KCNN4			BRD-K30071764-001-02-2	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1	KBFUQFVFYYBHBT-UHFFFAOYSA-N	Preclinical
tramadol	norepinephrine reputake inhibitor, opioid receptor agonist, serotonin reuptake inhibitor	CHRFAM7A, CHRM3, GRIN3A, HTR2C, OPRD1, OPRK1, OPRM1, SLC6A2, SLC6A4	neurology/psychiatry	acute pain, chronic pain	BRD-K51033547-003-02-6	COc1cccc(c1)[C@]1(O)CCCC[C@H]1CN(C)C	TVYLLZQTGLZFBW-GOEBONIOSA-N	Launched
trametinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	BRD-K12343256-001-14-7, BRD-K12343256-001-11-3, BRD-K12343256-001-08-9, BRD-K12343256-001-18-8	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N, LIRYPHYGHXZJBZ-UHFFFAOYSA-N	Launched
tramiprosate	beta amyloid protein neurotoxicity inhibitor	APP			BRD-K82234479-001-09-4	NCCCS(O)(=O)=O	SNKZJIOFVMKAOJ-UHFFFAOYSA-N	Phase 3
trandolapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction	BRD-A32505112-001-04-4	CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O	VXFJYXUZANRPDJ-UPUXWEDPSA-N	Launched
tranexamic-acid	antifibrinolytic, plasminogen activator inhibitor	PLG	hematology	hemophilia	BRD-K15014948-001-10-3, BRD-K79165417-001-01-7, BRD-K15014948-213-01-3, BRD-K15014948-001-09-5	NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O, NC[C@H]1CC[C@@H](CC1)C(O)=O	GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-KNVOCYPGSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N, GYDJEQRTZSCIOI-LJGSYFOKSA-N	Launched
tranilast	angiogenesis inhibitor	HPGDS, HRH1	pulmonary	asthma	BRD-K17849083-001-32-9, BRD-K17849083-001-31-1, BRD-K17849083-001-29-5, BRD-K17849083-001-30-3	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC, COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N, NZHGWWWHIYHZNX-CSKARUKUSA-N	Launched
trans-2-Undecenoic-acid					BRD-K42959922-001-01-5	CCCCCCCC\C=C\C(O)=O	IGBBVTAVILYDIO-MDZDMXLPSA-N	Preclinical
trans-4-Hydroxycrotonic-acid	gamma hydroxybutyric acid ligand				BRD-K91614056-001-02-2	OC\C=C\C(O)=O	RMQJECWPWQIIPW-OWOJBTEDSA-N	Preclinical
trans-4-Methoxycinnamic-acid					BRD-K26273521-001-07-3	COc1ccc(cc1)\C=C\C(O)=O	AFDXODALSZRGIH-QPJJXVBHSA-N	Preclinical
tranylcypromine	monoamine oxidase inhibitor	KDM1A, MAOA, MAOB	neurology/psychiatry	depression	BRD-K47029922-003-11-7, BRD-K47029922-003-10-9, BRD-K88809146-003-04-7, BRD-A43974575-065-05-1	N[C@@H]1C[C@H]1c1ccccc1, N[C@@H]1C[C@H]1c1ccccc1, N[C@H]1C[C@@H]1c1ccccc1, NC1C[C@H]1c1ccccc1	AELCINSCMGFISI-DTWKUNHWSA-N, AELCINSCMGFISI-DTWKUNHWSA-N, AELCINSCMGFISI-BDAKNGLRSA-N, AELCINSCMGFISI-IENPIDJESA-N	Launched
trap-101	nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist	OPRL1			BRD-K69837166-003-02-0	CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O	DCRGHMJXEBSRQG-UHFFFAOYSA-N	Preclinical
trapidil	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	BRD-K95763993-001-19-3	CCN(CC)c1cc(C)nc2ncnn12	GSNOZLZNQMLSKJ-UHFFFAOYSA-N	Launched
travoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	BRD-K23976833-001-01-0	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	MKPLKVHSHYCHOC-AHTXBMBWSA-N	Launched
traxoprodil	glutamate receptor antagonist	GRIN2B			BRD-K38158531-001-02-1	C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1	QEMSVZNTSXPFJA-HNAYVOBHSA-N	Phase 2
trazodone	adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4	neurology/psychiatry	depression	BRD-K70778732-003-26-7, BRD-K70778732-003-27-5	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1, Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	PHLBKPHSAVXXEF-UHFFFAOYSA-N, PHLBKPHSAVXXEF-UHFFFAOYSA-N	Launched
trebenzomine					BRD-A20686268-001-01-4	CC1Oc2ccccc2CC1N(C)C	FDJAKSHVOONYHX-UHFFFAOYSA-N	Phase 2
trelagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-A88369366-001-01-7	Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O	IWYJYHUNXVAVAA-UHFFFAOYSA-N	Launched
tremorine	acetylcholine receptor agonist				BRD-K08619838-300-05-7	C(C#CCN1CCCC1)N1CCCC1	JSUAJTLKVREZHV-UHFFFAOYSA-N	Preclinical
treosulfan	DNA synthesis inhibitor		oncology	ovarian cancer	BRD-K20902145-001-01-2	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	YCPOZVAOBBQLRI-WDSKDSINSA-N	Launched
trepibutone	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	irritable bowel syndrome	BRD-K37543758-001-01-3	CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O	YPTFHLJNWSJXKG-UHFFFAOYSA-N	Launched
trequinsin	phosphodiesterase inhibitor	PDE5A			BRD-K84663978-003-02-9	COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	MCMSJVMUSBZUCN-YYDJUVGSSA-N	Phase 1
tretazicar	DNA replication inhibitor	NQO2			BRD-K08748705-001-08-2	NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O	WOCXQMCIOTUMJV-UHFFFAOYSA-N	Phase 2
tretinoin	retinoid receptor agonist, retinoid receptor ligand	ALDH1A1, ALDH1A2, GPRC5A, NR0B1, NR2C2, PPARD, RARA, RARB, RARG, RARRES1, RORB, RORC, RXRB, RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	BRD-K71879491-001-44-0, BRD-K71879491-001-48-1, BRD-K71879491-001-39-0, BRD-K71879491-001-38-2, BRD-K71879491-001-47-3, BRD-K71879491-001-37-4	CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O, CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O	SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N, SHGAZHPCJJPHSC-YCNIQYBTSA-N	Launched
triacetin					BRD-K92844263-001-09-8	CC(=O)OCC(COC(C)=O)OC(C)=O	URAYPUMNDPQOKB-UHFFFAOYSA-N	Launched
triamcinolone	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	BRD-K77554836-001-11-6, BRD-A37780065-001-04-5, BRD-K97780336-001-01-9	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@H](O)[C@@]3(F)C(CCC4=CC(=O)C=C[C@]34C)C1C[C@@H](O)[C@]2(O)C(=O)CO, C[C@]12C[C@@H](O)[C@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@@]2(O)C(=O)CO	GFNANZIMVAIWHM-OBYCQNJPSA-N, GFNANZIMVAIWHM-MGVPRKGPSA-N, GFNANZIMVAIWHM-BHOVCMIXSA-N	Launched
triamcinolone-acetonide	glucocorticoid receptor agonist, immunosuppressant	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K41708980-001-01-6, BRD-A92439610-001-04-0	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@]4(F)[C@H](O)C[C@]3(C)[C@]2(O1)C(=O)CO, CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO	YNDXUCZADRHECN-MUQQULFASA-N, YNDXUCZADRHECN-BPHAHLGOSA-N	Launched
triamterene	sodium channel blocker	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	BRD-K92049597-001-20-8, BRD-K92049597-001-19-0	Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1, Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1	FNYLWPVRPXGIIP-UHFFFAOYSA-N, FNYLWPVRPXGIIP-UHFFFAOYSA-N	Launched
triapine	ribonucleotide reductase inhibitor	RRM1, RRM2			BRD-K01669786-001-03-0, BRD-K01669786-001-02-2, BRD-K01669786-001-01-4	NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N, NC(=S)N\N=C\c1ncccc1N	XMYKNCNAZKMVQN-NYYWCZLTSA-N, XMYKNCNAZKMVQN-NYYWCZLTSA-N, XMYKNCNAZKMVQN-NYYWCZLTSA-N	Phase 2
triazolam	GABA benzodiazepine site receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO			BRD-K76890464-001-02-3	Cc1nnc2CN=C(c3ccccc3Cl)c3cc(Cl)ccc3-n12	JOFWLTCLBGQGBO-UHFFFAOYSA-N	Withdrawn
tribenoside	anti-inflammatory agent, capillary stabilizing agent				BRD-A60294240-001-03-7	CCOC1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O	ULLNJSBQMBKOJH-VIVFLBMVSA-N	Launched
tribomsalan					BRD-K09118247-001-03-3	Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1	KVSKGMLNBAPGKH-UHFFFAOYSA-N	Preclinical
tribromoethanol	analgesic agent				BRD-K69632891-001-01-3	OCC(Br)(Br)Br	YFDSDPIBEUFTMI-UHFFFAOYSA-N	Preclinical
tributyrin	HDAC inhibitor				BRD-K38969488-001-01-6	CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC	UYXTWWCETRIEDR-UHFFFAOYSA-N	Phase 1
tricaprylin			dermatology	cosmetic	BRD-K24790130-001-07-1	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	VLPFTAMPNXLGLX-UHFFFAOYSA-N	Launched
trichlormethiazide	chloride channel blocker	ATP1A1, CA1, CA2, CA4, SLC12A1, SLC12A3	cardiology	hypertension, edema	BRD-A28940325-001-24-0, BRD-A28940325-001-23-2, BRD-A28940325-001-25-7	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl, NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl	LMJSLTNSBFUCMU-UHFFFAOYSA-N, LMJSLTNSBFUCMU-UHFFFAOYSA-N, LMJSLTNSBFUCMU-UHFFFAOYSA-N	Launched
trichlormethine	DNA alkylating agent				BRD-K29888499-003-03-8	ClCCN(CCCl)CCCl	FDAYLTPAFBGXAB-UHFFFAOYSA-N	Preclinical
trichloroacetic-acid			dermatology	warts	BRD-K42090719-001-06-5	OC(=O)C(Cl)(Cl)Cl	YNJBWRMUSHSURL-UHFFFAOYSA-N	Launched
trichloroethylene					BRD-K46435528-001-04-4	ClC=C(Cl)Cl	XSTXAVWGXDQKEL-UHFFFAOYSA-N	Preclinical
trichostatin-a	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			BRD-K68202742-001-16-5, BRD-K68202742-001-13-2	C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C, C[C@H](\C=C(C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	RTKIYFITIVXBLE-QEQCGCAPSA-N, RTKIYFITIVXBLE-QEQCGCAPSA-N	Preclinical
triciribine	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K80431395-001-07-3, BRD-K85975921-001-01-0, BRD-K80431395-001-04-0	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23, Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	HOGVTUZUJGHKPL-HTVVRFAVSA-N, HOGVTUZUJGHKPL-CUCYUNINSA-N, HOGVTUZUJGHKPL-HTVVRFAVSA-N	Phase 1/Phase 2
triclabendazole	microtubule inhibitor	DNMT1	infectious disease	tapeworm	BRD-K81916719-001-13-9, BRD-K81916719-001-14-7	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1, CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	NQPDXQQQCQDHHW-UHFFFAOYSA-N, NQPDXQQQCQDHHW-UHFFFAOYSA-N	Launched
triclocarban	other antibiotic				BRD-K25029121-001-05-8	Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	ICUTUKXCWQYESQ-UHFFFAOYSA-N	Launched
triclosan	antibacterial agent	DNMT1			BRD-K41731458-001-15-1	Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl	XEFQLINVKFYRCS-UHFFFAOYSA-N	Launched
tridihexethyl	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology, ophthalmology	peptic ulcer disease (PUD), nystagmus	BRD-A22152765-003-10-0	CC[N+](CC)(CC)CCC(O)(C1CCCCC1)c1ccccc1	NPRHVSBSZMAEIN-UHFFFAOYSA-N	Launched
trientine	chelating agent	CA14	metabolism	Wilsons disease" "BRD-K37111771-300-02-6" "NCCNCCNCCN" "VILCJCGEZXAXTO-UHFFFAOYSA-N" "Launched"
"2949" "trifluoperazine" "dopamine receptor antagonist" "ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1" "neurology/psychiatry" "schizophrenia" "BRD-K89732114-300-14-7, BRD-K89732114-300-15-4, BRD-K89732114-300-13-9" "CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1, CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1" "ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N, ZEWQUBUPAILYHI-UHFFFAOYSA-N" "Launched"
"2950" "triflupromazine" "dopamine receptor antagonist" "CHRM1, CHRM2, DRD1, DRD2, HTR2B" "neurology/psychiatry, gastroenterology" "psychosis, nausea, vomiting" "BRD-K63675182-003-23-6, BRD-K63675182-003-22-8" "CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F, CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F" "XSCGXQMFQXDFCW-UHFFFAOYSA-N, XSCGXQMFQXDFCW-UHFFFAOYSA-N" "Launched"
"2951" "trifluridine" "DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor" "TYMS" "infectious disease" "virus herpes simplex (HSV)" "BRD-A64485570-001-11-0, BRD-K03243820-001-23-8, BRD-K03243820-001-22-0" "OC[C@H]1OC(C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F, OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F" "VSQQQLOSPVPRAZ-GFCOJPQKSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N, VSQQQLOSPVPRAZ-RRKCRQDMSA-N" "Launched"
"2952" "triflusal" "cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor" "NFKB1, NOS2, PDE10A, PTGS1" "neurology/psychiatry, cardiology" "stroke, myocardial infarction, atrial fibrillation (AF)" "BRD-K71696703-001-07-9, BRD-K71696703-001-09-5, BRD-K71696703-001-06-1, BRD-K71696703-001-08-7" "CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F, CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F" "RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N, RMWVZGDJPAKBDE-UHFFFAOYSA-N" "Launched"
"2953" "trigonelline" "" "" "" "" "BRD-K69231085-003-05-7" "C[n+]1cccc(c1)C(O)=O" "WWNNZCOKKKDOPX-UHFFFAOYSA-O" "Phase 1"
"2954" "trihexyphenidyl" "acetylcholine receptor antagonist" "CHRM1, CHRM2, CHRM3, CHRM4, CHRM5" "neurology/psychiatry" "parkinsonism" "BRD-A48180038-003-24-3" "OC(CCN1CCCCC1)(C1CCCCC1)c1ccccc1" "HWHLPVGTWGOCJO-UHFFFAOYSA-N" "Launched"
"2955" "trilostane" "3beta-hydroxy-delta5-steroid dehydrogenase inhibitor" "ESR1, ESR2, HSD3B1, HSD3B2" "endocrinology" "Cushings syndrome	BRD-A04497688-001-03-4, BRD-A66155091-001-01-8, BRD-A99644790-001-02-4	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O, C[C@]12CC[C@@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)[C@@H]1CC[C@H]2O, C[C@]12CCC3[C@@H](CC[C@@]45O[C@@H]4C(=O)C(C[C@]35C)C#N)C1CC[C@@H]2O	RLQVKDVIBJCQGE-WDUCDQOOSA-N, RLQVKDVIBJCQGE-VWWPZJNLSA-N, RLQVKDVIBJCQGE-NZQVXXBDSA-N	Launched
TRIM					BRD-K36851334-001-12-1	FC(F)(F)c1ccccc1-n1ccnc1	WZBWBNCQUTXYEL-UHFFFAOYSA-N	Preclinical
trimebutine	opioid receptor agonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	BRD-A92630576-050-24-1, BRD-A92630576-001-02-0	CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1, CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1	LORDFXWUHHSAQU-UHFFFAOYSA-N, LORDFXWUHHSAQU-UHFFFAOYSA-N	Launched
trimeprazine	histamine receptor ligand, histamine receptor antagonist	HRH1	allergy, neurology/psychiatry, pulmonary	urticaria, itching, cough suppressant	BRD-M58473998-046-01-0	CC(CN(C)C)CN1c2ccccc2Sc2ccccc12.CC(CN(C)C)CN1c2ccccc2Sc2ccccc12	QVKSGMJGGSXIQM-UHFFFAOYSA-N	Launched
trimetazidine	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	BRD-K88366685-300-06-0	COc1ccc(CN2CCNCC2)c(OC)c1OC	UHWVSEOVJBQKBE-UHFFFAOYSA-N	Launched
trimethadione	oxazolidine antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	BRD-K16606819-001-10-1, BRD-K16606819-001-12-7, BRD-K16606819-001-11-9	CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O, CN1C(=O)OC(C)(C)C1=O	IRYJRGCIQBGHIV-UHFFFAOYSA-N, IRYJRGCIQBGHIV-UHFFFAOYSA-N, IRYJRGCIQBGHIV-UHFFFAOYSA-N	Launched
trimethobenzamide	histamine receptor antagonist	DRD2	gastroenterology	vomiting, nausea, gastroenteritis	BRD-K34415467-003-13-0	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	FEZBIKUBAYAZIU-UHFFFAOYSA-N	Launched
trimethoprim	dihydrofolate reductase inhibitor	DHFR, TYMS	infectious disease, gastroenterology	urinary tract infections, ear infections, diarrhea	BRD-K07208025-001-29-7, BRD-K07208025-001-31-3	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC, COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	IEDVJHCEMCRBQM-UHFFFAOYSA-N, IEDVJHCEMCRBQM-UHFFFAOYSA-N	Launched
trimethoquinol	adrenergic receptor antagonist	ADRB2, ADRB3			BRD-A56241705-003-01-2	COc1cc(CC2NCCc3cc(O)c(O)cc23)cc(OC)c1OC	RGVPOXRFEPSFGH-UHFFFAOYSA-N	Launched
trimethylolpropane-triacrylate					BRD-K24483849-001-01-8	CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C	DAKWPKUUDNSNPN-UHFFFAOYSA-N	Preclinical
trimetozine	sedative		neurology/psychiatry	sedative	BRD-K53220666-001-02-6	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	XWVOEFLBOSSYGM-UHFFFAOYSA-N	Launched
trimipramine	norepinephrine reputake inhibitor, tricyclic antidepressant	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR1D, HTR2A, HTR2C, HTR3A, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-A19195498-050-14-1, BRD-A19195498-050-13-3	CC(CN(C)C)CN1c2ccccc2CCc2ccccc12, CC(CN(C)C)CN1c2ccccc2CCc2ccccc12	ZSCDBOWYZJWBIY-UHFFFAOYSA-N, ZSCDBOWYZJWBIY-UHFFFAOYSA-N	Launched
trioxsalen	DNA synthesis inhibitor		dermatology	vitiligo, eczema	BRD-K54790157-001-15-5	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	FMHHVULEAZTJMA-UHFFFAOYSA-N	Launched
tripelennamine	histamine receptor antagonist	HRH1	pulmonary, allergy	asthma, allergic rhinitis, urticaria	BRD-K57033106-003-19-7, BRD-K57033106-048-04-4	CN(C)CCN(Cc1ccccc1)c1ccccn1, CN(C)CCN(Cc1ccccc1)c1ccccn1	UFLGIAIHIAPJJC-UHFFFAOYSA-N, UFLGIAIHIAPJJC-UHFFFAOYSA-N	Launched
triprolidine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	BRD-K11742128-003-23-4, BRD-K11742128-003-22-6	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1, Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	CBEQULMOCCWAQT-WOJGMQOQSA-N, CBEQULMOCCWAQT-WOJGMQOQSA-N	Launched
triptan	serotonin receptor agonist	HTR1B, HTR1D			BRD-K19427720-001-01-6	CC(C)C(C)(C)C	ZISSAWUMDACLOM-UHFFFAOYSA-N	Phase 1
triptolide	RNA polymerase inhibitor	RELA			BRD-K81258678-001-01-0	CC(C)[C@@]12O[C@@H]1[C@@H]1O[C@]11[C@]3(O[C@@H]3C[C@@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O	DFBIRQPKNDILPW-LKUXBXJISA-N	Phase 3
triptorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology, endocrinology, obstetrics/gynecology	prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria	BRD-K62685538-001-01-7	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	VXKHXGOKWPXYNA-PGBVPBMZSA-N	Launched
troclosene					BRD-K76375510-237-01-1	Cln1c(=O)[nH]c(=O)n(Cl)c1=O	CEJLBZWIKQJOAT-UHFFFAOYSA-N	Launched
trofinetide	cytokine production inhibitor	IFNG, IL6, TNF			BRD-K83502127-001-01-6	NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O	JJGBXTYGTKWGAT-YUMQZZPRSA-N	Phase 2
troglitazone	insulin sensitizer, PPAR receptor agonist	ACSL4, ESRRA, ESRRG, PPARG, SERPINE1, SLC29A1, TRPM3			BRD-A13084692-001-17-3	Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O	GXPHKUHSUJUWKP-UHFFFAOYSA-N	Withdrawn
troleandomycin	protein synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, tonsillitis, sinusitis	BRD-A24297246-001-03-9	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](OC3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	LQCLVBQBTUVCEQ-RFHKDOLOSA-N	Launched
trolox	antioxidant				BRD-A17846016-001-13-9	Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(O)=O	GLEVLJDDWXEYCO-UHFFFAOYSA-N	Launched
tromaril	prostanoid receptor antagonist				BRD-K91422571-001-01-8	OC(=O)c1ccccc1NCCc1ccccc1	HLNLBEFKHHCAMV-UHFFFAOYSA-N	Launched
trometamol		AMD1, CANT1, DCN, NEIL1, VEGFA			BRD-K47978074-001-02-4, BRD-K47978074-001-03-2	NC(CO)(CO)CO, NC(CO)(CO)CO	LENZDBCJOHFCAS-UHFFFAOYSA-N, LENZDBCJOHFCAS-UHFFFAOYSA-N	Launched
tropesin	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A34603619-001-01-9	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(C(O)=O)c3ccccc3)c2c1	UCCJWNPWWPJKGL-UHFFFAOYSA-N	Launched
tropicamide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	ophthalmology	mydriasis diagnostic, cycloplegia diagnostic	BRD-A79672927-001-20-7, BRD-A79672927-001-19-9, BRD-A79672927-001-18-1	CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1, CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1, CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1	BGDKAVGWHJFAGW-UHFFFAOYSA-N, BGDKAVGWHJFAGW-UHFFFAOYSA-N, BGDKAVGWHJFAGW-UHFFFAOYSA-N	Launched
tropisetron	serotonin receptor antagonist	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting, nausea, vomiting	BRD-M19407551-300-01-6, BRD-A79226577-003-19-3	CN1[C@H]2CC[C@@H]1C[C@H](C2)OC(=O)c1c[nH]c2ccccc12.CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12, CN1[C@H]2CC[C@@H]1CC(C2)OC(=O)C1C=Nc2ccccc12	CQDDGMICHZFTFU-SCIQOOLUSA-N, RIJFNUHYNBVLOZ-DOOHLRMFSA-N	Launched
trospium	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence, urinary frequency	BRD-K69469734-003-02-5	OC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)(c1ccccc1)c1ccccc1	OYYDSUSKLWTMMQ-JKHIJQBDSA-N	Launched
trovafloxacin	bacterial DNA gyrase inhibitor	TOP2A			BRD-K00494077-066-01-9	N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	WVPSKSLAZQPAKQ-CDMJZVDBSA-N	Withdrawn
troventol					BRD-A35868371-005-01-6	CCC(CO)(C(=O)OC1CC2CCC(C1)[N+]2(C)C)c1ccccc1	QFWSRMACUIYPGS-UHFFFAOYSA-N	Phase 1
trovirdine	non-nucleoside reverse transcriptase inhibitor				BRD-K00989047-001-01-2	Brc1ccc(NC(=S)NCCc2ccccn2)nc1	HOCFDYZWQYGULA-UHFFFAOYSA-N	Phase 1
troxerutin	antioxidant				BRD-A74160776-001-04-4, BRD-K73529671-001-02-9, BRD-K03928833-001-01-5	C[C@@H]1O[C@@H](OC[C@H]2OC(Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O, C[C@@H]1O[C@@H](OC[C@@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IYVFNTXFRYQLRP-IIXSESAUSA-N, IYVFNTXFRYQLRP-VVSTWUKXSA-N, IYVFNTXFRYQLRP-QVBBQYAOSA-N	Launched
troxipide	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	BRD-A68589262-001-05-0, BRD-A68589262-001-04-3	COc1cc(cc(OC)c1OC)C(=O)NC1CCCNC1, COc1cc(cc(OC)c1OC)C(=O)NC1CCCNC1	YSIITVVESCNIPR-UHFFFAOYSA-N, YSIITVVESCNIPR-UHFFFAOYSA-N	Launched
TRO19622	apoptosis inhibitor				BRD-A33931310-001-01-7	CC(C)CCCC(C)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(CC[C@]4(C)[C@H]3CC[C@]12C)=NO	QNTASHOAVRSLMD-SHLKSLFASA-N	Phase 2/Phase 3
TRV130	opioid receptor agonist	OPRM1			BRD-K35626314-003-01-1	COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1	DMNOVGJWPASQDL-OAQYLSRUSA-N	Phase 3
tryptanthrin	cyclooxygenase inhibitor	IDO1			BRD-K76973696-001-12-6	O=C1c2ccccc2-n2c1nc1ccccc1c2=O	VQQVWGVXDIPORV-UHFFFAOYSA-N	Preclinical
tryptophan	serotonin receptor partial agonist	CASR, IDO1, SLC36A1, WARS, WARS2	neurology/psychiatry, gastroenterology	anxiety, bloating, constipation, fatigue, sleeplessness	BRD-K83776863-001-08-9, BRD-K83776863-001-05-5	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O, N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	QIVBCDIJIAJPQS-VIFPVBQESA-N, QIVBCDIJIAJPQS-VIFPVBQESA-N	Launched
TTNPB	retinoid receptor agonist	RARA, RARB, RARG			BRD-K49685476-001-15-9, BRD-K49685476-001-16-7, BRD-K49685476-001-14-2	C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C, C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	FOIVPCKZDPCJJY-JQIJEIRASA-N, FOIVPCKZDPCJJY-JQIJEIRASA-N, FOIVPCKZDPCJJY-JQIJEIRASA-N	Phase 1
TU-2100					BRD-K44590731-001-01-7	CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	LIBAUACOIKWWKP-UHFFFAOYSA-N	Phase 2
tuaminoheptane			otolaryngology	nasal congestion	BRD-A19958636-065-04-4	CCCCCC(C)N	VSRBKQFNFZQRBM-UHFFFAOYSA-N	Launched
tubastatin-a	HDAC inhibitor	HDAC6			BRD-K00627859-003-03-7, BRD-K00627859-001-07-2, BRD-K00627859-001-06-4	CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO, CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N, GOVYBPLHWIEHEJ-UHFFFAOYSA-N	Preclinical
tubocurarine	acetylcholine receptor antagonist	ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN	neurology/psychiatry	anesthetic	BRD-K99621550-300-01-8	COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5c(O)c(OC)cc6CC[N+](C)(C)[C@H](Cc7ccc(O)c(Oc1cc23)c7)c56)cc4	JFJZZMVDLULRGK-URLMMPGGSA-O	Launched
tucatinib	EGFR inhibitor	ERBB2			BRD-K26026438-001-01-0	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1	SDEAXTCZPQIFQM-UHFFFAOYSA-N	Phase 2
TUG-770	free fatty acid receptor agonist	FFAR1			BRD-K56086081-001-01-7	OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N	KIZUBVPJNPVIIN-UHFFFAOYSA-N	Preclinical
tulobuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	BRD-A37441042-003-04-8	CC(C)(C)NCC(O)c1ccccc1Cl	YREYLAVBNPACJM-UHFFFAOYSA-N	Launched
TW-37	BCL inhibitor	BCL2, BCL2L1, MCL1			BRD-K28360340-001-08-3, BRD-K28360340-001-05-9	CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O, CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	PQAPVTKIEGUPRN-UHFFFAOYSA-N, PQAPVTKIEGUPRN-UHFFFAOYSA-N	Preclinical
TWS-119	glycogen synthase kinase inhibitor	GSK3B, JUN, MYC			BRD-K94176593-362-01-7, BRD-K94176593-001-09-4	Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1, Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	VPVLEBIVXZSOMQ-UHFFFAOYSA-N, VPVLEBIVXZSOMQ-UHFFFAOYSA-N	Preclinical
TXA127	angiotensin receptor agonist				BRD-K36040345-001-02-9, BRD-K36040345-001-01-1	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(O)=O, CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(O)=O	PVHLMTREZMEJCG-GDTLVBQBSA-N, PVHLMTREZMEJCG-GDTLVBQBSA-N	Phase 2
TY-52156	sphingosine 1-phosphate receptor antagonist	S1PR3			BRD-K66584608-001-01-3	CC(C)(C)C(=O)C(\NNc1ccc(Cl)cc1)=N\c1ccc(Cl)cc1	XONRRGIRSGNWFP-UHFFFAOYSA-N	Preclinical
tylosin	protein synthesis inhibitor		infectious disease, gastroenterology	gram-positive bacterial infections, colitis	BRD-K90749417-046-01-8, BRD-K37753391-046-02-4	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC, CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC	WBPYTXDJUQJLPQ-FEYMKQPTSA-N, WBPYTXDJUQJLPQ-VMXQISHHSA-N	Launched
tyloxapol	NFkB pathway inhibitor	LPL, NFKB2			BRD-M08959712-001-01-9, BRD-U25960968-000-01-9, BRD-U48018661-000-01-9	C=O.C1CO1.CC(C)(C)CC(C)(C)c1ccc(O)cc1, , 	MDYZKJNTKZIUSK-UHFFFAOYSA-N, , 	Launched
tymazoline			allergy	allergic rhinitis	BRD-K64414150-001-01-7	CC(C)c1ccc(C)cc1OC=C1NCCN1	AFQQVNXTHGUXEQ-UHFFFAOYSA-N	Launched
tyrphostin-AG-1296	FLT3 inhibitor	FLT3			BRD-K76064317-001-08-1, BRD-K76064317-001-07-3	COc1cc2ncc(nc2cc1OC)-c1ccccc1, COc1cc2ncc(nc2cc1OC)-c1ccccc1	QNOXYUNHIGOWNY-UHFFFAOYSA-N, QNOXYUNHIGOWNY-UHFFFAOYSA-N	Preclinical
tyrphostin-AG-1478	EGFR inhibitor	EGFR, MAPK14			BRD-K68336408-001-10-9	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	GFNNBHLJANVSQV-UHFFFAOYSA-N	Preclinical
tyrphostin-AG-18	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			BRD-K49657628-001-15-5, BRD-K49657628-001-14-8, BRD-K49657628-001-13-0	Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O, Oc1ccc(C=C(C#N)C#N)cc1O	VTJXFTPMFYAJJU-UHFFFAOYSA-N, VTJXFTPMFYAJJU-UHFFFAOYSA-N, VTJXFTPMFYAJJU-UHFFFAOYSA-N	Preclinical
tyrphostin-AG-494	EGFR inhibitor	EGFR			BRD-K34533029-001-08-5	Oc1ccc(cc1O)\C=C(/C#N)C(=O)Nc1ccccc1	HKHOVJYOELRGMV-XYOKQWHBSA-N	Preclinical
tyrphostin-AG-825	protein tyrosine kinase inhibitor	ERBB2			BRD-K87919739-001-07-5	COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O	KXDONFLNGBQLTN-WUXMJOGZSA-N	Preclinical
tyrphostin-AG-835	protein tyrosine kinase inhibitor	EGFR			BRD-K17415526-001-03-5	C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	UMGQVUWXNOJOSJ-DGGAMASNSA-N	Preclinical
tyrphostin-AG-879	tyrosine kinase inhibitor	ERBB2, KDR, NTRK1			BRD-K59469039-001-09-8, BRD-K59469039-001-08-0	CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S, CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S	XRZYELWZLNAXGE-KPKJPENVSA-N, XRZYELWZLNAXGE-KPKJPENVSA-N	Preclinical
tyrphostin-AG-99	tyrosine kinase inhibitor	EGFR			BRD-K60184833-001-05-6	NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	USOXQZNJFMKTKJ-XVNBXDOJSA-N	Preclinical
tyrphostin-A9	protein tyrosine kinase inhibitor, tyrosine kinase inhibitor				BRD-K40255344-001-17-6	CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	MZOPWQKISXCCTP-UHFFFAOYSA-N	Preclinical
U-0124	MEK inhibitor				BRD-K63169195-001-01-5	CS\C(N)=C(C#N)\C(C#N)=C(/N)SC	LBQNBMSPTURKGS-KQQUZDAGSA-N	Preclinical
U-0126	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			BRD-K91701654-001-03-1, BRD-K18787491-001-08-6, BRD-K91701654-001-02-3	N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N, N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(/N)Sc1ccccc1N	DVEXZJFMOKTQEZ-MJZABRMRSA-N, DVEXZJFMOKTQEZ-JYFOCSDGSA-N, DVEXZJFMOKTQEZ-MJZABRMRSA-N	Preclinical
U-0521	catechol O methyltransferase inhibitor	COMT			BRD-K08953028-001-09-6	CC(C)C(=O)c1ccc(O)c(O)c1	VDQLKIBLTMPAHI-UHFFFAOYSA-N	Preclinical
U-104	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA9			BRD-K77867004-001-02-7, BRD-K77867004-001-03-5	NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1, NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	YJQZNWPYLCNRLP-UHFFFAOYSA-N, YJQZNWPYLCNRLP-UHFFFAOYSA-N	Preclinical
U-18666A	oxidosqualene cyclase inhibitor				BRD-K22025381-003-01-9	CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1	DMZCCFMMPHJWQY-BKWLFHPQSA-N	Preclinical
U-50488-(+/-)	opioid receptor agonist	OPRK1			BRD-M57185017-300-01-9	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1.CN([C@@H]1CCCC[C@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	OWQBPOUTHXCWAF-PTQCACIQSA-N	Preclinical
U-50488-(-)	opioid receptor agonist	OPRK1			BRD-K53532120-003-09-5	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	VQLPLYSROCPWFF-ROUUACIJSA-N	Preclinical
U-54494A	opioid receptor agonist	OPRK1			BRD-K20995441-001-02-5	CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	JUBNVWGVNWIXMB-SJORKVTESA-N	Preclinical
U-75799E	growth hormone releasing factor agonist	GHSR			BRD-K77070363-001-01-5	C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	WZHKXNSOCOQYQX-FUAFALNISA-N	Phase 1
U-99194	dopamine receptor antagonist	DRD3			BRD-K70281171-050-08-9	CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1	UOLJKAPABHXFRE-UHFFFAOYSA-N	Preclinical
UB-165	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNB2			BRD-A14574269-051-02-2	Clc1ccc(cn1)C1=CCCC2CCC1N2	TVSNVPGPFGAKPT-UHFFFAOYSA-N	Preclinical
ubenimex	leukotriene synthesis inhibitor	LTA4H, RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K59574735-001-11-8, BRD-K59574735-001-12-6	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O, CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	VGGGPCQERPFHOB-RDBSUJKOSA-N, VGGGPCQERPFHOB-RDBSUJKOSA-N	Launched
UBP-302	glutamate receptor antagonist	GRIK1			BRD-K79753741-001-01-7, BRD-A45499626-001-03-6	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O, NC(Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	UUIYULWYHDSXHL-NSHDSACASA-N, UUIYULWYHDSXHL-UHFFFAOYSA-N	Preclinical
UCL-2077	slow afterhyperpolarization channel blocker				BRD-K50325075-001-02-1	C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	PQFNWDHABGBCHB-UHFFFAOYSA-N	Preclinical
ufenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	dermatology	eczema, dermatitis	BRD-K84173274-001-01-6	CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	JDLSRXWHEBFHNC-UHFFFAOYSA-N	Launched
UH-232-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR1A			BRD-K66715657-050-01-0	CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	BTOJYCTUJJHANF-WMLDXEAASA-N	Preclinical
UK-383367	Procollagen C-Endopeptidase Inhibitors	BMP1			BRD-K06294530-001-02-3, BRD-K06294530-001-01-5	NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO, NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	ARJCBSRIPGJMAD-LLVKDONJSA-N, ARJCBSRIPGJMAD-LLVKDONJSA-N	Phase 1
ulifloxacin					BRD-A61633223-001-02-8, BRD-A61633223-001-01-0	CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1, CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1	SUXQDLLXIBLQHW-UHFFFAOYSA-N, SUXQDLLXIBLQHW-UHFFFAOYSA-N	Launched
ulipristal	progesterone receptor antagonist	PGR	endocrinology	contraceptive	BRD-K76197012-001-01-2, BRD-K55641198-001-01-0	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12, CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12	OOLLAFOLCSJHRE-ONBAZCQBSA-N, HKDLNTKNLJPAIY-WKWWZUSTSA-N	Launched
umeclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	BRD-K46692793-004-01-8	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	FVTWTVQXNAJTQP-UHFFFAOYSA-N	Launched
UNBS-5162	CC chemokine receptor antagonist				BRD-K30933884-001-01-0	CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	WCKZRLOUKYFJDY-UHFFFAOYSA-N	Phase 1
UNC0224	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K77428767-001-01-7	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	XIVUGRBSBIXXJE-UHFFFAOYSA-N	Preclinical
UNC0321	histone lysine methyltransferase inhibitor	EHMT2			BRD-K74236984-001-04-8, BRD-K74236984-001-05-5	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1, COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	AULLUGALUBVBDD-UHFFFAOYSA-N, AULLUGALUBVBDD-UHFFFAOYSA-N	Preclinical
UNC0631	histone lysine methyltransferase inhibitor	EHMT2			BRD-K13060017-001-02-1, BRD-K13060017-001-01-3	COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	XFAXSWXKPQWHDW-UHFFFAOYSA-N, XFAXSWXKPQWHDW-UHFFFAOYSA-N	Preclinical
UNC0638	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K86856088-001-06-9, BRD-K86856088-001-07-7	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	QOECJCJVIMVJGX-UHFFFAOYSA-N, QOECJCJVIMVJGX-UHFFFAOYSA-N	Preclinical
UNC0642	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K60130390-001-02-1, BRD-K60130390-001-03-9	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1, COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	RNAMYOYQYRYFQY-UHFFFAOYSA-N, RNAMYOYQYRYFQY-UHFFFAOYSA-N	Preclinical
UNC0646	histone lysine methyltransferase inhibitor	EHMT2			BRD-K87465484-001-02-7, BRD-K87465484-001-03-5	COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C, COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	OUKWLRHRXOPODD-UHFFFAOYSA-N, OUKWLRHRXOPODD-UHFFFAOYSA-N	Preclinical
UNC0737	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K02988401-001-01-2	COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C	ATORKVYCKKBNTF-UHFFFAOYSA-N	Preclinical
UNC1215	L3MBTL antagonist	L3MBTL3			BRD-K83189926-001-04-9, BRD-K83189926-001-03-1	O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1, O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	PQOOIERVZAXHBP-UHFFFAOYSA-N, PQOOIERVZAXHBP-UHFFFAOYSA-N	Preclinical
UNC1999	histone lysine methyltransferase inhibitor	EZH2			BRD-K26989966-001-03-5, BRD-K26989966-001-04-3	CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C, CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	DPJNKUOXBZSZAI-UHFFFAOYSA-N, DPJNKUOXBZSZAI-UHFFFAOYSA-N	Preclinical
UNC2025	MER tyrosine kinase inhibitor, FLT3 inhibitor	FLT3, MERTK			BRD-K91283740-003-01-6	CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1	MJSHVHLADKXCML-RQNOJGIXSA-N	Preclinical
UNC2250	MER tyrosine kinase inhibitor	MERTK			BRD-K01773560-001-02-4, BRD-K01773560-001-01-6	CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1, CCCCNc1ncc(-c2ccc(CN3CCOCC3)cn2)c(N[C@H]2CC[C@H](O)CC2)n1	HSYSSKFCQHXOBP-MXVIHJGJSA-N, HSYSSKFCQHXOBP-MXVIHJGJSA-N	Preclinical
UNC669	L3MBTL antagonist	L3MBTL1			BRD-K21906513-001-04-0, BRD-K21906513-001-03-2	Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1, Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	CQERVFFAOOUFEQ-UHFFFAOYSA-N, CQERVFFAOOUFEQ-UHFFFAOYSA-N	Preclinical
undecylenic-acid	other antifungal		infectious disease	tinea pedis, tinea corporis	BRD-K19189338-001-03-2, BRD-K19189338-001-05-7	OC(=O)CCCCCCCCC=C, OC(=O)CCCCCCCCC=C	FRPZMMHWLSIFAZ-UHFFFAOYSA-N, FRPZMMHWLSIFAZ-UHFFFAOYSA-N	Launched
UPF-1069	PARP inhibitor	PARP2			BRD-K77950083-001-03-3, BRD-K77950083-001-02-5	O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1, O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	JJWMRRNGWSITSQ-UHFFFAOYSA-N, JJWMRRNGWSITSQ-UHFFFAOYSA-N	Preclinical
uprosertib	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K38332599-001-01-3	Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	AXTAPYRUEKNRBA-JTQLQIEISA-N	Phase 2
uracil		DPYD, UCKL1			BRD-K80129304-001-09-9, BRD-K80129304-001-08-1	Oc1ccnc(O)n1, Oc1ccnc(O)n1	ISAKRJDGNUQOIC-UHFFFAOYSA-N, ISAKRJDGNUQOIC-UHFFFAOYSA-N	Launched
uracil-mustard	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	BRD-K10180294-001-04-0, BRD-K10180294-001-06-5	Oc1ncc(N(CCCl)CCCl)c(O)n1, Oc1ncc(N(CCCl)CCCl)c(O)n1	IDPUKCWIGUEADI-UHFFFAOYSA-N, IDPUKCWIGUEADI-UHFFFAOYSA-N	Launched
urapidil	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	BRD-K73196317-003-14-8, BRD-K73196317-003-13-0, BRD-K73196317-003-15-5	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1, COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N, ICMGLRUYEQNHPF-UHFFFAOYSA-N	Launched
URB597	FAAH inhibitor	FAAH, FAAH2, TRPA1			BRD-K92169341-001-11-2, BRD-K92169341-001-10-4	NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1, NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	ROFVXGGUISEHAM-UHFFFAOYSA-N, ROFVXGGUISEHAM-UHFFFAOYSA-N	Phase 1
urea	hydroxy radical formation stimulant	ARG1, CA2, CTNNB1	dermatology	psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis	BRD-K88052444-001-08-8	NC(N)=O	XSQUKJJJFZCRTK-UHFFFAOYSA-N	Launched
urethane	local anesthetic				BRD-K24297741-001-05-2	CCOC(N)=O	JOYRKODLDBILNP-UHFFFAOYSA-N	Preclinical
uric-acid		PYGL			BRD-K01295354-001-02-8	O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	LEHOTFFKMJEONL-UHFFFAOYSA-N	Phase 3
uridine	dopamine receptor agonist	LSM6, TYMP			BRD-K13050303-001-17-3, BRD-K32566431-001-01-4	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O, OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	DRTQHJPVMGBUCF-XVFCMESISA-N, DRTQHJPVMGBUCF-CCXZUQQUSA-N	Phase 2
uridine-triacetate			nephrology	orotic aciduria	BRD-K18323388-001-01-1	CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O	AUFUWRKPQLGTGF-FMKGYKFTSA-N	Launched
uridine-5-triphosphate" "purinergic receptor activator" "P2RY11, P2RY2, P2RY4, P2RY6, UCK2" "" ""
"2956" "BRD-A89637065-001-01-0" "O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O" "PGAVKCOVUIYSFO-XVFCMESISA-N" "Launched" "" "" "" "" ""
"2957" "URMC-099" "mixed lineage kinase inhibitor" "CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2" "" "" "BRD-K66908976-001-01-8" "CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1" "QKKIWEILHCXECO-UHFFFAOYSA-N" "Preclinical"
"2958" "ursodeoxycholyltaurine" "cholesterol inhibitor" "" "" "" "BRD-K45245728-335-01-4" "C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C" "BHTRKEVKTKCXOH-LBSADWJPSA-N" "Phase 2"
"2959" "ursodiol" "nuclear factor erythroid derived, like (NRF2) activator" "NR1H4" "gastroenterology" "gallstones" "BRD-K15697815-001-15-4, BRD-K87300616-001-01-9" "C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C, C[C@H](CCC(O)=O)[C@@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C" "RUDATBOHQWOJDD-UZVSRGJWSA-N, RUDATBOHQWOJDD-QLEQUTGBSA-N" "Launched"
"2960" "ursolic-acid" "ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor" "HSD11B1, PLA2G1B, PTPN1, PYGM" "" "" "BRD-A61767428-001-01-9, BRD-K68185022-001-12-2" "C[C@@H]1C[C@H](C2CC[C@]3(C)C(=CC[C@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@H]2[C@@H]1C)C(O)=O, C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O" "FZRIRHAXJWMMFP-PYQRESMBSA-N, WCGUUGGRBIKTOS-GPOJBZKASA-N" "Phase 1"
"2961" "usniacin-(+)" "MAP kinase activator" "PTPN1" "" "" "BRD-A12417644-001-07-6, BRD-A12417644-001-06-8" "CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O, CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O" "CUCUKLJLRRAKFN-MCEAHNFKSA-N, CUCUKLJLRRAKFN-MCEAHNFKSA-N" "Preclinical"
"2962" "V-51" "adrenergic receptor antagonist" "" "" "" "BRD-K75052463-001-01-4" "COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC" "KKCOGNFFBYOKMA-UHFFFAOYSA-N" "Phase 1"
"2963" "val" "" "BCAT1, PCCB, VARS" "" "" "BRD-K59424860-001-01-4" "CC(C)[C@@H](N)C(O)=O" "KZSNJWFQEVHDMF-SCSAIBSYSA-N" "Phase 2"
"2964" "valaciclovir" "DNA polymerase inhibitor" "" "infectious disease" "shingles, virus herpes simplex (HSV)" "BRD-K46435977-003-11-1, BRD-K46435977-003-12-9" "CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O, CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O" "HDOVUKNUBWVHOX-QMMMGPOBSA-N, HDOVUKNUBWVHOX-QMMMGPOBSA-N" "Launched"
"2965" "valdecoxib" "cyclooxygenase inhibitor" "CA12, PTGS2" "" "" "BRD-K12994359-001-18-4" "Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1" "LNPDTQAFDNKSHK-UHFFFAOYSA-N" "Withdrawn"
"2966" "valethamate" "acetylcholine receptor antagonist" "CHRM1, CHRM4, CHRM5" "obstetrics/gynecology" "labor induction" "BRD-A56613951-004-01-1" "CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1" "UPPMZCXMQRVMME-UHFFFAOYSA-N" "Launched"
"2967" "valganciclovir" "DNA synthesis inhibitor" "" "infectious disease" "cytomegalovirus (CMV)" "BRD-A50922295-001-01-3, BRD-A50922295-003-05-0" "CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O, CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c1nc(N)[nH]c2=O" "WPVFJKSGQUFQAP-GKAPJAKFSA-N, WPVFJKSGQUFQAP-GKAPJAKFSA-N" "Launched"
"2968" "valnemulin" "bacterial 50S ribosomal subunit inhibitor" "" "infectious disease, gastroenterology" "dysentry, colitis, pneumonia" "BRD-K33813875-003-01-8" "CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@]1(C)[C@H](C)CC3" "LLYYNOVSVPBRGV-LWVOSLLHSA-N" "Launched"
"2969" "valnoctamide" "arachidonic acid acylation inhibitor, benzodiazepine receptor agonist" "" "" "" "BRD-A96644976-001-01-5" "CCC(C)C(CC)C(N)=O" "QRCJOCOSPZMDJY-UHFFFAOYSA-N" "Phase 3"
"2970" "valproic-acid" "HDAC inhibitor" "ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "seizures" "BRD-K41260949-236-16-8, BRD-K41260949-236-15-0, BRD-K41260949-236-18-4, BRD-K41260949-236-17-6" "CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O, CCCC(CCC)C(O)=O" "NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N, NIJJYAXOARWZEE-UHFFFAOYSA-N" "Launched"
"2971" "valpromide" "epoxide hydolase inhibitor" "" "neurology/psychiatry" "epilepsy" "BRD-K54698528-001-01-2" "CCCC(CCC)C(N)=O" "OMOMUFTZPTXCHP-UHFFFAOYSA-N" "Launched"
"2972" "valrocemide" "" "" "" "" "BRD-K32804101-001-01-8" "CCCC(CCC)C(=O)NCC(N)=O" "RALGCAOVRLYSMA-UHFFFAOYSA-N" "Phase 2"
"2973" "valrubicin" "DNA inhibitor, topoisomerase inhibitor" "TOP2A" "oncology" "bladder cancer" "BRD-K72951360-001-01-4" "CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1" "ZOCKGBMQLCSHFP-KQRAQHLDSA-N" "Launched"
"2974" "valsartan" "angiotensin receptor antagonist" "AGTR1" "cardiology" "hypertension, congestive heart failure" "BRD-K45158365-001-11-4, BRD-K45158365-001-10-6" "CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O" "ACWBQPMHZXGDFX-QFIPXVFZSA-N, ACWBQPMHZXGDFX-QFIPXVFZSA-N" "Launched"
"2975" "valsartan-sacubitril-combination" "angiotensin receptor antagonist, neprilysin inhibitor" "AGTR1" "cardiology" "congestive heart failure" "BRD-M75836831-385-01-0" "CCOC(=O)C(C)CC(Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)C(C(C)C)C(O)=O" "XTKIDERFOUYBDE-UHFFFAOYSA-N" "Launched"
"2976" "valspodar" "P glycoprotein inhibitor" "ABCB1" "" "" "BRD-K19412342-001-01-6, BRD-K19412342-001-02-4" "C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C, C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C" "YJDYDFNKCBANTM-QCWCSKBGSA-N, YJDYDFNKCBANTM-QCWCSKBGSA-N" "Phase 3"
"2977" "vancomycin" "bacterial cell wall synthesis inhibitor" "" "infectious disease" "endocarditis" "BRD-K60071190-003-01-7, BRD-K91065602-001-01-8, BRD-K91065602-003-04-8" "CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2, CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2" "MYPYJXKWCTUITO-OSESMKSSSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N, MYPYJXKWCTUITO-LYRMYLQWSA-N" "Launched"
"2978" "vandetanib" "EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor" "EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA" "oncology" "medullary thyroid cancer (MTC)" "BRD-K77625799-001-07-7" "COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1" "UHTHHESEBZOYNR-UHFFFAOYSA-N" "Launched"
"2979" "vanillin" "" "ABAT, ALDH5A1" "" "" "BRD-K24258499-001-05-8" "COc1cc(C=O)ccc1O" "MWOOGOJBHIARFG-UHFFFAOYSA-N" "Preclinical"
"2980" "vanillylacetone" "" "" "" "" "BRD-K33510429-001-03-1, BRD-K33510429-001-02-3" "COc1cc(CCC(C)=O)ccc1O, COc1cc(CCC(C)=O)ccc1O" "OJYLAHXKWMRDGS-UHFFFAOYSA-N, OJYLAHXKWMRDGS-UHFFFAOYSA-N" "Preclinical"
"2981" "vanitiolide" "" "" "" "" "BRD-K26502378-001-07-9" "COc1cc(ccc1O)C(=S)N1CCOCC1" "WQYRHRAZNNRDIA-UHFFFAOYSA-N" "Preclinical"
"2982" "vanoxerine" "dopamine uptake inhibitor" "SLC6A3" "" "" "BRD-K32501161-300-06-2" "Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1" "NAUWTFJOPJWYOT-UHFFFAOYSA-N" "Phase 3"
"2983" "vardenafil" "phosphodiesterase inhibitor" "PDE5A, PDE6G, PDE6H" "urology" "erectile dysfunction" "BRD-K13926615-003-03-3, BRD-K13926615-394-02-8" "CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1, CCCc1nc(C)c2n1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1" "SECKRCOLJRRGGV-UHFFFAOYSA-N, SECKRCOLJRRGGV-UHFFFAOYSA-N" "Launched"
"2984" "varenicline" "acetylcholine receptor agonist" "CHRNA3, CHRNA4, CHRNA6, CHRNA7" "neurology/psychiatry" "smoking cessation" "BRD-A86216746-046-02-6" "C1C2CNCC1c1cc3nccnc3cc21" "JQSHBVHOMNKWFT-UHFFFAOYSA-N" "Launched"
"2985" "varespladib" "secretory phospholipase inhibitor" "PLA2G2A" "" "" "BRD-K09711437-001-04-3" "CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1" "BHLXTPHDSZUFHR-UHFFFAOYSA-N" "Phase 3"
"2986" "vasopressin" "vasopressin receptor agonist" "AVPR1A, AVPR1B, AVPR2, OXTR" "gastroenterology" "abdominal distension" "BRD-K73028949-001-02-8" "N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O" "KBZOIRJILGZLEJ-LGYYRGKSSA-N" "Launched"
"2987" "vatalanib" "KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor" "EGFR, FLT1, FLT4, KDR, PDGFRB" "" "" "BRD-K70163715-036-01-6, BRD-K70163715-300-05-7, BRD-K70163715-300-04-0" "Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1, Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1" "YCOYDOIWSSHVCK-UHFFFAOYSA-N, YCOYDOIWSSHVCK-UHFFFAOYSA-N, YCOYDOIWSSHVCK-UHFFFAOYSA-N" "Phase 3"
"2988" "VBY-825" "cathepsin inhibitor" "CTSB, CTSL, CTSS" "" "" "BRD-K36338614-001-01-3" "CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1" "PPUXXDKQNAHHON-BJLQDIEVSA-N" "Preclinical"
"2989" "VCH-916" "HCV inhibitor" "" "" "" "BRD-K75956464-237-01-5" "CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1" "LNYKGELUODVSNS-YSXIEMCBSA-N" "Phase 1"
"2990" "VE-821" "ATR kinase inhibitor" "ATR" "" "" "BRD-K26756394-001-02-2" "CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1" "DUIHHZKTCSNTGM-UHFFFAOYSA-N" "Preclinical"
"2991" "VE-822" "ATR kinase inhibitor" "ATM, ATR, MTOR, PIK3CG" "" "" "BRD-K04701033-001-04-7, BRD-K04701033-001-03-9, BRD-K04701033-001-01-3" "CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C, CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C" "JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N, JZCWLJDSIRUGIN-UHFFFAOYSA-N" "Phase 2"
"2992" "vecuronium" "acetylcholine receptor antagonist" "CHRNA2" "neurology/psychiatry" "muscle relaxant" "BRD-K07365190-004-01-7, BRD-A82463680-004-02-5" "CC(=O)O[C@@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1, CC(=O)O[C@H]1[C@H](CC2C3CCC4C[C@H](OC(C)=O)[C@H](C[C@]4(C)C3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1" "BGSZAXLLHYERSY-VNKJPRCTSA-N, BGSZAXLLHYERSY-HKCZGGMBSA-N" "Launched"
"2993" "veliflapon" "leukotriene synthesis inhibitor" "ALOX5AP" "" "" "BRD-K12852738-001-01-2" "OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1" "ZEYYDOLCHFETHQ-JOCHJYFZSA-N" "Phase 3"
"2994" "veliparib" "PARP inhibitor" "PARP1, PARP2" "" "" "BRD-K12737986-001-01-4" "C[C@]1(CCCN1)c1nc2c(cccc2[nH]1)C(N)=O" "JNAHVYVRKWKWKQ-ZDUSSCGKSA-N" "Phase 3"
"2995" "velneperit" "neuropeptide receptor antagonist" "NPY5R" "" "" "BRD-K06357403-001-01-4" "CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F" "WGEWUYACXPEFPO-AULYBMBSSA-N" "Phase 2"
"2996" "vemurafenib" "RAF inhibitor" "BRAF, RAF1" "oncology" "melanoma" "BRD-K56343971-001-12-2, BRD-K56343971-001-10-6, BRD-K56343971-001-14-8" "CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F" "GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N, GPXBXXGIAQBQNI-UHFFFAOYSA-N" "Launched"
"2997" "venetoclax" "BCL inhibitor" "BCL2" "hematologic malignancy" "chronic lymphocytic leukemia (CLL)" "BRD-K62391742-001-09-7, BRD-K62391742-001-03-0, BRD-K62391742-001-08-9" "CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1" "LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N, LQBVNQSMGBZMKD-UHFFFAOYSA-N" "Launched"
"2998" "venlafaxine" "adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor (SNRI)" "SLC6A2, SLC6A3, SLC6A4" "neurology/psychiatry" "depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder" "BRD-A51714012-003-13-6, BRD-A51714012-003-12-8" "COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1, COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1" "PNVNVHUZROJLTJ-UHFFFAOYSA-N, PNVNVHUZROJLTJ-UHFFFAOYSA-N" "Launched"
"2999" "VER-49009" "HSP inhibitor" "HSP90AA1" "" "" "BRD-K38548312-001-01-0" "CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O" "HUNAOTXNHVALTN-UHFFFAOYSA-N" "Preclinical"
"3000" "verapamil" "calcium channel blocker" "CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4" "cardiology" "hypertension" "BRD-A09533288-003-31-2, BRD-A09533288-003-29-6" "COc1ccc(CCN(C)CCCC(C" "" ""
"3001" "verbascoside" "PKC inhibitor, NFkB pathway inhibitor" "" "" "" "BRD-K36201510-001-06-7" "C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O" "FBSKJMQYURKNSU-ZLSOWSIRSA-N" "Phase 2/Phase 3"
"3002" "vercirnon" "CC chemokine receptor antagonist" "CCR9" "" "" "BRD-K47929404-001-01-0" "CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1" "JRWROCIMSDXGOZ-UHFFFAOYSA-N" "Phase 3"
"3003" "verinurad" "urate transporter inhibitor" "SLC22A12" "" "" "BRD-K36741660-001-01-1" "CC(C)(Sc1ccncc1-c1ccc(C" "" ""
"3004" "vernakalant" "potassium channel blocker" "KCNA5" "cardiology" "atrial fibrillation (AF)" "BRD-K19741547-003-01-7" "COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC" "VBHQKCBVWWUUKN-KZNAEPCWSA-N" "Launched"
"3005" "verteporfin" "photosensitizing agent" "" "ophthalmology" "macular degeneration" "BRD-K81849500-001-02-8, BRD-K81849500-001-07-7, BRD-K81849500-001-05-1, BRD-K81849500-001-06-9, BRD-K81849500-001-01-0" "COC(=O)CCc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC, COC(=O)CCc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC, COC(=O)CCc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC, COC(=O)CCc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC, COC(=O)CCc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC" "YTZALCGQUPRCGW-ZSFNYQMMSA-N, YTZALCGQUPRCGW-ZSFNYQMMSA-N, YTZALCGQUPRCGW-ZSFNYQMMSA-N, YTZALCGQUPRCGW-ZSFNYQMMSA-N, YTZALCGQUPRCGW-ZSFNYQMMSA-N" "Launched"
"3006" "verubulin" "tubulin polymerization inhibitor" "TUBB" "" "" "BRD-K42673188-001-01-1, BRD-K42673188-003-01-7" "COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12, COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12" "SNHCRNMVYDHVDT-UHFFFAOYSA-N, SNHCRNMVYDHVDT-UHFFFAOYSA-N" "Phase 2"
"3007" "vesamicol" "acetylcholinesterase inhibitor" "SLC18A3" "" "" "BRD-K14765469-003-12-2" "O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1" "YSSBJODGIYRAMI-IAGOWNOFSA-N" "Preclinical"
"3008" "vesnarinone" "phosphodiesterase inhibitor" "KCNH2, PDE3A" "cardiology" "congestive heart failure" "BRD-K13414800-001-01-3" "COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1" "ZVNYJIZDIRKMBF-UHFFFAOYSA-N" "Launched"
"3009" "VGX-1027" "tumor necrosis factor receptor antagonist" "TLR4" "" "" "BRD-A32269193-001-01-5" "OC(=O)CC1CC(=NO1)c1ccccc1" "MUFJHYRCIHHATF-UHFFFAOYSA-N" "Phase 1"
"3010" "vicriviroc" "CC chemokine receptor antagonist" "CCR5" "" "" "BRD-K84748119-050-01-1" "COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F" "CNPVJJQCETWNEU-CYFREDJKSA-N" "Phase 3"
"3011" "vidarabine" "antiviral" "ADA" "infectious disease" "virus herpes simplex (HSV), varicella-zoster virus (VZV)" "BRD-K72093121-001-16-3, BRD-K72093121-001-17-1" "Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O" "OIRDTQYFTABQOQ-UHTZMRCNSA-N, OIRDTQYFTABQOQ-UHTZMRCNSA-N" "Launched"
"3012" "vigabatrin" "GABA aminotransferase inhibitor" "ABAT, GABBR1, SLC32A1" "neurology/psychiatry" "seizures, spasms" "BRD-A07893380-213-01-7" "NC(CCC(O)=O)C=C" "PJDFLNIOAUIZSL-UHFFFAOYSA-N" "Launched"
"3013" "vilanterol" "adrenergic receptor agonist" "ADRB2" "pulmonary" "chronic obstructive pulmonary disease (COPD)" "BRD-M36487418-001-03-0, BRD-M36487418-001-01-4, BRD-M36487418-001-02-2" "OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl, OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl, OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl" "KLOLZALDXGTNQE-JIDHJSLPSA-N, KLOLZALDXGTNQE-JIDHJSLPSA-N, KLOLZALDXGTNQE-JIDHJSLPSA-N" "Launched"
"3014" "vilazodone" "serotonin reuptake inhibitor" "DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4" "neurology/psychiatry" "depression" "BRD-K58010567-003-03-0, BRD-K58010567-003-02-2, BRD-K58010567-003-01-4" "NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C" "" ""
"3015" "vildagliptin" "dipeptidyl peptidase inhibitor" "DPP4" "endocrinology" "diabetes mellitus" "BRD-A94993966-001-05-1, BRD-A94993966-001-04-4" "OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C" "" ""
"3016" "viloxazine" "norepinephrine reuptake inhibitor" "SLC6A2" "neurology/psychiatry" "depression" "BRD-A59198242-003-02-9" "CCOc1ccccc1OCC1CNCCO1" "YWPHCCPCQOJSGZ-UHFFFAOYSA-N" "Launched"
"3017" "vinblastine" "microtubule inhibitor, tubulin polymerization inhibitor" "JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1" "hematologic malignancy, infectious disease, oncology" "Hodgkins lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	BRD-A66484359-001-01-9, BRD-K01188359-065-23-1, BRD-K12515392-065-01-7, BRD-A55594068-065-04-9, BRD-A39708826-001-01-0, BRD-K01188359-001-03-8	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1C22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)CC2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1C22CCN3CC=C[C@](CC)([C@@H]23)[C@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	JXLYSJRDGCGARV-JQQWJEIDSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N, JXLYSJRDGCGARV-XQKSVPLYSA-N, JXLYSJRDGCGARV-CUGARIAGSA-N, JXLYSJRDGCGARV-HAVDPRAOSA-N, JXLYSJRDGCGARV-CFWMRBGOSA-N	Launched
vinburnine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	stroke	BRD-K40227168-001-12-9	CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	WYJAPUKIYAZSEM-MOPGFXCFSA-N	Launched
vincamine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K89704198-001-12-3	CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@@](O)(C2)C(=O)OC	RXPRRQLKFXBCSJ-HLAWJBBLSA-N	Withdrawn
vincristine	tubulin polymerization inhibitor	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	BRD-K49229349-065-02-4, BRD-A60578817-065-01-5, BRD-K49229349-065-01-6, BRD-K98953900-065-01-2, BRD-A60414806-065-02-4	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1C22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CC[C@]1(O)CC2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	OGWKCGZFUXNPDA-XQKSVPLYSA-N, OGWKCGZFUXNPDA-JQQWJEIDSA-N, OGWKCGZFUXNPDA-XQKSVPLYSA-N, OGWKCGZFUXNPDA-JVZLHVILSA-N, OGWKCGZFUXNPDA-CUGARIAGSA-N	Launched
vindesine	tubulin polymerization inhibitor	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	BRD-K59753975-001-02-6	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O	HHJUWIANJFBDHT-KOTLKJBCSA-N	Launched
vinflunine	microtubule inhibitor		oncology	bladder cancer	BRD-K10549975-001-01-8, BRD-A52946717-045-01-7	CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@H]3C[C@H](CN(C3)Cc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC, CCC12C=CCN3CCC4(C13)C(N(C)c1cc(OC)c(cc41)C1(CC3CC(CN(C3)Cc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)C(O)(C2OC(C)=O)C(=O)OC	NMDYYWFGPIMTKO-HBVLKOHWSA-N, NMDYYWFGPIMTKO-UHFFFAOYSA-N	Launched
vinorelbine	tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	BRD-K69280563-001-01-8, BRD-K69280563-346-01-7	CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC, CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC	GBABOYUKABKIAF-IELIFDKJSA-N, GBABOYUKABKIAF-IELIFDKJSA-N	Launched
vinpocetine	phosphodiesterase inhibitor, sodium channel blocker	PDE1A, PDE1C			BRD-K53318339-001-24-9, BRD-K53318339-001-23-1, BRD-K25429851-001-01-5	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41, CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41, CCOC(=O)C1=C[C@@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41	DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IRLDBZIGSA-N, DDNCQMVWWZOMLN-IFMALSPDSA-N	Launched
viomycin	protein synthesis inhibitor		infectious disease	tuberculosis	BRD-A42379279-065-03-8	NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)=C\NC(N)=O)C1C[C@H](O)N=C(N)N1	GXFAIFRPOKBQRV-IKZNKTFNSA-N	Launched
vipadenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K56565215-001-01-9	Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N	HQSBCDPYXDGTCL-UHFFFAOYSA-N	Phase 1
vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	BRD-K44827188-001-06-0	Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O	BPQMGSKTAYIVFO-UHFFFAOYSA-N	Launched
vitamin-b12			hematology	megaloblastic anemia	BRD-A75369945-001-01-2	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N+]3=C1C(C)=C1[C@@H](CCC(N)=O)C(C)(C)C4=[N+]1[Co]31(C#N)N3C([C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]23C)=C(C)C2=[N+]1C(=C4)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12	FMCRMSOQAVOHRD-WZHZPDAFSA-M	Launched
vitamin-E	PKC inhibitor, LDL oxidation inhibitor	ALOX5, DGKA, NR1I2, PPP2CA, PPP2CB, PRKCA, PRKCB, SEC14L2, SEC14L3, SEC14L4			BRD-K97091514-001-11-4	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1	GVJHHUAWPYXKBD-IEOSBIPESA-N	Phase 2/Phase 3
VLX600	ubiquitin C-terminal hydrolase inhibitor	USP14			BRD-K89053832-001-01-0	C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	UQOSBPRTQFFUOA-NHDPSOOVSA-N	Phase 1
voglibose	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus, hyperglycemia	BRD-K66850609-001-05-8, BRD-K59331299-001-01-2	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, OCC(CO)N[C@H]1C[C@@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	FZNCGRZWXLXZSZ-CIQUZCHMSA-N, FZNCGRZWXLXZSZ-GENCIFFESA-N	Launched
volasertib	PLK inhibitor	PLK1			BRD-K69776681-001-06-1, BRD-K69776681-001-03-8	CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	SXNJFOWDRLKDSF-STROYTFGSA-N, SXNJFOWDRLKDSF-STROYTFGSA-N	Phase 3
volinanserin	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, KCNH2			BRD-K23647661-001-02-2	COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	HXTGXYRHXAGCFP-OAQYLSRUSA-N	Phase 3
vonoprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	BRD-K32768103-051-03-4, BRD-K32768103-051-02-6	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1, CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	BFDBKMOZYNOTPK-UHFFFAOYSA-N, BFDBKMOZYNOTPK-UHFFFAOYSA-N	Launched
vorapaxar	thrombin receptor antagonist	F2R	cardiology	myocardial infarction, peripheral artery disease (PAD)	BRD-K93442924-001-03-4	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1	ZBGXUVOIWDMMJE-QHNZEKIYSA-N	Launched
voreloxin	topoisomerase inhibitor	TOP2A			BRD-K23677682-003-01-2	CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	XZAFZXJXZHRNAQ-STQMWFEESA-N	Phase 3
voriconazole	cytochrome P450 inhibitor	CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1	infectious disease	esophageal candidiasis, aspergillosis, skin infections	BRD-K06557128-001-07-0, BRD-K06557128-001-06-2, BRD-K06557128-001-08-8	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F, C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N, BCEHBSKCWLPMDN-MGPLVRAMSA-N	Launched
vorinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	BRD-K81418486-001-47-5, BRD-K81418486-001-44-2	ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1	WAEXFXRVDQXREF-UHFFFAOYSA-N, WAEXFXRVDQXREF-UHFFFAOYSA-N	Launched
vortioxetine	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4	neurology/psychiatry	depression	BRD-K53963539-004-02-0, BRD-K53963539-001-01-8	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1, Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	YQNWZWMKLDQSAC-UHFFFAOYSA-N, YQNWZWMKLDQSAC-UHFFFAOYSA-N	Launched
voxtalisib	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			BRD-K56291712-001-01-0	CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	RGHYDLZMTYDBDT-UHFFFAOYSA-N	Phase 2
VP-20629	beta amyloid antagonist	PLA2G2E, SLC36A1			BRD-K21071223-001-02-8	OC(=O)CCc1c[nH]c2ccccc12	GOLXRNDWAUTYKT-UHFFFAOYSA-N	Phase 1
VS-4718	focal adhesion kinase inhibitor				BRD-K09877029-001-01-2	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	IGUBBWJDMLCRIK-UHFFFAOYSA-N	Phase 1
VT-464	cytochrome P450 inhibitor	CYP17A1			BRD-K72005722-001-01-2	CC(C)[C@@](O)(c1c[nH]nn1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	ZBRAJOQFSNYJMF-SFHVURJKSA-N	Phase 2
VTP-27999	renin inhibitor	REN			BRD-K81694556-003-01-9	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	NXWASIVXQMMPLM-ZXMXYHOLSA-N	Phase 1
VU-0240551	potassium/chloride cotransporter inhibitor	SLC12A5			BRD-K27074404-001-08-4	Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1	WJRWSLORVIHRNX-UHFFFAOYSA-N	Preclinical
VUF10166	serotonin receptor antagonist	HTR3A, HTR3B			BRD-K11046126-001-02-0	CN1CCN(CC1)c1nc2ccccc2nc1Cl	FFXVTQDGTKEXHF-UHFFFAOYSA-N	Preclinical
VU0155069	phospholipase inhibitor	PLD1			BRD-K48535733-003-01-2	C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	DRIMIUYGTDAQOX-KRWDZBQOSA-N	Preclinical
VU0238429	acetylcholine receptor allosteric modulator	CHRM5			BRD-K24187789-001-01-7	COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	CKLGZXFOLMHCMC-UHFFFAOYSA-N	Preclinical
VU0357121	glutamate receptor positive allosteric modulator	GRM5			BRD-K86109159-001-02-6	CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	AHCYOTLTLQTPSU-UHFFFAOYSA-N	Preclinical
VU0361737	glutamate receptor positive allosteric modulator	GRM4			BRD-K45462423-001-03-7, BRD-K45462423-001-02-9	COc1cc(NC(=O)c2ccccn2)ccc1Cl, COc1cc(NC(=O)c2ccccn2)ccc1Cl	ARYUXFNGXHNNDM-UHFFFAOYSA-N, ARYUXFNGXHNNDM-UHFFFAOYSA-N	Preclinical
VU0364439	glutamate receptor positive allosteric modulator	GRM4			BRD-K72687424-001-02-6	Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	IXHCGJXBIHHIEF-UHFFFAOYSA-N	Preclinical
VU0364770	glutamate receptor positive allosteric modulator	GRM4			BRD-K66527818-001-02-6	Clc1cccc(NC(=O)c2ccccn2)c1	SUYUTNCKIOLMAJ-UHFFFAOYSA-N	Preclinical
VX-11e	MAP kinase inhibitor	MAPK1			BRD-K93725829-001-03-8	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1	WUTVMXLIGHTZJC-OAQYLSRUSA-N	Preclinical
VX-222	HCV inhibitor				BRD-K70610771-001-02-9	C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C	WPMJNLCLKAKMLA-UGLKCIBTSA-N	Phase 2
VX-661	CFTR channel agonist	CFTR			BRD-K97101532-001-02-8	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	MJUVRTYWUMPBTR-MRXNPFEDSA-N	Phase 3
VX-702	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			BRD-K07736136-001-04-6, BRD-K07736136-001-03-8	NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F, NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	FYSRKRZDBHOFAY-UHFFFAOYSA-N, FYSRKRZDBHOFAY-UHFFFAOYSA-N	Phase 2
VX-745	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			BRD-K91900765-001-07-6, BRD-K91900765-001-05-0, BRD-K91900765-001-06-8	Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1, Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N, VEPKQEUBKLEPRA-UHFFFAOYSA-N	Phase 2
VX-765	caspase inhibitor	CASP1			BRD-K26712974-001-01-5	CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	SJDDOCKBXFJEJB-QQSSDERHSA-N	Phase 2
W-54011	anaphylatoxin chemotactic receptor antagonist	C5AR1			BRD-A00559310-003-01-1	COc1ccc2CCCC(C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1	DVYASSBBADJRAS-UHFFFAOYSA-N	Preclinical
walrycin-b	transcriptional regulatory protein WalR				BRD-K01129913-001-01-5	Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F	XRVMPTWWKLKLPB-UHFFFAOYSA-N	Preclinical
warfarin	vitamin K antagonist	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	BRD-A24514565-001-09-7	CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O	PJVWKTKQMONHTI-UHFFFAOYSA-N	Launched
WAY-100635	serotonin receptor antagonist	HTR1A			BRD-K69812556-305-02-0	COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	SBPRIAGPYFYCRT-UHFFFAOYSA-N	Phase 1
WAY-161503	serotonin receptor agonist	HTR2C			BRD-A62021152-003-03-4	Clc1cc2NC(=O)C3CNCCN3c2cc1Cl	PHGWDAICBXUJDU-UHFFFAOYSA-N	Preclinical
WAY-170523	metalloproteinase inhibitor	MMP13			BRD-K36198571-001-02-0	Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	FARMEEAGJWMFSZ-UHFFFAOYSA-N	Preclinical
WAY-200070	estrogen receptor agonist	ERBB2, ERBB3, ERBB4, ESR2			BRD-K08223200-001-01-1	Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	BAAILVWEAXFTSF-UHFFFAOYSA-N	Preclinical
WAY-213613	glutamate inhibitor	SLC1A2			BRD-K96758128-001-01-8	N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	BNYDDAAZMBUFRG-ZDUSSCGKSA-N	Preclinical
WAY-316606	secreted frizzled related protein inhibitor	SFRP1			BRD-K61871885-001-01-3	FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1	ITBGJNVZJBVPLJ-UHFFFAOYSA-N	Preclinical
WAY-362450	FXR agonist	NR1H4			BRD-K54640016-001-04-7	CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1	INASOKQDNHHMRE-UHFFFAOYSA-N	Phase 1
WAY-600	mTOR inhibitor	MTOR			BRD-K85920262-001-02-1	C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	FPEIJQLXFHKLJV-UHFFFAOYSA-N	Preclinical
WAY-629	serotonin receptor agonist	HTR2C			BRD-K55430733-003-02-4	C1CCc2c(C1)n1CCNCc3cccc2c13	OIGHTPDWPMLMGT-UHFFFAOYSA-N	Preclinical
WB-4101	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A			BRD-A01493904-003-12-1	COc1cccc(OC)c1OCCNCC1COc2ccccc2O1	GYSZUJHYXCZAKI-UHFFFAOYSA-N	Preclinical
WEHI-345-analog	src inhibitor				BRD-K55487946-001-01-3	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C	ZCZGSEXBXXYQQC-UHFFFAOYSA-N	Preclinical
WHI-P154	JAK inhibitor	EGFR, JAK1, JAK2, JAK3			BRD-K07487750-001-04-1, BRD-K07487750-001-03-3	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC, COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	CBIAKDAYHRWZCU-UHFFFAOYSA-N, CBIAKDAYHRWZCU-UHFFFAOYSA-N	Preclinical
WIKI4	Wnt pathway inhibitor, tankyrase inhibitor	TNKS2			BRD-K19316653-001-02-0	COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1	RNUXIZKXJOGYQP-UHFFFAOYSA-N	Preclinical
WIN-18446	aldehyde dehydrogenase inhibitor	ALDH1A2			BRD-K30930903-001-01-3	ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl	FAOMZVDZARKPFJ-UHFFFAOYSA-N	Preclinical
WIN-64338	bradykinin receptor antagonist	BDKRB2			BRD-K22662557-300-01-7	CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	UKMJWGFHXMGRNG-QLKFWGTOSA-O	Preclinical
wnt-c59	porcupine inhibitor	PORCN			BRD-K78455053-001-01-2	Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	KHZOJCQBHJUJFY-UHFFFAOYSA-N	Preclinical
wortmannin	PI3K inhibitor	PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC			BRD-K62662086-001-01-2, BRD-K87343924-001-12-3	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@@H]1OC(C)=O)C3=O, COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O	QDLHCMPXEPAAMD-BCXCVGBNSA-N, QDLHCMPXEPAAMD-QAIWCSMKSA-N	Preclinical
WP1066	STAT inhibitor	STAT3			BRD-K05445342-001-05-3, BRD-K05445342-001-02-0	C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	VFUAJMPDXIRPKO-LQELWAHVSA-N, VFUAJMPDXIRPKO-LQELWAHVSA-N	Phase 1
WP1130	deubiquitinase inhibitor	JAK2, UCHL5, USP14, USP9X			BRD-K43644456-001-04-0, BRD-K43644456-001-03-2	CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1, CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	LIDOPKHSVQTSJY-VMEIHUARSA-N, LIDOPKHSVQTSJY-VMEIHUARSA-N	Preclinical
WR99210	dihydrofolate reductase inhibitor	TYMS	infectious disease	malaria	BRD-K45973863-001-01-4	CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl	MJZJYWCQPMNPRM-UHFFFAOYSA-N	Preclinical
Wy-16922	histamine release inhibitor				BRD-K43419711-001-01-4	CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O	GGLRYZACPLNCKB-UHFFFAOYSA-N	Phase 1
WYE-125132	mTOR inhibitor	MTOR			BRD-A45498368-001-07-1	CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1	QLHHRYZMBGPBJG-UHFFFAOYSA-N	Preclinical
WYE-354	mTOR inhibitor	MTOR			BRD-K77008974-001-03-2	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	IMXHGCRIEAKIBU-UHFFFAOYSA-N	Preclinical
WZ-3146	EGFR inhibitor	EGFR			BRD-K73293050-001-03-1	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	APHGZZPEOCCYNO-UHFFFAOYSA-N	Preclinical
WZ-4002	EGFR inhibitor	EGFR, ERBB2			BRD-K72420232-001-13-1, BRD-K72420232-001-12-3	COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	ITTRLTNMFYIYPA-UHFFFAOYSA-N, ITTRLTNMFYIYPA-UHFFFAOYSA-N	Preclinical
WZ4003	AMPK inhibitor	NUAK1, NUAK2			BRD-K45909031-001-01-5	CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1	SDGJBAUIGHSMRI-UHFFFAOYSA-N	Preclinical
WZ8040	EGFR inhibitor	EGFR			BRD-K81728688-001-04-4	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	KIISCIGBPUVZBF-UHFFFAOYSA-N	Preclinical
WZ811	CC chemokine receptor antagonist	CXCR4			BRD-K25359048-001-02-6	C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	KBVFRXIGQQRMEF-UHFFFAOYSA-N	Preclinical
xaliproden	serotonin receptor agonist	HTR1A			BRD-K88358234-003-04-8	FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1	WJJYZXPHLSLMGE-UHFFFAOYSA-N	Phase 3
xamoterol	adrenergic receptor agonist	ADRB1			BRD-A59337442-051-05-3	OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	DXPOSRCHIDYWHW-UHFFFAOYSA-N	Phase 3
xanomeline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7			BRD-K72815923-034-01-2	CCCCCCOc1nsnc1C1=CCCN(C)C1	JOLJIIDDOBNFHW-UHFFFAOYSA-N	Phase 3
xanthone	antimalarial agent				BRD-K27135764-001-08-7	O=c1c2ccccc2oc2ccccc12	JNELGWHKGNBSMD-UHFFFAOYSA-N	Preclinical
XAV-939	tankyrase inhibitor	TNKS, TNKS2			BRD-K12762134-001-06-2, BRD-K12762134-001-07-0	Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F, Oc1nc(nc2CCSCc12)-c1ccc(cc1)C(F)(F)F	KLGQSVMIPOVQAX-UHFFFAOYSA-N, KLGQSVMIPOVQAX-UHFFFAOYSA-N	Preclinical
XBD173	benzodiazepine receptor ligand	TSPO			BRD-K45875383-001-01-2	CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	NBMBIEOUVBHEBM-UHFFFAOYSA-N	Phase 2
XE-991	potassium channel blocker	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5			BRD-K42748308-300-02-0	O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	KHJFBUUFMUBONL-UHFFFAOYSA-N	Preclinical
xenalipin					BRD-K99506538-001-03-8	OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F	IQOMYCGTGFGDFN-UHFFFAOYSA-N	Phase 2
xibenolol	adrenergic receptor antagonist				BRD-A21446384-001-01-1	Cc1cccc(OCC(O)CNC(C)(C)C)c1C	RKUQLAPSGZJLGP-UHFFFAOYSA-N	Phase 3
xilobam					BRD-K79633074-001-01-8	CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	PAXRPWSXCPTPCA-QINSGFPZSA-N	Phase 1
xipamide	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	BRD-K27393415-001-01-0	Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O	MTZBBNMLMNBNJL-UHFFFAOYSA-N	Launched
XL-147	PI3K inhibitor	PIK3CA, PIK3CD, PIK3CG			BRD-K95901403-001-04-5	Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	MQMKRQLTIWPEDM-UHFFFAOYSA-N	Phase 2
XL-647	EGFR inhibitor, VEGFR inhibitor	EGFR, EPHB4, ERBB2, FLT4, KDR			BRD-K03765900-001-01-9	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	HVXKQKFEHMGHSL-QKDCVEJESA-N	Phase 3
XL019	JAK inhibitor	JAK1, JAK2, JAK3			BRD-K04266228-001-03-8, BRD-K04266228-001-04-6, BRD-K04266228-001-02-0	O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1, O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N, ISOCDPQFIXDIMS-QHCPKHFHSA-N	Phase 1
XL228	Abl kinase inhibitor, insulin growth factor receptor inhibitor, src inhibitor	IGF1R, SRC			BRD-K14274271-001-02-8, BRD-K14274271-001-01-0	CC(C)c1cc(CNc2nc(Nc3cc([nH]n3)C3CC3)cc(n2)N2CCN(C)CC2)on1, CC(C)c1cc(CNc2nc(Nc3cc([nH]n3)C3CC3)cc(n2)N2CCN(C)CC2)on1	ALKJNCZNEOTEMP-UHFFFAOYSA-N, ALKJNCZNEOTEMP-UHFFFAOYSA-N	Phase 1
XL388	mTOR inhibitor	MTOR			BRD-K03549949-001-01-0	Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	LNFBAYSBVQBKFR-UHFFFAOYSA-N	Preclinical
XL888	HSP inhibitor				BRD-A03506276-001-01-5	CC[C@@H](C)Nc1cc(C(=O)NC2CC3CCC(C2)N3c2ccc(cn2)C(=O)C2CC2)c(C)cc1C(N)=O	LHGWWAFKVCIILM-LAQKFSSHSA-N	Phase 1
XMD17-109	MAP kinase inhibitor	MAPK7			BRD-K48449981-001-02-7, BRD-K48449981-001-01-9	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	XVBGRTMNFNMINE-UHFFFAOYSA-N, XVBGRTMNFNMINE-UHFFFAOYSA-N	Preclinical
XMD8-92	MAP kinase inhibitor	DCLK2, MAPK7, PLK4, TNK1			BRD-K50387473-001-09-4, BRD-K50387473-001-10-2	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1, CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	QAPAJIZPZGWAND-UHFFFAOYSA-N, QAPAJIZPZGWAND-UHFFFAOYSA-N	Preclinical
xylazine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	BRD-K21565985-001-22-5, BRD-K21565985-003-02-3	Cc1cccc(C)c1NC1=NCCCS1, Cc1cccc(C)c1NC1=NCCCS1	BPICBUSOMSTKRF-UHFFFAOYSA-N, BPICBUSOMSTKRF-UHFFFAOYSA-N	Launched
xylometazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	otolaryngology, allergy	nasal congestion, allergic rhinitis	BRD-K08356259-003-24-7, BRD-K08356259-003-23-9	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C, Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C	HUCJFAOMUPXHDK-UHFFFAOYSA-N, HUCJFAOMUPXHDK-UHFFFAOYSA-N	Launched
xylose					BRD-K10759144-001-04-3, BRD-K10759144-001-03-5	OC[C@@H](O)[C@H](O)[C@@H](O)C=O, OC[C@@H](O)[C@H](O)[C@@H](O)C=O	PYMYPHUHKUWMLA-VPENINKCSA-N, PYMYPHUHKUWMLA-VPENINKCSA-N	Launched
Y-134	estrogen receptor antagonist	ESR1, ESR2			BRD-K94832621-001-02-3	CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	LQEOPHGPHCWOAC-UHFFFAOYSA-N	Preclinical
Y-26763	potassium channel activator	KCNJ8			BRD-K45117373-001-02-9	CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	IWTCFIIOUXJOOV-OLZOCXBDSA-N	Phase 1
Y-27152	potassium channel activator	KCNJ8			BRD-K42679050-001-02-1	CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	RHFUXPCCELGMFC-UXHICEINSA-N	Phase 1
Y-27632	rho associated kinase inhibitor	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2			BRD-K44084986-300-09-2, BRD-K44084986-300-08-4, BRD-K44084986-300-07-6	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1, C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	IYOZTVGMEWJPKR-IJLUTSLNSA-N, IYOZTVGMEWJPKR-IJLUTSLNSA-N, IYOZTVGMEWJPKR-IJLUTSLNSA-N	Preclinical
Y-29794	prolyl endopeptidase inhibitor	PREP			BRD-K48449073-034-02-7	CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1	HAGHKJDWBDSFKC-UHFFFAOYSA-N	Preclinical
Y-320	interleukin inhibitor	IL17A			BRD-K96259238-001-01-4	Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	BWZNJVZTAWBIFG-UHFFFAOYSA-N	Preclinical
Y-39983	rho associated kinase inhibitor	ROCK1, ROCK2			BRD-K56751279-300-01-4	C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	JTVBXQAYBIJXRP-SNVBAGLBSA-N	Phase 2
YK-4-279	apoptosis inhibitor	EWSR1, FLI1			BRD-A62182663-001-03-0	COc1ccc(cc1)C(=O)CC1(O)C(=O)Nc2c1c(Cl)ccc2Cl	HLXSCTYHLQHQDJ-UHFFFAOYSA-N	Preclinical
YM-155	survivin inhibitor	BIRC5			BRD-K76703230-004-04-1, BRD-K76703230-004-03-3	COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C, COCCn1c2c(C(=O)c3ccccc3C2=O)[n+](Cc2cnccn2)c1C	OTSOOHRUMBRSHZ-UHFFFAOYSA-N, OTSOOHRUMBRSHZ-UHFFFAOYSA-N	Phase 2
YM-201636	PI3K inhibitor				BRD-K48488978-001-05-3	Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	YBPIBGNBHHGLEB-UHFFFAOYSA-N	Preclinical
YM-298198	glutamate receptor antagonist	GRM1			BRD-K48059230-003-02-9, BRD-K59650319-003-03-3	Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1, CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C	VWOMTTIMBHBPBI-UHFFFAOYSA-N, KCBXOMYXOBVLED-UHFFFAOYSA-N	Preclinical
YM-511	aromatase inhibitor	CYP19A1			BRD-K38398115-001-01-9	Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	GGPPBTSXFROGAE-UHFFFAOYSA-N	Phase 2
YM-58483	calcium channel blocker	TRPC3, TRPC5, TRPM4			BRD-K42563464-001-01-9	Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	XPRZIORDEVHURQ-UHFFFAOYSA-N	Preclinical
YM-750	ACAT inhibitor	SOAT1			BRD-K91716465-001-01-2	Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1	FMLJREWZCZHGGW-UHFFFAOYSA-N	Phase 1
YM-90709	IL5 inhibitor	CSF2RB, IL5RA			BRD-K06712146-001-03-8, BRD-K06712146-001-02-0	COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC, COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	HIXSPVQXXDULHS-UHFFFAOYSA-N, HIXSPVQXXDULHS-UHFFFAOYSA-N	Preclinical
YM-976	phosphodiesterase inhibitor	PDE4A			BRD-K12932420-001-02-3	CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	MNHXYNNKDDXKNP-UHFFFAOYSA-N	Phase 1
YM022	CCK receptor antagonist	CCKBR			BRD-K09436144-001-01-7	Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1	YCXFHPUBGMMWJQ-PMERELPUSA-N	Phase 2
YO-01027	gamma secretase inhibitor				BRD-K04622161-001-02-3	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	QSHGISMANBKLQL-OWJWWREXSA-N	Preclinical
yohimbine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8	cardiology	cardiac arrythmia, bradycardia	BRD-K35586044-003-15-4, BRD-A87445400-003-04-4, BRD-K35586044-003-14-7, BRD-K77474816-003-13-3	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)C1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12, COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-SCYLSFHTSA-N, BLGXFZZNTVWLAY-AMZRAFDVSA-N, BLGXFZZNTVWLAY-SCYLSFHTSA-N, BLGXFZZNTVWLAY-DIRVCLHFSA-N	Launched
YS-035	calcium channel blocker				BRD-K06208435-003-08-2	COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	OXZMQFKVNVQMLI-UHFFFAOYSA-N	Preclinical
Y16	rho associated kinase inhibitor	RHOA			BRD-K81865756-001-01-7	Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1	ITMLWGWTDWJSRZ-PXLXIMEGSA-N	Preclinical
zacopride	serotonin receptor antagonist	HTR3A, HTR3B, HTR4, HTR5A			BRD-A65615053-003-02-2	COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2	FEROPKNOYKURCJ-UHFFFAOYSA-N	Phase 2
zafirlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2	pulmonary	asthma	BRD-K71289571-001-11-4	COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C	YEEZWCHGZNKEEK-UHFFFAOYSA-N	Launched
zalcitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K85925969-001-17-4, BRD-K85925969-001-16-6	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1, Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	WREGKURFCTUGRC-POYBYMJQSA-N, WREGKURFCTUGRC-POYBYMJQSA-N	Launched
zaldaride	calmodulin antagonist	CALM1			BRD-A26032986-050-02-1	CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12	HTGCJAAPDHZCHL-UHFFFAOYSA-N	Phase 3
zaleplon	benzodiazepine receptor agonist	GABRA1, GABRB1, GABRG2, TSPO	neurology/psychiatry	insomnia	BRD-K92657060-001-05-7	CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N	HUNXMJYCHXQEGX-UHFFFAOYSA-N	Launched
zaltidine	histamine receptor antagonist	HRH2			BRD-K12261274-001-02-4, BRD-K12261274-001-01-6	Cc1ncc([nH]1)-c1csc(NC(N)=N)n1, Cc1ncc([nH]1)-c1csc(NC(N)=N)n1	GIMNAEMRNXUAQP-UHFFFAOYSA-N, GIMNAEMRNXUAQP-UHFFFAOYSA-N	Phase 3
zaltoprofen	cyclooxygenase inhibitor		endocrinology, neurology/psychiatry	fever, pain relief	BRD-A00578795-001-04-3	CC(C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1	MUXFZBHBYYYLTH-UHFFFAOYSA-N	Launched
ZAMI-633	urease inhibitor				BRD-K11984358-001-01-3	CCC(=O)NO	RSIPQHOWTCNEBI-UHFFFAOYSA-N	Phase 3
zamifenacin	acetylcholine receptor antagonist	CHRM3			BRD-K80451230-051-02-6	C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	BDNFQGRSKSQXRI-XMMPIXPASA-N	Phase 3
zanamivir	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	BRD-K23067689-001-02-1, BRD-K75153898-001-01-5	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O, CC(=O)N[C@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	ARAIBEBZBOPLMB-UFGQHTETSA-N, ARAIBEBZBOPLMB-JXNGDSLSSA-N	Launched
ZAPA					BRD-K44825564-065-01-4	NC(=N)S\C=C/C(O)=O	QEYNZJBVNYDZKZ-UPHRSURJSA-N	Preclinical
zaprinast	phosphodiesterase inhibitor	GPR35, PDE1A, PDE4D, PDE5A, PDE9A			BRD-K16542329-001-13-5, BRD-K16542329-001-14-3	CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1, CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1	REZGGXNDEMKIQB-UHFFFAOYSA-N, REZGGXNDEMKIQB-UHFFFAOYSA-N	Phase 2
zardaverine	phosphodiesterase inhibitor	PDE4D			BRD-K37561857-001-17-1, BRD-K37561857-001-15-5	COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1, COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	HJMQDJPMQIHLPB-UHFFFAOYSA-N, HJMQDJPMQIHLPB-UHFFFAOYSA-N	Phase 2
zatebradine	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			BRD-K92446736-003-03-0, BRD-K92446736-001-01-8, BRD-K92446736-003-02-2	COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC, COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	KEDQCFRVSHYKLR-UHFFFAOYSA-N, KEDQCFRVSHYKLR-UHFFFAOYSA-N, KEDQCFRVSHYKLR-UHFFFAOYSA-N	Phase 3
ZCL-278	CDC inhibitor	CDC42			BRD-K22829793-001-03-6, BRD-K22829793-001-01-0, BRD-K22829793-001-02-8	Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1, Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	XKZDWYDHEBCGCG-UHFFFAOYSA-N, XKZDWYDHEBCGCG-UHFFFAOYSA-N, XKZDWYDHEBCGCG-UHFFFAOYSA-N	Preclinical
ZD-2079	adrenergic receptor agonist	ADRB3			BRD-K64157027-003-02-7	O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	SRBPKVWITYPHQR-KRWDZBQOSA-N	Phase 2
ZD-7114	adrenergic receptor agonist	ADRB3			BRD-K28971625-003-01-4	COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	RVMBDLSFFNKKLG-SFHVURJKSA-N	Phase 1
ZD-7155	angiotensin receptor antagonist	AGTR1			BRD-K11373525-003-02-1	CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nnn[nH]3)C(=O)CCc2c(CC)n1	BFVNEYDCFJNLGN-UHFFFAOYSA-N	Preclinical
ZD-7288	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			BRD-K18678457-003-02-8	CCN(c1ccccc1)c1cc(NC)[n+](C)c(C)n1	JABSKGQQWUDVRU-UHFFFAOYSA-O	Phase 2
zeatin					BRD-K90033078-001-08-7	C\C(CO)=C/CNc1[nH]cnc2ncnc12	UZKQTCBAMSWPJD-FARCUNLSSA-N	Phase 1
zebularine	DNA methyltransferase inhibitor	CDA, DNMT1			BRD-A01145011-001-07-1, BRD-K87714311-001-02-7, BRD-K58673634-001-01-2	OC[C@H]1O[C@H](C(O)[C@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O, OC[C@H]1O[C@H]([C@@H](O)[C@H]1O)n1cccnc1=O	RPQZTTQVRYEKCR-JJFBUQMESA-N, RPQZTTQVRYEKCR-WCTZXXKLSA-N, RPQZTTQVRYEKCR-VGRMVHKJSA-N	Preclinical
zibotentan	endothelin receptor antagonist	EDNRA			BRD-K31553034-001-03-0	COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1	FJHHZXWJVIEFGJ-UHFFFAOYSA-N	Phase 3
zidovudine	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)	BRD-A33692381-001-01-9, BRD-K72903603-001-24-4	Cc1cn(C2CC(N=[N+]=[N-])C(CO)O2)c(=O)[nH]c1=O, Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	HBOMLICNUCNMMY-UHFFFAOYSA-N, HBOMLICNUCNMMY-XLPZGREQSA-N	Launched
zileuton	leukotriene synthesis inhibitor, lipoxygenase inhibitor	ALOX5	pulmonary	asthma	BRD-A56359832-001-13-7, BRD-A56359832-001-11-1, BRD-A56359832-001-12-9	CC(N(O)C(N)=O)c1cc2ccccc2s1, CC(N(O)C(N)=O)c1cc2ccccc2s1, CC(N(O)C(N)=O)c1cc2ccccc2s1	MWLSOWXNZPKENC-UHFFFAOYSA-N, MWLSOWXNZPKENC-UHFFFAOYSA-N, MWLSOWXNZPKENC-UHFFFAOYSA-N	Launched
zilpaterol	adrenergic receptor agonist	ADRB2	endocrinology	weight-gain aid	BRD-K42816473-001-01-0	CC(C)N[C@H]1CCn2c(O)nc3cccc([C@@H]1O)c23	ZSTCZWJCLIRCOJ-AAEUAGOBSA-N	Launched
zimelidine	selective serotonin reuptake inhibitor (SSRI)	MAOA, MAOB, SLC6A4			BRD-K46914825-300-01-0	CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	OYPPVKRFBIWMSX-SXGWCWSVSA-N	Withdrawn
zinc-undecylenate	other antifungal		infectious disease	tinea pedis	BRD-K13330768-001-01-1	C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C	YMCOHQVWOBMDCZ-UHFFFAOYSA-L	Launched
zindotrine	phosphodiesterase inhibitor				BRD-K26598477-001-01-0	Cc1cc(nn2cnnc12)N1CCCCC1	YYHWOTFWBVRTQD-UHFFFAOYSA-N	Phase 2
ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K29582115-066-01-2, BRD-K29582115-003-03-1	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12, Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	MVWVFYHBGMAFLY-UHFFFAOYSA-N, MVWVFYHBGMAFLY-UHFFFAOYSA-N	Launched
ZK-164015	estrogen receptor antagonist	ESR1, ESR2			BRD-K05151076-001-02-6	CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	LYJSJVYJLZOMCD-UHFFFAOYSA-N	Preclinical
ZK-200775	kainate receptor antagonist				BRD-K67525671-001-02-5	OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	WZMQMKNCWDCCMT-UHFFFAOYSA-N	Phase 2
ZK-93423	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			BRD-K33882852-003-02-8	CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	ALBKMJDFBZVHAK-UHFFFAOYSA-N	Phase 3
ZK-93426	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA5			BRD-K68392338-003-02-0	CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	VMDUABMKBUKKPG-UHFFFAOYSA-N	Phase 1
ZK811752	CC chemokine receptor antagonist	CCR1			BRD-K91825936-001-01-2	C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	XQYASZNUFDVMFH-CQSZACIVSA-N	Phase 2
ZLN005					BRD-K73073971-001-01-7	CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	LQUNNCQSFFKSSK-UHFFFAOYSA-N	Preclinical
ZM-226600	Kir6 channel (KATP) activator				BRD-A62209527-001-04-5	CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F	LJLXQHHFAKVTNP-UHFFFAOYSA-N	Preclinical
ZM-241385	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K19605405-001-02-7	Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	PWTBZOIUWZOPFT-UHFFFAOYSA-N	Preclinical
ZM-306416	Abl kinase inhibitor, src inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR			BRD-K41337261-001-03-0, BRD-K41337261-003-02-8	COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC, COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	YHUIUSRCUKUUQA-UHFFFAOYSA-N, YHUIUSRCUKUUQA-UHFFFAOYSA-N	Preclinical
ZM-323881	VEGFR inhibitor	KDR			BRD-K67831364-003-05-8, BRD-K67831364-003-03-3, BRD-K67831364-003-04-1	Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O, Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N, NVBNDZZLJRYRPD-UHFFFAOYSA-N	Preclinical
ZM-336372	RAF inhibitor	BRAF, LCK, MAPK14, RAF1			BRD-K73789395-001-13-1, BRD-K73789395-001-10-7, BRD-K73789395-001-14-9, BRD-K73789395-001-09-9	CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1, CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N, PYEFPDQFAZNXLI-UHFFFAOYSA-N	Preclinical
ZM-39923	JAK inhibitor	JAK1, JAK3			BRD-K40624912-003-14-8, BRD-K40624912-003-13-0, BRD-K40624912-003-12-2	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1, CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N, JSASWRWALCMOQP-UHFFFAOYSA-N	Preclinical
ZM-447439	Aurora kinase inhibitor	AURKA, AURKB			BRD-K72703948-001-10-1, BRD-K72703948-001-12-7, BRD-K72703948-001-09-3	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1, COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	OGNYUTNQZVRGMN-UHFFFAOYSA-N, OGNYUTNQZVRGMN-UHFFFAOYSA-N, OGNYUTNQZVRGMN-UHFFFAOYSA-N	Preclinical
zofenopril-calcium	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-K46654563-238-01-0	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	IAIDUHCBNLFXEF-MNEFBYGVSA-N	Launched
zolantidine	histamine receptor antagonist				BRD-K08996725-332-01-7	C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	KUBONGDXTUOOLM-UHFFFAOYSA-N	Preclinical
zoledronic-acid	bone resorption inhibitor	FDPS, GGPS1	endocrinology	Pagets disease" "BRD-K84253429-001-04-4, BRD-K84253429-001-03-6" "OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O, OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O" "XRASPMIURGNCCH-UHFFFAOYSA-N, XRASPMIURGNCCH-UHFFFAOYSA-N" "Launched"
"3018" "zolimidine" "mucus protecting agent" "" "" "" "BRD-K45125084-001-01-4" "CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1" "VSLIUWLPFRVCDL-UHFFFAOYSA-N" "Launched"
"3019" "zolmitriptan" "serotonin receptor agonist" "HTR1A, HTR1B, HTR1D, HTR1E, HTR1F" "neurology/psychiatry" "migraine headache" "BRD-K54314721-001-10-2, BRD-K54314721-001-09-4" "CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12, CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12" "ULSDMUVEXKOYBU-ZDUSSCGKSA-N, ULSDMUVEXKOYBU-ZDUSSCGKSA-N" "Launched"
"3020" "zolpidem" "benzodiazepine receptor agonist" "GABRA1, GABRA2, GABRA3" "neurology/psychiatry" "insomnia" "BRD-K44876623-001-03-7" "CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1" "ZAFYATHCZYHLPB-UHFFFAOYSA-N" "Launched"
"3021" "zomepirac" "prostaglandin synthesis inhibitor" "PTGDR2" "" "" "BRD-K81326768-236-12-5, BRD-K81326768-236-11-7, BRD-K81326768-001-04-0" "Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1, Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1" "ZXVNMYWKKDOREA-UHFFFAOYSA-N, ZXVNMYWKKDOREA-UHFFFAOYSA-N, ZXVNMYWKKDOREA-UHFFFAOYSA-N" "Withdrawn"
"3022" "zometapine" "" "" "" "" "BRD-K14571191-001-01-6" "Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1" "YCWROMXNZZIJDQ-UHFFFAOYSA-N" "Phase 2"
"3023" "zonisamide" "sodium channel blocker, T-type calcium channel blocker" "CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A" "neurology/psychiatry" "seizures, epilepsy" "BRD-K48300629-001-14-5, BRD-K48300629-001-13-7" "NS(=O)(=O)Cc1noc2ccccc12, NS(=O)(=O)Cc1noc2ccccc12" "UBQNRHZMVUUOMG-UHFFFAOYSA-N, UBQNRHZMVUUOMG-UHFFFAOYSA-N" "Launched"
"3024" "zopolrestat" "" "" "" "" "BRD-K84459715-001-01-6" "OC(=O)C=C1NN(Cc2nc3cc(ccc3s2)C(F)(F)F)C(=O)c2ccccc12" "KODQZSCTFAQIRL-UHFFFAOYSA-N" "Phase 2"
"3025" "zosuquidar" "P glycoprotein inhibitor" "ABCB1, ABCB4" "" "" "BRD-K70557564-305-03-6" "O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F" "IHOVFYSQUDPMCN-DBEBIPAYSA-N" "Phase 3"
"3026" "zotarolimus" "mTOR inhibitor" "FKBP1A" "cardiology" "coronary artery restenosis" "BRD-K46843573-001-01-9" "CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1" "CGTADGCBEXYWNE-JUKNQOCSSA-N" "Launched"
"3027" "zotepine" "dopamine receptor antagonist, serotonin receptor antagonist" "ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4" "neurology/psychiatry" "schizophrenia" "BRD-K64557645-001-02-4" "CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12" "HDOZVRUNCMBHFH-UHFFFAOYSA-N" "Launched"
"3028" "zoxazolamine" "myorelaxant" "" "" "" "BRD-K66353228-001-14-6, BRD-K66353228-001-13-8" "Nc1nc2cc(Cl)ccc2o1, Nc1nc2cc(Cl)ccc2o1" "YGCODSQDUUUKIV-UHFFFAOYSA-N, YGCODSQDUUUKIV-UHFFFAOYSA-N" "Phase 2"
"3029" "ZSTK-474" "PI3K inhibitor" "PIK3CB, PIK3CD, PIK3CG" "" "" "BRD-K63068307-001-08-9" "FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1" "HGVNLRPZOWWDKD-UHFFFAOYSA-N" "Phase 1/Phase 2"
"3030" "zuclopenthixol" "dopamine receptor antagonist" "ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A" "neurology/psychiatry" "schizophrenia, bipolar disorder" "BRD-K28761384-300-01-0" "OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1" "WFPIAZLQTJBIFN-DVZOWYKESA-N" "Launched"
"3031" "Z160" "N-type calcium channel blocker" "CACNA2D1" "" "" "BRD-K16037980-001-01-1" "O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1" "VCPMZDWBEWTGNW-UHFFFAOYSA-N" "Phase 2"
"3032" "1-(piperidin-1-yl)prop-2-en-1-one" "" "" "" "" "BRD-K28042756-001-01-9" "C=CC(=O)N1CCCCC1" "RESPXSHDJQUNTN-UHFFFAOYSA-N" "Preclinical"
"3033" "1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol" "" "" "" "" "BRD-A95802703-001-01-0" "CC(C)NCC(O)COc1cc(C)ccc1Cl" "NJEIOWSBPCZKTL-UHFFFAOYSA-N" "Preclinical"
"3034" "1-acetyl-4-methylpiperazine" "acetylcholine receptor agonist" "" "" "" "BRD-K96055017-003-02-7" "CN1CCN(CC1)C(C)=O" "YSDBJKNOEWSFGA-UHFFFAOYSA-N" "Preclinical"
"3035" "1-azakenpaullone" "glycogen synthase kinase inhibitor" "CCNB1, CDK1, CDK5, GSK3B" "" "" "BRD-K03273112-001-01-8" "Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1" "NTSBZVCEIVPKBJ-UHFFFAOYSA-N" "Preclinical"
"3036" "1-deoxymannojirimycin" "alpha mannosidase inhibitor" "MAN2A1" "" "" "BRD-K89665618-003-02-5" "OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O" "LXBIFEVIBLOUGU-KVTDHHQDSA-N" "Preclinical"
"3037" "1-EBIO" "potassium channel activator" "KCNN1, KCNN2, KCNN3, KCNN4" "" "" "BRD-K70586315-001-02-4" "CCn1c2ccccc2[nH]c1=O" "CXUCKELNYMZTRT-UHFFFAOYSA-N" "Preclinical"
"3038" "1-ethyl-2-pyrrolidone" "transdermal absorption-enhancing compound" "" "" "" "BRD-K08288352-001-03-6" "CCN1CCCC1=O" "ZFPGARUNNKGOBB-UHFFFAOYSA-N" "Preclinical"
"3039" "1-hexadecanal" "sphingosine 1 phosphate receptor substrate" "DBI, RHO" "" "" "BRD-K35114608-001-01-7" "CCCCCCCCCCCCCCCC=O" "NIOYUNMRJMEDGI-UHFFFAOYSA-N" "Preclinical"
"3040" "1-hexadecanol" "" "" "dermatology" "cosmetic" "BRD-K37203094-001-03-3, BRD-K37203094-001-02-5" "CCCCCCCCCCCCCCCCO, CCCCCCCCCCCCCCCCO" "BXWNKGSJHAJOGX-UHFFFAOYSA-N, BXWNKGSJHAJOGX-UHFFFAOYSA-N" "Launched"
"3041" "1-naphthyl-PP1" "src inhibitor" "SRC" "" "" "BRD-K29542628-001-03-9, BRD-K29542628-001-04-7" "CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12, CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12" "XSHQBIXMLULFEV-UHFFFAOYSA-N, XSHQBIXMLULFEV-UHFFFAOYSA-N" "Preclinical"
"3042" "1-octacosanol" "" "" "" "" "BRD-K03083257-001-01-6" "CCCCCCCCCCCCCCCCCCCCCCCCCCCCO" "CNNRPFQICPFDPO-UHFFFAOYSA-N" "Phase 2"
"3043" "1-octanol" "" "GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1" "" "" "BRD-K09338665-001-07-1" "CCCCCCCCO" "KBPLFHHGFOOTCA-UHFFFAOYSA-N" "Phase 2"
"3044" "1-phenylbiguanide" "serotonin receptor agonist" "HTR3A, HTR3B" "" "" "BRD-K31491153-003-05-9" "NC(=N)NC(=N)Nc1ccccc1" "CUQCMXFWIMOWRP-UHFFFAOYSA-N" "Preclinical"
"3045" "1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone oxime" "" "" "" "" "BRD-A37752546-001-01-9" "CCCCCCCCCCCC([N+][O-])c1cc(C)ccc1O" "NFONIVRMILHYLH-UHFFFAOYSA-N" "Preclinical"
"3046" "10-deacetylbaccatin" "antitumor agent" "" "" "" "BRD-K96631475-001-02-4, BRD-K61920224-001-01-8" "CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C" "YWLXLRUDGLRYDR-ZHPRIASZSA-N, YWLXLRUDGLRYDR-LUPIKGFISA-N" "Preclinical"
"3047" "10-DEBC" "AKT inhibitor" "PIM1" "" "" "BRD-K70792160-003-04-6" "CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12" "GYBXAGDWMCJZJK-UHFFFAOYSA-N" "Preclinical"
"3048" "10-hydroxycamptothecin" "topoisomerase inhibitor" "TOP1" "" "" "BRD-K63784565-001-06-2, BRD-K63784565-001-05-4" "CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O, CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O" "HAWSQZCWOQZXHI-FQEVSTJZSA-N, HAWSQZCWOQZXHI-FQEVSTJZSA-N" "Preclinical"
"3049" "10058-F4" "c-Myc inhibitor" "" "" "" "BRD-K49460120-001-05-8, BRD-K49460120-001-02-5" "CCc1ccc(cc1)\C=C1\SC(=S)NC1=O, CCc1ccc(cc1)\C=C1\SC(=S)NC1=O" "SVXDHPADAXBMFB-JXMROGBWSA-N, SVXDHPADAXBMFB-JXMROGBWSA-N" "Preclinical"
"3050" "12-O-tetradecanoylphorbol-13-acetate" "PKC activator" "KCNT2, TRPV4" "" "" "BRD-K68552125-001-05-3" "CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O" "PHEDXBVPIONUQT-RGYGYFBISA-N" "Phase 2"
"3051" "1400W" "nitric oxide synthase inhibitor" "NOS1, NOS2, NOS3" "" "" "BRD-K30237152-300-02-5" "CC(=N)NCc1cccc(CN)c1" "RODUKNYOEVZQPR-UHFFFAOYSA-N" "Preclinical"
"3052" "17-alpha-methyltestosterone" "aromatase inhibitor" "AR" "" "" "BRD-K84036904-001-08-8" "C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C" "GCKMFJBGXUYNAG-HLXURNFRSA-N" "Launched"
"3053" "17-hydroxyprogesterone-caproate" "progesterone receptor agonist" "AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR" "" "" "BRD-A29731977-001-04-5" "CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O" "DOMWKUIIPQCAJU-JKPPDDDBSA-N" "Launched"
"3054" "17-PA" "glucocorticoid receptor agonist" "" "" "" "BRD-K07395323-001-01-0" "C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1" "SINAMTXBCYKFDL-WBJZGETLSA-N" "Preclinical"
"3055" "2-c-methylguanosine	HCV inhibitor				BRD-K78092779-001-01-6	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(O)nc(N)nc12	NVKAMPJSWMHVDK-GITKWUPZSA-N	Preclinical
2-MeCCPA" "adenosine receptor agonist" "ADORA1" "" "" "BRD-K63932022-001-01-5" "C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12" "MMPAUXMIDJWGFO-ROMFRFKVSA-N" "Preclinical"
"3056" "2-(3-mercaptopropyl)pentanedioic acid" "glutamate carboxypeptidase inhibitor" "FOLH1" "" "" "BRD-A66788520-001-01-7" "OC(=O)CCC(CCCS)C(O)=O" "FNLNSQHJKVQCBP-UHFFFAOYSA-N" "Phase 1"
"3057" "2-[1-(4-piperonyl)piperazinyl]benzothiazole" "serotonin receptor agonist" "HTR4" "" "" "BRD-K91868854-001-03-6" "C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1" "BYHKGNWKJMGHGE-UHFFFAOYSA-N" "Preclinical"
"3058" "2-aminobenzenesulfonamide" "carbonic anhydrase inhibitor" "CA12, CA14, CA2, CA6, CA9" "" "" "BRD-K32681104-001-11-6" "Nc1ccccc1S(N)(=O)=O" "YAZSBRQTAHVVGE-UHFFFAOYSA-N" "Preclinical"
"3059" "2-APB" "1,4,5-trisphosphate inhibitor" "TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6" "" "" "BRD-K13346085-001-04-7" "NCCOB(c1ccccc1)c1ccccc1" "BLZVCIGGICSWIG-UHFFFAOYSA-N" "Preclinical"
"3060" "2-BFI" "imidazoline receptor ligand" "ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB" "" "" "BRD-K22745370-003-02-3" "C1CN=C(N1)c1cc2ccccc2o1" "YTJOHEUHUVBKSB-UHFFFAOYSA-N" "Preclinical"
"3061" "2-chloro-N6-cyclopentyladenosine" "adenosine receptor agonist" "ADORA1, ADORA2A, ADORA2B, ADORA3" "" "" "BRD-K70088346-001-01-6" "OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12" "XSMYYYQVWPZWIZ-IDTAVKCVSA-N" "Preclinical"
"3062" "2-Chloropyrazine" "" "" "" "" "BRD-K84075000-001-05-5" "Clc1cnccn1" "GELVZYOEQVJIRR-UHFFFAOYSA-N" "Preclinical"
"3063" "2-CMDO" "dopamine receptor antagonist" "DRD2, DRD4" "" "" "BRD-K92588747-051-02-7" "CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12" "OTKUTGIVEREJLL-UHFFFAOYSA-N" "Preclinical"
"3064" "2-cyanopyrimidine" "cathepsin inhibitor" "" "" "" "BRD-K95015809-001-02-8" "N" "" ""
"3065" "2-Deoxy-2-{[methyl(nitroso)carbamoyl]amino}hexose" "" "" "oncology, endocrinology" "pancreatic cancer, hypoglycemia" "BRD-A55902763-001-01-3" "CN([N+][O-])C(=O)NC(C=O)C(O)C(O)C(O)CO" "AGRCPNMCOXLKFO-UHFFFAOYSA-N" "Preclinical"
"3066" "2-deoxyglucose" "glycolysis inhibitor" "SLC2A1, SLC2A2, SLC2A3, SLC2A4" "" "" "BRD-K97808269-001-02-7" "OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O" "PMMURAAUARKVCB-ZXXMMSQZSA-N" "Phase 2"
"3067" "2-ethoxybenzoic-acid" "analgesic agent" "" "" "" "BRD-K04843302-001-02-5" "CCOc1ccccc1C(O)=O" "XDZMPRGFOOFSBL-UHFFFAOYSA-N" "Phase 1"
"3068" "2-fluoro-2-deoxy-D-galactose" "" "LCT" "" "" "BRD-A53037300-001-01-0" "OCC1OC(O)C(F)C(O)C1O" "ZCXUVYAZINUVJD-UHFFFAOYSA-N" "Phase 1"
"3069" "2-hydroxyethyl-salicylate" "" "" "" "" "BRD-K41866823-001-01-3" "OCCOC(=O)c1ccccc1O" "LVYLCBNXHHHPSB-UHFFFAOYSA-N" "Launched"
"3070" "2-hydroxyflutamide" "androgen receptor antagonist" "AR" "" "" "BRD-K82027074-001-07-5, BRD-K82027074-001-08-3" "CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O, CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O" "YPQLFJODEKMJEF-UHFFFAOYSA-N, YPQLFJODEKMJEF-UHFFFAOYSA-N" "Phase 1/Phase 2"
"3071" "2-hydroxysaclofen" "GABA receptor antagonist" "GABBR1, GABBR2" "" "" "BRD-A27924917-001-03-3" "NCC(O)(CS(O)(=O)=O)c1ccc(Cl)cc1" "WBSMZVIMANOCNX-UHFFFAOYSA-N" "Preclinical"
"3072" "2-iminobiotin" "nitric oxide synthase inhibitor" "NOS1, NOS2" "" "" "BRD-K07954936-001-01-3" "OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12" "WWVANQJRLPIHNS-ZKWXMUAHSA-N" "Phase 2"
"3073" "2-iodohippuric-acid" "" "" "" "" "BRD-K56634222-001-03-0" "OC(=O)CNC(=O)c1ccccc1I" "CORFWQGVBFFZHF-UHFFFAOYSA-N" "Preclinical"
"3074" "2-iodomelatonin" "melatonin receptor agonist" "MTNR1A, MTNR1B, NQO2" "" "" "BRD-K25649279-001-02-0" "COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1" "FJDDSMSDZHURBJ-UHFFFAOYSA-N" "Preclinical"
"3075" "2-methoxyestradiol" "hypoxia inducible factor inhibitor" "COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB" "" "" "BRD-K44408410-001-17-6, BRD-K42136116-001-01-6" "COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@@H]3CC[C@]4(C)[C@H](O)CC[C@H]4[C@@H]3CCc2cc1O" "CQOQDQWUFQDJMK-SSTWWWIQSA-N, CQOQDQWUFQDJMK-ZGPDXJMCSA-N" "Phase 2"
"3076" "2-methyl-5-hydroxytryptamine" "serotonin receptor agonist" "HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6" "" "" "BRD-K64137799-003-02-5" "Cc1[nH]c2ccc(O)cc2c1CCN" "WYWNEDARFVJQSG-UHFFFAOYSA-N" "Preclinical"
"3077" "2-methyl-5-nitrophenol" "" "" "" "" "BRD-K22327730-001-01-1" "Cc1ccc(cc1O)[N+]([O-])=O" "UMFDLIXUUJMPSI-UHFFFAOYSA-N" "Preclinical"
"3078" "2-methylimidazole" "cholesterol inhibitor" "" "" "" "BRD-K68534611-001-07-8" "Cc1ncc[nH]1" "LXBGSDVWAMZHDD-UHFFFAOYSA-N" "Preclinical"
"3079" "2-octyldodecan-1-ol" "" "" "" "" "BRD-A51407134-001-01-9" "CCCCCCCCCCC(CO)CCCCCCCC" "LEACJMVNYZDSKR-UHFFFAOYSA-N" "Preclinical"
"3080" "2-Oleoylglycerol" "glucose dependent insulinotropic receptor ligand" "GPR119" "" "" "BRD-K77087341-001-02-4" "CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO" "UPWGQKDVAURUGE-KTKRTIGZSA-N" "Phase 1"
"3081" "2-oxoglutaric-acid" "" "OXGR1" "" "" "BRD-K89712525-001-02-1" "OC(=O)CCC(=O)C(O)=O" "KPGXRSRHYNQIFN-UHFFFAOYSA-N" "Preclinical"
"3082" "2-oxopropanoate" "pyruvate dehydrogenase kinase inhibitor" "ABAT, AGXT2, PC, PDHB, PKLR, PKM, SLC16A1, SLC16A2, SLC16A3, SLC16A4, SLC16A5, SLC16A6, SLC16A7, SLC16A8" "" "" "BRD-K86587225-236-02-5" "CC(=O)C(O)=O" "LCTONWCANYUPML-UHFFFAOYSA-N" "Preclinical"
"3083" "2-phenylmelatonin" "melatonin receptor agonist" "MTNR1A, MTNR1B" "" "" "BRD-K41869275-001-02-8" "COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1" "OFCLARYYBGKCHN-UHFFFAOYSA-N" "Preclinical"
"3084" "2-PMDQ" "adrenergic receptor antagonist" "ADRA1A" "" "" "BRD-A04661934-001-02-9" "O=C1Nc2ccccc2C2=NC(CN3CCN(CC3)c3ccccc3)CN12" "ONSOQRPYFKDOEB-UHFFFAOYSA-N" "Preclinical"
"3085" "2-pyridylethylamine" "histamine receptor agonist" "HRH1" "" "" "BRD-K17874705-300-03-2" "NCCc1ccccn1" "XPQIPUZPSLAZDV-UHFFFAOYSA-N" "Preclinical"
"3086" "2-TEDC" "lipoxygenase inhibitor" "ALOX12" "" "" "BRD-K89072800-001-01-8" "Oc1ccc(\C=C(/C" "" ""
"3087" "2-thiouracil" "" "" "" "" "BRD-K58819470-001-05-9, BRD-K58819470-001-04-2" "Oc1ccnc(S)n1, Oc1ccnc(S)n1" "ZEMGGZBWXRYJHK-UHFFFAOYSA-N, ZEMGGZBWXRYJHK-UHFFFAOYSA-N" "Preclinical"
"3088" "20-hydroxyecdysone" "ecdysone receptor modulator" "" "" "" "BRD-K28343777-001-01-6" "CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C" "NKDFYOWSKOHCCO-HMIIXLFTSA-N" "Preclinical"
"3089" "3-fluorobenzylspiperone	dopamine receptor ligand	DRD2			BRD-K45662124-050-01-5	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	DXZKTRNEOISOCA-UHFFFAOYSA-N	Preclinical
3-(4-methylbenzylidene)camphor	endocrine disruptor		dermatology	sunscreen lotion	BRD-A55464252-001-01-2	Cc1ccc(cc1)\C=C1\C2CCC(C)(C1=O)C2(C)C	HEOCBCNFKCOKBX-KAMYIIQDSA-N	Launched
3-alpha-bis-(4-fluorophenyl)-methoxytropane	dopamine uptake inhibitor	CHRM1, SLC6A2, SLC6A3, SLC6A4			BRD-A85216385-003-02-4	CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	MHNSOBBJZCWUGS-UHFFFAOYSA-N	Preclinical
3-alpha-Hydroxy-5-beta-androstan-17-one					BRD-A43598550-001-09-4	C[C@]12CCC3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-WRZMNKJASA-N	Preclinical
3-amino-benzamide	PARP inhibitor	PARP1			BRD-K08703257-001-12-1, BRD-K08703257-001-13-9	NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1	GSCPDZHWVNUUFI-UHFFFAOYSA-N, GSCPDZHWVNUUFI-UHFFFAOYSA-N	Phase 2
3-anilinopropan-1-ol					BRD-K49721826-001-02-7	OCCCNc1ccccc1	GZYBSURBYCLNSM-UHFFFAOYSA-N	Preclinical
3-AQC	serotonin receptor agonist	HTR3A			BRD-K38370968-050-01-3	C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	IDOXKFDPDOIUMG-UHFFFAOYSA-N	Preclinical
3-bromo-7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			BRD-K24689407-001-06-3	[O-][N+](=O)c1cccc2c(Br)n[nH]c12	NFSTZPMYAZRZPC-UHFFFAOYSA-N	Preclinical
3-bromocamphor					BRD-A62841832-001-01-1	CC1(C)C2CCC1(C)C(=O)C2Br	NJQADTYRAYFBJN-UHFFFAOYSA-N	Launched
3-bromopyruvate	hexokinase inhibitor	HK2			BRD-K92980438-001-04-1, BRD-K92980438-001-03-3	OC(=O)C(=O)CBr, OC(=O)C(=O)CBr	PRRZDZJYSJLDBS-UHFFFAOYSA-N, PRRZDZJYSJLDBS-UHFFFAOYSA-N	Preclinical
3-carboxy-4-hydroxyphenylglycine-(R)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			BRD-K76592088-001-02-1	N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-SSDOTTSWSA-N	Preclinical
3-carboxy-4-hydroxyphenylglycine-(S)	glutamate receptor antagonist	GRM1, GRM5			BRD-K61585876-001-01-0	N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-ZETCQYMHSA-N	Preclinical
3-CPMT	dopamine reuptake inhibitor				BRD-A51713165-003-02-6	CN1C2CCC1CC(C2)OC(c1ccccc1)c1ccc(Cl)cc1	OCAXFDULERPAJM-UHFFFAOYSA-N	Preclinical
3-deazaadenosine	adenosylhomocysteinase inhibitor	AHCY			BRD-A79431551-001-01-1	Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)C(O)C1O	DBZQFUNLCALWDY-JXACCQRMSA-N	Phase 2
3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	EZH2			BRD-K77791657-003-01-7, BRD-K55942458-001-01-7	Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O, Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@@H]1O	OMKHWTRUYNAGFG-IEBDPFPHSA-N, OMKHWTRUYNAGFG-FBIMIBRVSA-N	Preclinical
3-deazauridine	cytidine deaminase inhibitor				BRD-A26105646-001-06-1	OCC1OC(C(O)C1O)N1C=CC(=O)CC1=O	WIRVQQCUKDPURA-UHFFFAOYSA-N	Preclinical
3-hydroxy-3-phenylpentanamide	GABA receptor modulator				BRD-A66143912-001-01-1	CCC(O)(CC(N)=O)c1ccccc1	MOHYRCCDARWQRM-UHFFFAOYSA-N	Phase 1
3-indolebutyric-acid		B2M, HLA-A, TRAC, TRBC1			BRD-K43187796-001-02-3	OC(=O)CCCc1c[nH]c2ccccc12	JTEDVYBZBROSJT-UHFFFAOYSA-N	Preclinical
3-MATIDA		GRM1			BRD-A87125127-001-02-2	Cc1cc(sc1C(N)C(O)=O)C(O)=O	KOMWRBFEDDEWEP-UHFFFAOYSA-N	Preclinical
3-methyl-GABA	GABA aminotransferase activator	ABAT			BRD-A62890442-077-01-0	CC(CN)CC(O)=O	CZGLBWZXGIAIBU-UHFFFAOYSA-N	Preclinical
3-methyladenine	PI3K inhibitor	PI3			BRD-K81647657-001-04-3, BRD-K81647657-001-05-0	Cn1cnc(=N)c2nc[nH]c12, Cn1cnc(=N)c2nc[nH]c12	ZPBYVFQJHWLTFB-UHFFFAOYSA-N, ZPBYVFQJHWLTFB-UHFFFAOYSA-N	Preclinical
3-MPPI	adrenergic receptor ligand	ADRA1A			BRD-K62581435-001-03-8	COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	AQASGOHUMGAWJJ-UHFFFAOYSA-N	Preclinical
3PO	phosphofructokinase inhibitor	PFKFB3			BRD-K58413118-001-01-8	O=C(\C=C\c1cccnc1)c1ccncc1	UOWGYMNWMDNSTL-ONEGZZNKSA-N	Preclinical
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	HTR2A			BRD-K47337578-034-02-5	Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	FTJXZACAQRDRNT-UHFFFAOYSA-N	Preclinical
4-aminohippuric-acid		SLC22A6			BRD-K65544384-001-15-8, BRD-K65544384-001-14-1, BRD-K65544384-236-03-6, BRD-K65544384-236-01-0, BRD-K65544384-236-02-8	Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O, Nc1ccc(cc1)C(=O)NCC(O)=O	HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N, HSMNQINEKMPTIC-UHFFFAOYSA-N	Preclinical
4-carboxy-3-hydroxyphenylglycine-(RS)	glutamate receptor agonist, glutamate receptor antagonist	GRM1			BRD-A80383043-001-03-3	NC(C(O)=O)c1ccc(C(O)=O)c(O)c1	GXZSAQLJWLCLOX-UHFFFAOYSA-N	Preclinical
4-carboxy-3-hydroxyphenylglycine-(S)	glutamate receptor agonist, glutamate receptor antagonist	GRM1, GRM2			BRD-K74133873-001-01-7	N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1	GXZSAQLJWLCLOX-ZETCQYMHSA-N	Preclinical
4-chlorophenylguanidine	urokinase inhibitor	PLAUR			BRD-K39160765-003-02-9	NC(=N)Nc1ccc(Cl)cc1	ZSJNJAJDBNFVCA-UHFFFAOYSA-N	Preclinical
4-DAMP	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			BRD-K29313239-005-09-4	C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1	HYJRTXSYDAFGJK-UHFFFAOYSA-N	Preclinical
4-galactosyllactose		AMY2B			BRD-A32796301-001-01-6	OC[C@H]1O[C@@H](O[C@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](CO)OC(O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O	FYGDTMLNYKFZSV-YXENHOCSSA-N	Preclinical
4-HQN	PARP inhibitor	PARP1			BRD-K91758890-001-10-0	Oc1ncnc2ccccc12	QMNUDYFKZYBWQX-UHFFFAOYSA-N	Preclinical
4-hydroxy-phenazone					BRD-K49759007-001-11-9	Cc1c(O)c(=O)n(-c2ccccc2)n1C	SKVPTPMWXJSBTF-UHFFFAOYSA-N	Preclinical
4-IBP	sigma receptor agonist	SIGMAR1			BRD-K62537556-001-02-5	Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1	HELCSESNNDZLFM-UHFFFAOYSA-N	Preclinical
4-iodo-L-phenylalanine		DPP4			BRD-K66664625-001-01-2	N[C@H](Cc1ccc(I)cc1)C(O)=O	PZNQZSRPDOEBMS-MRVPVSSYSA-N	
4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	MIF			BRD-K25690923-001-02-4	Ic1cc(ncn1)-c1ccccc1	ZTCJXHNJVLUUMR-UHFFFAOYSA-N	Preclinical
4-methylgenistein	protein tyrosine kinase inhibitor	CYP19A1, ESRRA, ESRRB, ESRRG, FASN			BRD-K73303757-001-21-6	COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	WUADCCWRTIWANL-UHFFFAOYSA-N	Preclinical
4-methylhistamine	histamine receptor agonist	HRH4			BRD-K70821460-300-02-4	Cc1nc[nH]c1CCN	UGYXPZQILZRKJJ-UHFFFAOYSA-N	Preclinical
4-mu-8C	IRE1 inhibitor	ERN1			BRD-K81316007-001-01-8	Cc1cc(=O)oc2c(C=O)c(O)ccc12	RTHHSXOVIJWFQP-UHFFFAOYSA-N	Preclinical
4-P-PDOT	melatonin receptor antagonist	MTNR1A, MTNR1B			BRD-A67482312-001-02-6	CCC(=O)NC1CC(c2ccccc2)c2ccccc2C1	RCYLUNPFECYGDW-UHFFFAOYSA-N	Preclinical
4-phenolsulfonic-acid					BRD-K41024817-325-01-0	Oc1ccc(cc1)S(O)(=O)=O	FEPBITJSIHRMRT-UHFFFAOYSA-N	Preclinical
4-PPBP	sigma receptor ligand	SIGMAR1			BRD-K78061844-050-01-9	C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	HQGDPZPNAXRCSA-UHFFFAOYSA-N	Preclinical
4-propylbenzoic-acid					BRD-K42108215-001-01-5	CCCc1ccc(cc1)C(O)=O	ATZHGRNFEFVDDJ-UHFFFAOYSA-N	Preclinical
4-pyrimidinecarbonitrile					BRD-K04552268-001-01-6	N#Cc1ccncn1	ZIEWSZYVEDTXGH-UHFFFAOYSA-N	Preclinical
4-tert-butylphenol					BRD-K06338106-001-01-4	CC(C)(C)c1ccc(O)cc1	QHPQWRBYOIRBIT-UHFFFAOYSA-N	Preclinical
4EGI-1	protein synthesis inhibitor	EIF4E			BRD-K52366702-001-01-6, BRD-K52366702-001-02-4	OC(=O)C(\Cc1ccccc1[N+]([O-])=O)=N\Nc1nc(cs1)-c1ccc(Cl)c(Cl)c1, OC(=O)C(\Cc1ccccc1[N+]([O-])=O)=N\Nc1nc(cs1)-c1ccc(Cl)c(Cl)c1	KFRKRECSIYXARE-HYARGMPZSA-N, KFRKRECSIYXARE-HYARGMPZSA-N	Preclinical
4E1RCat	protein synthesis inhibitor	EIF4E, EIF4G1			BRD-K67173685-001-06-9, BRD-K56468417-001-01-2	OC(=O)c1ccc(cc1)N1C(=O)C(\C=C1c1ccccc1)=C\c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O, OC(=O)c1ccc(cc1)N1C(=O)C(=C/c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)\C=C1c1ccccc1	BBQRBOIMSKMFFO-LTGZKZEYSA-N, BBQRBOIMSKMFFO-PGMHBOJBSA-N	Preclinical
4SC-202	HDAC inhibitor	HDAC1			BRD-K11773281-075-02-4, BRD-K11773281-001-01-2, BRD-K11773281-075-01-6	Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1, Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N, PRXXYMVLYKJITB-IZZDOVSWSA-N	Phase 1
5-Chloro-5-deoxy-ENBA-(+/-)	adenosine receptor agonist	ADORA1			BRD-A13598753-001-01-2	O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12	PVJGDYDNVNCGBT-STHLEMNDSA-N	Preclinical
5-aminolevulinic-acid	oxidizing agent	ALAD			BRD-K57631554-003-07-0, BRD-K57631554-003-06-2	NCC(=O)CCC(O)=O, NCC(=O)CCC(O)=O	ZGXJTSGNIOSYLO-UHFFFAOYSA-N, ZGXJTSGNIOSYLO-UHFFFAOYSA-N	Launched
5-BDBD	purinergic receptor antagonist	P2RX4			BRD-K33690734-001-01-5	Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21	NKYMVQPXXTZHSF-UHFFFAOYSA-N	Preclinical
5-carboxamidotryptamine	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			BRD-K92382976-050-01-1	NCCc1c[nH]c2ccc(cc12)C(N)=O	WKZLNEWVIAGNAW-UHFFFAOYSA-N	Preclinical
5-fluoro-3-pyridyl-methanol					BRD-K73381198-001-01-1	OCc1cncc(F)c1	GGGJYJXAFSEWNM-UHFFFAOYSA-N	Preclinical
5-fluorouracil	thymidylate synthase inhibitor	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	BRD-K24844714-001-24-5, BRD-K24844714-001-25-2	Fc1c[nH]c(=O)[nH]c1=O, Fc1c[nH]c(=O)[nH]c1=O	GHASVSINZRGABV-UHFFFAOYSA-N, GHASVSINZRGABV-UHFFFAOYSA-N	Launched
5-FP	thymidylate synthase inhibitor	TYMS			BRD-K34437622-001-06-4, BRD-K34437622-001-08-0	Oc1ncc(F)cn1, Oc1ncc(F)cn1	HPABFFGQPLJKBP-UHFFFAOYSA-N, HPABFFGQPLJKBP-UHFFFAOYSA-N	Phase 1
5-HMF					BRD-K86799112-001-02-0, BRD-K86799112-001-03-8	OCc1ccc(C=O)o1, OCc1ccc(C=O)o1	NOEGNKMFWQHSLB-UHFFFAOYSA-N, NOEGNKMFWQHSLB-UHFFFAOYSA-N	Phase 2
5-hydroxyectoine					BRD-K03871161-001-01-9	O[C@H]1CNC(=C)N[C@@H]1C(O)=O	GJSUWVXFIISKPT-WHFBIAKZSA-N	Preclinical
5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	CHRM3			BRD-K24603946-001-03-9, BRD-K24603946-001-02-1	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C, CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	DUXZAXCGJSBGDW-HXUWFJFHSA-N, DUXZAXCGJSBGDW-HXUWFJFHSA-N	Phase 1
5-hydroxytryptophan	neurotransmitter	SLC36A1, SLC36A2	neurology/psychiatry	insomnia	BRD-A73930134-001-03-0, BRD-A73930134-001-02-2	NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O, NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O	LDCYZAJDBXYCGN-UHFFFAOYSA-N, LDCYZAJDBXYCGN-UHFFFAOYSA-N	Launched
5-iodo-A-85380	acetylcholine receptor agonist				BRD-K90065682-300-02-6	Ic1cncc(OC[C@@H]2CCN2)c1	RKVRGRXOYDTUEY-QMMMGPOBSA-N	Phase 2
5-methylfurmethiodide	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K45437867-005-03-3	Cc1ccc(C[N+](C)(C)C)o1	KOWVJDFMEZKDDT-UHFFFAOYSA-N	Preclinical
5-methylhydantoin-(D)					BRD-K06050544-001-03-1, BRD-K06050544-001-04-9	C[C@H]1NC(=O)NC1=O, C[C@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-UWTATZPHSA-N, VMAQYKGITHDWKL-UWTATZPHSA-N	Preclinical
5-methylhydantoin-(L)					BRD-K56033645-001-07-5	C[C@@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-REOHCLBHSA-N	Preclinical
6-aminochrysene	transferase inhibitor				BRD-K00656370-001-10-5	Nc1cc2c3ccccc3ccc2c2ccccc12	KIVUHCNVDWYUNP-UHFFFAOYSA-N	Phase 2
6-aminopenicillanic-acid					BRD-K30284967-001-01-8	CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O	NGHVIOIJCVXTGV-ALEPSDHESA-N	Preclinical
6-benzylaminopurine	purinergic receptor activator				BRD-K62929068-001-16-5	N(Cc1ccccc1)c1ncnc2nc[nH]c12	NWBJYWHLCVSVIJ-UHFFFAOYSA-N	Preclinical
6-chloromelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			BRD-K34663752-001-09-1	COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	LUINDDOUWHRIPW-UHFFFAOYSA-N	Preclinical
6-iodo-nordihydrocapsaicin	TRPV antagonist	TRPV1			BRD-K49236613-001-02-3	CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	AAORACFZMYMFCG-UHFFFAOYSA-N	Preclinical
7-aminocephalosporanic-acid	beta lactamase inhibitor				BRD-K65377893-001-07-4, BRD-K15457970-001-01-4	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O, CC(=O)OCC1=C(N2[C@H](SC1)[C@@H](N)C2=O)C(O)=O	HSHGZXNAXBPPDL-HZGVNTEJSA-N, HSHGZXNAXBPPDL-IMTBSYHQSA-N	Preclinical
7-chlorokynurenic-acid	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			BRD-K84214706-001-05-7	OC(=O)c1cc(O)c2ccc(Cl)cc2n1	UAWVRVFHMOSAPU-UHFFFAOYSA-N	Preclinical
7-hydroxy-DPAT	dopamine receptor agonist	DRD2, DRD3			BRD-A18795974-004-07-3	CCCN(CCC)C1CCc2ccc(O)cc2C1	BLYMJBIZMIGWFK-UHFFFAOYSA-N	Preclinical
7-hydroxy-PIPAT	dopamine receptor ligand	DRD3			BRD-A01295252-050-01-2	CCCN(C\C=C\I)C1CCc2ccc(O)cc2C1	RTMIJLQPWFKAFE-FPYGCLRLSA-N	Preclinical
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	CHEK1, MARK3, PDPK1			BRD-K45293975-001-02-0	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	Phase 2
7-keto-DHEA	steroid				BRD-K07785030-001-01-6	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1	VVSMJVQHDZUPIL-XFKPDKBWSA-N	Launched
7-methoxytacrine	acetylcholinesterase inhibitor	ACHE			BRD-K53156626-001-01-3	COc1ccc2nc3CCCCc3c(N)c2c1	APQPVVOYBLOJDY-UHFFFAOYSA-N	Phase 2
7-methylxanthine	adenosine receptor antagonist				BRD-K41592905-001-01-6	Cn1cnc2nc(O)nc(O)c12	PFWLFWPASULGAN-UHFFFAOYSA-N	Phase 2
7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			BRD-K04430056-001-17-7, BRD-K04430056-236-02-1	[O-][N+](=O)c1cccc2cn[nH]c12, [O-][N+](=O)c1cccc2cn[nH]c12	PQCAUHUKTBHUSA-UHFFFAOYSA-N, PQCAUHUKTBHUSA-UHFFFAOYSA-N	Preclinical
8-bromo-cAMP	PKA activator				BRD-A09554849-236-07-6	Nc1ncnc2n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c(Br)nc12	DVKQVRZMKBDMDH-UUOKFMHZSA-N	Preclinical
8-bromo-cGMP	PKA activator	PRKG1			BRD-A00077618-236-07-6	Nc1nc(O)c2nc(Br)n([C@@H]3O[C@@H]4COP(O)(=O)O[C@H]4[C@H]3O)c2n1	YUFCOOWNNHGGOD-UMMCILCDSA-N	Preclinical
8-hydroxy-DPAT	serotonin receptor agonist	CDK1, CHEK1, CHEK2, GSK3B, HTR5A, HTR7, LCK, MAPK14, MARK1, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG			BRD-A48015106-004-08-9	CCCN(CCC)C1CCc2cccc(O)c2C1	ASXGJMSKWNBENU-UHFFFAOYSA-N	Preclinical
8-hydroxy-PIPAT	dopamine receptor ligand	DRD2, DRD3			BRD-A60594020-034-01-1	CCCN(C\C=C\I)C1CCc2cccc(O)c2C1	QBXHUZJZYDSLRH-RUDMXATFSA-N	Preclinical
8-M-PDOT	melatonin receptor agonist	MTNR1A, MTNR1B			BRD-A07232941-001-02-7	CCC(=O)NC1CCc2cccc(OC)c2C1	RVIGBTUDFAGRTQ-UHFFFAOYSA-N	Preclinical
80841-78-7					BRD-K03044000-001-01-8	Cc1oc(=O)oc1CCl	QCLFSYYUWPUWQR-UHFFFAOYSA-N	Preclinical
9-aminoacridine					BRD-K00535541-001-05-5, BRD-K00535541-001-06-3, BRD-K00535541-001-04-8	Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12, Nc1c2ccccc2nc2ccccc12	XJGFWWJLMVZSIG-UHFFFAOYSA-N, XJGFWWJLMVZSIG-UHFFFAOYSA-N, XJGFWWJLMVZSIG-UHFFFAOYSA-N	Preclinical
9-aminocamptothecin	topoisomerase inhibitor	TOP1			BRD-K09291936-001-13-3	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O	FUXVKZWTXQUGMW-FQEVSTJZSA-N	Phase 2
9-anthracenecarboxylic-acid		ANO1, CLCN1			BRD-K62607075-001-03-6	OC(=O)c1c2ccccc2cc2ccccc12	XGWFJBFNAQHLEF-UHFFFAOYSA-N	Preclinical
" "" "" "" "" "" "" "" ""
